Clinical trial NCT02603120
Conditions: HIV-1 Infection
Sponsor: Gilead Sciences
Start date: 2015-11-11; Completion date: 2019-10-23
Enrollment: 567 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The primary objective of this study is to evaluate the efficacy of switching from a regimen of dolutegravir (DTG) and abacavir/lamivudine (ABC/3TC) or a fixed dose combination (FDC) of abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) to a FDC of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing DTG and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed Human Immunodeficiency Virus- 1 (HIV-1) infected adults.

Detailed description:

Arms: arm 1: B/F/TAF + ABC/DTG/3TC placebo for at least 48 weeks arm 2: ABC/DTG/3TC + B/F/TAF placebo for at least 48 weeks arm 3: At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.
Interventions: intervention 1: ABC/DTG/3TC intervention 2: B/F/TAF intervention 3: ABC/DTG/3TC Placebo intervention 4: B/F/TAF Placebo
Intervention descriptions: intervention 1: 600/50/300 mg FDC tablets administered orally once daily without regard to food intervention 2: 50/200/25 mg FDC tablets administered orally once daily without regard to food intervention 3: Tablets administered orally once daily without regard to food intervention 4: Tablets administered orally once daily without regard to food

Protocol documents:
SAP_008.pdf: 


67$7,67,&$/$1$/<6,63/$1


6WXG\7LWOH
$3KDVH5DQGRPL]HG'RXEOH%OLQG6WXG\WR(YDOXDWHWKH
6DIHW\DQG(IILFDF\RI6ZLWFKLQJIURPD5HJLPHQRI'ROXWHJUDYLU
DQG$%&7&RUD)L[HG'RVH&RPELQDWLRQ)'&RI
$%&'7*7&WRD)'&RI*6)7$)LQ+,9,QIHFWHG
6XEMHFWVZKRDUH9LURORJLFDOO\6XSSUHVVHG


1DPHRI7HVW'UXJ
%LFWHJDYLU(PWULFLWDELQH7HQRIRYLU$ODIHQDPLGH
%)7$)*6)7$)


6WXG\1XPEHU
*686


3URWRFRO9HUVLRQ'DWH
$PHQGPHQW2FWREHU


$QDO\VLV7\SH
:HHN,QWHULP$QDO\VLV


$QDO\VLV3ODQ9HUVLRQ
9HUVLRQ


$QDO\VLV3ODQ'DWH
0D\


$QDO\VLV3ODQ$XWKRUV



&21),'(17,$/$1'35235,(7$5<,1)250$7,21
33'


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
7$%/(2)&217(176
7$%/(2)&217(176 
/,672),17(;77$%/(6 
/,672)$%%5(9,$7,216 
3+$50$&2.,1(7,&$%%5(9,$7,216 
 
,1752'8&7,21 
 
6WXG\2EMHFWLYHV 
 
6WXG\'HVLJQ 
 
6DPSOH6L]HDQG3RZHU 
 
7<3(2)3/$11('$1$/<6,6 
 
'DWD0RQLWRULQJ&RPPLWWHH$QDO\VHV 
 
,QWHULP$QDO\VHV 
 
:HHN$QDO\VLV 
 
)LQDO$QDO\VLV 
 
*(1(5$/&216,'(5$7,216)25'$7$$1$/<6(6 
 
$QDO\VLV6HWV 
 
$OO5DQGRPL]HG$QDO\VLV6HW 
 
)XOO$QDO\VLV6HW 
 
3HU3URWRFRO$QDO\VLV6HW 
 
6DIHW\$QDO\VLV6HW 
 
';$$QDO\VLV6HW 
 
3KDUPDFRNLQHWLF$QDO\VLV6HW 
 
3KDUPDFRNLQHWLF6XEVWXG\$QDO\VLV6HW 
 
6XEMHFW*URXSLQJ 
 
6WUDWDDQG&RYDULDWHV 
 
([DPLQDWLRQRI6XEMHFW6XEJURXSV 
 
6XEMHFW6XEJURXSVIRU(IILFDF\$QDO\VHV 
 
6XEMHFW6XEJURXSVIRU6DIHW\$QDO\VHV 
 
0XOWLSOH&RPSDULVRQV 
 
0LVVLQJ'DWDDQG2XWOLHUV 
 
0LVVLQJ'DWD 
 
2XWOLHUV 
 
'DWD+DQGOLQJ&RQYHQWLRQVDQG7UDQVIRUPDWLRQV 
 
$QDO\VLV:LQGRZV 
 
'HILQLWLRQRI6WXG\'D\ 
 
$QDO\VLV:LQGRZV 
 
6HOHFWLRQRI'DWDLQWKH(YHQWRI0XOWLSOH5HFRUGVLQDQ$QDO\VLV
:LQGRZ 
 
68%-(&7',6326,7,21 
 
6XEMHFW(QUROOPHQWDQG'LVSRVLWLRQ 
 
6XEMHFW(QUROOPHQW 
 
6XEMHFW'LVSRVLWLRQ 
 
([WHQWRI6WXG\'UXJ([SRVXUHDQG$GKHUHQFH 
 
'XUDWLRQRI([SRVXUHWR6WXG\'UXJ 
 
$GKHUHQFHWR6WXG\'UXJ5HJLPHQ 
 
3URWRFRO'HYLDWLRQV 
 
%$6(/,1(&+$5$&7(5,67,&6 


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
 
'HPRJUDSKLFVDQG%DVHOLQH&KDUDFWHULVWLFV 
 
%DVHOLQH'LVHDVH&KDUDFWHULVWLFV 
 
0HGLFDO+LVWRU\ 
 
()),&$&<$1$/<6(6 
 
3ULPDU\(IILFDF\(QGSRLQW 
 
'HILQLWLRQRIWKH3ULPDU\(IILFDF\(QGSRLQW 
 
86)'$'HILQHG6QDSVKRW$OJRULWKP 
 
6WDWLVWLFDO+\SRWKHVLVIRUWKH3ULPDU\(IILFDF\(QGSRLQW 
 
3ULPDU\$QDO\VLVRIWKH3ULPDU\(IILFDF\(QGSRLQW 
 
6HFRQGDU\$QDO\VLVRIWKH3ULPDU\(IILFDF\(QGSRLQW 
 
6HFRQGDU\(IILFDF\(QGSRLQWV 
 
'HILQLWLRQRIWKH6HFRQGDU\(IILFDF\(QGSRLQWV 
 
$QDO\VLVRIWKH6HFRQGDU\(IILFDF\(QGSRLQWV 
 
7HUWLDU\(IILFDF\(QGSRLQWV 
 
'HILQLWLRQRIWKH7HUWLDU\(IILFDF\(QGSRLQWV 
 
$QDO\VLVRIWKH7HUWLDU\(IILFDF\(QGSRLQWV 
 
&KDQJHV)URP3URWRFRO6SHFLILHG(IILFDF\$QDO\VHV 
 
6$)(7<$1$/<6(6 
 
$GYHUVH(YHQWVDQG'HDWKV 
 
$GYHUVH(YHQW'LFWLRQDU\ 
 
$GYHUVH(YHQW6HYHULW\ 
 
6HULRXV$GYHUVH(YHQWV 
 
7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV 
 
6XPPDULHVRI$GYHUVH(YHQWVDQG'HDWK 
 
$GGLWLRQDO$QDO\VLVRI$GYHUVH(YHQWV 
 
/DERUDWRU\(YDOXDWLRQV 
 
6XPPDULHVRI1XPHULF/DERUDWRU\5HVXOWV 
 
*UDGHG/DERUDWRU\9DOXHV 
 
0HWDEROLF/DERUDWRU\(YDOXDWLRQV 
 
/LYHU5HODWHG/DERUDWRU\(YDOXDWLRQV 
 
5HQDO5HODWHG/DERUDWRU\(YDOXDWLRQV 
 
%RQH6DIHW\$QDO\VHV 
 
%RQH0LQHUDO'HQVLW\ 
 
%RG\:HLJKW+HLJKWDQG9LWDO6LJQV 
 
3ULRUDQG&RQFRPLWDQW0HGLFDWLRQV 
 
1RQVWXG\'UXJ$QWLUHWURYLUDO0HGLFDWLRQV 
 
&RQFRPLWDQW1RQ$590HGLFDWLRQV 
 
(OHFWURFDUGLRJUDP5HVXOWV 
 
2WKHU6DIHW\0HDVXUHV 
 
6XEMHFW6XEJURXSIRU6DIHW\(QGSRLQWV 
 
&KDQJHV)URP3URWRFRO6SHFLILHG6DIHW\$QDO\VHV 
 
3+$50$&2.,1(7,&$1$/<6(6 
 
(VWLPDWLRQRI3KDUPDFRNLQHWLF3DUDPHWHUV 
 
$QDO\VLVIRU,QWHQVLYH3.3.6XEVWXG\$QDO\VLV6HW 
 
$QDO\VLVIRU7URXJKDQG3RVWGRVH3.3.$QDO\VLV6HW 
 
&KDQJHVIURP3URWRFRO6SHFLILHG3KDUPDFRNLQHWLF$QDO\VLV 
 
63(&,$/3238/$7,21$1$/<6(6 
 
$QDO\VHVIRU+,9+%9&RLQIHFWHG6XEMHFWV 
 
$QDO\VHVIRU+,9+&9&RLQIHFWHG6XEMHFWV 


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
 5()(5(1&(6 
 62)7:$5( 
 6$35(9,6,21 
 $33(1',&(6 

$SSHQGL[ 
6WXG\3URFHGXUHV7DEOHV 
$SSHQGL[ 
)ORZFKDUWRI86)'$GHILQHG6QDSVKRW$OJRULWKPIRU6ZLWFK7ULDO 
$SSHQGL[ 
5HJLRQ'HILQLWLRQ 
$SSHQGL[ 
6HOHFWHG0HGLFDO+LVWRU\ 
$SSHQGL[ 
+HSDWLF(YHQWV 
$SSHQGL[ 
3URJUDPPLQJ6SHFLILFDWLRQ 


/,672),17(;77$%/(6

7DEOH 
6XEMHFWV([FOXGHGIURP:HHN33$QDO\VLV6HW'XHWR3UHPDWXUH
'LVFRQWLQXDWLRQRI6WXG\'UXJDQGRU0LVVLQJ+,951$$VVHVVPHQWLQ:HHN
$QDO\VLV:LQGRZ 
7DEOH 
$QDO\VLV:LQGRZVIRU+,951$&'FHOOFRXQW&'+HPDWRORJ\
&KHPLVWU\8ULQDO\VLVDQG8ULQH3UHJQDQF\/DERUDWRU\7HVWVH*)5&*9LWDO
6LJQVDQG:HLJKW 
7DEOH 
$QDO\VLV:LQGRZVIRU0HWDEROLF$VVHVVPHQWV 
7DEOH 
$QDO\VLV:LQGRZVIRU76+DQG5HQDO)XQFWLRQ 
7DEOH 
$QDO\VLV:LQGRZVIRU+%9DQG+&96HURORJ\+%9'1$DQG+&951$
$VVHVVPHQWV 
7DEOH 
$QDO\VLV:LQGRZVIRU6DIHW\(&* 
7DEOH 
$QDO\VLV:LQGRZVIRU';$%0' 
7DEOH 
1RUPDO2VWHRSHQLDDQG2VWHRSRURVLVDV'HILQHGE\7VFRUH 
7DEOH 
7UHDWPHQWDQG$VVRFLDWHG$QDO\WHV 


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
/,672)$%%5(9,$7,216

7&
ODPLYXGLQH
$%&
DEDFDYLU
$%&'7*7&
IL[HGGRVHFRPELQDWLRQRIDEDFDYLU$%&PJGROXWHJUDYLU'7*PJ
ODPLYXGLQH7&PJ
$(
DGYHUVHHYHQW
$/3
DONDOLQHSKRVSKDWDVH
$/7
DODQLQHDPLQRWUDQVIHUDVH
$129$
DQDO\VLVRIYDULDQFH
$59
DQWLUHWURYLUDO
$57
DQWLUHWURYLUDOWUHDWPHQW
$67
DVSDUWDWHDPLQRWUDQVIHUDVH
%,&
ELFWHJUDYLU
%)7$)
IL[HGGRVHFRPELQDWLRQRIELFWHJUDYLU%,&%PJHPWULFLWDELQH)7&)PJ
WHQRIRYLUDODIHQDPLGH7$)PJ
%/4
EHORZOLPLWRITXDQWLWDWLRQ
%0'
ERQHPLQHUDOGHQVLW\
%0,
ERG\PDVVLQGH[
&'(5
&HQWHUIRU'UXJ(YDOXDWLRQDQG5HVHDUFK
&*
&RFNFURIW*DXOW
&,
FRQILGHQFHLQWHUYDO
&0+
&RFKUDQ0DQWHO+DHQV]HO
&5)
FDVHUHSRUWIRUP
&65
FOLQLFDOVWXG\UHSRUW
&9
FRHIILFLHQWRIYDULDWLRQ
'&
SUHPDWXUHVWXG\GUXJGLVFRQWLQXDWLRQ
'1$
GHR[\ULERQXFOHLFDFLG
'63+
'UXJ6DIHW\DQG3XEOLF+HDOWK
'7*
GROXWHJUDYLUWLYLFD\
';$
GXDOHQHUJ\[UD\DEVRUSWLRPHWU\
(&*
HOHFWURFDUGLRJUDP
H&5)
HOHFWURQLFFDVHUHSRUWIRUP
H*)5
HVWLPDWHGJORPHUXODUILOWUDWLRQUDWH
H*)5&*
HVWLPDWHGJORPHUXODUILOWUDWLRQUDWHXVLQJ&RFNFURIW*DXOWIRUPXOD
)$6
IXOODQDO\VLVVHW
)'$
)RRGDQG'UXJ$GPLQLVWUDWLRQ
)'&
IL[HGGRVHFRPELQDWLRQ
)7$)
IL[HGGRVHFRPELQDWLRQRIHPWULFLWDELQH)7&)WHQRIRYLUDODIHQDPLGH7$)
)7&)
HPWULFLWDELQH
*(1
*HQYR\D(&)7$)


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
*)5
JORPHUXODUILOWUDWLRQUDWH
*LOHDG
*LOHDG6FLHQFHV,QF
*6
ELFWHJUDYLU
+%F$E
KHSDWLWLV%FRUHDQWLERG\
+%H$E
KHSDWLWLV%HDQWLERG\
+%H$J
KHSDWLWLV%HDQWLJHQ
+%V$E
KHSDWLWLV%VXUIDFHDQWLERG\
+%V$J
KHSDWLWLV%VXUIDFHDQWLJHQ
+%9
KHSDWLWLV%YLUXV
+&9
KHSDWLWLV&YLUXV
+&9$E
KHSDWLWLV&DQWLERG\
+'/
KLJKGHQVLW\OLSRSURWHLQ
+,9
KXPDQLPPXQRGHILFLHQF\YLUXV7\SH
+/*7
KLJKOHYHOJURXSWHUP
+/7
KLJKOHYHOWHUP
,&+
,QWHUQDWLRQDO&RQIHUHQFHRQ+DUPRQLVDWLRQRI7HFKQLFDO5HTXLUHPHQWVIRU5HJLVWUDWLRQRI
3KDUPDFHXWLFDOVIRU+XPDQ8VH
,'
LGHQWLILFDWLRQ
,'0&
LQGHSHQGHQWGDWDPRQLWRULQJFRPPLWWHH
,:56
LQWHUDFWLYHZHEUHVSRQVHV\VWHP
/'/
ORZGHQVLW\OLSRSURWHLQ
//7
ORZHVWOHYHOWHUP
0HG'5$
0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV
0+
0DQWHO+DHQV]HO
3(3
SRVWH[SRVXUHSURSK\OD[LV
3U(3
SUHH[SRVXUHSURSK\OD[LV
3.
SKDUPDFRNLQHWLF
33
SHUSURWRFRO
37
SUHIHUUHGWHUP
4
TXDUWLOH
4
ILUVWTXDUWLOH
4
WKLUGTXDUWLOH
4'
RQFHGDLO\
5%3
UHWLQROELQGLQJSURWHLQ
51$
ULERQXFOHLFDFLG
6$(
VHULRXVDGYHUVHHYHQWV
6$3
VWDWLVWLFDODQDO\VLVSODQ
6'
VWDQGDUGGHYLDWLRQ
604
6WDQGDUGLVHG0HG'5$4XHU\
62&
V\VWHPRUJDQFODVV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
67%
VWULELOG
7$)
WHQRIRYLUDODIHQDPLGH
7)/
WDEOHVILJXUHVDQGOLVWLQJV
7)9
WHQRIRYLU
76+
WK\URLGVWLPXODWLQJKRUPRQHWK\URWURSLQ
8/1
XSSHUOLPLWRIQRUPDO
:+2
:RUOG+HDOWK2UJDQL]DWLRQ



%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
3+$50$&2.,1(7,&$%%5(9,$7,216

$8&ODVW
DUHDXQGHUWKHFRQFHQWUDWLRQYHUVXVWLPHFXUYHIURPWLPH]HURWRWKHODVWTXDQWLILDEOH
FRQFHQWUDWLRQ
$8&WDX
DUHDXQGHUWKHFRQFHQWUDWLRQYHUVXVWLPHFXUYHRYHUWKHGRVLQJLQWHUYDO
&ODVW
ODVWREVHUYHGTXDQWLILDEOHFRQFHQWUDWLRQRIWKHGUXJLQSODVPD
&PD[
PD[LPXPREVHUYHGFRQFHQWUDWLRQRIGUXJLQSODVPD
&WDX
REVHUYHGGUXJFRQFHQWUDWLRQDWWKHHQGRIWKHGRVLQJLQWHUYDO
&/VV)
DSSDUHQWRUDOFOHDUDQFHDIWHUDGPLQLVWUDWLRQRIWKHGUXJ
DWVWHDG\VWDWH&/VV) 'RVH$8&WDXZKHUH³'RVH´LVWKHGRVHRIWKHGUXJ
/$0%'$=O]
WHUPLQDOHOLPLQDWLRQUDWHFRQVWDQWHVWLPDWHGE\OLQHDUUHJUHVVLRQRIWKHWHUPLQDOHOLPLQDWLRQ
SKDVHRIWKHSODVPDFRQFHQWUDWLRQRIGUXJYHUVXVWLPHFXUYH
7+$/)W
HVWLPDWHRIWKHWHUPLQDOHOLPLQDWLRQKDOIOLIHRIWKHGUXJLQSODVPDFDOFXODWHGE\GLYLGLQJ
WKHQDWXUDOORJRIE\WKHWHUPLQDOHOLPLQDWLRQUDWHFRQVWDQWO]
7ODVW
WLPHREVHUYHGWLPHSRLQWRI&ODVW
7PD[
WLPHREVHUYHGWLPHSRLQWRI&PD[
9])
DSSDUHQWYROXPHRIGLVWULEXWLRQRIWKHGUXJ



%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

,1752'8&7,21
7KLVVWDWLVWLFDODQDO\VLVSODQ6$3GHVFULEHVWKHVWDWLVWLFDODQDO\VLVPHWKRGVDQGGDWD
SUHVHQWDWLRQVWREHXVHGLQWDEOHVILJXUHVDQGOLVWLQJV7)/VRIWKH:HHNLQWHULPDQDO\VLV
IRU6WXG\*686ZKLFKZLOOEHSHUIRUPHGZKHQDOOVXEMHFWVKDYHFRPSOHWHGWKHLU
:HHNYLVLWRUSUHPDWXUHO\GLVFRQWLQXHGIURPWKHVWXG\GUXJ7KLV6$3LVEDVHGRQWKHVWXG\
SURWRFRODPHQGPHQWGDWHG2FWREHUDQGWKHHOHFWURQLFFDVHUHSRUWIRUPH&5)7KH
6$3ZLOOEHILQDOL]HGEHIRUHGDWDEDVHILQDOL]DWLRQIRUWKHLQWHULPDQDO\VLV$Q\FKDQJHVPDGH
DIWHUWKHILQDOL]DWLRQRIWKH6$3ZLOOEHGRFXPHQWHGLQWKHFOLQLFDOVWXG\UHSRUW&65

6WXG\2EMHFWLYHV
7KHSULPDU\REMHFWLYHRIWKLVVWXG\LV
x 7RHYDOXDWHWKHHIILFDF\RIVZLWFKLQJIURPDUHJLPHQRI'7*DQG$%&7&RUDIL[HGGRVH
FRPELQDWLRQ)'&RIDEDFDYLUGROXWHJUDYLUODPLYXGLQH$%&'7*7&WRD)'&RI
ELFWHJUDYLU*6%,&%HPWULFLWDELQH)7&)WHQRIRYLUDODIHQDPLGH7$)YHUVXV
FRQWLQXLQJ'7*DQG$%&7&DVWKH)'&$%&'7*7&LQYLURORJLFDOO\VXSSUHVVHG
+,9LQIHFWHGVXEMHFWVDVGHWHUPLQHGE\WKHSURSRUWLRQRIVXEMHFWVZLWK+,9ULERQXFOHLF
DFLG51$FRSLHVP/DW:HHN
7KHVHFRQGDU\REMHFWLYHVRIWKLVVWXG\DUH
x 7RHYDOXDWHWKHVDIHW\DQGWROHUDELOLW\RIWKHWZRWUHDWPHQWJURXSVWKURXJK:HHN
x 7RHYDOXDWHWKHERQHVDIHW\RIWKHWZRWUHDWPHQWJURXSVDVGHWHUPLQHGE\WKHSHUFHQWDJH
FKDQJHIURPEDVHOLQHLQKLSDQGVSLQHERQHPLQHUDOGHQVLW\%0'WKURXJK:HHN

6WXG\'HVLJQ
'HVLJQ&RQILJXUDWLRQDQG6XEMHFW3RSXODWLRQ
*686LVDUDQGRPL]HGGRXEOHEOLQGHGPXOWLFHQWHUDFWLYHFRQWUROOHGVWXG\WRHYDOXDWH
WKHVDIHW\DQGHIILFDF\RIVZLWFKLQJWRD)'&RI%)7$)WDEOHWYHUVXVFRQWLQXLQJ'7*DQG
$%&7&DVWKH)'&$%&'7*7&LQ+,9LQIHFWHGVXEMHFWVZKRDUHYLURORJLFDOO\VXSSUHVVHG
7UHDWPHQW*URXSV
6XEMHFWVZKRSURYLGHZULWWHQFRQVHQWDQGPHHWDOOHOLJLELOLW\FULWHULDZLOOEHUDQGRPL]HGLQD
UDWLRWRRQHRIWKHIROORZLQJWUHDWPHQWJURXSV
x 7UHDWPHQW*URXS)'&RIELFWHJUDYLUPJHPWULFLWDELQHPJWHQRIRYLUDODIHQDPLGH
PJ%)7$)3ODFHERWRPDWFK)'&RIDEDFDYLUPJGROXWHJUDYLUPJODPLYXGLQH
PJ$%&'7*7&DGPLQLVWHUHGRUDOO\RQFHGDLO\ZLWKRXWUHJDUGWRIRRGQ 
x 7UHDWPHQW*URXS)'&RIDEDFDYLUPJGROXWHJUDYLUPJODPLYXGLQHPJ
$%&'7*7&3ODFHERWRPDWFK)'&RIELFWHJUDYLUPJHPWULFLWDELQHPJWHQRIRYLU
DODIHQDPLGHPJ%)7$)DGPLQLVWHUHGRUDOO\RQFHGDLO\ZLWKRXWUHJDUGWRIRRGQ 


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
.H\(OLJLELOLW\&ULWHULD
0HGLFDOO\VWDEOH+,9LQIHFWHGVXEMHFWVZKRPHHWWKHIROORZLQJFULWHULD
x &XUUHQWO\UHFHLYLQJDQDQWLUHWURYLUDOUHJLPHQRI'7*$%&7&RU$%&'7*7&)'&
IRUPRQWKVSULRUWRVFUHHQLQJ
x &XUUHQWO\RQDVWDEOHUHJLPHQIRUPRQWKVSUHFHGLQJWKH6FUHHQLQJYLVLWZLWKGRFXPHQWHG
SODVPD+,951$FRSLHVP/IRUPRQWKVSUHFHGLQJWKH6FUHHQLQJYLVLWRU
XQGHWHFWDEOH+,951$OHYHODFFRUGLQJWRWKHORFDODVVD\EHLQJXVHGLIWKHOLPLWRI
GHWHFWLRQLVFRSLHVP/
 3ULRUFKDQJHVLQDQWLUHWURYLUDOUHJLPHQDUHRQO\DOORZHGGXHWRWROHUDELOLW\LVVXHVRUIRU
UHJLPHQVLPSOLILFDWLRQ8QFRQILUPHGYLURORJLFHOHYDWLRQVRIFRSLHVP/WUDQVLHQW
GHWHFWDEOHYLUHPLDRU³EOLS´SULRUWRVFUHHQLQJDUHDFFHSWDEOH,IWKHORZHUOLPLWRI
GHWHFWLRQRIWKHORFDO+,951$DVVD\LVFRSLHVP/HJFRSLHVP/WKH
SODVPD+,951$OHYHOFDQQRWH[FHHGFRSLHVP/RQWZRFRQVHFXWLYH+,951$
WHVWV
x (VWLPDWHG*)5P/PLQDFFRUGLQJWRWKH&RFNFURIW*DXOWIRUPXODIRUFUHDWLQLQH
FOHDUDQFH
x 1RFKURQLF+HSDWLWLV%9LUXV+%9LQIHFWLRQDVGHWHUPLQHGE\HLWKHU
 3RVLWLYH+%9VXUIDFHDQWLJHQ+%V$JDQGQHJDWLYH+%9VXUIDFHDQWLERG\+%V$E
UHJDUGOHVVRI+%9FRUHDQWLERG\+%F$EVWDWXVDWWKHVFUHHQLQJYLVLW
 3RVLWLYH+%9FRUHDQWLERG\DQGQHJDWLYH+%9VXUIDFHDQWLERG\UHJDUGOHVVRI+%9
VXUIDFHDQWLJHQVWDWXVDWWKHVFUHHQLQJYLVLW
6WXG\3HULRGV3KDVHV
6XEMHFWVZLOOEHWUHDWHGIRUDWOHDVWZHHNVGXULQJWKHEOLQGHGWUHDWPHQWSKDVH$IWHU:HHN
DOOVXEMHFWVZLOOFRQWLQXHWRWDNHWKHLUEOLQGHGVWXG\GUXJDQGDWWHQGYLVLWVHYHU\ZHHNVXQWLO
WKH(QGRI%OLQGHG7UHDWPHQW9LVLW2QFHWKHODVWVXEMHFWFRPSOHWHVWKH:HHNYLVLWDQG
*LOHDG6FLHQFHV,QF*LOHDGFRPSOHWHVWKH:HHNDQDO\VLVDOOVXEMHFWVZLOOUHWXUQWRWKH
FOLQLFSUHIHUDEOHZLWKLQGD\VIRUDQ(QGRI%OLQGHG7UHDWPHQW9LVLW$WWKH(QGRI%OLQGHG
7UHDWPHQW9LVLWLIVDIHW\DQGHIILFDF\RI%)7$)DUHGHPRQVWUDWHGIROORZLQJUHYLHZRI
XQEOLQGHGGDWDVXEMHFWVLQDFRXQWU\ZKHUH%)7$))'&LVQRWDYDLODEOHZLOOEHJLYHQWKH
RSWLRQWRUHFHLYH%)7$))'&LQDQRSHQODEHO2/H[WHQVLRQSKDVHIRUXSWRZHHNVRU
XQWLOWKHSURGXFWEHFRPHVDFFHVVLEOHWRVXEMHFWVWKURXJKDQDFFHVVSURJUDPRUXQWLO*LOHDG
HOHFWVWRGLVFRQWLQXHWKHVWXG\LQWKDWFRXQWU\ZKLFKHYHURFFXUVILUVW
$OOVXEMHFWVSDUWLFLSDWLQJLQWKH2/H[WHQVLRQSKDVHZLWKRXWUHJDUGWRWKHLUEOLQGHGWUHDWPHQW
UHJLPHQZLOOUHWXUQIRUVWXG\YLVLWVDW:HHN2/DQGHYHU\ZHHNVWKHUHDIWHUIRUXSWR
ZHHNV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
6XEMHFWVZKRFRPSOHWHWKHVWXG\WKURXJKWKH(QGRI%OLQGHG7UHDWPHQW9LVLWDQGGRQRW
FRQWLQXHRQWKH2/%)7$))'&H[WHQVLRQSKDVHZLOOEHUHTXLUHGWRUHWXUQWRWKHFOLQLF
GD\VDIWHUWKH(QGRI%OLQGHG7UHDWPHQWYLVLWIRUD'D\)ROORZ8S9LVLW
7UHDWPHQWDVVLJQPHQWVZLOOEHSURYLGHGWRWKHLQYHVWLJDWRUVZLWKLQGD\VRIWKHODVWVXEMHFW
FRPSOHWLQJWKH(QGRI%OLQGHG7UHDWPHQW9LVLW
6FKHGXOHRI$VVHVVPHQWV
$IWHUVFUHHQLQJSURFHGXUHVHOLJLEOHVXEMHFWVZLOOEHUDQGRPL]HGWR7UHDWPHQW*URXSRU
7UHDWPHQW*URXSDQGWUHDWHGIRUZHHNV)ROORZLQJWKH'D\YLVLWVXEMHFWVZLOOUHWXUQIRU
VWXG\YLVLWVDW:HHNVDQGDQGWKHQHYHU\ZHHNVWKURXJK:HHN$IWHU:HHNDOO
VXEMHFWVZLOOFRQWLQXHWRWDNHWKHLUEOLQGHGVWXG\GUXJVDQGDWWHQGVWXG\YLVLWVHYHU\ZHHNV
XQWLOWKH(QGRI%OLQGHG7UHDWPHQW9LVLW
)RUDOOHOLJLEOHVXEMHFWVEORRGZLOOEHFROOHFWHGDW'D\:HHNVDQGWKHQHYHU\
ZHHNVWKURXJKWKH(QGRI%OLQGHG7UHDWPHQWYLVLW/DERUDWRU\DQDO\VHVKHPDWRORJ\
FKHPLVWU\DQGXULQDO\VLV+,951$&'FHOOFRXQWDQGFRPSOHWHRUV\PSWRPGLUHFWHG
SK\VLFDOH[DPLQDWLRQVZLOOEHSHUIRUPHGDWWKH6FUHHQLQJ'D\DQGDOOVXEVHTXHQWVWXG\YLVLWV
,QDGGLWLRQEORRGZLOOEHFROOHFWHGDQGVWRUHGIRUSRVVLEOHHYDOXDWLRQRIPDUNHUVRI
LQIODPPDWLRQDQGLPPXQHDFWLYDWLRQZKLFKPD\LQFOXGHEXWQRWOLPLWHGWRF\VWDWLQ&,/
KV&53GGLPHUV&'DQGV&'3ODWHOHWIXQFWLRQHYDOXDWLRQVPD\DOVREHDVVHVVHG
LQFOXGLQJEXWQRWOLPLWHGWRVROXEOHJO\FRSURWHLQ9,V*39,3VHOHFWLQDQGVROXEOH&'
OLJDQG8ULQHZLOOEHFROOHFWHGIRUHYDOXDWLRQVRIUHQDOIXQFWLRQLQFOXGLQJXULQHDOEXPLQXULQH
FUHDWLQLQHXULQHSURWHLQUHWLQROELQGLQJSURWHLQ5%3DQGEHWDPLFURJOREXOLQ
)RUDOOVXEMHFWVRQVWXG\GUXJH[FHSWVXEMHFWVORFDWHGLQ*HUPDQ\GXDOHQHUJ\[UD\
DEVRUSWLRPHWU\';$VFDQVZLOOEHSHUIRUPHGSULRUWRRUZLWKLQKRXUVRIWKH'D\9LVLW
DQGWKHQDW:HHNVDQGDWWKH(QGRI%OLQGHG7UHDWPHQW9LVLWRU(DUO\6WXG\'UXJ
'LVFRQWLQXDWLRQ9LVLWEOLQGHGWUHDWPHQWSKDVHRQO\LI!ZHHNVVLQFHODVWVFDQ';$VFDQ
UHVXOWVZLOOEHSURYLGHGWRVWXG\VLWHVZKHQDYDLODEOH
$GYHUVHHYHQWVDQGFRQFRPLWDQWPHGLFDWLRQVZLOOEHDVVHVVHGDWHDFKYLVLW
0RUHGHWDLOVIRUVWXG\SURFHGXUHFRXOGEHIRXQGLQ$SSHQGL[
3KDUPDFRNLQHWLFV
$QLQWHQVLYHSKDUPDFRNLQHWLF3.VXEVWXG\ZLOOEHSHUIRUPHGDWWKH:HHNVRUYLVLWVLQD
VXEVHWRIVXEMHFWVWDUJHWQ DWVWXG\VLWHVDEOHWRFRQGXFWWKLVWHVWLQJ
)RUDOOVXEMHFWVRQVWXG\GUXJDVLQJOHDQ\WLPHSUHRUSRVWGRVH3.EORRGVDPSOHZLOOEH
FROOHFWHGDW:HHNVDQG
)RUDOOVXEMHFWVRQVWXG\GUXJDWURXJK3.EORRGVDPSOHZLOOEHREWDLQHGKRXUVIROORZLQJ
WKHODVWGRVHDW:HHNVDQG)ROORZLQJDQREVHUYHGGRVHRQHSRVWGRVH3.EORRGVDPSOH
ZLOOEHFROOHFWHGEHWZHHQDQGKRXUVSRVWGRVH


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
5DQGRPL]DWLRQ
6XEMHFWVZLOOEHUDQGRPL]HGLQDUDWLRWRRI7UHDWPHQW*URXSV
7UHDWPHQW*URXS7UHDWPHQW*URXS
6LWHDQGRU6WUDWXP(QUROOPHQW/LPLWV
$SSUR[LPDWHO\VWXG\VLWHVLQ1RUWK$PHULFD(XURSHDQG$VLD3DFLILFSDUWLFLSDWHG7KHUH
ZDVQRHQUROOPHQWOLPLWIRULQGLYLGXDOVLWHV
6WXG\'XUDWLRQ
7KHUDQGRPL]HGGRXEOHEOLQGSKDVHRIWKLVVWXG\LVDWOHDVWZHHNVLQGXUDWLRQ

6DPSOH6L]HDQG3RZHU
$WRWDORIDSSUR[LPDWHO\+,9LQIHFWHGVXEMHFWVUDQGRPL]HGLQDUDWLRWRWUHDWPHQW
JURXSVVXEMHFWVSHUWUHDWPHQWJURXSDFKLHYHVDWOHDVWSRZHUWRGHWHFWD
QRQLQIHULRULW\PDUJLQRIGLIIHUHQFHLQWKHSHUFHQWDJHRIVXEMHFWVZLWK+,951$
FRSLHVP/DW:HHNEHWZHHQWKHWUHDWPHQWJURXSV)RUWKHVDPSOHVL]HDQGSRZHU
FRPSXWDWLRQLWLVDVVXPHGWKDWERWKWUHDWPHQWJURXSVKDYHRIVXEMHFWVZLWK+,951$
FRSLHVP/DW:HHNEDVHGRQWKHKLVWRULFDO*LOHDG*HQYR\D*(1(&)7$)DQG
VWULELOG>67%@VWXGLHVWKDWWKHQRQLQIHULRULW\PDUJLQLVDQGWKDWWKHVLJQLILFDQFHOHYHORI
WKHWHVWLVDWDRQHVLGHGOHYHO6DPSOHVL]HDQGSRZHUFDOFXODWLRQVZHUHPDGHXVLQJWKH
VWDWLVWLFDOVRIWZDUHSDFNDJHQ4XHU\$GYLVRU9HUVLRQ


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

7<3(2)3/$11('$1$/<6,6

'DWD0RQLWRULQJ&RPPLWWHH$QDO\VHV
7KH:HHN,QGHSHQGHQW'DWD0RQLWRULQJ&RPPLWWHH,'0&DQDO\VLVZDVFRQGXFWHGDIWHU
DSSUR[LPDWHO\WKHILUVWRIVXEMHFWVHQUROOHGFRPSOHWHGWKHLU:HHNYLVLWRUSUHPDWXUHO\
GLVFRQWLQXHGWKHVWXG\GUXJ7KH:HHN,'0&DQDO\VLVZDVFRQGXFWHGDIWHUDOOVXEMHFWV
HQUROOHGFRPSOHWHGWKHLU:HHNYLVLWRUSUHPDWXUHO\GLVFRQWLQXHGWKHVWXG\GUXJ7KHSXUSRVH
RIWKHVHLQWHULPDQDO\VHVZDVWRSURYLGHWKH,'0&ZLWKDVWDWLVWLFDOUHSRUWIRUUHYLHZ0RUH
GHWDLOVDUHGRFXPHQWHGLQWKH,'0&FKDUWHU
*LOHDGGRHVQRWKDYHDSULRULQWHQWWRDVNWKH,'0&WRUHYLHZ:HHNUHVXOWVRUWRFRQVLGHU
HDUO\WHUPLQDWLRQRIWKHVWXG\HYHQLIWKHUHLVHDUO\HYLGHQFHRIIDYRUDEOHHIILFDF\IRU%)7$)

,QWHULP$QDO\VHV

:HHN$QDO\VLV
7KH:HHNDQDO\VLVZLOOEHFRQGXFWHGDIWHUDOOVXEMHFWVHLWKHUFRPSOHWHWKHLU:HHNYLVLWRU
SUHPDWXUHO\GLVFRQWLQXHIURPWKHVWXG\GUXJ
7KLVVWDWLVWLFDODQDO\VLVSODQGHVFULEHVWKHDQDO\VLVSODQIRUWKH:HHNLQWHULPDQDO\VLVWKH
SULPDU\DQDO\VLVRIWKLVVWXG\

)LQDO$QDO\VLV
7KHILQDOVWDWLVWLFDODQDO\VLVZLOOEHFRQGXFWHGDIWHUDOOVXEMHFWVHLWKHUFRPSOHWHWKHVWXG\RU
SUHPDWXUHO\GLVFRQWLQXHIURPWKHVWXG\


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

*(1(5$/&216,'(5$7,216)25'$7$$1$/<6(6
$QDO\VLVUHVXOWVZLOOEHSUHVHQWHGXVLQJGHVFULSWLYHVWDWLVWLFV)RUFDWHJRULFDOYDULDEOHVWKH
QXPEHUDQGSHUFHQWDJHRIVXEMHFWVLQHDFKFDWHJRU\ZLOOEHSUHVHQWHGIRUFRQWLQXRXVYDULDEOHV
WKHQXPEHURIVXEMHFWVQPHDQVWDQGDUGGHYLDWLRQ6'RUVWDQGDUGHUURU6(PHGLDQILUVW
TXDUWLOH4WKLUGTXDUWLOH4PLQLPXPDQGPD[LPXPZLOOEHSUHVHQWHG
$OOVWDWLVWLFDOWHVWVZLOOEHVLGHGDQGSHUIRUPHGDWWKHVLJQLILFDQFHOHYHOXQOHVVRWKHUZLVH
VSHFLILHG
%\VXEMHFWOLVWLQJVZLOOEHSUHVHQWHGIRUDOOVXEMHFWVLQWKH$OO5DQGRPL]HGDQDO\VLVVHWXQOHVV
RWKHUZLVHVSHFLILHGDQGVRUWHGE\VXEMHFW,'QXPEHUYLVLWGDWHDQGWLPHLIDSSOLFDEOH'DWD
FROOHFWHGRQORJIRUPVVXFKDV$(VZLOOEHSUHVHQWHGLQFKURQRORJLFDORUGHUZLWKLQDVXEMHFW
7KHWUHDWPHQWJURXSWRZKLFKVXEMHFWVZHUHUDQGRPL]HGZLOOEHXVHGLQWKHOLVWLQJV
,QJHQHUDODJHLQ\HDUVRQWKHGDWHRIWKHILUVWGRVHRIVWXG\GUXJZLOOEHXVHGIRUDQDO\VHVDQG
SUHVHQWDWLRQLQOLVWLQJV)RUUDQGRPL]HGEXWQHYHUGRVHGVXEMHFWVDJHRQWKHGDWHRI
UDQGRPL]DWLRQZLOOEHXVHG)RUVFUHHQIDLOXUHVDJHRQWKHGDWHRIWKHLQIRUPHGFRQVHQWZDV
VLJQHGZLOOEHXVHG,IRQO\ELUWK\HDULVFROOHFWHGRQWKHH&5)³-DQXDU\´ZLOOEHXVHGIRUWKH
XQNQRZQELUWKGD\DQGPRQWKIRUWKHSXUSRVHRIDJHFDOFXODWLRQVLPLODUO\LIRQO\ELUWK\HDUDQG
PRQWKDUHFROOHFWHGRQWKHH&5)³´ZLOOEHXVHGIRUWKHXQNQRZQELUWKGD\IRUWKHSXUSRVHRI
DJHFDOFXODWLRQ
,QJHQHUDOSHUPDQHQWGLVFRQWLQXDWLRQRIVWXG\GUXJUHIHUVWRSUHPDWXUHGLVFRQWLQXDWLRQRIVWXG\
GUXJRUFRPSOHWLRQRIVWXG\GUXJ

$QDO\VLV6HWV
$QDO\VLVVHWVGHILQHWKHVXEMHFWVWREHLQFOXGHGLQDQDQDO\VLV$QDO\VLVVHWVDQGWKHLUGHILQLWLRQV
DUHSURYLGHGLQWKLVVHFWLRQ6XEMHFWVLQFOXGHGLQHDFKDQDO\VLVVHWZLOOEHGHWHUPLQHGEHIRUHWKH
VWXG\EOLQGLVEURNHQIRUDQDO\VLV7KHDQDO\VLVVHWZLOOEHLQFOXGHGDVDVXEWLWOHRIHDFKWDEOH
ILJXUHDQGOLVWLQJ$VXPPDU\RIWKHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVLQHDFKDQDO\VLVVHWZLOO
EHSURYLGHGE\WUHDWPHQWJURXSDQGLQWRWDO

$OO5DQGRPL]HG$QDO\VLV6HW
7KH$OO5DQGRPL]HG$QDO\VLV6HWZLOOLQFOXGHDOOVXEMHFWVZKRDUHUDQGRPL]HGLQWRWKHVWXG\
7KLVLVWKHSULPDU\DQDO\VLVVHWIRUE\VXEMHFWOLVWLQJV

)XOO$QDO\VLV6HW
7KH)XOO$QDO\VLV6HW)$6ZLOOLQFOXGHDOOVXEMHFWVZKRDUHUDQGRPL]HGLQWRWKHVWXG\DQG
KDYHUHFHLYHGDWOHDVWGRVHRIVWXG\GUXJ6XEMHFWVZLOOEHJURXSHGDFFRUGLQJWRWKH
WUHDWPHQWWRZKLFKWKH\ZHUHUDQGRPL]HG)RUWKH)$6DOOHIILFDF\GDWDLQFOXGLQJGDWD
FROOHFWHGDIWHUWKHODVWGRVHRIVWXG\GUXJZLOOEHLQFOXGHGXQOHVVVSHFLILHGRWKHUZLVH7KLVLV
WKHSULPDU\DQDO\VLVVHWIRUHIILFDF\DQDO\VHV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

3HU3URWRFRO$QDO\VLV6HW
7KH:HHN3HU3URWRFRO33$QDO\VLV6HWZLOOLQFOXGHDOOVXEMHFWVZKRDUHUDQGRPL]HG
LQWRWKHVWXG\KDYHUHFHLYHGDWOHDVWGRVHRIVWXG\GUXJDQGKDYHQRWFRPPLWWHGDQ\
PDMRUSURWRFROYLRODWLRQLQFOXGLQJWKHYLRODWLRQRINH\HQWU\FULWHULD6XEMHFWVZLOOEHJURXSHG
DFFRUGLQJWRWKHWUHDWPHQWWKH\DFWXDOO\UHFHLYHG)RUWKH33DQDO\VLVHIILFDF\GDWDXSWRGD\
DIWHUSHUPDQHQWGLVFRQWLQXDWLRQRIVWXG\GUXJZLOOEHLQFOXGHG7KH:HHN33DQDO\VLVVHWLV
WKHVHFRQGDU\DQDO\VLVVHWIRUHIILFDF\DQDO\VLV
6XEMHFWVPHHWLQJDQ\RIWKHIROORZLQJFULWHULDZLOOEHH[FOXGHGIURPWKH:HHN33DQDO\VLV
VHW
x 6XEMHFWVZKRGRQRWKDYHRQWUHDWPHQW+,951$LQWKH:HHNDQDO\VLVZLQGRZH[FHSW
ZKHQPLVVLQJLVGXHWRGLVFRQWLQXDWLRQRIVWXG\GUXJIRUODFNRIHIILFDF\1RWHODFNRI
HIILFDF\LVGHILQHGDVKDYLQJWKHFKHFNER[IRU/DFNRI(IILFDF\PDUNHGDVWKHUHDVRQIRU
SUHPDWXUHVWXG\GUXJGLVFRQWLQXDWLRQLQWKH³%OLQGHG7UHDWPHQW´VWXG\SKDVHRQWKHVWXG\
GUXJFRPSOHWLRQH&5)SDJH7DEOH
7DEOH
6XEMHFWV([FOXGHGIURP:HHN33$QDO\VLV6HW'XHWR3UHPDWXUH
'LVFRQWLQXDWLRQRI6WXG\'UXJDQGRU0LVVLQJ+,951$
$VVHVVPHQWLQ:HHN$QDO\VLV:LQGRZ
'LVFRQWLQXDWLRQIURP6WXG\'UXJSULRUWRRURQWKH
8SSHU%RXQGRI:HHN$QDO\VLV:LQGRZ
+,951$'DWDRQ5DQGRPL]HG7UHDWPHQW
$YDLODEOHLQ:HHN$QDO\VLV:LQGRZ
<HV
1R
<HV
'XHWR/DFNRI(IILFDF\


'XHWR2WKHU5HDVRQV


1R


 ,QFOXVLRQRI6XEMHFWVLQ:HHN33DQDO\VLVVHW ([FOXVLRQRI6XEMHFWVLQ:HHN33DQDO\VLVVHW
x 6XEMHFWVZKRGRQRWPHHWWKHLQFOXVLRQFULWHULRQRIUHFHLYLQJDQDQWLUHWURYLUDOUHJLPHQRI
'7*$%&7&RU$%&'7*7&)'&IRUPRQWKVSULRUWRWKHVFUHHQLQJYLVLW
x 6XEMHFWVZKRGRQRWPHHWWKHLQFOXVLRQFULWHULRQRIEHLQJRQDVWDEOHUHJLPHQIRUPRQWKV
SUHFHGLQJWKHVFUHHQLQJYLVLWZLWKGRFXPHQWHGSODVPD+,951$FRSLHVP/IRU
PRQWKVSUHFHGLQJWKH6FUHHQLQJYLVLWRUXQGHWHFWDEOH+,951$OHYHODFFRUGLQJWRWKH
ORFDODVVD\EHLQJXVHGLIWKHOLPLWRIGHWHFWLRQLVFRSLHVP/
x 6XEMHFWVZKRGRQRWPHHWWKHLQFOXVLRQFULWHULRQRIKDYLQJQRGRFXPHQWHGRUVXVSHFWHG
UHVLVWDQFHWR)7&7)9'7*$%&RU7&LQFOXGLQJEXWQRWOLPLWHGWRWKHUHYHUVH
WUDQVFULSWDVHUHVLVWDQFHPXWDWLRQV.5DQG09,
x 6XEMHFWVZKRGRQRWPHHWWKHLQFOXVLRQFULWHULRQRIKDYLQJ+,951$FRSLHVP/DWWKH
VFUHHQLQJYLVLW


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
x 6XEMHFWVZKRPHHWWKHH[FOXVLRQFULWHULRQIRUUHFHLYLQJRQJRLQJWKHUDS\ZLWKDQ\RIWKH
PHGLFDWLRQVOLVWHGLQWKHWDEOHLQSURWRFRO6HFWLRQLQFOXGLQJGUXJVQRWWREHXVHGZLWK
%,&)7&7$)'7*$%&DQG7&
x 1RQDGKHUHQFHWRVWXG\GUXJVXEMHFWVZLWKDGKHUHQFHUDWHIRUDFWLYHVWXG\GUXJXSWRWKH
:HHN9LVLWEHORZWKHWKSHUFHQWLOH

6DIHW\$QDO\VLV6HW
7KH6DIHW\$QDO\VLV6HWZLOOLQFOXGHDOOVXEMHFWVZKRDUHUDQGRPL]HGLQWRWKHVWXG\DQG
KDYHUHFHLYHGDWOHDVWGRVHRIVWXG\GUXJ$OOWKHGDWDFROOHFWHGXSWRGD\VDIWHU
SHUPDQHQWGLVFRQWLQXDWLRQRIWKHVWXG\GUXJZLOOEHLQFOXGHGLQWKHVDIHW\VXPPDULHVXQOHVV
VSHFLILHGRWKHUZLVH6XEMHFWVZLOOEHJURXSHGDFFRUGLQJWRWKHWUHDWPHQWWKH\DFWXDOO\UHFHLYHG
7KLVLVWKHSULPDU\DQDO\VLVVHWIRUVDIHW\DQDO\VHV

';$$QDO\VLV6HW

+LS';$$QDO\VLV6HW
7KH+LS';$$QDO\VLV6HWZLOOLQFOXGHDOOVXEMHFWVZKRDUHUDQGRPL]HGLQWRWKHVWXG\
KDYHUHFHLYHGDWOHDVWGRVHRIVWXG\GUXJDQGKDYHQRQPLVVLQJEDVHOLQHKLS%0'
YDOXHV6XEMHFWVZLOOEHJURXSHGDFFRUGLQJWRWKHWUHDWPHQWWKH\DFWXDOO\UHFHLYHG

6SLQH';$$QDO\VLV6HW
7KH6SLQH';$$QDO\VLV6HWZLOOLQFOXGHDOOVXEMHFWVZKRDUHUDQGRPL]HGLQWRWKHVWXG\
KDYHUHFHLYHGDWOHDVWGRVHRIVWXG\GUXJDQGKDYHQRQPLVVLQJEDVHOLQHVSLQH%0'
YDOXHV6XEMHFWVZLOOEHJURXSHGDFFRUGLQJWRWKHWUHDWPHQWWKH\DFWXDOO\UHFHLYHG
)RUWKHKLS';$DQGVSLQH';$DQDO\VLVVHWVDOOGDWDLQFOXGLQJGDWDFROOHFWHGDIWHUWKHODVWGRVH
RIVWXG\GUXJZLOOEHXVHGIRUDQDO\VLVXQOHVVVSHFLILHGRWKHUZLVH

3KDUPDFRNLQHWLF$QDO\VLV6HW
7KH3.$QDO\VLV6HWZLOOLQFOXGHDOOVXEMHFWVZKRDUHUDQGRPL]HGLQWRWKHVWXG\
KDYHUHFHLYHGDWOHDVWGRVHRIDFWLYH%)7$)DQGKDYHDWOHDVWQRQPLVVLQJ3.
FRQFHQWUDWLRQYDOXHIRUDQ\DQDO\WHRILQWHUHVWUHSRUWHGE\WKH3.ODE7KH3.DQDO\VLVVHWZLOO
EHXVHGIRUJHQHUDO3.DQDO\VHV

3KDUPDFRNLQHWLF6XEVWXG\$QDO\VLV6HW
7KH3.6XEVWXG\$QDO\VLV6HWZLOOLQFOXGHDOOVXEMHFWVZKRDUHUDQGRPL]HGLQWRWKHVWXG\
DUHHQUROOHGLQWRWKH3.6XEVWXG\KDYHUHFHLYHGDWOHDVWGRVHRIDFWLYH%)7$)DQG
KDYHDWOHDVWQRQPLVVLQJLQWHQVLYH3.FRQFHQWUDWLRQYDOXHIRUDQ\DQDO\WHRILQWHUHVW
UHSRUWHGE\WKH3.ODE7KH3.VXEVWXG\DQDO\VLVVHWZLOOEHXVHGIRULQWHQVLYH3.DQDO\VHV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

6XEMHFW*URXSLQJ
)RUDQDO\VHVEDVHGRQWKH$OO5DQGRPL]HG$QDO\VLV6HWRUWKH)$6VXEMHFWVZLOOEHJURXSHGE\
UDQGRPL]HGWUHDWPHQW)RURWKHUDQDO\VHVVXEMHFWVZLOOEHJURXSHGE\DFWXDOWUHDWPHQWUHFHLYHG
7KHDFWXDOWUHDWPHQWUHFHLYHGZLOOGLIIHUIURPWKHUDQGRPL]HGWUHDWPHQWRQO\ZKHQWKHDFWXDO
WUHDWPHQWUHFHLYHGGLIIHUVIURPUDQGRPL]HGWUHDWPHQWIRUWKHHQWLUHWUHDWPHQWGXUDWLRQ

6WUDWDDQG&RYDULDWHV
7KHUHLVQRVWUDWLILFDWLRQIRUUDQGRPL]DWLRQ

([DPLQDWLRQRI6XEMHFW6XEJURXSV

6XEMHFW6XEJURXSVIRU(IILFDF\$QDO\VHV
7KHSURSRUWLRQRIVXEMHFWVZLWK+,951$FRSLHVP/DW:HHNDVGHWHUPLQHGE\WKH
86)'$GHILQHGVQDSVKRWDOJRULWKP^86'HSDUWPHQWRI+HDOWKDQG+XPDQ6HUYLFHV`
ZLOOEHDQDO\]HGIRUWKHIROORZLQJVXEMHFWVXEJURXSVDOVRVHH6HFWLRQIRUGHWDLOV
x $JH\HDUVDDQGE
x 6H[DPDOHDQGEIHPDOH
x 5DFHDEODFNDQGEQRQEODFN
x 5HJLRQD86DQGE([86
x 6WXG\GUXJDGKHUHQFHDDQGEEDVHGRQDGKHUHQFHXSWR:HHNYLVLW

6XEMHFW6XEJURXSVIRU6DIHW\$QDO\VHV
,QFLGHQFHRIDOOWUHDWPHQWHPHUJHQW$(V7($(VZLOOEHDQDO\]HGIRUWKHIROORZLQJVXEMHFW
VXEJURXSVDOVRVHH6HFWLRQ
x $JH\HDUVDDQGE
x 6H[DPDOHDQGEIHPDOH
x 5DFHDEODFNDQGEQRQEODFN
x 5HJLRQD86DQGE([86
6HOHFWHGVDIHW\HQGSRLQWVPD\EHDQDO\]HGIRUWKHIROORZLQJVXEMHFWVXEJURXSVVHH6HFWLRQ
IRUGHWDLOV
x 6XEMHFWVZLWKLQFLGHQW+,9+%9FRLQIHFWLRQZKLOHRQVWXG\GUXJLIDQ\


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
6HOHFWHGVDIHW\HQGSRLQWVZLOOEHDQDO\]HGIRUWKHIROORZLQJVXEMHFWVXEJURXSVVHH6HFWLRQ
IRUGHWDLOV
x 6XEMHFWVZLWK+,9KHSDWLWLV&YLUXV+&9FRLQIHFWLRQDWEDVHOLQH
x 6XEMHFWVZLWKLQFLGHQW+,9+&9FRLQIHFWLRQZKLOHRQVWXG\GUXJLIDQ\

0XOWLSOH&RPSDULVRQV
7KHQRQLQIHULRULW\HYDOXDWLRQRIWKHSURSRUWLRQRIVXEMHFWVZLWK+,951$FRSLHVP/DW
:HHNDVGHWHUPLQHGE\86)'$GHILQHGVQDSVKRWDOJRULWKPZDVWKHSUHVSHFLILHGSULPDU\
FRPSDULVRQ+RZHYHULQWHULP,'0&DQDO\VHVZHUHSHUIRUPHGSULRUWRWKHDQDO\VLVIRUWKH
SULPDU\HQGSRLQWDQGDQDOSKDSHQDOW\RIZDVDSSOLHGIRUHDFKLQWHULP,'0&PHHWLQJ
7KHUHIRUHWKHDOSKDOHYHOIRUWKHSULPDU\HQGSRLQWLHWKHSURSRUWLRQRIVXEMHFWVZLWK
+,951$FRSLHVP/DW:HHNDVGHWHUPLQHGE\WKH86)'$GHILQHGVQDSVKRW
DOJRULWKPZDVDGMXVWHGWRFRUUHVSRQGLQJWRFRQILGHQFHLQWHUYDO>&,@XVLQJ
ERWKWKH)$6DQGWKH:HHN33DQDO\VLVVHW7KHDOSKDOHYHOIRUWKHNH\VHFRQGDU\HIILFDF\
HQGSRLQWWKHSURSRUWLRQRIVXEMHFWVZLWK+,951$FRSLHVP/DW:HHNDVGHILQHGE\
WKH86)'$GHILQHGVQDSVKRWDOJRULWKPZLOOEHDOVRDGMXVWHGWRFRUUHVSRQGLQJWR
&,WREHFRQVHUYDWLYH

0LVVLQJ'DWDDQG2XWOLHUV

0LVVLQJ'DWD
$PLVVLQJGDWXPIRUDJLYHQVWXG\DQDO\VLVZLQGRZPD\EHGXHWRDQ\RIWKHIROORZLQJUHDVRQV
x $YLVLWRFFXUULQJLQWKHZLQGRZEXWGDWDZHUHQRWFROOHFWHGRUZHUHXQXVDEOH
x $YLVLWQRWRFFXUULQJLQWKHZLQGRZ
x $VXEMHFWSUHPDWXUHO\GLVFRQWLQXLQJIURPWKHVWXG\EHIRUHUHDFKLQJWKHZLQGRZ
,QJHQHUDOYDOXHVIRUPLVVLQJGDWDZLOOQRWEHLPSXWHGXQOHVVPHWKRGVIRUKDQGOLQJPLVVLQJGDWD
DUHVSHFLILHG
)RUPLVVLQJODVWGRVLQJGDWHRIVWXG\GUXJLPSXWDWLRQUXOHVDUHGHVFULEHGLQ6HFWLRQ7KH
KDQGOLQJRIPLVVLQJRULQFRPSOHWHGDWHVIRUDGYHUVHHYHQW$(RQVHWLVGHVFULEHGLQ
6HFWLRQDQGIRUFRQFRPLWDQWQRQ$59PHGLFDWLRQVLQ6HFWLRQ

2XWOLHUV
2XWOLHUVZLOOEHLGHQWLILHGGXULQJWKHGDWDPDQDJHPHQWDQGGDWDDQDO\VLVSURFHVVEXWQR
VHQVLWLYLW\DQDO\VHVZLOOEHGRQHWRHYDOXDWHWKHLPSDFWRIRXWOLHUVRQHIILFDF\RUVDIHW\
RXWFRPHVXQOHVVVSHFLILHGRWKHUZLVH$OOGDWDZLOOEHLQFOXGHGLQWKHDQDO\VHV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

'DWD+DQGOLQJ&RQYHQWLRQVDQG7UDQVIRUPDWLRQV
/DERUDWRU\GDWDWKDWDUHFRQWLQXRXVLQQDWXUHEXWDUHOHVVWKDQWKHORZHUOLPLWRITXDQWLWDWLRQRU
DERYHWKHXSSHUOLPLWRITXDQWLWDWLRQZLOOEHLPSXWHGDVIROORZVH[FHSWIRUXULQHFUHDWLQLQH
x $YDOXHWKDWLVXQLWOHVVWKDQWKHOLPLWRITXDQWLWDWLRQZLOOEHXVHGIRUFDOFXODWLRQRI
GHVFULSWLYHVWDWLVWLFVLIWKHGDWXPLVUHSRUWHGLQWKHIRUPRI³[´ZKHUH[LVFRQVLGHUHGWKH
OLPLWRITXDQWLWDWLRQ)RUH[DPSOHLIWKHYDOXHVDUHUHSRUWHGDVDQGYDOXHVRI
DQGUHVSHFWLYHO\ZLOOEHXVHGIRUFDOFXODWLRQRIVXPPDU\VWDWLVWLFV$QH[FHSWLRQWR
WKLVUXOHLVDQ\YDOXHUHSRUWHGDVRUHWF)RUYDOXHVUHSRUWHGDVRUDYDOXH
RIRUUHVSHFWLYHO\ZLOOEHXVHGIRUFDOFXODWLRQRIVXPPDU\VWDWLVWLFV
x $YDOXHWKDWLVXQLWDERYHWKHOLPLWRITXDQWLWDWLRQZLOOEHXVHGIRUFDOFXODWLRQRI
GHVFULSWLYHVWDWLVWLFVLIWKHGDWXPLVUHSRUWHGLQWKHIRUPRI³![´ZKHUH[LVFRQVLGHUHGWKH
OLPLWRITXDQWLWDWLRQ9DOXHVZLWKGHFLPDOSRLQWVZLOOIROORZWKHVDPHORJLFDVDERYH
x 7KHOLPLWRITXDQWLWDWLRQZLOOEHXVHGIRUFDOFXODWLRQRIGHVFULSWLYHVWDWLVWLFVLIWKHGDWXPLV
UHSRUWHGLQWKHIRUPRI³[´RU³[´ZKHUH[LVFRQVLGHUHGWKHOLPLWRITXDQWLWDWLRQ
)RUXULQHFUHDWLQLQHDYDOXHRI³´LVKDQGOHGDVDPLVVLQJYDOXHLQLWVVXPPDU\DQGWKH
FDOFXODWLRQRIUHODWHGUDWLRV
/RJDULWKPLFEDVHWUDQVIRUPDWLRQVZLOOEHDSSOLHGWR+,951$DQG+%9
'HR[\ULERQXFOHLF$FLG'1$GDWDIRUHIILFDF\DQDO\VHV+,951$UHVXOWVRIµ1R+,9
51$GHWHFWHG¶DQG³FSP/+,951$'HWHFWHG´ZLOOEHLPSXWHGDVFRSLHVP/IRU
DQDO\VLVSXUSRVHV+%9'1$UHVXOWVRI³,8P/+%9'1$GHWHFWHG´RU³1R+%9'1$
GHWHFWHG´ZLOOEHLPSXWHGDV,8P/IRUDQDO\VLVSXUSRVHV+&951$UHVXOWVRI³,8P/
+&951$GHWHFWHG´RU³1R+&951$GHWHFWHG´ZLOOEHLPSXWHGDV,8P/IRUDQDO\VLV
SXUSRVHV
1DWXUDOORJDULWKPLFWUDQVIRUPDWLRQVZLOOEHXVHGIRUDQDO\]LQJFRQFHQWUDWLRQVDQG3.SDUDPHWHUV
LQLQWHQVLYHSODVPDVDPSOHV&RQFHQWUDWLRQYDOXHVLQFOXGLQJLQWHQVLYHWURXJKSRVWGRVH
DQ\WLPH3.FRQFHQWUDWLRQHWFWKDWDUHEHORZWKHORZHUOLPLWRITXDQWLWDWLRQ%/4ZLOOEH
SUHVHQWHGDV³%/4´LQWKHFRQFHQWUDWLRQOLVWLQJ,QWHQVLYH3.FRQFHQWUDWLRQYDOXHVWKDWDUH%/4
ZLOOEHWUHDWHGDVDWSUHGRVHWLPHSRLQWVDQGRQHKDOIWKHYDOXHRIWKHORZHUOLPLWRI
TXDQWLWDWLRQ//24DWSRVWGRVHWLPHSRLQWVIRUVXPPDU\SXUSRVHV2WKHU3.FRQFHQWUDWLRQ
YDOXHVLQFOXGLQJWURXJKSUHGRVHSRVWGRVHDQ\WLPH3.FRQFHQWUDWLRQWKDWDUH%/4ZLOOEH
WUHDWHGDVRQHKDOIRIWKH//24
7KHIROORZLQJFRQYHQWLRQVZLOOEHXVHGIRUWKHSUHVHQWDWLRQRIRUGHUVWDWLVWLFVDQGVXPPDU\
VWDWLVWLFVIRULQWHQVLYH3.FRQFHQWUDWLRQ
x ,IDWOHDVWVXEMHFWKDVDFRQFHQWUDWLRQYDOXHRI%/4IRUWKHWLPHSRLQWWKHPLQLPXPYDOXH
ZLOOEHGLVSOD\HGDV³%/4´
x ,IPRUHWKDQRIWKHVXEMHFWVKDYHDFRQFHQWUDWLRQYDOXHRI%/4IRUDJLYHQWLPHSRLQW
WKHPLQLPXPDQG4YDOXHVZLOOEHGLVSOD\HGDV³%/4´


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
x ,IPRUHWKDQRIWKHVXEMHFWVKDYHDFRQFHQWUDWLRQYDOXHRI%/4IRUDJLYHQWLPHSRLQW
WKHPLQLPXP4DQGPHGLDQYDOXHVZLOOEHGLVSOD\HGDV³%/4´
x ,IPRUHWKDQRIWKHVXEMHFWVKDYHDFRQFHQWUDWLRQYDOXHRI%/4IRUDJLYHQWLPHSRLQW
WKHPLQLPXP4PHGLDQDQG4YDOXHVZLOOEHGLVSOD\HGDV³%/4´
x ,IDOOVXEMHFWVKDYHFRQFHQWUDWLRQYDOXHVRI%/4IRUDJLYHQWLPHSRLQWDOORUGHUVWDWLVWLFV
PLQLPXP4PHGLDQ4DQGPD[LPXPDQGVXPPDU\VWDWLVWLFVZLOOEHGLVSOD\HGDV
³%/4´

$QDO\VLV:LQGRZV

'HILQLWLRQRI6WXG\'D\
6WXG\'D\LVGHILQHGDVWKHGD\ZKHQWKHILUVWGRVHRIVWXG\GUXJLH%)7$)RU3ODFHERRU
$%&'7*7&RU3ODFHERZDVWDNHQDVUHFRUGHGRQWKH6WXG\'UXJ$GPLQLVWUDWLRQH&5)
IRUP
6WXG\'D\VDUHFDOFXODWHGUHODWLYHWR6WXG\'D\)RUHYHQWVWKDWRFFXUUHGRQRUDIWHUWKH
6WXG\'D\GDWHVWXG\GD\VDUHFDOFXODWHGDVYLVLWGDWHPLQXV6WXG\'D\SOXV)RUHYHQWV
WKDWRFFXUUHGSULRUWR6WXG\'D\VWXG\GD\VDUHFDOFXODWHGDVYLVLWGDWHPLQXV6WXG\'D\
/DVW'RVH'DWHLVWKHODWHVWRIWKHEOLQGHGVWXG\GUXJHQGGDWHVUHFRUGHGRQWKH6WXG\'UXJ
$GPLQLVWUDWLRQH&5)IRUPZLWK³3HUPDQHQWO\:LWKGUDZQ´ER[FKHFNHGIRUVXEMHFWVZKR
SUHPDWXUHO\GLVFRQWLQXHGRUFRPSOHWHGVWXG\GUXJLQWKH³%OLQGHG7UHDWPHQW´VWXG\SKDVH
DFFRUGLQJWRWKH6WXG\'UXJ&RPSOHWLRQ%OLQGHGH&5)
,IWKHGDWHRIODVWGRVHLVPLVVLQJHJRQO\\HDURIODVWGRVHLVNQRZQRUFRPSOHWHO\PLVVLQJGXH
WRORVWWRIROORZXSIRUVXEMHFWVZKRSUHPDWXUHO\GLVFRQWLQXHGRUFRPSOHWHGEOLQGHGVWXG\GUXJ
DWWKHGDWDFXWGDWHWKHODWHVWRIWKHVWXG\GUXJVWDUWGDWHVDQGHQGGDWHVWKHFOLQLFDOYLVLWGDWHV
DQGWKHODERUDWRU\YLVLWGDWHVH[FOXGLQJWKHGDWHRIGD\IROORZXSYLVLWZLOOEHXVHGWR
LPSXWHWKHODVWGRVHGDWH)RURWKHUSDUWLDOPLVVLQJODVWGRVHGDWHSOHDVHVHHWKHSURJUDPPLQJ
VSHFLILFDWLRQVIRULPSXWDWLRQUXOHGHWDLOV
/DVW6WXG\'DWHLVWKHODWHVWRIWKHVWXG\GUXJVWDUWGDWHVDQGHQGGDWHVWKHFOLQLFYLVLWGDWHV
DQGWKHODERUDWRU\YLVLWGDWHVLQFOXGLQJWKHGD\IROORZXSYLVLWGDWHIRUVXEMHFWVZKR
SUHPDWXUHO\GLVFRQWLQXHGVWXG\RUZKRFRPSOHWHGVWXG\DFFRUGLQJWRWKH6WXG\&RPSOHWLRQ
H&5)
%DVHOLQHYDOXHLVGHILQHGDVWKHODVWYDOXHREWDLQHGRQRUSULRUWR6WXG\'D\IRUDOO
DVVHVVPHQWVH[FHSWIRU';$%0'7KHEDVHOLQHYDOXHIRU';$%0'LVGHILQHGDVWKHODVW
YDOXHREWDLQHGRQRUSULRUWR6WXG\'D\


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

$QDO\VLV:LQGRZV
6XEMHFWYLVLWVPLJKWQRWRFFXURQSURWRFROVSHFLILHGGD\V7KHUHIRUHIRUWKHSXUSRVHRIDQDO\VLV
REVHUYDWLRQVZLOOEHDVVLJQHGWRDQDO\VLVZLQGRZV
7KHDQDO\VLVZLQGRZVIRU+,951$&'FHOOFRXQW&'KHPDWRORJ\FKHPLVWU\
XULQDO\VLVXULQHSUHJQDQF\ODERUDWRU\WHVWVH*)5&*YLWDOVLJQVDQGZHLJKWDUHSUHVHQWHGLQ
7DEOH
7DEOH
$QDO\VLV:LQGRZVIRU+,951$&'FHOOFRXQW&'
+HPDWRORJ\&KHPLVWU\8ULQDO\VLVDQG8ULQH3UHJQDQF\/DERUDWRU\
7HVWVH*)5&*9LWDO6LJQVDQG:HLJKW
9LVLW,'
1RPLQDO'D\
/RZHU/LPLW
8SSHU/LPLW
%DVHOLQH



:HHN



:HHN



:HHN



:HHN



:HHN



:HHN



:HHN



:HHN



:HHN



:HHN



:HHN.
.LVHYHU\ZHHNVDIWHUSUHYLRXVYLVLW
.
.
.

7KHDQDO\VLVZLQGRZVIRUPHWDEROLFDVVHVVPHQWVLQFOXGLQJIDVWLQJJOXFRVHDQGOLSLGSDQHOWRWDO
FKROHVWHUROKLJKGHQVLW\OLSRSURWHLQ>+'/@GLUHFWORZGHQVLW\OLSRSURWHLQ>/'/@WULJO\FHULGHV
DQGWRWDOFKROHVWHUROWR+'/UDWLRDUHSUHVHQWHGLQ7DEOH


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
7DEOH
$QDO\VLV:LQGRZVIRU0HWDEROLF$VVHVVPHQWV
9LVLW,'
1RPLQDO'D\
/RZHU/LPLW
8SSHU/LPLW
%DVHOLQH



:HHN



:HHN



:HHN



:HHN



:HHN



:HHN.
.LVHYHU\ZHHNVDIWHUSUHYLRXVYLVLW
.
.
.

7KHDQDO\VLVZLQGRZVIRUWK\URLGVWLPXODWLQJKRUPRQH76+WK\URWURSLQDQGUHQDOIXQFWLRQ
LQFOXGLQJXULQHDOEXPLQXULQHFUHDWLQLQHXULQHSURWHLQXULQH5%3DQGXULQHEHWD
PLFURJOREXOLQDQGGHULYHGUDWLRVDUHSUHVHQWHGLQ7DEOH
7DEOH
$QDO\VLV:LQGRZVIRU76+DQG5HQDO)XQFWLRQ
9LVLW,'
1RPLQDO'D\
/RZHU/LPLW
8SSHU/LPLW
%DVHOLQH



:HHN



:HHN



:HHN



:HHN



:HHN.
.LVHYHU\ZHHNVDIWHUSUHYLRXVYLVLW
.
.
.

7KHDQDO\VLVZLQGRZVIRU+%9DQG+&96HURORJ\LQFOXGLQJ+%V$E+%V$JKHSDWLWLV%
HDQWLJHQ>+%H$J@KHSDWLWLV%HDQWLERG\>+%H$E@+%F$EDQG+&9DQWLERG\>+&9$E@
+%9'1$DQG+&951$DVVHVVPHQWVDUHSUHVHQWHGLQ7DEOH


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
7DEOH
$QDO\VLV:LQGRZVIRU+%9DQG+&96HURORJ\+%9'1$DQG
+&951$$VVHVVPHQWV
9LVLW,'
1RPLQDO'D\
/RZHU/LPLW
8SSHU/LPLW
%DVHOLQH



:HHN



:HHN



:HHN.
.LVHYHU\ZHHNVDIWHUSUHYLRXVYLVLW
.
.
.

7KHDQDO\VLVZLQGRZVIRUVDIHW\HOHFWURFDUGLRJUDP(&*DUHSUHVHQWHGLQ7DEOH
7DEOH
$QDO\VLV:LQGRZVIRU6DIHW\(&*
9LVLW,'
1RPLQDO'D\
/RZHU/LPLW
8SSHU/LPLW
%DVHOLQH



:HHN



:HHN



:HHN



:HHN.
.LVHYHU\ZHHNVDIWHUSUHYLRXVYLVLW
.
.
.

7KHDQDO\VLVZLQGRZVIRU';$%0'DUHSUHVHQWHGLQ7DEOH
7DEOH
$QDO\VLV:LQGRZVIRU';$%0'
9LVLW,'
1RPLQDO'D\
/RZHU/LPLW
8SSHU/LPLW
%DVHOLQH



:HHN



:HHN



3RVW:HHN
1$

1$
1RWH7KHEDVHOLQHYDOXHRI';$%0'LVGHILQHGDVWKHODVWYDOXHREWDLQHGRQRUSULRUWR6WXG\'D\
1$ 1RW$SSOLFDEOH


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

6HOHFWLRQRI'DWDLQWKH(YHQWRI0XOWLSOH5HFRUGVLQDQ$QDO\VLV:LQGRZ
'HSHQGLQJRQWKHVWDWLVWLFDODQDO\VLVPHWKRGVLQJOHYDOXHVDUHUHTXLUHGIRUHDFKDQDO\VLV
ZLQGRZ)RUH[DPSOHFKDQJHIURPEDVHOLQHE\YLVLWXVXDOO\UHTXLUHVDVLQJOHYDOXHZKHUHDVD
WLPHWRHYHQWDQDO\VLVZRXOGQRWUHTXLUHRQHYDOXHSHUDQDO\VLVZLQGRZ:KHQDVLQJOHYDOXHLV
QHHGHGWKHIROORZLQJUXOHVZLOOEHXVHG
,IPXOWLSOHQRQPLVVLQJQXPHULFREVHUYDWLRQVH[LVWLQDZLQGRZWKHQUHFRUGVZLOOEHFKRVHQDV
IROORZV
x )RUEDVHOLQHWKHODWHVWDYDLODEOHUHFRUGRQRUSULRUWRWKHILUVWGRVHGDWHRIVWXG\GUXJZLOOEH
VHOHFWHG,IWKHUHDUHPXOWLSOHUHFRUGVZLWKWKHVDPHWLPHRUQRWLPHUHFRUGHGRQWKHVDPH
GD\DYHUDJHZLOOEHXVHGIRUWKHEDVHOLQHYDOXHH[FHSWIRU+,951$VHHEHORZ
x )RUSRVWEDVHOLQHYLVLWV
 )RU&'FHOOFRXQW&'DQG%0'GDWDWKHUHFRUGVFROOHFWHGRQWKHODWHVWGD\LQ
WKHZLQGRZZLOOEHVHOHFWHGIRUDQDO\VLV
 )RURWKHUQXPHULFREVHUYDWLRQVLHH[FHSW+,951$&'FHOOFRXQW&'DQG
%0'GDWDWKHUHFRUGVFROOHFWHGRQWKHGD\FORVHVWWRWKHQRPLQDOGD\IRUWKDWYLVLW
ZLOOEHVHOHFWHG,IWKHUHDUHGD\VHTXLGLVWDQWIURPWKHQRPLQDOGD\WKHODWHUGD\ZLOOEH
VHOHFWHG
 )RUDQ\QXPHULFREVHUYDWLRQVH[FHSW+,951$LIWKHUHDUHPXOWLSOHUHFRUGVRQWKH
VHOHFWHGGD\WKHDYHUDJHZLOOEHWDNHQ
x )RUEDVHOLQHDQGSRVWEDVHOLQH+,951$WKHODWHVWFRQVLGHULQJERWKGDWHDQGWLPH
UHFRUGVLQWKHZLQGRZZLOOEHVHOHFWHG,IERWK³+,951$7DTPDQ´DQG³+,951$
5HSHDW´LHWKH+,951$UHVXOWREWDLQHGIURPDQDGGLWLRQDODOLTXRWRIWKHRULJLQDOVDPSOH
DUHDYDLODEOHZLWKWKHVDPHFROOHFWLRQWLPHWKHUHVXOWVIURPWKH³+,951$5HSHDW´ZLOOEH
VHOHFWHGIRUDQDO\VLVSXUSRVHVRWKHUZLVHLIWKHUHDUHPXOWLSOH³+,951$7DTPDQ´
UHFRUGVZLWKWKHVDPHFROOHFWLRQWLPHWKHJHRPHWULFPHDQZLOOEHWDNHQIRUDQDO\VLVSXUSRVHV
,IPXOWLSOHYDOLGQRQPLVVLQJFDWHJRULFDOREVHUYDWLRQVH[LVWLQDZLQGRZUHFRUGVZLOOEHFKRVHQ
DVIROORZV
x )RUEDVHOLQHWKHODVWDYDLODEOHUHFRUGRQRUSULRUWRWKHILUVWGRVHGDWHRIVWXG\GUXJZLOOEH
VHOHFWHG,IWKHUHDUHPXOWLSOHUHFRUGVZLWKWKHVDPHWLPHRUQRWLPHUHFRUGHGRQWKHVDPH
GD\WKHYDOXHZLWKWKHORZHVWVHYHULW\ZLOOEHVHOHFWHGHJQRUPDOZLOOEHVHOHFWHGRYHU
DEQRUPDOIRUVDIHW\(&*ILQGLQJV
x )RUSRVWEDVHOLQHYLVLWVWKHPRVWFRQVHUYDWLYHYDOXHZLWKLQWKHZLQGRZZLOOEHVHOHFWHG
HJDEQRUPDOZLOOEHVHOHFWHGRYHUQRUPDOIRUVDIHW\(&*ILQGLQJV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

68%-(&7',6326,7,21

6XEMHFW(QUROOPHQWDQG'LVSRVLWLRQ

6XEMHFW(QUROOPHQW
7KHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVUDQGRPL]HGDWHDFKUHJLRQFRXQWU\DQGLQYHVWLJDWRUZLOO
EHVXPPDUL]HGE\WUHDWPHQWJURXSDQGRYHUDOOXVLQJWKHVDIHW\DQDO\VLVVHW7KHUHJLRQ
GHILQLWLRQLVSURYLGHGLQ$SSHQGL[7KHGHQRPLQDWRUIRUWKLVFDOFXODWLRQZLOOEHWKHQXPEHURI
VXEMHFWVLQWKHVDIHW\DQDO\VLVVHW

6XEMHFW'LVSRVLWLRQ
7KHVXPPDU\RIVXEMHFWGLVSRVLWLRQZLOOEHSURYLGHGE\WUHDWPHQWJURXSDQGRYHUDOOIRUDOO
VFUHHQHGVXEMHFWV7KLVVXPPDU\ZLOOLQFOXGHWKHQXPEHURIVXEMHFWVVFUHHQHGVFUHHQIDLOXUH
VXEMHFWVZKRZHUHQRWUDQGRPL]HGVXEMHFWVZKRPHWDOOHOLJLELOLW\FULWHULDDQGZHUHQRW
UDQGRPL]HGVXEMHFWVUDQGRPL]HGVXEMHFWVUDQGRPL]HGEXWQHYHUWUHDWHGVXEMHFWVLQWKHVDIHW\
DQDO\VLVVHWDQGVXEMHFWVLQWKH)$6
,QDGGLWLRQWKHQXPEHUDQGSHUFHQWDJHRIWKHVXEMHFWVLQWKHIROORZLQJFDWHJRULHVZLOOEH
VXPPDUL]HG
x 6WLOORQVWXG\GUXJXSWRWKHGDWDFXWGDWH
x 3UHPDWXUHO\GLVFRQWLQXLQJVWXG\GUXJSULRUWRWKHGDWDFXWGDWHZLWKVXPPDU\RIUHDVRQVIRU
GLVFRQWLQXLQJVWXG\GUXJ
x 6WLOORQVWXG\XSWRWKHGDWDFXWGDWH
x 3UHPDWXUHO\GLVFRQWLQXLQJIURPVWXG\SULRUWRWKHGDWDFXWGDWHZLWKVXPPDU\RIUHDVRQVIRU
GLVFRQWLQXLQJVWXG\
7KHGHQRPLQDWRUIRUWKHSHUFHQWDJHVRIVXEMHFWVLQHDFKFDWHJRU\ZLOOEHWKHQXPEHURIVXEMHFWV
LQWKHVDIHW\DQDO\VLVVHW
1RLQIHUHQWLDOVWDWLVWLFVZLOOEHJHQHUDWHG$GDWDOLVWLQJRIUHDVRQVIRUSUHPDWXUHVWXG\
GUXJVWXG\GLVFRQWLQXDWLRQZLOOEHSURYLGHG

([WHQWRI6WXG\'UXJ([SRVXUHDQG$GKHUHQFH

'XUDWLRQRI([SRVXUHWR6WXG\'UXJ
'XUDWLRQRIH[SRVXUHWRVWXG\GUXJZLOOEHGHILQHGDVWKHODVWGRVHGDWH±WKHILUVWGRVHGDWH
UHJDUGOHVVRIWHPSRUDU\LQWHUUXSWLRQVLQVWXG\GUXJDGPLQLVWUDWLRQDQGZLOOEHH[SUHVVHGLQZHHNV
XVLQJXSWRGHFLPDOSODFHHJZHHNV)RUWKHFDOFXODWLRQRIWKHGXUDWLRQRIH[SRVXUHWR
VWXG\GUXJWKHGDWDFXWGDWHZLOOEHXVHGWRLPSXWHWKHODVWGRVHGDWHIRUVXEMHFWVZKRKDYHQRW
SHUPDQHQWO\GLVFRQWLQXHGVWXG\GUXJDWWKHWLPHRIWKHGDWDFXWGDWH


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
'XUDWLRQRIH[SRVXUHWRVWXG\GUXJZLOOEHVXPPDUL]HGXVLQJGHVFULSWLYHVWDWLVWLFVQPHDQ6'
PHGLDQ44PLQLPXPDQGPD[LPXPDQGDVWKHQXPEHUDQGSHUFHQWDJHRIVXEMHFWV
H[SRVHGIRUVSHFLILHGSHULRGVHJZHHNVGD\VZHHNVGD\VZHHNV
GD\VZHHNVGD\VZHHNVGD\VZHHNVGD\VZHHNV
GD\VZHHNVGD\VZHHNVGD\VHWF
6XPPDULHVZLOOEHSURYLGHGE\WUHDWPHQWJURXSIRUVXEMHFWVLQWKHVDIHW\DQDO\VLVVHW1R
LQIHUHQWLDOVWDWLVWLFVZLOOEHSURYLGHG
7LPHWRSHUPDQHQWGLVFRQWLQXDWLRQRIVWXG\GUXJZLOOEHDQDO\]HGXVLQJWKH.DSODQ0HLHU
PHWKRGE\WUHDWPHQWJURXSEDVHGRQWKHVDIHW\DQDO\VLVVHW7KHORJUDQNWHVWZLOOEHXVHGWR
FRPSDUHWKHGLIIHUHQFHLQVWXG\GUXJH[SRVXUHEHWZHHQWKHWUHDWPHQWJURXSV6XEMHFWVZKRDUH
VWLOORQWKHUDQGRPL]HGVWXG\GUXJZLOOEHFHQVRUHGRQWKHLPSXWHGODVWGRVHGDWHDVGHILQHGLQ
WKLVVHFWLRQ$SORWRI.0HVWLPDWHVIRUWKHWLPHWRSUHPDWXUHGLVFRQWLQXDWLRQRIVWXG\GUXJE\
WUHDWPHQWJURXSZLOOEHJHQHUDWHG

$GKHUHQFHWR6WXG\'UXJ5HJLPHQ
6WXG\GUXJUHJLPHQDGKHUHQFHZLOOEHFRPSXWHGEDVHGRQSLOOFRXQWVIRUDFWLYHGUXJRQO\
HJVWXG\GUXJUHJLPHQLQ7UHDWPHQW*URXSLQFOXGHVVWXG\GUXJ%)7$)DFWLYH6WXG\GUXJ
UHJLPHQLQ7UHDWPHQW*URXSLQFOXGHVVWXG\GUXJ$%&'7*7&DFWLYH7KHQXPEHUVRI
SLOOVRIVWXG\GUXJGLVSHQVHGDQGUHWXUQHGDUHFDSWXUHGRQVWXG\GUXJDFFRXQWDELOLW\H&5)
$GKHUHQFHRIVWXG\GUXJUHJLPHQZLOOEHFDOFXODWHGDVIROORZV
¦
¦
u
 
u
 
@

>
@

>
SHULRG

GLVSHQVLQJ
HDFK
DW

SUHVFULEHG

SLOOV

RI

1R
SHULRG

GLVSHQVLQJ
HDFK
DW
WDNHQ
SLOOV

RI

1R


SUHVFULEHG

SLOOV

RI

1R

7RWDO
WDNHQ
SLOOV

RI

1R

7RWDO





$GKHUHQFH

>@ 1XPEHURISLOOVWDNHQDWDGLVWLQFWGLVSHQVLQJSHULRGIRUDVWXG\GUXJLVFDOFXODWHGDVWKHPLQLPXPRIDWKHGDLO\QXPEHU
RISLOOVSUHVFULEHGIRUWKHVWXG\GUXJPXOWLSOLHGE\WKHGXUDWLRQRIWUHDWPHQWDWWKHGLVSHQVLQJSHULRGDQGEWKHQXPEHURI
SLOOVWDNHQIRUWKHVWXG\GUXJQXPEHURISLOOVGLVSHQVHGPLQXVWKHQXPEHURISLOOVUHWXUQHG7RWDOQXPEHURISLOOVWDNHQLV
GHWHUPLQHGE\VXPPLQJWKHQXPEHURISLOOVWDNHQIURPDOOHYDOXDEOHGLVSHQVLQJSHULRGV
>@ 1XPEHURISLOOVSUHVFULEHGDWDGLVWLQFWGLVSHQVLQJSHULRGIRUDVWXG\GUXJLVFDOFXODWHGDVWKHGDLO\QXPEHURISLOOV
SUHVFULEHGIRUWKHVWXG\GUXJPXOWLSOLHGE\WKHGXUDWLRQRIWUHDWPHQWDWWKHGLVSHQVLQJSHULRG7RWDOQXPEHURISLOOV
SUHVFULEHGLVGHWHUPLQHGE\VXPPLQJWKHQXPEHURISLOOVSUHVFULEHGIURPDOOHYDOXDEOHGLVSHQVLQJSHULRGV
7KHGXUDWLRQRIWUHDWPHQWDWDGLVSHQVLQJSHULRGIRUDVWXG\GUXJLVFDOFXODWHGDVWKHPLQLPXPRI
DWKHODVWUHWXUQHGGDWHRIVWXG\GUXJDWDGLVSHQVLQJSHULRGEGDWHRISUHPDWXUH
GLVFRQWLQXDWLRQRIWKHVWXG\GUXJDQGFQH[WSLOOGLVSHQVLQJGDWHRIWKHVWXG\GUXJPLQXV
GLVSHQVLQJGDWHRIWKHVWXG\GUXJ
7KHQH[WSLOOGLVSHQVLQJGDWHLVWKHIROORZLQJGLVSHQVLQJGDWHRIWKHVWXG\GUXJUHJDUGOHVVRIWKH
ERWWOHUHWXUQGDWH


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
)RUDUHFRUGZKHUHWKHQXPEHURISLOOVUHWXUQHGZDVPLVVLQJZLWK³<HV´DQVZHUHGIRU
³:DV%RWWOHUHWXUQHG"´TXHVWLRQLWLVDVVXPHGWKHQXPEHURISLOOVUHWXUQHGZDV]HUR,IWKH
QXPEHURISLOOVGLVSHQVHGZDVPLVVLQJRUDQ\VWXG\GUXJERWWOHZDVQRWUHWXUQHGRUWKHERWWOH
UHWXUQVWDWXVZDVXQNQRZQWKHQDOOUHFRUGVLQWKDWGLVSHQVLQJSHULRGIRUWKDWVWXG\GUXJZLOOEH
H[FOXGHGIURPERWKGHQRPLQDWRUDQGQXPHUDWRUFDOFXODWLRQ
$GKHUHQFHXSWRWKHGDWDFXWGDWHZLOOEHFDOFXODWHGXVLQJDOOGDWDIURPWKHHQWLUHGRVLQJSHULRG
XSWRWKHGDWHRISHUPDQHQWGLVFRQWLQXDWLRQRIWKHVWXG\GUXJIRUVXEMHFWVZKRSUHPDWXUHO\
GLVFRQWLQXHGVWXG\GUXJRUFRPSOHWHGVWXG\GUXJRUXVLQJDOOGDWDDYDLODEOHIRUVXEMHFWVZKRDUH
RQJRLQJRQVWXG\GUXJ
$GKHUHQFHXSWR:HHNYLVLWZLOODOVREHFDOFXODWHGXVLQJDOOGDWDIURPWKHHQWLUHGRVLQJ
SHULRGXSWRWKHGDWHRISHUPDQHQWGLVFRQWLQXDWLRQRIWKHVWXG\GUXJIRUVXEMHFWVZKR
SUHPDWXUHO\GLVFRQWLQXHGVWXG\GUXJRUFRPSOHWHGVWXG\GUXJRUWKH:HHNVWXG\GUXJ
GLVSHQVLQJGDWHZKLFKHYHURFFXUVHDUOLHVW
'HVFULSWLYHVWDWLVWLFVIRUDGKHUHQFHXSWRWKHGDWDFXWGDWHDQGDGKHUHQFHXSWR:HHNYLVLWIRU
DVWXG\GUXJUHJLPHQQPHDQ6'PHGLDQ44PLQLPXPDQGPD[LPXPDORQJZLWKWKH
QXPEHUDQGSHUFHQWDJHRIVXEMHFWVEHORQJLQJWRDGKHUHQFHFDWHJRULHVHJWR
WRZLOOEHSURYLGHGE\WUHDWPHQWJURXSIRUVXEMHFWVZKRUHWXUQDW
OHDVWERWWOHDQGKDYHFDOFXODEOHDGKHUHQFHGXULQJWKHVWXG\LQWKHVDIHW\DQDO\VLVVHW1R
LQIHUHQWLDOVWDWLVWLFVZLOOEHSURYLGHG

3URWRFRO'HYLDWLRQV
$OLVWLQJZLOOEHSURYLGHGIRUDOOUDQGRPL]HGVXEMHFWVZKRYLRODWHGDWOHDVWLQFOXVLRQRU
H[FOXVLRQFULWHULRQ7KHOLVWLQJZLOOLQFOXGHWKHFULWHULDQRWPHW$OLVWLQJRIVXEMHFWVZKR
UHFHLYHGWKHZURQJVWXG\GUXJZLOODOVREHSURYLGHG


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

%$6(/,1(&+$5$&7(5,67,&6

'HPRJUDSKLFVDQG%DVHOLQH&KDUDFWHULVWLFV
6XEMHFWGHPRJUDSKLFGDWDHJDJHVH[DWELUWKUDFHDQGHWKQLFLW\DQGEDVHOLQHFKDUDFWHULVWLFV
HJERG\ZHLJKWKHLJKWDQGERG\PDVVLQGH[>%0,@ZLOOEHVXPPDUL]HGE\WUHDWPHQWJURXS
DQGRYHUDOOXVLQJGHVFULSWLYHVWDWLVWLFVQPHDQ6'PHGLDQ44PLQLPXPDQGPD[LPXP
IRUFRQWLQXRXVGDWDDQGE\WKHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVIRUFDWHJRULFDOGDWD7KH
VXPPDULHVRIGHPRJUDSKLFGDWDDQGEDVHOLQHVXEMHFWFKDUDFWHULVWLFVZLOOEHSURYLGHGIRUWKH
VDIHW\DQDO\VLVVHW
)RUFDWHJRULFDOGDWDWKH&RFKUDQ0DQWHO+DHQV]HO&0+WHVWLHJHQHUDODVVRFLDWLRQVWDWLVWLF
IRUQRPLQDOGDWDZLOOEHXVHGWRFRPSDUHWKHWUHDWPHQWJURXSV)RUFRQWLQXRXVGDWDWKH
VLGHG:LOFR[RQUDQNVXPWHVWZLOOEHXVHGWRFRPSDUHWKHWUHDWPHQWJURXSV

%DVHOLQH'LVHDVH&KDUDFWHULVWLFV
7KHIROORZLQJEDVHOLQHGLVHDVHFKDUDFWHULVWLFVZLOOEHVXPPDUL]HGE\WUHDWPHQWJURXSDQG
RYHUDOOXVLQJGHVFULSWLYHVWDWLVWLFV
x +,951$FDWHJRULHVFRSLHVP/DE
x &'FHOOFRXQWȝ/
x &'FHOOFRXQWFDWHJRULHVȝ/DEWRFWR
GWRDQGH
x &'SHUFHQWDJH
x 0RGHRILQIHFWLRQ+,9ULVNIDFWRUV
x +,9GLVHDVHVWDWXV
x H*)5&*P/PLQ
x 0HGLFDOKLVWRU\GLDEHWHVPHOOLWXV<HV1RK\SHUWHQVLRQ<HV1RFDUGLRYDVFXODUGLVHDVH
<HV1RDQGK\SHUOLSLGHPLD<HV1RVHH6$3$SSHQGL[IRUGHWDLOV
x +,9+%9FRLQIHFWLRQVWDWXV<HV1R0LVVLQJVHH6HFWLRQIRUGHILQLWLRQ
x +,9+&9FRLQIHFWLRQVWDWXV<HV1R0LVVLQJVHH6HFWLRQIRUGHILQLWLRQ
x 6PRNLQJVWDWXVD1HYHU6PRNHUE)RUPHU6PRNHUDQGF&XUUHQW6PRNHU
VHH6$3$SSHQGL[IRUGHWDLOV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
)RUFDWHJRULFDOGDWDWKH&0+WHVWJHQHUDODVVRFLDWLRQVWDWLVWLFIRUQRPLQDOGDWDDQGURZPHDQV
VFRUHVGLIIHUVWDWLVWLFIRURUGLQDOGDWDZLOOEHXVHGWRFRPSDUHWKHWUHDWPHQWJURXSV)RU
FRQWLQXRXVGDWDWKHVLGHG:LOFR[RQUDQNVXPWHVWZLOOEHXVHGWRFRPSDUHWKHWUHDWPHQW
JURXSV

0HGLFDO+LVWRU\
*HQHUDOPHGLFDOKLVWRU\GDWDZLOOEHFROOHFWHGDWVFUHHQLQJDQGOLVWHGRQO\*HQHUDOPHGLFDO
KLVWRU\GDWDZLOOEHFRGHGXVLQJWKHFXUUHQWYHUVLRQRI0HGLFDO'LFWLRQDU\IRU5HJXODWRU\
$FWLYLWLHV0HG'5$


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

()),&$&<$1$/<6(6

3ULPDU\(IILFDF\(QGSRLQW

'HILQLWLRQRIWKH3ULPDU\(IILFDF\(QGSRLQW
7KHSULPDU\HIILFDF\HQGSRLQWLVWKHSURSRUWLRQRIVXEMHFWVZLWK+,951$FRSLHVP/DW
:HHNDVGHWHUPLQHGE\WKH86)'$GHILQHGVQDSVKRWDOJRULWKP^86'HSDUWPHQWRI+HDOWK
DQG+XPDQ6HUYLFHV`7KHSURSRUWLRQVDUHH[SUHVVHGDVSHUFHQWDJHVIRUSUHVHQWDWLRQSXUSRVH

86)'$'HILQHG6QDSVKRW$OJRULWKP
7KHDQDO\VLVZLQGRZDW:HHNLVGHILQHGDVIURP6WXG\'D\WR6WXG\'D\LQFOXVLYH
$OO+,951$GDWDFROOHFWHGRQWUHDWPHQWLHGDWDFROOHFWHGXSWRGD\DIWHUSHUPDQHQW
GLVFRQWLQXDWLRQRIVWXG\GUXJRUDOODYDLODEOHGDWDIRUVXEMHFWVZKRZHUHVWLOORQVWXG\GUXJZLOO
EHXVHGLQWKH86)'$GHILQHGVQDSVKRWDOJRULWKP9LURORJLFRXWFRPHZLOOEHGHILQHGDVWKH
IROORZLQJFDWHJRULHV
x +,951$FRSLHVP/WKLVLQFOXGHVVXEMHFWVZKRKDYHWKHODVWDYDLODEOHRQWUHDWPHQW
+,951$FRSLHVP/LQWKH:HHNDQDO\VLVZLQGRZ
x +,951$FRSLHVP/WKLVLQFOXGHVVXEMHFWV
D :KRKDYHWKHODVWDYDLODEOHRQWUHDWPHQW+,951$FRSLHVP/LQWKH:HHN
DQDO\VLVZLQGRZRU
E :KRGRQRWKDYHRQWUHDWPHQW+,951$GDWDLQWKH:HHNDQDO\VLVZLQGRZDQG
 :KRGLVFRQWLQXHVWXG\GUXJSULRUWRRULQWKH:HHNDQDO\VLVZLQGRZGXHWRODFN
RIHIILFDF\RU
 :KRGLVFRQWLQXHVWXG\GUXJSULRUWRRULQWKH:HHNDQDO\VLVZLQGRZGXHWR$(RU
GHDWKDQGKDYHWKHODVWDYDLODEOHRQWUHDWPHQW+,951$FRSLHVP/RU
 :KRGLVFRQWLQXHVWXG\GUXJSULRUWRRULQWKH:HHNDQDO\VLVZLQGRZGXHWR
UHDVRQVRWKHUWKDQ$(GHDWKRUODFNRIHIILFDF\DQGKDYHWKHODVWDYDLODEOH
RQWUHDWPHQW+,951$FRSLHVP/
x 1R9LURORJLF'DWDLQWKH:HHN:LQGRZWKLVLQFOXGHVVXEMHFWVZKRGRQRWKDYH
RQWUHDWPHQW+,951$GDWDLQWKH:HHNDQDO\VLVZLQGRZEHFDXVHRIWKHIROORZLQJ
D 'LVFRQWLQXDWLRQRIVWXG\GUXJSULRUWRRULQWKH:HHNDQDO\VLVZLQGRZGXHWR$(RU
GHDWKDQGWKHODVWDYDLODEOHRQWUHDWPHQW+,951$FRSLHVP/RU
E 'LVFRQWLQXDWLRQRIVWXG\GUXJSULRUWRRULQWKH:HHNDQDO\VLVZLQGRZGXHWRUHDVRQV
RWKHUWKDQ$(GHDWKRUODFNRIHIILFDF\DQGWKHODVWDYDLODEOHRQWUHDWPHQW+,951$
FRSLHVP/RU
F 0LVVLQJGDWDGXULQJWKHZLQGRZEXWRQVWXG\GUXJ


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
7KHIORZFKDUWRIWKH86)'$GHILQHGVQDSVKRWDOJRULWKPLVSURYLGHGLQ$SSHQGL[
7KH:HHNYLURORJLFRXWFRPHVIRUWKH86)'$GHILQHGVQDSVKRWDOJRULWKPZLOOEHOLVWHG
1RWH)RUVZLWFKWULDOVWKH86)'$GHILQHGVQDSVKRWDOJRULWKPFODVVLILHVVXEMHFWVZKR
GLVFRQWLQXHVWXG\GUXJGXHWR$(RUGHDWKDQGKDYHWKHODVWDYDLODEOHRQWUHDWPHQW+,951$
YDOXHFRSLHVP/LQWKH³+,951$FRSLHVP/´FDWHJRU\)RUWUHDWPHQWQDwYHVWXG\
SRSXODWLRQWKHVHVXEMHFWVZLOOEHFODVVLILHGLQWKH³1R9LURORJLF'DWDLQWKH:HHN:LQGRZ´
FDWHJRU\

6WDWLVWLFDO+\SRWKHVLVIRUWKH3ULPDU\(IILFDF\(QGSRLQW
1XOOK\SRWKHVLV7KH%)7$)JURXS7UHDWPHQW*URXSLVDWOHDVWKLJKHUWKDQWKH
$%&'7*7&JURXS7UHDWPHQW*URXSZLWKUHVSHFWWRWKHSURSRUWLRQRIVXEMHFWVZLWK
+,951$FRSLHVP/DVGHWHUPLQHGE\WKH86)'$GHILQHGVQDSVKRWDOJRULWKPDW
:HHN
$OWHUQDWLYHK\SRWKHVLV7KH%)7$)JURXS7UHDWPHQW*URXSLVOHVVWKDQKLJKHUWKDQ
WKH$%&'7*7&JURXS7UHDWPHQW*URXSZLWKUHVSHFWWRWKHSURSRUWLRQRIVXEMHFWVZLWK
+,951$FRSLHVP/DW:HHN

3ULPDU\$QDO\VLVRIWKH3ULPDU\(IILFDF\(QGSRLQW
7KHDQDO\VLVSXUSRVHRIWKHSULPDU\HIILFDF\HQGSRLQWLVWRDVVHVVWKHQRQLQIHULRULW\RIVZLWFKLQJ
WR%)7$)UHODWLYHWRFRQWLQXLQJRQ$%&'7*7&1RQLQIHULRULW\ZLOOEHDVVHVVHGXVLQJD
FRQYHQWLRQDO&,DSSURDFKZLWKDQRQLQIHULRULW\PDUJLQRI
)RUHDFKLQWHULPDQDO\VHVSHUIRUPHGIRUWKH,'0&DW:HHNVDQGDQDOSKDRIKDV
EHHQVSHQW7KHUHIRUHWKHVLJQLILFDQFHOHYHOIRUWKHVLGHGWHVWLQWKHSULPDU\DQDO\VLVDW
:HHNZLOOEHFRUUHVSRQGLQJWR&,
7KHSRLQWHVWLPDWHRIWUHDWPHQWGLIIHUHQFH%)7$)JURXS±$%&'7*7&JURXSLQWKH
SHUFHQWDJHRIVXEMHFWVZLWK+,951$FRSLHVP/DQGWKHDVVRFLDWHGVLGHG&,
ZLOOEHFRQVWUXFWHGEDVHGRQDQXQFRQGLWLRQDOH[DFWPHWKRGXVLQJLQYHUWHGVLGHGWHVWV
,WZLOOEHFRQFOXGHGWKDW%)7$)LVQRQLQIHULRUWR$%&'7*7&LIWKHXSSHUERXQGRIWKH
VLGHG&,RIWKHGLIIHUHQFHEHWZHHQWUHDWPHQWJURXSV%)7$)JURXS±$%&'7*7&
JURXSLQWKHSHUFHQWDJHRIVXEMHFWVZLWK+,951$FRSLHVP/LVOHVVWKDQ
7KHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVZLWK+,951$FRSLHVP/+,951$
FRSLHVP/DQGUHDVRQVIRUQRYLURORJLFGDWDDW:HHNZLOOEHVXPPDUL]HG
,IQRQLQIHULRULW\RI%)7$)YHUVXV$%&'7*7&LVHVWDEOLVKHGWKHVDPH&,XVHGLQ
HYDOXDWLQJQRQLQIHULRULW\DW:HHNZLOOEHXVHGWRHYDOXDWHVXSHULRULW\,IWKHXSSHUERXQGRI
WKH&,LVOHVVWKDQWKHQVXSHULRULW\RI%)7$)RYHU$%&'7*7&LVHVWDEOLVKHG
7KHVLGHG)LVKHU¶VH[DFWWHVWZLOODOVREHXVHGWRDVVHVVVXSHULRULW\DVDVHFRQGDU\DVVHVVPHQW
7KH)$6ZLOOEHXVHGIRUWKHSULPDU\HIILFDF\HQGSRLQWDQDO\VLVDQGWKHVXSHULRULW\HYDOXDWLRQ


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

6HFRQGDU\$QDO\VLVRIWKH3ULPDU\(IILFDF\(QGSRLQW
$VHFRQGDU\DQDO\VLVEDVHGRQWKH:HHN33DQDO\VLVVHWZLOODOVREHSHUIRUPHGWRHYDOXDWH
WKHUREXVWQHVVRIWKHSULPDU\DQDO\VLVRIWKHSULPDU\HQGSRLQW)RUWKLVVHFRQGDU\DQDO\VLV
&,IRUWKHWUHDWPHQWGLIIHUHQFHLQWKHSULPDU\HIILFDF\HQGSRLQWZLOODOVREHFDOFXODWHG
EDVHGRQDQXQFRQGLWLRQDOH[DFWPHWKRGXVLQJLQYHUWHGVLGHGWHVWV

6HFRQGDU\(IILFDF\(QGSRLQWV

'HILQLWLRQRIWKH6HFRQGDU\(IILFDF\(QGSRLQWV
7KHVHFRQGDU\HIILFDF\HQGSRLQWVLQFOXGH
x 7KHSURSRUWLRQRIVXEMHFWVZLWK+,951$FRSLHVP/DW:HHNDVGHWHUPLQHGE\
WKH86)'$GHILQHGVQDSVKRWDOJRULWKP
x 7KHFKDQJHIURPEDVHOLQHLQ&'FHOOFRXQWDW:HHN
7KHDQDO\VHVIRUWKHVHFRQGDU\HIILFDF\HQGSRLQWVZLOOEHFRQGXFWHGXVLQJWKH)$6DQGWKH
:HHN33DQDO\VLVVHWUHVSHFWLYHO\

$QDO\VLVRIWKH6HFRQGDU\(IILFDF\(QGSRLQWV

$QDO\VLVRIWKH3URSRUWLRQRI6XEMHFWVZLWK+,951$FRSLHVP/DV
'HWHUPLQHGE\86)'$GHILQHG6QDSVKRW$OJRULWKP
7KHSURSRUWLRQRIVXEMHFWVZLWK+,951$FRSLHVP/DW:HHNZLOODOVREHDQDO\]HG
E\WKH86)'$GHILQHGVQDSVKRWDOJRULWKPEDVHGRQWKH)$6DQG:HHN33DQDO\VLVVHW
UHVSHFWLYHO\
3URSRUWLRQRIVXEMHFWVZLWK+,951$FRSLHVP/DW:HHNDVGHWHUPLQHGE\86
)'$GHILQHGVQDSVKRWDOJRULWKPZLOOEHDQDO\]HGVLPLODUO\WRWKHSULPDU\HIILFDF\HQGSRLQW
+RZHYHUWKHQRQLQIHULRULW\PDUJLQXVHGIRUWKHSURSRUWLRQRIVXEMHFWVZLWK+,951$
FRSLHVP/ZLOOEH
6LPLODUO\WRWKHSULPDU\HIILFDF\HQGSRLQWQRQLQIHULRULW\ZLOOEHDVVHVVHGXVLQJWKHFRQYHQWLRQDO
&,DSSURDFK7KHSRLQWHVWLPDWHRIWUHDWPHQWGLIIHUHQFH%)7$)JURXS$%&'7*7&JURXS
LQWKHSHUFHQWDJHRIVXEMHFWVZLWK+,951$FRSLHVP/DQGWKHDVVRFLDWHGVLGHG
&,ZLOOEHFRQVWUXFWHGEDVHGRQDQXQFRQGLWLRQDOH[DFWPHWKRGXVLQJLQYHUWHGVLGHG
WHVWV
,WZLOOEHFRQFOXGHGWKDW%)7$)LVQRQLQIHULRUWR$%&'7*7&LIWKHORZHUERXQGRIWKH
VLGHG&,RIWKHGLIIHUHQFHEHWZHHQWUHDWPHQWJURXSV%)7$)JURXS±$%&'7*7&
JURXSLQWKHSHUFHQWDJHRIVXEMHFWVZLWK+,951$FRSLHVP/LVJUHDWHUWKDQí
7KHDERYHDQDO\VLVZLOOEHSHUIRUPHGXVLQJERWKWKH)$6DQGWKH:HHN33DQDO\VLVVHW


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
,QDGGLWLRQWKHIROORZLQJDQDO\VHVZLOOEHSHUIRUPHGXVLQJWKH)$6WRHYDOXDWHWKHLQWHUDFWLRQ
EHWZHHQUHJLRQDQGWUHDWPHQWWRDVVHVVKRPRJHQHLW\RIWUHDWPHQWHIIHFWDFURVVGLIIHUHQWUHJLRQV
$UHJLRQLVGHILQHGDVPXOWLSOHVLWHVFRPELQHGEDVHGRQJHRJUDSKLFDOORFDWLRQVVHH$SSHQGL[
IRUUHJLRQGHILQLWLRQ
)RUHDFKUHJLRQWKHGLIIHUHQFHLQWKHSURSRUWLRQRIVXEMHFWVZLWK+,951$FRSLHVP/
EHWZHHQWUHDWPHQWJURXSVDQGLWV&,ZLOOEHFDOFXODWHGEDVHGRQDQXQFRQGLWLRQDOH[DFW
PHWKRGXVLQJLQYHUWHGVLGHGWHVWV
7KH&0+DQDO\VLVZLOOEHXVHGWRHVWLPDWHWKHRGGVUDWLRDQGFRUUHVSRQGLQJ&,IRUHDFK
UHJLRQDQGRYHUDOO7KHKRPRJHQHLW\RIWKHRGGVUDWLRVDFURVVGLIIHUHQWUHJLRQVZLOOEHWHVWHG
XVLQJD%UHVORZ'D\WHVWDQGDFRUUHVSRQGLQJSYDOXHZLOOEHUHSRUWHG

6XEJURXS$QDO\VLVRIWKH3URSRUWLRQRI6XEMHFWVZLWK+,951$
FRSLHVP/DW:HHNDV'HWHUPLQHGE\86)'$GHILQHG6QDSVKRW
$OJRULWKP
6LQFHWKHSURSRUWLRQRIVXEMHFWVZLWK+,951$FRSLHVP/DW:HHNDVGHWHUPLQHGE\WKH
86)'$GHILQHGVQDSVKRWDOJRULWKPSULPDU\HQGSRLQWLVH[SHFWHGWREHYHU\ORZDURXQG
WKHHIILFDF\DQDO\VLVE\VXEJURXSZLOOEHFRQGXFWHGE\DVVHVVLQJWKHSURSRUWLRQRIVXEMHFWVZLWK
+,951$FRSLHVP/GHWHUPLQHGE\WKH86)'$GHILQHGVQDSVKRWDOJRULWKPDW:HHN
DVHFRQGDU\HIILFDF\HQGSRLQWZLWKLQHDFKVXEJURXSVSHFLILHGLQ6HFWLRQEDVHGRQWKH
)$6
)RUHDFKOHYHORIVXEJURXSIDFWRUVWKHSURSRUWLRQGLIIHUHQFHEHWZHHQWUHDWPHQWJURXSVDQGWKH
DVVRFLDWHGVLGHG&,VZLOOEHFRPSXWHGEDVHGRQDQXQFRQGLWLRQDOH[DFWPHWKRGXVLQJ
LQYHUWHGVLGHGWHVWV
$GGLWLRQDOO\DORJLVWLFUHJUHVVLRQPRGHOZLOOEHSHUIRUPHGZKLFKLQFOXGHVXEJURXSWUHDWPHQW
DQGWUHDWPHQWE\VXEJURXSLQWHUDFWLRQ7KHRGGVUDWLRDQGWKHDVVRFLDWHG&,ZLOOEH
HVWLPDWHGZLWKLQHDFKVXEJURXS7KHKRPRJHQHLW\RIWKHWUHDWPHQWHIIHFWVEHWZHHQVXEJURXSV
ZLOOEHHYDOXDWHGXVLQJD:DOGWHVWEDVHGRQWKHLQWHUDFWLRQEHWZHHQWUHDWPHQWDQGWKHVXEJURXS
IDFWRU
$IRUHVWSORWRIWKHWUHDWPHQWGLIIHUHQFHVLQ+,951$FRSLHVP/86)'$GHILQHG
VQDSVKRWDOJRULWKPDW:HHNDQGWKHLUDVVRFLDWHG&,VIRUHDFKVXEJURXSZLOOEH
JHQHUDWHG

$QDO\VLVRI&'&HOO&RXQW
$OO&'FHOOFRXQWZLOOEHVXPPDUL]HGXVLQJREVHUYHGRQWUHDWPHQWGDWDLHGDWDFROOHFWHGXS
WRGD\DIWHUSHUPDQHQWGLVFRQWLQXDWLRQRIVWXG\GUXJRUDOODYDLODEOHGDWDIRUVXEMHFWVZKRZHUH
VWLOORQVWXG\GUXJIRUVXEMHFWVLQWKH)$6
7KHFKDQJHVIURPEDVHOLQHLQ&'FHOOFRXQWDW:HHNZLOOEHVXPPDUL]HGE\WUHDWPHQW
JURXSXVLQJGHVFULSWLYHVWDWLVWLFV7KHGLIIHUHQFHVLQFKDQJHVIURPEDVHOLQHLQ&'FHOOFRXQW
EHWZHHQWKHWUHDWPHQWJURXSVDQGWKHDVVRFLDWHG&,ZLOOEHFRQVWUXFWHGXVLQJDQDO\VLVRI








%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

6$)(7<$1$/<6(6
6DIHW\GDWDZLOOEHVXPPDUL]HGIRUWKHVXEMHFWVLQWKHVDIHW\DQDO\VLVVHW$OOVDIHW\GDWD
FROOHFWHGXSWRGD\VDIWHUSHUPDQHQWGLVFRQWLQXDWLRQRIVWXG\GUXJDQGDOODYDLODEOHGDWDIRU
VXEMHFWVZKRZHUHVWLOORQVWXG\GUXJZLOOEHVXPPDUL]HGE\WUHDWPHQWJURXSXQOHVVVSHFLILHG
RWKHUZLVH$OOVDIHW\GDWDZLOOEHLQFOXGHGLQGDWDOLVWLQJV

$GYHUVH(YHQWVDQG'HDWKV

$GYHUVH(YHQW'LFWLRQDU\
&OLQLFDODQGODERUDWRU\$(VZLOOEHFRGHGXVLQJWKHFXUUHQWYHUVLRQRI0HG'5$6\VWHPRUJDQ
FODVV62&KLJKOHYHOJURXSWHUP+/*7KLJKOHYHOWHUP+/7SUHIHUUHGWHUP37DQG
ORZHVWOHYHOWHUP//7ZLOOEHSURYLGHGLQWKH$(GDWDVHW

$GYHUVH(YHQW6HYHULW\
$GYHUVHHYHQWVDUHJUDGHGE\WKHLQYHVWLJDWRUDV*UDGHPLOG*UDGHPRGHUDWH*UDGH
VHYHUHRU*UDGHOLIHWKUHDWHQLQJDFFRUGLQJWRWR[LFLW\FULWHULDVSHFLILHGLQWKHSURWRFRO7KH
VHYHULW\JUDGHRIHYHQWVIRUZKLFKWKHLQYHVWLJDWRUGLGQRWUHFRUGVHYHULW\ZLOOEHOHIWDV
³PLVVLQJ´IRUGDWDOLVWLQJV5HODWLRQVKLSRI$GYHUVH(YHQWVWR6WXG\'UXJ
5HODWHG$(VDUHWKRVHIRUZKLFKWKHLQYHVWLJDWRUVHOHFWHG³5HODWHG´RQWKH$(H&5)WRWKH
TXHVWLRQRI³5HODWHGWR6WXG\7UHDWPHQW´(YHQWVIRUZKLFKWKHLQYHVWLJDWRUGLGQRWUHFRUG
UHODWLRQVKLSWRVWXG\GUXJZLOOEHFRQVLGHUHGUHODWHGWRVWXG\GUXJIRUVXPPDU\SXUSRVHV
+RZHYHUE\VXEMHFWGDWDOLVWLQJVZLOOVKRZWKHUHODWLRQVKLSDVPLVVLQJ

6HULRXV$GYHUVH(YHQWV
6HULRXVDGYHUVHHYHQWV6$(VZLOOEHLGHQWLILHGDQGFDSWXUHGDV6$(VLI$(VPHWWKHGHILQLWLRQV
RI6$(VSHFLILHGLQWKHVWXG\SURWRFRO6HULRXVDGYHUVHHYHQWVFDSWXUHGDQGVWRUHGLQWKHFOLQLFDO
GDWDEDVHZLOOEHUHFRQFLOHGZLWKWKH6$(GDWDEDVHIURPWKH*LOHDG'UXJ6DIHW\DQG3XEOLF
+HDOWK'63+'HSDUWPHQWEHIRUHGDWDILQDOL]DWLRQ

7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV

'HILQLWLRQRI7UHDWPHQW(PHUJHQW$GYHUVH(YHQWV
7UHDWPHQWHPHUJHQWDGYHUVHHYHQWV7($(VDUHGHILQHGDVRUERWKRIWKHIROORZLQJ
x $Q\$(VZLWKDQRQVHWGDWHRQRUDIWHUWKHVWXG\GUXJVWDUWGDWHDQGQRODWHUWKDQGD\V
DIWHUSHUPDQHQWGLVFRQWLQXDWLRQRIWKHVWXG\GUXJRU
x $Q\$(VOHDGLQJWRSUHPDWXUHGLVFRQWLQXDWLRQRIVWXG\GUXJ


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

,QFRPSOHWH'DWHV
,IWKHRQVHWGDWHRIWKH$(LVLQFRPSOHWHDQGWKH$(VWRSGDWHLVQRWSULRUWRWKHILUVWGRVLQJGDWH
RIVWXG\GUXJWKHQWKHPRQWKDQG\HDURU\HDUDORQHLIPRQWKLVQRWUHFRUGHGRIRQVHW
GHWHUPLQHZKHWKHUDQ$(LVWUHDWPHQWHPHUJHQW7KHHYHQWLVFRQVLGHUHGWUHDWPHQWHPHUJHQWLI
ERWKRIWKHIROORZLQJFULWHULDDUHPHW
x 7KHPRQWKDQG\HDURU\HDURIWKH$(RQVHWLVWKHVDPHDVRUDIWHUWKHPRQWKDQG\HDU
RU\HDURIWKHILUVWGRVLQJGDWHRIVWXG\GUXJDQG
x 7KHPRQWKDQG\HDURU\HDURIWKH$(RQVHWLVWKHVDPHDVRUEHIRUHWKHPRQWKDQG\HDU
RU\HDURIWKHGDWHFRUUHVSRQGLQJWRGD\VDIWHUWKHGDWHRIWKHODVWGRVHRIVWXG\GUXJ
$Q$(ZLWKFRPSOHWHO\PLVVLQJRQVHWDQGVWRSGDWHVRUZLWKWKHRQVHWGDWHPLVVLQJDQGDVWRS
GDWHPDUNHGDVRQJRLQJRURQRUDIWHUWKHILUVWGRVLQJGDWHRIVWXG\GUXJZLOOEHFRQVLGHUHGWREH
WUHDWPHQWHPHUJHQW,QDGGLWLRQDQ$(ZLWKWKHRQVHWGDWHPLVVLQJDQGLQFRPSOHWHVWRSGDWH
ZLWKWKHVDPHRUODWHUPRQWKDQG\HDURU\HDUDORQHLIPRQWKLVQRWUHFRUGHGDVWKHILUVWGRVLQJ
GDWHRIVWXG\GUXJZLOOEHFRQVLGHUHGWUHDWPHQWHPHUJHQW

6XPPDULHVRI$GYHUVH(YHQWVDQG'HDWK
7KHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVZKRH[SHULHQFHGDWOHDVW7($(ZLOOEHSURYLGHGDQG
VXPPDUL]HGE\62&+/737DQGWUHDWPHQWJURXS)RURWKHU$(VGHVFULEHGEHORZVXPPDULHV
ZLOOEHSURYLGHGE\62&37DQGWUHDWPHQWJURXSXVLQJWKHVDIHW\DQDO\VLVVHW
x $Q\*UDGHRUWUHDWPHQWHPHUJHQW$(V
x $Q\*UDGHRUWUHDWPHQWHPHUJHQW$(V
x $OOWUHDWPHQWHPHUJHQWVWXG\GUXJUHODWHG$(V
x $Q\*UDGHRUWUHDWPHQWHPHUJHQWVWXG\GUXJUHODWHG$(V
x $Q\*UDGHRUWUHDWPHQWHPHUJHQWVWXG\GUXJUHODWHG$(V
x $OOWUHDWPHQWHPHUJHQW6$(V
x $OOWUHDWPHQWHPHUJHQWVWXG\GUXJUHODWHG6$(V
x $OOWUHDWPHQWHPHUJHQW$(VWKDWFDXVHGSUHPDWXUHGLVFRQWLQXDWLRQIURPVWXG\GUXJ
$EULHIKLJKOHYHOVXPPDU\RI$(VGHVFULEHGDERYHZLOOEHSURYLGHGE\WUHDWPHQWJURXSDQGE\
WKHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVZKRH[SHULHQFHGWKHDERYH$(V7UHDWPHQWHPHUJHQW
GHDWKVREVHUYHGLQWKHVWXG\ZLOOEHDOVRLQFOXGHGLQWKLVVXPPDU\


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
7UHDWPHQWHPHUJHQWGHDWKUHIHUVWRGHDWKVWKDWRFFXUUHGEHWZHHQWKHILUVWGRVHGDWHDQGWKHODVW
GRVHGDWHSOXVGD\VLQFOXVLYH
0XOWLSOHHYHQWVZLOOEHFRXQWHGRQO\RQFHSHUVXEMHFWLQHDFKVXPPDU\$GYHUVHHYHQWVZLOOEH
VXPPDUL]HGDQGOLVWHGILUVWLQDOSKDEHWLFRUGHURI62&DQG+/7ZLWKLQHDFK62&LIDSSOLFDEOH
DQGWKHQE\37LQGHVFHQGLQJRUGHURIWRWDOIUHTXHQF\ZLWKLQHDFK62&)RUVXPPDULHVE\
VHYHULW\JUDGHWKHPRVWVHYHUHJUDGHZLOOEHXVHGIRUWKRVH$(VWKDWRFFXUUHGPRUHWKDQRQFHLQ
DQLQGLYLGXDOVXEMHFWGXULQJWKHVWXG\
,QDGGLWLRQWRWKHDERYHVXPPDU\WDEOHVDOOWUHDWPHQWHPHUJHQW$(V*UDGHRU
WUHDWPHQWHPHUJHQW$(VWUHDWPHQWHPHUJHQWVWXG\GUXJUHODWHG$(V*UDGHRU
WUHDWPHQWHPHUJHQWVWXG\GUXJUHODWHG$(VDQGWUHDWPHQWHPHUJHQW6$(VZLOOEHVXPPDUL]HG
E\37RQO\LQGHVFHQGLQJRUGHURIWRWDOIUHTXHQF\
6XPPDU\RIWUHDWPHQWHPHUJHQW$(VE\62&DQG37ZLOODOVREHFRQGXFWHGIRUDOOVXEJURXSV
OLVWHGLQ6HFWLRQ
,QDGGLWLRQGDWDOLVWLQJVZLOOEHSURYLGHGIRUWKHIROORZLQJ
x $OO$(V
x *UDGHDQG$(V
x 6$(V
x 6WXG\'UXJ5HODWHG6$(V
x 'HDWKVUHSRUW
x $(VOHDGLQJWRSUHPDWXUHGLVFRQWLQXDWLRQRIVWXG\GUXJ

$GGLWLRQDO$QDO\VLVRI$GYHUVH(YHQWV

6WDJH2SSRUWXQLVWLF,OOQHVVHVLQ+,9
2QDQRQJRLQJEDVLV$(VZLOOEHUHYLHZHGIRUHYHQWVWKDWPLJKWPHHWWKHGHILQLWLRQRIVWDJH
RSSRUWXQLVWLFLOOQHVVHVLQ+,9WKDWDUHLQGLFDWLYHRIDQ$,'6GHILQLQJGLDJQRVHVVHH3URWRFRO
$SSHQGL[7KH*LOHDGPHGLFDOPRQLWRUZLOOUHYLHZWKHSRVVLEOHVWDJHRSSRUWXQLVWLFLOOQHVVHV
DQGDSSURYHWKHHYHQWVWKDWPHHWWKHGHILQLWLRQ(YHQWVWKDWPHHWWKHVWDJHRSSRUWXQLVWLFLOOQHVV
GHILQLWLRQRIDQ$,'6'HILQLQJ'LDJQRVLVZLOOEHOLVWHG

&DUGLRYDVFXODURU&HUHEURYDVFXODU(YHQWV
3UHIHUUHGWHUPVIRUFDUGLRYDVFXODURUFHUHEURYDVFXODUHYHQWVDUHIURPUHOHYDQW6WDQGDUGLVHG
0HG'5$4XHU\6047KHVHOHFWHG37OLVWLQJZDVSURYLGHGE\*LOHDG'63+DQGUHYLHZHGE\
*LOHDGPHGLFDOPRQLWRUVZKLFKLVWKHVDPH37OLVWLQJXVHGWRVHDUFK³&DUGLRYDVFXODU'LVHDVH´
PHGLFDOKLVWRU\VHHGHWDLOVLQ$SSHQGL[


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
7KHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVZLWKWUHDWPHQWHPHUJHQWFDUGLRYDVFXODURU
FHUHEURYDVFXODUHYHQWVDQGVHULRXVFDUGLRYDVFXODURUFHUHEURYDVFXODUHYHQWVE\37ZLOOEH
VXPPDUL]HGE\WUHDWPHQWJURXSEDVHGRQWKHVDIHW\DQDO\VLVVHW6WDWLVWLFDOFRPSDULVRQVRIWKH
VXEMHFWLQFLGHQFHUDWHVEHWZHHQWKHWUHDWPHQWJURXSVZLOOEHSHUIRUPHGXVLQJWKH)LVKHU¶VH[DFW
WHVW$GDWDOLVWLQJRIFDUGLRYDVFXODURUFHUHEURYDVFXODUHYHQWVZLOOEHSURYLGHG

+HSDWLF(YHQWV
3UHIHUUHGWHUPVIRUKHSDWLFHYHQWVDUHIURPUHOHYDQW604VZKLFKDUHLGHQWLILHGDV
QRQLQIHFWLRXVDQGQRQFRQJHQLWDOKHSDWRELOLDU\GLVRUGHUV7KHVHOHFWHG37OLVWLQJZDVSURYLGHG
E\*LOHDG'63+DQGUHYLHZHGE\*LOHDGPHGLFDOPRQLWRUVVHHGHWDLOVLQ$SSHQGL[
7KHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVZLWKWUHDWPHQWHPHUJHQWKHSDWLFHYHQWVDQGVHULRXV
KHSDWLFHYHQWVE\37ZLOOEHVXPPDUL]HGE\WUHDWPHQWJURXSEDVHGRQWKHVDIHW\DQDO\VLVVHW
6WDWLVWLFDOFRPSDULVRQVRIWKHVXEMHFWLQFLGHQFHUDWHVEHWZHHQWKHWUHDWPHQWJURXSVZLOOEH
SHUIRUPHGXVLQJWKH)LVKHU¶VH[DFWWHVW$GDWDOLVWLQJRIKHSDWLFHYHQWVZLOOEHSURYLGHG

/DERUDWRU\(YDOXDWLRQV
/DERUDWRU\GDWDFROOHFWHGGXULQJWKHVWXG\ZLOOEHDQDO\]HGDQGVXPPDUL]HGXVLQJERWK
TXDQWLWDWLYHDQGTXDOLWDWLYHPHWKRGV6XPPDULHVRIODERUDWRU\GDWDZLOOEHSURYLGHGIRUWKH
6DIHW\$QDO\VLV6HW7KHDQDO\VLVZLOOEHEDVHGRQYDOXHVUHSRUWHGLQFRQYHQWLRQDOXQLWV:KHQ
YDOXHVDUHEHORZWKH/24WKH\ZLOOEHOLVWHGDVVXFKDQGWKHLPSXWHGYDOXHZLOOEHXVHGIRUWKH
SXUSRVHRIFDOFXODWLQJVXPPDU\VWDWLVWLFVDVVSHFLILHGLQ6HFWLRQ
$E\VXEMHFWOLVWLQJIRUODERUDWRU\WHVWUHVXOWVZLOOEHSURYLGHGE\VXEMHFW,'QXPEHUDQGYLVLWLQ
FKURQRORJLFDORUGHUIRUKHPDWRORJ\VHUXPFKHPLVWU\DQGXULQDO\VLVVHSDUDWHO\9DOXHVIDOOLQJ
RXWVLGHRIWKHUHIHUHQFHUDQJHDQGRUKDYLQJDVHYHULW\JUDGHRIRUKLJKHURQWKH*LOHDG
*UDGLQJ6FDOHIRU6HYHULW\RI$GYHUVH(YHQWVDQG/DERUDWRU\$EQRUPDOLWLHVZLOOEHIODJJHGLQ
WKHGDWDOLVWLQJVDVDSSURSULDWH

6XPPDULHVRI1XPHULF/DERUDWRU\5HVXOWV
'HVFULSWLYHVWDWLVWLFVZLOOEHSURYLGHGE\WUHDWPHQWJURXSIRUHDFKODERUDWRU\WHVWVSHFLILHGLQWKH
VWXG\SURWRFRODVIROORZV
x %DVHOLQHYDOXHV
x 9DOXHVDWHDFKSRVWEDVHOLQHDQDO\VLVZLQGRZ
x &KDQJHIURPEDVHOLQHDWHDFKSRVWEDVHOLQHDQDO\VLVZLQGRZ
x 3HUFHQWDJHFKDQJHIURPEDVHOLQHWRHDFKSRVWEDVHOLQHDQDO\VLVZLQGRZLIVSHFLILHG


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
$EDVHOLQHODERUDWRU\YDOXHZLOOEHGHILQHGDVWKHODVWQRQPLVVLQJYDOXHREWDLQHGRQRUSULRUWR
WKHGDWHRIILUVWGRVHRIVWXG\GUXJ&KDQJHIURPEDVHOLQHWRDSRVWEDVHOLQHYLVLWZLOOEHGHILQHG
DVWKHSRVWEDVHOLQHYDOXHPLQXVWKHEDVHOLQHYDOXH7KHPHDQPHGLDQ44PLQLPXPDQG
PD[LPXPYDOXHVZLOOEHGLVSOD\HGWRWKHUHSRUWHGQXPEHURIGLJLWV6'YDOXHVZLOOEHGLVSOD\HG
WRWKHUHSRUWHGQXPEHURIGLJLWVSOXV
,QWKHFDVHRIPXOWLSOHYDOXHVLQDQDQDO\VLVZLQGRZGDWDZLOOEHVHOHFWHGIRUDQDO\VLVDV
GHVFULEHGLQ6HFWLRQ
&DOFLXP&RUUHFWHGIRU$OEXPLQ
&DOFLXPFRUUHFWHGIRUDOEXPLQZLOOEHFDOFXODWHGDQGVXPPDUL]HGIRUWKHVWXG\7KHIROORZLQJ
IRUPXODZLOOEHXVHGZKHQERWKVHUXPFDOFLXPDQGDOEXPLQUHVXOWVIRUDJLYHQEORRGGUDZQDUH
DYDLODEOHDQGVHUXPDOEXPLQYDOXHLVJG/
x &DOFLXPFRUUHFWHGIRUDOEXPLQPJG/ VHUXPFDOFLXPPJG/î±DOEXPLQJG/
7R[LFLW\JUDGLQJIRUFDOFLXPZLOOEHDSSOLHGEDVHGRQWKHFRUUHFWHGYDOXHV
(VWLPDWHG*)5
7KHIROORZLQJIRUPXODZLOOEHXVHGWRFDOFXODWHH*)5&*
x H*)5&*P/PLQ >±DJH\UVîZHLJKWNJîLIIHPDOH@
6&UPJG/îZKHUHZHLJKWLVWRWDOERG\PDVVLQNLORJUDPVDQG6&ULVVHUXP
FUHDWLQLQH

*UDGHG/DERUDWRU\9DOXHV
7KH*LOHDG*UDGLQJ6FDOHIRU6HYHULW\RI$GYHUVH(YHQWVDQG/DERUDWRU\$EQRUPDOLWLHVZLOOEH
XVHGIRUDVVLJQLQJWR[LFLW\JUDGHVWRWRODERUDWRU\UHVXOWVIRUDQDO\VLV*UDGHLQFOXGHVDOO
YDOXHVWKDWGRQRWPHHWWKHFULWHULDIRUDQDEQRUPDOLW\RIDWOHDVW*UDGH)RUODERUDWRU\WHVWV
ZLWKFULWHULDIRUERWKLQFUHDVHGDQGGHFUHDVHGOHYHOVDQDO\VHVIRUHDFKGLUHFWLRQ
LHLQFUHDVHGGHFUHDVHGZLOOEHSUHVHQWHGVHSDUDWHO\
,IWKHUHLVDQ\ODERUDWRU\WR[LFLW\JUDGLQJVFDOHRYHUODSSLQJZLWKWKHQRUPDOUHIHUHQFHUDQJHV
HJJUDGHVFDOHRYHUODSVZLWKQRUPDOUHIHUHQFHUDQJHVODERUDWRU\YDOXHVWKDWDUHZLWKLQWKH
QRUPDOUDQJHZLOOEHJUDGHH[FHSWIRUOLSLGWHVWV
)RUWULJO\FHULGHV/'/DQGFKROHVWHUROWKHSURWRFROVSHFLILHGWR[LFLW\JUDGLQJVFDOHLVIRUIDVWLQJ
WHVWYDOXHVVRQRQIDVWLQJOLSLGUHVXOWVRUOLSLGUHVXOWVZLWKRXWNQRZQIDVWLQJVWDWXVZLOOQRWEH
JUDGHGRUVXPPDUL]HGE\WR[LFLW\JUDGHV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

7UHDWPHQW(PHUJHQW/DERUDWRU\$EQRUPDOLWLHV
7UHDWPHQWHPHUJHQWODERUDWRU\DEQRUPDOLWLHVDUHGHILQHGDVYDOXHVWKDWLQFUHDVHDWOHDVW
WR[LFLW\JUDGHIURPEDVHOLQHDWDQ\SRVWEDVHOLQHWLPHSRLQWXSWRGD\VDIWHUSHUPDQHQW
GLVFRQWLQXDWLRQRIVWXG\GUXJRUWKHODVWDYDLODEOHGDWHIRUVXEMHFWVZKRZHUHVWLOORQVWXG\GUXJ
DWWKHWLPHRIDQLQWHULPDQDO\VLV,IWKHUHOHYDQWEDVHOLQHODERUDWRU\YDOXHLVPLVVLQJDQ\
DEQRUPDOLW\RIDWOHDVW*UDGHREVHUYHGZLWKLQWKHWLPHIUDPHVSHFLILHGDERYHZLOOEH
FRQVLGHUHGWUHDWPHQWHPHUJHQW
)DVWLQJJOXFRVHDQGQRQIDVWLQJJOXFRVHLQFOXGLQJJOXFRVHUHVXOWVZLWKRXWDNQRZQIDVWLQJ
VWDWXVDUHJUDGHGEDVHGRQGLIIHUHQWJUDGLQJVFDOHVDVVSHFLILHGLQWKHSURWRFRO
7UHDWPHQWHPHUJHQWODERUDWRU\DEQRUPDOLWLHVZLOOEHVXPPDUL]HGIRUIDVWLQJJOXFRVH0D[LPXP
SRVWEDVHOLQHJUDGHLQVWHDGRIWUHDWPHQWHPHUJHQWJUDGHIRUQRQIDVWLQJJOXFRVHLQFOXGLQJ
JOXFRVHUHVXOWVZLWKRXWDNQRZQIDVWLQJVWDWXVZLOOEHVXPPDUL]HGDVQRQIDVWLQJJOXFRVHZDV
QRWDVVHVVHGDWEDVHOLQHYLVLWIRUPRVWRIWKHVXEMHFWVWKHUHIRUHDQDEQRUPDOLW\LV
WUHDWPHQWHPHUJHQWRUQRWFDQQRWEHGHWHUPLQHGIRUWKHVHVXEMHFWV
%RWKXULQH5%&EDVHGRQPLFURVFRSLFH[DPLQDWLRQODEHOHGDV+HPDWXULD4XDQWLWDWLYHDQG
XULQHEORRGEDVHGRQDGLSVWLFNODEHOHGDV+HPDWXULD'LSVWLFNDUHDVVHVVHGURXWLQHO\DQG
DVVLJQHGDWR[LFLW\JUDGHLQWKLVVWXG\8ULQH5%&EDVHGRQPLFURVFRSLFH[DPLQDWLRQZLOOEH
SUHVHQWHGLQODERUDWRU\WR[LFLW\VXPPDU\WDEOHVDQGOLVWLQJVZKLOHXULQHEORRGEDVHGRQD
GLSVWLFNZLOOEHSUHVHQWHGLQWKHOLVWLQJVRQO\

6XPPDULHVRI/DERUDWRU\$EQRUPDOLWLHV
7KHIROORZLQJVXPPDULHVQXPEHUDQGSHUFHQWDJHRIVXEMHFWVIRUWUHDWPHQWHPHUJHQWODERUDWRU\
DEQRUPDOLWLHVZLOOEHSURYLGHGE\ODEWHVWDQGWUHDWPHQWJURXSVXEMHFWVZLOOEHFDWHJRUL]HG
DFFRUGLQJWRWKHPRVWVHYHUHSRVWEDVHOLQHDEQRUPDOLW\JUDGHIRUDJLYHQODEWHVW
x 7UHDWPHQWHPHUJHQWODERUDWRU\DEQRUPDOLWLHV
x 7UHDWPHQWHPHUJHQW*UDGHDQGODERUDWRU\DEQRUPDOLWLHV
x 7UHDWPHQWHPHUJHQW*UDGHDQGODERUDWRU\DEQRUPDOLWLHV
)RUDOOVXPPDULHVRIODERUDWRU\DEQRUPDOLWLHVWKHGHQRPLQDWRULVWKHQXPEHURIVXEMHFWVZLWK
DQ\QRQPLVVLQJSRVWEDVHOLQHYDOXHVXSWRGD\VDIWHUODVWGRVLQJGDWH
$E\VXEMHFWOLVWLQJRIDOOWUHDWPHQWHPHUJHQWODERUDWRU\DEQRUPDOLWLHVDQGWUHDWPHQWHPHUJHQW
*UDGHRUODERUDWRU\DEQRUPDOLWLHVZLOOEHSURYLGHGE\VXEMHFW,'QXPEHUDQGYLVLWLQ
FKURQRORJLFDORUGHU


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

0HWDEROLF/DERUDWRU\(YDOXDWLRQV
)RUPHWDEROLFDVVHVVPHQWVLQFOXGLQJIDVWLQJJOXFRVHDQGWKHOLSLGSDQHOLHWRWDOFKROHVWHURO
WULJO\FHULGHV/'/+'/WRWDOFKROHVWHUROWR+'/UDWLRRQO\WKRVHPHDVXUHPHQWVXQGHUIDVWLQJ
VWDWXVZLOOEHVXPPDUL]HG3YDOXHVFRPSDULQJWKHGLIIHUHQFHEHWZHHQWKHWUHDWPHQWJURXSVLQ
EDVHOLQHYDOXHVDQGWKHFKDQJHIURPEDVHOLQHLQPHWDEROLFDVVHVVPHQWZLOOEHHVWLPDWHGIURPD
VLGHG:LOFR[RQUDQNVXPWHVW
,QDGGLWLRQWKHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVZKRWRRNOLSLGPRGLI\LQJPHGLFDWLRQVDW
VWXG\HQWU\DQGLQLWLDWHGWKHPHGLFDWLRQVGXULQJWKHVWXG\ZLOOEHSURYLGHGUHVSHFWLYHO\
6WDWLVWLFDOFRPSDULVRQVRIWKHVXEMHFWLQFLGHQFHUDWHVEHWZHHQWKHWUHDWPHQWJURXSVZLOOEH
SHUIRUPHGXVLQJ)LVKHU¶VH[DFWWHVW
$OLSLGPRGLI\LQJPHGLFDWLRQLVGHILQHGDVDPHGLFDWLRQZLWKGUXJFODVV ³/,3,'02',)<,1*
$*(176´DQG&0'(&2'FRQWDLQLQJWKHZRUGLQJRI³67$7,1´
$VHQVLWLYLW\DQDO\VLVRIIDVWLQJOLSLGWHVWVZLOOEHSHUIRUPHGE\H[FOXGLQJVXEMHFWVZKRWRRN
OLSLGPRGLI\LQJPHGLFDWLRQVDWVWXG\HQWU\RULQLWLDWHGWKHPHGLFDWLRQVGXULQJWKHVWXG\EDVHOLQH
YDOXHV:HHNYDOXHVDQGFKDQJHVIURPEDVHOLQHDW:HHNZLOOEHVXPPDUL]HGE\WUHDWPHQW
JURXSXVLQJGHVFULSWLYHVWDWLVWLFV%DVHOLQHDQGFKDQJHIURPEDVHOLQHDW:HHNZLOOEH
FRPSDUHGEHWZHHQWKHWUHDWPHQWJURXSVXVLQJDVLGHG:LOFR[RQUDQNVXPWHVW2QO\VXEMHFWV
ZLWKERWKEDVHOLQHDQG:HHNSRVWEDVHOLQHYDOXHVZLOOEHLQFOXGHGLQWKHDQDO\VLV
0HGLDQ44RIFKDQJHIURPEDVHOLQHLQIDVWLQJPHWDEROLFDVVHVVPHQWVRYHUWLPHZLOOEH
SORWWHGE\WUHDWPHQWJURXS

/LYHU5HODWHG/DERUDWRU\(YDOXDWLRQV
/LYHUUHODWHGDEQRUPDOLWLHVDIWHULQLWLDOVWXG\GUXJGRVLQJZLOOEHH[DPLQHGDQGVXPPDUL]HG
XVLQJWKHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVZKRZHUHUHSRUWHGWRKDYHWKHIROORZLQJODERUDWRU\
WHVWYDOXHVIRUSRVWEDVHOLQHPHDVXUHPHQWV
x $VSDUWDWHDPLQRWUDQVIHUDVH$67D!î8SSHUOLPLWRIQRUPDO8/1E!î8/1
F!î8/1G!î8/1
x $ODQLQHDPLQRWUDQVIHUDVH$/7D!î8/1E!î8/1F!î8/1
G!î8/1
x $67RU$/7D!î8/1E!î8/1F!î8/1G!î8/1
x 7RWDOELOLUXELQD!î8/1E!î8/1
x $ONDOLQHSKRVSKDWDVH$/3!î8/1
x $67RU$/7!î8/1DQGWRWDOELOLUXELQD!î8/1E!î8/1
x $67RU$/7!î8/1DQGWRWDOELOLUXELQ!î8/1DQG$/3î8/1


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
7KHVXPPDU\ZLOOLQFOXGHGDWDIURPDOOSRVWEDVHOLQHYLVLWVXSWRGD\VDIWHUWKHODVWGRVHRI
VWXG\GUXJ)RULQGLYLGXDOODERUDWRU\WHVWVVXEMHFWVZLOOEHFRXQWHGRQFHEDVHGRQWKHPRVW
VHYHUHSRVWEDVHOLQHYDOXH)RUERWKWKHFRPSRVLWHHQGSRLQWRI$67RU$/7DQGWRWDOELOLUXELQ
DQGWKHFRPSRVLWHHQGSRLQWRI$67RU$/7WRWDOELOLUXELQDQG$/3VXEMHFWVZLOOEHFRXQWHG
RQFHZKHQWKHFULWHULDDUHPHWDWWKHVDPHSRVWEDVHOLQHYLVLWGDWH7KHGHQRPLQDWRULVWKHQXPEHU
RIVXEMHFWVLQWKHVDIHW\DQDO\VLVVHWZLWKQRQPLVVLQJSRVWEDVHOLQHYDOXHRIWKHWHVWVLQHYDOXDWLRQ
DWWKHVDPHSRVWEDVHOLQHYLVLWGDWH
6XEMHFWVZLWK$67RU$/7!î8/1ZLOODOVREHOLVWHG
,QDGGLWLRQEDVHOLQHSRVWEDVHOLQHDQGFKDQJHIURPEDVHOLQHLQ$67$/7$/3DQGWRWDO
ELOLUXELQZLOOEHVXPPDUL]HGE\WUHDWPHQWJURXSDQGYLVLWXVLQJGHVFULSWLYHVWDWLVWLFV%DVHOLQH
DQGFKDQJHIURPEDVHOLQHZLOOEHFRPSDUHGEHWZHHQWKHWUHDWPHQWJURXSVXVLQJDVLGHG
:LOFR[RQUDQNVXPWHVW

5HQDO5HODWHG/DERUDWRU\(YDOXDWLRQV

6HUXP&UHDWLQLQHDQGH*)5&*
%DVHOLQHSRVWEDVHOLQHDQGFKDQJHIURPEDVHOLQHLQVHUXPFUHDWLQLQHDQGH*)5&*ZLOOEH
VXPPDUL]HGE\WUHDWPHQWJURXSDQGYLVLWXVLQJGHVFULSWLYHVWDWLVWLFV%DVHOLQHDQGFKDQJHIURP
EDVHOLQHZLOOEHFRPSDUHGEHWZHHQWKHWUHDWPHQWJURXSVXVLQJDVLGHG:LOFR[RQUDQNVXP
WHVW
0HGLDQ44RIFKDQJHIURPEDVHOLQHLQVHUXPFUHDWLQLQHDQGH*)5&*RYHUWLPHZLOOEH
SORWWHGE\WUHDWPHQWJURXS

8ULQH5HWLQRO%LQGLQJ3URWHLQWR&UHDWLQLQH5DWLR%HWD0LFURJOREXOLQWR
&UHDWLQLQH5DWLRDQG8ULQH&UHDWLQLQH
%DVHOLQHSRVWEDVHOLQHFKDQJHIURPEDVHOLQHDQGSHUFHQWDJHFKDQJHIURPEDVHOLQHLQXULQH5%3
WRFUHDWLQLQHUDWLRDQGEHWDPLFURJOREXOLQWRFUHDWLQLQHUDWLRZLOOEHVXPPDUL]HGE\WUHDWPHQW
JURXSDQGYLVLWXVLQJGHVFULSWLYHVWDWLVWLFV%DVHOLQHDQGSHUFHQWDJHFKDQJHIURPEDVHOLQHZLOOEH
FRPSDUHGEHWZHHQWKHWUHDWPHQWJURXSVXVLQJDVLGHG:LOFR[RQUDQNVXPWHVW
0HGLDQ44SHUFHQWDJHFKDQJHIURPEDVHOLQHLQXULQH5%3WRFUHDWLQLQHUDWLRDQG
EHWDPLFURJOREXOLQWRFUHDWLQLQHUDWLRRYHUWLPHZLOOEHSORWWHGE\WUHDWPHQWJURXS
%DVHOLQHSRVWEDVHOLQHDQGFKDQJHIURPEDVHOLQHLQXULQHFUHDWLQLQHZLOOEHVXPPDUL]HGE\
WUHDWPHQWJURXSDQGYLVLWXVLQJGHVFULSWLYHVWDWLVWLFV%DVHOLQHDQGFKDQJHIURPEDVHOLQHZLOOEH
FRPSDUHGEHWZHHQWKHWUHDWPHQWJURXSVXVLQJDVLGHG:LOFR[RQUDQNVXPWHVW


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

$OEXPLQXULDE\4XDQWLWDWLYH$VVHVVPHQW
7KHEDVHOLQHSRVWEDVHOLQHFKDQJHVIURPEDVHOLQHDQGSHUFHQWDJHFKDQJHIURPEDVHOLQHLQXULQH
DOEXPLQWRFUHDWLQLQHUDWLR8$&5ZLOOEHVXPPDUL]HGE\WUHDWPHQWJURXSDQGYLVLWXVLQJ
GHVFULSWLYHVWDWLVWLFV%DVHOLQHDQGSHUFHQWDJHFKDQJHIURPEDVHOLQHZLOOEHFRPSDUHGEHWZHHQ
WKHWUHDWPHQWJURXSVXVLQJDVLGHG:LOFR[RQUDQNVXPWHVW
7KHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVZLWK8$&5PJJYHUVXVPJJZLOOEH
VXPPDUL]HGE\EDVHOLQHFDWHJRU\DW:HHNVDQGEDVHGRQWKHODVWRQWUHDWPHQWYDOXH
LHGDWDFROOHFWHGDIWHUWKHILUVWGRVHGDWHXSWRGD\DIWHUWKHODVWGRVHGDWH
^.',*2*XLGHOLQH'HYHORSPHQW6WDII`
0HGLDQ44SHUFHQWDJHFKDQJHIURPEDVHOLQHLQ8$&5RYHUWLPHZLOOEHSORWWHGE\
WUHDWPHQWJURXS

%RQH6DIHW\$QDO\VHV

%RQH0LQHUDO'HQVLW\

3HUFHQWDJH&KDQJHIURP%DVHOLQHLQ+LSDQG6SLQH%RQH0LQHUDO'HQVLW\
7KHSHUFHQWDJHFKDQJHIURPEDVHOLQHLQKLS%0'DQGVSLQH%0'ZLOOEHVXPPDUL]HGE\
WUHDWPHQWJURXSDQGYLVLWXVLQJGHVFULSWLYHVWDWLVWLFVIRUVXEMHFWVLQWKHKLSDQGVSLQH';$
DQDO\VLVVHWVUHVSHFWLYHO\DQGFRPSDUHGEHWZHHQWKHWUHDWPHQWJURXSVDWHDFKYLVLWXVLQJ
$129$ZKLFKLQFOXGHVWUHDWPHQWDVDIL[HGHIIHFW
$VDVHQVLWLYLW\DQDO\VLVPLVVLQJYDOXHVIRUKLS%0'DQGVSLQH%0'ZLOOEHLPSXWHGXVLQJWKH
/2&)LPSXWDWLRQPHWKRGIRUWKHDQDO\VHVRISHUFHQWDJHFKDQJHIURPEDVHOLQH7KHDOJRULWKPIRU
/2&)LVDVIROORZV
x ,IDYDOXHLVPLVVLQJLQDQDQDO\VLVYLVLWZLQGRZWKHPLVVLQJYDOXHZLOOEHUHSODFHGZLWKWKH
ODVWYDOXHREVHUYHGEHIRUHWKHDQDO\VLVYLVLWZLQGRZWKDWKDVWKHPLVVLQJYDOXH
x %DVHOLQHYDOXHVZLOOEHFDUULHGIRUZDUGWRLPSXWHWKHSRVWEDVHOLQHYDOXHDWDVSHFLILFYLVLWLI
WKHUHLVQRQRQPLVVLQJSRVWEDVHOLQHREVHUYDWLRQFROOHFWHGSULRUWRWKDWYLVLW
6LPLODUWRWKHDQDO\VLVRIREVHUYHGGDWDWKHSHUFHQWDJHFKDQJHIURPEDVHOLQHLQKLS%0'DQG
VSLQH%0'E\/2&)ZLOODOVREHDQDO\]HGXVLQJWKHKLSDQGVSLQH';$VXEVWXG\DQDO\VLVVHWV
0HGLDQ44DQGPHDQ&,RIWKHSHUFHQWDJHFKDQJHIURPEDVHOLQHLQREVHUYHGKLS
%0'DQGVSLQH%0'RYHUWLPHZLOOEHSORWWHGE\WUHDWPHQWJURXS/LVWLQJVRIKLSDQGVSLQH
';$UHVXOWVZLOOEHSURYLGHG


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

+LSDQG6SLQH%0'&OLQLFDO6WDWXV
$QDO\VLVRIKLSDQGVSLQH%0'FOLQLFDOVWDWXVZLOOEDVHGRQWKHREVHUYHG%0'YDOXHV
LHPLVVLQJZLOOEHH[FOXGHG
)RUHDFKVXEMHFWDQGHDFKYLVLWWKH%0'FOLQLFDOVWDWXVZLOOEHGHILQHGIRUKLS%0'DQGVSLQH
%0'DVIROORZVEDVHGRQWKHWVFRUH
7DEOH
1RUPDO2VWHRSHQLDDQG2VWHRSRURVLVDV'HILQHGE\7VFRUH
&OLQLFDO6WDWXV
%0'7VFRUH
1RUPDO
7VFRUH
2VWHRSHQLD
7VFRUH
2VWHRSRURVLV
7VFRUH

7KHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVLQHDFK%0'FOLQLFDOVWDWXVQRUPDORVWHRSHQLDDQG
RVWHRSRURVLVZLOOEHVXPPDUL]HGE\YLVLWDQGE\EDVHOLQHFOLQLFDOVWDWXVIRUERWKKLSDQGVSLQH
7KHGLVWULEXWLRQRIWKH%0'FOLQLFDOVWDWXVZLOOEHFRPSDUHGEHWZHHQWKHWUHDWPHQWJURXSV
DGMXVWLQJIRUEDVHOLQHFOLQLFDOVWDWXVXVLQJUDQNDQDO\VLVRIFRYDULDQFH^/D9DQJH`

*UDGDWLRQRIWKH3HUFHQWDJH&KDQJHLQ+LS)HPXU1HFNDQG6SLQH%0'
)RUHDFKVXEMHFWDQGHDFKYLVLWSHUFHQWDJHFKDQJHIURPEDVHOLQHLQVSLQH%0'ZLOOEHFODVVLILHG
LQWRFDWHJRULHVGHFUHDVHWRGHFUHDVH!WRGHFUHDVHWR
LQFUHDVHWRLQFUHDVHDQGLQFUHDVH6LPLODUO\WKHSHUFHQWDJHFKDQJHIURP
EDVHOLQHLQ+LS%0'DQG)HPXU1HFN%0'ZLOOEHFODVVLILHGLQWRFDWHJRULHVGHFUHDVH
WRGHFUHDVH!WRGHFUHDVHWRLQFUHDVHWRLQFUHDVH
DQGLQFUHDVH7KHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVLQHDFKFDWHJRU\ZLOOEHVXPPDUL]HG
E\YLVLW7KHGLIIHUHQFHLQWKHGLVWULEXWLRQRIWKHVHFDWHJRULHVEHWZHHQWKHWUHDWPHQWJURXSVZLOO
EHFRPSDUHGXVLQJD&0+WHVWURZPHDQVFRUHVGLIIHUVWDWLVWLF
,QDGGLWLRQWKHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVZLWKSHUFHQWDJHFKDQJHIURPEDVHOLQHLQHDFK
FXPXODWLYHFDWHJRULHVLHGHFUHDVHGHFUHDVHQRGHFUHDVH>LQFUHDVH@
LQFUHDVHDQGLQFUHDVHIRU6SLQH%0'GHFUHDVHGHFUHDVHQRGHFUHDVH
>LQFUHDVH@LQFUHDVHDQGLQFUHDVHIRU+LSDQG)HPXU1HFN%0'ZLOOEH
FRPSDUHGEHWZHHQWUHDWPHQWJURXSVXVLQJ)LVKHUH[DFWWHVWEDVHGRQWKHGLFKRWRPL]HGUHVSRQVH
HJGHFUHDVHYVGHFUHDVH

%RG\:HLJKW+HLJKWDQG9LWDO6LJQV
'HVFULSWLYHVWDWLVWLFVZLOOEHSURYLGHGE\WUHDWPHQWJURXSIRUYLWDOVLJQVDQGERG\ZHLJKWDV
IROORZV
x %DVHOLQHYDOXHV
x 9DOXHVDWHDFKSRVWEDVHOLQHDQDO\VLVZLQGRZ
x &KDQJHIURPEDVHOLQHWRHDFKSRVWEDVHOLQHDQDO\VLVZLQGRZ


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
$EDVHOLQHYDOXHZLOOEHGHILQHGDVWKHODVWQRQPLVVLQJYDOXHREWDLQHGRQRUSULRUWRWKHGDWHRI
ILUVWGRVHRIVWXG\GUXJ&KDQJHIURPEDVHOLQHWRDSRVWEDVHOLQHYLVLWZLOOEHGHILQHGDVWKH
SRVWEDVHOLQHYDOXHPLQXVWKHEDVHOLQHYDOXH
,QWKHFDVHRIPXOWLSOHYDOXHVLQDQDQDO\VLVZLQGRZGDWDZLOOEHVHOHFWHGIRUDQDO\VLVDV
GHVFULEHGLQ6HFWLRQ1RIRUPDOVWDWLVWLFDOWHVWLQJLVSODQQHG
$E\VXEMHFWOLVWLQJRIYLWDOVLJQVZLOOEHSURYLGHGE\VXEMHFW,'QXPEHUDQGYLVLWLQ
FKURQRORJLFDORUGHU,QWKHVDPHOLVWLQJDE\VXEMHFWOLVWLQJRIERG\ZHLJKWKHLJKWDQG%0,
ZLOOEHSURYLGHG

3ULRUDQG&RQFRPLWDQW0HGLFDWLRQV

1RQVWXG\'UXJ$QWLUHWURYLUDO0HGLFDWLRQV
$Q\QRQVWXG\GUXJ$59PHGLFDWLRQVXVHGSULRUWRGXULQJRUDIWHUWKHVWXG\LIFROOHFWHGZLOO
EHFRGHGXVLQJWKH*LOHDGPRGLILHG:RUOG+HDOWK2UJDQL]DWLRQ:+2'UXJ'LFWLRQDU\IRU
$59PHGLFDWLRQV7KH:+2SUHIHUUHGQDPHDQGGUXJFRGHZLOOEHDWWDFKHGWRWKHFOLQLFDO
GDWDEDVH$OOQRQVWXG\GUXJ$59PHGLFDWLRQVZLOOEHOLVWHG1RLQIHUHQWLDOVWDWLVWLFVZLOOEH
SURYLGHG

&RQFRPLWDQW1RQ$590HGLFDWLRQV
&RQFRPLWDQWQRQ$59PHGLFDWLRQVLHPHGLFDWLRQVRWKHUWKDQVWXG\GUXJWKDWDUHWDNHQZKLOH
UHFHLYLQJVWXG\GUXJZLOOEHFRGHGXVLQJWKH:+2'UXJ'LFWLRQDU\7KH:+2SUHIHUUHGQDPH
DQGGUXJFRGHZLOOEHDWWDFKHGWRWKHFOLQLFDOGDWDEDVH8VHRIFRQFRPLWDQWPHGLFDWLRQVIURP
6WXG\'D\XSWRWKHGDWHRIODVWGRVHRIVWXG\GUXJZLOOEHVXPPDUL]HGQXPEHUDQG
SHUFHQWDJHRIVXEMHFWVE\WUHDWPHQWJURXS:+2GUXJFODVVDQGSUHIHUUHGQDPH0XOWLSOHGUXJ
XVHE\SUHIHUUHGQDPHZLOOEHFRXQWHGRQO\RQFHSHUVXEMHFW7KHVXPPDU\ZLOOEHVRUWHG
DOSKDEHWLFDOO\E\GUXJFODVVDQGWKHQE\GHFUHDVLQJWRWDOIUHTXHQF\ZLWKLQDFODVV
,IWKHVWDUWRUVWRSGDWHRIQRQ$59PHGLFDWLRQVLVLQFRPSOHWHWKHPRQWKDQG\HDURU\HDUDORQH
LIPRQWKLVQRWUHFRUGHGRIWKHVWDUWRUVWRSGDWHZLOOEHXVHGWRGHWHUPLQHZKHWKHUWKH
QRQ$59VDUHFRQFRPLWDQWRUQRW7KHPHGLFDWLRQLVFRQFRPLWDQWLIWKHPRQWKDQG\HDURIWKH
VWDUWRUVWRSRU\HDURIWKHVWDUWRUVWRSLIPRQWKLVQRWUHFRUGHGRIWKHPHGLFDWLRQGRHVQRW
PHHWHLWKHURIWKHIROORZLQJFULWHULD
x 7KHPRQWKDQG\HDURIVWDUWRIWKHPHGLFDWLRQLVDIWHUWKHGDWHRIWKHODVWGRVHRIVWXG\GUXJ
x 7KHPRQWKDQG\HDURIVWRSRIWKHPHGLFDWLRQLVEHIRUHWKHGDWHRIWKHILUVWGRVHRIVWXG\GUXJ
,IWKHVWDUWDQGVWRSGDWHRIQRQ$59PHGLFDWLRQVDUHFRPSOHWHWKHVWDUWGDWHLVQRWDIWHUODVWGRVH
GDWHDQGWKHVWRSGDWHLVQRWEHIRUHILUVWGRVHGDWHRUWKHQRQ$59PHGLFDWLRQVDUHPDUNHGDV
RQJRLQJDQGVWDUWGDWHLVRQRUEHIRUHODVWGRVHGDWHWKHQRQ$59PHGLFDWLRQVDUHFRQFRPLWDQW
6XPPDULHVRIQRQ$59FRQFRPLWDQWPHGLFDWLRQVZLOOEHSURYLGHGIRUWKHVDIHW\DQDO\VLVVHW
6XEMHFWVZLWKDQ\QRQ$59FRQFRPLWDQWPHGLFDWLRQVZLOOEHOLVWHG1RLQIHUHQWLDOVWDWLVWLFVZLOO
EHSURYLGHG


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

(OHFWURFDUGLRJUDP5HVXOWV
$VKLIWWDEOHRIWKHLQYHVWLJDWRUV¶DVVHVVPHQWRI(&*UHVXOWVDWHDFKVFKHGXOHGSRVWEDVHOLQHYLVLW
FRPSDUHGZLWKEDVHOLQHYDOXHVZLOOEHSUHVHQWHGE\WUHDWPHQWJURXSXVLQJWKHIROORZLQJ
FDWHJRULHVQRUPDODEQRUPDOQRWFOLQLFDOO\VLJQLILFDQWDEQRUPDOFOLQLFDOO\VLJQLILFDQWRU
PLVVLQJ7KHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVLQHDFKFURVVFODVVLILFDWLRQJURXSRIWKHVKLIW
WDEOHZLOOEHSUHVHQWHG6XEMHFWVZLWKDPLVVLQJYDOXHDWEDVHOLQHRUSRVWEDVHOLQHZLOOQRWEH
LQFOXGHGLQWKHGHQRPLQDWRUIRUSHUFHQWDJHFDOFXODWLRQ1RLQIHUHQWLDOVWDWLVWLFVZLOOEHSURYLGHG
$E\VXEMHFWOLVWLQJIRU(&*DVVHVVPHQWUHVXOWVZLOOEHSURYLGHGE\VXEMHFW,'QXPEHUDQGYLVLWV
LQFKURQRORJLFDORUGHU

2WKHU6DIHW\0HDVXUHV
$GDWDOLVWLQJZLOOEHSURYLGHGIRUVXEMHFWVH[SHULHQFLQJSUHJQDQF\GXULQJWKHVWXG\3K\VLFDO
H[DPLQDWLRQGDWDZDVQRWFROOHFWHGLQWKHH&5)7KHUHIRUHLWZLOOQRWEHLQFOXGHGLQWKH
DQDO\VLV

6XEMHFW6XEJURXSIRU6DIHW\(QGSRLQWV
,QFLGHQFHRIDOOWUHDWPHQWHPHUJHQW$(VZLOOEHUHSHDWHGZLWKLQHDFKVXEJURXSGHILQHGLQ
6HFWLRQXVLQJWKHVDIHW\DQDO\VLVVHW

&KDQJHV)URP3URWRFRO6SHFLILHG6DIHW\$QDO\VHV
1RFKDQJHIURPWKHSURWRFROVSHFLILHGVDIHW\DQDO\VLVLVSODQQHG


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

3+$50$&2.,1(7,&$1$/<6(6
3KDUPDFRNLQHWLFSDUDPHWHUVZLOOEHFRPSXWHGIRUDOOVXEMHFWVLQWKH3.VXEVWXG\DQDO\VLVVHW
2QO\DQDO\WHVIURP%)7$)JURXSSUHVHQWHGLQ7DEOHZLOOEHDQDO\]HGDQGHYDOXDWHG
7DEOH
7UHDWPHQWDQG$VVRFLDWHG$QDO\WHV
7UHDWPHQW
$QDO\WH
%)7$)
%,&
)7&
7$)

3.SDUDPHWHUVWREHHVWLPDWHGDQGDQDO\]HGLQWKLVVXEVWXG\DUHOLVWHGDQGGHILQHGLQ3.
DEEUHYLDWLRQV

(VWLPDWLRQRI3KDUPDFRNLQHWLF3DUDPHWHUV
3KDUPDFRNLQHWLFSDUDPHWHUVZLOOEHHVWLPDWHGE\DSSOLFDWLRQRIDQRQOLQHDUPRGHOXVLQJVWDQGDUG
QRQFRPSDUWPHQWDOPHWKRGV:LQ1RQOLQVRIWZDUH7KHOLQHDUXSORJGRZQWUDSH]RLGDOUXOHZLOO
EHXVHGLQFRQMXQFWLRQZLWKWKHDSSURSULDWHQRQFRPSDUWPHQWDOPRGHOXVXDOO\LQSXW0RGHO
IRURUDOGRVLQJZLWKLQSXWYDOXHVIRUGRVHWLPHRIGRVHSODVPDFRQFHQWUDWLRQDQG
FRUUHVSRQGLQJUHDOWLPHYDOXHVEDVHGRQGUXJGRVLQJWLPHVZKHQHYHUSRVVLEOH
$OOSUHGRVHVDPSOHWLPHVRIOHVVWKDQWLPH]HURZLOOEHFRQYHUWHGWR]HUR6DPSOHVEHORZWKH
OLPLWRITXDQWLWDWLRQRIWKHELRDQDO\WLFDODVVD\VWKDWRFFXUSULRUWRWKHDFKLHYHPHQWRIWKHILUVW
TXDQWLILDEOHFRQFHQWUDWLRQZLOOEHDVVLJQHGDFRQFHQWUDWLRQYDOXHRI]HURWRSUHYHQW
RYHUHVWLPDWLRQRIWKHLQLWLDO$8&6DPSOHVWKDWDUH%/4DWDOORWKHUWLPHSRLQWVZLOOEHWUHDWHG
DVPLVVLQJGDWD7KHQRPLQDOWLPHSRLQWIRUDNH\HYHQWRUGRVLQJLQWHUYDOWDXPD\EHXVHGWR
SHUPLWGLUHFWFDOFXODWLRQRI$8&RYHUVSHFLILFWLPHLQWHUYDOV7KHDSSURSULDWHQHVVRIWKLV
DSSURDFKZLOOEHDVVHVVHGE\WKHSKDUPDFRNLQHWLFLVWRQDSURILOHE\SURILOHEDVLV
$FFXUDWHHVWLPDWLRQRIVHYHUDO3.SDUDPHWHUVVXFKDVȜ]DQGWDUHGHSHQGHQWRQWKHDFFXUDWH
HVWLPDWLRQRIWKHWHUPLQDOHOLPLQDWLRQSKDVHRIWKHGUXJ7KHDSSURSULDWHQHVVRIFDOFXODWLQJWKHVH
SDUDPHWHUVZLOOEHHYDOXDWHGXSRQLQVSHFWLRQRI3.GDWDRQDSURILOHE\SURILOHEDVLVE\WKH
SKDUPDFRNLQHWLFLVW

$QDO\VLVIRU,QWHQVLYH3.3.6XEVWXG\$QDO\VLV6HW
3ODVPDFRQFHQWUDWLRQZLOOEHOLVWHGIRUDOOVXEMHFWVDQGVXPPDUL]HGE\QRPLQDOWLPHSRLQWIRU
VXEMHFWVLQWKH3.VXEVWXG\DQDO\VLVVHW
3.SDUDPHWHUVHVWLPDWHGIRUHDFKDQDO\WHZLOOEHOLVWHGIRUDOOVXEMHFWVDQGVXPPDUL]HGIRU
VXEMHFWVLQWKH3.VXEVWXG\DQDO\VLVVHW


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
7KHGHVFULSWLYHVWDWLVWLFVQPHDQ6'FRHIILFLHQWRIYDULDWLRQ>&9@PLQLPXPPHGLDQ
PD[LPXP44JHRPHWULFPHDQDQGLWV&,ZLOOEHSUHVHQWHGIRUSODVPDFRQFHQWUDWLRQ
DQGSDUDPHWHUGDWD)RUFRQFHQWUDWLRQYDOXHV%/4WKHQXPEHURIVXEMHFWVZLWKYDOXHVRI%/4
ZLOOEHSUHVHQWHG)RU3.SDUDPHWHUGDWDWKHPHDQDQG6'RIWKHQDWXUDOORJWUDQVIRUPHGYDOXHV
ZLOOEHSUHVHQWHGLQDGGLWLRQWRWKHVXPPDULHVPHQWLRQHGDERYH
7KHIROORZLQJWDEOHVILJXUHVDQGOLVWLQJV7)/VZLOOEHSURYLGHGIRUWKHLQWHQVLYH3.DQDO\VLVDW
:HHNVRUIRUHDFKDQDO\WHIRUVXEMHFWVLQWKH3.VXEVWXG\DQDO\VLVVHW
x 7DEOHZLWKLQGLYLGXDOVXEMHFWFRQFHQWUDWLRQDQGVXPPDU\VWDWLVWLFVDWHDFKWLPHSRLQWIRU
HDFKDQDO\WH
x 7DEOHZLWKLQGLYLGXDOVXEMHFW3.SDUDPHWHUVDQGVXPPDU\VWDWLVWLFVIRUHDFKDQDO\WH
x 0HDQ6'FRQFHQWUDWLRQYVWLPHILJXUHV±OLQHDUDQGVHPLORJSORWVIRUHDFKDQDO\WH
x 0HGLDQ44FRQFHQWUDWLRQYVWLPHILJXUHV±OLQHDUDQGVHPLORJSORWVIRUHDFKDQDO\WH
x ,QGLYLGXDOSODVPDFRQFHQWUDWLRQYVWLPHILJXUHV±OLQHDUDQGVHPLORJSORWVIRUHDFKDQDO\WH
x /LVWLQJRIWKHWLPHSRLQWVXVHGLQWKHFDOFXODWLRQRIWKHWHUPLQDOHOLPLQDWLRQUDWHFRQVWDQWO=
IRUHDFKDQDO\WH
x /LVWLQJRI3.VDPSOLQJGHWDLOVE\VXEMHFWLQFOXGLQJGHYLDWLRQVLQVFKHGXOHGDQGDFWXDOGUDZ
WLPHVDQGSURFHGXUHVLQGLYLGXDOEORRGVDPSOLQJWLPHGHYLDWLRQVLQPLQXWHV
x /LVWLQJRIVWXG\GUXJDGPLQLVWUDWLRQUHFRUGIRULQWHQVLYH3.GRVLQJ

$QDO\VLVIRU7URXJKDQG3RVWGRVH3.3.$QDO\VLV6HW
2QO\3.SODVPDVDPSOHVFROOHFWHGWKURXJK2FWREHUWKZHUHDQDO\]HGDQGWKHLU
FRQFHQWUDWLRQGDWDDUHDYDLODEOHLQWKH:HHNLQWHULPDQDO\VLV7KHIROORZLQJOLVWLQJVZLOOEH
SURYLGHGIRUWURXJKDQGSRVWGRVH3.DQDO\VLVIRUVXEMHFWVLQWKH3.DQDO\VLVVHW
x /LVWLQJRI3.VDPSOLQJGHWDLOV3.VDPSOHVFROOHFWHGDV³3UHGRVH´GXULQJLQWHQVLYH3.
FROOHFWLRQRU³7URXJK´3.VDPSOHV>GHILQHGDVVDPSOHVFROOHFWHGZLWKLQDUDQJHRI
WRKRXUVLQFOXVLYHDIWHUSUHYLRXVGRVLQJWLPH@ZLOOEHPDUNHGLQWKHOLVWLQJ
x /LVWLQJRIVWXG\GUXJDGPLQLVWUDWLRQUHFRUGIRU3.GRVLQJ
3.VDPSOLQJGHWDLOVIRUWKHLQWHQVLYH3.WURXJK3.DQGSRVWGRVH3.VDPSOHVZLOOEHLQFOXGHG
LQRQHOLVWLQJ6LPLODUO\VWXG\GUXJDGPLQLVWUDWLRQUHFRUGVIRUWKHLQWHQVLYH3.WURXJK3.DQG
SRVWGRVH3.VDPSOHVZLOODOVREHLQFOXGHGLQRQHOLVWLQJ

&KDQJHVIURP3URWRFRO6SHFLILHG3KDUPDFRNLQHWLF$QDO\VLV
1RFKDQJHIURPWKHSURWRFROVSHFLILHG3.DQDO\VHVLVSODQQHG


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

63(&,$/3238/$7,21$1$/<6(6

$QDO\VHVIRU+,9+%9&RLQIHFWHG6XEMHFWV
6XEMHFWVZLWK+,9+%9FRLQIHFWLRQDWEDVHOLQHDUHGHILQHGDVVXEMHFWVZKRPHHWDQ\RIWKH
IROORZLQJWZRFULWHULD
x 3RVLWLYH+%V$JRQRUSULRUWRWKHILUVWGRVHGDWHRU
x 1HJDWLYH+%V$JQHJDWLYH+%V$ESRVLWLYH+%F$EDQGTXDQWLILDEOH+%9'1$
LH+%9'1$,8P/RQRUSULRUWRWKHILUVWGRVHGDWH
6XEMHFWVZLWKLQFLGHQW+,9+%9FRLQIHFWLRQZKLOHRQVWXG\GUXJLIDQ\DUHGHILQHGDVVXEMHFWV
ZKRDUHQRW+,9+%9FRLQIHFWHGDWEDVHOLQHDQGPHHWDQ\RIWKHIROORZLQJFULWHULD
x 3RVLWLYH+%V$JDIWHUWKHILUVWGRVHGDWHDQGRQRUSULRUWRWKHGDWHRISHUPDQHQW
GLVFRQWLQXDWLRQRIVWXG\GUXJRU
x 1HJDWLYH+%V$JQHJDWLYH+%V$ESRVLWLYH+%F$EDQGTXDQWLILDEOH+%9'1$
LH+%9'1$,8P/DIWHUWKHILUVWGRVHGDWHDQGRQRUSULRUWRWKHGDWHRISHUPDQHQW
GLVFRQWLQXDWLRQRIVWXG\GUXJRU
x ([SHULHQFHDQ\RIWKHIROORZLQJDGYHUVHHYHQWVLHVHOHFWHG0HG'5$SUHIHUUHGWHUPVIURP
WKH604RI³/LYHU,QIHFWLRQV´DIWHUWKHILUVWGRVHGDWHDQGRQRUSULRUWRWKHGDWHRI
SHUPDQHQWGLVFRQWLQXDWLRQRIVWXG\GUXJ$FXWHKHSDWLWLV%&KURQLFKHSDWLWLV%&RQJHQLWDO
KHSDWLWLV%LQIHFWLRQ+HSDWLWLV%+HSDWLWLV%FRUHDQWLERG\SRVLWLYH+HSDWLWLV%'1$DVVD\
SRVLWLYH+HSDWLWLV%VXUIDFHDQWLJHQSRVLWLYH+HSDWLWLV%YLUXVWHVWSRVLWLYH
7KHIROORZLQJOLVWLQJVZLOOEHSURYLGHGIRUVXEMHFWVZLWKLQFLGHQW+,9+%9FRLQIHFWLRQZKLOHRQ
VWXG\GUXJLIDQ\
x /LVWLQJRIDGYHUVHHYHQWV
x /LVWLQJRIOLYHUUHODWHGODERUDWRU\WHVWVDQG+%9'1$UHVXOWV

$QDO\VHVIRU+,9+&9&RLQIHFWHG6XEMHFWV
6XEMHFWVZLWK+,9+&9FRLQIHFWLRQDWEDVHOLQHDUHGHILQHGDVVXEMHFWVZLWKSRVLWLYH+&9$E
DQGTXDQWLILDEOH+&951$LH+&951$,8P/RQRUSULRUWRWKHILUVWGRVHGDWH7KH
IROORZLQJOLVWLQJVZLOOEHSURYLGHGIRUVXEMHFWVZLWK+,9+&9FRLQIHFWLRQDWEDVHOLQH
x /LVWLQJRIDGYHUVHHYHQWV
x /LVWLQJRIOLYHUUHODWHGODERUDWRU\WHVWVDQG+&951$UHVXOWV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
6XEMHFWVZLWKLQFLGHQW+,9+&9FRLQIHFWLRQZKLOHRQVWXG\GUXJDUHGHILQHGDVVXEMHFWVZKRDUH
QRW+,9+&9FRLQIHFWHGDWEDVHOLQHDQGPHHWDQ\RIWKHIROORZLQJFULWHULD
x 3RVLWLYH+&9$EDIWHUWKHILUVWGRVHGDWHDQGRQRUSULRUWRWKHGDWHRISHUPDQHQW
GLVFRQWLQXDWLRQRIVWXG\GUXJZLWKEDVHOLQH+&9$E1HJDWLYHRUPLVVLQJRU
x 4XDQWLILDEOH+&951$LH+&951$,8P/DIWHUWKHILUVWGRVHGDWHDQGRQRUSULRU
WRWKHGDWHRISHUPDQHQWGLVFRQWLQXDWLRQRIVWXG\GUXJRU
x ([SHULHQFHDQ\RIWKHIROORZLQJDGYHUVHHYHQWVLHVHOHFWHG0HG'5$37VIURPWKH604RI
³/LYHU,QIHFWLRQV´DIWHUWKHILUVWGRVHGDWHDQGRQRUSULRUWRWKHGDWHRISHUPDQHQW
GLVFRQWLQXDWLRQRIVWXG\GUXJ$FXWHKHSDWLWLV&&KURQLFKHSDWLWLV&+HSDWLWLV&
+HSDWLWLV&DQWLERG\SRVLWLYH+HSDWLWLV&51$SRVLWLYH+HSDWLWLV&YLUXVWHVWSRVLWLYH
7KHIROORZLQJOLVWLQJVZLOOEHSURYLGHGIRUVXEMHFWVZLWKLQFLGHQW+,9+&9FRLQIHFWLRQZKLOHRQ
VWXG\GUXJ
x /LVWLQJRIDGYHUVHHYHQWV
x /LVWLQJRIOLYHUUHODWHGODERUDWRU\WHVWVDQG+&951$UHVXOWV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

5()(5(1&(6
.',*2*XLGHOLQH'HYHORSPHQW6WDII.',*2&OLQLFDO3UDFWLFH*XLGHOLQHIRUWKH
(YDOXDWLRQDQG0DQDJHPHQWRI&KURQLF.LGQH\'LVHDVH.LGQH\LQWHUQDWLRQDO
6XSSOHPHQWY
/D9DQJH/0.RFK**5DQGRPL]DWLRQ%DVHG1RQSDUDPHWULF$1&29$,Q'
$JRVWLQR6U
5%6XOOLYDQ/00DVVDUR-0HGV:LOH\(QF\FORSHGLDRI&OLQLFDO7ULDOV-RKQ
:LOH\	6RQV,QFYRO
86'HSDUWPHQWRI+HDOWKDQG+XPDQ6HUYLFHV)RRGDQG'UXJ$GPLQLVWUDWLRQ)'$&HQWHU
IRU'UXJ(YDOXDWLRQDQG5HVHDUFK&'(5+XPDQ,PPXQRGHILFLHQF\9LUXV
,QIHFWLRQ'HYHORSLQJ$QWLUHWURYLUDO'UXJVIRU7UHDWPHQW*XLGDQFHIRU,QGXVWU\
5HYLVLRQ1RYHPEHU




%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

62)7:$5(
6$69HUVLRQ6$6,QVWLWXWH,QF&DU\1&LVWREHXVHGIRUDOOSURJUDPPLQJRIWDEOHV
OLVWLQJVDQGILJXUHV
Q4XHU\$GYLVRU9HUVLRQ6WDWLVWLFDO6ROXWLRQV&RUN,UHODQGLVWREHXVHGIRUVDPSOHVL]H
DQGSRZHUFDOFXODWLRQ
3KRHQL[:LQ1RQOLQ9HUVLRQ&HUWDUD86$,QF3ULQFHWRQ1-86$LVWREHXVHGIRUDOO
3.DQDO\VHV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

6$35(9,6,21
5HYLVLRQ'DWH
GGPRQWK\\\\
6HFWLRQ
6XPPDU\RI5HYLVLRQ
5HDVRQIRU5HYLVLRQ











%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\

$33(1',&(6
$SSHQGL[ 
6WXG\3URFHGXUHV7DEOHV 
$SSHQGL[ 
)ORZFKDUWRI86)'$GHILQHG6QDSVKRW$OJRULWKPIRU6ZLWFK7ULDO 
$SSHQGL[ 
5HJLRQ'HILQLWLRQ 
$SSHQGL[ 
6HOHFWHG0HGLFDO+LVWRU\ 
$SSHQGL[ 
+HSDWLF(YHQWV 
$SSHQGL[ 
3URJUDPPLQJ6SHFLILFDWLRQ 



%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV

9HUVLRQ
&21),'(17,$/

3DJH

0D\
$SSHQGL[
6WXG\3URFHGXUHV7DEOHV
$SSHQGL[7DEOH
6WXG\3URFHGXUHV7DEOH%OLQGHG3KDVH
6WXG\3URFHGXUHV
6FUHHQLQJD
'D\E
(QGRI:HHNHS
3RVW:HHNHT
(QGRI%OLQGHG
7UHDWPHQW9LVLW
'D\
)ROORZXSR
(DUO\6WXG\
'UXJV'&F






(YHU\:HHNV
,QIRUPHG&RQVHQW
;











0HGLFDO+LVWRU\
;











&RQFRPLWDQW0HGLFDWLRQV
;
;
;
;
;
;
;
;
;
;
;
;
$GYHUVH(YHQWV
;
;
;
;
;
;
;
;
;
;
;I
;I
&RPSOHWH6\PSWRP'LUHFWHG
3K\VLFDO([DP
;
;
;G
;G
;G
;
;G
;
;G
;
;GI
;I
/HDG(&*SHUIRUPHGVXSLQH
;
;



;

;

;

;
4XHVWLRQQDLUHV

;
;

;


;




';$VFDQVSLQH	KLSJ

;



;

;

;

;
+HLJKW
;











9LWDOVLJQVEORRGSUHVVXUHSXOVH
UHVSLUDWLRQUDWHDQGWHPSHUDWXUH
LQFOXGLQJ:HLJKW
;
;
;
;
;
;
;
;
;
;
;
;
8ULQDO\VLV
;
;
;
;
;
;
;
;
;
;
;I
;I
8ULQH3UHJQDQF\7HVWK

;
;
;
;
;
;
;
;
;
;
;
6HUXP3UHJQDQF\7HVW
;











&KHPLVWU\3URILOHL
;
;
;
;
;
;
;
;
;
;
;I
;I
0HWDEROLF$VVHVVPHQWVM

;


;
;

;
;U
;


(VWLPDWHG*ORPHUXODU)LOWUDWLRQ5DWH
;
;
;
;
;
;
;
;
;
;
;I
;
+HPDWRORJ\3URILOHN
;
;
;
;
;
;
;
;
;
;
;I
;I
3ODVPD+,951$
;
;
;
;
;
;
;
;
;
;
;
;
&'&HOO&RXQW
;
;
;
;
;
;
;
;
;
;
;
;
(YDOXDWLRQVRILQIODPPDWLRQDQG
LPPXQHDFWLYDWLRQSODWHOHWIXQFWLRQ
DQGUHQDOWXEXODUIXQFWLRQ

;



;

;
;U
;






%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV

9HUVLRQ
&21),'(17,$/

3DJH

0D\
M
)DVWLQJQRIRRGRUGULQNVH[FHSWZDWHUDWOHDVWKRXUVSULRUWREORRGFROOHFWLRQJOXFRVHDQGOLSLGSDQHOWRWDOFKROHVWHURO+'/GLUHFW/'/WULJO\FHULGHV,IWKHVXEMHFWKDV
QRWIDVWHGSULRUWRWKHYLVLWWKHYLVLWPD\SURFHHGEXWWKHVXEMHFWPXVWUHWXUQZLWKLQKRXUVLQDIDVWHGVWDWHWRGUDZEORRGIRUWKHPHWDEROLFDVVHVVPHQWV
N
&%&ZLWKGLIIHUHQWLDODQGSODWHOHWFRXQW
O
$VLQJOH3.EORRGVDPSOHZLOOEHFROOHFWHGDWDQ\WLPHSUHRUSRVWGRVH
P
$WURXJK3.EORRGVDPSOHZLOOEHFROOHFWHGEHWZHHQKRXUVIROORZLQJWKHODVWGRVH)ROORZLQJDQREVHUYHGGRVHDVLQJOHSRVWGRVHEORRGVDPSOHZLOOEHFROOHFWHG
EHWZHHQDQGKRXUVSRVWGRVH
Q
$3.VXEVWXG\ZLOOEHSHUIRUPHGLQDVXEVHWRIVXEMHFWVQ DWVHOHFWHGVWXG\VLWHV7KHSKDUPDFRNLQHWLFVXEVWXG\YLVLWPXVWRFFXUDWWKH:HHNRU:HHNYLVLWV7KH
VXEVWXG\ZLOOLQFOXGHLQWHQVLYH3.SURILOLQJLQSODVPD
R
2QO\UHTXLUHGIRUWKRVHVXEMHFWVQRWHQUROOLQJLQWKH2/5ROORYHU([WHQVLRQWKRVHVXEMHFWVZKRSUHPDWXUHO\GLVFRQWLQXHVWXG\GUXJVDQGGRQRWFRQWLQXHLQWKHVWXG\WKURXJK
DWOHDVWRQHVXEVHTXHQWYLVLWDIWHUWKH(DUO\6WXG\'UXJV'LVFRQWLQXDWLRQ9LVLW)RUWKHSXUSRVHRIVFKHGXOLQJD'D\)ROORZ8S9LVLWDGD\VZLQGRZPD\EHXVHG
S
6WXG\YLVLWVDUHWREHFRPSOHWHGZLWKLQGD\VRIWKHSURWRFROVSHFLILHGYLVLWGDWHEDVHGRQWKH'D\YLVLWWKURXJK:HHNDQGFRPSOHWHGZLWKLQGD\VWKURXJKWR
:HHNXQOHVVRWKHUZLVHVSHFLILHG7KHYLVLWZLQGRZDW:HHNVZLOOEHZHHNVRIWKHSURWRFROVSHFLILHGYLVLWGDWH
T
$IWHU:HHNDOOVXEMHFWVZLOOFRQWLQXHWRWDNHWKHLUEOLQGHGVWXG\GUXJDQGDWWHQGYLVLWVHYHU\ZHHNVXQWLOWKH(QGRI%OLQGHG7UHDWPHQW9LVLW9LVLWZLQGRZRIGD\V
IRUVWXG\YLVLWVSRVW:HHN
U
7REHSHUIRUPHGHYHU\ZHHNVDIWHU:HHNXQWLO(QGRI%OLQGHG7UHDWPHQW9LVLW
V
2SHQODEHOVWXG\GUXJ*6)7$))'&ZLOOEHGLVSHQVHGWRVXEMHFWVSDUWLFLSDWLQJLQWKH2/5ROORYHU([WHQVLRQIRUXSWRZHHNV
W
5DQGRPL]DWLRQPD\EHSHUIRUPHGXSWRGD\VSULRUWRWKHLQFOLQLF'D\YLVLWSURYLGHGWKDWDOOVFUHHQLQJSURFHGXUHVKDYHEHHQFRPSOHWHGDQGVXEMHFWHOLJLELOLW\KDVEHHQ
FRQILUPHG
X
7REHSHUIRUPHGHYHU\ZHHNV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV

9HUVLRQ
&21),'(17,$/

3DJH

0D\
$SSHQGL[7DEOH
6WXG\3URFHGXUHV7DEOH2SHQ/DEHO5ROORYHU([WHQVLRQ
6WXG\3URFHGXUHV
(QGRI%OLQGHG
7UHDWPHQW9LVLWD
(QGRI:HHNHO
'D\
)ROORZXSN
(DUO\6WXG\
'UXJV'&F
2/
2/
2/
2/
2/
2/
2/
2/
&RQFRPLWDQW0HGLFDWLRQV
;
;
;
;
;
;
;
;
;
;
;
$GYHUVH(YHQWV
;
;
;
;
;
;
;
;
;
;I
;I
&RPSOHWH6\PSWRP'LUHFWHG
3K\VLFDO([DP
;
;G
;G
;G
;
;G
;G
;G
;
;GI
;I
/HDG(&*SHUIRUPHGVXSLQH
;



;



;


';$VFDQVSLQH	KLSP
;










9LWDOVLJQVEORRGSUHVVXUHSXOVH
UHVSLUDWLRQUDWHDQGWHPSHUDWXUH
LQFOXGLQJ:HLJKW
;
;
;
;
;
;
;
;
;
;
;
8ULQDO\VLV
;
;
;
;
;
;
;
;
;
;I
;I
8ULQH3UHJQDQF\7HVWJ
;
;
;
;
;
;
;
;
;
;
;
&KHPLVWU\3URILOHK
;
;
;
;
;
;
;
;
;
;I
;I
0HWDEROLF$VVHVVPHQWVL
;

;

;

;

;


(VWLPDWHG*ORPHUXODU)LOWUDWLRQ5DWH
;
;
;
;
;
;
;
;
;
;I
;
+HPDWRORJ\3URILOHM
;
;
;
;
;
;
;
;
;
;I
;I
3ODVPD+,951$
;
;
;
;
;
;
;
;
;
;
;
&'&HOO&RXQW
;
;
;
;
;
;
;
;
;
;
;
(YDOXDWLRQVRILQIODPPDWLRQDQG
LPPXQHDFWLYDWLRQSODWHOHWIXQFWLRQ
DQGUHQDOWXEXODUIXQFWLRQ
;










3ODVPD	8ULQH6WRUDJH6DPSOH
;
;
;
;
;
;
;
;
;

;
+%9DQG+&96HURORJ\




;



;


+,9*HQRW\SH3KHQRW\SHH










;H


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV

9HUVLRQ
&21),'(17,$/

3DJH

0D\
6WXG\3URFHGXUHV
(QGRI%OLQGHG
7UHDWPHQW9LVLWD
(QGRI:HHNHO
'D\
)ROORZXSN
(DUO\6WXG\
'UXJV'&F
2/
2/
2/
2/
2/
2/
2/
2/
6WXG\'UXJ'LVSHQVDWLRQE
;
;
;
;
;
;
;
;



6WXG\'UXJ$FFRXQWDELOLW\
;
;
;
;
;
;
;
;
;

;
D
2QFHWKHODVWVXEMHFWFRPSOHWHVWKH:HHNYLVLWDQG*LOHDGFRPSOHWHVWKH:HHNDQDO\VLVDOOVXEMHFWVZLOOUHWXUQWRWKHFOLQLFSUHIHUDEO\ZLWKLQGD\VIRUDQ(QGRI
%OLQGHG7UHDWPHQW9LVLW$WWKH(QGRI%OLQGHG7UHDWPHQW9LVLWLIVDIHW\DQGHIILFDF\RI*6)7$)LVGHPRQVWUDWHGIROORZLQJUHYLHZRIXQEOLQGHGGDWDVXEMHFWVLQD
FRXQWU\ZKHUH*6)7$))'&LVQRWDYDLODEOHZLOOEHJLYHQWKHRSWLRQWRUHFHLYH*6)7$))'&LQDQ2/H[WHQVLRQSKDVHIRUXSWRZHHNVRUXQWLOWKH
SURGXFWEHFRPHVDFFHVVLEOHWRVXEMHFWVWKURXJKDQDFFHVVSURJUDPRUXQWLO*LOHDGHOHFWVWRGLVFRQWLQXHWKHVWXG\LQWKDWFRXQWU\ZKLFKHYHURFFXUVILUVW7UHDWPHQW
DVVLJQPHQWVZLOOEHSURYLGHGWRWKHLQYHVWLJDWRUVZLWKLQGD\VRIWKHODVWVXEMHFWFRPSOHWLQJWKH(QGRI%OLQGHG7UHDWPHQW9LVLW
E
2SHQODEHOVWXG\GUXJ*6)7$))'&ZLOOEHGLVSHQVHGWRVXEMHFWVSDUWLFLSDWLQJLQWKH2/5ROORYHU([WHQVLRQIRUXSWRZHHNV
F
6XEMHFWVZKRGLVFRQWLQXHVWXG\GUXJGXULQJWKH2/UROORYHUH[WHQVLRQSRUWLRQRIWKHVWXG\ZLOOEHDVNHGWRUHWXUQWRWKHFOLQLFZLWKLQKRXUVRIVWRSSLQJVWXG\GUXJVIRUWKH
(DUO\6WXG\'UXJV'LVFRQWLQXDWLRQ9LVLWIROORZHGE\D'D\)ROORZ8S9LVLW7KHVXEMHFWZLOOQRWFRQWLQXHDWWHQGLQJWKHVFKHGXOHGVWXG\YLVLWV
G
6\PSWRPGLUHFWHGSK\VLFDOH[DPLQDWLRQDVQHHGHG
H
+,9JHQRW\SHDQGSKHQRW\SHWHVWLQJIRUVXEMHFWVZLWKYLURORJLFIDLOXUH)ROORZLQJYLURORJLFUHERXQGVXEMHFWVZLOOEHDVNHGWRUHWXUQWRWKHFOLQLFZHHNVODWHUSULRUWR
WKHQH[WVFKHGXOHGYLVLWRUDWWKHQH[WVFKHGXOHGVWXG\YLVLWIRUD+,951$DQG+,9JHQRW\SHDQGSKHQRW\SHUHYHUVHWUDQVFULSWDVHSURWHDVHDQGLQWHJUDVHJHQRW\SHDQG
SKHQRW\SHEORRGGUDZ%DVHGRQWKHUHVXOWVRIWKLVWHVWLQJVXEMHFWVVKRXOGEHPDQDJHGDFFRUGLQJWRWKH9LURORJLF5HERXQG6FKHPD3URWRFRO6HFWLRQVDQG
I
$Q\DGYHUVHHYHQWRUWHVWVKRZLQJDEQRUPDOUHVXOWVWKDWLVEHOLHYHGWRKDYHDSRVVLEOHRUSUREDEOHFDXVDOUHODWLRQVKLSZLWKWKHVWXG\GUXJZLOOEHUHSHDWHGZHHNO\RUDVRIWHQ
DVGHHPHGSUXGHQWE\WKH,QYHVWLJDWRUXQWLOWKHDEQRUPDOLW\LVUHVROYHGUHWXUQVWREDVHOLQHRULVRWKHUZLVHH[SODLQHG
J
)HPDOHVRIFKLOGEHDULQJSRWHQWLDORQO\3RVLWLYHXULQHSUHJQDQF\WHVWVZLOOEHFRQILUPHGZLWKDVHUXPWHVW
K
&KHPLVWU\SURILOHDONDOLQHSKRVSKDWDVH$67$/7**7WRWDOELOLUXELQGLUHFWDQGLQGLUHFWELOLUXELQWRWDOSURWHLQDOEXPLQ/'+&3.ELFDUERQDWH%81FDOFLXP
FKORULGHFUHDWLQLQHJOXFRVHSKRVSKRUXVPDJQHVLXPSRWDVVLXPVRGLXPXULFDFLGDQGDP\ODVHUHIOH[OLSDVHWHVWLQJLVSHUIRUPHGLQVXEMHFWVZLWKWRWDODP\ODVH
!î8/1$WWKH(QGRI%OLQGHG7UHDWPHQW9LVLW:HHN2/DQG:HHN2/DQDO\VHVRIJOXFRVHZLOOEHGRQHDVSDUWRIWKHIDVWLQJPHWDEROLFDVVHVVPHQWVDQGQRWDV
SDUWRIWKHFKHPLVWU\SURILOH)RUDOOVXEMHFWV76+ZLOOEHGRQHDWWKH(QGRI%OLQGHG7UHDWPHQW9LVLW:HHN2/:HHN2/:HHN2/:HHN2/DQG
(DUO\6WXG\'UXJ'LVFRQWLQXDWLRQ9LVLW
L
)DVWLQJQRIRRGRUGULQNVH[FHSWZDWHUDWOHDVWKRXUVSULRUWREORRGFROOHFWLRQJOXFRVHDQGOLSLGSDQHOWRWDOFKROHVWHURO+'/GLUHFW/'/WULJO\FHULGHV,IWKHVXEMHFWKDV
QRWIDVWHGSULRUWRWKHYLVLWWKHYLVLWPD\SURFHHGEXWWKHVXEMHFWPXVWUHWXUQZLWKLQKRXUVLQDIDVWHGVWDWHWRGUDZEORRGIRUWKHPHWDEROLFDVVHVVPHQWV
M
&%&ZLWKGLIIHUHQWLDODQGSODWHOHWFRXQW
N
6XEMHFWVZKRFRPSOHWHWKH2/5ROORYHU([WHQVLRQZLOOEHUHTXLUHGWRUHWXUQWRWKHFOLQLFGD\VDIWHUWKHFRPSOHWLRQRIVWXG\GUXJVIRUWKH'D\)ROORZ8S9LVLW
6XEMHFWVZKRSHUPDQHQWO\GLVFRQWLQXHVWXG\GUXJVGXULQJWKH2/5ROORYHU([WHQVLRQZLOOEHDVNHGWRUHWXUQWRWKHFOLQLFGD\VDIWHUWKHFRPSOHWLRQRIWKH(DUO\6WXG\
'UXJV'LVFRQWLQXDWLRQ9LVLWIRUWKH'D\)ROORZ8S9LVLW)RUWKHSXUSRVHRIVFKHGXOLQJD'D\)ROORZ8S9LVLWDGD\VZLQGRZPD\EHXVHG
O
6WXG\YLVLWVDUHWREHFRPSOHWHGZLWKLQGD\VRIWKHSURWRFROVSHFLILHGYLVLWGDWHEDVHGRQWKH(QGRI%OLQGHG7UHDWPHQW9LVLWGDWHXQOHVVRWKHUZLVHVSHFLILHG
P
';$VFDQVWREHSHUIRUPHGLQDOOHOLJLEOHVXEMHFWVRQVWXG\GUXJH[FHSWIRUWKRVHLQ*HUPDQ\DWWKH(QGRI%OLQGHG7UHDWPHQW9LVLWGD\VLIWKHODVWVFDQZDVDFTXLUHG
!ZHHNVIURPWKHGDWHRIWKH(QGRI%OLQGHG7UHDWPHQW9LVLW




%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
$SSHQGL[
5HJLRQ'HILQLWLRQ
5HJLRQ
&RXQWU\1DPH
6WDWH
1RRI6XEMHFWVLQ6DIHW\
$QDO\VLV6HWRU)$6
1 
7RWDO1RRI6XEMHFWVE\
5HJLRQLQ6DIHW\
$QDO\VLV6HWRU)$66HW
1 
5HJLRQ
$8675$/,$$86



&$1$'$&$1


5HJLRQ
%(/*,80%(/



)5$1&()5$



*(50$1<'(8



,7$/<,7$



63$,1(63



81,7('.,1*'20*%5



5HJLRQ
8QLWHG6WDWHV86$
&$


8QLWHG6WDWHV
+,


8QLWHG6WDWHV
:$


5HJLRQ
8QLWHG6WDWHV
$=


8QLWHG6WDWHV
10


8QLWHG6WDWHV
7;


5HJLRQ
8QLWHG6WDWHV
,/


8QLWHG6WDWHV
,1


8QLWHG6WDWHV
.<


8QLWHG6WDWHV
0,


8QLWHG6WDWHV
01


8QLWHG6WDWHV
02


8QLWHG6WDWHV
2+


5HJLRQ
8QLWHG6WDWHV
'&


8QLWHG6WDWHV
0$


8QLWHG6WDWHV
1-


8QLWHG6WDWHV
1<


8QLWHG6WDWHV
3$


5HJLRQ
8QLWHG6WDWHV
*$


8QLWHG6WDWHV
/$

8QLWHG6WDWHV
1&


8QLWHG6WDWHV
6&


5HJLRQ
8QLWHG6WDWHV
)/


8QLWHG6WDWHV
35


1RWH$UHJLRQLVGHILQHGDVPXOWLSOHVLWHVFRPELQHGEDVHGRQJHRJUDSKLFDOORFDWLRQV)RUH[DPSOHIRULQWHUQDWLRQDOVWXGLHVVLWHV
IURPHDFKFRXQWU\RUPXOWLSOHQHLJKERULQJFRXQWLHVZHUHFRPELQHGDQGIRU86VWXGLHVVLWHVIURPHDFKVWDWHRUPXOWLSOH
QHLJKERULQJVWDWHVZHUHFRPELQHG


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
$SSHQGL[
6HOHFWHG0HGLFDO+LVWRU\
1XPEHUDQGSHUFHQWDJHRIVXEMHFWVZLWKVHOHFWHGPHGLFDOKLVWRU\RI'LDEHWHV0HOOLWXV
+\SHUWHQVLRQ&DUGLRYDVFXODU'LVHDVHDQG+\SHUOLSLGHPLDZLOOEHVXPPDUL]HGE\WUHDWPHQWDV
EDVHOLQHGLVHDVHFKDUDFWHULVWLFV$VXEMHFWZKRKDGPHGLFDOKLVWRU\RIRQHRIWKHVHGLVHDVHVLVD
VXEMHFWZKRH[SHULHQFHDWOHDVWRQHRIWKHIROORZLQJHYHQWV
x $WOHDVWPHGLFDOKLVWRU\UHFRUGZLWK0HG'5$37PK0'537LQWKHVHOHFWHG37OLVWLQJ
IRUWKHFRUUHVSRQGLQJGLVHDVHZLWKVWDUWGDWHRQRUSULRUWRWKHILUVWGRVHGDWH
x $WOHDVWDGYHUVHHYHQWUHFRUGZLWK0HG'5$37DH0'537LQWKHVHOHFWHG37OLVWLQJIRU
WKHFRUUHVSRQGLQJGLVHDVHZLWKVWDUWGDWHRQRUSULRUWRWKHILUVWGRVHGDWH
x $WOHDVWFRQFRPLWDQWPHGLFDWLRQVUHFRUGZLWKPHGLFDWLRQFODVVDQGLQGLFDWLRQLQWKH
VHOHFWHGOLVWLQJIRUWKHFRUUHVSRQGLQJGLVHDVHZLWKVWDUWGDWHRQRUSULRUWRWKHILUVWGRVHGDWH
,IWKHVWDUWGDWHLVLQFRPSOHWHEXWWKHPRQWKDQG\HDURU\HDURIWKHVWDUWGDWHLVWKHVDPHDVRU
EHIRUHWKHPRQWKDQG\HDURU\HDURIWKHILUVWGRVLQJGDWHRIVWXG\GUXJWKHQWKHHYHQWZLOOEH
LQFOXGHG,IWKHVWDUWGDWHLVFRPSOHWHGPLVVLQJWKHHYHQWZLOOEHLQFOXGHG
)RXUYDULDEOHVLH',$%(7(6+7(16,21&$5'',6DQG+/,3'(0ZLOOEHDGGHGWRUDZ
0HGLFDO+LVWRU\DQG$GYHUVH(YHQWVGDWDVHWV$PHGLFDOKLVWRU\RUDQDGYHUVHHYHQWUHFRUGZLOO
EHIODJJHGIRUDGLVHDVHRILQWHUHVWLILWV0HG'5$SUHIHUUHGWHUP37LVLQFOXGHGLQWKH
SUHVSHFLILHG37OLVWIRUWKHFRUUHVSRQGLQJGLVHDVHRILQWHUHVWZKLFKLQFOXGHDOO37VIURPWKH
QDUURZRUEURDGVHDUFKRIWKHIROORZLQJ604VXQGHU0HG'5$SURYLGHGE\*LOHDG'63+
DQGUHYLHZHGE\*LOHDGPHGLFDOPRQLWRUV
'LVHDVHRI,QWHUHVW
6046RXUFH
'LDEHWHV0HOOLWXV',$%(7(6
+\SHUJO\FDHPLDQHZRQVHWGLDEHWHVPHOOLWXV604±1DUURZ6FRSH7HUP
+\SHUOLSLGHPLD+/,3'(0
'\VOLSLGDHPLD604
+\SHUWHQVLRQ+7(16,21
+\SHUWHQVLRQ604
&DUGLRYDVFXODUGLVHDVH
&$5'',6
,VFKDHPLFFHQWUDOQHUYRXVV\VWHPYDVFXODUFRQGLWLRQV6041DUURZ6FRSH7HUP
0\RFDUGLDOLQIDUFWLRQ6041DUURZ6FRSH7HUP
2WKHULVFKDHPLFKHDUWGLVHDVH6041DUURZ6FRSH7HUP

6LPLODUO\IRXUYDULDEOHVLH',$%(7(6+7(16,21&$5'',6DQG+/,3'(0ZLOOEH
DGGHGWRUDZ&RQFRPLWDQW0HGLFDWLRQGDWDVHW$FRQFRPLWDQWPHGLFDWLRQUHFRUGZLOOEHIODJJHG
IRUDGLVHDVHRILQWHUHVWLILWVPHGLFDWLRQFODVVDQGLQGLFDWLRQLQFOXGHGLQWKHIROORZLQJOLVWLQJIRU
WKHFRUUHVSRQGLQJGLVHDVHRILQWHUHVW
7KHVHOHFWHGFRPELQDWLRQRIPHGLFDWLRQFODVVDQGLQGLFDWLRQDUHOLVWHGDVIROORZVZKLFKZDV
UHYLHZHGE\*LOHDGPHGLFDOPRQLWRUV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1
+\SHUWHQVLRQ+7(16,21

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0

/,6,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
$17,+<3(57(16,9(
/26$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
$57(5,$/+<3(17(16,21
5$0,35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
$57(5,$/+<3(57(16,21
&$37235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
$57(5,$/+<3(57(16,21
(1$/$35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
$57(5,$/+<3(57(16,21
+<'52&+/2527+,$=,'(
:2/0(6$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
$57(5,$/+<3(57(16,21
2/0(6$57$10('2;20,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
$57(5,$/+<3(57(16,21
5$0,35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
$57(5,$/+<3(57(16,21
6$/87(&

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
$57(5,$/+<3(57(16,21
9$/6$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
$57(5,$/+<3(57(16,21
67$*(,
&$37235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
$57(5,$/+<3(57(16,21
67$*(
&$1'(6$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
%(1,*1(66(17,$/
+<3(57(16,21
/,6,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
%(1,*1(66(17,$/
+<3(57(16,21
/26$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
(66(17,$/
35,0$5<+<3(57(6,21
=(6725(7,&

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
(66(17,$/+<3(57(16,21
&2529$/%

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
(66(17,$/+<3(57(16,21
(1$/$35,/0$/($7(

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
(66(17,$/+<3(57(16,21
/,6,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
(66(17,$/+<3(57(16,21
/26$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
(66(17,$/+<3(57(16,21
75,%(1=25


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
(66(17,$/+<3(57(16,21
=(6725(7,&

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
(66(17,$/35,0$5<
+<3(57(16,21
,5%(6$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+,*+%/22'35(6685(
&29(5$0

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+,*+%/22'35(6685(
(1$/$35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+,*+%/22'35(6685(
,5%(6$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+,*+%/22'35(6685(
/,6,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+,*+%/22'35(6685(
/26$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+,*+%/22'35(6685(
/26$57$1327$66,80

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+,*+%/22'35(6685(
5$0,35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+,*+%2/'35(6685(
/26$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+,6725<2)0<2&$5',7,6
5$0,35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+71
=(6725(7,&

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(557(16,21
=(6725(7,&

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57((16,21
/,6,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
$0/2',3,1(
:+<'52&+/2527+,$=,'(
9$/6$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
$0/2',3,1(
:9$/6$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
%(1$=(35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
%(1$=(35,/
+<'52&+/25,'(

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
%(1,&$5+&7

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
%,35('21,80


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
&$1'(6$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
&$1'(6$57$1&,/(;(7,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
&$37235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
&2',29$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
&2529$/%

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
',29$1$0/2

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
',29$175,3/(

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
('$5%<&/25

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
(1$/$35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
(1$/$35,/0$/($7(

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
)26,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
+<'52&+/2527+,$=,'(
:/26$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
+<=$$5

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
,5%(6$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
.$59($+&7

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
/,6,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
/26$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
/26$57$1327$66,80

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
1$35,;$

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
2/0(6$57$10('2;20,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
3(5,1'235,/(5%80,1(


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
35,7253/86

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
48,1$35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
5$0,35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
6$/87(&

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
7(/0,6$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
75,%(1=25

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
9$/6$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
9$6(5(7,&

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
=(6725(7,&

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21(66(17,$/
&$1'(6$57$1&,/(;(7,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21(66(17,$/
',29$175,3/(

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21%(1,*1
/,6,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21%,/$7(5$/
/2:(5/(*6:(//,1*
/,6,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21(66(17,$/
=(6725(7,&

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,21
:256(1,1*+<3(57(16,21
/,6,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,213523+</$;,6
5$0,35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,9(
5$0,35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(16,9(&5,6,6
&$37235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(57(17,21
/,6,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(5721,$
5$0,35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<32.$/(0,$
/26$57$1327$66,80


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
3225&21752/2)
%/22'35(6685(
/,6,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
35(9(17$7,9(
)2//2:,1*$&87(
0<&$5',$/,1)$5&7,21
3(5,1'235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
35,0$5<(66(17,$/
+<3(57(16,21
(1$/$35,/0$/($7(

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
3527(,185,$
%(1$=(35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
3527(,185,$
(1$/$35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
3527(,185,$
/,6,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
:256(1,1*
+<3(57(16,21
%(1$=(35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
:256(1,1*
+<3(57(16,21
3(5,1'235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
:256(1,1*
+<3(57(16,21
35(7(5$;$5*,1,1(

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
:256(1,1*2)
+<3(57(16,21
/,6,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
:256(1,1*2)
+<3(57(16,21
5$0,35,/

$17,+<3(57(16,9(6
%(1,*1+,*+%/22'
35(6685(
'2;$=26,1

$17,+<3(57(16,9(6
(;$&(5%$7,212)
+<3(57(16,21
&/21,',1(

$17,+<3(57(16,9(6
+($'$&+(
+<'5$/$=,1(

$17,+<3(57(16,9(6
+,*+%/22'35(6685(
&/21,',1(
+<'52&+/25,'(

$17,+<3(57(16,9(6
+,*+%/22'35(6685(
5,/0(1,',1(

$17,+<3(57(16,9(6
+<3(57(16,21
&/21,',1(

$17,+<3(57(16,9(6
+<3(57(16,21
&/21,',1(+<'52&+/25,'(

$17,+<3(57(16,9(6
+<3(57(16,21
'2;$=26,1

$17,+<3(57(16,9(6
+<3(57(16,21
'2;$=26,10(6,/$7(

$17,+<3(57(16,9(6
+<3(57(16,21
+<'5$/$=,1(

$17,+<3(57(16,9(6
+<3(57(16,21
+<'5$/$=,1(
+<'52&+/25,'(

$17,+<3(57(16,9(6
+<3(57(16,21
0(7+</'23$

$17,+<3(57(16,9(6
+<3(57(16,21
7$'$/$),/


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

$17,+<3(57(16,9(6
38/021$5<
+<3(57(16,21
7$'$/$),/

$17,+<3(57(16,9(6
9$62',/$7,2167(17
352&('85(
+<'5$/$=,1(

$17,+<3(57(16,9(6
:256(1,1*
+<3(57(16,21
+<'5$/$=,1(
+<'52&+/25,'(

%(7$%/2&.,1*$*(176
$57(5,$/+<3(57(16,21
$7(12/2/

%(7$%/2&.,1*$*(176
$57(5,$/+<3(57(16,21
0(72352/2/68&&,1$7(

%(7$%/2&.,1*$*(176
$57(5,$/+<3(57(16,21
,&+(0,&+($57',6($6(
%,62352/2/

%(7$%/2&.,1*$*(176
(66(17,$/+<3(57(16,21
0(72352/2/

%(7$%/2&.,1*$*(176
+($57)$,/85($1'
+<3(57(16,21
&$59(',/2/

%(7$%/2&.,1*$*(176
+($57+($/7+
$7(12/2/

%(7$%/2&.,1*$*(176
+,*+%/22'35(6685(
$7(12/2/

%(7$%/2&.,1*$*(176
+,*+%/22'35(6685(
%,62352/2/
:+<'52&+/2527+,$=,'(

%(7$%/2&.,1*$*(176
+,*+%/22'35(6685(
0(72352/2/

%(7$%/2&.,1*$*(176
+,6725<2)0<2&$5',7,6
%,62352/2/

%(7$%/2&.,1*$*(176
+<3(57(16,21
$7(12/2/

%(7$%/2&.,1*$*(176
+<3(57(16,21
%,62352/2/)80$5$7(

%(7$%/2&.,1*$*(176
+<3(57(16,21
&$59(',/2/

%(7$%/2&.,1*$*(176
+<3(57(16,21
/$%(7$/2/

%(7$%/2&.,1*$*(176
+<3(57(16,21
0(72352/2/

%(7$%/2&.,1*$*(176
+<3(57(16,21
0(72352/2/68&&,1$7(

%(7$%/2&.,1*$*(176
+<3(57(16,21
0(72352/2/7$575$7(

%(7$%/2&.,1*$*(176
+<3(57(16,21
1(%,&$5'9

%(7$%/2&.,1*$*(176
+<3(57(16,21
1(%,&$5'+

%(7$%/2&.,1*$*(176
+<3(57(16,21
1(%,92/2/

%(7$%/2&.,1*$*(176
+<3(57(16,21
1(%,92/2/
+<'52&+/25,'(

%(7$%/2&.,1*$*(176
+<3(57(16,21
35235$12/2/

%(7$%/2&.,1*$*(176
+<3(57(16,21
35235$12/2/
+<'52&+/25,'(

%(7$%/2&.,1*$*(176
+<3(57(16,21$1'
0,*5$,1(
$7(12/2/

%(7$%/2&.,1*$*(176
+<3(57(16,21(66(17,$/
$7(12/2/


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

%(7$%/2&.,1*$*(176
+<3(57(17,21
0(72352/2/68&&,1$7(

%(7$%/2&.,1*$*(176
+<3(7(16,21
%,62352/2/

%(7$%/2&.,1*$*(176
3$52;<602)6,186
7$&+<&$5',$
35235$12/2/

%(7$%/2&.,1*$*(176
35,0$5<(66(17,$/
+<3(57(16,21
&$59(',/2/

%(7$%/2&.,1*$*(176
5$3,'+($57%($7
0(72352/2/68&&,1$7(

&$/&,80&+$11(/%/2&.(56
$17,+<3(57(16,9(
$0/2',3,1(

&$/&,80&+$11(/%/2&.(56
$57(5,$/+<3(57(16,21
$0/2',3,1(

&$/&,80&+$11(/%/2&.(56
$57(5,$/+<3(57(16,21
9(5$3$0,/

&$/&,80&+$11(/%/2&.(56
$75,$/),%5,//$7,21
',/7,$=(0

&$/&,80&+$11(/%/2&.(56
(/(9$7('%/22'35(6685(
$0/2',3,1(

&$/&,80&+$11(/%/2&.(56
(/(9$7('%/22'35(6685(
$0/2',3,1(%(6,/$7(

&$/&,80&+$11(/%/2&.(56
(66(17,$/+<3(57(16,21
$0/2',3,1(

&$/&,80&+$11(/%/2&.(56
(66(17,$/+<3(57(16,21
$0/2',3,1(%(6,/$7(

&$/&,80&+$11(/%/2&.(56
(66(17,$/+<3(57(16,21
)(/2',3,1(

&$/&,80&+$11(/%/2&.(56
(66(17,$/35,0$5<
+<3(57(16,21
$0/2',3,1(

&$/&,80&+$11(/%/2&.(56
+,*+%/22'35(6685(
$0/2',3,1(

&$/&,80&+$11(/%/2&.(56
+71
$0/2',3,1(

&$/&,80&+$11(/%/2&.(56
+<3(57(16,21
$0/2',3,1(

&$/&,80&+$11(/%/2&.(56
+<3(57(16,21
$0/2',3,1(%(6,/$7(

&$/&,80&+$11(/%/2&.(56
+<3(57(16,21
%$51,',3,1(
+<'52&+/25,'(

&$/&,80&+$11(/%/2&.(56
+<3(57(16,21
',/7,$=(0

&$/&,80&+$11(/%/2&.(56
+<3(57(16,21
',/7,$=(0
+<'52&+/25,'(

&$/&,80&+$11(/%/2&.(56
+<3(57(16,21
)(/2',3,1(

&$/&,80&+$11(/%/2&.(56
+<3(57(16,21
1,)(',3,1(

&$/&,80&+$11(/%/2&.(56
+<3(57(16,21
9(5$3$0,/

&$/&,80&+$11(/%/2&.(56
+<3(57(16,21
(66(17,$/35,0$5<
9(5$3$0,/
+<'52&+/25,'(

&$/&,80&+$11(/%/2&.(56
+<3(57(16,21(66(17,$/
)(/2',3,1(

&$/&,80&+$11(/%/2&.(56
+<3(571(6,21
$0/2',3,1(%(6,/$7(

&$/&,80&+$11(/%/2&.(56
+<37(57(16,21
$0/2',3,1(

&$/&,80&+$11(/%/2&.(56
35(678'<+<3(57(16,21
$0/2',3,1(


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

&$/&,80&+$11(/%/2&.(56
6(&21'$5<6752.(
35(9(17,21
$0/2',3,1(

&$/&,80&+$11(/%/2&.(56
6,&.6,1866<1'520(
9(5$3$0,/

&$/&,80&+$11(/%/2&.(56
:256(1,1*2)
+<3(57(16,21
$0/2',3,1(

&$5',$&7+(5$3<
+<3(57(16,21
8%,'(&$5(121(

',85(7,&6
$57(5,$/+<3(57(16,21
+<'52&+/2527+,$=,'(

',85(7,&6
%(1,*1(66(17,$/
+<3(57(16,21
+<'52&+/2527+,$=,'(

',85(7,&6
%25'(5/,1(+<3(57(16,21
+<'52&+/2527+,$=,'(

',85(7,&6
',85(7,&
)8526(0,'(

',85(7,&6
(/(9$7('
%/22'35(6685(5($',1*
:,7+287',$*126,62)
+<3(57(16,21
+<'52&+/2527+,$=,'(

',85(7,&6
(66(17,$/+<3(57(16,21
)8526(0,'(

',85(7,&6
(66(17,$/+<3(57(16,21
+<'52&+/2527+,$=,'(

',85(7,&6
+,*+%/22'35(6685(
+<'52&+/2527+,$=,'(

',85(7,&6
+<3(57(16,21
$0,/25,'(

',85(7,&6
+<3(57(16,21
%80(7$1,'(

',85(7,&6
+<3(57(16,21
&+/257$/,'21(

',85(7,&6
+<3(57(16,21
'<$=,'(

',85(7,&6
+<3(57(16,21
)8526(0,'(

',85(7,&6
+<3(57(16,21
+<'52&+/2527+,$=,'(

',85(7,&6
+<3(57(16,21
,1'$3$0,'(

',85(7,&6
+<3(57(16,21
02'85(7,&

',85(7,&6
+<3(57(16,21
63,5212/$&721(

',85(7,&6
+<3(57(16,21
75,$07(5(1(

',85(7,&6
+<3(57(16,21%(1,*1
+<'52&+/2527+,$=,'(

',85(7,&6
+<3(57(17,21
+<'52&+/2527+,$=,'(

',85(7,&6
:256(1,1*
+<3(57(16,21
+<'52&+/2527+,$=,'(

/,3,'02',)<,1*$*(176
+,*+%/22'35(6685(
35$9$67$7,1

/,3,'02',)<,1*$*(176
+,*+%/22'35(6685(
35$9$67$7,162',80


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1
'LDEHWHV0HOOLWXV',$%(7(6

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
',$%(7(60(//,7867<3(,,
/,6,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
7<3(',$%(7(6
/,6,1235,/

$17,+<3(57(16,9(6
81&21752//('',$%(7(6
0(//,786
&/21,',1(
+<'52&+/25,'(

$17,+<3(57(16,9(6
81&21752//('',$%(7(6
0(//,786
+<'5$/$=,1(
+<'52&+/25,'(

%(7$%/2&.,1*$*(176
7<3(',$%(7(6
0(72352/2/7$575$7(

'58*686(',1',$%(7(6
%25'(5/,1(',$%(7(6
0(7)250,1

'58*686(',1',$%(7(6
',$%(7(6
'8/$*/87,'(

'58*686(',1',$%(7(6
',$%(7(6
*/,%(1&/$0,'(

'58*686(',1',$%(7(6
',$%(7(6
*/,&/$=,'(

'58*686(',1',$%(7(6
',$%(7(6
*/,0(3,5,'(

'58*686(',1',$%(7(6
',$%(7(6
*/,3,=,'(

'58*686(',1',$%(7(6
',$%(7(6
+80$10,;7$5'

'58*686(',1',$%(7(6
',$%(7(6
,168/,1

'58*686(',1',$%(7(6
',$%(7(6
,168/,1$63$57

'58*686(',1',$%(7(6
',$%(7(6
,168/,1'(7(0,5

'58*686(',1',$%(7(6
',$%(7(6
,168/,1*/$5*,1(

'58*686(',1',$%(7(6
',$%(7(6
,168/,1+80$1

'58*686(',1',$%(7(6
',$%(7(6
,168/,1/,6352

'58*686(',1',$%(7(6
',$%(7(6
0(7$*/,3

'58*686(',1',$%(7(6
',$%(7(6
0(7)250,1

'58*686(',1',$%(7(6
',$%(7(6
0(7)250,1
+<'52&+/25,'(

'58*686(',1',$%(7(6
',$%(7(6
3,2*/,7$=21(

'58*686(',1',$%(7(6
',$%(7(6
3,2*/,7$=21(
+<'52&+/25,'(

'58*686(',1',$%(7(6
',$%(7(6
6,7$*/,37,1

'58*686(',1',$%(7(6
',$%(7(67<3(,
,168/,1*/$5*,1(

'58*686(',1',$%(7(6
',$%(7(67<3(,
,168/,1/,6352

'58*686(',1',$%(7(6
',$%(7(6
*/,&/$=,'(

'58*686(',1',$%(7(6
',$%(7(6,,
0(7)250,1

'58*686(',1',$%(7(6
',$%(7(6.(72$&,'26,6
,168/,1


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

'58*686(',1',$%(7(6
',$%(7(60(//7<3(
,168/,1'(7(0,5

'58*686(',1',$%(7(6
',$%(7(60(//7<3(
,168/,1/,6352

'58*686(',1',$%(7(6
',$%(7(60(//7<3(
0(7)250,1

'58*686(',1',$%(7(6
',$%(7(60(//,7,67<3(
(03$*/,)/2=,1

'58*686(',1',$%(7(6
',$%(7(60(//,7,67<3(
*/,%(1&/$0,'(

'58*686(',1',$%(7(6
',$%(7(60(//,7,67<3(
,168/,1'(7(0,5

'58*686(',1',$%(7(6
',$%(7(60(//,7,67<3(
,168/,1/,6352

'58*686(',1',$%(7(6
',$%(7(60(//,786
'8/$*/87,'(

'58*686(',1',$%(7(6
',$%(7(60(//,786
(;(1$7,'(

'58*686(',1',$%(7(6
',$%(7(60(//,786
*/,3,=,'(

'58*686(',1',$%(7(6
',$%(7(60(//,786
+80$10,;7$5'

'58*686(',1',$%(7(6
',$%(7(60(//,786
,168/,1$63$57

'58*686(',1',$%(7(6
',$%(7(60(//,786
,168/,1'(7(0,5

'58*686(',1',$%(7(6
',$%(7(60(//,786
,168/,1*/$5*,1(

'58*686(',1',$%(7(6
',$%(7(60(//,786
,168/,1+80$1

'58*686(',1',$%(7(6
',$%(7(60(//,786
,168/,1/,6352

'58*686(',1',$%(7(6
',$%(7(60(//,786
/,5$*/87,'(

'58*686(',1',$%(7(6
',$%(7(60(//,786
0(7)250,1

'58*686(',1',$%(7(6
',$%(7(60(//,786
0(7)250,1
+<'52&+/25,'(

'58*686(',1',$%(7(6
',$%(7(60(//,786
5,67)25

'58*686(',1',$%(7(6
',$%(7(60(//,786
6,7$*/,37,13+263+$7(

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3,,
,168/,1/,6352

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3,,
9(/0(7,$

'58*686(',1',$%(7(6
',$%(7(60(//,786
,168/,1*/$5*,1(

'58*686(',1',$%(7(6
',$%(7(60(//,786
,168/,1/,6352

'58*686(',1',$%(7(6
',$%(7(60(//,786
*/,3,=,'(

'58*686(',1',$%(7(6
',$%(7(60(//,786
&$1$*/,)/2=,1

'58*686(',1',$%(7(6
',$%(7(60(//,786
'8/$*/87,'(

'58*686(',1',$%(7(6
',$%(7(60(//,786
(;(1$7,'(

'58*686(',1',$%(7(6
',$%(7(60(//,786
*/,%20(7

'58*686(',1',$%(7(6
',$%(7(60(//,786
*/,0(3,5,'(

'58*686(',1',$%(7(6
',$%(7(60(//,786
*/,3,=,'(

'58*686(',1',$%(7(6
',$%(7(60(//,786
+80$10,;7$5'


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

'58*686(',1',$%(7(6
',$%(7(60(//,786
,168/,1$63$57

'58*686(',1',$%(7(6
',$%(7(60(//,786
,168/,1'(7(0,5

'58*686(',1',$%(7(6
',$%(7(60(//,786
,168/,1*/$5*,1(

'58*686(',1',$%(7(6
',$%(7(60(//,786
0(7)250,1

'58*686(',1',$%(7(6
',$%(7(60(//,786
0(7)250,1
+<'52&+/25,'(

'58*686(',1',$%(7(6
',$%(7(60(//,786,,
*/,3,=,'(

'58*686(',1',$%(7(6
',$%(7(60(//,786,,
0(7)250,1

'58*686(',1',$%(7(6
',$%(7(60(//,786,,
6,7$*/,37,1

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3
0(7)250,1

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(
*/,3,=,'(

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(
,168/,1*/$5*,1(

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(
,168/,1/,6352

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(
0(7)250,1

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(
0(7)250,1
+<'52&+/25,'(

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(
6,7$*/,37,13+263+$7(

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(,,
&$1$*/,)/2=,1
:0(7)250,1
+<'52&+/25,'(

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(,,
'8/$*/87,'(

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(,,
*/,3,=,'(

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(,,
+80$10,;7$5'

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(,,
,168/,1

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(,,
,168/,1$63$57

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(,,
,168/,1'(7(0,5

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(,,
,168/,1*/$5*,1(

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(,,
,168/,1/,6352

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(,,
0(7)250,1

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(,,
0(7)250,1
+<'52&+/25,'(

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(,,
1$7(*/,1,'(

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(,,
6,7$*/,37,13+263+$7(

'58*686(',1',$%(7(6
',$%(7(60(//,7867<3(,,
0(7)250,1
+<'52&+/25,'(

'58*686(',1',$%(7(6
',$%(7(67<3(
*/,3,=,'(


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

'58*686(',1',$%(7(6
',$%(7(67<3(
+80$10,;7$5'

'58*686(',1',$%(7(6
',$%(7(67<3(
,168/,1$63$57

'58*686(',1',$%(7(6
',$%(7(67<3(
,168/,1'(7(0,5

'58*686(',1',$%(7(6
',$%(7(67<3(
,168/,1*/$5*,1(

'58*686(',1',$%(7(6
',$%(7(67<3(
,168/,1/,6352

'58*686(',1',$%(7(6
',$%(7(67<3(
.20%,*/<=(

'58*686(',1',$%(7(6
',$%(7(67<3(
0(7)250,1

'58*686(',1',$%(7(6
',$%(7(67<3(
6,7$*/,37,13+263+$7(

'58*686(',1',$%(7(6
',$%(7(67<3(,,
0(7)250,1

'58*686(',1',$%(7(6
',$%(7(67<3(
*/,0(3,5,'(

'58*686(',1',$%(7(6
',$%(7(67<3(
/,5$*/87,'(

'58*686(',1',$%(7(6
',$%(7(67<3(
3,2*/,7$=21(

'58*686(',1',$%(7(6
',$%(7,6
,168/,1*/$5*,1(

'58*686(',1',$%(7(6
'0
*/,3,=,'(

'58*686(',1',$%(7(6
'0
0(7)250,1
+<'52&+/25,'(

'58*686(',1',$%(7(6
+<3(5*/,&(0,$
*/,3,=,'(

'58*686(',1',$%(7(6
+<3(5*/<&(0,$
,168/,1+80$1

'58*686(',1',$%(7(6
+<3(5*/<&(0,$
0(7)250,1

'58*686(',1',$%(7(6
+<3(5*/<&(0,$
0(7)250,1
+<'52&+/25,'(

'58*686(',1',$%(7(6
+<3(5,168/,1,60
0(7)250,1

'58*686(',1',$%(7(6
+<3(57(16,21
0(7)250,1

'58*686(',1',$%(7(6
121$/&2+2/,&
67($72+(3$7,7,6
0(7)250,1

'58*686(',1',$%(7(6
7<3(',$%(7(6
,168/,1'(*/8'(&

'58*686(',1',$%(7(6
7<3(',$%(7(60(//,786
,168/,1$63$57

'58*686(',1',$%(7(6
7<3(',$%(7(60(//,786
,168/,1*/$5*,1(

'58*686(',1',$%(7(6
7<3(',$%(7(6
*/,&/$=,'(

'58*686(',1',$%(7(6
7<3(',$%(7(6
+80$10,;7$5'

'58*686(',1',$%(7(6
7<3(',$%(7(6
,168/,1$63$57

'58*686(',1',$%(7(6
7<3(',$%(7(6
,168/,1*/$5*,1(

'58*686(',1',$%(7(6
7<3(',$%(7(6
,168/,1/,6352

'58*686(',1',$%(7(6
7<3(',$%(7(6
0(7)250,1


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

'58*686(',1',$%(7(6
7<3(',$%(7(6
0(7)250,1
+<'52&+/25,'(

'58*686(',1',$%(7(6
7<3(',$%(7(6
6,7$*/,37,13+263+$7(

'58*686(',1',$%(7(6
7<3(',$%(7(60(//,786
*/,0(3,5,'(

'58*686(',1',$%(7(6
7<3(',$%(7(60(//,786
+80$10,;7$5'

'58*686(',1',$%(7(6
7<3(',$%(7(60(//,786
,168/,1+80$1

'58*686(',1',$%(7(6
7<3(',$%(7(60(//,786
/,5$*/87,'(

'58*686(',1',$%(7(6
7<3(',$%(7(60(//,786
0(7)250,1
+<'52&+/25,'(

'58*686(',1',$%(7(6
7<3(',$%(7(60(//,786
3,2*/,7$=21(

'58*686(',1',$%(7(6
7<3(,,',$%(7(6
&$1$*/,)/2=,1
:0(7)250,1
+<'52&+/25,'(

'58*686(',1',$%(7(6
7<3(,,',$%(7(6
'$3$*/,)/2=,1
3523$1(',2/
0212+<'5$7(:0(7)2

'58*686(',1',$%(7(6
7<3(,,',$%(7(6
*/,3,=,'(

'58*686(',1',$%(7(6
7<3(,,',$%(7(6
,168/,1

'58*686(',1',$%(7(6
7<3(,,',$%(7(6
,168/,1'(7(0,5

'58*686(',1',$%(7(6
7<3(,,',$%(7(6
,168/,1*/$5*,1(

'58*686(',1',$%(7(6
7<3(,,',$%(7(6
/,5$*/87,'(

'58*686(',1',$%(7(6
7<3(,,',$%(7(6
0(7)250,1

'58*686(',1',$%(7(6
7<3(,,',$%(7(6
6,7$*/,37,13+263+$7(

'58*686(',1',$%(7(6
7<3(,,',$%(7(60(//,786
(;(1$7,'(

'58*686(',1',$%(7(6
7<3(,,',$%(7(60(//,786
0(7)250,1

'58*686(',1',$%(7(6
7<3(,,',$%(7(60(//,786
0(7)250,1
+<'52&+/25,'(

'58*686(',1',$%(7(6
81&21752//('',$%(7(6
0(//,786
,168/,1/,6352

'58*686(',1',$%(7(6
81&21752//('',$%(7(6
0(//,786:,7+
+<3(5*/,&(0,$
*/,3,=,'(

'58*686(',1',$%(7(6
81&21752//('',$%(7(6
0(//,786:,7+
+<3(5*/,&(0,$
+80$10,;7$5'

'58*686(',1',$%(7(6
81&21752//(''0
,168/,1'(7(0,5

8163(&,),('+(5%$/$1'
75$',7,21$/0(',&,1(
+(5%$/6833/(0(17
*/<&,1(0$;(;75$&7

/,3,'02',)<,1*$*(176
',$%(7(60(//,786
7<3(,,
35$9$67$7,1


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1
&DUGLRYDVFXODU&$5'',6

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
$&87(0<2&$5',$/
,1)$5&7,21
,5%(6$57$1

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
&$5',20<23$7+<
/,6,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
&$5',20<23$7+<
5$0,35,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
&21*(67,9(+($57
)$,/85(
/,6,1235,/

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
&2521$5<$57(5<
',6($6(
5$0,35,/

%(7$%/2&.,1*$*(176
$&87(0<2&$5',$/
,1)$5&7,21
%,62352/2/)80$5$7(

%(7$%/2&.,1*$*(176
$17,$55+<7+0,&
627$/2/

%(7$%/2&.,1*$*(176
$7+(526&/(527,&+($57
',6($6(2)1$7,9(
&2521$5<$57(5<
:,7+287$1*,1$3(&725,6
&$59(',/2/

%(7$%/2&.,1*$*(176
$75,$/),%5,/$7,21
$7(12/2/

%(7$%/2&.,1*$*(176
$75,$/),%5,/$7,21
0(72352/2/

%(7$%/2&.,1*$*(176
$75,$/),%5,//$7,21
0(72352/2/

%(7$%/2&.,1*$*(176
$75,$/),%5,//$7,21
0(72352/2/7$575$7(

%(7$%/2&.,1*$*(176
$7<3,&$/&+(673$,1
/$%(7$/2/

%(7$%/2&.,1*$*(176
%58*$'$6<1'520(
%,62352/2/

%(7$%/2&.,1*$*(176
&$'
0(72352/2/68&&,1$7(

%(7$%/2&.,1*$*(176
&$'5,20<23$7+<
%,62352/2/

%(7$%/2&.,1*$*(176
&$5',$&3$&(0$.(5
,16,78
0(72352/2/

%(7$%/2&.,1*$*(176
&$5',$&3523+</$;,6
&$59(',/2/

%(7$%/2&.,1*$*(176
&$5',20<23$7+<
&$59(',/2/

%(7$%/2&.,1*$*(176
&+(677,*+71(66
%,62352/2/

%(7$%/2&.,1*$*(176
&21*(67,9(+($57
)$,/85(
$7(12/2/

%(7$%/2&.,1*$*(176
&21*(67,9(+($57
)$,/85(
&$59(',/2/

%(7$%/2&.,1*$*(176
&21752//('
+<3(57(16,21
7(125(7,&

%(7$%/2&.,1*$*(176
&2521$5<$57(5<',6($6(
0(72352/2/

%(7$%/2&.,1*$*(176
&2521$5<$57(5<',6($6(
0(72352/2/68&&,1$7(


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

%(7$%/2&.,1*$*(176
&2521$5<$57(5<
67(126,6
0(72352/2/

%(7$%/2&.,1*$*(176
'<65+<7+0,$
%,62352/2/)80$5$7(

%(7$%/2&.,1*$*(176
+($57)$,/85($1'
+<3(57(16,21
&$59(',/2/

%(7$%/2&.,1*$*(176
,17(50,77(17
$55+<7+0,$
%,62352/2/

%(7$%/2&.,1*$*(176
0,75$/,168)),&,(1&<
%,62352/2/

%(7$%/2&.,1*$*(176
35(9(17$7,9(
)2//2:,1*$&87(
0<&$5',$/,1)$5&7,21
%,62352/2/

%(7$%/2&.,1*$*(176
6,&.6,1866<1'520(
0(72352/2/

%(7$%/2&.,1*$*(176
6835$9(175,&8/$5
7$&+<&$5',$
$7(12/2/

%(7$%/2&.,1*$*(176
6835$9(175,&8/$5
7$&+<&$5',$
$7(12/2/

%(7$%/2&.,1*$*(176
6835$9(175,&8/$5
7$&+<&$5',$
0(72352/2/

%(7$%/2&.,1*$*(176
7$&+<&$5',$
$7(12/2/

&$/&,80&+$11(/%/2&.(56
&2521$5<$57(5<',6($6(
$0/2',3,1(

&$/&,80&+$11(/%/2&.(56
&2521$5<$57(5<',6($6(
$0/2',3,1(%(6,/$7(

&$/&,80&+$11(/%/2&.(56
6835$9(175,&8/$5
7$&+<&$5',$
9(5$3$0,/

&$5',$&7+(5$3<
$&87(0<2&$5',$/
,1)$5&7,21
$0,2'$521(
+<'52&+/25,'(

&$5',$&7+(5$3<
$&87(0<2&$5',$/
,1)$5&7,21
,62625%,'(',1,75$7(

&$5',$&7+(5$3<
$//(5*,&5($&7,21
(3,1(3+5,1(

&$5',$&7+(5$3<
$1*,1$
*/<&(5</75,1,75$7(

&$5',$&7+(5$3<
$1*,1$3(&725,6
5$12/$=,1(

&$5',$&7+(5$3<
$1*,2*5$067(17
$'(126,1(

&$5',$&7+(5$3<
$1*,21(8527,&('(0$
(3,1(3+5,1(

&$5',$&7+(5$3<
$17,$55+<7+0,&$*(17
)/(&$,1,'($&(7$7(

&$5',$&7+(5$3<
$75,$/),%5,//$7,21
',*2;,1

&$5',$&7+(5$3<
$75,$/),%5,//$7,21
)/(&$,1,'($&(7$7(

&$5',$&7+(5$3<
$7<3,&$/&+(673$,1
*/<&(5</75,1,75$7(

&$5',$&7+(5$3<
&$'
8%,'(&$5(121(

&$5',$&7+(5$3<
&$5',20<23$7+<
,62625%,'(',1,75$7(


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

&$5',$&7+(5$3<
&$5',29$6&8/$5
',6($6(3523+</$;,6
8%,'(&$5(121(

&$5',$&7+(5$3<
&+(673$,1
*/<&(5</75,1,75$7(

&$5',$&7+(5$3<
&+(673$,16
*/<&(5</75,1,75$7(

&$5',$&7+(5$3<
&+(673$,1
*/<&(5</75,1,75$7(

&$5',$&7+(5$3<
&2521$5<$57(5<',6($6(
*/<&(5</75,1,75$7(

&$5',$&7+(5$3<
&2521$5<$57(5<',6($6(
,62625%,'(02121,75$7(

&$5',$&7+(5$3<
+<3(5/,3,'(0,$
,62625%,'(02121,75$7(

&$5',$&7+(5$3<
167(0,
,62625%,'(',1,75$7(

&$5',$&7+(5$3<
3(5,23675(667(67
5(*$'(12621

&$5',$&7+(5$3<
3523+</$;,6
*/<&(5</75,1,75$7(

&$5',$&7+(5$3<
3523+</$;,6)25
&$5',$&+($/7+
8%,'(&$5(121(

&$5',$&7+(5$3<
6835$9(175,&8/$5
7$&+<&$5',$
$'(126,1(

&$5',$&7+(5$3<
81&21752//('',$%(7(6
0(//,786
$0,2'$521(
+<'52&+/25,'(

&$5',$&7+(5$3<
81&21752//('',$%(7(6
0(//,786
*/<&(5</75,1,75$7(

',85(7,&6
$&87(5(63,5$725<
)$,/85(
)8526(0,'(

',85(7,&6
$257,&9$/9(
5(3/$&(0(17
)8526(0,'(

',85(7,&6
&+)
%80(7$1,'(

',85(7,&6
&+)
+<'52&+/2527+,$=,'(

',85(7,&6
&+)
0(72/$=21(

',85(7,&6
&21*(67,9(+($57
)$,/85(
%80(7$1,'(

',85(7,&6
&21*(67,9(+($57
)$,/85(
)8526(0,'(

',85(7,&6
&21*(67,9(+($57
)$,/85(
+<'52&+/2527+,$=,'(

',85(7,&6
&21*(67,9(+($57
)$,/85(
0(72/$=21(

',85(7,&6
&21*(67,9(+($57
)$,/85(
63,5212/$&721(

',85(7,&6
&2521$5<$57(5<',6($6(
+<'52&+/2527+,$=,'(

',85(7,&6
&2521$5<$57(5<',6($6(
)8526(0,'(


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

',85(7,&6
(/(9$7,212)%/22'
35(6685(
)8526(0,'(

',85(7,&6
0,75$/,168)),&,(1&<
725$6(0,'(

',85(7,&6
75$16*(1*(5
63,5212/$&721(

/,3,'02',)<,1*$*(176
$&87(0<2&$5',$/
,1)$5&7,21
$7259$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
$&87(0<2&$5',$/
,1)$5&7,21
20(*$75,*/<&(5,'(6

/,3,'02',)<,1*$*(176
$7+(526&/(527,&+($57
',6($6(2)1$7,9(
&2521$5<$57(5<
:,7+287$1*,1$3(&725,6
6,09$67$7,1

/,3,'02',)<,1*$*(176
%$6,/$5$57(5<
7+520%86
$7259$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
&$'
35$9$67$7,162',80

/,3,'02',)<,1*$*(176
&$'
52689$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
&$5',$&3523+</$;,6
$7259$67$7,1

/,3,'02',)<,1*$*(176
&$5',$&3523+</$;,6
),6+2,/

/,3,'02',)<,1*$*(176
&$5',29$6&8/$5
3523+</$;,6
$7259$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
&+(677,*+71(66
$7259$67$7,1
+\SHUOLSLGHPLD+/,3'(0

$*(176$&7,1*217+(
5(1,1$1*,27(16,16<67(0
+<3(575,*/<&(5,'(0,$
/,6,1235,/

$17,+<3(57(16,9(6
+<3(5&+2/(67(52/(0,$
'2;$=26,10(6,/$7(

&$5',$&7+(5$3<
+<3(5&+2/(67(52/(0,$
8%,'(&$5(121(

/,3,'02',)<,1*$*(176
$%1250$//,3,'6
$7259$67$7,1

/,3,'02',)<,1*$*(176
&$5',$&3523+</$;,6
52689$67$7,1

/,3,'02',)<,1*$*(176
&+2/(67(52/
52689$67$7,1

/,3,'02',)<,1*$*(176
&+2/(67(52/
52689$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
&+2/(67(52/($0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
&+2/(67(525/
52689$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
&2521$5<$57(5<',6($6(
$7259$67$7,1

/,3,'02',)<,1*$*(176
&2521$5<$57(5<',6($6(
(=(7,0,%(

/,3,'02',)<,1*$*(176
&2521$5<$57(5<',6($6(
)(12),%5$7(

/,3,'02',)<,1*$*(176
&2521$5<$57(5<',6($6(
52689$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
&2521$5<$57(5<
',6($6(3523+</$;,6
$7259$67$7,1


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

/,3,'02',)<,1*$*(176
',(76833/(0(17
),6+2,/

/,3,'02',)<,1*$*(176
',(7$5<6833/(0(17
),6+2,/

/,3,'02',)<,1*$*(176
',(7$5<6833/(0(176
),6+2,/

/,3,'02',)<,1*$*(176
'<6/,3('(0,$
52689$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
'<6/,3,'$(0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
'<6/,3,'(0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
'<6/,3,'(0,$
)(12),%5$7(

/,3,'02',)<,1*$*(176
'<6/,3,'(0,$
),6+2,/

/,3,'02',)<,1*$*(176
'<6/,3,'(0,$
*(0),%52=,/

/,3,'02',)<,1*$*(176
'<6/,3,'(0,$
35$9$67$7,1

/,3,'02',)<,1*$*(176
'<6/,3,'(0,$
52689$67$7,1

/,3,'02',)<,1*$*(176
'<6/,3,'(0,$
:256(1,1*
52689$67$7,1

/,3,'02',)<,1*$*(176
'<6/,3,'(50,$
35$9$67$7,1

/,3,'02',)<,1*$*(176
(/(9$7('&+2/(67(52/
6,09$67$7,1

/,3,'02',)<,1*$*(176
(/(9$7('/,3,'6
$7259$67$7,1

/,3,'02',)<,1*$*(176
(/(9$7('/,3,'6
$7259$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
(/(9$7('75,*/<&(5,'(6
),6+2,/

/,3,'02',)<,1*$*(176
+,*+&+2/(67(52/
$7259$67$7,1

/,3,'02',)<,1*$*(176
+,*+&+2/(67(52/
$7259$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+,*+&+2/(67(52/
*(0),%52=,/

/,3,'02',)<,1*$*(176
+,*+&+2/(67(52/
/29$67$7,1

/,3,'02',)<,1*$*(176
+,*+&+2/(67(52/
35$9$67$7,1

/,3,'02',)<,1*$*(176
+,*+&+2/(67(52/
52689$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+,*+&+2/(67(52/
6,09$67$7,1

/,3,'02',)<,1*$*(176
+,*+&+2/(6752/
$7259$67$7,1

/,3,'02',)<,1*$*(176
+,*+3/$60$/,3,'6
$7259$67$7,1

/,3,'02',)<,1*$*(176
+,*+75,*/<&(5,'(6
)(12),%5$7(

/,3,'02',)<,1*$*(176
+,*+75,*/<&(5,'(6$1'
+<3(5&+2/(67(52/(0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
+,3(5&2/(67(52/(0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
+,3(5&2/(67(52/(0,$
$7259$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+,3(5&2/(67(52/(0,$
6,09$67$7,1

/,3,'02',)<,1*$*(176
+<(5/,3,'(0,$
20(*$$&,'(7+</(67(5

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(5,0,$
)(12),%5$7(


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(5,1$(0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(5,1$(0,$
35$9$67$7,1

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(5,1(0,$
35$9$67$7,1

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(5,1(0,$
6,09$67$7,1

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/
35$9$67$7,1

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/$(0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/$(0,$
35$9$67$7,1

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/$(0,$
52689$67$7,1

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/$(0,$
6,09$67$7,1

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/(0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/(0,$
$7259$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/(0,$
(=(7,0,%(

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/(0,$
)(12),%5$7(

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/(0,$
),6+2,/

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/(0,$
/29$67$7,1

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/(0,$
3,7$9$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/(0,$
35$9$67$7,1

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/(0,$
35$9$67$7,162',80

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/(0,$
52689$67$7,1

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/(0,$
52689$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/(0,$
6,09$67$7,1

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/(0,$
385($1'0,;('
+<3(5/,3,'(0,$
52689$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/0,$
35$9$67$7,162',80

/,3,'02',)<,1*$*(176
+<3(5&+2/(6752/(0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
+<3(5&+2/(6752/(0,$
$7259$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+<3(5&+2/(6752/(0,$
)(12),%5$7(

/,3,'02',)<,1*$*(176
+<3(5&+2/67(52$(0,$
$7259$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+<3(5&2/(67(52/(0,$
6,09$67$7,1

/,3,'02',)<,1*$*(176
+<3(5/,'(0,$
52689$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+<3(5/,',3(0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
+<3(5/,3'(0,$
52689$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+<3(5/,3('0,$0,;('
$7259$67$7,1

/,3,'02',)<,1*$*(176
+<3(5/,3,'$(0,$
$7259$67$7,1


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

/,3,'02',)<,1*$*(176
+<3(5/,3,'$(0,$
)(12),%5$7(

/,3,'02',)<,1*$*(176
+<3(5/,3,'$(0,$
35$9$67$7,1

/,3,'02',)<,1*$*(176
+<3(5/,3,'$(0,$
35$9$67$7,162',80

/,3,'02',)<,1*$*(176
+<3(5/,3,'$(0,$
52689$67$7,1

/,3,'02',)<,1*$*(176
+<3(5/,3,'$(0,$
52689$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0$
$7259$67$7,1

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
$7259$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
&2/(6(9(/$0
+<'52&+/25,'(

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
(,&26$3(17$(12,&$&,'
(7+</(67(5

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
(=(7,0,%(

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
)(12),%5$7(

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
)(12),%5,&$&,'

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
),6+2,/

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
*(0),%52=,/

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
/29$67$7,1

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
20(*$$&,'(7+</(67(5

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
3(/$*2

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
35$9$67$7,1

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
35$9$67$7,162',80

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
52689$67$7,1

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
52689$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
6,09$67$7,1

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
35(9(17,21
52689$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
35$9$67$7,1

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$0,;('
$7259$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$0,;('
)(12),%5$7(

/,3,'02',)<,1*$*(176
+<3(57(16,21
$7259$67$7,1

/,3,'02',)<,1*$*(176
+<3(57(16,21
35$9$67$7,1

/,3,'02',)<,1*$*(176
+<3(575,*/<&(5'(0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
+<3(575,*/<&(5,'(0,$
$7259$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
+<3(575,*/<&(5,'(0,$
)(12),%5$7(


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

/,3,'02',)<,1*$*(176
+<3(575,*/<&(5,'(0,$
)(12),%5,&$&,'

/,3,'02',)<,1*$*(176
+<3(575,*/<&(5,'(0,$
),%5$7(6

/,3,'02',)<,1*$*(176
+<3(575,*/<&(5,'(0,$
),6+2,/

/,3,'02',)<,1*$*(176
+<3(575,*/<&(5,'(0,$
20(*$75,*/<&(5,'(6

/,3,'02',)<,1*$*(176
+<3(575,*/<&(5,'(0,$
35$9$67$7,1

/,3,'02',)<,1*$*(176
+<3(575,*/<&(5,'(0,$+
<3(5&+2/(67(52/(0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
+<3(575,*/<(5,'(0,$
*(0),%52=,/

/,3,'02',)<,1*$*(176
+<3(575<*/<&(5,'(0,$
35$9$67$7,1

/,3,'02',)<,1*$*(176
,1',&$7,21
+<3(5/,3,'(0,$
)(12),%5$7(

/,3,'02',)<,1*$*(176
,55,7$%/(%2:(/
6<1'520(
),6+2,/

/,3,'02',)<,1*$*(176
,6&+(0,&+($57',6($6(
52689$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
/'/&+2/(67(52/
*5$'((/(9$7,21
52689$67$7,1

/,3,'02',)<,1*$*(176
0,;(''<6/,3,'(0,$
)(12),%5$7(

/,3,'02',)<,1*$*(176
0,;(''<6/,3,'(0,$
52689$67$7,1&$/&,80

/,3,'02',)<,1*$*(176
0,;('+<3(5/,3'(0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
0,;('+<3(5/,3,'(0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
0,;('+<3(5/,3,'(0,$
)(12),%5$7(

/,3,'02',)<,1*$*(176
0,;('+<3(5/,3,'(0,$
*(0),%52=,/

/,3,'02',)<,1*$*(176
1875,7,216833/(0(17
),6+2,/

/,3,'02',)<,1*$*(176
1875,7,21$/6833/(0(17
),6+2,/

/,3,'02',)<,1*$*(176
1875,7,21$/6833/(0(17
20(*$)$77<$&,'6

/,3,'02',)<,1*$*(176
35(9(17$7,9(
)2//2:,1*$&87(
0<&$5',$/,1)$5&7,21
$7259$67$7,1

/,3,'02',)<,1*$*(176
35(9(17,21)25
+<3(5&+2/(67(52/(0,$
20(*$)$77<$&,'6

/,3,'02',)<,1*$*(176
35(9(17,9(
),6+2,/:/,180
86,7$7,66,0806(('2,/

/,3,'02',)<,1*$*(176
3523+</$;,6
),6+2,/

/,3,'02',)<,1*$*(176
385(
+<3(5&+2/(67(52/(0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
6(&21'$5<6752.(
35(9(17,21
$7259$67$7,1

/,3,'02',)<,1*$*(176
6752.(3523+</$;,6
$7259$67$7,1


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
0HGLFDWLRQ&ODVV:+2$7&
,QGLFDWLRQ&0,1'&
:+2*(1

/,3,'02',)<,1*$*(176
6833/(0(17
),6+2,/

/,3,'02',)<,1*$*(176
6833/(0(17
20(*$

/,3,'02',)<,1*$*(176
6833/(0(17
20(*$)$77<$&,'6

/,3,'02',)<,1*$*(176
6833/(0(17
20(*$)$77<$&,'6
:20(*$)$77<$&,'6

/,3,'02',)<,1*$*(176
6833/(0(17
20(*$$&,'(7+</(67(5

/,3,'02',)<,1*$*(176
6833/(0(17
+<3(5/,3,'(0,$
),6+2,/

/,3,'02',)<,1*$*(176
6833/(0(17$/86(
),6+2,/

/,3,'02',)<,1*$*(176
6833/(0(71
),6+2,/

/,3,'02',)<,1*$*(176
81&21752//('',$%(7(6
0(//,786
$7259$67$7,1

/,3,'02',)<,1*$*(176
:256(1,1*
+<3(5/,3,'(0,$
$7259$67$7,1

/,3,'02',)<,1*$*(176
:256(1,1*2)
+<3(5/,3,'(0,$
),6+2,/

/,3,'02',)<,1*$*(176
+,*+&+2/(67(52/
1,&27,1,&$&,'

/,3,'02',)<,1*$*(176
+<3(5&+2/(67(52/(0,$
1,&27,1,&$&,'

/,3,'02',)<,1*$*(176
+<3(5/,3,'(0,$
1,&27,1,&$&,'

/,3,'02',)<,1*$*(176
0,;('+<3(5/,3,'(0,$
1,&27,1,&$&,'



%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
$SSHQGL[
+HSDWLF(YHQWV
$QDGYHUVHHYHQWUHFRUGZLOOEHIODJJHGDVDKHSDWLFHYHQWLILWV0HG'5$37LVLQFOXGHGLQWKLV
SUHVSHFLILHG37OLVWZKLFKLQFOXGHVDOO37VIURPWKHEURDGVHDUFKRIWKHIROORZLQJ604V
XQGHU0HG'5$SURYLGHGE\*LOHDG'63+DQGUHYLHZHGE\*LOHDGPHGLFDOPRQLWRUV
6046RXUFH
+HSDWLF(YHQWV+(3
%LOLDU\QHRSODVPVEHQLJQLQFOF\VWVDQGSRO\SV604
%LOLDU\PDOLJQDQWWXPRXUV604
%LOLDU\WXPRXUVRIXQVSHFLILHGPDOLJQDQF\604
%LOLDU\V\VWHPUHODWHGLQYHVWLJDWLRQVVLJQVDQGV\PSWRPV604
%LOLDU\WUDFWGLVRUGHUV604
*DOOEODGGHUUHODWHGGLVRUGHUV604
*DOOVWRQHUHODWHGGLVRUGHUV604
&KROHVWDVLVDQGMDXQGLFHRIKHSDWLFRULJLQ604
+HSDWLFIDLOXUHILEURVLVDQGFLUUKRVLVDQGRWKHUOLYHUGDPDJHUHODWHGFRQGLWLRQV604
+HSDWLWLVQRQLQIHFWLRXV604
/LYHUQHRSODVPVEHQLJQLQFOF\VWVDQGSRO\SV604
/LYHUPDOLJQDQWWXPRXUV604
/LYHUWXPRXUVRIXQVSHFLILHGPDOLJQDQF\604
/LYHUUHODWHGLQYHVWLJDWLRQVVLJQVDQGV\PSWRPV604
/LYHUUHODWHGFRDJXODWLRQDQGEOHHGLQJGLVWXUEDQFHV604



%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
$SSHQGL[
3URJUDPPLQJ6SHFLILFDWLRQ
 $*(FDOFXODWHGDVIROORZV
D $*(\HDUVLVFDOFXODWHGIURPWKHQXPEHURIGD\VEHWZHHQWKHGDWHRIELUWK'2%DQG
'D\ILUVWGRVHGDWH
E 8VHWKH6$6,17&.IXQFWLRQWRGHWHUPLQHWKHQXPEHURI³VWRIPRQWKGD\V´
HJ-DQXDU\VW)HEUXDU\VW0DUFKVWEHWZHHQ'2%DQG'D\LQFOXVLYH
F 'LYLGHWKHUHVXOWLQEE\
G $*( WKHLQWHJHURIWKHUHVXOWLQF
H ,IWKH'2%DQG'D\KDYHWKHPRQWKLQFRPPRQDQGWKHELUWKGD\LVODWHULQWKHPRQWK
WKDQWKHGDWHRI6WXG\'D\WKHQVXEWUDFWRQHIURPWKH$*(UHVXOWDERYH
)RUVXEMHFWVUDQGRPL]HGDQGQHYHUGRVHGZLWKVWXG\GUXJDJHZLOOEHFDOFXODWHGIURPWKH
GDWHRIUDQGRPL]DWLRQ
$JHIRUODERUDWRU\WHVWUHIHUHQFHUDQJHZLOOEHEDVHGRQWKHDJHDWWKHVDPSOHFROOHFWLRQGDWH
 $OOVFUHHQHGVXEMHFWVUHIHUWRDOOVXEMHFWVZKRDUHVFUHHQHGLHZLWKQRQPLVVLQJVFUHHQLQJ
GDWHDQGKDYHDVFUHHQLQJQXPEHU)RUVXPPDULHVWKHVDPHVXEMHFWLVFRXQWHGRQO\RQFH
'2%DQGRWKHUGHPRJUDSKLFLQIRUPDWLRQVXFKDVVH[UDFHHWKQLFLW\FRXQWU\DQGLQLWLDOV
ZLOOEHXVHGWRLGHQWLI\XQLTXHVFUHHQHGVXEMHFWV
 6FUHHQIDLOXUHVXEMHFWVDUHWKHVXEMHFWVZKRZHUHVFUHHQHGDQGDQVZHUHG³1R´IRUDQ\
LQFOXVLRQFULWHULDRU³<HV´IRUDQ\H[FOXVLRQFULWHULDUHJDUGOHVVRIZKLFKYHUVLRQRISURWRFRO
WKHVXEMHFWZDVFRQVHQWWR
 6XEMHFWVLQWKHUDQGRPL]HGDQDO\VLVVHWDUHGHILQHGDVVXEMHFWVUDQGRPL]HGLQWRWKHVWXG\
,;565$1'LVWKHVRXUFHWRGHWHUPLQHZKHWKHUWKHVXEMHFWLVUDQGRPL]HGLHVXEMHFWZLWK
QRQPLVVLQJ5*01'71LQWKH,;565$1'GDWDVHWDQGFRQILUPHGE\WKHH&5)(152//
GDWDVHWLH(152//<1 ³<HV´LQ(152//GDWDVHW
 5DQGRPL]HGWUHDWPHQWLH7573LQ$'6/DUHGHULYHGIURP,;565$1'ZKLOHDFWXDO
WUHDWPHQWUHFHLYHGLH757$LQ$'6/LVDVVLJQHGDVWKHUDQGRPL]HGWUHDWPHQWLIVXEMHFW
WRRNDWOHDVWGRVHRIVWXG\GUXJDQGDVVLJQHGDVEODQNLIVXEMHFWQHYHUGRVHG
 ,QGLVSRVLWLRQWDEOHWKHUHDVRQVIRUSUHPDWXUHGLVFRQWLQXDWLRQDUHGLVSOD\HGLQWKHRUGHUDV
WKH\DSSHDURQWKHH&5)


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
 %RG\PDVVLQGH[%0,DQG%RG\6XUIDFH$UHD%6$
%0,DQG%6$ZLOOEHFDOFXODWHGRQO\DWEDVHOLQHDVIROORZV
x %0, ZHLJKW>NJ@KHLJKW>PHWHUV@
x %6$P 6457>+HLJKWFPî:HLJKWNJ@
%DVHOLQHKHLJKWDQGZHLJKWZLOOEHXVHGIRUWKLVFDOFXODWLRQ
 6$6FRGHVIRUWKHWUHDWPHQWFRPSDULVRQIRUGHPRJUDSKLFVDQGEDVHOLQHFKDUDFWHULVWLFVWDEOHV
D &0+WHVWIRUQRPLQDOYDULDEOH<WKHSYDOXHIURPJHQHUDODVVRFLDWLRQWHVWVKRXOGEH
XVHGIRUQRPLQDOYDULDEOH
SURFIUHTRUGHU DGVO

WDEOHVWUWJUS<FPKJHQHUDODVVRFLDWLRQWHVW
UXQ
E &0+WHVWIRURUGLQDOYDULDEOH<WKHSYDOXHIURPURZPHDQVFRUHWHVWVKRXOGEHXVHG
IRURUGLQDOYDULDEOH
FSURFIUHTRUGHU DGVO
 WDEOHVWUWJUS<FPKURZPHDQVFRUHWHVW
UXQ
F :LOFR[RQUDQNVXPWHVWIRUFRQWLQXRXVYDULDEOH<WKHSYDOXHIURPWKHQRUPDO
DSSUR[LPDWLRQWZRVLGHGWHVWVKRXOGEHXVHGIRUFRQWLQXRXVYDULDEOH
SURFQSDUZD\ZLOFR[RQGDWD DGVO

FODVVWUWJUS

YDU<
UXQ
 3OHDVHQRWH³1RW3HUPLWWHG´³8QNQRZQ´RUPLVVLQJFDWHJRULHVZLOOEHH[FOXGHGSHUFHQWDJH
FDOFXODWLRQDQGDOVRH[FOXGHGIRUIRUSYDOXHJHQHUDWLRQIRUFDWHJRULFDOGDWDDQDO\VLV
HJ&0+WHVWRU)LVKHUH[DFWWHVW([FHSWIRU0RGHRILQIHFWLRQ+,95LVN)DFWRUVZKHUH
³8QNQRZQ´ZLOOEHLQFOXGHGIRUSHUFHQWDJHFDOFXODWLRQVLQFHDVXEMHFWPD\ILWPRUHWKDQ
+,9ULVNIDFWRUVWKHUHIRUHSHUFHQWDJHPD\DGGWRPRUHWKDQDQGQRSYDOXHZLOOEH
JHQHUDWHG
6XEMHFWVZLWK5DFH ³1RW3HUPLWWHG´ZLOODOVREHH[FOXGHGWRGHILQH5DFHVXEJURXS
LHEODFNYVQRQEODFNIRUHIILFDF\VXEJURXSDQDO\VLV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
6$6FRGHIRUWUHDWPHQWFRPSDULVRQIRUGXUDWLRQRIH[SRVXUH7KHSYDOXHIURPORJUDQNWHVW
VKRXOGEHXVHG
SURFOLIHWHVWGDWD $'6/PHWKRG NP

WLPH757'85'(6'''HULYH(6''IURP&207)/ZKHUH(6'' 

LQGLFDWHVFHQVRUHGREVHUYDWLRQLHVXEMHFWLVVWLOORQVWXG\GUXJ

6WUDWD757$1

ODEHO757'85' 'XUDWLRQRI([SRVXUH'D\V
UXQ
/DVW'RVH'DWHDQG/DVW6WXG\'DWH
D /DVW'RVH'DWHLH757('7&757('775('7RU75('7&LQ$'6/ZDV
GHILQHGLQ6$36HFWLRQ
)RUVXEMHFWVZLWKDSDUWLDOODVWGRVLQJGDWHLHPRQWKDQG\HDURIODVWGRVHDUHNQRZQ
WKHODWHVWRIWKHGLVSHQVLQJGDWHVRIVWXG\GUXJERWWOHVVWXG\GUXJVWDUWGDWHVDQGHQG
GDWHVDQGWKHLPSXWHGODVWGRVHGDWH>GD\LPSXWHGDV@ZLOOEHXVHGDVWKHILQDO
LPSXWHGODVWGRVHGDWH+RZHYHULIGLVSHQVLQJGDWH¶VPRQWKLVDIWHUODVWGRVHGDWH¶V
PRQWKGDWDTXHU\LVQHHGHG
,IVXEMHFWGLHGDQGWKHGHDWKGDWHLVFRPSOHWHLHQRWSDUWLDOGDWHDQGEHIRUHWKHLPSXWHG
ODVWGRVHGDWHWKHFRPSOHWHGHDWKGDWHVKRXOGEHXVHGDVWKHLPSXWHGODVWGRVHGDWH
/DVWGRVHGDWHLVQRWGHILQHGIRUVXEMHFWVVWLOORQVWXG\GUXJLQ6$3+RZHYHUIRUWKH
FDOFXODWLRQRIWKHGXUDWLRQRIH[SRVXUHWRVWXG\GUXJWKHGDWDFXWGDWHZLOOEHXVHGWR
LPSXWHWKHODVWGRVHGDWHIRUVXEMHFWVZKRKDYHQRWSHUPDQHQWO\GLVFRQWLQXHGVWXG\GUXJ
DWWKHWLPHRIWKHGDWDFXWGDWHLH&5)GDWDFXWGDWHIURPWKHGDWDFXWSODQ
)RU:HHNLQWHULPDQDO\VLVZLOOEHWKHGDWDFXWGDWHIRUVXEMHFWVZLWK
:HHNYLVLWVRQRUSULRUWRVXEMHFWVPLVVLQJZHHNYLVLWVZKLOHRQVWXG\
GUXJRUVXEMHFWVSUHPDWXUHO\GLVFRQWLQXHGVWXG\GUXJ)RUVXEMHFWVZLWK:HHNYLVLW
DIWHUEXWEHIRUHGDWDILQDOL]DWLRQWKHODVW:HHNYLVLWGDWHZLOOEHXVHGDV
WKHGDWDFXWGDWHDVDSSURSULDWH
E /DVW6WXG\'DWHLVWKHODWHVWRIWKHVWXG\GUXJVWDUWGDWHVDQGHQGGDWHVWKHFOLQLFYLVLW
GDWHVDQGWKHODERUDWRU\YLVLWGDWHVLQFOXGLQJWKHGD\IROORZXSYLVLWGDWHIRUVXEMHFWV
ZKRSUHPDWXUHO\GLVFRQWLQXHGVWXG\RUZKRFRPSOHWHGVWXG\DFFRUGLQJWRWKH6WXG\
&RPSOHWLRQH&5),IVWXG\GUXJVWDUWGDWHRUHQGGDWHLVSDUWLDOO\PLVVLQJLHRQO\\HDU
DQGPRQWKDUHNQRZQWKHGD\ZLOOEHLPSXWHGDVIRUWKHSXUSRVHRIWKLVDQDO\VLV
,IVXEMHFWGLHGDQGWKHGHDWKGDWHLVFRPSOHWHLHQRWSDUWLDOGDWHDQGEHIRUHWKHLPSXWHG
ODVWVWXG\GDWHWKHFRPSOHWHGHDWKGDWHVKRXOGEHXVHGDVWKHLPSXWHGODVWVWXG\GDWH
/DVWVWXG\GDWHLVQRWGHILQHGIRUVXEMHFWVVWLOORQVWXG\LQ6$3+RZHYHUIRUSURJUDPLQJ
SXUSRVHWKHODWHVWRIGDWDFXWGDWHLH&5)GDWDFXWGDWHIURPWKHGDWDFXWSODQWKH
FOLQLFYLVLWGDWHVDQGWKHODERUDWRU\YLVLWGDWHVLQFOXGLQJWKHGD\IROORZXSYLVLWGDWH
ZLOOEHXVHGWRLPSXWHWKHODVWVWXG\GDWHIRUVXEMHFWVVWLOORQVWXG\


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
7R[LFLW\*UDGHV
D )RUWR[LFLW\JUDGHVXPPDULHVLQFOXGHDOOSRVWEDVHOLQHJUDGHGUHVXOWVXSWRGD\VDIWHU
WKHODVWGRVHRIVWXG\GUXJQRWMXVWWKRVHXVHGLQE\YLVLWVXPPDULHV
E )RUJOXFRVHJUDGLQJDVVSHFLILHGLQ6$36HFWLRQWKHWUHDWPHQWHPHUJHQWIODJ
FDQQRWEHGHWHUPLQHGIRUQRQIDVWLQJJOXFRVHLQFOXGLQJJOXFRVHUHVXOWVZLWKRXWDNQRZQ
IDVWLQJVWDWXV$VDUHVXOWWKHVHUHFRUGVZLOOEHH[FOXGHGIURPWKH³0D[LPXP
7UHDWPHQWHPHUJHQW7R[LFLW\*UDGH´VXPPDU\LQWKH³7UHDWPHQWHPHUJHQW/DERUDWRU\
$EQRUPDOLWLHV´RU³7UHDWPHQWHPHUJHQW*UDGHRU/DERUDWRU\$EQRUPDOLWLHV´
VXPPDU\WDEOHV,QDGGLWLRQIDVWLQJJOXFRVHDQGQRQIDVWLQJJOXFRVHZLOOEHOLVWHGDV
WZRVHSDUDWHODERUDWRU\WHVWVLQWKH³/DERUDWRU\$EQRUPDOLWLHV´DQG³*UDGHRU
/DERUDWRU\$EQRUPDOLWLHV´OLVWLQJV2QO\DPD[LPXPSRVWEDVHOLQHWR[LFLW\IODJZLOOEH
GLVSOD\HGDQGWKHWUHDWPHQWHPHUJHQWIODJZLOOQRWEHGLVSOD\HGIRUQRQIDVWLQJJOXFRVHDV
WKHWUHDWPHQWHPHUJHQWIODJFDQQRWEHGHWHUPLQHGIRUQRQIDVWLQJJOXFRVH
(IILFDF\DQDO\VHV
D )RUFDWHJRULFDOHIILFDF\UHVSRQVHHJ6XEMHFWVZLWK+,951$FRSLHVP/RU
6XEMHFWVZLWK+,951$FRSLHVP/DVGHWHUPLQHGE\86)'$GHILQHGVQDSVKRW
DOJRULWKP0 )RU0 ($QDO\VHVWKHSURSRUWLRQGLIIHUHQFHEHWZHHQWZRWUHDWPHQW
JURXSVDQGLWV&,VIRU+,951$DWZNE\VQDSVKRWDOJRULWKPIRU
)$6RU:HHN33VHWRU&,VDUHFDOFXODWHGEDVHGRQWKHDQXQFRQGLWLRQDOH[DFW
PHWKRGXVLQJLQYHUWHGVLGHGWHVWVLQ6$6YRUDERYH
E 7KHIROORZLQJ6$6FRGHZLOOEHXVHGWRFRPSXWHFHOOFRXQWVDQGSYDOXH
data example; 
input  grp trt01a $  outcome $ count ; 
datalines; 
1       Treat-A        2-Fail        1      
1       Treat-A        1-Succ      189      
1       Treat-B        2-Fail        4      
1       Treat-B        1-Succ       88      
run; 
proc freq data = example; 
table trt01a*outcome /riskdiff(CL=(exact)) DOSKD ; 
weight count; exact RISKDIFF(METHOD=SCORE); 
output out=ciexact(keep=_RDIF1_ XL_RDIF1 XU_RDIF1 _RSK11_  _RSK21) riskdiff; 
run; 


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
c 
data final(keep=A1 B1 Estimate LowerCL UpperCL ocharc1); 
set ciexact; 
label Estimate ="Percentage Difference" 
LowerCL = "95% Lower Confidence Limit" 
UpperCL = "95% Upper Confidence Limit" 
A1 = "Percentage of Success in Treat-A" 
B1 = "Percentage of Success in Treat-B"; 
Estimate=100*_RDIF1_; 
LowerCL = 100*XL_RDIF1; 
UpperCL = 100*XU_RDIF1; 
A1 = 100*_RSK11_; 
B1 = 100*_RSK21_; 
ocharc1 = right(compress(put(Estimate,8.1)) || '% (' || compress(put(LowerCL,8.1)) || '% 
to ' || compress(put(UpperCL,8.1)) || '%)'); 
run; 
F 3OHDVHQRWHDOSKD LVRQO\XVHGIRUWKHSULPDU\HIILFDF\HQGSRLQW+,951$
! FP/E\VQDSVKRWDOJRULWKPDW:HHNWRREWDLQ&,VDQGWKHHQGSRLQW
RIVXEMHFWVZLWK+,951$FP/E\VQDSVKRWDOJRULWKPDW:HHNLQ)$6DQG
:HHN33DQDO\VLVVHWRWKHUZLVHIRUWKHHIILFDF\HQGSRLQWVZLWKSURSRUWLRQVWKH
DOSKD LVXVHGWRREWDLQ&,V
G 7KH&,IRUSHUFHQWDJHHVWLPDWHRI+,951$FRSLHVP/IRUHDFKWUHDWPHQWLV
FDOFXODWHGEDVHGRQWKH&ORSSHU3HDUVRQH[DFWPHWKRG
H )LVKHU¶VH[DFWWHVWIRUFDWHJRULFDOHIILFDF\UHVSRQVHHJ+,951$FRSLHVP/E\
86)'$GHILQHGVQDSVKRWDOJRULWKPZKHUHWUWJUSLVWKHWUHDWPHQWDQGUHVSRQVHLVWKH
FDWHJRULFDOHIILFDF\UHVSRQVH3YDOXHIURPVLGHG)LVKHU¶VH[DFWWHVWVKRXOGEHXVHGWR
WHVWVXSHULRULW\
SURFIUHTGDWD DGHII

WDEOHVWUWJUSUHVSRQVHILVKHUSYDOXHIURP)LVKHU¶VH[DFWWHVW
UXQ
I +RPRJHQHLW\WHVW+RPRJHQHLW\7HVWRI7UHDWPHQW(IIHFW+,951$FRSLHVP/
E\86)'$GHILQHGVQDSVKRWDOJRULWKP$FURVV5HJLRQLQ+,951$FRSLHVP/
DW:HHN6QDSVKRW$OJRULWKP)RUHDFKUHJLRQWKHRGGVUDWLRDQGLWV&,DUH
FDOFXODWHGIURPWKH&0+WHVW)RURYHUDOOWKHRGGVUDWLRDQGLWV&,DUHFDOFXODWHG
EDVHGRQWKHFRPPRQRGGVUDWLRHVWLPDWHIURPWKH&0+WHVW7KHSYDOXHIRUWKH
KRPRJHQHLW\WHVWLVEDVHGRQWKH%UHVORZ'D\WHVWRIWKHLQWHUDFWLRQEHWZHHQUHJLRQDQG
WUHDWPHQWJURXSDVIROORZV
SURFIUHTGDWD [[[

WDEOHVUHJLRQWUWJUSUHVSRQVHDOOSYDOXHIURP%UHVORZ'D\WHVW

WUWJUSUHVSRQVH! 
UXQ


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
J 6XEJURXSDQDO\VHVIRU+,951$FRSLHVP/E\86)'$GHILQHGVQDSVKRW
DOJRULWKP
)RUWKHVXEJURXSVRIDJHVH[UDFHEDVHOLQH&'FHOOFRXQWDQGVWXG\GUXJDGKHUHQFH
WKHSURSRUWLRQGLIIHUHQFHEHWZHHQWZRWUHDWPHQWJURXSVDQGLWV&,VDUHFDOFXODWHG
EDVHGRQDQXQFRQGLWLRQDOH[DFWPHWKRGXVLQJLQYHUWHGVLGHGWHVWVVLPLODUO\WRWKDW
IRUWKHSULPDU\HIILFDF\HQGSRLQW
K +RPRJHQHLW\WHVW+RPRJHQHLW\7HVWRI7UHDWPHQW(IIHFW+,951$FRSLHVP/
E\86)'$GHILQHGVQDSVKRWDOJRULWKPEHWZHHQ6XEJURXSVLQ+,951$
FRSLHVP/DW:HHN6QDSVKRW$OJRULWKP
D )RUWKHVXEJURXSVRIDJHVH[UDFHUHJLRQDQGVWXG\GUXJDGKHUHQFHWKHRGGVUDWLR
DQGWKHDVVRFLDWHG&,VDUHHVWLPDWHGIRUWKHUHVSRQVHYDULDEOHUHVSRQVHFRGHG
DVIRUVXFFHVVDQGIRUQRQVXFFHVVXVLQJDORJLVWLFUHJUHVVLRQPRGHOLQFOXGLQJ
VXEJURXSIDFWRUFRGHGDVIRUWKHILUVWVXEJURXSDQGIRUWKHVHFRQGVXEJURXS
WUHDWPHQWWUWJUSFRGHGDVIRUDFWLYH>LH%)7$)@DQGIRUFRQWURODQGWUHDWPHQW
E\VXEJURXSIDFWRU
HJUHJLRQVWUDWXPUHJLRQFRGHGDVIRU³86´DQGIRU³([86´
)RUH[DPSOHIRUWKHDJHVXEJURXSDJHJUSFRGHGDVIRUDQGIRU! WKH
IROORZLQJ6$6FRGHZLOOEHXVHGWRJHQHUDWHWKH2GGV5DWLRDQGLWV&,ZLWKLQ
WKHVXEJURXS
1RWH)RUWKHIROORZLQJFRGHLWLVDVVXPHGWKDWQRQHRIWKHYDULDEOHVKDYHDQ\
IRUPDWVDSSOLHGWRWKHP,IWKH\GRWKH\PXVWEHUHPRYHGEHIRUHFDOOLQJWKHFRGH
HJIRUWKHDJHVXEJURXSWKHIROORZLQJFRGHVZLOOEHXVHGWRJHW2GGV5DWLRDQG
&,ZLWKLQVXEJURXS
SURFJHQPRGGDWD GDWDGHVFHQGLQJPRGHOIRUVXFFHVV

FODVVWUWJUSQDJHJUS

PRGHOUHVSRQVH WUWJUSQDJHJUSWUWJUSQDJHJUSGLVW ELQ

OLQN ORJLWOUFL

HVWLPDWH
*URXS
WUWJUSQWUWJUSQDJHJUSH[S

HVWLPDWH
*URXS
WUWJUSQWUWJUSQDJHJUSH[S
UXQ
1RWHWUWJUSQLVWKHQXPHULFWUHDWPHQWJURXSYDULDEOHUHVSRQVHLVWKHUHVSRQVH
RXWFRPHYDULDEOHYV¶¶YV¶! ¶DJHJUSLVWKHVXEJURXSYDULDEOHIRUDJH
YV! 
3YDOXHIRUWKHKRPRJHQHLW\WHVWZDVEDVHGRQWKH:DOGWHVWRIWKHLQWHUDFWLRQ
EHWZHHQWUHDWPHQWDQGVXEJURXS2GGVUDWLRLVIURP/
%HWDHVWLPDWHLWV&,LV
IURP/
%HWDFRQILGHQFHOLPLWVIRUHDFKVXEJURXS


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
L $129$PRGHOIRUFRQWLQXRXVHIILFDF\YDULDEOHHJ&'7KHGLIIHUHQFHVLQFKDQJHV
IURPEDVHOLQHLQ&'FHOOFRXQWEHWZHHQWUHDWPHQWJURXSVDQGWKHDVVRFLDWHG&,
ZLOOEHFRQVWUXFWHGXVLQJDQ$129$LQFOXGLQJWUHDWPHQWDVIL[HGHIIHFWLQWKHPRGHO
SURFJOPGDWD DGHII

FODVVWUWJUS

PRGHO&' WUWJUS

OVPHDQVWUWJUSDOSKD FOSGLII

UXQ
M /LVWLQJIRU86)'$GHILQHGVQDSVKRWRXWFRPH
,QDGGLWLRQWRIODJJLQJWKHYDOXHVRI+,951$RUFRSLHVP/IRUYLURORJLF
RXWFRPHVIODJWKHODVWDYDLODEOH+,951$YDOXHZKLOHRQWUHDWPHQWIRUWKHIROORZLQJ
FDWHJRULHV
L +,951$! FRSLHVP/'LVFRQWLQXHG6WXG\'UXJ'XHWR$(RU'HDWKDQG
/DVW$YDLODEOH+,951$! FRSLHVP/
LL +,951$! FRSLHVP/'LVFRQWLQXHG6WXG\'UXJ'XHWR2WKHUUHDVRQDQG
/DVW$YDLODEOH+,951$! FRSLHVP/
LLL1RYLURORJLF'DWD±'LVFRQWLQXHG6WXG\'UXJ'XHWR$(RU'HDWKDQG/DVW$YDLODEOH
+,951$FRSLHVP/
LY1RYLURORJLF'DWD±'LVFRQWLQXHG6WXG\'UXJ'XHWR2WKHUUHDVRQDQG/DVW
$YDLODEOH+,951$FRSLHVP/
1RWH 2WKHUUHDVRQVLQFOXGHVXEMHFWVZKRGLVFRQWLQXHGVWXG\GUXJGXHWR
LQYHVWLJDWRU¶VGLVFUHWLRQVXEMHFWGHFLVLRQORVWWRIROORZXSQRQFRPSOLDQFH
ZLWKVWXG\GUXJSURWRFROYLRODWLRQSUHJQDQF\DQGVWXG\WHUPLQDWHGE\
VSRQVRU
';$$QDO\VLV
D 9DULDEOHXVHGIRUDQDO\VLV
L 9DULDEOH&255%0'ZKHQ5HJLRQ ³6SLQH7RWDO$GHTXDWH´IRUVSLQH5HJLRQ 
³)HPXU7RWDO´IRUKLSDQG5HJLRQ ³)HPXU1HFN´IRUIHPXUQHFNZLOOEHXVHGIRU
SHUFHQWDJHFKDQJHIURPEDVHOLQHLQ%0'DQDO\VLV
LL 9DULDEOH&25576&5ZKHQ5HJLRQ ³6SLQH7RWDO$GHTXDWH´IRUVSLQHDQG5HJLRQ 
³)HPXU7RWDO´IRUKLSZLOOEHXVHGIRUGHILQLQJWKH%0'FOLQLFDOVWDWXV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
E %0'FOLQLFDOVWDWXVFRPSDULVRQ5DQN$QDO\VLVRIFRYDULDQFH
EDVHLVWKHEDVHOLQH%0'FOLQLFDOVWDWXVDQGSRVWLVWKHSRVWEDVHOLQHFOLQLFDOVWDWXVERWK
FRGHGDVIRUQRUPDOIRU2VWHRSHQLDIRU2VWHRSRURVLVIRUPLVVLQJ7KHSYDOXH
IURPURZPHDQVFRUHWHVWIURPWKHODVWSURFIUHTSURFHGXUHLVWKHSYDOXHIRUUDQN
DQDO\VLVRIFRYDULDQFH
SURFUDQNGDWD DGG[DQSOXVWLHV PHDQRXW UDQNV

YDUEDVHSRVW

UDQNEDVHUDQNSRVWUDQN
UXQ
SURFUHJGDWD UDQNV

PRGHOSRVWUDQN EDVHUDQN

RXWSXWRXW UHVLGXDOU UHVLG
UXQ
SURFIUHTGDWD UHVLGXDO

WDEOHVWUWJUSUHVLGQRSULQWFPKURZPHDQVFRUHWHVW
UXQ
)RUJUDGDWLRQFDWHJRULHVRISHUFHQWDJHFKDQJHIURPEDVHOLQHLQWKHKLS%0'DQGVSLQHWKH
GLVWULEXWLRQGLIIHUHQFHLQWKHVHFDWHJRULHVEHWZHHQWKHWUHDWPHQWJURXSVZLOOEHFRPSDUHG
XVLQJ&0+WHVWURZPHDQVFRUHVGLIIHUVWDWLVWLF
6$6FRGHVIRUWUHDWPHQWFRPSDULVRQZLOOEH
SURFIUHTRUGHU GDWD

WDEOHVWUWJUS<FPKURZPHDQVFRUHWHVW
UXQ
&ODULILFDWLRQRIWKHIROORZLQJ/2&)DOJRULWKPV
x %DVHOLQHYDOXHVZLOOEHFDUULHGIRUZDUG
x )RU&'
,IDYDOXHLVPLVVLQJLQDQDQDO\VLVYLVLWZLQGRZUHSODFHWKHPLVVLQJYDOXHZLWKWKHODVW
RQWUHDWPHQWYDOXHREVHUYHGEHIRUHWKHDQDO\VLVYLVLWZLQGRZWKDWKDVWKHPLVVLQJYDOXH
x )RU';$%0'
,IDYDOXHLVPLVVLQJLQDQDQDO\VLVYLVLWZLQGRZWKHPLVVLQJYDOXHZLOOEHUHSODFHGZLWK
WKHODVWYDOXHREVHUYHGEHIRUHWKHDQDO\VLVYLVLWZLQGRZWKDWKDVWKHPLVVLQJYDOXH


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
)RUVDIHW\(&*VDWSRVWEDVHOLQHYLVLWVWKHPRVWFRQVHUYDWLYHZRUVWYDOXHZLWKLQWKH
ZLQGRZZLOOEHVHOHFWHGHJDEQRUPDOZLOOEHVHOHFWHGRYHUQRUPDOIRUVDIHW\(&*RU
FOLQLFDOVLJQLILFDQWDEQRUPDOZLOOEHVHOHFWHGRYHUQRWFOLQLFDOVLJQLILFDQWDEQRUPDOLIWKHUH
DUHPXOWLSOHDEQRUPDOILQGLQJV
7($(
(YHQWVZLWK0LVVLQJ2QVHW'D\DQGRU0RQWK
$QHYHQWLVWUHDWPHQWHPHUJHQWLIWKHIROORZLQJFULWHULDDUHPHW
 7KHPRQWKDQG\HDURU\HDURIRQVHWGDWHLVWKHVDPHDVRUDIWHUWKHPRQWKDQG\HDURU
\HDURIWKHILUVWGRVHRIVWXG\GUXJDQG
 7KHPRQWKDQG\HDURU\HDURIWKHRQVHWGDWHLVWKHVDPHDVRUEHIRUHWKHPRQWKDQG
\HDURU\HDURIWKHWKGD\DIWHUWKHGDWHRIWKHODVWGRVHRIVWXG\GUXJDQG
 (QGGDWHLVDVIROORZV
D 7KHFRPSOHWHHQGGDWHLVRQRUDIWHUWKHILUVWGRVHGDWHRU
E 7KHPRQWKDQG\HDURU\HDURIHQGGDWHLVWKHVDPHRUDIWHUWKHPRQWKDQG\HDU
RU\HDURIWKHILUVWGRVHRIVWXG\GUXJRU
F (QGGDWHLVFRPSOHWHO\PLVVLQJ
(YHQWVZLWK&RPSOHWHO\0LVVLQJ2QVHW'DWH
$Q$(ZLWKDFRPSOHWHO\PLVVLQJRQVHWGDWHLVGHILQHGDV7($(LIHQGGDWHPHHWVDQ\RIWKH
FULWHULDVSHFLILHGLQDERYH
*UDGHG/DERUDWRU\$EQRUPDOLWLHV6XPPDU\
7KHIROORZLQJODEHOVZLOOEHXVHGIRUWUHDWPHQWHPHUJHQWODERUDWRU\DEQRUPDOLWLHVDQG
WUHDWPHQWHPHUJHQW*UDGHRUODERUDWRU\DEQRUPDOLWLHVVXPPDU\WDEOHVDQGOLVWLQJV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
%DWWHU\
/DE7HVW/DEHO
8VHGLQOODEWR[/LVWLQJ
7R[LFLW\'LUHFWLRQ
/DE7HVW/DEHO
8VHGLQWODEWR[7DEOH
+HPDWRORJ\
+HPRJORELQ
'HFUHDVH
+HPRJORELQ'HFUHDVHG
1HXWURSKLOV
'HFUHDVH
1HXWURSKLOV'HFUHDVHG
3ODWHOHWV
'HFUHDVH
3ODWHOHWV'HFUHDVHG
:%&
'HFUHDVH
:%&'HFUHDVHG
&KHPLVWU\
$OEXPLQ
'HFUHDVH
$OEXPLQ'HFUHDVHG
$ONDOLQH3KRVSKDWDVH
,QFUHDVH
$ONDOLQH3KRVSKDWDVH,QFUHDVHG
$/7
,QFUHDVH
$/7,QFUHDVHG
$P\ODVH
,QFUHDVH
$P\ODVH,QFUHDVHG
$67
,QFUHDVH
$67,QFUHDVHG
%LFDUERQDWH
'HFUHDVH
%LFDUERQDWH'HFUHDVHG
&RUUHFWHG&DOFLXP
,QFUHDVH
&RUUHFWHG&DOFLXP+\SHUFDOFHPLD
&RUUHFWHG&DOFLXP
'HFUHDVH
&RUUHFWHG&DOFLXP+\SRFDOFHPLD
&UHDWLQH.LQDVH&.
,QFUHDVH
&UHDWLQH.LQDVH,QFUHDVHG
&UHDWLQLQH
,QFUHDVH
&UHDWLQLQH,QFUHDVHG
**7
,QFUHDVH
**7,QFUHDVHG
/LSDVH
,QFUHDVH
/LSDVH,QFUHDVHG
0DJQHVLXP
'HFUHDVH
0DJQHVLXP+\SRPDJQHVHPLD
3KRVSKDWH
'HFUHDVH
3KRVSKDWH+\SRSKRVSKDWHPLD
6HUXP*OXFRVH)DVWLQJ
,QFUHDVH
6HUXP*OXFRVH)DVWLQJ+\SHUJO\FHPLD
6HUXP*OXFRVH)DVWLQJ
'HFUHDVH
6HUXP*OXFRVH)DVWLQJ+\SRJO\FHPLD
6HUXP*OXFRVH1RQIDVWLQJ
,QFUHDVH
6HUXP*OXFRVH1RQIDVWLQJ+\SHUJO\FHPLD
6HUXP*OXFRVH1RQIDVWLQJ
'HFUHDVH
6HUXP*OXFRVH1RQIDVWLQJ+\SRJO\FHPLD
6HUXP3RWDVVLXP
,QFUHDVH
6HUXP3RWDVVLXP+\SHUNDOHPLD
6HUXP3RWDVVLXP
'HFUHDVH
6HUXP3RWDVVLXP+\SRNDOHPLD
6HUXP6RGLXP
,QFUHDVH
6HUXP6RGLXP+\SHUQDWUHPLD
6HUXP6RGLXP
'HFUHDVH
6HUXP6RGLXP+\SRQDWUHPLD
7RWDO%LOLUXELQ
,QFUHDVH
7RWDO%LOLUXELQ+\SHUELOLUXELQHPLD
7RWDO&KROHVWHURO)DVWLQJ
,QFUHDVH
7RWDO&KROHVWHURO)DVWLQJ+\SHUFKROHVWHUROHPLD
7ULJO\FHULGHV)DVWLQJ
,QFUHDVH
7ULJO\FHULGHV)DVWLQJ,QFUHDVHG
/'/)DVWLQJ
,QFUHDVH
/'/)DVWLQJ,QFUHDVHG
8UHD1LWURJHQ%81
,QFUHDVH
8UHD1LWURJHQ,QFUHDVHG
8ULF$FLG
,QFUHDVH
8ULF$FLG+\SHUXULFHPLD
8ULF$FLG
'HFUHDVH
8ULF$FLG+\SRXULFHPLD
8ULQDO\VLV
8ULQH%ORRG
,QFUHDVH
1$
8ULQH*OXFRVH
,QFUHDVH
8ULQH*OXFRVH*O\FRVXULD
8ULQH3URWHLQ
,QFUHDVH
8ULQH3URWHLQ3URWHLQXULD
8ULQH5%&
,QFUHDVH
8ULQH5%&+HPDWXULD4XDQWLWDWLYH



%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
5HQDOUHODWHGODERUDWRU\HYDOXDWLRQ
D 8QLWFRQYHUVLRQIRUUHQDOVDIHW\WHVWVGHULYHGIURPUHODWHGWHVWVZLWKFRQYHQWLRQDOXQLWV
x 8ULQH5%3XJ/WRFUHDWLQLQHPJG/UDWLRXJ/PJG/ îXJJ
x 8ULQH%HWDPLFURJOREXOLQPJ/WRFUHDWLQLQHPJG/UDWLRPJ/PJG/ 
XJJ
x 8ULQH$OEXPLQPJG/WRFUHDWLQLQHPJG/UDWLRPJG/PJG/ 
îPJJ
E &DOFXODWLRQRIUDWLRV
7RFDOFXODWHODERUDWRU\UDWLRVHJXULQH5%3WRFUHDWLQLQHUDWLRODEYDOXHRIHDFKWHVWLQ
WKHUDWLRQHHGVWREHIURPWKHVDPHDFFHVVLRQQXPEHULIDQ\WHVWYDOXHXVHGIRUWKHUDWLR
FDOFXODWLRQIURPWKHVDPHDFFHVVLRQQXPEHULVPLVVLQJWKHUDWLRLVQRWFDOFXODEOH
LHPLVVLQJ
0HGLFDOKLVWRU\RILQWHUHVWDWEDVHOLQH
0HGLFDOKLVWRU\RIGLDEHWHVK\SHUWHQVLRQFDUGLRYDVFXODUGLVHDVHDQGK\SHUOLSLGHPLDZLOOEH
VXPPDUL]HGDVEDVHOLQHGLVHDVHFKDUDFWHULVWLFV$VXEMHFWZKRKDGPHGLFDOKLVWRU\RIRQHRI
WKHVHGLVHDVHVLVDVXEMHFWZKRH[SHULHQFHGDWOHDVWRQHRIWKHIROORZLQJVHOHFWHGPHGLFDO
KLVWRU\VHOHFWHG$(SUHIHUUHGWHUPVRUVHOHFWHGFRQFRPLWDQWPHGLFDWLRQVZLWKVWDUWGDWHSULRU
WRRURQWKHILUVWGRVHGDWH
6PRNLQJVWDWXVDWEDVHOLQH
6PRNLQJVWDWXVDWEDVHOLQHLHQHYHUVPRNHUIRUPHUVPRNHUDQGFXUUHQWVPRNHUZLOOEH
VXPPDUL]HGDVSDUWRIWKHEDVHOLQHGLVHDVHFKDUDFWHULVWLFV
)RUPHUVPRNHUDWEDVHOLQHUHIHUVWRWKHVXEMHFWVZKRKDVVWRSSHGWKHXVHRIDQ\&LJDUHWWHVRU
&LJDUVEHIRUHVWXG\GD\LHWKHILUVWGRVHGDWH
&XUUHQW6PRNHUDWEDVHOLQHUHIHUVWRWKHVPRNHUVZKRKDVXVHRIDQ\&LJDUHWWHVRU&LJDUVDW
VWXG\GD\
1HYHUVPRNHUDWEDVHOLQHUHIHUVWRVXEMHFWVZKRKDYHQRUHFRUGZLWK7\SHRI6XEVWDQFH8VH 
³&LJDUHWWHV´RU³&LJDUV´RQRUSULRUWRVWXG\GD\


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
+RZWRFODVVLI\DVXEMHFWDVQHYHUVPRNHUIRUPHUVPRNHURUFXUUHQWVPRNHUDWEDVHOLQHLV
VSHFLILHGDVIROORZV
D )LUVWVHOHFWRQO\UHFRUGVZLWK7\SHRI6XEVWDQFH8VH ³&LJDUHWWHV´RU³&LJDUV´5HFRUGV
ZLWK7\SHRI6XEVWDQFH8VH ³2WKHU´LQFOXGLQJFKHZWREDFFRHFLJDUHWWHVHWFZLOOQRW
EHFRQVLGHUHGDVVPRNLQJ
E 6HFRQGIRUHDFKVHOHFWHGVXEVWDQFHXVHUHFRUGIODJZKHWKHULWLV³3ULRU´³3UHVHQW´RU
³3RVW´UHODWLYHWRWKHILUVWGRVHGDWHDFFRUGLQJWRWKHDOJRULWKPEHORZ
F )LQDOO\WKHVXEMHFWZLOOEHIODJJHGDV³1HYHU´VPRNHULIWKHVXEMHFWKDVQRUHFRUG
ZLWK7\SHRI6XEVWDQFH8VH ³&LJDUHWWHV´RU³&LJDUV´RUDOOVHOHFWHGUHFRUGVKDYHDIODJ
RI³3RVW´WKHVXEMHFWZLOOEHIODJJHGDVD³)RUPHU´VPRNHULIDQ\VHOHFWHGUHFRUGKDV
IODJRI³3ULRU´DQGQRUHFRUGRI³3UHVHQW´2WKHUZLVHWKHVXEMHFWZLOOEHIODJJHGDVD
³&XUUHQW´VPRNHULIDQ\VHOHFWHGUHFRUGVKDVDIODJRI³3UHVHQW´

6HOHFWHG6XEVWDQFH8VH5HFRUGV
3ULRU
1R
1R
<HV
<HV
<HV
1R
1R
<HV
3UHVHQW
1R
1R
1R
1R
<HV
<HV
<HV
<HV
3RVW
1R
<HV
1R
<HV
1R
1R
<HV
<HV
6PRNLQJ6WDWXV
1HYHU
1HYHU
)RUPHU
)RUPHU
&XUUHQW
&XUUHQW
&XUUHQW
&XUUHQW

$OJRULWKPWRIODJZKHWKHUDVHOHFWHGUHFRUGLV³3ULRU´³3UHVHQW´RU³3RVW´UHODWLYHWR
WKHILUVWGRVHGDWH
 7KHVWDUWDQGVWRSGDWHVRIWKHVHOHFWHGUHFRUGDUHQRWFRPSOHWHO\PLVVLQJLHDWOHDVW\HDU
LVNQRZQRUWKHVWDUWGDWHLVQRWPLVVLQJDQGUHFRUGLVRQJRLQJ7KHFRPSOHWHVWDUWRU
VWRSGDWHVZLOOEHXVHGWRFRPSDUHZLWKWKHILUVWGRVHGDWHZKHQHYHUSRVVLEOH2WKHUZLVH
WKHPRQWKDQG\HDURU\HDUDORQHLIPRQWKLVQRWUHFRUGHGRIWKHVWDUWRUVWRSGDWHVZLOO
EHXVHGWRFRPSDUHZLWKWKHILUVWGRVHGDWHZKHQWKHVWDUWRUVWRSGDWHRIWKHVHOHFWHG
UHFRUGLVLQFRPSOHWH
D 7KHUHFRUGLVIODJJHGDV³3ULRU´LIWKHVWRSGDWHLVEHIRUHWKHILUVWGRVHGDWH
E 7KHUHFRUGLVIODJJHGDV³3UHVHQW´LIWKHVWDUWGDWHLVRQRUEHIRUHUWKHILUVWGRVHGDWH
DQGWKHVWRSGDWHLVRQRUDIWHUWKHILUVWGRVHGDWHRUWKHVHOHFWHGUHFRUGLVPDUNHGDV
RQJRLQJDQGWKHVWDUWGDWHLVRQRUEHIRUHWKHILUVWGRVHGDWH
F 7KHUHFRUGLVIODJJHGDV³3RVW´LIWKHVWDUWGDWHLVDIWHUWKHILUVWGRVHGDWH


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
 7KHVWDUWGDWHRIWKHVHOHFWHGUHFRUGLVFRPSOHWHO\PLVVLQJ:HDVVXPHWKDWWKHVWDUWGDWH
LVEHIRUHWKHILUVWGRVHGDWHWKHVWRSGDWHRUWKHPRQWKDQGRU\HDURIWKHVWRSGDWHLI
VWRSGDWHLVLQFRPSOHWHRU³RQJRLQJ´ZLOOEHXVHGWRGHWHUPLQHZKHWKHUWKHVHOHFWHG
UHFRUGLV³3ULRU´RU³3UHVHQW´DVIROORZV
D 7KHUHFRUGLVIODJJHGDV³3ULRU´LIWKHVWRSGDWHLVEHIRUHWKHILUVWGRVHGDWHRUWKH
VWRSGDWHLVFRPSOHWHGPLVVLQJDQGWKHUHFRUGLVQRWPDUNHGDVRQJRLQJ
E 7KHUHFRUGLVIODJJHGDV³3UHVHQW´LIWKHVWRSGDWHLVRQRUDIWHUWKHILUVWGRVHGDWHRU
WKHVHOHFWHGUHFRUGLVPDUNHGDVRQJRLQJ
 7KHVWDUWGDWHRIWKHVHOHFWHGUHFRUGLVEHIRUHWKHILUVWGRVHGDWHEXWWKHVWRSGDWHLV
FRPSOHWHO\PLVVLQJDQGWKHUHFRUGLVQRWPDUNHGDVRQJRLQJ:HDVVXPHWKDWWKHHQGGDWH
LVEHIRUHWKHILUVWGRVHGDWHWKHUHFRUGLVIODJJHGDV³3ULRU´
 7KHVWDUWGDWHRIWKHVHOHFWHGUHFRUGLVRQRUDIWHUWKHILUVWGRVHGDWHEXWWKHVWRSGDWHLV
FRPSOHWHO\PLVVLQJDQGWKHUHFRUGLVQRWPDUNHGDVRQJRLQJ7KLVLVDGDWDLVVXHVKRXOG
EHTXHULHGILUVW+RZHYHUWKLVUHFRUGLVIODJJHGDV³3UHVHQW´LIWKHVWDUWGDWHLVRQWKH
ILUVWGRVHWKLVUHFRUGLVIODJJHGDV³3RVW´LIWKHVWDUWGDWHLVDIWHUWKHILUVWGRVH
&ODULILFDWLRQIRU³3KDUPDFRNLQHWLF%ORRG6DPSOLQJ7LPH5HFRUG´OLVWLQJ
x $QHZYDULDEOH³6DPSOHDJH´ZLOOEHDGGHGLQWKLVOLVWLQJGHILQHGDVWKHGXUDWLRQLQGD\
EHWZHHQVDPSOHFROOHFWLRQGDWHDQGDVVD\GDWHLHVDPSOHDJH DVVD\GDWH±VDPSOH
FROOHFWLRQGDWH
x 6$07,0(KRXUV VDPSOHFROOHFWLRQWLPH[[[[ODVWGRVHWLPHEHIRUHVDPSOH
FROOHFWLRQ[[[[
([FHSWIRU6$07,0(IRULQWHQVLYH3.VDPSOHVDWSUHGRVH
6$07,0(KRXUV SUHGRVHVDPSOHFROOHFWLRQWLPH[[[[GRVHWLPHDIWHUSUHGRVH
VDPSOHFROOHFWLRQ[[[[
1RWHSOHDVHURXQGWKH6$07,0(WRGHFLPDOSODFHDQGWKHQXVLQJ
 6$07,0( KRXUVFULWHULDWRIODJWURXJKVDPSOHV,QOSNOLVWLQJ
SOHDVHGLVSOD\GHFLPDOSODFHIRU6$07,0(
3.SDUDPHWHUVDWWKHLQGLYLGXDOVXEMHFWOHYHOVKRXOGEHGLVSOD\HGZLWKWKHIROORZLQJUHSRUWHG
QXPEHURIGHFLPDOSODFHV
x /DPEGD=UUDGMDQG&255;<GHFLPDOSODFHV
x W7ODVW7PD[%(*+285DQG(1'+285GHFLPDOSODFHV
x $8&WDX$8&ODVW$8&LQI$8&H[S9])&/)&/VV)&PD[&ODVWDQG&WDX
GHFLPDOSODFH
x 132,176GHFLPDOSODFH
3.FRQFHQWUDWLRQGDWDZLOOEHUHSRUWHGZLWKGHFLPDOSODFH


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
3.SDUDPHWHUVLQFOXGHGLQ3.VXPPDU\WDEOHVDUHGHILQHGLQ3.DEHUUDWLRQOLVWLQJH[FHSW
WKDW7$)&WDXZLOOQRWEHLQFOXGHGLQFRUUHVSRQGLQJ3.VXPPDU\WDEOHVLQFH7$)&WDX
VKRXOGEH%/4IRUDOOVXEMHFWVGXHWRWKHVKRUWKDOIOLIHRI7$)
x 3.SDUDPHWHUVVKRXOGEHGLVSOD\HGDVDOSKDEHWLFRUGHUDVOLVWHGLQ3.DEEUHYLDWLRQ
OLVWLQJ
x 6'70333363,'VKRXOGEHXVHGDVWKHODEHOIRUHDFK3.SDUDPHWHUZKLFKDOVROLVWHG
LQ3.DEEUHYLDWLRQOLVWLQJ
&RQFRPLWDQWQRQVWXG\GUXJ$59PHGLFDWLRQVLH$59PHGLFDWLRQVRWKHUWKDQVWXG\GUXJ
WKDWDUHWDNHQZKLOHUHFHLYLQJVWXG\GUXJZLOOEHIODJJHGLQ³1RQVWXG\'UXJ$QWLYLUDO
0HGLFDWLRQ´OLVWLQJ7KHORJLFWRGHILQHFRQFRPLWDQWQRQVWXG\GUXJ$59LVVLPLODUWR
FRQFRPLWDQWQRQ$590HGLFDWLRQVVHHGHWDLOVLQ6HFWLRQ
/LSLGPRGLI\LQJPHGLFDWLRQDQDO\VHV
x /LSLGPRGLI\LQJPHGLFDWLRQLVGHILQHGWREHWKHFRQFRPLWDQWPHGLFDWLRQZLWK
&0&/$6 ³/,3,'02',)<,1*$*(176´DQG&0'(&2'FRQWDLQVZRUGLQJRI
³67$7,1´LQWKH$'&0GDWDVHW
x 6XEMHFWVZKRWRRNOLSLGPRGLI\LQJPHGLFDWLRQVDWVWXG\HQWU\UHIHUWRWKHVXEMHFWVZKR
KDVDQ\XVHRIWKHOLSLGPRGLI\LQJDJHQWVDWVWXG\GD\LHWKHILUVWGRVHGDWH
D 0RUHVSHFLILFDOO\VXEMHFWVZLWK³/LSLG0RGLI\LQJ$JHQW8VHDW6WXG\(QWU\´LQFOXGH
WKRVHVXEMHFWVLQVDIHW\DQDO\VLVVHWZLWKPHHWLQJERWKWKHIROORZLQJFULWHULD
DQ\VHOHFWHG&0UHFRUGZLWKWKHVWDUWGDWHWKHILUVWGRVHGDWHDQGWKHHQGGDWH
RIWKHVHOHFWHG&0UHFRUGWKHILUVWGRVHGDWHRUWKHHQGGDWHRIWKHVHOHFWHG&0
UHFRUGLVRQJRLQJ
E )RUOLSLGPRGLI\LQJPHGLFDWLRQVZLWKWKHVWDUWGDWHFRPSOHWHO\XQNQRZQZHDVVXPH
WKHVWDUWGDWHLVRQRUEHIRUHWKHILUVWGRVHGDWHOLSLGPRGLI\LQJPHGLFDWLRQZDV
FRQVLGHUHGDVEHLQJWDNHQDWVWXG\HQWU\LIWKHHQGGDWHLVQRWSULRUWRWKHILUVWGRVH
GDWHLHWKHHQGGDWHLVRQRUDIWHUWKHILUVWGRVHGDWHFRPSOHWHO\XQNQRZQRU
RQJRLQJ
F /LSLGPRGLI\LQJPHGLFDWLRQVZLWKWKHVWDUWGDWHSULRUWRWKHILUVWGRVHGDWHDQGWKHHQG
GDWHXQNQRZQFRPSOHWHO\PLVVLQJZHUHFRQVLGHUHGDVEHLQJWDNHQDWVWXG\HQWU\
WKHXQNQRZQHQGGDWHLVDVVXPHGRQRUDIWHUWKHILUVWGRVHGDWH
x 6XEMHFWVZKRLQLWLDWHGOLSLGPRGLI\LQJPHGLFDWLRQVGXULQJWKHVWXG\UHIHUWRWKHVXEMHFWV
LQWKHVDIHW\DQDO\VLVVHWZKRGLGQ¶WWDNHOLSLGPRGLI\LQJPHGLFDWLRQVDWVWXG\HQWU\DQG
PHWWKHIROORZLQJFULWHULDIRUVXEMHFWVZKRSHUPDQHQWO\GLVFRQWLQXHGVWXG\GUXJZLWK
DQ\VHOHFWHG&0UHFRUGVWDUWHGDIWHUWKHILUVWGRVHGDWHDQGRQDQGSULRUWRWKHODVWGRVH
GDWHIRUVXEMHFWVZKRDUHVWLOORQVWXG\GUXJZLWKDQ\VHOHFWHG&0UHFRUGVILUVWVWDUWHG
DIWHUWKHILUVWGRVHGDWH


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
)RUILJXUHVLIDWDYLVLWZKHUHQVDPSOHVL]HIRUDQ\WUHDWPHQWJURXS GDWDIRUWKDW
WUHDWPHQWJURXSZLOOQRWEHGLVSOD\HGDWWKHYLVLWLQILJXUHH[FHSWWKH.DSODQ0HLHUILJXUH
EXWDOOGDWDZLOOEHLQFOXGHGLQWKHFRUUHVSRQGLQJWDEOHVXPPDU\
9LWDOVLJQVDQGZHLJKWKHLJKW%0,ZLOOEHLQWKHVDPHOLVWLQJ
+,9+%9DQG+,9+&9&RLQIHFWLRQ
x 7KHIROORZLQJWDEOHSUHVHQWVWKH+%9DQG+&9WHVWVZLWKDOOSRVVLEOHYDOXHV9DOXHVWKDW
KDYHDQDVWHULVNDIWHUWKHPGHQRWHD³SRVLWLYH´RU³TXDQWLILDEOH´IRU+%9'1$DQG
+&951$UHVXOWZKLOHDOORWKHUVGHQRWHD³QHJDWLYH´UHVXOW
/DEHO
/%7(67&'
/%7(67
3RVVLEOH9DOXHV
+%V$J
&17
+HS%6XUIDFH$J
³3RVLWLYH´³3RVLWLYH&RQILUPHG´³1HJDWLYH´
+%V$J
$77
+HS%6XUI$J4XDO36
³5HSHDWUHDFWLYHFRQILUPHG´³5HSHDW5HDFWLYH
8QFRQILUPHG´³1RQ5HDFWLYH´
+%V$E
&17
DQWL+HS%6XUIDFH$J4XDO
³3RVLWLYH´³1HJDWLYH´
+%F$E
&17
+HSDWLWLV%&RUH7RWDO
³3RVLWLYH´³1HJDWLYH´
+%9'1$
*(7
+%9'1$&$3&70
('7$&/
³1R+%9'1$GHWHFWHG´³,8P/+%9'1$
GHWHFWHG´³!´180(5,&$/9$/8(
+&9$E
&17
+HSDWLWLV&9LUXV$QWLERG\
³3RVLWLYH´³,QGHWHUPLQDWH´³1HJDWLYH´
+&951$
*(7
+&951$&$3&70
('7$&/
³1R+&951$GHWHFWHG´³,8P/+&951$
GHWHFWHG´180(5,&$/9$/8(

x )RUEDVHOLQHFRLQIHFWLRQZKHQFRQVLGHULQJWKHGLIIHUHQWODERUDWRU\WHVWVWDNHWKHODWHVW
QRQPLVVLQJUHFRUGRQRUSULRUWRWKHILUVWGRVHGDWHIRUHDFKWHVWHJ+%V$J+%V$E
+%F$EDQG+%9'1$
 7KHEDVHOLQHFRLQIHFWLRQVWDWXVZLOOEHRQHRIWKHWKUHHYDOXHV<HV1R1XOO
 7KHIROORZLQJWDEOHVSURYLGHFRPELQDWLRQVRI+%9DQG+&9WHVWVDQGWKH
FRUUHVSRQGLQJEDVHOLQHFRLQIHFWLRQVWDWXV


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
+%V$J
+%V$E
+%F$E
+%9'1$
&RLQIHFWLRQ6WDWXV
3RVLWLYH



<
1HJDWLYH
3RVLWLYH


1
1HJDWLYH
3RVLWLYH
4XDQWLILDEOH
<
1RW4XDQWLILDEOH
1
0LVVLQJ
1XOO
1HJDWLYH

1
0LVVLQJ
4XDQWLILDEOH
1XOO
1RW4XDQWLILDEOH
1
0LVVLQJ
1XOO
0LVVLQJ
3RVLWLYH
4XDQWLILDEOH
1XOO
1RW4XDQWLILDEOH
1
0LVVLQJ
1XOO
1HJDWLYH

1
0LVVLQJ
4XDQWLILDEOH
1XOO
1RW4XDQWLILDEOH
1
0LVVLQJ
1XOO
0LVVLQJ
3RVLWLYH


1XOO
1HJDWLYH
3RVLWLYH
4XDQWLILDEOH
<
1RW4XDQWLILDEOH
1XOO
0LVVLQJ
1XOO
1HJDWLYH

1XOO
0LVVLQJ

1XOO
0LVVLQJ


1XOO

+&9$E
+&951$
&RLQIHFWLRQ6WDWXV
3RVLWLYH
4XDQWLILDEOH
<
1RW4XDQWLILDEOH
1
0LVVLQJ
1XOO
1HJDWLYH

1
0LVVLQJ
4XDQWLILDEOH
1XOO
1RW4XDQWLILDEOH
1
0LVVLQJ
1XOO
³´PHDQVDQ\YDOXHFDQEHSUHVHQWDVLWGRHVQRWDIIHFWWKHFODVVLILFDWLRQ


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
x )RULQFLGHQWFRLQIHFWLRQDOOODERUDWRU\WHVWVPXVWVKDUHWKHVDPHDFFHVVLRQQXPEHUDQGLI
DQ\VHWRIYDOXHVPHHWVWKHFULWHULDWKHQWKHVXEMHFWLVFRQVLGHUHGWRKDYHLQFLGHQW
FRLQIHFWLRQ
 7KHLQFLGHQWFRLQIHFWLRQVWDWXVZLOOEHRQHRIWZRYDOXHV<HV1XOO
 7KHIROORZLQJWDEOHVSURYLGHFRPELQDWLRQVRI+%9DQG+&9WHVWVWKDWDUH
FRQVLGHUHG³<´IRULQFLGHQWFRLQIHFWLRQVWDWXVDOORWKHUVDUHFRQVLGHUHG1XOO
+%V$J
+%V$E
+%F$E
+%9'1$
&RLQIHFWLRQ6WDWXV
3RVLWLYH



<
1HJDWLYH
1HJDWLYH
3RVLWLYH
4XDQWLILDEOH
<
0LVVLQJ
1HJDWLYH
3RVLWLYH
4XDQWLILDEOH
<

+&9$E
+&951$
&RLQIHFWLRQ6WDWXV
3RVLWLYH

<

4XDQWLILDEOH
<

6XEMHFWVZLWKSRVLWLYH+&9$ESRVWEDVHOLQHPXVWDOVRKDYHQHJDWLYHRUPLVVLQJ+&9$EDWEDVHOLQHLQRUGHUWREH
FRQVLGHUHGDVKDYLQJLQFLGHQW+,9+&9FRLQIHFWLRQ
³´PHDQVDQ\YDOXHFDQEHSUHVHQWDVLWGRHVQRWDIIHFWWKHFODVVLILFDWLRQ
 )RUDGYHUVHHYHQWVWKHVWDUWGDWHPXVWEHDIWHUWKHILUVWGRVHGDWHDQGRQRUSULRUWR
WKHODVWGRVHGDWH
 )RULQFRPSOHWH$(VWDUWGDWHVSOHDVHIROORZWKHORJLFVSHFLILHGLQ6HFWLRQEXW
PRGLI\WKHVHFRQGFULWHULRQWRUHDG³7KHPRQWKDQG\HDURU\HDURIWKH$(RQVHWLV
WKHVDPHDVRUEHIRUHWKHPRQWKDQG\HDURU\HDURIWKHGDWHRIWKHODVWGRVHRIVWXG\
GUXJ´
+%9'1$WHVWFRGHV,IWKHUHVXOWRIWKHODEWHVWFRGH*(7+%9'1$&$3&70
('7$&/LVOLVWHGDV³!´WKHQDUHIOH[LYHWHVWFRGH*(7+%9'1$
&$3&70'LO('7$&/VKRXOGEHSHUIRUPHGDQGZLOOVKDUHWKHVDPHDFFHVVLRQ
QXPEHUDVWKHRULJLQDO*(7WHVW,QWKLVLQVWDQFHXVHWKHUHVXOWIURP*(7LQVWHDG
RI*(7ZKHQGHWHUPLQLQJ+%9'1$


%)7$)
*686
6WDWLVWLFDO$QDO\VLV3ODQí:HHN,QWHULP$QDO\VLV
9HUVLRQ
&21),'(17,$/
3DJH

0D\
)RUH[FOXVLRQFULWHULDIRUVXEMHFWVLQ3HUSURWRFROVHWZKRZHUHH[FOXGHGIURPIXOODQDO\VLV
VHW
x 6XEMHFWVZKRGRQRWPHHWWKHLQFOXVLRQFULWHULRQRIEHLQJRQDVWDEOHUHJLPHQIRU
PRQWKVSUHFHGLQJWKHVFUHHQLQJYLVLWZLWKGRFXPHQWHGSODVPD+,951$
FRSLHVP/IRUPRQWKVSUHFHGLQJWKH6FUHHQLQJYLVLWRUXQGHWHFWDEOH+,9
51$OHYHODFFRUGLQJWRWKHORFDODVVD\EHLQJXVHGLIWKHOLPLWRIGHWHFWLRQLV
FRSLHVP/
7KHDERYHVXEMHFWVLQFOXGHVXEMHFWVGRQRWPHHWLQFOXVLRQFULWHULDLQERWKRULJLQDO
SURWRFRODQGSURWRFRODPHQGPHQW
,QFOXVLRQFULWHULDLQRULJLQDOSURWRFRO&XUUHQWO\RQWKHILUVWRUVHFRQG$59UHJLPHQ
ZLWKGRFXPHQWHGSODVPD+,951$FRSLHVP/RQDVWDEOHUHJLPHQIRUPRQWKV
SUHFHGLQJWKH6FUHHQLQJYLVLW
,QFOXVLRQFULWHULDLQSURWRFRODPHQGPHQW&XUUHQWO\RQDVWDEOHUHJLPHQIRU
PRQWKVSUHFHGLQJWKHVFUHHQLQJYLVLWZLWKGRFXPHQWHGSODVPD+,951$
FRSLHVP/IRUPRQWKVSUHFHGLQJWKH6FUHHQLQJYLVLWRUXQGHWHFWDEOH+,9
51$OHYHODFFRUGLQJWRWKHORFDODVVD\EHLQJXVHGLIWKHOLPLWRIGHWHFWLRQLV
FRSLHVP/
5HDVRQVIRU6XEMHFWVZKRH[FOXGHGIURP:HHN33$QDO\VLV6HWZLOOEHVXPPDUL]HGDV
IROORZVLQWDEOH
D 'LG1RW+DYH2Q7UHDWPHQW+,951$LQ:HHN:LQGRZ8QOHVVGXHWR
'LVFRQWLQXDWLRQRI6WXG\'UXJIRU/DFNRI(IILFDF\
E 'LG1RW0HHWWKH&ULWHULDRI7DNLQJ'7*$%&7&RU$%&'7*7&)'&IRU
! 0RQWKV%HIRUH6FUHHQLQJ9LVLW
F 'LG1RW0HHWWKH&ULWHULDRI+,951$FRSLHVP/IRU! PRQWKVEHIRUH
6FUHHQLQJYLVLW
G 'LG1RW0HHWWKH&ULWHULDRI+DYLQJQR5HVLVWDQFHWRDQ\FRPSRQHQWRIVWXG\UHJLPHQ
H 'LG1RW0HHWWKH&ULWHULDRI+,951$FRSLHVP/DW6FUHHQLQJ9LVLW
I 7RRN3URWRFRO3URKLELWHG0HGLFDWLRQV
J $GKHUHQFH5DWHIRU$FWLYH6WXG\'UXJXSWR:HHN9LVLW%HORZWKHWK
7KHQXPEHURIGHFLPDOSODFHVLQUHSRUWLQJSYDOXHVVKRXOGEHDVIROORZV
D YDOXHVOHVVWKDQÆ
E YDOXHVWROHVVWKDQÆURXQGWRGHFLPDOSODFHV
F YDOXHVDQGJUHDWHUÆURXQGWRGHFLPDOSODFHV

Prot_007.pdf: 
Study Title: 
Sponsor: 
IND Number: 
EudraCT Number: 
Clinical Trials.gov 
Identifier: 
Indication: 
Protocol ID: 
Gilead Study Clinical 
Program Manager: 
Gilead Medical 
Monitor: 
(rJ GILEAU 
CLINICAL STUDY PROTOCOL 
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety 
and Efficacy of Switching from a Regimen of Dolutegravir and 
ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC 
to a FDC of GS-9883/F IT AF in HIV -1 Infected Subjects who are 
Virologically Suppressed 
Gilead Sciences, Inc. 
333 Lakeside Drive 
Foster City, CA 94404 
125589 
2015-004025-14 
NCT02603120 
HIV -1 Infection 
GS-US-3 80-1844 
Name: 
PPD 
Telephone: PPD 
Fax: 
PPD 
Name: 
Telephone: 
Fax: 
Mobile: 
...._ ____ _, 
Javier Szwarcberg, MD 
PPD 
PPD 
PPD 
Protocol Version/Date: 
Original: 
21 October 2015 
19 Febmmy 2016 
Amendment 1 
CONFIDENTIALITY STATEMENT 
The inf01mation contained in this document, pmi iculm·ly unpublished data, is the propeliy or 
under conu·ol of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review by you, your staff, and an applicable Institutional 
Review Board or Independent Ethics Committee. The infonnation is only to be used by you in 
connection with authorized clinical studies of the investigational dmg described in the protocol. 
You will not disclose any of the inf01mation to others without written authorization from 
Gilead Sciences, Inc., except to the extent necessruy to obtain infonned consent from those 
persons to whom the dmg may be administered. 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 2
19 February 2016
TABLE OF CONTENTS
TABLE OF CONTENTS ..............................................................................................................................................2
LIST OF IN-TEXT TABLES........................................................................................................................................5
LIST OF IN-TEXT FIGURES ......................................................................................................................................5
PROTOCOL SYNOPSIS ..............................................................................................................................................6
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS....................................................................12
1.
INTRODUCTION ..............................................................................................................................................15
1.1.
Background ............................................................................................................................................15
1.2.
GS-9883 .................................................................................................................................................16
1.2.1.
General Information .............................................................................................................16
1.2.2.
Preclinical Pharmacology and Toxicology...........................................................................16
1.2.3.
Clinical Trials of GS-9883 ...................................................................................................18
1.3.
Information about Emtricitabine (Emtriva®, FTC) ...............................................................................27
1.4.
Information about Tenofovir alafenamide (TAF, GS-7340)..................................................................27
1.4.1.
Clinical Trials of Single Agent Tenofovir Alafenamide (TAF, GS-7340) 
or Fixed Dose Combination emtricitabine/tenofovir alafenamide 
(FTC/TAF)...........................................................................................................................27
1.4.2.
Clinical Trials of FTC/TAF as part of 
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) ...........................29
1.5.
Information about GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) ...........................31
1.5.1.
GS-US-141-1233: Relative Bioavailability of GS-9883, FTC, and TAF 
between GS-9883/F/TAF and GS-9883 + F/TAF................................................................31
1.6.
Information about abacavir/dolutegravir/lamivudine (ABC/DTG/3TC Triumeq®)...............................32
1.7.
Rationale for this Study..........................................................................................................................32
1.8.
Risk/Benefit Assessment for the Study..................................................................................................33
1.9.
Rationale for Dose Selection..................................................................................................................33
1.10.
Compliance ............................................................................................................................................35
2.
OBJECTIVES.....................................................................................................................................................36
3.
STUDY DESIGN................................................................................................................................................37
3.1.
Endpoints ...............................................................................................................................................37
3.2.
Study Design..........................................................................................................................................37
3.3.
Study Treatments ...................................................................................................................................37
3.4.
Duration of Treatment............................................................................................................................37
3.5.
Biomarker Testing..................................................................................................................................38
3.5.1.
Biomarker Samples for Optional Pharmacogenomic Research............................................38
3.5.2.
Additional Sample Storage...................................................................................................39
4.
SUBJECT POPULATION..................................................................................................................................40
4.1.
Number of Subjects and Subject Selection ............................................................................................40
4.2.
Inclusion Criteria....................................................................................................................................40
4.3.
Exclusion Criteria...................................................................................................................................41
5.
INVESTIGATIONAL MEDICINAL PRODUCTS ...........................................................................................43
5.1.
Randomization, Blinding and Treatment Codes ....................................................................................43
5.1.1.
Procedures for Breaking Treatment Codes...........................................................................43
5.2.
Description and Handling.......................................................................................................................44
5.2.1.
Formulation..........................................................................................................................44
5.2.2.
Packaging and Labeling .......................................................................................................44


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 3
19 February 2016
5.2.3.
Storage and Handling...........................................................................................................45
5.3.
Dosage and Administration of GS-9883/Emtricitabine/Tenofovir alafenamide and 
Abacavir/Dolutegravir/Lamivudine .......................................................................................................45
5.4.
Prior and Concomitant Medications.......................................................................................................46
5.5.
Accountability for Investigational Medicinal Product (IMP).................................................................47
5.5.1.
Investigational Medicinal Product Return or Disposal.........................................................47
6.
STUDY PROCEDURES ....................................................................................................................................48
6.1.
Subject Enrollment and Treatment Assignment.....................................................................................48
6.2.
Pretreatment Assessments......................................................................................................................48
6.2.1.
Screening Visit .....................................................................................................................48
6.2.2.
Day 1 Assessments...............................................................................................................50
6.3.
Randomization .......................................................................................................................................51
6.4.
Treatment Assessments (Week 4 - 48)...................................................................................................52
6.5.
Treatment Assessments (Post Week 48 until the Unblinding Visit) ......................................................54
6.5.1.
Post Week 48 Assessments ..................................................................................................54
6.5.2.
Unblinding Visit...................................................................................................................56
6.6.
Post-treatment Assessments ...................................................................................................................57
6.6.1.
Early Study Drugs Discontinuation Assessments.................................................................57
6.6.2.
30 Day Follow Up................................................................................................................59
6.7.
Criteria for Discontinuation of Study Treatment....................................................................................60
6.8.
Bone Mineral Density Evaluations.........................................................................................................60
6.9.
Other Evaluations...................................................................................................................................61
6.9.1.
Markers of Renal Tubular Function .....................................................................................61
6.9.2.
Markers of Inflammation and Immune Activation...............................................................61
6.9.3.
Markers of Platelet Function ................................................................................................61
6.9.4.
Blood and Urine Storage......................................................................................................61
6.10.
Assessments for Premature Discontinuation from Study.......................................................................61
6.11.
End of Study...........................................................................................................................................61
6.12.
Post Study Care......................................................................................................................................62
6.13.
Virologic Failure....................................................................................................................................62
6.13.1.
Management of Virologic Rebound .....................................................................................62
6.13.2.
Subjects with HIV-1 RNA ≥50 copies/mL at Study Drug 
Discontinuation, or Week 48................................................................................................63
7.
ADVERSE EVENTS AND TOXICITY MANAGEMENT...............................................................................64
7.1.
Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events.................................64
7.1.1.
Adverse Events.....................................................................................................................64
7.1.2.
Serious Adverse Events........................................................................................................64
7.1.3.
Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events .........................................................................65
7.2.
Assessment of Adverse Events and Serious Adverse Events.................................................................65
7.2.1.
Assessment of Causality for Study Drugs and Procedures...................................................65
7.2.2.
Assessment of Severity ........................................................................................................66
7.3.
Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead.......................................................................................................................66
7.3.1.
Adverse Events.....................................................................................................................66
7.3.2.
Serious Adverse Events........................................................................................................67
7.4.
Gilead Reporting Requirements.............................................................................................................68
7.5.
Toxicity Management ............................................................................................................................68
7.5.1.
Grades 1 and 2 Laboratory Abnormality or Clinical Event..................................................68
7.5.2.
Grade 3 Laboratory Abnormality or Clinical Event.............................................................69
7.5.3.
Grade 4 Laboratory Abnormality or Clinical Event.............................................................69
7.5.4.
Management of Possible Abacavir Hypersensitivity Reaction.............................................69


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 4
19 February 2016
7.5.5.
Management of Potential Hepatobiliary Toxicity ................................................................70
7.5.6.
On-Treatment Hepatitis C Management...............................................................................70
7.6.
Special Situations Reports......................................................................................................................71
7.6.1.
Definitions of Special Situations..........................................................................................71
7.6.2.
Instructions for Reporting Special Situations.......................................................................71
8.
STATISTICAL CONSIDERATIONS................................................................................................................73
8.1.
Analysis Objectives and Endpoints........................................................................................................73
8.1.1.
Analysis Objectives..............................................................................................................73
8.1.2.
Primary Endpoint .................................................................................................................73
8.1.3.
Secondary Endpoint .............................................................................................................73
8.2.
Analysis Conventions.............................................................................................................................73
8.2.1.
Analysis Sets ........................................................................................................................73
8.3.
Data Handling Conventions ...................................................................................................................75
8.4.
Demographic Data and Baseline Characteristics ...................................................................................75
8.5.
Efficacy Analysis ...................................................................................................................................76
8.5.1.
Primary Analysis..................................................................................................................76
8.5.2.
Secondary Analyses .............................................................................................................77
8.6.
Safety Analysis.......................................................................................................................................78
8.6.1.
Extent of Exposure...............................................................................................................78
8.6.2.
Adverse Events.....................................................................................................................78
8.6.3.
Laboratory Evaluations ........................................................................................................79
8.6.4.
Bone Safety Evaluations ......................................................................................................79
8.6.5.
Other Safety Evaluations......................................................................................................79
8.7.
Pharmacokinetic Analysis......................................................................................................................79
8.8.
Biomarker Analysis................................................................................................................................80
8.9.
Patient Reported Outcomes (PRO).........................................................................................................80
8.10.
Sample Size............................................................................................................................................80
8.11.
Data Monitoring Committee ..................................................................................................................80
8.12.
Analysis Schedule ..................................................................................................................................80
9.
RESPONSIBILITIES..........................................................................................................................................81
9.1.
Investigator Responsibilities ..................................................................................................................81
9.1.1.
Good Clinical Practice..........................................................................................................81
9.1.2.
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval...........................................................................................................81
9.1.3.
Informed Consent.................................................................................................................81
9.1.4.
Confidentiality......................................................................................................................82
9.1.5.
Study Files and Retention of Records ..................................................................................82
9.1.6.
Case Report Forms...............................................................................................................83
9.1.7.
Investigational Medicinal Product Accountability and Return.............................................84
9.1.8.
Inspections............................................................................................................................84
9.1.9.
Protocol Compliance............................................................................................................84
9.2.
Sponsor Responsibilities ........................................................................................................................85
9.2.1.
Protocol Modifications.........................................................................................................85
9.2.2.
Study Report and Publications .............................................................................................85
9.3.
Joint Investigator/Sponsor Responsibilities ...........................................................................................85
9.3.1.
Payment Reporting...............................................................................................................85
9.3.2.
Access to Information for Monitoring..................................................................................86
9.3.3.
Access to Information for Auditing or Inspections ..............................................................86
9.3.4.
Study Discontinuation..........................................................................................................86
10.
REFERENCES ...................................................................................................................................................87
11.
APPENDICES ....................................................................................................................................................88


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 5
19 February 2016
Appendix 1.
Investigator Signature Page....................................................................................................89
Appendix 2.
Study Procedures Table (Blinded Phase) ...............................................................................90
Appendix 3.
Management of Clinical and Laboratory Adverse Events......................................................93
Appendix 4.
GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities...............94
Appendix 5.
Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines) ...........................116
Appendix 6.
Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements.................................................................................................117
LIST OF IN-TEXT TABLES
Table 1-1.
GS-US-141-1218: GS-9883 Mean (%CV) PK Parameters Following Single Doses 
of GS-9883 in Healthy Subjects (GS-9883 PK Analysis Set; Part A: Single Dosing) ...........20
Table 1-2.
GS-US-141-1218: GS-9883 Plasma Pharmacokinetic Parameters by GS-9883 Dose 
Following Multiple-Dose Administration of GS-9883 (Analysis Set: GS-9883 PK 
Part B: Multiple-Dose) ...........................................................................................................21
Table 1-3.
GS-US-141-1218: Statistical Comparison of GS-9883 Pharmacokinetic Parameters 
Following Single-Dose Administration of GS-9883 in the Fasted and Fed States 
(GS-9883 PK Analysis Set)....................................................................................................22
Table 1-4.
Trough GS-9883 Plasma Concentrations at Steady State Following GS-9883 
Administration Under Fasting Conditions and Corresponding Protein-Adjusted 
IQ95 Values (GS-9883 PK Analysis Set)...............................................................................23
Table 1-5.
GS-US-141-1219: Trough GS-9883 Plasma Concentrations at Steady State 
Following GS-9883 Administration Under Fasting Conditions and Corresponding 
Protein-Adjusted IQ95 Values.................................................................................................34
Table 5-1.
Prior and Concomitant Medications.......................................................................................46
LIST OF IN-TEXT FIGURES
Figure 1-1.
GS-US-141-1219: Mean and 95% CIs of Change from Baseline in HIV-1 RNA 
(log10 copies/mL) (PP Analysis Set).......................................................................................23
Figure 3-1.
Study Schema.........................................................................................................................38
Figure 6-1.
Virologic Rebound Schema....................................................................................................63


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 6
19 February 2016
PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Study Title: 
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety 
and Efficacy of Switching from a Regimen of Dolutegravir and 
ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC
to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects who are 
Virologically Suppressed
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:
125589
2015-004025-14
NCT02603120
Study Centers Planned:
Approximately 120 centers in North America, Europe and 
Asia Pacific
Objectives:
The primary objective of this study is:

To evaluate the efficacy of switching from a regimen of DTG 
and ABC/3TC or a fixed dose combination (FDC) of 
ABC/DTG/3TC to a FDC of GS-9883/F/TAF versus continuing 
DTG and ABC/3TC as the FDC ABC/DTG/3TC in 
virologically suppressed HIV-1 infected subjects as determined 
by the proportion of subjects with HIV-1 RNA ≥50 copies/mL 
at Week 48
The secondary objectives of this study are:

To evaluate the safety and tolerability of the two treatment 
groups through Week 48

To evaluate the bone safety of the two treatment groups as 
determined by the percentage change from baseline in hip and 
spine bone mineral density (BMD) through Week 48
Study Design:
Randomized, double-blind, multicenter, active-controlled study to 
evaluate the safety and efficacy of switching to a FDC of 
GS-9883/F/TAF tablet versus continuing DTG and ABC/3TC as the 
FDC ABC/DTG/3TC in HIV-1 infected subjects who are 
virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable 
regimen of DTG + ABC/3TC or ABC/DTG/3TC FDC for 
3 months prior to screening.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 7
19 February 2016
Subjects who provide written consent and meet all eligibility criteria 
will be randomized in a 1:1 ratio to one of the following 2 treatment 
groups:
Treatment Group 1: FDC of GS-9883 50 mg/ emtricitabine 
200 mg/ tenofovir alafenamide 25 mg (GS-9883/F/TAF) + Placebo 
to match FDC of abacavir 600 mg/ dolutegravir 50 mg/lamivudine 
300 mg (ABC/DTG/3TC) administered orally, once daily, without 
regard to food (n=260)
Treatment Group 2: FDC of abacavir 600 mg/dolutegravir 
50 mg/ lamivudine 300 mg (ABC/DTG/3TC) + Placebo to match 
FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir 
alafenamide 25 mg (GS-9883/F/TAF) administered orally, 
once daily, without regard to food (n=260)
Number of Subjects 
Planned:
Approximately 520 subjects in total.
260 subjects in each Treatment Group 1 and Treatment Group 2
Target Population:
HIV-1 infected adult subjects who are virologically suppressed 
(HIV-1 RNA < 50 copies/mL) on a stable regimen of
DTG + ABC/3TC or ABC/DTG/3TC FDC for 3 months prior to 
screening.
Duration of 
Treatment:
Subjects will be treated for at least 48 weeks. Subjects’ treatments 
will be unblinded after the last subject completes the Week 48 visit 
and Gilead completes the Week 48 analysis. Subjects will continue 
to take their blinded study drug and attend visits every 12 weeks 
until treatment assignments have been unblinded. At the Unblinding 
Visit, subjects in a country where GS-9883/F/TAF FDC is not 
available will be given the option to receive GS-9883/F/TAF FDC 
in an open label extension phase for 48 weeks, or until the product 
becomes accessible to subjects through an access program, or until 
Gilead Sciences elects to discontinue the study in that country, 
whichever occurs first.
Subjects who complete the study through the Unblinding Visit and 
do not continue on the open-label GS-9883/F/TAF FDC extension 
phase, will be required to return to the clinic 30 days after 
unblinding visit for a 30-Day Follow-Up Visit.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 8
19 February 2016
Diagnosis and Main 
Eligibility Criteria:
Medically stable HIV-1 infected subjects who meet the following 
criteria:

Currently receiving an antiretroviral regimen of 
DTG + ABC/3TC, or ABC/DTG/3TC FDC for 3 months prior 
to screening

Currently on a stable regimen for ≥ 3 months preceding the 
Screening visit with documented plasma HIV 1 RNA 
< 50 copies/mL for ≥ 3 months preceding the Screening visit (or 
undetectable HIV-1 RNA level according to the local assay 
being used if the limit of detection is ≥50 copies/mL).
Prior changes in antiretroviral regimen are only allowed due 
to tolerability issues or for regimen simplification. 
Unconfirmed virologic elevations of ≥50 copies/mL 
(transient detectable viremia, or “blip”) prior to screening are 
acceptable. If the lower limit of detection of the local HIV-1 
RNA assay is <50 copies/mL (eg, <20 copies/mL), the 
plasma HIV-1 RNA level cannot exceed 50 copies/mL on 
two consecutive HIV-1 RNA tests.

Estimated GFR 50 mL/min according to the Cockcroft-Gault 
formula for creatinine clearance

No chronic Hepatitis B Virus (HBV) infection, as determined by 
either
Positive HBV surface antigen and negative HBV surface 
antibody, regardless of HBV core antibody status, at the 
screening visit
Positive HBV core antibody and negative HBV surface 
antibody, regardless of HBV surface antigen status, at the 
screening visit
Study Procedures/
Frequency:
After screening procedures, eligible subjects will be randomized 1:1 
to Treatment Group 1 or Treatment Group 2 and treated for 
48 weeks. Following the Day 1 visit, subjects will return for study 
visits at Weeks 4, 8, and 12, and then every 12 weeks through 
Week 48. After 48 weeks, subjects will continue to take their 
blinded study drugs and attend study visits every 12 weeks until 
treatment assignments have been unblinded.
For all eligible subjects, blood will be collected at Day 1, Weeks 4, 
8, 12, and then every 12 weeks through the unblinding visit.
Laboratory analyses (hematology, chemistry, and urinalysis), HIV-1 
RNA, CD4+ cell count, and complete or symptom-directed physical 
examinations will be performed at the Screening, Day 1 and all 
subsequent study visits.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 9
19 February 2016
In addition, blood will be collected and stored for possible 
evaluation of markers of inflammation and immune activation, 
which may include but not limited to: cystatin C, IL-6, hs-CRP, 
d-dimer, sCD14, and sCD163. Platelet function evaluations may 
also be assessed, including but not limited to soluble glycoprotein 
VI (sGPVI), P-selectin, and soluble CD40 ligand. Urine will be 
collected for evaluations of renal tubular function including urine 
albumin, urine creatinine, urine protein, retinol binding protein and 
beta-2 microglobulin.
For all subjects on study drug, except subjects located in Germany, 
dual energy x-ray absorptiometry (DXA) scans will be performed 
prior to or within 24 hours of the Day 1 Visit , and then at 
Weeks 24, 48 and at the Unblinding Visit or Early Study Drug 
Discontinuation Visit, if > 12 weeks since last scan. DXA scan 
results will be provided to study sites when available.
Adverse events and concomitant medications will be assessed at 
each visit.
Test Product, Dose, and 
Mode of 
Administration:
FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir 
alafenamide 25 mg (GS-9883/F/TAF) administered orally, 
once daily without regard to food.
Reference Therapy, 
Dose, and Mode of 
Administration:
FDC of abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg 
(ABC/DTG/3TC) administered orally, once daily without regard to 
food.
Criteria for Evaluation:
Safety:
Adverse events, clinical laboratory tests and DXA
Efficacy:
The primary efficacy endpoint is:

The proportion of subjects with HIV-1 RNA ≥50 copies/mL at 
Week 48 as defined by the United States (US) Food and Drug 
Administration (FDA)-defined snapshot algorithm
The secondary endpoints include: 

The proportion of subjects with HIV-1 RNA < 50 copies/mL at 
Week 48 as defined by the US FDA-defined snapshot algorithm

The change from baseline in CD4+ cell count at Week 48


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
Phrum acokinetics: 
Optional Genomic 
Testing: 
Patient Rep01ted 
Outcome: 
CONFIDENTIAL 
Final 
Amendment 1 
An intensive phrumacokinetic (PK) substudy will be perf01med at 
the Weeks 4 or 8 visits in a subset of subjects (target n=30) at study 
sites able to conduct this testing. 
For all subjects on study dmg a single anytime pre or post-dose PK 
blood sample will be collected at Weeks 8, 24 and 36. 
For all subjects on study dmg a trough PK blood sainple will be 
obtained 20-28 hours following the last dose at Weeks 4 and 12. 
Following an observed dose, one post-dose PK blood sample will be 
collected between 1 and 4 hours post-dose. 
For intensive PK substudy, the following PK paraineters for 
GS-9883 may be explored as applicable: 
Cmax, Tmax, Clast, Tiast, Ctau,Tll2, AUCtau,AUCo-Iast, VzJF, CLss/F 
The concentration of GS-9883 may be summarized using descriptive 
statistics. The phrumacokinetics of GS-9883 may be evaluated using 
population approaches. T AF and FTC concentrations may be 
analyzed and PK pru·ameters may be sllilllnru·ized as applicable. 
PPD 
Sho1t F01m 36 Health Survey (SF-36), HIV Symptoms Distress 
Module, Work Productivity and Activity Impanment Questionnan·e 
(WPAI) and Pittsburgh Sleep Quality Index (PSQI) will be 
administered at Day 1, Weeks 4, 12 and 48. 
Page 10 
19 Febmaty 2016 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 11
19 February 2016
Statistical Methods:
The primary analysis will consist of a non-inferiority test of 
switching to FDC GS-9883/F/TAF versus continuing DTG and 
ABC/3TC as the FDC of ABC/DTG/3TC, with respect to the 
proportion of subjects with HIV-1 RNA ≥50 copies/mL at Week 48
as defined by the US FDA-defined snapshot algorithm. It will be 
concluded that GS-9883/F/TAF is non-inferior to the 
ABC/3TC/DTG if the upper bound of the 2-sided 95% confidence 
interval (CI) of the difference between treatment groups 
(GS-9883/F/TAF – ABC/3TC/DTG) in the percentage of subjects 
with HIV-1 RNA ≥50 copies/mL is less than 4%; ie, a margin of 
4% is applied to non-inferiority assessment. The 2-sided 95% CIs 
will be constructed based on the exact method.
The proportion of subjects with HIV-1 RNA < 50 copies/mL at 
Week 48 as defined by the US FDA-defined snapshot algorithm will 
also be summarized. The 95% CIs will be constructed in the same 
manner as described for the primary efficacy endpoint.
The change from baseline in CD4+ cell count at Weeks 48 will be 
summarized by treatment using descriptive statistics. The 
differences and the associated 95% CIs will be constructed using an 
Analysis of Variance (ANOVA) model, including treatment 
(GS-9883/F/TAF vs. ABC/DTG/3TC) as a fixed effect in the model.
The percentage change from baseline in hip and spine BMD at 
Week 48 will be summarized by treatment using descriptive 
statistics. The differences and the associated 95% CIs will be 
conducted using an ANOVA model, including treatment group as a 
fixed effect in the model.
Adverse events, clinical laboratory assessment, and pharmacokinetic 
parameters will be summarized using descriptive statistics.
A total of approximately 520 HIV-1 infected subjects, randomized 
in a 1:1 ratio to 2 treatment groups (260 subjects per treatment 
group), achieves at least 90% power to detect a non-inferiority 
margin of 4% in difference in percentage of subjects with HIV-1 
RNA ≥50 copies/mL at Week 48 between the 2 treatment groups.
For sample size and power computation, it is assumed that both 
treatment groups have 2% of subjects with HIV-1 RNA 
≥50 copies/mL at Week 48 (based on the historical Gilead 
E/C/F/TAF and STB studies), that a non-inferiority margin is 4%, 
and that the significance level of the test is at a one-sided 0.025 level
This study will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 12
19 February 2016
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C
degrees Celsius
F
degrees Fahrenheit
ABC/3TC
abacavir/lamivudine, EpzicomKivexa
ABC/DTG/3TC
abacavir/dolutegravir/lamivudine, Triumeq
AE
adverse event
ALT
alanine aminotransferase
ANC
absolute neutrophil counts
ARV
antiretroviral
AST
aspartate aminotransferase
AUC
area under the plasma/serum/peripheral blood mononuclear cell concentration 
versus time curve
BID
twice a day 
BUN
blood urea nitrogen
CBC
complete blood count
CI
confidence interval
CLcr
creatinine clearance
Cmax
the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
CMH
Cochran-Mantel-Haenszel
CNS
central nervous system
COBI, /co
cobicistat (GS-9350)
Ctau
the observed drug concentration at the end of the dosing interval
CPK
creatine phosphokinase
CRF
case report form(s)
CRO
contract (or clinical) research organization 
CYP
cytochrome P450
DHHS
Department of Health and Human Services
DNA
deoxyribonucleic acid
DSPH
Drug Safety and Public Health
DTG
dolutegravir, Tivicay
ECG
electrocardiogram
eCRF
electronic case report form(s)
eGFR
estimated glomerular filtration rate
EVG
elvitegravir
E/C/F/TAF
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide 
E/C/F/TDF
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate, Stribild
FAS
full analysis set
FDA
(United States) Food and Drug Administration
FDC
fFixed dose combination


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 13
19 February 2016
FTC/TAF 
emtricitabine/tenofovir alafenamide 
FSH
follicle-stimulating hormone
FTC, F
emtricitabine, Emtriva
GCP
Good Clinical Practice (Guidelines)
GGT
gamma glutamyl transferase
GLSM
geometric least squares mean
GSI
Gilead Sciences, Inc.
GS-9883/F/TAF
GS-9883/emtricitabine/tenofovir alafenamide
HAART
highly active antiretroviral therapy
HBV
hepatitis B virus
HBcAb
hepatitis B core antibody
HBsAb
hepatitis B surface antibody
HBsAg
hepatitis B surface antigen
HCV
hepatitis C virus
HDPE
high-density polyethylene
hERG
human Ether-à-go-go-Related Gene
HIV
human immunodeficiency virus
HIV Sx
HIV Symptoms  Distress Module
HLA
human leukocyte antigen
IB
investigator’s brochure
ICH
International Conference on Harmonisation
IDMC
Independent Data Monitoring Committee
IND
Investigational New Drug (Application)
INSTI
integrase strand-transfer inhibitors
IRB
institutional review board
IWRS
interactive web response system
KS
Kaposi’s sarcoma
LDH
lactate dehydrogenase
LLN
lower limit of the normal range
MedDRA
Medical Dictionary for Regulatory Activities
mg
milligram
MH
Mantel-Haenszel
min
minute
mmHg
millimeters mercury
NNRTI
non-nucleoside reverse transcriptase inhibitor
NOAEL
no observed adverse effect level
NRTI
nucleoside/nucleotide reverse transcriptase inhibitor
P-gp
P-glycoprotein
PI
protease inhibitor
PK
pharmacokinetic


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 14
19 February 2016
PSQI
Pittsburgh Sleep Quality Index
PT
preferred term 
PT
prothrombin time 
PTM
placebo-to-match
QD
once daily 
RAL
raltegravir
RNA
ribonucleic acid
SA
single agent
SAE
serious adverse eventt
SF-36
Short Form 36 Health Survey
SUSAR
Suspected Unexpected Serious Adverse Reaction
TAF
tenofovir alafenamide 
TDF
tenofovir disoproxil fumarate, Viread
TFV-DP
tenofovir diphosphate (TFVpp)
tmax
the time (observed time point) of Cmax
TSH
thyroid stimulating hormone
UGT1A1
uridine 5'-diphospho-glucuronosyltransferase 
UGT
uridine glucuronosyltransferase
ULN
upper limit of the normal range
US
United States
WPAI
Work Productivity and Activity Impairment Questionnaire


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 15
19 February 2016
1.
INTRODUCTION
1.1.
Background
Human immunodeficiency virus-1 (HIV-1) infection is a life-threatening and serious disease that 
is of major public health interest around the world. There are approximately 2.4 million people in 
North America and Western and Central Europe living with HIV-1 and 36 million people 
worldwide {The Joint United Nations Programme 2014}. The infection, if left untreated or 
suboptimally treated, is characterized by deterioration in immune function, ultimately resulting 
in death. Therapeutic strategies for the treatment of HIV-1 disease have been significantly 
advanced by the availability of highly active antiretroviral therapy (HAART); the introduction of 
HAART was associated with a dramatic decrease in acquired immune deficiency syndrome 
(AIDS)-related morbidity and mortality {Palella et al 1998}, {Mocroft et al 1998}, {Sterne et al 
2005}.
The success of potent and well-tolerated ART means that morbidity and mortality in the 
HIV-infected population is increasingly driven by non-AIDS–associated comorbidities. Clinical 
attention has become more focused on the optimization of tolerability, long-term safety, and 
adherence of potent ART regimens {Costagliola 2014}. In addition, there remains a significant 
medical need for new, effective therapies that take into consideration HIV genetic variability, the 
aging HIV-infected population, ARV resistance, non-HIV comorbidities, and regimen 
simplification.
For ART-naive HIV-infected patients, current treatment guidelines suggest that initial therapy 
consist of 2 nucleos(t)ide reverse transcriptase inhibitors (N[t]RTI) and either an integrase 
strand-transfer inhibitor (INSTI) or the boosted protease inhibitor darunavir {Department for 
Health and Human Services (DHHS) 2015}. Virologically suppressed, HIV-infected patients 
may switch from their current regimen because of safety or tolerability concerns or for regimen 
simplification. All patient populations may benefit from once-daily fixed-dose combination 
(FDC) regimens as these have been shown to provide increased adherence and improved clinical 
and virologic outcomes {Sterrantino et al 2012}, {Aldir et al 2013}
Tenofovir (TFV) is a nucleotide analog that inhibits HIV-1 reverse transcription. While tenofovir 
disoproxil fumarate (TDF), an oral prodrug of TFV, is a preferred NtRTI for initial therapy, 
nephrotoxicity is an identified risk, and reductions in bone mineral density (BMD) have been 
shown that are larger than those seen with other NRTIs. Tenofovir alafenamide (TAF) is also an 
oral prodrug of TFV. TAF is more stable in plasma than TDF, provides higher intracellular 
levels of the active phosphorylated metabolite tenofovir diphosphate (TFV-DP), and 
approximately 90% lower circulating levels of TFV relative to TDF at the clinical doses. 
The distinct metabolism of TAF offers the potential for an improved clinical profile compared 
with TDF.
GS-9883 is a potent inhibitor of HIV-1 integrase that is being evaluated for the treatment of 
HIV-1 infection.  Antiviral testing has shown that GS-9883 is active against a broad panel of 
HIV-1 viral lab strains and clinical isolates.  GS-9883 is fully active against a panel of mutant 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 16
19 February 2016
viruses with resistance to NRTIs, non-nucleoside reverse-transcriptase inhibitors (NNRTIs), and 
protease inhibitors (PIs).  Integrase mutant viruses that are resistant to the INSTIs raltegravir 
(RAL) and elvitegravir (EVG) remain largely sensitive to GS-9883.
Gilead Sciences (Gilead) has coformulated GS-9883 with the NRTI emtricitabine (FTC; F) and 
the NtRTI tenofovir alafenamide (TAF) into an FDC tablet that is suitable for once-daily use. 
This GS-9883/F/TAF FDC may provide a potent, convenient, tolerable, and practical regimen 
for the long-term treatment of patients with HIV infection.
1.2.
GS-9883
1.2.1.
General Information
GS-9883, a potent inhibitor of HIV-1 integrase is being evaluated for the treatment of HIV 
infection. Antiviral testing has shown that GS-9883 is active against a broad panel of HIV-1 viral 
lab strains and clinical isolates. GS-9883 is fully active against a panel of mutant viruses with 
resistance to NRTIs, NNRTIs, and PIs. Integrase mutant viruses that are resistant to the INSTIs
RAL and EVG remain largely sensitive to GS-9883.
1.2.2.
Preclinical Pharmacology and Toxicology
A core battery of safety pharmacology studies have been conducted with GS-9883. These 
include assessments of cytotoxicity, off-target receptor and ion-channel binding, effects on 
human Ether-à-go-go-Related Gene (hERG) potassium current and papillary muscle action 
potential, and in vivo studies in rats and dogs that evaluated effects of GS-9883 on all major 
organ systems. The volume of distribution of GS-9883 ranged between 0.09 and 0.22 L/kg in the 
preclinical species, which indicates that the distribution of GS-9883 is limited to the extracellular 
compartment due to its high binding to plasma proteins. The projected half-life of GS-9883 in 
humans is approximately 20 hours based upon the estimates of clearance and volume of 
distribution.
1.2.2.1.
Pharmacology
GS-9883 has IC50 values ranging from 1.5 to 2.4 nM, similar to the inhibitory effect of DTG and 
EVG. GS-9883 is highly potent against HIV replication in MT4 cells with an EC50 (50% 
effective inhibitory concentration) value of 1.9 nM and a protein adjusted EC95 value of 361 nM. 
GS-9883 does not show significant cytotoxicity against dividing and non-dividing human 
PBMCs, primary human hepatocytes and various non-target human cell lines.
GS-9883 is mainly metabolized by uridine 5'-diphospho-glucuronosyltransferase (UGT1A1) and 
CYP3A. GS-9883 does not inhibit major human CYP isoforms or UGT1A1 at concentrations up 
to 25 M. Consequently, GS-9883 is unlikely to be a clinically relevant inhibitor of these
enzymes, and is not expected to inhibit the metabolic clearance of drugs metabolized by these 
enzymes. GS-9883 only modestly inhibits renal transporter OCT2 (IC50 = 0.42 M). As a result, 
GS-9883 is not expected to significantly interfere with the key transporter responsible for 
creatinine tubular elimination at the clinically projected Cmax. Additionally, the risk that GS-9883 
will affect the OCT2-mediated excretion of co-administered drugs is considered to be low.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 17
19 February 2016
GS-9883 does not activate AhR and only weakly activates PXR at concentrations up to 50 M 
(less than 5% and 40% of activation, respectively, compared to positive control compound). 
Therefore, GS-9883 is not expected to act as an inducer through PXR- or AhR-mediated 
pathways at the doses and exposure levels projected in clinical use.
1.2.2.2.
Toxicology
Single oral doses of GS-9883 up to 1000 mg/kg were well-tolerated in rats (AD-141-2286). The 
increase in exposure was limited (< 2-fold) between 100 and 300 mg/kg and similar exposure 
was observed between 300 and 1000 mg/kg suggesting saturation of absorption at 300 mg/kg 
(AUC0-24 2205 gh/mL and 1931 gh/mL, respectively). In monkeys, single oral doses of 
GS-9883 up to 1000 mg/kg were well-tolerated (AD-141-2284). The increase in exposure was 
limited (< 2-fold) between 300 to 1000 mg/kg (AUC0-24 803 gh/mL and 1078 g h/mL, 
respectively).
In 2-week (TX-141-2029) and 26-week (TX-141-2031) oral toxicity studies in rats at doses up to 
300 mg/kg/day, GS-9883 was well-tolerated with no GS-9883-related effects on clinical 
observations, body weight, food consumption, ophthalmic examinations, and anatomic 
pathology.  The high dose of 300 mg/kg/day was considered the maximum feasible dose based 
upon saturation of absorption. The no observed effect level (NOEL) in the 26-week study was 
considered to be the high dose of 300 mg/kg/day.  At the NOEL, GS-9883 exposures in the rat 
were considered to be approximately 12-/31-fold higher (males/females) than the projected 
steady state human exposure of GS-9883 following administration of GS-9883/F/TAF 
(50/200/25 mg) QD under fed conditions.
In a 39-week study in monkeys (TX-141-2032), following administration of 1000 mg/kg/day 
(high dose) of GS-9883 for 39 weeks, pathology data indicated minimal to marked bile duct 
hyperplasia and minimal or moderate hepatocyte hypertrophy in both sexes, and minimal 
regenerative hyperplasia and minimal or slight neutrophil infiltrate in males.  The macroscopic 
finding of rough surface on the liver in one male administered 1000 mg/kg/day correlated with 
moderate hepatocyte hypertrophy and marked bile duct hyperplasia. After a 4-week recovery 
period, GS-9883-related microscopic liver findings included marked bile duct hyperplasia, slight 
hepatocyte hypertrophy, minimal regenerative hyperplasia, and slight lymphocyte infiltrate in 
one male and slight bile duct hyperplasia in one female administered 1000 mg/kg/day, while the 
other two animals in the high dose group had no hepatobiliary findings. Minimally to mildly 
increased ALT activities (≤3.5-fold versus baseline values), likely associated with liver findings, 
exhibited reversibility. There were no other adverse findings in the study, including clinical 
observations, or effects on body weight, body weight change, food consumption, ECGs, 
hematology, coagulation, clinical chemistry, urinalysis, and ophthalmoscopy.
No GS-9883-related effects were observed in the mid-dose group (200 mg/kg/day) which was 
considered the no-observed-effect-level (NOEL).  The estimated margin of exposure at the 
NOEL was approximately 5.1-fold based on expected human exposure with the once daily 
dosing of the GS-9883/F/TAF (50/200/25 mg) tablet.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 18
19 February 2016
A standard battery of in vitro and in vivo studies was performed to assess the genotoxic potential 
of GS-9883. There was no evidence of mutagenic or clastogenic activity in an in vitro bacterial 
reverse mutation assay (Study TX-141-2026), a chromosomal aberration assay in human 
lymphocytes (Study TX-141-2027), or in a rat micronucleus test (Study TX-141-2029).
1.2.3.
Clinical Trials of GS-9883
Clinical trials entailing the use of GS-9883 include:

GS-US-141-1218, a Phase 1 double blind, randomized, placebo-controlled, first-in-human, 
single- and multiple-ascending dose study evaluating the safety, tolerability, and PK of oral 
GS-9883 in healthy subjects and a randomized, open-label, 2-cohort, 3-period, crossover, PK 
study evaluating the drug interaction potential between F/TAF FDC tablet and GS-9883 in 
healthy subjects (completed)

GS-US-141-1219, a Phase 1b randomized, double-blinded, sequential cohort
placebo-controlled study of the safety, PK, and antiviral activity of GS-9883 in HIV-1 
infected subjects (5 mg, 25 mg, 50 mg, 100 mg) (completed)

GS-US-141-1233, a Phase 1,Open-label, Two-Cohort, Multiple-Period, Fixed-Sequence,
Crossover Study to Evaluate 1) the Relative Bioavailability of
Two GS-9883/Emtricitabine/Tenofovir Alafenamide (75/200/25 mg and 50/200/25 mg)
Fixed-Dose Combination Tablets Versus a GS-9883 (75 mg) Tablet and a 
Emtricitabine/Tenofovir Alafenamide (200/25 mg) Fixed-Dose Combination Tablet 
Administered Simultaneously and 2) the Effect of Food on the Pharmacokinetics of 
GS-9883, Emtricitabine and Tenofovir Alafenamide When Administered as 
GS-9883/Emtricitabine/Tenofovir Alafenamide (75/200/25 mg and 50/200/25 mg)
Fixed-Dose Combination Tablets (in life portion completed)

GS-US-141-1479, a Phase 1, open-label, parallel-group, adaptive single-dose study to 
evaluate the PK of GS-9883 in subjects with normal and impaired renal function (completed)

GS-US-141-1480, a Phase 1 partially-blinded, randomized, placebo- and positive-controlled 
study to evaluate the effect of GS-9883 on the QT/QTc interval in healthy subjects 
(completed)

GS-US-141-1481, a Phase 1 study to evaluate the pharmacokinetics, metabolism, and 
excretion of GS-9883 in healthy subjects (completed)

GS-US-141-1485, a Phase 1 adaptive study to evaluate transporter, CYP-mediated and 
UGT1A1 drug-drug interactions between GS-9883 and probe drugs (completed)

GS-US-141-1487, a Phase 1 randomized, Blinded, Placebo-Controlled Phase 1 Study 
Evaluating the Effect of GS-9883 on Renal Function as Assessed by Markers of Glomerular 
Filtration Rate (In life portion completed)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 19
19 February 2016

GS-US-311-1790, a Phase 1Randomized, Open Label, Drug Interaction Study Evaluating the 
Effect of F/TAF FDC Tablet or GS-9883 on the Pharmacokinetics of a Representative 
Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol (completed)

GS-US-380-1761, a Phase 1 Study to Evaluate Pharmacokinetic Drug-Drug Interaction 
Potential between GS-9883/Emtricitabine/Tenofovir Alafenamide Fumarate 
(GS-9883/F/TAF) and Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) 
Tablets (completed)

GS-US-141-1475, a Phase 2 Randomized, Double-Blinded Study of the Safety and Efficacy 
of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + 
Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive 
Adults (ongoing)

Please refer to the GS-9883/F/TAF Investigators’ Brochure for further information about 
these
1.2.3.1.
Phase 1 Safety and Pharmacokinetics
Study GS-US-141-1218 was a four part, first-in-human study.  Parts A and B were randomized, 
double-blind, placebo-controlled, single and multiple ascending dose studies of GS-9883 in 
healthy male and female subjects.  Part C was an open label, fixed sequence food effect study 
evaluating the effect of food on the PK of GS-9883.  Part D was a randomized, open-label, 
2-cohort, 3-period, crossover PK study evaluating the drug interaction potential between 
FTC/TAF FDC tablet and GS-9883 in healthy subjects.
There was no difference in the overall incidence or type of AEs when GS-9883 was administered 
in the fasted and fed states. There was no difference in the overall incidence of AEs when 
GS-9883 or FTC/TAF was each administered alone or in combination.
No deaths or pregnancies were reported. No Grade 3 or 4 AEs or SAEs, were reported in any 
cohort.
Increases in serum creatinine were observed in this study, presumably via inhibition of the renal 
transporter OCT2.  In the MAD cohorts (fasted), serum creatinine change at Day 14 ranged from 
0.05 mg/dL for the 5 mg cohort to 0.18 mg/dL for the 300 mg/dL cohort. In Part D (DDI), 
conducted in the fed state (regular meal), subjects received 100 mg GS-9883 monotherapy for 
7 days and 100 mg GS-9883 with FTC/TAF for 7 days, the mean serum creatinine change at 
Day 7 was 0.14 mg/dL following GS-9883 and 0.17 mg/dL following GS-9883 + FTC/TAF. All 
changes returned to baseline after discontinuation of GS-9883.
The majority of laboratory abnormalities were Grade 1 or Grade 2 in severity. Grade 3 laboratory 
abnormalities included 10 subjects with Grade 3 urine dipstick tests for blood. All of these 
subjects were female, none of the labs were considered by the Investigator to be clinically 
significant, and all were associated with menstruation. No other Grade 3 or 4 laboratory 
abnormalities were observed.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 20
19 February 2016
Based on results in study GS-US-141-1218, pharmacokinetic profile of GS-9883 was 
characterized by rapid absorption with time to peak plasma concentrations (median Tmax of 
cohorts) ranging between 1 and 4 hours following administration under fasted conditions. 
GS-9883 exposures were appropriately dose proportional following single dose 25-100 mg dose 
administration, with decreasing dose proportional at higher doses.  The half-life of GS-9883 was 
approximately 18 hours, with no changes observed across studied dose range as evidenced by 
parallel terminal phase slopes. A high-fat meal increased AUCinf and Cmax (geometric mean, 
84% and 101%, respectively) following 100 mg single dose administration. Steady state was 
achieved after 4-6 days of once daily dosing of GS-9883 with average accumulation ratios for 
AUC24hr of 1.6.
Table 1-1.
GS-US-141-1218: GS-9883 Mean (%CV) PK Parameters Following 
Single Doses of GS-9883 in Healthy Subjects (GS-9883 PK Analysis 
Set; Part A: Single Dosing)
GS-9883 PK 
Parameter
Mean 
(%CV)
5mg
(N=6)
25 mg
(N=6)
50 mg
(N=6)
100 mg
(N=6)
300 mg
(N=6)
600 mg
(N=6)
Cmax (ng/mL)
691.2
(22.1)
1618.3
(26.7)
3965.0
(40.1)
6998.3
(36.1)
14605.0 
(27.1)
20050.0
(7.5)
Tmax (hr)
1.25 
(1.00-1.50)
2.00
(1.00-3.00)
3.00
(1.50-4.00)
2.25
(1.50-3.00)
3.50
(2.00-6.00)
3.5
(2.00-4.00)
AUCinf 
(ng.hr/mL)
13059.7
(25.1)
35718.2 
(21.3)
78399.5 
(29.7)
163028.2 
(24.3)
355917.3 
(32.9)
454446.8 
(19.9)
T1/2 (hr)
18.51
(16.81-19.99)
18.08
(16.63-19.64)
16.72
(15.77-17.11)
18.90
(17.96-20.05)
18.14
(17.86-20.53)
17.89
(16.38-19.52)
T1/2 and Tmax: Median (Q1, Q3)
Table 1-2 presents GS-9883 plasma PK parameters following administration of GS-9883 
(5, 25, 50, 100, and 300 mg) once daily for 7 days. Following administration of either GS-9883 
(5, 25, 50, 100, or 300 mg) once daily for 7 days, the PK absorption profile observed on Days 1 
and 7 was similar to that observed in Part A (SAD). The median Tmax values ranged from 1.5 to 
2.5 hours on Day 1 and 1.5 to 4.0 hours on Day 7. Linearity was observed comparing GS-9883 
AUC and Cmax on Days 1 and 7 over the dose range of 25 to 50 mg. Steady state levels of 
GS-9883 were achieved between Study Days 4 to 6 of dosing and maintained through Day 14. 
Accumulation is approximately 1.6-fold, which is consistent with the observed half-life of the 
GS-9883 (approximately 18 hours).


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 21
19 February 2016
Table 1-2.
GS-US-141-1218: GS-9883 Plasma Pharmacokinetic Parameters by 
GS-9883 Dose Following Multiple-Dose Administration of GS-9883 
(Analysis Set: GS-9883 PK Part B: Multiple-Dose)
GS-9883 PK Parameter Mean
(%CV)a
Multiple-Dose GS-9883
5 mg
(N = 6)
25 mg
(N = 6)
50 mg
(N = 6)
100 mg
(N = 6)
300 mg
(N = 6)
Day 1
AUC0-24 (hr*ng/mL)
9033.6
(8.2)
27,775.1
(28.3)
58,371.4
(18.9)
79,773.8
(18.9)
180,714.3
(17.6)
Cmax (ng/mL)
709.7
(9.5)
2220.0
(35.6)
4648.3
(18.7)
6248.3
(26.8)
13,716.7
(19.1)
Tmax (hr)
1.50
(1.50, 1.50)
1.75
(1.00, 3.00)
1.50
(1.00, 2.00)
2.50
(2.00, 3.00)
2.50
(2.00, 4.00)
Day 7
AUCtau (hr*ng/mL)
14,392.0
(16.7)
50,008.2
(26.6)
89,710.1
(22.7)
126,785.8 
(23.7)
277,200.2 
(16.7)
Cmax (ng/mL)
982.5
(7.9)
3455.0
(24.1)
6538.3
(17.6)
9396.7
(20.8)
19,900.0 
(21.2)
Ctau (ng/mL)
400.83
(26.9)
1322.00
(27.8)
2241.67
(28.2)
3145.00 
(26.1)
6758.33 
(21.6)
Tmax (hr)
1.50
(1.00, 2.00)
3.00
(2.00, 3.00)
1.75
(1.50, 2.00)
1.75
(1.50, 3.00)
4.00
(2.00, 4.00)
Accumulation Ratio of AUC (%)
160.5
(19.0)
182.2
(17.1)
154.0
(15.9)
158.5
(12.1)
157.5
(22.6)
a
Data are presented as mean (%CV), except for Tmax, and t½, which are presented as median (Q1, Q3)
Table 1-3 presents the GLSM ratios and associated 90% CIs for the test (fed) versus reference 
(fasted) treatments for the primary plasma PK parameters of GS-9883. Administration of a single 
dose of GS-9883 100 mg with food (high-calorie/high-fat breakfast) increased the GLSM values 
of Cmax and AUCinf 101% (90% CI of GLSM ratio 165.93% to 242.74%) and 84% (90% CI of 
GLSM ratio 152.05% to 222.59%), respectively. There were no apparent changes in clearance 
and T1/2 following administration with food, indicating that food enhanced the bioavailability of 
GS-9883 by improving its solubility and/or absorption.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 22
19 February 2016
Table 1-3.
GS-US-141-1218: Statistical Comparison of GS-9883 Pharmacokinetic 
Parameters Following Single-Dose Administration of GS-9883 in the 
Fasted and Fed States (GS-9883 PK Analysis Set)
GS-9883 PK Parameter 
Mean (%CV)
% GLSM Ratio 
(90% CI)
Test
GS-9883 100 mg Fed
(n=8)
Reference
GS-9883 100 mg Fasted
(n=8)
AUCinf (hr*ng/mL)
214,146.3 (15.9)
117,777.1 (23.3)
183.97 (152.05, 222.59)
AUClast (hr*ng/mL)
209,259.9 (15.1)
115,681.7 (24.0)
183.58 (151.91, 221.86)
Cmax (ng/mL)
11,268.8 (15.1)
5885.0 (34.9)
200.69 (165.93, 242.74)
CI = confidence interval; GLSM = geometric least squares mean
1.2.3.2.
Phase 1b Proof of Concept
The first HIV-1 positive human subjects were dosed in the fasted state with 10 days of GS-9883 
in study (GS-US-141-1219).  Four cohorts of 5 subjects each were randomized 4:1 to receive 
GS-9883 or placebo to match at doses of 5 mg, 25 mg, 50 mg, and 100 mg once daily for 
10 days.
GS-9883 was generally well tolerated at the doses evaluated. A total of 9 of 20 subjects had an 
AE in this study. The most frequently reported AEs across all subjects were diarrhea (2 subjects), 
and headache (3 subjects).  No other AE was reported in more than 1 subject. There was no 
increase in the incidence of AEs with increasing doses of GS-9883.
The majority of AEs were considered by the investigator to be not related to study drug. A total 
of 2 subjects experienced mild diarrhea that was considered related to study drug (1 in the 5 mg 
cohort, 1 in the 100 mg cohort).
No deaths or pregnancies were reported. No Grade 3 or 4 AEs, SAEs, or AEs leading to 
discontinuation of study drug were reported in any cohort.
The majority of laboratory abnormalities were Grade 1 or Grade 2 in severity. No Grade 3 
treatment emergent laboratory abnormalities were observed. Median serum creatinine changes at 
Day 10 were: 0.05 mg/dL (5 mg), 0.04 mg/dL (25 mg), 0.06 mg/dL (50 mg), and 0.15 mg/dL 
(100 mg). These changes in serum creatinine appeared to be transient and returned close to 
baseline values on discontinuation of study drug. One Grade 4 new onset laboratory abnormality 
was seen in 1 subject who received 5 mg GS-9883. This was a Grade 4 CPK seen on Day 17, 
7 days following his last dose of study medication. The subject was asymptomatic. The 
Investigator felt that this was unrelated to study medication and was due to resumption of crystal 
methamphetamine use by the subject. An adverse event of elevated CK was reported unrelated to
study medication.
Based on PK information collected in study GS-US-141-1219, which was in line with PK 
observed in study GS-US-141-1218, the median IQ for each dose were calculated and are 
presented in Table 1-4 below.


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Final 
Gilead Sciences, Inc. 
Amendment 1 
Table 1-4. 
Trough GS-9883 Plasma Concentrations at Steady State Following 
GS-9883 Administration Under Fasting Conditions and 
Corresponding Protein-Adjusted IQ9s Values (GS-9883 PK Analysis 
Set) 
GS-9883 dose 
n 
Median (range) C 1au, ss (ng!mL) 
Median (range) pai Q95• 
5mg 
4 
206.5 (146.0 to 342.0) 
1.3 (0.9 to 2.1) 
25mg 
4 
797.5 (714.0 to 1900.0) 
4.9 ( 4.4 to 11. 7) 
50mg 
4 
2170.0 (852.0 to 3020.0) 
13.4 (5.3 to 18.6) 
100mg 
4 
4190.0 (3730.0 to 5970.0) 
25.9 (23.0 to 36.9) 
a. 
The protein adjusted IQ95 (paiQ95) value is estimated based on steady-state Ctau values and the in vitro paiC95 value for 
wild-type HIV-1 (162 ng/ml). 
The mean and 95% Cis of change from baseline in HIV -1 RNA (log10 copies/mL) are presented 
in Figure 1-1. 
Figure 1-1. 
G$-9883 5 mg (~): 
G$-9883 25 mg (~): 
G$-9883 50 mg (~): 
G$-9883 100 mg (~ ): 
Placebo (n= ): 
GS-US-141-1219: Mean and 95% Cis of Change from Baseline in 
HIV-1 RNA (log10 copies/mL) (PP Analysis Set) 
• 
= GS-9883 5 mg 
0 
= GS-9883 25 mg 
/:; = GS-9883 50 mg 
0 = GS-9883 100 mg 
<> = Placebo 
BL 
2 
3 
3 
3 
3 
4 
3 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
7 
8 
9 
Day 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
3 
4 
4 
4 
4 
4 
4 
4 
10 
11 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
14 
3 
4 
4 
4 
4 
17 
3 
3 
4 
4 
4 
NOTE: Baseline value was the last available value collected prior to the time of the first dose of study drug. 
2 
-1 
-2 
-3 
Mean viral load change on Day 11 was -2.08 log10 in the 25 mg coh011, -2.06 log10 in the 50 mg 
coh01i , and -2.43 log10 in the 100 mg coh01i . Time weighted average change from baseline at 
Day 11 (DA VG 11) was -0.92 log10 in the 5 mg coh01i, -1.33 log10 in the 25 mg 
CONFIDENTIAL 
Page23 
19 Februa1y 2016 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 24
19 February 2016
cohort, -1.37 log10 in the 50 mg cohort and -1.61 log10 in the 100 mg cohort.  Viral suppression 
(HIV-1 RNA < 50 copies/mL) was ever achieved by the end of the study (Day 17) by 1 subject 
(25.0%) in the GS-9883 50 mg group and 2 subjects (50%) in the GS-9883 100 mg group.
1.2.3.3.
Summary of Phase 2 Study (GS-US-141-1475)
Study GS-US-141-1475 is an ongoing Phase 2, randomized, double-blind, multicenter, 
active-controlled study to assess the safety and efficacy of a regimen containing 
GS-9883+F/TAF versus dolutegravir (DTG)+F/TAF in HIV-infected, ART-naive adult subjects.
Eligible subjects were randomized in a 2:1 ratio to one of the following treatment groups, 
stratified by HIV-1 RNA level (≤ 100,000 copies/mL, 100,000 copies/mL to 
400,000 copies/mL, or > 400,000 copies/mL) at screening:

Treatment Group 1: GS-9883 75 mg + F/TAF (200/25 mg) + placebo-to-match DTG 50 mg 
once daily

Treatment Group 2: DTG 50 mg + F/TAF (200/25 mg) + placebo-to-match GS-9883 75 mg 
once daily
Week 24 interim data are summarized below. 
Subject Disposition and Baseline Characteristics
A total of 98 subjects were randomized and treated in the study: 65 subjects in the 
GS-9883+F/TAF group and 33 subjects in the DTG+F/TAF group. At the time of the Week 24 
data analysis, 2 subjects (2.0%) had prematurely discontinued from the study, 1 in each treatment 
group; both subjects were lost to follow-up.
Demographic and baseline characteristics were similar between the 2 treatment groups.
Key baseline disease characteristics (ie, viral load, CD4 cell count, and eGFRCG) were similar 
between the 2 treatment groups.
Median (first quartile [Q1], third quartile [Q3]) baseline HIV-1 RNA was 4.45 (3.96, 
4.79) log10 copies/mL, with 82.7% of subjects having ≤ 100,000 copies/mL at baseline; 
5 subjects had > 400,000 copies/mL at baseline; 4 of these subjects were randomized to 
GS-9883+F/TAF and 1 subject was randomized to DTG+F/TAF.
Median (Q1, Q3) baseline CD4 cell count was 444 (316, 595) cells/μL, with 41.8% of subjects 
having ≥ 500 cells/μL at baseline. Median (Q1, Q3) baseline eGFRCG was 125.3 (105.7, 
147.0) mL/min.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 25
19 February 2016
Efficacy Results
Virologic success at Weeks 12 and 24 was assessed using the US FDA-defined snapshot 
algorithm, defined as plasma HIV-1 RNA < 50 copies/mL. At Weeks 12 and 24, virologic 
success was high and similar between the 2 treatment groups as follows: Week 12 
GS-9883+F/TAF 93.8%, DTG+F/TAF 93.9% (stratum-adjusted difference in percentages: 
−1.3%; 95% CI: −12.9% to 10.2%; p = 0.79); Week 24 GS-9883+F/TAF 95.4%, DTG+F/TAF 
93.9% (1.0%; 95% CI: −10.7% to 12.7%; p = 0.84).
Of the 5 subjects with baseline viral load > 400,000 copies/mL, 4 had HIV-1 RNA 
< 50 copies/mL at Week 24, and had 60 copies/mL. 
Following initiation of study drug, the increases from baseline in CD4 cell count were similar 
between treatment groups. Mean (SD) baseline CD4 cell counts were as follows: 
GS-9883+F/TAF 471 (190.9) cells/μL; DTG+F/TAF 507 (271.0) cells/μL; p = 0.35. The mean 
(SD) change in CD4 cell count from baseline to Week 12 was similar between the 2 treatment 
groups as follows: GS-9883+F/TAF, +170 (150.0) cells/μL; DTG+F/TAF, +173 (220.5) cells/μL 
(difference in least squares mean [LSM]: 0; 95% CI: −76 to 76; p = 1.00). There were similar 
increases in the mean (SD) CD4 cell count in both treatment groups Week 24: GS-9883+F/TAF, 
+189 (177.8) cells/μL; DTG+F/TAF, +157 (163.2) cells/μL (difference in LSM: 39; 95% CI: 
−35 to 113; p = 0.30).
Interim Virology Resistance Data
Through Week 24, no emergent drug resistance was detected.
Safety Results
Adverse Events
The overall incidence of treatment-emergent AEs was balanced between treatment groups as 
follows: GS-9883+F/TAF 66.2%, 43 subjects; DTG+F/TAF 57.6%, 19 subjects. The most 
common treatment-emergent AEs (occurring in > 2 subjects) by treatment group were as 
follows:

GS-9883+F/TAF: diarrhea and headache (7.7%, 5 subjects each); and nausea, decreased 
appetite, arthralgia, and cough (4.6%, 3 subjects each)

DTG+F/TAF: nausea (12.1%, 4 subjects); diarrhea (9.1%, 3 subjects)
Most treatment-emergent AEs were Grade 1 in severity. Grade 3 or 4 AEs were reported in only 
1 subject (Grade 3 diabetic ketoacidosis), in the GS-9883+F/TAF group; this event was also 
reported as an SAE. One other SAE (appendicitis), also in the GS-9883+F/TAF group, was 
reported. Neither SAE was considered related to study drug by the investigator or resulted in 
study drug discontinuation or interruption, and both SAEs resolved.
The overall incidence of study drug-related treatment-emergent AEs was balanced between 
treatment groups as follows: GS-9883+F/TAF 15.4%, 10 subjects; DTG+F/TAF 18.2%, 
6 subjects. Most study drug-related treatment-emergent AEs were Grade 1 in severity. Grade 2 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 26
19 February 2016
study drug-related treatment-emergent AEs were reported in 1 subject in the GS-9883+F/TAF 
group (somnolence and headache) and 1 subject in the DTG+F/TAF group (vomiting). There 
were no Grade 3 or 4 treatment-emergent AEs or SAEs reported that were considered related to 
study drug.
No Grade 4 AEs, deaths, pregnancies, or AEs leading to premature study drug discontinuation 
were reported in either treatment group.
Clinical Laboratory Evaluations
The percentage of subjects with at least 1 treatment-emergent laboratory abnormality (ie, at least 
1 grade level increase from baseline in graded abnormality) was similar between treatment 
groups as follows: GS-9883+F/TAF 76.6%, 49 subjects; DTG+F/TAF 78.1%, 25 subjects. The 
majority of treatment-emergent laboratory abnormalities were Grade 1 or 2 in severity. The 
percentage of subjects with at least 1 Grade 3 or 4 treatment-emergent laboratory abnormality 
was similar between treatment groups as follows: GS-9883+F/TAF 17.2%, 11 subjects; 
DTG+F/TAF 12.5%, 4 subjects. Grade 3 or 4 laboratory abnormalities occurring in at least 
2 subjects in either treatment group were as follows: creatine kinase (GS-9883+F/TAF, 7.8% 
[5 subjects]), fasting serum glucose (DTG+F/TAF, 6.3% [2 subjects]), aspartate 
aminotransferase (AST) (GS-9883+F/TAF, 3.1% [2 subjects]), and fasting low-density 
lipoprotein (LDL) (GS-9883+F/TAF, 3.1% [2 subjects]). The only Grade 4 laboratory 
abnormalities were for creatine kinase, reported in 2 subjects (3.1%) in the GS-9883+F/TAF 
group. All increased creatine kinase values appeared to be transient, and none were associated 
with AEs. Of the 2 subjects with increased AST, 1 subject had Grade 3 AST and Grade 3 ALT at 
Week 24 in the setting of alcohol abuse; the other subject had Grade 3 AST at Week 8 that 
returned to normal by Week 24.
There were no clinically significant changes from baseline or differences between treatment 
groups in the median values for hematology, chemistry, or metabolic parameters. There were 
similar increases from baseline in median (Q1, Q3) serum creatinine in both treatment groups at 
Week 24: GS-9883+F/TAF 0.12 (0.06, 0.18) mg/dL; DTG+F/TAF 0.13 (0.05, 0.21) mg/dL. 
There were decreases in median (Q1, Q3) eGFRCG at Week 24, which were smaller in the 
GS-9883+F/TAF compared with the DTG+F/TAF group: GS-9883+F/TAF 
−13.3 (−19.9, −4.0) mL/min; DTG+F/TAF −17.2 (−25.7, −6.9) mL/min.
Conclusions
Key Week 24 conclusions from Study GS-US-141-1475 include the following:

Virologic success at Week 24 when assessed using the US FDA-defined snapshot algorithm, 
defined as plasma HIV-1 RNA < 50 copies/mL, was similar between the 2 treatment groups 
as follows: GS-9883+F/TAF 95.4%; DTG+F/TAF 93.9%; stratum-adjusted difference in 
percentages: 1.0%; 95% CI: −10.7% to 12.7%; p = 0.84. There was a similar increase in the 
mean (SD) CD4 cell count between the 2 treatment groups, GS-9883+F/TAF,
+189 (177.8) cells/μL; DTG+F/TAF, +157 (163.2) cells/μL (difference in LSM: 39; 95% CI: 
−35 to 113; p = 0.30).


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 27
19 February 2016

No resistance to any INSTIs, NRTIs, NNRTIs, or PIs was detected through Week 24.

No AEs led to study drug discontinuation in either treatment group.
Both GS-9883+F/TAF and DTG+F/TAF were generally well tolerated through 24 weeks of 
treatment. The most commonly reported treatment-emergent AEs were diarrhea and headache 
(7.7% each) in the GS-9883+F/TAF group and nausea (12.1%) and diarrhea (9.1%) in the 
DTG+F/TAF group. There were 2 SAEs, 1 of which was also a Grade 3 AE; neither of these 
events was considered related to study drug by the investigator, or led to study drug 
discontinuation. There were no other Grade 3 or 4 AEs, and no deaths, pregnancies, or AEs 
leading to premature study drug discontinuation reported. The percentage of subjects with at 
least 1 treatment-emergent laboratory abnormality was similar between treatment groups. The 
majority of treatment-emergent laboratory abnormalities were Grade 1 or 2 in severity. There 
were similar increases from baseline in serum creatinine in both treatment groups at Week 24.
1.3.
Information about Emtricitabine (Emtriva®, FTC)
Emtricitabine (5-fluoro-1-[(2R, 5S)-2-(hydroxymethyl)-[1, 3]-oxathiolan-5-yl] cytosine, FTC) is 
a NRTI that has demonstrated potent and selective inhibition of the HIV. In HIV-infected adults, 
FTC is administered as a 200 mg QD dose concurrently with other ARVdrugs. The 200 mg FTC 
capsule formulation was approved by the US FDA for marketing on 2 July 2003 and is available 
under the name Emtriva®. In the European Union (EU), marketing authorization was granted for 
both the 200 mg Emtrivacapsule formulation and a 10 mg/mL Emtrivaoral Solution 
formulation on 24 October 2003, with indications for the treatment of HIV infection concurrently 
with other antiretroviral drugs in both adult and pediatric patients.
Further information is available in the current Prescribing Information for Emtriva®.
1.4.
Information about Tenofovir alafenamide (TAF, GS-7340)
Tenofovir alafenamide (GS-7340, TAF) is a second generation oral prodrug of tenofovir (TFV), 
a nucleotide analog that inhibits HIV-1 reverse transcription. Tenofovir is metabolized 
intracellularly to the active metabolite, tenofovir diphosphate (TFV-DP), a competitive inhibitor 
of HIV-1 reverse transcriptase (RT) that terminates the elongation of the viral DNA chain. The 
intracellular metabolism of TAF and TFV are consistent with the 600-fold enhancement in 
anti-HIV activity in cell culture of TAF over TFV.
Please refer to the GS-9883/F/TAF Investigator’s Brochure for further information.
1.4.1.
Clinical Trials of Single Agent Tenofovir Alafenamide (TAF, GS-7340) or
Fixed Dose Combination emtricitabine/tenofovir alafenamide (FTC/TAF)
Clinical trials entailing the use of tenofovir alafenamide include:

GS-US-120-1101, a Phase 1/2 study of the pharmacokinetics and antiviral activity of 
GS-7340 (50 mg and 150 mg) in HIV-infected subjects (completed)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 28
19 February 2016

GS-US-120-0104, a Phase 1b study of the pharmacokinetics and antiviral activity of 
GS-7340 (8 mg, 25 mg, 40 mg) in HIV infected subjects (completed)

GS-US-120-0107, a Phase 1, partially-blinded, randomized, placebo- and positive controlled 
study to evaluate the effect of GS-7340 on the QT/QTc interval in healthy subjects 
(completed)

GS-US-120-0108, a Phase 1, open-label, parallel-design study to evaluate the 
pharmacokinetics of GS-7340 in subjects with severe renal impairment (completed)

GS-US-120-0109, a Phase 1 study to evaluate the pharmacokinetics, metabolism and 
excretion of GS-7340 (completed)

GS-US-120-0114, a Phase 1, open-label, parallel-group, single dose study to evaluate the 
pharmacokinetics of tenofovir alafenamide in subjects with normal and impaired hepatic 
function (completed)

GS-US-120-0117, a Phase 1 single-dose study evaluating the pharmacokinetic drug 
interaction potential between rilpivirine and tenofovir alafenamide (completed)

GS-US-120-0118, a Pharmacokinetic study evaluating the drug interaction potential of
tenofovir alafenamide with a boosted protease inhibitor or unboosted integrase inhibitor in
healthy subjects (completed)

GS-US-311-1386, a Phase 1 study to determine the effect of food on the pharmacokinetics of 
tenofovir alafenamide when administered as F/TAF FDC in healthy volunteers (completed)

GS-US-311-0101, a Phase 1 healthy volunteer study evaluating the drug interaction potential
between once-daily FTC/GS-7340 fixed-dose combination and efavirenz (EFV) or
COBI-boosted darunavir (DRV) (completed)

GS-US-311-1088, a Phase 1, Relative Bioavailability Study of Emtricitabine/Tenofovir
Alafenamide Fixed Dose Combination Tablet to evaluate the formulation performance of
emtricitabine (FTC) and tenofovir alafenamide (TAF) fixed dose combination tablets relative
to co-administration of individual agents (completed)

GS-US-311-1089, a Phase 3 study of the safety and efficacy of FTC/TAF in HIV infected,
virologically suppressed patients (ongoing)
In Study GS-US-311-1386, the effect of food (high-calorie, high-fat meal) on the PK of the TAF 
component of the F/TAF FDC was evaluated. The GLSM ratio of the AUClast of TAF when 
administered with a high-fat meal was 177% (90% CI: 166% to 188%), and the TAF Cmax
GLSM ratio was 84.5% (90% CI: 74.9% to 95.4%). This ~75% increase in TAF plasma 
exposure and ~15% decrease in TAF plasma Cmax when administered with food was 
accompanied by a delay in Tmax (increase from 1.00 hour under fasted conditions to 2.00 hours 
under fed conditions). The exposures of TAF observed under fed or fasted conditions in this 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 29
19 February 2016
study are within the range of exposures observed in the E/C/F/TAF clinical development 
program and are commensurate with safe and effective plasma levels of TAF (see investigator 
brochure for further details). Therefore, the changes in TAF exposures when F/TAF is 
administered with food should not result in differences in efficacy and thus are not clinically 
relevant. TAF can be administered without regard for food and these findings can be 
extrapolated to F/TAF (as FTC can be taken without regard to food). 
1.4.2.
Clinical Trials of FTC/TAF as part of 
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)
Clinical trials using tenofovir alafenamide, coformulated into the E/C/F/TAF STR include: 

GS-US-292-0101, a Phase 1 healthy volunteer study evaluating the relative bioavailability of 
EVG, FTC, TFV, and COBI administered as E/C/F/TAF STR relative to E/C/F/TDF or TAF
(completed)

GS-US-292-0103, a Phase 1 healthy volunteer study to evaluate the pharmacokinetics and 
relative bioavailability of the E/C/F/TAF STR relative to the individual components at 
GS-7340 doses of 10 mg (STR) or 25 mg Single Agent (SA) (completed)

GS-US-292-0102, a Phase 2 randomized, double-blinded study of the safety and efficacy of 
E/C/F/TAF STR versus E/C/F/TDF STR in HIV-1 infected, antiretroviral treatment-naive 
adults (ongoing)

GS-US-292-0104 and GS-US-292-0111, Phase 3 randomized, double-blinded study of the 
safety and efficacy of E/C/F/TAF STR versus E/C/F/TDF STR in HIV-1 infected, 
antiretroviral treatment-naive adults (ongoing)

GS-US-292-0109, a Phase 3 open-label study to evaluate switching from a TDF-containing 
combination regimen to a TAF-containing combination single tablet regimen (STR) in 
virologically-suppressed, HIV-1 positive subjects (ongoing)

GS-US-292-0112, a Phase 3 Open-label Safety Study of 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide single-tablet Regimen in HIV-1 
positive patients with mild to moderate renal impairment (ongoing)

GS-US-292-0117, a Phase 3, two-part study to evaluate the efficacy of Tenofovir 
Alafenamide versus placebo added to a failing regimen followed by treatment with 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 positive, 
antiretroviral treatment-experienced adults (ongoing)

GS-US-292-0119, a Phase 3 open-label study to evaluate switching from optimized stable 
antiretroviral regimens containing darunavir to 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) single tablet 
regimen (STR) plus darunavir (DRV) in treatment experienced HIV-1 positive adults
(ongoing)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 30
19 February 2016

GS-US-292-0106, a Phase 2/3, open-label study of the pharmacokinetics, safety, and 
antiviral activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 
(E/C/F/TAF) single tablet regimen (STR) in HIV-1 infected antiretroviral treatment-naive 
adolescents (ongoing)
Study GS-US-292-0101 is a Phase 1 study of 40 subjects evaluating the relative bioavailability 
of two different formulations of E/C/F/TAF STR, each with TAF dose of 25 mg or 40 mg, versus 
E/C/F/TDF STR or TAF 25 mg alone. Exposures of EVG, COBI, and FTC were comparable 
between E/C/F/TAF vs E/C/F/TDF regardless of formulation (monolayer or bi-layer). In 
contrast, TAF exposures were ~2.2-fold higher (and corresponding tenofovir exposures ~ 3-fold 
higher) when administered as E/C/F/TAF (25 mg) vs TAF single agent (SA) 25 mg for both 
formulations of the E/C/F/TAF, likely mediated by inhibition of P-gp-mediated intestinal
secretion of TAF by COBI.
Study GS-US-292-0103 is a completed Phase 1 healthy volunteer study which evaluated the PK
and relative bioavailability of the E/C/F/TAF STR relative to the individual components at TAF
doses of 10 (STR) or 25 mg SA. Results indicate that when dosed as the E/C/F/TAF 10 mg STR, 
TAF and TFV exposures were comparable to those observed with TAF 25 mg dosed alone. 
Exposures of EVG, COBI, and FTC were also comparable between the STR and individually 
dosed formulations. 
Study GS-US-292-0102 is an ongoing, randomized, active-controlled Phase 2 study, compares 
E/C/F/TAF (10 mg) versus Stribild® (STB, E/C/F/TDF) in treatment-naïve, HIV-1 infected 
subjects. At Week 48, the E/C/F/TAF demonstrated potent antiviral efficacy (HIV-1 RNA 
< 50 copies/mL) similar to STB (88.4% [99/112] vs 87.9% [51/58] using the snapshot 
algorithm); in the E/C/F/TAF group, no patient had emergent resistance to 1 or more components 
of the E/C/F/TAF. Importantly, E/C/F/TAF demonstrated a potential benefit over E/C/F/TDF in 
terms of renal and bone safety: smaller median decreases in eGFR (mL/min) (at Week 48, 
E/C/F/TAF -5.5 vs E/C/F/TDF -10.0 [P<0.001) and smaller median percentage decreases in 
BMD (at Week 48, spine E/C/F/TAF -1.00 vs E/C/F/TDF -3.37 [p<0.001], hip -0.62 
vs -2.39 [p<0.001]).
Studies GS-US-292-0104 and GS-US-292-0111 are ongoing, Phase 3 randomized, 
double-blinded studies of the safety and efficacy of E/C/F/TAF versus E/C/F/TDF in HIV-1 
infected, antiretroviral treatment-naive adults. The interim Week 48 key conclusions from pooled 
data showed that E/C/F/TAF once daily was noninferior to STB once daily when administered 
for 48 weeks to HIV-infected, ART-naive adults, as assessed using the US FDA-defined 
snapshot algorithm with HIV-1 RNA < 50 copies/mL (E/C/F/TAF 92.4%; STB 90.4%; 
difference in percentages: 2.0%, 95% CI: -0.7% to 4.7%). Administration of E/C/F/TAF resulted 
in > 90% lower plasma TFV and higher intracellular TFV-DP relative to STB.  E/C/F/TAF 
showed an improved renal and bone safety profile with significantly less decline in hip and spine 
BMD, less increase in serum creatinine and reduction in estimated glomerular filtration rate 
(eGFR).


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 31
19 February 2016
1.5.
Information about GS-9883/emtricitabine/tenofovir alafenamide 
(GS-9883/F/TAF)
Please refer to the GS-9883/F/TAF Investigator’s Brochure for further information.
1.5.1.
GS-US-141-1233: Relative Bioavailability of GS-9883, FTC, and TAF 
between GS-9883/F/TAF and GS-9883 + F/TAF
Study GS-US-141-1233 is an ongoing Phase 1, open-label, 2-cohort, multiple-period,
fixed-sequence, crossover study conducted at a single center in the US to evaluate 1) the relative 
bioavailability (BA) of 2 GS-9883/F/TAF (75/200/25 mg and 50/200/25 mg) FDC tablets 
compared with the GS-9883 (75 mg) tablet and the F/TAF (200/25 mg) FDC tablet administered 
simultaneously and 2) the effect of food on the PK of GS-9883, FTC, and TAF when 
administered as GS-9883/F/TAF (75/200/25 mg and 50/200/25 mg) FDC tablets. 
Cohort 1 evaluated the relative BA and food effect of GS-9883/F/TAF (75/200/25 mg) FDC 
tablet in a 3-period sequence. Following review of preliminary data from Cohort 1, Cohort 2 was 
added to the study via protocol amendment. Cohort 2  evaluated the relative BA and food effect 
of GS-9883/F/TAF (50/200/25 mg) FDC tablet in a 4-period sequence. 
The in-life portion of Cohorts 1 and 2 are complete.Preliminary results are summarized below.
Cohort 1 Results:

Pharmacokinetic Results

Under fasted conditions, GS-9883 AUCinf and Cmax were 27% and 31% higher, respectively, 
following GS-9883/F/TAF (75/200/25 mg) FDC administration than following 
administration of single-agent GS-9883 (75 mg ) with the F/TAF (200/25 mg) FDC. FTC and 
TAF exposure was similar following administration of GS-9883/F/TAF (75/200/25 mg) or 
single-agent GS-9883 (75 mg) with the F/TAF (200/25 mg) FDC. Compared with 
administration under fasted conditions, administration of the GS-9883/F/TAF 
(75/200/25 mg) FDC with a high-fat meal resulted in a 46% higher GS-9883 AUCinf and a 
27% higher GS-9883 Cmax. The impact of food on TAF and FTC exposure was similar to that 
previously observed for F/TAF (Study GS-US-311-1386). GS-9883/F/TAF may be taken 
without regard to food.  Based on these results, Cohort 2 was added to the study via protocol 
amendment to evaluate the relative BA of the GS-9883/F/TAF (50/200/25 mg) FDC tablet 
compared with the single-agent GS-9883 (75 mg) tablet and the F/TAF (200/25 mg) FDC 
tablet administered simultaneously.
Safety Results
Of the 28 subjects included in the Safety Analysis Set for Cohort 1, 12 subjects (43%) had at 
least 1 treatment-emergent AE. All treatment emergent AEs were assessed as Grade 1 or 2 in 
severity. No deaths or other SAEs occurred during this study, and no subject discontinued the 
study due to an AE.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 32
19 February 2016
Cohort 2 Results:
Pharmacokinetic Results
The PK results from Study GS-US-141-1233 demonstrated that the GS-9883 AUCinf and Cmax
following administration of the 50mg GS-9883 FDC tablets was 79% and 78%, respectively of 
those observed in the same study following co-administration of GS-9883 75 mg single agent 
with F/TAF (200/25 mg) under fasted conditions. The GS-9883 exposures of 50 and 75 mg fixed 
dose combination tablets were approximately dose proportional under fasted and fed conditions 
and a high fat and moderate fat meal had similar impact on GS-9883 with AUCinf increasing by 
24%. The steady state paIQ95 of GS-9883/F/TAF (50/200/25 mg) was predicted to be 
17 (fasted)-23 (fed). The exposures of TAF and FTC of the 50 mg GS-9883 FDC were similar 
to those of GS-9883 75 mg single agent with F/TAF FDC, and the food effect on TAF and FTC 
was similar to the historical results.  
Safety Results
Of the 28 subjects included in the Safety Analysis Set for Cohort 2, 12 subjects (43%) had at 
least 1 treatment-emergent AE. All treatment emergent AEs were assessed as Grade 1 or 2 in 
severity. No deaths or other SAEs occurred during this study, and no subject discontinued the 
study due to an AE. 
1.6.
Information about abacavir/dolutegravir/lamivudine (ABC/DTG/3TC 
Triumeq®)
For more detailed information, refer to the current Prescribing Information and local product 
labeling for abacavir/dolutegravir/lamivudine.
1.7.
Rationale for this Study
HIV standard of care has relied upon nucleos(t)ide backbones for effective and durable virologic 
suppression, but nucleos(t)ide-associated toxicities are increasingly important as HIV-infected 
patients are often diagnosed earlier, initiate therapy earlier, and look toward lifelong therapy 
(often greater than 50 years). Where patients have access to treatment, morbidity and mortality 
are driven by non–AIDS-associated comorbidities, which are observed earlier than in 
HIV-uninfected age-matched controls despite the best available ART. The contribution of 
specific nucleos(t)ides, including abacavir and tenofovir disoproxil fumarate, to long-term 
morbidity and mortality is increasingly important in this context.
The GS-9883/F/TAF FDC has the potential to offer a simple, once-daily regimen containing a 
second generation INSTI that provides a high barrier to resistance, does not require a boosting 
agent, and offers an effective and safer alternative to standard nucleos(t)ide based regimens, 
without the need for HLA testing or close monitoring of renal or bone toxicities. It could provide 
a FDC treatment that avoids the risk of hypersensitivity reactions, would not contribute to an 
increased risk of cardiovascular events; could be used in patients with chronic hepatitis B or C 
infection or renal impairment, and that could be continued as patients age and confront 
non-HIV-related comorbidities.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 33
19 February 2016
The objective of this study is to evaluate the efficacy of switching from a regimen of DTG and 
ABC/3TC or a Fixed dose combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF
versus continuing DTG and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed 
HIV-1 infected subjects as determined by the proportion of subjects with virologic failure 
(HIV-1 RNA ≥ 50 copies/mL) at Week 48. ABC/DTG/3TC was selected as the active 
comparator for this study as it is a second-generation integrase inhibitor-based, once-daily fixed 
dose combination, and is a DHHS Guidelines preferred regimen that includes the 3TC/ABC 
backbone. Use of ABC/DTG/3TC as a comparator in this study will therefore allow comparison
of two single tablet regiments containing second generation, unboosted INSTIs.
1.8.
Risk/Benefit Assessment for the Study
All patients with HIV-1 infection should receive effective antiretroviral therapy. Potential risks 
associated with all classes of ARVs include immune reconstitution syndrome, lipodystrophy, and 
lactic acidosis with steatosis.  The risk of class effects is considered to be low.  Important 
identified risks appropriately managed by study inclusion/exclusion criteria as well as through 
close clinical and laboratory monitoring during the study, are as follows: hypersensitivity 
reaction to abacavir and allergy to any components of the tablets.  Some observational studies 
have shown increased risk of cardiovascular disease with abacavir.  Interim data will also be 
reviewed by an independent data monitoring committee.  Potential benefits may include 
provision of a new antiretroviral therapy that is not currently available and which may have 
fewer side effects than alternative therapies.  Other potential benefits include provisions of fixed 
dose combination therapy, and the knowledge that patient participation will contribute to the 
body of knowledge of HIV therapies.
In a study of GS-9883 in monkeys, administration of 1000 mg/kg/day (highest dose) for 
39 weeks resulted in histologic findings of bile duct hyperplasia and hepatocyte hypertrophy.  No 
adverse effects were noted at the mid-dose group (200 mg/kg/day), which resulted in exposures 
of GS-9883 5.1 times higher than the expected human exposure with administration of 
GS-9883/F/TAF (50/200/25 mg) tablets. No such findings were seen in rats at any dose.  
However, the risk of liver or biliary abnormalities in humans receiving GS-9883/F/TAF 
(50/200/25 mg) for chronic use is unknown. Potential hepatobiliary toxicity is appropriately 
managed by study inclusion/exclusion criteria, close clinical and laboratory monitoring, as well 
as specific toxicity management guidance to investigators (Refer to Section 7.5.5). The overall 
benefit-risk assessment for GS-9883/F/TAF is favorable at this time.
The overall benefit-risk assessment for GS-9883/F/TAF is favorable at this time. 
1.9.
Rationale for Dose Selection
FTC
The 200 mg dose of FTC represents the marketed dose for this agent that is currently available as 
single agent capsules (EMTRIVA) and as a component of a number of fixed-dose combination 
tablets, including: TRUVADA, ATRIPLA, COMPLERA (EVIPLERA), and STRIBILD.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 34
19 February 2016
TAF
Based upon results of the Phase 1 Study GS-US-120-0104, in which various doses of TAF 
(8 mg, 25 mg, and 40 mg) were administered to HIV-infected subjects in 10 days of 
monotherapy, the range of exposure achieved with TAF 25 mg was chosen as the reference 
exposure. In this study, TAF 25 mg resulted in near-maximal antiviral activity and plasma TFV 
exposure > 90% lower relative to TDF.
The recommended dose of TAF is based on ensuring that patients have a TAF systemic exposure 
that is within the range of the reference exposure achieved with TAF 25 mg, or with TAF 10 mg 
when administered with the boosting agent COBI as E/C/F/TAF, for which an extensive safety 
and efficacy database exists. Specifically, TAF 25 mg is recommended with third agents that do 
not have a clinically relevant effect on TAF exposure. Study GS-US-141-1418 showed that 
GS-9883 does not have a clinically relevant effect on TAF exposure. Therefore, the dose of TAF 
25 mg is appropriate for the GS-9883/F/TAF FDC.
GS-9883
The dose of GS-9883 for Phase 2 was selected based upon data from Study GS-US-141-1219 
(Table 1-5), in which HIV-1-infected subjects were administered 5, 25, 50, or 100 mg doses of 
GS-9883 monotherapy under fasting conditions for 10 days.
Table 1-5.
GS-US-141-1219: Trough GS-9883 Plasma Concentrations at Steady 
State Following GS-9883 Administration Under Fasting Conditions 
and Corresponding Protein-Adjusted IQ95 Values
GS-9883 dose
n
Median (range) Ctau,SS (ng/mL)
Median (range) paIQ95
a
5 mg
4
206.5 (146.0 – 342.0)
1.3 (0.9 – 2.1)
25 mg
4
797.5 (714.0 – 1900.0)
4.9 (4.4 – 12)
50 mg
4
2170.0 (852.0 – 3020.0)
13 (5.3 – 19)
100 mg
4
4190.0 (3730.0 – 5970.0)
26 (23 – 37)
a
The paIQ95 value is estimated based on steady-state Ctau values and the in vitro paIC95 value for wild-type HIV-1 
(162 ng/mL).
Source: Data on File
Single-agent GS-9883 was well tolerated at all doses administered. The range of GS-9883 
plasma exposure at steady state (Ctau,SS) observed in the 50-mg cohort correlated with protein 
adjusted 95% inhibitory quotient (paIQ95) values ranging from 5.3 to 19, while the range of 
GS-9883 plasma exposure at steady state (Ctau,SS) observed in the 100-mg cohort correlated with 
paIQ95 values ranging from 23 to 37 (Table 1-5).
Based on PK/PD analyses, exposure following a 75-mg dose of single-agent GS-9883 is 
expected to provide near-maximal virologic response, with a predicted paIQ95 of approximately 
20, providing considerable coverage above the target concentration of 162 ng/mL (paIC95).
GS-9883 (75 mg) single agent coadministered with F/TAF (200/25 mg) is currently being 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 35
19 February 2016
evaluated in a Phase 2 study, GS-US-141-1475 (GS-9883+F/TAF vs DTG+F/TAF). The 
Week 24 data from this study support the safety and efficacy of GS-9883 exposures obtained 
with the 75 mg dose of the single agent.
GS-9883/F/TAF FDC Dose Selection
A fixed dose formulation of GS-9883/F/TAF was developed for use in Phase 3 studies. 
Preliminary results from the relative bioavailability (rBA) study (GS-US-141-1233) of 
GS-9883/F/TAF (75/200/25 mg) showed that GS-9883 plasma exposure was higher (with Cmax
and AUCinf increase of 31% and 27%, respectively) following administration of the FDC as 
compared with exposure following administration of GS-9883 (75 mg) + F/TAF (200/25 mg) 
under fasted conditions. The increase in GS-9883 exposures associated with the FDC 
formulation results in an estimated mean paIQ95 of 24.3, compared to an estimated mean paIQ95
of 19.2 for the GS-9883 (75 mg) single agent coadministered with F/TAF, in the fasted state.
In order to bridge exposures of GS-9883 in the FDC to the exposure observed with GS-9883 
75 mg administered as a single agent, and to bridge to the safe and effective exposures observed 
in the Phase 2 study GS-US-141-1475, a lower strength GS-9883/F/TAF FDC was developed for 
use in the Phase 3 studies. Comparability of GS-9883 exposures was confirmed in an rBA study 
of GS-9883/F/TAF (50/200/25 mg) and GS-9883 (75 mg) + F/TAF prior to initiation of dosing 
in the Phase 3 studies.
1.10.
Compliance
This study will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory requirements.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 36
19 February 2016
2.
OBJECTIVES
The primary objective of this study is:

To evaluate the efficacy of switching from a regimen of DTG and ABC/3TC or a fixed dose 
combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF versus continuing DTG 
and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed HIV-1 infected 
subjects as determined by the proportion of subjects with HIV-1 RNA ≥50 copies/mL at 
Week 48
The secondary objectives of this study are:

To evaluate the safety, and tolerability of the two treatment groups through Week 48

To evaluate the bone safety of the two treatment groups as determined by the percentage 
change from baseline in hip and spine bone mineral density (BMD) through Week 48


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 37
19 February 2016
3.
STUDY DESIGN
3.1.
Endpoints
The primary efficacy endpoint is:

The proportion of subjects with HIV-1 RNA ≥50 copies/mL at Week 48 as defined by the 
US FDA-defined snapshot algorithm.
The secondary endpoints of this study include:

The proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the 
US FDA-defined snapshot algorithm

The change from baseline in CD4+ cell count at Week 48

The percentage change from baseline in hip and spine BMD at Week 48
3.2.
Study Design
This protocol describes a randomized, double-blind, multicenter, active-controlled study to 
evaluate the safety and efficacy of switching to GS-9883/F/TAF FDC versus continuing 
DTG + ABC/3TC as the FDC ABC/DTG/3TC in HIV-1 infected subjects who are virologically 
suppressed (HIV-1 RNA < 50 copies/mL) on a stable regimen (of DTG + ABC/3TC or the FDC 
ABC/DTG/3TC) for ≥ 3 months prior to screening.
3.3.
Study Treatments
Subjects who provide written informed consent and meet all eligibility criteria will be 
randomized in a 1:1 ratio to one of the following two treatment groups:
Treatment Group 1: FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir alafenamide 
25 mg (GS-9883/F/TAF) + Placebo to match FDC of abacavir 600 mg/ dolutegravir 
50 mg/lamivudine 300 mg (ABC/DTG/3TC) administered orally, once daily, without regard to 
food (n=260)
Treatment Group 2: FDC of abacavir 600 mg/dolutegravir 50 mg/ lamivudine 300 mg 
(ABC/DTG/3TC) QD + Placebo to match FDC of GS-9883 50 mg/ emtricitabine 
200 mg/ tenofovir alafenamide 25 mg (GS-9883/F/TAF) administered orally, once daily, without 
regard to food (n=260)
3.4.
Duration of Treatment
Subjects will be treated for at least 48 weeks. Subjects’ treatments will be unblinded after the last 
subject completes the Week 48 visit and Gilead completes the Week 48 analysis. Subjects will 
continue to take their blinded study drug and attend visits every 12 weeks until treatment 


GS-9883/Fff AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
Final 
Amendment 1 
assignments have been unblinded. At the Unblinding Visit, subjects in a countiy where 
GS-9883/F/TAF FDC is not available will be given the option to receive GS-9883/F/TAF FDC 
in an open label extension phase for 48 weeks, or until the product becomes accessible to 
subjects through an access program, or until Gilead Sciences elects to discontinue the study in 
that countiy, whichever occurs first. 
Figure 3-1. 
Study Schema 
Day 1• 
Week4S•b 
Primary [ndpolnt 
lnblindiot-4 
Streeoing 
:S 30 tla>-s pnor 
to Oay l 
Treacmeot Arm 1: $\\-itch to FDC ofGS-9883 TIOTAF 
QD- Placebo to match FDCABODTG 3TC QD C\•260) ---
JfthyF11 
Trearm ent.~nn 2: FOCofABCDTG 3TC QD- Placebo ~ 
to match FDC ofGS-9883 TICT.<\f QD f.\•260) 
~ 
~ 
a. 
Following the Day 1 visit, subjects will be required to retum for study visits at Weeks 4, 8, 12, and then every 12 weeks 
through Week 48. 
b. 
After Week 48, subjects will continue to take their blinded study drug and attend visits every 12 weeks tmtil treatment 
assignments have been tmblinded. Subjects' treatments will be tmblinded after the last subject completes the Week 48 visit 
and Gilead completes the Week 48 analysis. 
c. 
Once Gilead Sciences provides unblinded treatment assignments to the Investigators, all subjects willretmn to the clinic 
(preferably within 30 days) for an Unblinding Visit. At the Unblinding Visit, subjects in a country where GS-9883/FffAF 
FDC is not available will be given the option to receive GS-9883/FffAF FDC in an open label extension for 48 weeks, or 
tmtil the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue 
the study in that cotmtly, whichever occurs ftrst. 
d. 
Subjects who complete the study through the Unblinding Visit and do not continue on the open-label GS-9883/F/TAF FDC 
extension phase will be required to retmn to the clinic 30 days after the completion of study dmgs for a 30-Day Follow-Up 
Visit. 
3.5. 
Biomarker Testing 
3.5.1. 
Biomarker Samples for Optional Pharmacogenomic Research 
PPD 
CONFIDENTIAL 
Page 38 
19 Febmary 2016 


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
3.5.2. 
Additional Sample Storage 
Final 
Amendment 1 
For subjects who provide additional consent, residual blood and urine samples taken throughout 
the study will be stored. Stored samples may be used by the Sponsor or its research partners to 
help answer questions about the study dmg, and HIV disease and its associated conditions, or to 
provide additional safety data. At the conclusion of this study, these samples may be retained in 
storage by Gilead Sciences for a period up to 15 years. 
CONFIDENTIAL 
Page 39 
19 Febmaty 2016 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 40
19 February 2016
4.
SUBJECT POPULATION
4.1.
Number of Subjects and Subject Selection
Approximately 520 subjects who meet the eligibility criteria will be enrolled.
4.2.
Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study.
1) The ability to understand and sign a written informed consent form, which must be obtained 
prior to initiation of study procedures
2) Age 18 years
3) Currently receiving an antiretroviral regimen of DTG + ABC/3TC, or ABC/DTG/3TC FDC
for ≥ 3 months prior to the screening visit
4) HIV RNA < 50 copies/mL at the screening visit
5) Normal ECG (or if abnormal, determined by the Investigator to be not clinically significant)
6) Adequate renal function:
Estimated glomerular filtration rate ≥50 mL/min (≥0.83 mL/sec) according to the 
Cockcroft-Gault formula {Cockcroft et al 1976}:
a) Male:
(140 – age in years) (wt in kg) CLcr (mL/min)
72 (serum creatinine in mg/dL)
        (140 – age in years) (wt in kg)          CLcr (mL/sec)
72 (serum creatinine in umol/L) 0.6786
b) Female:
(140 – age in years) (wt in kg) 0.85 CLcr (mL/min)
72 (serum creatinine in mg/dL)
        (140 – age in years) (wt in kg)           0.85 CLcr (mL/sec)
72 (serum creatinine in umol/L) 0. 6786
7) Hepatic transaminases (AST and ALT) 5 upper limit of normal (ULN)
8) Total bilirubin 1.5 mg/dL (26 umol/L), or normal direct bilirubin
9) Adequate hematologic function (absolute neutrophil count ≥750/mm3 (≥ 0.75 GI/L); 
platelets ≥50,000/mm3 (≥50 GI/L); hemoglobin ≥ 8.5 g/dL (≥85 g/L))
10) Serum amylase ≤ 5 × ULN (subjects with serum amylase > 5 × ULN will remain eligible if 
serum lipase is ≤5 × ULN)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 41
19 February 2016
11) Females of childbearing potential must agree to utilize protocol recommended highly 
effective contraceptive methods or be non-heterosexually active or practice sexual abstinence 
(as defined in Appendix 6) from screening, throughout the duration of the study period, and 
for 30 days following the last dose of study drug.
a) Female subjects who utilize hormonal contraceptive as one of their birth control methods 
must have used the same method for at least 3 months prior to study drug dosing.
12) Male subjects who engage in heterosexual intercourse must agree to use protocol specified 
method(s) of contraception (as described in Appendix 6) throughout the study period and for 
90 days following the last dose of study drug.
13) Male subjects must agree to refrain from sperm donation from first study drug dose until at 
least 90 days following the last study drug dose
14) Life expectancy ≥ 1 year
15) Currently on a stable regimen for ≥ 3 months preceding the screening visit  with documented 
plasma HIV-1 RNA < 50 copies/mL for ≥ 3 months preceding the Screening visit (or 
undetectable HIV-1 RNA level according to the local assay being used if the limit of 
detection is ≥50 copies/mL).
Prior changes in antiretroviral regimen are only allowed due to tolerability issues or for 
regimen simplification. Unconfirmed virologic elevations of ≥ 50 copies/mL (transient 
detectable viremia, or “blip”) prior to screening are acceptable. If the lower limit of detection 
of the local HIV-1 RNA assay is <50 copies/mL (eg, <20 copies/mL), the plasma HIV-1 
RNA level cannot exceed 50 copies/mL on two consecutive HIV-1 RNA tests.
16) Have no documented or suspected resistance to FTC, TFV, DTG, ABC or 3TC including, but 
not limited, to the reverse transcriptase resistance mutations K65R and M184V/I
4.3.
Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study.
1) An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to 
screening (refer to Appendix 5)
2) Subjects experiencing decompensated cirrhosis (e.g, ascites, encephalopathy, or variceal 
bleeding)
3) Have been treated with immunosuppressant therapies or chemotherapeutic agents within 
3 months of study screening, or expected to receive these agents or systemic steroids during 
the study (e.g, corticosteroids, immunoglobulins, and other immune- or cytokine-based 
therapies)
4) Current alcohol or substance use judged by the Investigator to potentially interfere with 
subject study compliance


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 42
19 February 2016
5) A history of or ongoing malignancy (including untreated carcinoma in-situ) other than 
cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous 
squamous carcinoma. Subjects with biopsy-confirmed cutaneous KS are eligible, but must 
not have received any systemic therapy for KS within 30 days of Day 1 and are not 
anticipated to require systemic therapy during the study
6) Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or 
antifungal therapy within 30 days prior to Day 1
7) Participation in any other clinical trial, including observational studies,  without prior 
approval from the sponsor is prohibited while participating in this trial
8) Any other clinical condition or prior therapy that, in the opinion of the Investigator, would 
make the subject unsuitable for the study or unable to comply with the dosing requirements
9) Any known allergies to the excipients of GS-9883/F/TAF FDC or ABC/DTG/3TC FDC 
tablets
10) Females who are pregnant (as confirmed by positive serum pregnancy test)
11) Females who are breastfeeding
12) Subjects receiving ongoing therapy with any of the following medications in the table below, 
including drugs not to be used with FTC, TAF, GS-9883, DTG, ABC and 3TC
Drug Class
Agents Disallowed*
Antiarrhythmic Agent
Dofetilide
Anticonvulsants
Phenobarbital, Phenytoin, Carbamazepine, Oxcarbazepine
Antimycobacterials
Rifampin, Rifapentine
Antiretrovirals
Any antiretroviral drug that is not part of the study regimen
GI Motility Agents
Cisapride
Herbal/Natural Supplements
St. John’s Wort, Echinacea
*
Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the
duration of the study.
13) Acute hepatitis in the 30 days prior to study entry
14) Chronic Hepatitis B Virus (HBV) infection, as determined by either: 
a) Positive HBV surface antigen and negative HBV surface antibody, regardless of HBV 
core antibody status, at the screening visit
b) Positive HBV core antibody and negative HBV surface antibody, regardless of HBV 
surface antigen status, at the screening visit
15) Active tuberculosis infection


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 43
19 February 2016
5.
INVESTIGATIONAL MEDICINAL PRODUCTS
5.1.
Randomization, Blinding and Treatment Codes
Subjects will be assigned a screening number at the time of consent. Randomization and Day 1 
visits cannot occur until subject eligibility has been confirmed.
Once eligibility has been confirmed and prior to or during the Day 1, visit the Investigator or 
designee will randomize the subject using the Interactive Web Response System (IWRS). Once a 
subject number has been assigned to a subject, it will not be reassigned to any other subject. The 
subject number assignment and randomization may be performed up to 3 days prior to the 
in-clinic Day 1 visit provided that all screening procedures have been completed and subject 
eligibility has been confirmed.
Subjects will be randomized in a 1:1 ratio to Treatment Group 1 or Treatment Group 2.
The IWRS will assign study drug bottle numbers of blinded FDC of GS-9883/F/TAF + Placebo 
to match FDC of ABC/DTG/3TC, or FDC of ABC/DTG/3TC + Placebo to match FDC of 
GS-9883/F/TAF at each study visit for each subject. 
5.1.1.
Procedures for Breaking Treatment Codes
In the event of a medical emergency where breaking the blind is required to provide medical care 
to the subject, the investigator may obtain treatment assignment directly from the IWRS system 
for that subject. Gilead strongly recommends but does not require that the investigator contact 
the Gilead medical monitor before breaking the blind. Treatment assignment should remain 
blinded unless that knowledge is necessary to determine subject emergency medical care. The 
rationale for unblinding must be clearly explained in source documentation and on the electronic 
case report form (eCRF), along with the date on which the treatment assignment was 
obtained. The investigator is requested to contact the Gilead medical monitor promptly in case of 
any treatment unblinding.
Blinding of study treatment is critical to the integrity of this clinical trial and therefore, if a 
subject’s treatment assignment is disclosed to the investigator, the subject will have study 
treatment discontinued. All subjects will be followed until study completion unless consent to do 
so is specifically withdrawn by the subject.
Gilead Drug Safety and Public Health (DSPH) may independently unblind cases for expedited 
reporting of suspected unexpected serious adverse reactions (SUSARs).


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 44
19 February 2016
5.2.
Description and Handling
5.2.1.
Formulation
5.2.1.1.
GS-9883/Emtricitabine/Tenofovir alafenamide (GS-9883/F/TAF) 
50 mg/200 mg/25 mg and Placebo to Match Tablets
GS-9883 50 mg/Emtricitabine 200 mg/Tenofovir alafenamide 25 mg tablets are capsule-shaped, 
film-coated purplish-brown, debossed with "GSI" on one side of the tablet and "9883" on the 
other side of the tablet. Each tablet core contains 50 mg of GS-9883, 200 mg of emtricitabine, 
and 25 mg of tenofovir alafenamide. In addition to the active ingredients, the GS-9883/F/TAF
tablets contain croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The 
tablet cores are film-coated with iron oxide red, iron oxide black, polyethylene glycol, polyvinyl 
alcohol, talc, and titanium dioxide.
The placebo to match (PTM) GS-9883/F/TAF tablets are capsule-shaped, film-coated 
purplish-brown, debossed with "GSI" on one side of the tablet and "9883" on the other side and 
are identical in physical appearance to GS-9883/F/TAF tablets. The placebo tablets contain 
microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and magnesium stearate. 
The tablet cores are film-coated with iron oxide red, iron oxide black, polyethylene glycol, 
polyvinyl alcohol, talc, and titanium dioxide.
5.2.1.2.
Abacavir/Dolutegravir/Lamivudine (ABC/DTG/3TC Triumeq®) 
600 mg/50 mg/300 mg and Placebo to Match Tablets
Abacavir 600 mg/Dolutegravir 50 mg/Lamivudine 300 mg tablets are oval, film coated purple, 
and debossed with “572 Tri” on one side. Each tablet core contains 600 mg of abacavir, 50 mg of 
dolutegravir, and 300 mg of lamivudine. In addition to the active ingredients, the 
ABC/DTG/3TC tablets contain the inactive ingredients D-mannitol, magnesium stearate, 
microcrystalline cellulose, povidone, and sodium starch glycolate. The tablet cores are film 
coated with iron oxide black, iron oxide red, polyethylene glycol, polyvinyl alcohol, talc, and 
titanium oxide.
The PTM ABC/DTG/3TC tablets are oval, film coated purple, and debossed with “572 Tri” on 
one side. The placebo tablets are identical in physical appearance to ABC/DTG/3TC tablets. The 
placebo tablets contain microcrystalline cellulose, lactose monohydrate, croscarmellose sodium 
and magnesium stearate.  The tablet cores are film-coated with iron oxide black, iron oxide red, 
polyethylene glycol, polyvinyl alcohol, talc, and titanium oxide.
5.2.2.
Packaging and Labeling
5.2.2.1.
GS-9883/Emtricitabine/Tenofovir alafenamide (GS-9883/F/TAF) 
50 mg/200 mg/25 mg and Placebo to Match Tablets
GS-9883/F/TAF tablets and PTM GS-9883/F/TAF tablets are packaged in white, high density 
polyethylene (HDPE) bottles. Each bottle contains 30 tablets, silica gel desiccant and polyester 
packing material.  Each bottle is enclosed with a white, continuous thread, child-resistant 
polypropylene screw cap with an induction-sealed and aluminum-faced liner.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 45
19 February 2016
Study drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the US FDA, EU Guideline to Good Manufacturing 
Practice - Annex 13 (Investigational Medicinal Products), and/or other local regulations
5.2.2.2.
Abacavir/Dolutegravir/Lamivudine (ABC/DTG/3TC Triumeq®) 
600 mg/50 mg/300 mg and Placebo to Match Tablets
ABC/DTG/3TC tablets and PTM ABC/DTG/3TC tablets are packaged in white, high density 
polyethylene (HDPE) bottles. Each bottle contains 30 tablets and silica gel desiccant. Each bottle 
is enclosed with a white, continuous thread, child-resistant polypropylene screw cap with an 
induction-sealed and aluminum-faced liner.
Study drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the US FDA, EU Guideline to Good Manufacturing 
Practice - Annex 13 (Investigational Medicinal Products), and/or other local regulations.
5.2.3.
Storage and Handling
Study drug GS-9883/F/TAF FDC, ABC/DTG/3TC FDC and placebo-to-match tablets for both 
FDCs should be stored at controlled room temperature of 25°C (77°F); excursions are permitted 
between 15°C and 30°C (59°F and 86°F). Storage conditions are specified on the label. Until 
dispensed to the subjects, all bottles of study drugs should be stored in a securely locked area, 
accessible only to authorized site personnel.
To ensure the stability and proper identification, study drug(s) should not be stored in a container 
other than the container in which they were supplied.
Consideration should be given to handling, preparation, and disposal through measures that 
minimize drug contact with the body. Appropriate precautions should be followed to avoid direct 
eye contact or exposure through inhalation when handling.
5.3.
Dosage and Administration of GS-9883/Emtricitabine/Tenofovir alafenamide 
and Abacavir/Dolutegravir/Lamivudine
Study drug GS-9883/F/TAF FDC, ABC/DTG/3TC FDC and placebo-to-match tablets for both 
FDCs will be provided by Gilead Sciences.
Treatment Group 1: FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir alafenamide 
25 mg (GS-9883/F/TAF) + Placebo to match FDC of abacavir 600 mg/ dolutegravir 
50 mg/lamivudine 300 mg (ABC/DTG/3TC) administered orally, once daily, without regard to 
food
Treatment Group 2: FDC of abacavir 600 mg/dolutegravir 50 mg/ lamivudine 300 mg 
(ABC/DTG/3TC) + Placebo to match FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir 
alafenamide 25 mg (GS-9883/F/TAF) administered orally, once daily, without regard to food


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 46
19 February 2016
Subjects will be instructed to bring all study medication in the original container at each clinic 
visit for drug accountability. The Investigator will be responsible for maintaining accurate 
records for all study drug bottles dispensed and tablets returned. The inventory and dispensing 
logs must be available for inspection by the study monitor. Study medication supplies, including 
partially used or empty bottles, must be accounted for by the study monitor prior to destruction 
or return.
5.4.
Prior and Concomitant Medications

The use of medications for the treatment of HIV, other than study drug, is prohibited.

Medications listed in the following table and use of herbal/natural supplements are excluded 
or should be used with caution while subjects are participating in the study.  Subjects will 
refrain from consumption of grapefruit juice and Seville orange juice throughout 
participation in the study.
Table 5-1.
Prior and Concomitant Medications
Drug Class
Agents Disallowed*
Use Discouraged and To Be Used With 
Caution
Acid Reducing Agents
Antacids
Buffered medications 
Concentration of study drug may decrease 
with antacids. Subjects may not take antacids 
(eg, Tums or Rolaids); the ulcer medication 
sucralfate (Carafate); or vitamin or mineral 
supplements that contain calcium, iron or 
zinc for a minimum of 2 hours before and 
6 hours after any dose of study drug.
Antiarrhythmic Agent
Dofetilide
Anticonvulsants
Phenobarbital, Phenytoin, 
Carbamazepine, Oxcarbazepine
Antimycobacterials
Rifampin, Rifapentine
Antiretrovirals
Any antiretroviral drug that is not 
part of the study regimen
GI Motility Agents
Cisapride
Herbal/Natural Supplements
St. John’s Wort, Echinacea
Oral Hypoglycemic Agent
Metformin: close monitoring is 
recommended. A dose adjustment of 
Metformin may be necessary. Limit total 
daily doses of Metformin to 1000mg when 
initiating study medication or if initiating 
metformin while on study drug.
*
Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the 
duration of the study. 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 47
19 February 2016
Should subjects have a need to initiate treatment with any excluded concomitant medication, the 
Gilead Sciences Medical Monitor must be consulted prior to initiation of the new medication. In 
instances where an excluded medication is initiated prior to discussion with the Sponsor, the 
Investigator must notify Gilead Sciences as soon as he/she is aware of the use of the excluded 
medication.
5.5.
Accountability for Investigational Medicinal Product (IMP)
The investigator is responsible for ensuring adequate accountability of all used and unused IMP.
This includes acknowledgement of receipt of each shipment of IMP (quantity and condition). All 
used and unused IMP dispensed to subjects must be returned to the site.
Study Drug accountability records will be provided to each study site to:

Record the date received and quantity of IMP kits

Record the date, subject number, subject initials, the IMP kit number dispensed

Record the date, quantity of used and unused IMP returned, along with the initials of the 
person recording the information
5.5.1.
Investigational Medicinal Product Return or Disposal
Study drug return and disposal will be performed as outlined in Section 9.1.7.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 48
19 February 2016
6.
STUDY PROCEDURES
The study procedures to be conducted for each subject enrolled in the study are presented in 
tabular form in Appendix 2 and described in the text that follows.
The investigator must document any deviation from protocol procedures and notify the sponsor 
or contract research organization (CRO).
6.1.
Subject Enrollment and Treatment Assignment
It is the responsibility of the Investigator to ensure that subjects are eligible for study prior to 
enrollment. Please refer to Section 6.2.2 for details about randomization and treatment 
assignment.
6.2.
Pretreatment Assessments
6.2.1.
Screening Visit
Subjects will be screened within 30-days before Day 1 to determine eligibility for participation in 
the study. The following will be performed and documented at screening:

Obtain written informed consent

Obtain medical history including history of HIV-1 disease-related events, smoking history
and prior medications within 30 days of the screening visit

Complete physical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)

12-lead ECG performed supine

Height

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

Urine collection for the following laboratory procedures:
Urinalysis

Blood sample collection for the following laboratory analyses:
Serum pregnancy test (females of childbearing potential only). If the test is positive, the 
subject will not be enrolled


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 49
19 February 2016
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, 
amylase (reflex lipase testing is performed in subjects with total amylase 1.5 ULN) 
and TSH.
Estimated glomerular filtration rate according to the Cockcroft-Gault formula:
■
Male:
(140 – age in years) (wt in kg) CLcr (mL/min)
72 (serum creatinine in mg/dL)
          (140 – age in years) (wt in kg)        CLcr (mL/sec)
72 (serum creatinine in umol/L) 0.6786
■
Female:
(140 – age in years) (wt in kg) 0.85 CLcr (mL/min)
72 (serum creatinine in mg/dL)
          (140 – age in years) (wt in kg)        0.85 CLcr (mL/sec)
72 (serum creatinine in umol/L) 0. 6786
Hematology profile: complete blood count (CBC) with differential and platelet count
CD4+ cell count
Plasma HIV-1 RNA
Hepatitis B virus surface antigen serology (HBsAg)
Hepatitis B surface antibody (HBsAb)
Hepatitis B virus core antibody (HBcAb)
Hepatitis C virus (HCVAb) serology. Subjects who are HCVAb positive will have a 
HCV RNA test performed.

Review of adverse events and concomitant medications
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within 30-days after screening for Day 1 Visit into the study. Subjects must continue to 
take their prior treatment regimen up until their scheduled Day 1 visit.
From the time of obtaining informed consent through the first administration of investigational 
medicinal product, record all serious adverse events (SAEs), as well as any adverse events 
related to protocol-mandated procedures on the adverse events case report form (eCRF). All 
other untoward medical occurrences observed during the screening period, including 
exacerbation or changes in medical history are to be captured on the medical history eCRF. See 
Section 7 Adverse Events and Toxicity Management for additional details.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 50
19 February 2016
6.2.2.
Day 1 Assessments
The following evaluations are to be completed at the Day 1 Visit. The Investigator must have 
confirmed eligibility before proceeding with the Day 1 visit. The subject must complete all 
study procedures, except DXA, before being administered the study drug:

DXA Scan (spine and hip). For subjects in Germany, DXA scans will not be performed.
The DXA scan will be performed on subjects once eligibility is confirmed. The scan may 
be performed prior to or within 24 hours of the Day 1 Visit.

Review of AEs and changes in concomitant medications

Complete physical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

12-lead ECG performed supine

Short Form 36 Health Survey (SF-36), HIV Symptoms Distress Module, Work Productivity 
and Activity Impairment Questionnaire (WPAI) and Pittsburgh Sleep Quality Index (PSQI) 
to be completed by the subject.  Subject is to read questionnaire by himself/herself and 
write/mark answers directly onto questionnaires.

Urine collection for the following laboratory procedures:
Urinalysis
Urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2
microglobulin
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test. If the test is positive, the subject will not be 
able to participate
Urine storage sample for possible additional clinical testing

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, phosphorus, magnesium, potassium, sodium, uric acid, and amylase 
(reflex lipase testing is performed in subjects with total amylase 1.5 ULN) and TSH


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
Final 
Amendment 1 
-
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 homs prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and 
triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the 
subject must retum within 72 homs in a fasted state to draw blood for the metabolic 
assessments. 
-
Estimated glomemlar filtration rate according to the Cockcroft-Gault f01mula 
-
Hematology profile: complete blood cmmt (CBC) with differential and platelet cmmt 
-
Plasma HIV-1 RNA 
-
CD4+ cell count 
-
Evaluations of inflammation and immlme activation, may include but not limited to 
cystatin C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163 
-
Evaluations of platelet function, may include but not limited to soluble glycoprotein VI 
(sGPVI), P-selectin, and soluble CD40 ligand. 
-
Plasma storage sample for safety, virology, or PK testing 
-
Whole blood sample for potential HIV DNA genotyping 
• 
Optional blood sample collection for the following laboratory analyses if 
pharmacogenomics consent is obtained 
I 
I 
I 
I 
6.3. 
Randomization 
Once eligibility has been confinned and prior to or dming the Day 1 visit, the Investigator or 
designee will randomize the subject using the Interactive Web Response System (IWRS). Once a 
subject number has been assigned to a subject, it will not be reassigned to any other subject. The 
subject number assignment and randomization may be perf01med up to 3 days prior to the 
in-clinic Day 1 visit provided that all screening procedmes have been completed and subject 
eligibility has been confi1med. 
CONFIDENTIAL 
Page 51 
19 Febmaty 2016 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 52
19 February 2016
6.4.
Treatment Assessments (Week 4 - 48)
The following evaluations are to be completed at the end of Weeks 4, 8, 12, 24, 36, and 48 unless 
otherwise specified.
Study visits are to be completed within ± 2 days of the protocol-specified visit date based on the 
Day 1 visit through Week 12 and completed within ± 6 days of the protocol-specified visit date 
through Week 36, unless otherwise specified.  The visit window at Week 48 will be ± 6 weeks of 
the protocol-specified visit date, and these clinical visit windows coincide with the Week 48 
statistical analysis window for HIV-1 RNA.
Regularly scheduled evaluations will be made on all subjects whether or not they continue to 
receive study drug.

Review of AEs and changes in concomitant medications

DXA scans (spine and hip) for all subjects who are on study drug (Weeks 24 and 48 
±10 days). For subjects in Germany, DXA scans will not be performed.

Complete physical examination (Weeks 24 and 48) (urogenital/anorectal exams will be 
performed at the discretion of the Investigator) or symptom-directed physical examination as 
needed

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

12-lead ECG performed supine (Weeks 24 and 48)

Short Form 36 Health Survey (SF-36), HIV Symptoms Distress Module, Work Productivity 
and Activity Impairment Questionnaire (WPAI) and Pittsburgh Sleep Quality Index (PSQI) 
to be completed by the subject at Weeks 4, 12 and 48. Subject is to read questionnaire by 
himself/herself and write/mark answers directly onto questionnaires.

Urine collection for the following laboratory procedures:
Urinalysis
Urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2
microglobulin. (Weeks 24 and 48)
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test. If the test is positive, the subject will be 
discontinued
Urine storage sample for possible additional clinical testing


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 53
19 February 2016

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium,
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amylase 1.5 ULN). 
At Weeks 12, 24 and 48, analyses of glucose will be done as part of the fasting metabolic 
assessments and not as part of the chemistry profile. At Weeks 24 and 48, TSH will also 
be analyzed.
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and 
triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments. (Weeks 12, 24, and 48)
Estimated glomerular filtration rate according to the Cockcroft-Gault formula
Hematology profile: complete blood count (CBC) with differential and platelet count
Plasma HIV-1 RNA
CD4+ cell count
Evaluations of inflammation and immune activation, may include but not limited to 
cystatin C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163 (Weeks 24 and 48)
Evaluations of platelet function, may include but not limited to soluble glycoprotein VI 
(sGPVI), P-selectin, and soluble CD40 ligand (Weeks 24 and 48)
Plasma storage sample for safety, virology, or PK testing

Pharmacokinetic Blood Collection for subjects who are on study drug. Details of 
pharmacokinetic blood sampling procedures and sample management will be documented in 
the Pharmacokinetic Sample Collection, Processing, Storage, and Shipment Manual.
Single Anytime, Trough and Post Dose PK Sample for all Subjects on Study Drug:
■
Subjects will have a single anytime pre or post-dose PK blood sample at Weeks 8, 24 
and 36.
■
Observed dosing at the clinic: Subjects will have a trough PK blood sample collected 
between 20-28 hours following their last dose at Weeks 4 and 12. Subjects must be 
instructed to not take their study drugs on the morning of their visit for the trough 
sample collection.   Subjects will then take an observed dose of study drug at the 
clinic.  A single post dose PK blood sample will be collected between 1 and 4 hours 


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
Final 
Amendment 1 
post dose. If the subject has taken their dose of study dmgs prior to the visit, the visit 
may proceed, but the subject must retum within 72 homs for the trough PK blood 
sample collection. In the event a subject routinely takes their study dmg in the 
evening, a single post dose sample may be drawn at Weeks 4 and 12 as the subject 
will not be instmcted to change their dosing time to accommodate this trough PK 
draw. 
• 
Dosing diaries will be collected from subjects for the single anytime PK and trough 
PK collection. If a dosing diruy is not retumed the site may ask the subject for the 
time of the last dose and if it was taken with or without food. 
-
Optional Pharmacokinetic (PK) Substudy: 
I 
I 
I 
6.5. 
6.5.1. 
Treatment Assessments (Post Week 48 until the Unblinding Visit) 
Post Week 48 Assessments 
After Week 48, subjects will continue to take their blinded study dmgs and attend visits evety 
12 weeks until treatment assignments have been unblinded, at which point they will retum for an 
Unblinding Visit (refer to Section 6.5.2) Study visits ru·e to be completed within± 6 days of the 
protocol-specified visit date unless othetw ise specified. 
• 
Review of AEs and changes in concomitant medications 
• 
Symptom-directed physical examination as needed 
CONFIDENTIAL 
Page 54 
19 Febmaty 2016 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 55
19 February 2016

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

Urine collection for the following laboratory procedures:
Urinalysis 
Urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2
microglobulin. (Every 24 weeks)
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test. If the test is positive, the subject will be 
discontinued.
Urine storage sample for possible additional clinical testing

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amylase 1.5 ULN). 
Every 24 weeks, analyses of glucose will be done as part of the fasting metabolic 
assessments and not as part of the chemistry profile. In addition, TSH will also be 
analyzed every 24 weeks.
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and 
triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments. (Every 24 weeks)
Estimated glomerular filtration rate according to the Cockcroft-Gault formula
Hematology profile: complete blood count (CBC) with differential and platelet count
Plasma HIV-1 RNA
CD4+ cell count
Evaluations of inflammation and immune activation, including but not limited to cystatin
C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163 (Every 24 weeks)
Evaluations of platelet function, may include but not limited to soluble glycoprotein VI 
(sGPVI), P-selectin, and soluble CD40 ligand (Every 24 weeks)
Plasma storage sample for safety, virology, or PK testing


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 56
19 February 2016

Document study drug dispensation and accountability for all study drugs dispensed.

Subjects who meet the criteria for virologic failure will be managed according to the 
Management of Virologic Rebound Section 6.13.1. and 6.13.2
6.5.2.
Unblinding Visit
Once Gilead Sciences provides unblinded treatment assignments to the Investigators, all subjects 
will return to the clinic (within 30 days ± 6 days) for an Unblinding Visit. At the Unblinding 
Visit, subjects in a country where GS-9883/F/TAF FDC is not available will be given the option 
to receive GS-9883/F/TAF FDC in an open label extension phase for 48 weeks, or until the 
product becomes accessible to subjects through an access program, or until Gilead Sciences 
elects to discontinue the study in that country, whichever occurs first.
Subjects who receive the open-label GS-9883/F/TAF FDC will return for study visits every 
12 weeks.
Subjects who choose to not receive the open label GS-9883/F/TAF FDC will be required to 
return to the clinic for a 30-Day Follow-up visit following the Unblinding Visit. Subjects who 
have discontinued drug study prior to the Unblinding Visit will not be eligible for the open-label 
rollover extension; these subjects will be asked to continue attending the scheduled study visits 
through the Unblinding Visit and discontinue the study after the Unblinding Visit.
The following will be performed at the Unblinding Visit:

Review of AEs and changes in concomitant medications

DXA scans (spine and hip) for all subjects who are on study drug (±10 days). For subjects in 
Germany, DXA scans will not be performed.

Complete physical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

12-lead ECG performed supine

Urine collection for the following laboratory procedures:
Urinalysis
Uurine albumin, urine creatinine, urine protein, retinol binding protein and beta-2
microglobulin.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 57
19 February 2016
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test. If the test is positive, the subject will not be 
able to participate.
Urine storage sample for possible additional clinical testing

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, phosphorus, magnesium, potassium, sodium, uric acid, and amylase 
(reflex lipase testing is performed in subjects with total amylase 1.5 ULN), and TSH
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and 
triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments
Estimated glomerular filtration rate according to the Cockcroft-Gault formula
Hematology profile: complete blood count (CBC) with differential and platelet count
Plasma HIV-1 RNA
CD4+ cell count
Evaluations of inflammation and immune activation, may include but not limited to 
cystatin C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163
Evaluations of platelet function, may include but not limited to soluble glycoprotein VI 
(sGPVI), P-selectin, and soluble CD40 ligand
Plasma storage sample for safety, virology, or PK testing

Document study drug dispensation, if applicable, and accountability for all study drugs 
dispensed

Subjects who wish to continue in the Open-Label Rollover extension study will receive open 
label GS-9883/F/TAF.
6.6.
Post-treatment Assessments
6.6.1.
Early Study Drugs Discontinuation Assessments
If the subject discontinues study drug prior to the Unblinding Visit, the subject will be asked to 
return to the clinic within 72 hours of stopping study drugs for the Early Study Drugs 
Discontinuation Visit. The subject will be asked to continue attending the scheduled study visits 
through the Unblinding Visit.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 58
19 February 2016
At the Early Study Drugs Discontinuation Visit, any evaluations showing abnormal results 
indicating that there is a possible or probable causal relationship with the study drug, will
be repeated weekly (or as often as deemed prudent by the Investigator) until the 
abnormality is resolved, returns to Day 1, or is otherwise explained.
The following evaluations are to be completed at the Early Study Drugs Discontinuation Visit:

Review of AEs and changes in concomitant medications

DXA scan required (spine and hip) for all subjects who are on study drug (±10 days) if last 
scan was acquired > 12 weeks from the date of the ESDD Visit. For subjects in Germany, 
DXA scans will not be performed.

Complete physical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)

12-lead ECG performed supine

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

Urine collection for the following laboratory procedures:
Urinalysis
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test
Urine storage sample for possible additional clinical testing

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amylase 1.5 ULN), 
and TSH
Estimated glomerular filtration rate according to the Cockcroft-Gault formula
Hematology profile: complete blood count (CBC) with differential and platelet count
Plasma HIV-1 RNA
CD4+ cell count
Plasma storage sample for safety, virology, or PK testing
HIV-1 genotype/phenotype testing for subjects with  virologic failure

Drug accountability


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 59
19 February 2016
6.6.2.
30 Day Follow Up
Subjects who complete the study through the Unblinding visit and who do not wish to participate 
in the open-label rollover extension, will be required to return to the clinic 30 days after the 
completion of study drug for the 30 Day Follow Up visit.
Subjects who permanently discontinue study drug during the blinded phase and refuse to 
continue in the study through the Unblinding Visit will be asked to return to the clinic 30 days 
after the completion of the Early Study Drugs Discontinuation Visit for the 30-Day Follow-Up 
Visit.
Those subjects who permanently discontinue study drug and continue in the study through 
at least one subsequent visit after the Early Study Drug Discontinuation Visit will not be 
required to complete the 30-Day Follow-Up Visit.
For the purpose of scheduling a 30-Day Follow-Up Visit, a 6 days window may be used. 
The following evaluations are to be completed at the 30-Day Follow-Up Visit:

Review of AEs and changes in concomitant medications

Symptom-directed physical examination

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

Urine collection for the following laboratory procedures:
Urinalysis
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test.

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amylase 1.5 ULN).
Estimated glomerular filtration rate according to the Cockcroft-Gault formula
Hematology profile: complete blood count (CBC) with differential and platelet count
Plasma HIV-1 RNA
CD4+ cell count


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 60
19 February 2016
At the 30-Day Follow-Up Visit, any evaluations showing abnormal results believed to be a 
reasonable possibility of a causal relationship with the study drugs will be repeated weekly (or as 
often as deemed prudent by the Investigator) until the abnormality is resolved, returns to 
baseline, or is otherwise explained. 
6.7.
Criteria for Discontinuation of Study Treatment
Study medication will be discontinued in the following instances:

Unacceptable toxicity, or toxicity that, in the judgment of the investigator, compromises the 
ability to continue study-specific procedures or is considered to not be in the subject’s best 
interest

Subject request to discontinue for any reason

Pregnancy during the study; refer to Appendix 6

Development of active tuberculosis infection
Study medication may be discontinued in the following instances:

Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree. Following resolution of intercurrent illness, the subject 
may resume study dosing at the discretion of the investigator

Lack of efficacy

Subject noncompliance

Discontinuation of the study at the request of Gilead, a regulatory agency or an institutional 
review board or independent ethics committee (IRB/IEC)
6.8.
Bone Mineral Density Evaluations
For all subjects who are on study drug, excluding those enrolled in sites based in Germany, dual 
energy x-ray absorptiometry (DXA) scans will be performed prior to or within 24 hours of 
Day 1, Weeks 24, 48, Unblinding Visit and the Early Study Drug Discontinuation Visit (if the 
last scan was acquired > 12 weeks from the date of the ESDD Visit).  Scans will cover the spine 
and hip to measure changes in bone mineral density. DXA scan results will be provided to study 
sites.
A complete description of the procedures performed for the DXA scans will be provided in a 
DXA manual.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 61
19 February 2016
6.9.
Other Evaluations
6.9.1.
Markers of Renal Tubular Function
For all subjects, urine will be collected for selected evaluations of renal tubular function, which 
will include urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2
microglobulin at Day 1 Visit, Weeks 24, 48, every 24 weeks post Week 48 and the Unblinding 
Visit.
6.9.2.
Markers of Inflammation and Immune Activation
For all subjects, blood will be collected at Day 1 Visit, Weeks 24, 48, every 24 weeks post 
Week 48 and the Unblinding Visit for selected evaluations of inflammation and immune 
activation, which may include but not limited to cystatin C, IL 6, hs CRP, d-dimer, sCD14, and 
sCD163.
6.9.3.
Markers of Platelet Function
For all subjects, blood will be collected at Day 1 Visit, Weeks 24, 48, every 24 weeks post 
Week 48 and the Unblinding Visit for selected evaluations of platelet function, which may 
include but not limited to soluble glycoprotein VI (sGPVI), P-selectin, and soluble CD40 ligand
6.9.4.
Blood and Urine Storage
A portion of the blood and urine samples drawn at all visits (except the Screening Visit, 30-day 
follow-up Visit and Unscheduled Visits) will be frozen and stored. These stored blood and urine 
samples may be used by the Sponsor or its research partners for HIV-1 genotyping/phenotyping 
assays or their development, for retesting the amount of HIV-1 in the blood, for measurement of 
antiviral drug levels in the blood, or for testing to learn more about how the study drug has 
worked against HIV-1 or clinical laboratory testing to provide additional safety data. No human 
genetic testing will be performed without expressed consent of study subjects. At the conclusion 
of this study, these samples may be retained in storage by Gilead Sciences for a period up to 
15 years.
6.10.
Assessments for Premature Discontinuation from Study
If a subject discontinues study dosing (for example, as a result of an AE), every attempt should 
be made to keep the subject in the study and continue to perform the required study-related 
follow-up and procedures (see Section 6.7, Criteria for Discontinuation of Study Treatment). If 
this is not possible or acceptable to the subject or investigator, the subject may be withdrawn 
from the study.
6.11.
End of Study
The end of study will be the last patient’s last observation (or visit).


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 62
19 February 2016
6.12.
Post Study Care
After a subject has completed/terminated their participation in the study, long-term care for the
subject will remain the responsibility of their primary treating physician.
6.13.
Virologic Failure
Virologic failure is defined as virologic rebound or having HIV-1 RNA ≥50 copies/mL at study
drug discontinuation, or Week 48.
6.13.1.
Management of Virologic Rebound
Subjects who meet the criteria listed below will be considered to have virologic rebound:

At any post Day 1 visit, a rebound in HIV-1 RNA ≥50 copies/mL, which is subsequently 
confirmed at the following scheduled or unscheduled visit; OR

Any subject with HIV RNA ≥ 50 copies/mL at study drug discontinuation
Following the unconfirmed virologic rebound, subjects will be asked to return to the clinic for a 
scheduled or unscheduled blood draw (2 to 3 weeks after the date of the original test that resulted 
in HIV-1 RNA virologic rebound) for confirmation of virologic rebound. If virologic rebound is 
confirmed at the scheduled or unscheduled visit and the HIV-1 RNA is ≥200 copies/mL, the 
blood sample from the confirmation visit will be the primary sample used for HIV-1 genotypic 
and phenotypic testing.  Subjects with documented non-adherence within 72 hours of the visit 
may not be tested for resistance. After a subject’s first post-baseline resistance test, additional 
testing will be conducted on a case-by-case basis.     Any subject may be discontinued at 
Investigator’s discretion or per local treatment guidelines.
If no resistance is detected from the genotype or phenotype, the subject may remain on study 
drugs and HIV-1 RNA test should be repeated (2 to 3 weeks after date of test with HIV-1 RNA 
≥50 copies/mL). Investigators should carefully evaluate the benefits and risks of remaining on 
study drug for each individual subject and document this assessment in the on-site medical 
record.
Subjects who are noncompliant on an ongoing basis will be considered for discontinuation per 
the Investigator’s discretion or local treatment guidelines. Investigators who opt to discontinue 
study drugs for an individual subject must discuss with the Medical Monitor prior to study drug 
discontinuation.
For subjects who are off study drug but remain on study, it will be the Investigator’s discretion to 
manage virologic rebound.
Please refer to Figure 6-1 for the management of subjects who meet the criteria for virologic 
rebound.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 63
19 February 2016
Figure 6-1.
Virologic Rebound Schema
a.
If virologic rebound is not confirmed, the subject will remain on their current regimen.
b.
If virologic rebound is confirmed and the HIV-1 RNA is ≥200 copies/mL, the HIV-1 genotype and phenotype (reverse 
transcriptase, protease and integrase) will be analyzed.
c.
Based on the results of the genotypic and phenotypic assays, the subject will remain on study drugs or study drugs will be 
discontinued. If genotyping or phenotyping fails, a new ARV regimen may be configured at the discretion of the 
Investigator.
d.
If no resistance is detected, HIV-1 RNA will be repeated (2-3 weeks later).  Investigator reviews study drug 
continuation/discontinuation options and discusses with the Medical Monitor prior to study drug discontinuation
e.
A new ARV regimen will be configured, at the Investigator’s discretion, and the subject will remain in the study.
6.13.2.
Subjects with HIV-1 RNA ≥50 copies/mL at Study Drug Discontinuation, or 
Week 48
Subjects with HIV-1 RNA ≥50 copies/mL at study drug discontinuation or last visit will be 
considered virologic failures. Subjects with HIV-1 RNA ≥50 copies/mL at Week 48 will be 
asked to return for an unscheduled visit within the visit window for a retest. 
Subjects with HIV-1 RNA ≥200 copies/mL at study drug discontinuation, last visit or Week 48, 
will also have resistance testing conducted. 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 64
19 February 2016
7.
ADVERSE EVENTS AND TOXICITY MANAGEMENT
7.1.
Definitions of Adverse Events, Adverse Reactions, and Serious Adverse 
Events
7.1.1.
Adverse Events
An adverse event (AE) is any untoward medical occurrence in a clinical study subject 
administered a medicinal product, which does not necessarily have a causal relationship with the 
treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease 
temporally associated with the use of a medicinal product, whether or not considered related to 
the medicinal product. AEs may also include pre- or post-treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or 
occupational exposure. Preexisting events that increase in severity or change in nature during or 
as a consequence of participation in the clinical study will also be considered AEs.
An AE does not include the following:

Medical or surgical procedures such as surgery, endoscopy, tooth extraction, and transfusion. 
The condition that led to the procedure may be an adverse event and must be reported.

Pre-existing diseases, conditions, or laboratory abnormalities present or detected before the 
screening visit that do not worsen

Situations where an untoward medical occurrence has not occurred (e.g., hospitalization for 
elective surgery, social and/or convenience admissions)

Overdose without clinical sequelae (see Section 7.6.1)

Any medical condition or clinically significant laboratory abnormality with an onset date 
before the consent form is signed and not related to a protocol-associated procedure is not an 
AE. It is considered to be pre-existing and should be documented on the medical history 
eCRF.
7.1.2.
Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at any dose, results in the following:

Death

Life-threatening (Note: The term “life-threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that hypothetically might have caused death if it were more severe.)

In-patient hospitalization or prolongation of existing hospitalization


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 65
19 February 2016

Persistent or significant disability/incapacity

A congenital anomaly/birth defect

A medically important event or reaction: such events may not be immediately 
life-threatening or result in death or hospitalization but may jeopardize the subject or may 
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; and development of drug dependency or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medically important event and subject to expedited reporting 
requirements.
7.1.3.
Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory abnormalities (eg, clinical chemistry, hematology, and urinalysis) that 
require medical or surgical intervention or lead to IMP interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. In addition, 
laboratory or other abnormal assessments (eg, electrocardiogram, x-rays, vital signs) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they meet the 
definition of an AE or SAE as described in Sections 7.1.1 and 7.1.2. If the laboratory 
abnormality is part of a syndrome, record the syndrome or diagnosis (eg, anemia), not the 
laboratory result (ie, decreased hemoglobin).
For specific information on handling of clinical laboratory abnormalities in this study, please 
refer to Section 7.5.
7.2.
Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality and severity, and for final review and confirmation of accuracy of event information 
and assessments.
7.2.1.
Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing the relationship to IMP
therapy using clinical judgment and the following considerations:

No: Evidence exists that the adverse event has an etiology other than the IMP. For SAEs, an 
alternative causality must be provided (eg, pre-existing condition, underlying disease, 
intercurrent illness, or concomitant medication).

Yes: There is reasonable possibility that the event may have been caused by the 
investigational medicinal product.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 66
19 February 2016
It should be emphasized that ineffective treatment should not be considered as causally related in 
the context of adverse event reporting.
The relationship to study procedures (eg, invasive procedures such as venipuncture or biopsy) 
should be assessed using the following considerations:

No: Evidence exists that the adverse event has an etiology other than the study procedure.

Yes: The adverse event occurred as a result of protocol procedures, (eg, venipuncture)
7.2.2.
Assessment of Severity
AE severity should be recorded and graded according to the GSI Grading Scale for Severity of 
Adverse Events and Laboratory Abnormalities (Appendix 4). For adverse events associated with 
laboratory abnormalities, the event should be graded on the basis of the clinical severity in the 
context of the underlying conditions; this may or may not be in agreement with the grading of 
the laboratory abnormality.
The distinction between the seriousness and the severity of an adverse event should be noted. 
Severe is a measure of intensity; thus, a severe reaction is not necessarily a serious reaction. For 
example, a headache may be severe in intensity, but would not be classified as serious unless it 
met one of the criteria for serious events.
For AEs associated with laboratory abnormalities, the event should be graded on the basis of the 
clinical severity in the context of the underlying conditions; this may or may not be in agreement 
with the grading of the laboratory abnormality.
7.3.
Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead
Requirements for collection prior to study drug initiation:
After informed consent, but prior to initiation of study medication, the following types of events 
should be reported on the eCRF:

all SAEs and adverse events related to protocol-mandated procedures.
7.3.1.
Adverse Events
Following initiation of study medication, collect all AEs, regardless of cause or relationship, 
until 30-days after last administration of study IMP must be reported to the eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Sciences may request that certain AEs be followed beyond the protocol defined follow up 
period.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 67
19 February 2016
7.3.2.
Serious Adverse Events
All SAEs, regardless of cause or relationship, that occurs after the subject first consents to 
participate in the study (i.e, signing the informed consent) and throughout the duration of the 
study, including the protocol-required post treatment follow-up period, must be reported to the 
eCRF database and Gilead Drug Safety and Public Health (DSPH) as instructed. This also 
includes any SAEs resulting from protocol-associated procedures performed after informed 
consent is signed.
Any SAEs and deaths that occur after the post treatment follow-up visit but within 30-days of the 
last dose of study IMP, regardless of causality, should also be reported.
Investigators are not obligated to actively seek SAEs after the protocol defined follow up period; 
however, if the investigator learns of any SAEs that occur after study participation has concluded 
and the event is deemed relevant to the use of IMP, he/she should promptly document and report 
the event to Gilead DSPH.
Electronic Serious Adverse Event (eSAE) Reporting Process

Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.

If for any reason it is not possible to record the SAE information electronically, ie, the eCRF 
database is not functioning, record the SAE on the paper serious adverse event reporting 
form and submit within 24 hours to:
Gilead DSPH contact 
information:
Email: Safety_FC@gilead.com
Fax: +1 (650) 522-5477

As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.

If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.

All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline.

Additional information may be requested to ensure the timely completion of accurate safety 
reports.

Any medications necessary for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s eCRF and the event description section of the SAE form


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 68
19 February 2016

For fatal or life-threatening events, copies of hospital case reports, autopsy reports, and other 
documents are also to be submitted by e-mail or fax only when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability of a document to the subject identifiers.
7.4.
Gilead Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country-specific legislation or regulations, Gilead may be required to expedite to 
worldwide regulatory agencies reports of SAEs, serious adverse drug reactions (SADRs), or 
suspected unexpected serious adverse reactions (SUSARs). In accordance with the EU Clinical 
Trials Directive (2001/20/EC), Gilead or a specified designee will notify worldwide regulatory 
agencies and the relevant IEC in concerned Member States of applicable SUSARs as outlined in 
current regulations.
Assessment of expectedness for SAEs will be determined by Gilead using reference safety 
information specified in the investigator’s brochure or relevant local label as applicable.
All investigators will receive a safety letter notifying them of relevant SUSAR reports associated 
with any study IMP. The investigator should notify the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required by local regulatory agencies, and in accordance with the local 
institutional policy.
7.5.
Toxicity Management
All clinical and clinically significant laboratory toxicities will be managed according to uniform 
guidelines detailed in Appendix 3 as outlined below.

Clinical events and clinically significant laboratory abnormalities will be graded according to 
the GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities 
(Appendix 4

Grade 3 and 4 clinically significant laboratory abnormalities should be confirmed by repeat 
testing within 3 calendar days of receipt of results and before investigational medicinal 
product discontinuation, unless such a delay is not consistent with good medical practice

Any questions regarding toxicity management should be directed to the Gilead Medical 
Monitor.
7.5.1.
Grades 1 and 2 Laboratory Abnormality or Clinical Event
Continue study drug at the discretion of the Investigator.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 69
19 February 2016
7.5.2.
Grade 3 Laboratory Abnormality or Clinical Event

For Grade 3 clinically significant laboratory abnormality or clinical event, investigational 
medicinal product may be continued if the event is considered to be unrelated t 
investigational medicinal product.

For a Grade 3 clinical event, or clinically significant laboratory abnormality confirmed by 
repeat testing, that is considered to be related to investigational medicinal product, 
investigational medicinal product will be withheld until the toxicity returns to Grade 2.
When restarting investigational medicinal product following resolution of the adverse event, 
the investigational medicinal product should be restarted at full dose upon discussion with 
the Gilead Sciences Medical Monitor.

If a laboratory abnormality recurs to Grade 3 following rechallenge with investigational 
medicinal product and is considered related to investigational medicinal product, then 
investigational medicinal product will be permanently discontinued and the subject managed 
according to local practice. Recurrence of laboratory abnormalities considered unrelated to 
investigational medicinal product may not require permanent discontinuation but requires 
discussion with the Gilead Sciences Medical Monitor.
7.5.3.
Grade 4 Laboratory Abnormality or Clinical Event

For a Grade 4 clinical event or clinically significant Grade 4 laboratory abnormality 
confirmed by repeat testing that is considered related to investigational medicinal product, 
investigational medicinal product will be permanently discontinued and the subject managed 
according to local practice. The subject should be followed as clinically indicated until the 
laboratory abnormality returns to baseline or is otherwise explained, whichever occurs first. 
A clinically significant Grade 4 laboratory abnormality that is not confirmed by repeat testing 
should be managed according to the algorithm for the new toxicity grade.

Investigational medicinal product may be continued without dose interruption for a clinically 
non-significant Grade 4 laboratory abnormality (eg, Grade 4 CK after strenuous exercise, or 
triglyceride elevation that is nonfasting or that can be medically managed) or a clinical event 
considered unrelated to investigational medicinal product requires discussion with the 
Gilead Sciences Medical Monitor.
7.5.4.
Management of Possible Abacavir Hypersensitivity Reaction
Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to increased 
risk of hypersensitivity reaction, unless no other therapeutic option is available based on the 
treatment history and resistance testing.
In a clinical study, 3.4 % of subjects with a negative HLA-B*5701 status receiving abacavir 
developed a hypersensitivity reaction. Therefore, even in the absence of HLA-B*5701 allele, it is 
important to permanently discontinue abacavir and not rechallenge with abacavir if a 
hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe 
or even fatal reaction.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 70
19 February 2016
Hypersensitivity reactions are characterized by the appearance of symptoms indicating 
multi-organ system involvement. Almost all hypersensitivity reactions will have fever and/or 
rash as part of the syndrome. Other signs and symptoms may include respiratory signs and 
symptoms such as dyspnoea, sore throat, cough, and abnormal chest x-ray findings 
(predominantly infiltrates, which can be localized), gastrointestinal symptoms, such as nausea, 
vomiting, diarrhea, or abdominal pain, and may lead to misdiagnosis of hypersensitivity as 
respiratory disease (pneumonia, bronchitis, pharyngitis), or gastroenteritis. Other frequently 
observed signs or symptoms of the hypersensitivity reaction may include lethargy or malaise and 
musculoskeletal symptoms (myalgia, rarely myolysis, arthralgia). The symptoms related to this
hypersensitivity reaction worsen with continued therapy and can be life- threatening. 
These symptoms usually resolve upon discontinuation of abacavir.
Hypersensitivity reaction symptoms usually appear within the first six weeks of initiation of 
treatment with abacavir, although these reactions may occur at any time during therapy. Patients 
should be monitored closely, especially during the first two months of treatment with abacavir.
Regardless of their HLA-B*5701 status, patients who are diagnosed with a hypersensitivity 
reaction whilst on therapy MUST discontinue study drug immediately and MUST NEVER be 
restarted. Restarting study drug following a hypersensitivity reaction results in a prompt return of 
symptoms within hours. This recurrence is usually more severe than on initial presentation, and 
may include life-threatening hypotension and death. To avoid a delay in diagnosis and minimize 
the risk of a life-threatening hypersensitivity reaction, study drug must be permanently 
discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible 
(respiratory diseases, flu-like illness, gastroenteritis or reactions to other medicinal products) 
{Ezzati et al 2003}.
7.5.5.
Management of Potential Hepatobiliary Toxicity
Monkeys given a high dose (1000 mg/kg/day) for 39 weeks had evidence of biliary hyperplasia 
and hepatocyte hypertrophy on histopathologic examination. The risk to humans given the 
clinical dose of GS-9883 (50 mg/day) is unknown. Investigators should be aware of this potential 
toxicity. Any study subject exhibiting signs/symptoms or laboratory abnormalities suggestive of 
possible hepatobiliary toxicity should undergo thorough examination and clinical workup as 
deemed appropriate by the Investigator, and the Investigator must communicate promptly with 
the Gilead Medical Monitor. Consideration should be given to appropriate imaging studies (for 
example, ultrasound of the liver and biliary tree) and potential consultation with a 
gastroenterologist with specialty training in hepatobiliary diseases. Management of graded 
laboratory and clinical abnormalities will be managed as outlined in Section 7.5.
7.5.6.
On-Treatment Hepatitis C Management
If a subject tests positive for HCV RNA at screening or develops signs or symptoms of active 
Hepatitis C virus Gilead recommends that local medical practice is followed at the discretion of 
the Investigator. Investigational medicinal product may be continued without dose 
interruption. Should the Investigator decide to initiate Hepatitis C treatment the Investigator 
must contact the Gilead Medical Monitor to confirm that no drug-drug interactions are expected.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 71
19 February 2016
Subjects should return to the clinic for scheduled or unscheduled follow up visit(s) according to 
local medical practice for laboratory evaluations. If Hepatitis C treatment is initiated, 
Investigators should use the Gilead provided retest laboratory kits to manage the active 
Hepatitis C.
7.6.
Special Situations Reports
7.6.1.
Definitions of Special Situations
Special situation reports include all reports of medication error, abuse, misuse, overdose, reports 
of adverse events associated with product complaints, and pregnancy reports regardless of an 
associated AE.  
Medication error is any unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by a 
subject.
Misuse is defined as any intentional and inappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing information.
An overdose is defined as an accidental or intentional administration of a quantity of a medicinal 
product given per administration or cumulatively which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the daily dose of the subject in 
question). In cases of a discrepancy in drug accountability, overdose will be established only 
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.
7.6.2.
Instructions for Reporting Special Situations
7.6.2.1.
Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study subjects that are identified after 
initiation of study medication and throughout the study, including the post study drug follow-up 
period, to the Gilead DSPH using the pregnancy report form within 24 hours of becoming aware 
of the pregnancy. 
Refer to below and the eCRF completion guidelines for full instructions on the mechanism of 
pregnancy reporting.
The pregnancy itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy without medical reasons.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 72
19 February 2016
Any premature termination of pregnancy (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported within 24 hours as an 
SAE. The underlying medical reason for this procedure should be recorded as the AE term.
A spontaneous abortion is always considered to be an SAE and will be reported as described in 
Section 7.3. Furthermore, any SAE occurring as an adverse pregnancy outcome post study must 
be reported to Gilead DSPH.
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy. The outcome should be reported to Gilead DSPH using the pregnancy outcome report 
form. If the end of the pregnancy occurs after the study has been completed, the outcome should 
be reported directly to Gilead DSPH. Gilead DSPH contact information is as follows:
Email: Safety_FC@gilead.com and Fax: +1 (650) 522-5477.
Pregnancies of female partners of male study subjects exposed to Gilead or other study drugs 
must also be reported and relevant information should be submitted to Gilead DSPH using the 
pregnancy and pregnancy outcome forms within 24 hours. Monitoring of the subject should 
continue until the conclusion of the pregnancy. If the end of the pregnancy occurs after the study 
has been completed, the outcome should be reported directly to Gilead DSPH, fax number 
+1 650 522-5477 or email Safety_FC@gilead.com.
Refer to Appendix 6 for Pregnancy Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
7.6.2.2.
Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to Gilead DSPH within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that involve study IMP and/or Gilead concomitant 
medications, but do not apply to non-Gilead concomitant medications.
Special situations involving non-Gilead concomitant medications does not need to be reported on 
the special situations report form; however, for special situations that result in AEs due to a 
non-Gilead concomitant medication, the AE should be reported on the AE form. 
Any inappropriate use of concomitant medications prohibited by this protocol should not be 
reported as “misuse,” but may be more appropriately documented as a protocol deviation.
Refer to Section 7.3 and the eCRF completion guidelines for full instructions on the mechanism 
of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the symptoms and 
signs, clinical management, and outcome will be reported, when available.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 73
19 February 2016
8.
STATISTICAL CONSIDERATIONS
8.1.
Analysis Objectives and Endpoints
8.1.1.
Analysis Objectives
The primary objective of this study is:

To evaluate the efficacy of switching from a regimen of DTG and ABC/3TC or a FDC of 
ABC/DTG/3TC to a FDC of GS-9883/F/TAF versus continuing DTG and ABC/3TC as the 
FDC ABC/DTG/3TC in virologically suppressed HIV-1 infected subjects as determined by 
the proportion of subjects with HIV-1 RNA ≥50 copies/mL at Week 48
The secondary objectives of this study are:

To evaluate the safety, and tolerability of the two treatment groups through Week 48

To evaluate the bone safety of the two treatment groups as determined by the percentage 
change from baseline in hip and spine BMD through Week 48
8.1.2.
Primary Endpoint
The primary efficacy endpoint is the proportion of subjects with HIV-1 RNA ≥50 copies/mL at 
Week 48 as defined by the US FDA-defined snapshot algorithm.
8.1.3.
Secondary Endpoint
Secondary endpoints include:

The proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the 
US FDA-defined snapshot algorithm

The change from baseline in CD4+ cell count at Week 48

The percentage change from baseline in hip and spine BMD at Week 48
8.2.
Analysis Conventions
8.2.1.
Analysis Sets
8.2.1.1.
All Randomized
The randomized analysis set includes all subjects who are randomized into the study. This is the 
primary analysis set for by-subject listings.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 74
19 February 2016
8.2.1.2.
Efficacy
8.2.1.2.1.
Full Analysis Set (FAS)
The primary analysis set for efficacy analyses is defined as full analysis set (FAS), which will 
include all subjects who (1) are randomized into the study and (2) have received at least 1 dose 
of study drug. Subjects will be grouped according to the treatment to which they were 
randomized.
8.2.1.2.2.
Per-Protocol (PP) Analysis Set
The secondary analysis set for efficacy analyses is defined as per-protocol (PP) analysis set, 
which will include all subjects who (1) are randomized into the study, (2) have received at least 
1 dose of study drug, and (3) have not committed any major protocol violation, including the 
violation of key entry criteria. Subjects will be grouped according to the treatment they actually 
received.
Subjects meeting any of the following criteria will be excluded from the Week 48 PP analysis
set:

Subjects who do not have on-treatment HIV-1 RNA in the Week 48 analysis window, except 
when missing is due to discontinuation of study drug for lack of efficacy.

Subjects who meet the exclusion criterion for receiving ongoing therapy with any of the 
medications listed in the table in protocol Section 4.3 including drugs not to be used with 
GS-9883, FTC, TAF, ABC, 3TC, and DTG.

Nonadherence to study drug: subjects with adherence rate for active study drug up to the 
Week 48 Visit below the 2.5th percentile
8.2.1.3.
Safety
The primary analysis set for safety analyses is defined as safety analysis set, which will include 
all subjects who (1) are randomized into the study and (2) have received at least 1 dose of study 
drug. All the data collected up to 30 days after subjects permanently discontinue their study drug 
will be included in the safety summaries, unless specified otherwise. Subjects will be grouped 
according to the treatment they actually received.
8.2.1.4.
Pharmacokinetics
8.2.1.4.1.
Pharmacokinetic (PK) Substudy Analysis Set
The primary analysis set for intensive PK analyses is defined as the PK substudy analysis set, 
which will include all subjects who (1) are randomized into the study, (2) enrolled into the PK 
Substudy, (3) have received at least 1 dose of study drug, and (4) have at least 1 nonmissing 
intensive PK concentration data for the analyte under evaluation reported by the PK lab.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 75
19 February 2016
8.2.1.4.2.
Pharmacokinetic (PK) Analysis Set
The primary analysis set for general PK analyses is defined as the PK analysis set, which will 
include all subjects who (1) are randomized into the study, (2) have received at least 1 dose of 
study drug, and (3) have at least 1 nonmissing PK concentration data for the analyte under 
evaluation reported by the PK lab.
8.2.1.5.
DXA
8.2.1.5.1.
Hip DXA Analysis Set
The primary analysis set for hip BMD analyses is defined as the Hip DXA analysis set, which
will include all subjects who (1) are randomized into the study, (2) have received at least 1 dose 
of study drug, and (3) have nonmissing baseline hip BMD value. Subjects will be grouped 
according to the treatment they actually received.
8.2.1.5.2.
Spine DXA Analysis Set
The primary analysis set for spine BMD analyses is defined as the Spine DXA analysis set, 
which will include all subjects who (1) are randomized into the study, (2) have received at least 
1 dose of study drug, and (3) have nonmissing baseline spine BMD value. Subjects will be 
grouped according to the treatment they actually received.
8.3.
Data Handling Conventions
HIV-1 RNA results of ‘No HIV-1 RNA detected’ and “<20 cp/mL HIV-1 RNA Detected” will 
be imputed as 19 copies/mL for analysis purpose.
Natural logarithmic transformation of plasma concentrations and PK parameters will be applied 
for PK analysis.
Laboratory data that are continuous in nature but are less than the lower limit of quantitation or 
above the upper limit of quantitation will be imputed to the value of the lower or upper limit plus 
or minus one significant digit, respectively (eg, if the result of a continuous laboratory test is 
< 20, a value of 19 will be assigned).
Missing data can have an impact upon the interpretation of the trial data. In general, values for 
missing data will not be imputed. However, a missing pre-treatment laboratory result would be 
treated as normal (ie, no toxicity grade) for the laboratory abnormality summary.
All available data for subjects that do not complete the study will be included in data listings.
8.4.
Demographic Data and Baseline Characteristics
Demographic and baseline characteristics will be summarized using standard descriptive 
methods including sample size, mean, SD, median, Q1, Q3, minimum, and maximum for 
continuous variables and frequency and percentages for categorical variables.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 76
19 February 2016
Demographic data will include sex, race, ethnicity, and age.
Baseline characteristics will include body weight, height, body mass index, eGFR, HIV-1 
infection, and enrollment distribution will be summarized.
For categorical demographic and baseline characteristics, the Cochran–Mantel–Haenszel (CMH)
test will be used to compare treatment groups. For continuous demographic and baseline 
characteristics, the Wilcoxon rank sum test will be used to compare treatment groups.
8.5.
Efficacy Analysis
8.5.1.
Primary Analysis
The primary efficacy endpoint is the proportion of subjects with HIV-1 RNA ≥50 copies/mL at 
Week 48 as defined by the US FDA-defined snapshot algorithm. The primary analysis of the 
efficacy will be based on the FAS.
8.5.1.1.
US FDA-defined Snapshot Algorithm
The analysis window at Week 48 is defined as from Study Day 295 to Study Day 378, inclusive. 
All HIV-1 RNA data collected on-treatment (ie, including data collected up to 1 day after the last 
dose date of study drug) will be used in the snapshot algorithm. Virologic outcome will be 
defined as the following categories:

HIV-1 RNA < 50 copies/mL: this includes subjects who have the last available on-treatment 
HIV-1 RNA < 50 copies/mL in the Week 48 analysis window 

HIV-1 RNA ≥50 copies/mL: this include subjects
a) Who have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 
analysis window, or
b) Who do not have on-treatment HIV-1 RNA data in the Week 48 analysis window and
1) Who discontinue study drug prior to or in the Week 48 analysis window due to lack 
of efficacy, or
2) Who discontinue study drug prior to or in the Week 48 analysis window due to reason 
other than lack of efficacy and have the last available on-treatment HIV-1 RNA 
≥50 copies/mL


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 77
19 February 2016

No Virologic Data in the Week 48 Analysis Window: this includes subjects who do not 
have on-treatment HIV-1 RNA data in the Week 48 analysis window because of the 
following:
a) Discontinuation of study drug prior to or in the Week 48 analysis window due to reasons
other than lack of efficacy and the last available on-treatment HIV-1 RNA 
< 50 copies/mL, or
b) Missing data during the window but on study drug
8.5.1.2.
Analysis of Primary Efficacy Endpoint
The null hypothesis is that the proportion of subjects with HIV-1 RNA ≥50 copies/mL at 
Week 48 in the GS-9883/F/TAF group is at least 4% higher than that in the ABC/DTG/3TC 
group; the alternative hypothesis is that the proportion of subjects with HIV-1 RNA 
≥50 copies/mL in the GS-9883/F/TAF group is less than 4% higher than that in the 
ABC/DTG/3TC group.
Non-inferiority will be assessed using the conventional confidence interval (CI) approach. The 
point estimate of treatment difference (GS-9883/F/TAF – ABC/DTG/3TC) and the associated 
2-sided 95% CI will be constructed based on the exact method.
It will be concluded that GS-9883/F/TAF is non-inferior to ABC/3TC/DTG if the upper bound of 
the 2-sided 95% CI of the difference between treatment groups 
(GS-9883/F/TAF - ABC/3TC/DTG) in the percentage of subjects with HIV-1 RNA 
≥50 copies/mL is less than 4%.
If non-inferiority of GS-9883/F/TAF to ABC/DTG/3TC is established, the upper bound of the 
95% CI will be compared to 0; if the upper bound of the 95% CI is less than 0, superiority of 
GS-9883/F/TAF over ABC/DTG/3TC will be established.
8.5.2.
Secondary Analyses
The proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the US 
FDA-defined snapshot algorithm will also be evaluated. The 95% CIs will be constructed in the 
same manner as for the primary efficacy endpoint. However, non-inferiority will be assessed 
using a margin of 10%. It will be concluded that GS-9883/F/TAF is non- inferior to 
ABC/DTG/3TC if the lower bound of the 2-sided 95% CI of the difference between treatment 
groups (GS-9883/F/TAF – ABC/DTG/3TC) in the response rate is greater than -10%.
The changes from baseline in CD4+ cell count at Weeks 48 will be summarized by treatment 
using descriptive statistics. The differences in changes from baseline in CD4+ cell count between 
the 2 treatment groups and the associated 95% CIs will be constructed using ANOVA models, 
including treatment (GS-9883/F/TAF vs. ABC/DTG/3TC) as a fixed effect in the model.
In addition, missing CD4+ cell count will be imputed using Last Observation Carried Forward 
(LOCF) method and analyzed similarly.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 78
19 February 2016
8.6.
Safety Analysis
All safety analyses will be performed using the safety analysis set.
All safety data collected on or after the date that the study drug was first administered up to the 
date of the last dose of study drug plus 30 days, unless specified otherwise, will be summarized 
for subjects in the safety analysis set according to the study drug received.
Data for the pretreatment period and the period post the date of last dose of study drug plus 
30 days will be included in data listings for all enrolled subjects.
8.6.1.
Extent of Exposure
A subject’s extent of exposure to study drug will be generated from the study drug
administration page in eCRF. Exposure data will be summarized by treatment.
Duration of exposure to study drug will be expressed as the number of weeks between the first 
and last dose of the study drug, inclusive, regardless of temporary interruptions in study drug
administration and summarized by treatment.
Dosing information for individual subjects will be listed.
8.6.2.
Adverse Events
Clinical and laboratory adverse events will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA). System Organ Class (SOC), High-Level Group Term 
(HLGT), High-Level Term (HLT), Preferred Term (PT), and Lower-Level Term (LLT) will be 
attached to the clinical database.
Events will be summarized on the basis of the date of onset for the event. A treatment-emergent 
adverse event will be defined as any adverse event with onset date on or after the study drug start 
date and no later than 30 days after the study drug stop date; or any adverse event leading to 
study drug discontinuation.
Summaries (number and percentage of subjects) of treatment-emergent adverse events (by SOC, 
HLT [if applicable], and PT) will be provided by treatment. Additional summaries will include 
summaries for adverse events by grade, Investigator’s assessment of relationship to study drug, 
and effect on study drug dosing.
On an ongoing basis adverse events will be reviewed for events that might meet the definition of 
Stage 3 Opportunistic Illnesses in HIV are indicative of an AIDS-Defining Diagnoses. The 
Gilead medical personnel will review the possible Stage 3 events and approve the events that 
meet the definition. Those events that do meet the Stage 3 Opportunistic Illness definition of an 
AIDS-Defining Diagnosis will be listed.
A listing of Stage 3 Opportunistic Illnesses in HIV can be found in Appendix 5.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 79
19 February 2016
8.6.3.
Laboratory Evaluations
Selected laboratory data (using conventional units) will be summarized using only observed data. 
Absolute values and changes from baseline at all scheduled visits will be summarized.
Graded laboratory abnormalities will be defined using the grading scheme defined in Grading of 
laboratory abnormalities attached in Appendix 4.
Incidence of treatment-emergent laboratory abnormalities, defined as values that increase at least 
1 toxicity grade from baseline at any time post baseline up to and including the date of last dose 
of study drug plus 30 days, will be summarized by treatment. If baseline data are missing, then 
any graded abnormality (ie, at least a Grade 1) will be considered treatment emergent. The 
maximum postbaseline toxicity grade will be summarized by laboratory parameter.
Laboratory abnormalities that occur before the first dose of study drug or after the last dose of 
study drug plus 30 days will be included in a data listing.
8.6.4.
Bone Safety Evaluations
The percentage changes from baseline in hip/spine BMD at Weeks 48 will be summarized by 
treatment using descriptive statistics. The differences in percentage changes from baseline in 
hip/spine BMD between 2 treatment groups and the associated 95% confidence intervals will be 
constructed using ANOVA models, including treatment as a fixed effect in the model.
In addition, missing values for BMD will be imputed using LOCF method and analyzed 
similarly.
8.6.5.
Other Safety Evaluations
Vital signs and safety ECG data will be summarized as appropriate.
8.7.
Pharmacokinetic Analysis
For the intensive PK substudy, plasma concentrations of GS-9883 may be summarized by 
nominal sampling time using descriptive statistics. Pharmacokinetic parameters (Cmax, Tmax, Ctau, 
AUCtau, and T½, as appropriate) may be listed and summarized using descriptive statistics (eg, 
sample size, arithmetic mean, geometric mean, coefficient of variation %, SD, median, Q1, Q3, 
minimum, and maximum). Plasma concentrations over time will be plotted in semi-logarithmic 
and linear formats as mean ± standard deviation, and median (Q1, Q3).
For the general PK analyses, the pharmacokinetics of GS-9883 may be evaluated using 
descriptive statistics or population approaches.
TAF and FTC concentrations may be analyzed and PK parameters summarized as applicable.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 80
19 February 2016
8.8.
Biomarker Analysis
For each biomarker of inflammation, immune activation, platelet function, and renal tubular 
function, the percentage changes from baseline will be summarized by treatment and visit using 
descriptive statistics. Differences in percentage changes from baseline in each biomarker
between the 2 treatment groups will be tested using a Wilcoxon rank sum test.
8.9.
Patient Reported Outcomes (PRO)
The PRO measures based on questionnaires (eg, SF-36 and HIV Symptoms Distress Module) 
will be summarized by treatment and visit using descriptive statistics.
8.10.
Sample Size
A total of approximately 520 HIV-1 infected subjects, randomized in a 1:1 ratio to 2 treatment
groups (260 subjects per treatment group), achieves at least 90% power to detect a 
non-inferiority margin of 4% difference in the percentage of subjects with HIV-1 RNA 
≥50 copies/mL at Week 48 between the 2 treatment groups. For the sample size and power 
computation, it is assumed that both treatment groups have 2% of subjects with HIV-1 RNA 
≥50 copies/mL at Week 48 (based on the historical Gilead ECF/TAF and STB studies), that the
non-inferiority margin is 4%, and that the significance level of the test is at a one-sided 
0.025 level.
8.11.
Data Monitoring Committee
An external Independent Data Monitoring Committee (IDMC) will review the progress, efficacy, 
and safety data of this study while the study is ongoing. The committee will convene after the 
first 260 subjects enrolled have completed Week 12 of the study or prematurely discontinues 
from the study drug, as well as after all subjects have completed Week 24 of the study or 
prematurely discontinues from the study drug. However, Gilead will defer to the IDMC for any 
decision to convene earlier or more frequently. The IDMC will examine the safety results of the 
trial and also focus on logistical issues such as accrual, retention, quality of clinical and 
laboratory data, and implications of results of external studies. Blinding will be preserved during 
the conduct of the study and access to unblinded data will be limited to designated parties.
No formal stopping rules will be used by the IDMC for safety outcomes. Rather, a clinical 
assessment will be made to determine if the nature, frequency, and severity of adverse events 
associated with a study regimen warrant the early termination of the study in the best interest of 
the participants.
For each IDMC analysis performed prior to the analysis of the primary efficacy endpoint, an 
alpha penalty of 0.00001 will be applied for the primary analysis of the primary endpoint.
8.12.
Analysis Schedule
The Week 48 analysis will be conducted after all subjects either complete their Week 48 visit or 
prematurely discontinue from the study drug, respectively. Final analysis will be performed after 
all subjects complete the study or prematurely discontinue from the study.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 81
19 February 2016
9.
RESPONSIBILITIES
9.1.
Investigator Responsibilities
9.1.1.
Good Clinical Practice
The investigator will ensure that this study is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Tokyo, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (ICH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study subject. These standards are consistent with the European Union Clinical 
Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, 
part 50, 1998, and 21 CFR, part 56, 1998.
The investigator and all applicable subinvestigators will comply with 21 CFR, Part 54, 1998, 
providing documentation of their financial interest or arrangements with Gilead, or proprietary 
interests in the investigational drug under study. This documentation must be provided prior to 
the investigator’s (and any subinvestigator’s) participation in the study. The investigator and 
subinvestigator agree to notify Gilead of any change in reportable interests during the study and 
for 1 year following completion of the study. Study completion is defined as the date when the 
last subject completes the protocol-defined activities.
9.1.2.
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and any accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study used to obtain 
informed consent) to an IRB/IEC. The investigator will not begin any study subject activities 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/IEC any modifications made to the protocol or any accompanying material to be 
provided to the subject after initial IRB/IEC approval, with the exception of those necessary to 
reduce immediate risk to study subjects.
9.1.3.
Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study and before undertaking any study-related procedures. The 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 82
19 February 2016
investigator must use the most current IRB- or IEC-approved consent form for documenting 
written informed consent. Each informed consent (or assent as applicable) will be appropriately 
signed and dated by the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, and also by an impartial witness if required by IRB or IEC or
local requirements. The consent form will inform subjects about pharmacogenomic testing and 
sample retention, and their right to receive clinically relevant pharmacogenomic analysis results.
9.1.4.
Confidentiality
The investigator must assure that subjects’ anonymity will be strictly maintained and that their 
identities are protected from unauthorized parties. Only subject initials, date of birth, another 
unique identifier (as allowed by local law) and an identification code will be recorded on any 
form or biological sample submitted to the Sponsor, or laboratory. Laboratory specimens must 
be labeled in such a way as to protect subject identity while allowing the results to be recorded to 
the proper subject. Refer to specific laboratory instructions. NOTE: The investigator must keep a 
screening log showing codes, names, and addresses for all subjects screened and for all subjects 
enrolled in the trial. Subject data will be processed in accordance with all applicable regulations.
The investigator agrees that all information received from Gilead, including but not limited to the 
investigator brochure, this protocol, eCRF, the IMP, and any other study information, remain the 
sole and exclusive property of Gilead during the conduct of the study and thereafter. This 
information is not to be disclosed to any third party (except employees or agents directly 
involved in the conduct of the study or as required by law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure by any employee or agent of the study site to any third party or otherwise into the 
public domain.
9.1.5.
Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified. These documents should 
be classified into at least the following two categories: (1) investigator’s study file, and 
(2) subject clinical source documents.
The investigator’s study file will contain the protocol/amendments, eCRF and query forms, IRB 
or IEC and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:

Subject identification (name, date of birth, gender);

Documentation that subject meets eligibility criteria, ie, history, physical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 83
19 February 2016

Documentation of the reason(s) a consented subject is not enrolled

Participation in study (including study number);

Study discussed and date of informed consent;

Dates of all visits;

Documentation that protocol specific procedures were performed;

Results of efficacy parameters, as required by the protocol;

Start and end date (including dose regimen) of IMP, including dates of dispensing and return;

Record of all adverse events and other safety parameters (start and end date, and including 
causality and severity);

Concomitant medication (including start and end date, dose if relevant; dose changes);

Date of study completion and reason for early discontinuation, if it occurs.
All clinical study documents must be retained by the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (ie, United States, Europe, or Japan) and until there are no pending or planned 
marketing applications in an ICH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory 
authorities have been notified. Investigators may be required to retain documents longer if 
specified by regulatory requirements, by local regulations, or by an agreement with Gilead. The 
investigator must notify Gilead before destroying any clinical study records.
Should the investigator wish to assign the study records to another party or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study site for any or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securely away from the site so that they can be returned sealed to the investigator 
in case of an inspection. When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away from the site.
9.1.6.
Case Report Forms
For each subject consented, an eCRF will be completed by an authorized study staff member 
whose training for this function is documented according to study procedures. eCRF should be 
completed on the day of the subject visit to enable the sponsor to perform central monitoring of 
safety data.  The Eligibility Criteria eCRF should be completed only after all data related to 
eligibility have been received.  Subsequent to data entry, a study monitor will perform source 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 84
19 February 2016
data verification within the EDC system. Original entries as well as any changes to data fields 
will be stored in the audit trail of the system.  Prior to database lock (or any interim time points 
as described in the clinical data management plan), the investigator will use his/her log in 
credentials to confirm that the forms have been reviewed, and that the entries accurately reflect 
the information in the source documents. The eCRF capture the data required per the protocol 
schedule of events and procedures. System-generated or manual queries will be issued to the 
investigative site staff as data discrepancies are identified by the monitor or internal Gilead staff, 
who routinely review the data for completeness, correctness, and consistency. The site 
coordinator is responsible for responding to the queries in a timely manner, within the system, 
either by confirming the data as correct or updating the original entry, and providing the reason 
for the update (e.g. data entry error). At the conclusion of the trial, Gilead will provide the site 
with a read-only archive copy of the data entered by that site. This archive must be stored in 
accordance with the records retention requirements outlined in Section 9.1.5.
9.1.7.
Investigational Medicinal Product Accountability and Return
Gilead recommends that used and unused IMP supplies be returned to the shipping facility from 
which it came for eventual destruction. The study monitor will provide instructions for return. If 
return is not possible, the study monitor will evaluate each study center’s IMP disposal 
procedures and provide appropriate instruction for destruction of unused IMP supplies. If the site 
has an appropriate standard operating procedure (SOP) for drug destruction as determined by 
Gilead QA, the site may destroy used (empty or partially empty) and unused IMP supplies in 
accordance with that site’s approved SOP. A copy of the site’s approved SOP will be obtained 
for central files.
If IMP is destroyed on site, the investigator must maintain accurate records for all IMP
destroyed. Records must show the identification and quantity of each unit destroyed, the method 
of destruction, and the person who disposed of the IMP. Upon study completion, copies of the 
IMP accountability records must be filed at the site. Another copy will be returned to Gilead.
The study monitor will review IMP supplies and associated records at periodic intervals.
9.1.8.
Inspections
The investigator will make available all source documents and other records for this trial to 
Gilead’s appointed study monitors, to IRBs or IECs, or to regulatory authority or health authority 
inspectors.
9.1.9.
Protocol Compliance
The investigator is responsible for ensuring the study is conducted in accordance with the 
procedures and evaluations described in this protocol.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 85
19 February 2016
9.2.
Sponsor Responsibilities
9.2.1.
Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study subjects, may be 
made only by Gilead. The investigator must submit all protocol modifications to the IRB or IEC 
in accordance with local requirements and receive documented IRB or IEC approval before 
modifications can be implemented.
9.2.2.
Study Report and Publications
A clinical study report (CSR) will be prepared and provided to the regulatory agency(ies). Gilead 
will ensure that the report meets the standards set out in the ICH Guideline for Structure and 
Content of Clinical Study Reports (ICH E3). Note that an abbreviated report may be prepared in 
certain cases.
Investigators in this study may communicate, orally present, or publish in scientific journals or 
other scholarly media only after the following conditions have been met:
the results of the study in their entirety have been publicly disclosed by or with the consent of 
Gilead in an abstract, manuscript, or presentation form or the study has been completed at all 
study sites for at least 2 years
The investigator will submit to Gilead any proposed publication or presentation along with the 
respective scientific journal or presentation forum at least 30 days before submission of the 
publication or presentation.
No such communication, presentation, or publication will include Gilead’s confidential 
information (see Section 9.1.4).
The investigator will comply with Gilead’s request to delete references to its confidential 
information (other than the study results) in any paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary.
9.3.
Joint Investigator/Sponsor Responsibilities
9.3.1.
Payment Reporting
Investigators and their study staff may be asked to provide services performed under this 
protocol, e.g. attendance at Investigator's Meetings.  If required under the applicable statutory 
and regulatory requirements, Gilead will capture and disclose to Federal and State agencies any 
expenses paid or reimbursed for such services, including any clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any other transfer of value.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 86
19 February 2016
9.3.2.
Access to Information for Monitoring
In accordance with regulations and guidelines, the study monitor must have direct access to the 
investigator’s source documentation in order to verify the accuracy of the data recorded in the 
eCRF.
The monitor is responsible for routine review of the eCRF at regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency, and accuracy of the 
data being entered on them. The monitor should have access to any subject records needed to 
verify the entries on the eCRF. The investigator agrees to cooperate with the monitor to ensure 
that any problems detected through any type of monitoring (central, on site) are resolved.
9.3.3.
Access to Information for Auditing or Inspections
Representatives of regulatory authorities or of Gilead may conduct inspections or audits of the 
clinical study. If the investigator is notified of an inspection by a regulatory authority the 
investigator agrees to notify the Gilead medical monitor immediately. The investigator agrees to 
provide to representatives of a regulatory agency or Gilead access to records, facilities, and 
personnel for the effective conduct of any inspection or audit.
9.3.4.
Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the study at any time. Should 
this be necessary, both parties will arrange discontinuation procedures and notify the appropriate 
regulatory authority(ies), IRBs, and IECs. In terminating the study, Gilead and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 87
19 February 2016
10.
REFERENCES
Aldir I, Horta A, Serrado M. Single-tablet regimens in HIV: does it really make a difference? 
Curr Med Res Opin 2013;30 (1):89-97.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31-41.
Costagliola D. Demographics of HIV and aging. Curr Opin HIV AIDS 2014;9 (4):294-301.
Department for Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral 
Agents in HIV-1-Infected Adults and Adolescents. Developed by the DHHS 
Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working 
Group of the Office of AIDS Research Advisory Council (OARAC). Downloaded 
from http://aidsinfo.nih.gov/guidelines on 5/11/2015. Last Updated 08 April, 
2015.
Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 
2003;362 (9387):847-52.
Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of 
mortality across Europe in patients infected with HIV-1. Lancet 1998;352 
(9142):1725-30.
Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining 
Morbidity and Mortality Among Patients With Advanced Human 
Immunodeficiency Virus Infection. N Eng J Med 1998;338 (13):853-60.
Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT. Revised 
surveillance case definitions for HIV infection among adults, adolescents, and 
children aged <18 months and for HIV infection and AIDS among children aged 
18 months to <13 years--United States, 2008. MMWR Recomm Rep 2008;57 
(RR-10):1-12.
Sterne J, Hernán M, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-term effectiveness 
of potent antiretroviral therapy in preventing AIDS and death: a prospective 
cohort study. Lancet 2005;366 (9483):378-84.
Sterrantino G, Santoro L, Bartolozzi D, Trotta M, Zaccarelli M. Self-reported adherence supports 
patient preference for the single tablet regimen (STR) in the current cART era. 
Patient preference and adherence 2012;6:427-33.
The Joint United Nations Programme oHAU. Fact Sheet: 2014 Global Statistics. Available at: 
http://www.unaids.org/sites/default/files/media_asset/20150714_FS_MDG6_Rep
ort_en.pdf.  2014.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 88
19 February 2016
11.
APPENDICES
Appendix 1.
Investigator Signature Page
Appendix 2.
Study Procedures Table (Blinded Phase)
Appendix 3.
Management of Clinical and Laboratory Adverse Events
Appendix 4.
GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5.
Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines)
Appendix 6.
Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Final 
Gilead Sciences, Inc. 
Amendment I 
Appendix 1. 
Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT 
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 
Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination 
(FDC) of ABC/DTG/3TC to a FDC ofGS-9883/F/TAF in HIV-1 Infected Subjects who are 
VirologicaUy Suppressed 
GS-US-380-1844 Amendment 1, 19 February 2016 
This protocol has been approved by Gilead Sciences, Inc. The following signature documents 
this approval. 
MM•It..t \ forA <L-
•• 1.<.1. .. 1~ ..q-
1 
/ 
P P D 
Javier Szwarcberg, MD (Printed) 
, ~~UlM '-t•'"l~ ignaturo._ ____________ ___. 
Date 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure 
that they are fully infom1ed about the drugs and the study. 
Principal Investigator Name (Printed) 
Signature 
Date 
Site Number 
CONFIDENTIAL 
Page 89 
19 February 20 16 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 90
19 February 2016
Appendix 2.
Study Procedures Table (Blinded Phase)
Study Procedures
Screeninga
Day 1b
End of Weeke, p
Post-Week 48e, q
Unblinding 
Visit
30-Day 
Follow-upo
Early 
Study 
Drugs DCc
4
8
12
24
36
48
Every 12 Weeks
Informed Consent
X
Medical History
X
Concomitant Medications
X
X
X
X
X
X
X
X
X
X
X
X
Adverse Events
X
X
X
X
X
X
X
X
X
X
Xf
Xf
Complete/Symptom-Directed 
Physical Exam
X
X
Xd
Xd
Xd
X
Xd
X
Xd
X
Xd,f
Xf
12-Lead ECG (performed 
supine)
X
X
X
X
X
X
Questionnaires
X
X
X
X
DXA scan (spine & hip)g
X
X
X
X
X
Height
X
Vital signs (blood pressure, 
pulse, respiration rate, and 
temperature), including 
Weight
X
X
X
X
X
X
X
X
X
X
X
X
Urinalysis
X
X
X
X
X
X
X
X
X
X
Xf
Xf
Urine Pregnancy Testh
X
X
X
X
X
X
X
X
X
X
X
Serum Pregnancy Test
X
Chemistry Profilei
X
X
X
X
X
X
X
X
X
X
Xf
Xf
Metabolic Assessmentsj
X
X
X
X
Xr
X
Estimated Glomerular 
Filtration Rate
X
X
X
X
X
X
X
X
X
X
Xf
X
Hematology Profilek
X
X
X
X
X
X
X
X
X
X
Xf
Xf


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
Study Procedures 
Plasma HIV -1 RNA 
CD4+ Cell Connt 
Evaluations of inflammation 
and immnne activation, 
platelet fimction and renal 
tubular fimction 
Plasma & Urine Storage 
Sample 
Whole Blood sample for 
potential HIV DNA 
genotyping 
HBV and HCV Serology 
HIV -1 Genotype/Phenotype e 
Single PK Sample' 
Trough PK Samplesm 
Optional PPD 
~· 
I 
r 
Randornization
1 
Provide subject dosing diruy 
to subjects 
Optional PK Substudyll 
Study Drug Dispensation 
Study Drug Acconntability 
Screening• 
Day 1b 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
~ 
a 
Evaluations to be completed within 30 days prior to Day 1. 
4 
8 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
End of Week•· P 
Post-Week 48e,q 
12 
24 
36 
48 
Every 12 Weeks 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
xr 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Unblinding 
30-Day 
Visit 
Follow-up
0 
X 
X 
X 
X 
X 
X 
X' 
X 
Final 
Amendment 1 
Early 
Study 
Drugs DC< 
X 
X 
X 
xe 
X 
b 
Initiation of the ftrst dose of study dmg is to take place in-clinic following completion of study procedures at the Day I visit, with the exception of DXA. 
CONFIDENTIAL 
Page 91 
19 Febmaty 2016 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 92
19 February 2016
c
Early Study Drugs Discontinuation visit to occur within 72 hours of last dose of study drug. Subjects will be asked to continue attending the scheduled study visits through the 
Unblinding Visit even if the subject discontinues study drug.
d
Symptom-directed physical examination as needed.
e
HIV-1 genotype and phenotype testing for subjects with virologic failure. Following virologic rebound, subjects will be asked to return to the clinic (2-3 weeks later) prior to 
the next scheduled visit or at the next scheduled study visit, for a HIV-1 RNA and HIV-1 genotype and phenotype (reverse transcriptase, protease, and integrase genotype and 
phenotype) blood draw. Based on the results of this testing, subjects should be managed according to the Virologic Rebound Schema (Section 6.13.1 and 6.13.2).
f
Any adverse event or test showing abnormal results that is believed to have a possible or probable causal relationship with the study drug will be repeated weekly (or as often 
as deemed prudent by the Investigator) until the abnormality is resolved, returns to Day 1, or is otherwise explained.
g
DXA scans to be performed in all eligible subjects on study drug, except for those in Germany, prior to or within 24 hours of the Day 1 Visit, Weeks 24, 48 (±10 days), and at
Unblinding Visit (±10 days) and the ESDD visit (if the last scan was acquired > 12 weeks from the date of the ESDD Visit).
h
Females of childbearing potential only. Positive urine pregnancy tests will be confirmed with a serum test.
i
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid and amylase (reflex lipase testing is performed in subjects with total amylase 
1.5 ULN) At Day 1, Weeks 12, 24, 48 and Unblinding Visit, analyses of glucose will be done as part of the fasting metabolic assessments and not as part of the chemistry 
profile. Additionally: TSH will be analyzed at Screening, Day 1, Weeks 24 and 48 followed by every 24 weeks post Week 48, Unblinding Visit and Early Study Drugs 
Discontinuation visit.
j
Fasting (no food or drinks, except water, at least 8 hours prior to blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, triglycerides). If the subject has 
not fasted prior to the visit, the visit may proceed, but the subject must return within 72 hours in a fasted state to draw blood for the metabolic assessments.
k
CBC with differential and platelet count.
l
A single PK blood sample will be collected at any time pre or post-dose 
m
A trough PK blood sample will be collected between 20-28 hours following the last dose. Following an observed dose, a single post dose blood sample will be collected 
between 1 and 4 hours post dose.
n
A PK substudy will be performed in a subset of subjects (n=30) at selected study sites.  The pharmacokinetic substudy visit must occur at the Week 4 or Week 8 visits. The 
substudy will include intensive PK profiling in plasma
o
Only required for those subjects not enrolling in the open-label rollover extension or those subjects who permanently discontinue study drugs and do not continue in the study 
through at least one subsequent visit after the Early Study Drugs Discontinuation Visit. For the purpose of scheduling a 30-Day Follow-Up Visit, a 6 days window may be 
used.
p
Study visits are to be completed within ± 2 days of the protocol-specified visit date based on the Day 1 visit through Week 12 and completed within ± 6 days through to 
Week 36, unless otherwise specified. The visit window at Weeks 48 will be ± 6 weeks of the protocol-specified visit date. 
q
After Week 48, subjects will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded. Visit window of 
6 days for study visits post Week 48.
r
To be performed every 24 weeks after Week 48 until Unblinding Visit.
s
Open label study drug, GS-9883/F/TAF FDC will be dispensed to subjects participating in the Open-Label Rollover extension.
t
Randomization may be performed up to 3 days prior to the in-clinic Day 1 visit provided that all screening procedures have been completed and subject eligibility has been 
confirmed.


GS-9883/Fff AF 
Protocol GS-US-380-1844 
Final 
Gilead Sciences, Inc. 
Amendment 1 
Appendix 3. 
Management of Clinical and Laboratory Adverse Events 
Grade I 
~-----G-r_a_d_e-2----~ 
Ll 
______ o_r_a_de-3------~ 
Ll 
__________ o_m_d_e_4--------~ 
! 
May continue dosing 
Repeat lab to 
at the discretion of 
confrrm toxicity 
the investigator 
grade 
If confrrmed and possibly and/or probably related to investigational 
medicinal products: 
I. Withhold investigational medicinal products until :5 Gmde 2 
2. 
Restart all investigational medicinal products at full dose 
1 
TfGmde 3 or 4 recurrence that is confirmed and possibly or probably 
related to investigational medicinal products, discontinue all 
investigational medicinal products dosing permanently 
1 
Repeat lab to 
confirm toxicity 
grade 
1 
If c 
inve 
dosi 
oft 
onfirmed and unrelated to 
stigational medicinal products, 
ng may continue at the discretion 
he investigator 
If confirmed and 
possibly or probably 
_. related to 
investigational 
medicinal products, 
discontinue 
investigational 
medicinal products 
dosing permanently and 
follow at periodic 
intervals at least weekly 
until a return to 
baseline or is otherwise 
explained 
If Grade 3 or 4 recurrence that is considered unrelated to 
investigational medicinal products, continue all investigational 
medicinal products at the same dose at the discretion of the 
investigator 
CONFIDENTIAL 
Page 93 
19 February 2016 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 94
19 February 2016
Appendix 4.
GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1
Grade 2
Grade 3
Grade 4
Hemoglobin
HIV POSITIVE
Adult and Pediatric 57 Days
8.5 to 10.0 g/dL 
85 to 100 g/L
7.5 to 8.5 g/dL 
75 to 85 g/L
6.5 to 7.5 g/dL 
65 to 75 g/L
6.5 g/dL
65 g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 
10.0 to 10.9 g/dL
100 to 109 g/L
OR
Any decrease from Baseline
2.5 to 3.5 g/dL
25 to 35 g/L
9.0 to 10.0 g/dL
90 to 100 g/L
OR
Any decrease from Baseline
3.5 to 4.5 g/dL
35 to 45 g/L
7.0 to 9.0 g/dL
70 to 90 g/L
OR
Any decrease from Baseline
4.5 g/dL
45 g/L
7.0 g/dL
70 g/L
Infant, 36–56 Days
(HIV POSITIVE OR
NEGATIVE)
8.5 to 9.4 g/dL
85 to 94 g/L
7.0 to 8.5 g/dL
70 to 85 g/L
6.0 to 7.0 g/dL
60 to < 70 g/L
6.0 g/dL
< 60 g/L
Infant, 22–35 Days
(HIV POSITIVE OR
NEGATIVE)
9.5 to 10.5 g/dL
95 to 105 g/L
8.0 to 9.5 g/dL
80 to 95 g/L
7.0 to 8.0 g/dL
70 to 80 g/L
7.0 g/dL
70 g/L
Infant, 1–21 Days
(HIV POSITIVE OR
NEGATIVE)
12.0 to 13.0 g/dL
120 to 130 g/L
10.0 to 12.0 g/dL
100 to 120 g/L
9.0 to 10.0 g/dL
90 to 100 g/L
9.0 g/dL
90 g/L
Absolute Neutrophil Count 
(ANC)
Adult and Pediatric, 
≥ 7 Months#
1000 to 1300/mm3
750 to 1000/mm3
500 to 750/mm3
500/mm3
1.00 to 1.30 GI/L
0.75 to 1.00 GI/L
0.50 to 0.75 GI/L
0.50 GI/L


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 95
19 February 2016
HEMATOLOGY
Grade 1
Grade 2
Grade 3
Grade 4
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
> 13 Years
300 to 400/mm3
300 to 400/μL
200 to 300/mm3
200 to 300/μL
100 to 200/mm3
100 to 200/μL
100/mm3
100/μL
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13 Years
600 to 650/mm3
0.60 to 0.65 GI/L
500 to 600/mm3
0.50 to 0.60 GI/L
350 to 500/mm3
0.35 to 0.50 GI/L
350/mm3
0.35 GI/L
Platelets 
100,000 to < 125,000/mm3
100 to 125 GI/L
50,000 to 100,000/mm3
50 to 100 GI/L
25,000 to 50,000/mm3
25 to 50 GI/L
25,000/mm3
25 GI/L
WBCs 
2000/mm3 to 2500/mm3
1,500 to 2,000/mm3
1000 to 1,500/mm3
1000/mm3
2.00 GI/L to 2.50 GI/L
1.50 to 2.00 GI/L
1.00 to 1.50 GI/L
1.00 GI/L
Hypofibrinogenemia
100 to 200 mg/dL
75 to 100 mg/dL
50 to 75 mg/dL
50 mg/dL
1.00 to 2.00 g/L
0.75 to 1.00 g/L
0.50 to 0.75 g/L
0.50 g/L
Hyperfibrinogenemia
ULN to 600 mg/dL
600 mg/dL
—
—
ULN  to 6.0 g/L
6.0 g/L
—
—
Fibrin Split Product 
20 to 40 μg/mL
40 to 50 μg/mL
50 to 60 μg/mL
60 μg/mL
20 to 40 mg/L
40 to 50 mg/L
50 to 60 mg/L
60 mg/L
Prothrombin Time (PT)
1.00 to 1.25 ULN
1.25 to 1.50 ULN 
1.50 to 3.00 ULN 
3.00 ULN 
International Normalized Ratio 
of prothrombin time (INR)
1.1 to 1.5 x ULN
>1.5 to 2.0 x ULN
>2.0 to 3.0 x ULN
>3.0 x ULN
Activated Partial
Thromboplastin Time (APTT)
1.00 to 1.66 ULN
1.66 to 2.33 ULN
2.33 to 3.00 ULN
3.00 ULN
Methemoglobin 
5.0 to 10.0%
10.0 to 15.0%
15.0 to 20.0%
20.0%
#
An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects.  Please follow the Gilead convention of grading 
any result within the LLN and ULN a 0.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 96
19 February 2016
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hyponatremia 
130 to <LLN mEq/L
125 to 130 mEq/L
121 to 125 mEq/L
121 mEq/L
130 to <LLN mmol/L
125 to 130 mmol/L
121 to 125 mmol/L
121 mmol/L
Hypernatremia 
>ULN  to 150 mEq/L
150 to 154 mEq/L
154 to 159 mEq/L
159 mEq/L
>ULN  to 150 mmol/L
150 to 154 mmol/L
154 to 159 mmol/L
159 mmol/L
Hypokalemia 
Adult and Pediatric
1 Year
3.0 to  <LLN mEq/L
2.5 to 3.0 mEq/L
2.0 to 2.5 mEq/L
2.0 mEq/L
3.0 to <LLN mmol/L
2.5 to 3.0 mmol/L
2.0 to 2.5 mmol/L
2.0 mmol/L
Infant <1 Year 
3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L
2.5 to 3.0 mEq/L                
2.5 to <3.0 mmolL
2.0 to 2.5 mEq/L                 
2.0 to <2.5 mmolL
2.0 mEq/L                         
<2.0 mmolL
Hyperkalemia 
Adult and Pediatric
1 Year
5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L
6.0 to 6.5 mEq/L
6.0 to 6.5 mmol/L
6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L
7.0 mEq/L
7.0 mmol/L
Infant <1 Year
>ULN to 6.0 mEq/L           
>ULN to 6.0 mmol/L
> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L
6.5 to 7.0 mEq/L             
6.5 to 7.0 mmol/L
7.0 mEq/L                  
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1 Month
55 to 64 mg/dL
3.03 to 3.58 mmol/L
40 to 55 mg/dL
2.20 to 3.03 mmol/L
30 to 40 mg/dL
1.64 to 2.20 mmol/L
30 mg/dL
1.64 mmol/L
Infant, 1 Month
50 to 54 mg/dL
2.8 to 3.0 mmol/L
40 to 50 mg/dL
2.2 to 2.8 mmol/L
30 to 40 mg/dL
1.7 to 2.2 mmol/L
30 mg/dL
1.7 mmol/L


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 97
19 February 2016
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hyperglycemia, Nonfasting 
116 to 160 mg/dL
160 to 250 mg/dL
250 to 500 mg/dL
500 mg/dL
6.42 to 8.91 mmol/L
8.91 to 13.90 mmol/L
13.90 to 27.79 mmol/L
27.79 mmol/L
Hyperglycemia, Fasting
110 to 125 mg/dL
6.08 to 6.96 mmol/L
>125 to 250 mg/dL
>6.96 to 13.90 mmol/L
>250 to 500 mg/dL
>13.90 to 27.79 mmol/L
>500 mg/dL
>27.79 mmol/L
Hypocalcemia 
(corrected for albumin if 
appropriate*)
Adult and Pediatric
2 Years
7.8 <LLN mg/dL
1.94 to <LLN mmol/L
7.0 to 7.8 mg/dL
1.74 to 1.94 mmol/L
6.1 to 7.0 mg/dL
1.51 to 1.74 mmol/L
6.1 mg/dL
1.51 mmol/L
Pediatric ≥7 days -2 Years
7.8 to 8.4 mg/dL                         
1.94 to 2.10 mmol/L
7.0 to <7.8 mg/dL              
1.74 to <1.94 mmolL
6.1 to  <7.0 mg/dL                      
1.51 to < 1.74 mmolL
< 6.1 mg/dL                           
< 1.51 mmol/L
Infant, 7 Days
6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L
6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L
5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 
5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate*)
Adult and Pediatric 
7 Days
>ULN to 11.5 mg/dL
11.5 to 12.5 mg/dL
12.5 to 13.5 mg/dL
13.5 mg/dL
>ULN to 2.88 mmol/L
2.88 to 3.13 mmol/L
3.13 to 3.38 mmol/L
3.38 mmol/L
Infant, 7 Days
11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L
12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L
12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L
13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized)
3.0 mg/dL to LLN
2.5 to < 3.0 mg/dL
2.0 to 2.5 mg/dL
2.0 mg/dL
0.74 mmol/L to LLN
0.62 to 0.74 mmol/L
0.49 to 0.62 mmol/L
0.49 mmol/L


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 98
19 February 2016
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hypercalcemia (ionized)
ULN to 6.0 mg/dL
6.0 to 6.5 mg/dL
6.5 to 7.0 mg/dL
7.0 mg/dL
ULN to 1.50 mmol/L
1.50 to 1.63 mmol/L
1.63 to 1.75 mmol/L
1.75 mmol/L
Hypomagnesemia
1.40 to <LLN mg/dL
1.2 to <LLN mEq/L
1.04 to 1.40 mg/dL
0.9 to   1.2 mEq/L
0.67 to 1.04 mg/dL
0.6 to 0.9 mEq/L
0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmol/L
0.43 to 0.58 mmol/L
0.28 to 0.43 mmol/L
0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14 Years
2.0 to < LLN mg/dL
0.63  to LLN mmol/L
1.5 to 2.0 mg/dL
0.47 to 0.63 mmol/L
1.0 to 1.5 mg/dL
0.31 to 0.47 mmol/L
1.0 mg/dL
0.31 mmol/L
Pediatric 1 Year–14 Years 
3.0 to <LLN mg/dL
0.96 to <LLN mmol/L
2.5 to 3.0 mg/dL
0.80 to < 0.96 mmol/L
1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L
1.5 mg/dL
< 0.47 mmol/L
Pediatric 1 Year
3.5 to <LLN mg/dL
1.12 to <LLN mmol/L
2.5 to 3.5 mg/dL
0.80 to < 1.12 mmol/L
1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L
1.5 mg/dL
< 0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
> 14 Days
1.0 to 1.5 ULN 
1.5 to 2.5 ULN
2.5 to 5.0 ULN 
5.0 ULN 
Infant, 14 Days
(non-hemolytic)
NA
20.0 to 25.0 mg/dL
342 to 428 μmol/L
25.0 to 30.0 mg/dL
> 428 to 513 μmol/L
30.0 mg/dL
> 513 μmol/L
Infant, 14 Days
(hemolytic)
NA
NA
20.0 to 25.0 mg/dL
342 to 428 μmol/L
25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen
1.25 to 2.50 ULN 
2.50 to 5.00 ULN 
5.00 to 10.00 ULN 
10.00 ULN


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 99
19 February 2016
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hyperuricemia
>ULN to 10.0 mg/dL 
10.0 to 12.0 mg/dL 
12.0 to 15.0 mg/dL 
15.0 mg/dL
>ULN to 597 μmol/L
597 to 716 μmol/L
716 to 895 μmol/L
895 μmol/L
Hypouricemia               
Adult and Pediatric           
≥ 1 year   
Infant  < 1 Year
1.5 mg/dL to LLN
87 μmol/L to LLN
1.0 to 1.5 mg/dL
57 to 87 μmol/L
0.5 to 1.0 mg/dL
27 to 57 μmol/L
0.5 mg/dL
27 μmol/L
N/A
1.0 mg/dl to <LLN-
57 μmol to <LLN
0.5 to 1.0 mg/dL
27 to 57 μmol/L
0.5 mg/dL
27 μmol/L
Creatinine** 
1.50 to 2.00 mg/dL
133 to 177 μmol/L
2.00 to 3.00 mg/dL
177 to 265 μmol/L
3.00 to 6.00 mg/dL 
265 to 530 μmol/L
6.00 mg/dL
530 μmol/L
Bicarbonate
Adult and Pediatric 
≥ 4 Years
16.0 mEq/L to LLN 
11.0 to 16.0 mEq/L
8.0 to 11.0 mEq/L
8.0 mEq/L
16.0 mmol/L to LLN
11.0 to 16.0 mmol/L
8.0 to 11.0 mmol/L
8.0 mmol/L
Pediatric < 4 Years
NA
11.0 mEq/Lto <LLN
8.0 to 11.0 mEq/L
8.0 mEq/L
11.0 mmol/L to <LLN
8.0 to 11.0 mmol/L
8.0 mmol/L
Triglycerides
(Fasting)
NA
500 to 750 mg/dL
5.64–8.47 mmol/L
750 to 1200 mg/dL
8.47–13.55 mmol/L
1200 mg/dL
13.55 mmol/L
LDL (Fasting)
Adult
130 to 160 mg/dL
>160 to 190 mg/dL
> 190 mg/dL
NA
3.35 to 4.15 mmol/L
>4.15 to 4.92 mmol/L
>4.92 mmol/L
LDL (Fasting)
Pediatric >2 to <18 years
110 to 130 mg/dL
>130 to 190 mg/dL
> 190 mg/dL
NA
2.84 to 3.37 mmol/L
>3.37 to  4.92 mmol/L
>4.92 mmol/L


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 100
19 February 2016
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hypercholesterolemia
(Fasting)
200 to 239 mg/dL
239 to 300 mg/dL
300 mg/dL
NA
5.16 to 6.19 mmol/L
6.19 to 7.77 mmol/L
7.77 mmol/L
Pediatric 18 Years
170 to 199 mg/dL
4.39 to 5.15 mmol/L
199 to 300 mg/dL
5.15 to 7.77 mmol/L
300 mg/dL
7.77 mmol/L
NA
Creatine Kinase
3.0 to 6.0 ULN
6.0 to 10.0 ULN
10.0 to 20.0 ULN
20.0 ULN
*
Calcium should be corrected for albumin if albumin is < 4.0 g/dL
**
An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may result for Male subjects >70 yrs. Please follow the Gilead convention of grading any 
result within the LLN and ULN a 0.
ENZYMES
Grade 1
Grade 2
Grade 3
Grade 4
AST (SGOT) 
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
ALT (SGPT) 
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
GGT
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
Alkaline Phosphatase 
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
Total Amylase
1.0 to 1.5 ULN
1.5 to 2.0 ULN
2.0 to 5.0 ULN
5.0 ULN
Pancreatic Amylase
1.0 to 1.5 ULN
1.5 to 2.0 ULN
2.0 to 5.0 ULN
5.0 ULN
Lipase 
1.0 to 1.5 ULN
1.5 to 3.0 ULN
3.0 to 5.0 ULN
5.0 ULN
Albumin
Pediatrics <16 years
≥ 16 years
-
2.0 to LLN g/dL
20 to LLN g/L
2.0 g/dL
20 g/L
NA
3.0 g/dL to LLN
30 g/L to LLN
2.0 to 3.0 g/dL
20 to 30 g/L
2.0 g/dL
20 g/L
NA


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 101
19 February 2016
URINALYSIS
Grade 1
Grade 2
Grade 3
Grade 4
Hematuria (Dipstick) 
1
2
3-4+
NA
Hematuria (Quantitative) 
See Note below
                              Females
>ULN - 10 RBC/HPF
10-75 RBC/HPF
> 75 RBC/HPF
NA
                              Males
6-10 RBC/HPF
10-75 RBC/HPF
> 75 RBC/HPF
NA
Proteinuria (Dipstick)
1
2–3
4
NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years
200 to 999 mg/24 h
>999 to 1999 mg/24 h
>1999 to 3500 mg/24 h
3500 mg/24 h
Pediatric 3 Mo to 
< 10 Years
201 to 499 mg/m2/24 h
>499 to 799 mg/m2/24 h
>799 to 1000 mg/m2/24 h
1000 mg/ m2/24 h
Glycosuria (Dipstick)
1+
2-3
4
NA
Notes:

Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratories, toxicity grades will only be assigned to 
Dipstick Hematuria.

With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigned Grade 0.

If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for 
the AE.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 102
19 February 2016
CARDIOVASCULAR
Grade 1
Grade 2
Grade 3
Grade 4
Cardiac Arrhythmia (general)
(By ECG or physical exam)
Asymptomatic AND No 
intervention indicated
Asymptomatic AND Non-
urgent medical intervention 
indicated
Symptomatic, non-life-
threatening AND Non-
urgent medical intervention 
indicated 
Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac-ischemia/Infarction
NA
NA
Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia 
Unstable angina OR Acute 
myocardial infarction
Hemorrhage (significant acute 
blood loss)
NA
Symptomatic AND No 
transfusion indicated
Symptomatic AND 
Transfusion of 2 units 
packed RBCs (for children 
10 cc/kg) indicated 
Life-threatening hypotension 
OR Transfusion of 2 units 
packed RBCs indicated (for 
children 10 cc/kg) indicated
Hypertension (with repeat 
testing at same visit)
140–159 mmHg systolic 
OR 
90–99 mmHg diastolic
159–179 mmHg systolic 
OR 
99–109 mmHg diastolic
179 mmHg systolic 
OR 
109 mmHg diastolic
Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization (other than 
ER visit) indicated
Pediatric 17 Years (with 
repeat testing at same visit)
NA
91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)
≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)
Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization indicated 
(other than emergency room 
visit)
Hypotension
NA
Symptomatic, corrected with 
oral fluid replacement
Symptomatic, IV fluids 
indicated
Shock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion
Asymptomatic, small 
effusion requiring no 
intervention
Asymptomatic, moderate or 
larger effusion requiring no 
intervention
Effusion with non-life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicated
Life-threatening consequences 
(eg, tamponade) OR Urgent 
intervention indicated


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 103
19 February 2016
CARDIOVASCULAR
Grade 1
Grade 2
Grade 3
Grade 4
Prolonged PR Interval
PR interval 
0.21 to 0.25 sec
PR interval
0.25 sec
Type II 2nd degree AV 
block OR Ventricular pause 
3.0 sec
Complete AV block 
Pediatric 16 Years
1st degree AV block
(PR > normal for age and 
rate)
Type I 2nd degree AV block 
Type II 2nd degree AV 
block 
Complete AV block
Prolonged QTc
Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baseline
Asymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baseline
Asymptomatic, QTc interval 
0.50 sec OR Increase in 
interval 0.06 sec above 
baseline
Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16 Years
Asymptomatic, QTc interval 
0.450 to 0.464 sec 
Asymptomatic, QTc interval 
0.465 to 0.479 sec 
Asymptomatic, QTc interval 
0.480 sec 
Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism
NA
Deep vein thrombosis AND 
No intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) 
Deep vein thrombosis AND 
Intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) 
Embolic event (eg, pulmonary 
embolism, life-threatening 
thrombus) 
Vasovagal Episode (associated 
with a procedure of any kind)
Present without loss of 
consciousness 
Present with transient loss of 
consciousness
NA 
NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)
NA
Asymptomatic diagnostic 
finding AND intervention 
indicated
New onset with symptoms 
OR Worsening symptomatic 
CHF
Life-threatening CHF


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 104
19 February 2016
RESPIRATORY
Grade 1
Grade 2
Grade 3
Grade 4
Bronchospasm (acute)
FEV1 or peak flow reduced to 
70% to 80%
FEV1 or peak flow 50% to 69%
FEV1 or peak flow 25% to 
49% 
Cyanosis OR FEV1 or peak flow 
25% OR Intubation
Dyspnea or Respiratory 
Distress
Dyspnea on exertion with no 
or minimal interference with 
usual social & functional 
activities 
Dyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activities 
Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
Respiratory failure with 
ventilatory support indicated
Pediatric 14 Years
Wheezing OR minimal 
increase in respiratory rate for 
age
Nasal flaring OR Intercostal 
retractions OR Pulse oximetry 
90% to 95%
Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%
Respiratory failure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1
Grade 2
Grade 3
Grade 4
Uveitis
Asymptomatic but detectable 
on exam
Symptomatic anterior uveitis OR 
Medical intervention indicated
Posterior or pan-uveitis OR 
Operative intervention 
indicated
Disabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)
Visual changes causing no or 
minimal interference with 
usual social & functional 
activities
Visual changes causing greater 
than minimal interference with 
usual social & functional 
activities
Visual changes causing 
inability to perform usual 
social & functional activities
Disabling visual loss in affected 
eye(s)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 105
19 February 2016
SKIN
Grade 1
Grade 2
Grade 3
Grade 4
Alopecia
Thinning detectable by 
study participant or  
caregiver (for disabled 
adults)
Thinning or patchy hair loss 
detectable by health care 
provider
Complete hair loss
NA
Cutaneous Reaction – Rash
Localized macular rash 
Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions 
Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one site
Extensive or generalized 
bullous lesions OR 
Stevens-Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epidermal 
necrolysis (TEN)
Hyperpigmentation
Slight or localized
Marked or generalized
NA
NA
Hypopigmentation
Slight or localized 
Marked or generalized
NA
NA
Pruritis (itching – no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)
Itching causing no or 
minimal interference with 
usual social & functional 
activities
Itching causing greater than 
minimal interference with 
usual social & functional 
activities
Itching causing inability to 
perform usual social & 
functional activities 
NA


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 106
19 February 2016
GASTROINTESTINAL
Grade 1
Grade 2
Grade 3
Grade 4
Anorexia
Loss of appetite without 
decreased oral intake
Loss of appetite associated with 
decreased oral intake without 
significant weight loss 
Loss of appetite associated 
with significant weight loss 
Life-threatening consequences 
OR Aggressive intervention 
indicated [eg, tube feeding or 
total parenteral nutrition]
Ascites
Asymptomatic
Symptomatic AND Intervention 
indicated (eg, diuretics or 
therapeutic paracentesis)
Symptomatic despite 
intervention
Life-threatening consequences
Cholecystitis
NA
Symptomatic AND Medical 
intervention indicated
Radiologic, endoscopic, or 
operative intervention 
indicated
Life-threatening consequences 
(eg, sepsis or perforation) 
Constipation 
NA
Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemas 
Obstipation with manual 
evacuation indicated
Life-threatening consequences 
(eg, obstruction)
Diarrhea 
Adult and Pediatric 
1 Year
Transient or intermittent 
episodes of unformed stools 
OR Increase of 3 stools 
over baseline/24 hr
Persistent episodes of unformed 
to watery stools OR Increase of 
4–6 stools over baseline per 
24 hrs. 
Bloody diarrhea OR Increase 
of 7 stools per 24-hour 
period OR IV fluid 
replacement indicated
Life-threatening consequences 
(eg, hypotensive shock)
Pediatric 1 Year
Liquid stools (more 
unformed than usual) but 
usual number of stools
Liquid stools with increased 
number of stools OR Mild 
dehydration
Liquid stools with moderate 
dehydration
Liquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicated OR Hypotensive 
shock
Dysphagia-Odynophagia 
Symptomatic but able to eat 
usual diet
Symptoms causing altered 
dietary intake without medical 
intervention indicated
Symptoms causing severely 
altered dietary intake with 
medical intervention indicated
Life-threatening reduction in 
oral intake


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 107
19 February 2016
GASTROINTESTINAL
Grade 1
Grade 2
Grade 3
Grade 4
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, 
Dysphagia-Odynophagia
Erythema of the mucosa
Patchy pseudomembranes or 
ulcerations 
Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor trauma
Tissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life-threatening 
consequences (eg, aspiration, 
choking)
Nausea 
Transient (24 hours) or 
intermittent nausea with no 
or minimal interference with 
oral intake
Persistent nausea resulting in 
decreased oral intake for 24–48 
hours
Persistent nausea resulting in 
minimal oral intake for 48 
hours OR Aggressive 
rehydration indicated (eg, 
IV fluids)
Life-threatening consequences 
(eg, hypotensive shock)
Pancreatitis
NA
Symptomatic AND 
Hospitalization not indicated 
(other than ER visit)
Symptomatic AND 
Hospitalization indicated 
(other than ER visit)
Life-threatening consequences 
(eg, sepsis, circulatory failure, 
hemorrhage)
Proctitis (functional-
symptomatic)
Also see Mucositis/ 
Stomatitis for Clinical 
Exam
Rectal discomfort AND No 
intervention indicated
Symptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated 
Symptoms causing inability to 
perform usual social/
functional activities OR 
Operative intervention 
indicated 
Life-threatening consequences 
(eg, perforation)
Vomiting
Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intake
Frequent episodes of vomiting 
with no or mild dehydration
Persistent vomiting resulting 
in orthostatic hypotension OR 
Aggressive rehydration 
indicated
Life-threatening consequences 
(eg, hypotensive shock)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 108
19 February 2016
NEUROLOGICAL
Grade 1
Grade 2
Grade 3
Grade 4
Alteration in Personality-
Behavior or in Mood (eg, 
agitation, anxiety, 
depression, mania, 
psychosis)
Alteration causing no or 
minimal interference with 
usual social & functional 
activities 
Alteration causing greater than 
minimal interference with 
usual social & functional 
activities 
Alteration causing inability to 
perform usual social & 
functional activities 
Behavior potentially harmful 
to self or others (eg, 
suicidal/homicidal ideation or 
attempt, acute psychosis) OR 
Causing inability to perform 
basic self-care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)
Changes causing no or 
minimal interference with 
usual social & functional 
activities
Mild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activities
Confusion, memory 
impairment, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activities
Delirium OR obtundation, OR 
coma
Ataxia 
Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activities
Symptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activities
Symptomatic ataxia causing 
inability to perform usual 
social & functional activities 
Disabling ataxia causing 
inability to perform basic self-
care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) 
Disability causing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicated
Disability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part-time basis 
indicated
Disability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicated
Disability causing inability to 
perform basic self-care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)
NA
NA
Transient ischemic attack
Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
Developmental delay –
Pediatric 16 Years
Mild developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate 
for the setting 
Moderate developmental 
delay, either motor or 
cognitive, as determined by 
comparison with a 
developmental screening tool 
appropriate for the setting 
Severe developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting 
Developmental regression, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 109
19 February 2016
NEUROLOGICAL
Grade 1
Grade 2
Grade 3
Grade 4
Headache 
Symptoms causing no or 
minimal interference with 
usual social & functional 
activities
Symptoms causing greater 
than minimal interference with 
usual social & functional 
activities
Symptoms causing inability to 
perform usual social & 
functional activities
Symptoms causing inability to 
perform basic self-care 
functions OR Hospitalization 
indicated (other than ER visit) 
OR Headache with significant 
impairment of alertness or
other neurologic function 
Insomnia
NA
Difficulty sleeping causing 
greater than minimal 
interference with usual 
social/functional activities
Difficulty sleeping causing 
inability to perform usual 
social & functional activities
Disabling insomnia causing 
inability to perform basic self-
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) 
Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak-
ness causing no or minimal 
interference with usual 
social & functional activities
Muscle weakness causing 
greater than minimal 
interference with usual social 
& functional activities
Muscle weakness causing 
inability to perform usual 
social & functional activities 
Disabling muscle weakness 
causing inability to perform 
basic self-care functions OR 
Respiratory muscle weakness 
impairing ventilation
Neurosensory Alteration 
(including paresthesia and 
painful neuropathy)
Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social &
functional activities 
Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities 
Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activities
Disabling sensory alteration or 
paresthesia causing inability to 
perform basic self-care 
functions
Seizure: (new onset) 
NA
1 seizure 
2–4 seizures 
Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or difficult 
to control (eg, refractory 
epilepsy)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 110
19 February 2016
NEUROLOGICAL
Grade 1
Grade 2
Grade 3
Grade 4
Seizure: (pre-existing) 
For Worsening of Existing 
Epilepsy the Grades Should 
Be Based on an Increase 
from Previous Level of 
Control to Any of These 
Levels
NA
Increased frequency of pre-
existing seizures (non-
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorder
Change in seizure character 
from baseline either in 
duration or quality (eg, 
severity or focality) 
Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or difficult 
to control (eg, refractory 
epilepsy)
Seizure 
– Pediatric 18 Years
Seizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5 minutes with < 24 hours 
post ictal state
Seizure, generalized onset 
with or without secondary 
generalization, lasting 5–20 
minutes with 
< 24 hours post ictal state
Seizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes 
Seizure, generalized onset 
with or without secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)
NA
Present
NA
NA
Vertigo
Vertigo causing no or 
minimal interference with 
usual social & functional 
activities
Vertigo causing greater than 
minimal interference with 
usual social & functional 
activities 
Vertigo causing inability to 
perform usual social & 
functional activities
Disabling vertigo causing 
inability to perform basic self-
care functions


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 111
19 February 2016
MUSCULOSKELETAL
Grade 1
Grade 2
Grade 3
Grade 4
Arthralgia
See also Arthritis
Joint pain causing no or 
minimal interference with 
usual social & functional 
activities
Joint pain causing greater than 
minimal interference with usual 
social & functional activities
Joint pain causing inability 
to perform usual social & 
functional activities
Disabling joint pain causing 
inability to perform basic self-
care functions
Arthritis
See also Arthralgia
Stiffness or joint swelling 
causing no or minimal 
interference with usual 
social & functional activities
Stiffness or joint swelling causing 
greater than minimal interference 
with usual social & functional 
activities
Stiffness or joint swelling 
causing inability to perform 
usual social & functional 
activities
Disabling joint stiffness or 
swelling causing inability to 
perform basic self-care 
functions
Bone Mineral Loss
BMD t-score or z-score
–2.5 to –1.0 
BMD t-score or z-score –2.5
Pathological fracture 
(including loss of vertebral 
height)
Pathologic fracture causing 
life-threatening consequences 
Pediatric 21 Years
BMD z-score 
–2.5 to –1.0
BMD z-score < –2.5
Pathological fracture 
(including loss of vertebral 
height)
Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)
Muscle pain causing no or 
minimal interference with 
usual social & functional 
activities
Muscle pain causing greater than 
minimal interference with usual 
social & functional activities
Muscle pain causing 
inability to perform usual 
social & functional activities
Disabling muscle pain causing 
inability to perform basic self-
care functions
Osteonecrosis
NA
Asymptomatic with radiographic 
findings AND No operative 
intervention indicated
Symptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicated
Disabling bone pain with 
radiographic findings causing 
inability to perform basic self-
care functions


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 112
19 February 2016
SYSTEMIC
Grade 1
Grade 2
Grade 3
Grade 4
Acute Systemic Allergic 
Reaction 
Localized urticaria 
(wheals) with no medical 
intervention indicated
Localized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicated
Generalized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasm
Acute anaphylaxis OR Life-
threatening bronchospasm OR 
laryngeal edema
Chills
Symptoms causing no or 
minimal interference with 
usual social & functional 
activities
Symptoms causing greater than 
minimal interference with usual 
social & functional activities 
Symptoms causing inability to 
perform usual social & 
functional activities
NA
Fatigue
Malaise
Symptoms causing no or 
minimal interference with 
usual social & functional 
activities
Symptoms causing greater than 
minimal interference with usual 
social & functional activities
Symptoms causing inability to 
perform usual social & 
functional activities
Incapacitating fatigue/malaise 
symptoms causing inability to 
perform basic self-care 
functions
Fever (nonaxillary)
37.7C to 38.6C
99.8F to 101.5F
38.7C to 39.3C
101.6F to 102.8F
39.4C to 40.5C
102.9F to 104.9F
40.5C 
104.9F
Pain- Indicate Body Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and Myalgia
Pain causing no or 
minimal interference with 
usual social & functional 
activities
Pain causing greater than minimal 
interference with usual social & 
functional activities
Pain causing inability to 
perform usual social & 
functional activities
Disabling pain causing 
inability to perform basic self-
care functions OR 
Hospitalization (other than ER 
visit) indicated
Unintentional Weight 
Loss
NA
5% to 9% loss in body weight from 
baseline
10% to 19% loss in body 
weight from baseline
20% loss in body weight 
from baseline OR  Aggressive 
intervention indicated [eg, 
tube feeding or total parenteral 
nutrition]


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 113
19 February 2016
INJECTION SITE REACTION
Grade 1
Grade 2
Grade 3
Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when 
area is touched) 
Pain/tenderness causing no 
or minimal limitation of use 
of limb
Pain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activities
Pain/tenderness causing 
inability to perform usual 
social & functional activities
Pain/tenderness causing inability 
to perform basic self-care 
function OR Hospitalization 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15 Years
Erythema OR Induration
of 5 5 cm to 9 9 cm (or 
2581 cm2)
Erythema OR Induration OR 
Edema 9 cm any diameter 
(or 81 cm2)
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR Drainage
Necrosis (involving dermis and 
deeper tissue)
Pediatric 15 Years
Erythema OR Induration 
OR Edema present but 
2.5 cm diameter
Erythema OR Induration 
OR Edema > 2.5 cm 
diameter but < 50% surface 
area of the extremity 
segment (eg, upper 
arm/thigh)
Erythema OR Induration 
OR Edema involving 
50% surface area of the 
extremity segment (eg, 
upper arm/thigh) OR 
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR 
Drainage
Necrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching—no skin lesions)
Itching localized to injection 
site AND Relieved 
spontaneously or with 
48 h treatment 
Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48 h treatment 
Generalized itching causing 
inability to perform usual 
social & functional activities
NA


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 114
19 February 2016
ENDOCRINE/METABOLIC
Grade 1
Grade 2
Grade 3
Grade 4
Lipodystrophy (eg, back 
of neck, breasts, 
abdomen)
Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)
Detectable on physical exam by 
health care provider
Disfiguring OR Obvious 
changes on casual visual 
inspection
NA
Diabetes Mellitus
NA
New onset without need to initiate 
medication OR Modification of 
current meds to regain glucose 
control
New onset with initiation of 
indicated med OR Diabetes 
uncontrolled despite treatment 
modification
Life-threatening consequences 
(eg, ketoacidosis, 
hyperosmolar non-ketotic 
coma) 
Gynecomastia
Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)
Detectable on physical exam by 
health care provider
Disfiguring OR Obvious on 
casual visual inspection
NA
Hyperthyroidism 
Asymptomatic
Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid suppression therapy 
indicated
Symptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification 
Life-threatening consequences 
(eg, thyroid storm)
Hypothyroidism
Asymptomatic
Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicated
Symptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification 
Life-threatening consequences 
(eg, myxedema coma)
Lipoatrophy (eg, fat loss 
from the face, extremities, 
buttocks)
Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)
Detectable on physical exam by 
health care provider
Disfiguring OR Obvious on 
casual visual inspection
NA


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 115
19 February 2016
GENITOURINARY
Grade 1
Grade 2
Grade 3
Grade 4
Intermenstrual Bleeding 
(IMB)
Spotting observed by participant 
OR Minimal blood observed 
during clinical or colposcopic 
exam
Intermenstrual bleeding not 
greater in duration or amount 
than usual menstrual cycle
Intermenstrual bleeding greater 
in duration or amount than usual 
menstrual cycle
Hemorrhage with life-
threatening hypotension OR 
Operative intervention 
indicated
Urinary Tract 
obstruction (eg, stone)
NA
Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunction
Signs or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunction
Obstruction causing life-
threatening consequences
INFECTION
Grade 1
Grade 2
Grade 3
Grade 4
Infection (any other 
than HIV infection)
Localized, no systemic antiμbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activities
Systemic antiμbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional activities
Systemic antiμbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than simple 
incision and drainage) indicated
Life-threatening 
consequences (eg, septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, pursuing a hobby, etc.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 116
19 February 2016
Appendix 5.
Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC 
Guidelines)
1. Candidiasis of bronchi, trachea, or lungs
2. Candidiasis of esophagus
3. Cervical cancer, invasive
4. Coccidioidomycosis, disseminated or extrapulmonary
5. Cryptococcosis, extrapulmonary
6. Cryptosporidiosis, chronic intestinal (1 month duration)
7. Cytomegalovirus disease (other than liver, spleen or nodes)
8. Cytomegalovirus retinitis (with loss of vision)
9. Encephalopathy, HIV-related
10. Herpes simplex: chronic ulcer(s) (1 month duration); or bronchitis, pneumonitis or 
esophagitis
11. Histoplasmosis, disseminated or extrapulmonary
12. Isosporiasis, chronic intestinal (1 month duration)
13. Kaposi’s sarcoma
14. Lymphoma, Burkitt’s (or equivalent term)
15. Lymphoma, immunoblastic (or equivalent term)
16. Lymphoma, primary, of brain
17. Mycobacterium avium complex or Myobacterium kansasii, disseminated or extrapulmonary
18. Mycobacterium tuberculosis, of any site,  pulmonary, disseminated or extrapulmonary
19. Mycobacterium, other species or unidentified species, disseminated or extrapulmonary
20. Pneumocystis jirovecii (previously known as “Pneumocystis carinii) pneumonia
21. Pneumonia, recurrent
22. Progressive multifocal leukoencephalopathy
23. Salmonella septicemia, recurrent
24. Toxoplasmosis of brain
25. Wasting syndrome attributed to HIV infection
CDC Stage-3-Defining Opportunistic Illnesses in HIV Infection - 2014 {Schneider et al 2008}


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 117
19 February 2016
Appendix 6.
Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)
Definitions
a)
Definition of Childbearing Potential
For the purposes of this study, a female born subject is considered of childbearing potential 
following the initiation of puberty (Tanner stage 2) until becoming post-menopausal, unless 
permanently sterile or with medically documented ovarian failure.
Women are considered to be in a postmenopausal state when they are > 54 years of age with 
cessation of previously occurring menses for > 12 months without an alternative cause. In 
addition, women of any age with amenorrhea of > 12 months may also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they are not using hormonal contraception or hormonal replacement therapy.
Permanent sterilization includes hysterectomy, bilateral oophorectomy, or bilateral 
salpingectomy in a female subject of any age.
b)
Definition of Male Fertility
For the purposes of this study, a male born subject is considered to be fertile after the initiation 
of puberty unless permanently sterile by bilateral orchidectomy or medical documentation.
2)
Contraception Requirements for Female Subjects
a)
Study Drug Effects on Pregnancy and Hormonal Contraception
The data on GS-9883/F/TAF in pregnant women is limited or not available. There is no 
suspicion of human teratogenicity based on class effects or genotoxic potential. Relevant non-
clinical reproductive studies for human pregnancy do not indicate a strong suspicion of human 
teratogenicity/fetotoxicity. Data from clinical pharmacokinetic interaction studies of GS-9883 
and F/TAF have demonstrated that there is no reduction in the clinical efficacy of hormonal 
contraception or that the effect on hormonal contraception is insignificant. Please refer to the 
latest version of the GS-9883/F/TAF investigator’s brochure and the current Prescribing 
Information and local product labeling for ABC/DTG/3TC for additional information.
b)
Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highly effective 
contraceptive measures.  They must have a negative serum pregnancy test at Screening and a 
negative pregnancy test on the Day 1 visit prior to randomization. At minimum a pregnancy test 
will be performed at the end of relevant systemic exposure. In the event of a delayed menstrual 
period (over one month between menstruations), a pregnancy test must be performed to rule out 
pregnancy. This is true even for women of childbearing potential with infrequent or irregular 
periods. Female subjects must agree to one of the following from Screening until 30 days 
following the end of relevant systemic exposure.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 118
19 February 2016

Complete abstinence from intercourse of reproductive potential.  Abstinence is an acceptable 
method of contraception only when it is in line with the subject’s preferred and usual 
lifestyle. 
Or

Consistent and correct use of 1 of the following methods of birth control listed below.
Intrauterine device (IUD) with a failure rate of <1% per year
Intrauterine hormone-releasing system (IUS) with a failure rate of <1% per year
Tubal sterilization
Essure micro-insert system (provided confirmation of success 3 months after procedure)
Vasectomy in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Or

Consistent and correct use of one hormonal method and one barrier method
Barrier methods
■
Diaphragm with spermicide
■
Cervical cap with spermicide
■
Male condom (with or without spermicide)
Hormonal methods
■
Oral contraceptives (either combined or progesterone only)
■
Injectable progesterone
■
Implants of levonorgestrel
■
Transdermal contraceptive patch
■
Contraceptive vaginal ring
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 30 days after the end of relevant systemic exposure.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 1
CONFIDENTIAL
Page 119
19 February 2016
3)
Contraception Requirements for Male Subjects
It is theoretically possible that a relevant systemic concentration may be achieved in a female 
partner from exposure of the male subject’s seminal fluid.  Therefore, male subjects with female 
partners of childbearing potential must use condoms during treatment and until 90 days after the 
end of relevant systemic exposure.  Additional contraception recommendations should also be 
considered if the female partner is not pregnant.
Male subjects must also refrain from sperm donation during treatment and until at least 90 days 
after the end of relevant systemic exposure.
4)
Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, 
ovulation, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides 
only, and lactational amenorrhea method (LAM).  Female condom and male condom should not 
be used together.
5)
Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify the investigator if they become pregnant at any time during 
the study, or if they become pregnant within 30 days of last study drug dose. Subjects who 
become pregnant or who suspect that they are pregnant during the study must report the 
information to the investigator and discontinue study drug immediately. Subjects whose partner 
has become pregnant or suspects she is pregnant during the study must report the information to 
the investigator.  Instructions for reporting pregnancy, partner pregnancy, and pregnancy 
outcome are outlined in Section 7.3.

Prot_004.pdf: 
Study Title: 
Sponsor: 
IND Number: 
EudraCT Number: 
Clinical Trials.gov 
Identifier: 
Indication: 
Protocol ID: 
Gilead Study Clinical 
Program Manager: 
Gilead Medical 
Monitor: 
Protocol Version/Date: 
(rJ GILEAU 
CLINICAL STUDY PROTOCOL 
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety 
and Efficacy of Switching from a Regimen of Dolutegravir and 
ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC 
to a FDC of GS-9883/F IT AF in HIV -1 Infected Subjects who are 
Virologically Suppressed 
Gilead Sciences, Inc. 
333 Lakeside Drive 
Foster City, CA 94404 
125589 
2015-004025-14 
Not Available 
HIV -1 Infection 
GS-US-3 80-1844 
Name: 
PPD 
Telephone: PPD 
Fax: 
PPD 
Name: 
Telephone: 
Fax: 
Mobile: 
Original: 
...._ ____ _, 
Javier Szwarcberg, MD 
PPD 
PPD 
PPD 
21 October 2015 
CONFIDENTIALITY STATEMENT 
The inf01mation contained in this document, pmiicularly unpublished data, is the prope1iy or 
under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review by you, your staff, and an applicable Institutional 
Review Bom·d or Independent Ethics Committee. The infonnation is only to be used by you in 
connection with authorized clinical studies of the investigational dmg described in the protocol. 
You will not disclose any of the infonnation to others without written authorization from 
Gilead Sciences, Inc., except to the extent necessmy to obtain infonned consent from those 
persons to whom the dmg may be administered. 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 2
21 October 2015
TABLE OF CONTENTS
TABLE OF CONTENTS ..............................................................................................................................................2
LIST OF IN-TEXT TABLES........................................................................................................................................5
LIST OF IN-TEXT FIGURES ......................................................................................................................................5
PROTOCOL SYNOPSIS ..............................................................................................................................................6
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS....................................................................13
1.
INTRODUCTION ..............................................................................................................................................16
1.1.
Background ............................................................................................................................................16
1.2.
GS-9883 .................................................................................................................................................17
1.2.1.
General Information .............................................................................................................17
1.2.2.
Preclinical Pharmacology and Toxicology...........................................................................17
1.2.3.
Clinical Trials of GS-9883 ...................................................................................................19
1.3.
Information about Emtricitabine (Emtriva®, FTC) ...............................................................................27
1.4.
Information about Tenofovir alafenamide (TAF, GS-7340)..................................................................27
1.4.1.
Clinical Trials of Single Agent Tenofovir Alafenamide (TAF, GS-7340) 
or Fixed Dose Combination emtricitabine/tenofovir alafenamide 
(FTC/TAF)...........................................................................................................................28
1.4.2.
Clinical Trials of FTC/TAF as part of 
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) ...........................29
1.5.
Information about GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) ...........................31
1.5.1.
GS-US-141-1233: Relative Bioavailability of GS-9883, FTC, and TAF 
between GS-9883/F/TAF and GS-9883 + F/TAF................................................................31
1.6.
Information about abacavir/dolutegravir/lamivudine (ABC/DTG/3TC Triumeq®)...............................32
1.7.
Rationale for this Study..........................................................................................................................32
1.8.
Risk/Benefit Assessment for the Study..................................................................................................33
1.9.
Rationale for Dose Selection..................................................................................................................33
1.10.
Compliance ............................................................................................................................................35
2.
OBJECTIVES.....................................................................................................................................................36
3.
STUDY DESIGN................................................................................................................................................37
3.1.
Endpoints ...............................................................................................................................................37
3.2.
Study Design..........................................................................................................................................37
3.3.
Study Treatments ...................................................................................................................................37
3.4.
Duration of Treatment............................................................................................................................37
3.5.
Biomarker Testing..................................................................................................................................38
3.5.1.
Biomarker Samples for Optional Pharmacogenomic Research............................................38
3.5.2.
Additional Sample Storage...................................................................................................39
4.
SUBJECT POPULATION..................................................................................................................................40
4.1.
Number of Subjects and Subject Selection ............................................................................................40
4.2.
Inclusion Criteria....................................................................................................................................40
4.3.
Exclusion Criteria...................................................................................................................................41
5.
INVESTIGATIONAL MEDICINAL PRODUCTS ...........................................................................................43
5.1.
Randomization, Blinding and Treatment Codes ....................................................................................43
5.1.1.
Procedures for Breaking Treatment Codes...........................................................................43
5.2.
Description and Handling.......................................................................................................................44
5.2.1.
Formulation..........................................................................................................................44
5.2.2.
Packaging and Labeling .......................................................................................................44


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 3
21 October 2015
5.2.3.
Storage and Handling...........................................................................................................45
5.3.
Dosage and Administration of GS-9883/Emtricitabine/Tenofovir alafenamide and 
Abacavir/Dolutegravir/Lamivudine .......................................................................................................45
5.4.
Prior and Concomitant Medications.......................................................................................................46
5.5.
Accountability for Investigational Medicinal Product (IMP).................................................................47
5.5.1.
Investigational Medicinal Product Return or Disposal.........................................................47
6.
STUDY PROCEDURES ....................................................................................................................................48
6.1.
Subject Enrollment and Treatment Assignment.....................................................................................48
6.2.
Pretreatment Assessments......................................................................................................................48
6.2.1.
Screening Visit .....................................................................................................................48
6.2.2.
Day 1 Assessments...............................................................................................................50
6.3.
Randomization .......................................................................................................................................51
6.4.
Treatment Assessments (Week 4 - 48)...................................................................................................52
6.5.
Treatment Assessments (Post Week 48 until the Unblinding Visit) ......................................................54
6.5.1.
Post Week 48 Assessments ..................................................................................................54
6.5.2.
Unblinding Visit...................................................................................................................56
6.6.
Post-treatment Assessments ...................................................................................................................58
6.6.1.
Early Study Drugs Discontinuation Assessments.................................................................58
6.6.2.
30 Day Follow Up................................................................................................................59
6.7.
Criteria for Discontinuation of Study Treatment....................................................................................60
6.8.
Bone Mineral Density Evaluations.........................................................................................................61
6.9.
Other Evaluations...................................................................................................................................61
6.9.1.
Markers of Renal Tubular Function .....................................................................................61
6.9.2.
Markers of Inflammation and Immune Activation...............................................................61
6.9.3.
Markers of Platelet Function ................................................................................................61
6.9.4.
Blood and Urine Storage......................................................................................................61
6.10.
Assessments for Premature Discontinuation from Study.......................................................................62
6.11.
End of Study...........................................................................................................................................62
6.12.
Post Study Care......................................................................................................................................62
6.13.
Virologic Failure....................................................................................................................................62
6.13.1.
Management of Virologic Rebound .....................................................................................62
6.13.2.
Subjects with HIV-1 RNA ≥50 copies/mL at Study Drug 
Discontinuation, or Week 48................................................................................................64
7.
ADVERSE EVENTS AND TOXICITY MANAGEMENT...............................................................................65
7.1.
Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events.................................65
7.1.1.
Adverse Events.....................................................................................................................65
7.1.2.
Serious Adverse Events........................................................................................................65
7.1.3.
Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events .........................................................................66
7.2.
Assessment of Adverse Events and Serious Adverse Events.................................................................66
7.2.1.
Assessment of Causality for Study Drugs and Procedures...................................................66
7.2.2.
Assessment of Severity ........................................................................................................67
7.3.
Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead.......................................................................................................................67
7.3.1.
Adverse Events.....................................................................................................................67
7.3.2.
Serious Adverse Events........................................................................................................68
7.4.
Gilead Reporting Requirements.............................................................................................................69
7.5.
Toxicity Management ............................................................................................................................69
7.5.1.
Grades 1 and 2 Laboratory Abnormality or Clinical Event..................................................69
7.5.2.
Grade 3 Laboratory Abnormality or Clinical Event.............................................................70
7.5.3.
Grade 4 Laboratory Abnormality or Clinical Event.............................................................70
7.5.4.
Management of Possible Abacavir Hypersensitivity Reaction.............................................70


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 4
21 October 2015
7.5.5.
On-Treatment Hepatitis C Management...............................................................................71
7.6.
Special Situations Reports......................................................................................................................71
7.6.1.
Definitions of Special Situations..........................................................................................71
7.6.2.
Instructions for Reporting Special Situations.......................................................................72
8.
STATISTICAL CONSIDERATIONS................................................................................................................74
8.1.
Analysis Objectives and Endpoints........................................................................................................74
8.1.1.
Analysis Objectives..............................................................................................................74
8.1.2.
Primary Endpoint .................................................................................................................74
8.1.3.
Secondary Endpoint .............................................................................................................74
8.2.
Analysis Conventions.............................................................................................................................74
8.2.1.
Analysis Sets ........................................................................................................................74
8.3.
Data Handling Conventions ...................................................................................................................76
8.4.
Demographic Data and Baseline Characteristics ...................................................................................76
8.5.
Efficacy Analysis ...................................................................................................................................77
8.5.1.
Primary Analysis..................................................................................................................77
8.5.2.
Secondary Analyses .............................................................................................................78
8.6.
Safety Analysis.......................................................................................................................................79
8.6.1.
Extent of Exposure...............................................................................................................79
8.6.2.
Adverse Events.....................................................................................................................79
8.6.3.
Laboratory Evaluations ........................................................................................................80
8.6.4.
Bone Safety Evaluations ......................................................................................................80
8.6.5.
Other Safety Evaluations......................................................................................................80
8.7.
Pharmacokinetic Analysis......................................................................................................................80
8.8.
Biomarker Analysis................................................................................................................................81
8.9.
Patient Reported Outcomes (PRO).........................................................................................................81
8.10.
Sample Size............................................................................................................................................81
8.11.
Data Monitoring Committee ..................................................................................................................81
9.
RESPONSIBILITIES..........................................................................................................................................82
9.1.
Investigator Responsibilities ..................................................................................................................82
9.1.1.
Good Clinical Practice..........................................................................................................82
9.1.2.
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval...........................................................................................................82
9.1.3.
Informed Consent.................................................................................................................82
9.1.4.
Confidentiality......................................................................................................................83
9.1.5.
Study Files and Retention of Records ..................................................................................83
9.1.6.
Case Report Forms...............................................................................................................84
9.1.7.
Investigational Medicinal Product Accountability and Return.............................................85
9.1.8.
Inspections............................................................................................................................85
9.1.9.
Protocol Compliance............................................................................................................85
9.2.
Sponsor Responsibilities ........................................................................................................................86
9.2.1.
Protocol Modifications.........................................................................................................86
9.2.2.
Study Report and Publications .............................................................................................86
9.3.
Joint Investigator/Sponsor Responsibilities ...........................................................................................86
9.3.1.
Payment Reporting...............................................................................................................86
9.3.2.
Access to Information for Monitoring..................................................................................87
9.3.3.
Access to Information for Auditing or Inspections ..............................................................87
9.3.4.
Study Discontinuation..........................................................................................................87
10.
REFERENCES ...................................................................................................................................................88
11.
APPENDICES ....................................................................................................................................................89


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 5
21 October 2015
Appendix 1.
Investigator Signature Page....................................................................................................90
Appendix 2.
Study Procedures Table (Blinded Phase) ...............................................................................91
Appendix 3.
Management of Clinical and Laboratory Adverse Events......................................................95
Appendix 4.
GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities...............96
Appendix 5.
Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines) ...........................120
Appendix 6.
Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements.................................................................................................121
LIST OF IN-TEXT TABLES
Table 1-1.
GS-US-141-1218: GS-9883 Mean (%CV) PK Parameters Following Single Doses 
of GS-9883 in Healthy Subjects (GS-9883 PK Analysis Set; Part A: Single Dosing) ...........21
Table 1-2.
GS-US-141-1218: GS-9883 Plasma Pharmacokinetic Parameters by GS-9883 Dose 
Following Multiple-Dose Administration of GS-9883 (Analysis Set: GS-9883 PK 
Part B: Multiple-Dose) ...........................................................................................................22
Table 1-3.
GS-US-141-1218: Statistical Comparison of GS-9883 Pharmacokinetic Parameters 
Following Single-Dose Administration of GS-9883 in the Fasted and Fed States 
(GS-9883 PK Analysis Set)....................................................................................................23
Table 1-4.
Trough GS-9883 Plasma Concentrations at Steady State Following GS-9883 
Administration Under Fasting Conditions and Corresponding Protein-Adjusted 
IQ95 Values (GS-9883 PK Analysis Set)...............................................................................24
Table 1-5.
GS-US-141-1219: Trough GS-9883 Plasma Concentrations at Steady State 
Following GS-9883 Administration Under Fasting Conditions and Corresponding 
Protein-Adjusted IQ95 Values.................................................................................................34
Table 5-1.
Prior and Concomitant Medications.......................................................................................46
LIST OF IN-TEXT FIGURES
Figure 1-1.
GS-US-141-1219: Mean and 95% CIs of Change from Baseline in HIV-1 RNA 
(log10 copies/mL) (PP Analysis Set).......................................................................................24
Figure 3-1.
Study Schema.........................................................................................................................38
Figure 6-1.
Virologic Rebound Schema....................................................................................................63


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 6
21 October 2015
PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Study Title: 
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety 
and Efficacy of Switching from a Regimen of Dolutegravir and 
ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC
to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects who are 
Virologically Suppressed
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:
125589
2015-004025-14
Not Available
Study Centers Planned:
Approximately 75 centers in North America
Approximately 4 centers in Asia Pacific
Approximately 26 centers in Europe
Objectives:
The primary objective of this study is:

To evaluate the efficacy of switching from a regimen of DTG 
and ABC/3TC or a fixed dose combination (FDC) of 
ABC/DTG/3TC to a FDC of GS-9883/F/TAF versus continuing 
DTG and ABC/3TC as the FDC ABC/DTG/3TC in 
virologically suppressed HIV-1 infected subjects as determined 
by the proportion of subjects with virologic failure (HIV-1 RNA 
≥50 copies/mL) at Week 48
The secondary objectives of this study are:

To evaluate the safety and tolerability of the two treatment 
groups through Week 48

To evaluate the bone safety of the two treatment groups as 
determined by the percentage change from baseline in hip and 
spine bone mineral density (BMD) through Week 48
Study Design:
Randomized, double-blind, multicenter, active-controlled study to 
evaluate the safety and efficacy of switching to a FDC of 
GS-9883/F/TAF tablet versus continuing DTG and ABC/3TC as the 
FDC ABC/DTG/3TC in HIV-1 infected subjects who are 
virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable 
regimen of DTG + ABC/3TC or ABC/DTG/3TC FDC for 
3 months prior to screening.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 7
21 October 2015
Subjects who provide written consent and meet all eligibility criteria 
will be randomized in a 1:1 ratio to one of the following 2 treatment 
groups:
Treatment Group 1: FDC of GS-9883 50 mg/ emtricitabine 
200 mg/ tenofovir alafenamide 25 mg (GS-9883/F/TAF) + Placebo 
to match FDC of abacavir 600 mg/ dolutegravir 50 mg/lamivudine 
300 mg (ABC/DTG/3TC) administered orally, once daily, without 
regard to food (n=260)
Treatment Group 2: FDC of abacavir 600 mg/dolutegravir 
50 mg/ lamivudine 300 mg (ABC/DTG/3TC) + Placebo to match 
FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir 
alafenamide 25 mg (GS-9883/F/TAF) administered orally, 
once daily, without regard to food (n=260)
Number of Subjects 
Planned:
Approximately 520 subjects in total.
260 subjects in each Treatment Group 1 and Treatment Group 2
Target Population:
HIV-1 infected adult subjects who are virologically suppressed 
(HIV-1 RNA < 50 copies/mL) on a stable regimen of
DTG + ABC/3TC or ABC/DTG/3TC FDC for 3 months prior to 
screening.
Duration of 
Treatment:
Subjects will be treated for at least 48 weeks. Subjects’ treatments 
will be unblinded after the last subject completes the Week 48 visit 
and Gilead completes the Week 48 analysis. Subjects will continue 
to take their blinded study drug and attend visits every 12 weeks 
until treatment assignments have been unblinded. At the Unblinding 
Visit, subjects in a country where GS-9883/F/TAF FDC is not 
available will be given the option to receive GS-9883/F/TAF FDC 
in an open label extension phase for 48 weeks, or until the product 
becomes accessible to subjects through an access program, or until 
Gilead Sciences elects to discontinue the study in that country, 
whichever occurs first.
After Week 48 Visit, subjects in the United Kingdom (UK) and 
Sweden (SWE) will stop taking study drug and complete a 30 day 
follow up visit and return to standard of care.
Subjects who complete the study through the Unblinding Visit and 
do not continue on the open-label GS-9883/F/TAF FDC extension 
phase, will be required to return to the clinic 30 days after 
unblinding visit for a 30-Day Follow-Up Visit.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 8
21 October 2015
Diagnosis and Main 
Eligibility Criteria:
Medically stable HIV-1 infected subjects who meet the following 
criteria:

Currently receiving an antiretroviral regimen of 
DTG + ABC/3TC, or ABC/DTG/3TC FDC for 3 months prior 
to screening

Currently on the first or second antiretroviral regimen, with 
documented plasma HIV 1 RNA < 50 copies/mL on a stable 
regimen (or undetectable HIV-1 RNA level according to the 
local assay being used if the limit of detection is 
≥50 copies/mL) for ≥ 3 months preceding the Screening visit.
Prior changes in antiretroviral regimen are only allowed due 
to tolerability issues or for regimen simplification. 
Unconfirmed virologic elevations of ≥50 copies/mL 
(transient detectable viremia, or “blip”) prior to screening are 
acceptable. If the lower limit of detection of the local HIV-1 
RNA assay is <50 copies/mL (eg, <20 copies/mL), the 
plasma HIV-1 RNA level cannot exceed 50 copies/mL on 
two consecutive HIV-1 RNA tests.

Estimated GFR 50 mL/min according to the Cockcroft-Gault 
formula for creatinine clearance

No chronic Hepatitis B Virus (HBV) infection, as determined by 
either
Positive HBV surface antigen and negative HBV surface 
antibody, regardless of HBV core antibody status, at the 
screening visit
Positive HBV core antibody and negative HBV surface 
antibody, regardless of HBV surface antigen status, at the 
screening visit
Study Procedures/
Frequency:
After screening procedures, eligible subjects will be randomized 1:1 
to Treatment Group 1 or Treatment Group 2 and treated for 
48 weeks. Following the Day 1 visit, subjects will return for study 
visits at Weeks 4, 8, and 12, and then every 12 weeks through 
Week 48. After 48 weeks, subjects will continue to take their 
blinded study drugs and attend study visits every 12 weeks until 
treatment assignments have been unblinded (except the UK and 
SWE).


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 9
21 October 2015
For all eligible subjects, blood will be collected at Day 1, Weeks 4, 
8, 12, and then every 12 weeks through the unblinding visit.
Laboratory analyses (hematology, chemistry, and urinalysis), HIV-1 
RNA, CD4+ cell count, and complete or symptom-directed physical 
examinations will be performed at the Screening, Day 1 and all 
subsequent study visits.
In addition, blood will be collected and stored for possible 
evaluation of markers of inflammation and immune activation, 
which may include but not limited to: cystatin C, IL-6, hs-CRP, 
d-dimer, sCD14, and sCD163. Platelet function evaluations may 
also be assessed, including but not limited to soluble glycoprotein 
VI (sGPVI), P-selectin, and soluble CD40 ligand. Urine will be 
collected for evaluations of renal tubular function including urine 
albumin, urine creatinine, urine protein, retinol binding protein and 
beta-2 microglobulin.
For all subjects on study drug, except subjects located in Germany, 
dual energy x-ray absorptiometry (DXA) scans will be performed 
prior to or within 24 hours of the Day 1 Visit , and then at 
Weeks 24, 48 and at the Unblinding Visit or Early Study Drug 
Discontinuation Visit, if > 12 weeks since last scan. DXA scan
results will be provided to study sites when available.
Adverse events and concomitant medications will be assessed at 
each visit.
Test Product, Dose, and 
Mode of 
Administration:
FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir 
alafenamide 25 mg (GS-9883/F/TAF) administered orally, 
once daily without regard to food.
Reference Therapy, 
Dose, and Mode of 
Administration:
FDC of abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg 
(ABC/DTG/3TC) administered orally, once daily without regard to 
food.
Criteria for Evaluation:
Safety:
Adverse events, clinical laboratory tests and DXA
Efficacy:
The primary efficacy endpoint is:

The proportion of subjects with virologic failure (HIV-1 RNA 
≥50 copies/mL) at Week 48 as defined by the modified United 
States (US) Food and Drug Administration (FDA) snapshot 
algorithm


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
Phrum acokinetics: 
Optional Genomic 
Testing: 
CONFIDENTIAL 
The secondruy endpoints include: 
Final 
Original 
• 
The prop01iion of subjects with HIV -1 RNA < 50 copies/mL at 
Week 48 as defmed by the US FDA snapshot algorithm 
• 
The change from baseline in CD4+ cell count at Week 48 
An intensive phan nacokinetic (PK) substudy will be perf01m ed at 
the Weeks 4 or 8 visits in a subset of subjects (target n=30) at study 
sites able to conduct this testing. 
For all subjects on study dmg a single anytime pre or post-dose PK 
blood sample will be collected at Weeks 8, 24 and 36. 
For all subjects on study dmg a trough PK blood srunple will be 
obtained 20-28 hours following the last dose at Weeks 4 and 12. 
Following an observed dose, one post-dose PK blood srunple will be 
collected between 1 and 4 hours post-dose. 
For intensive PK substudy, the following PK parruneters for 
GS-9883 may be explored as applicable: 
Cmax, Tmax, Clast, Tiast, Ctau,Tll2, AUCtau,AUCo-Iast, VzJF, CLss/F 
The concentration of GS-9883 may be summarized using descriptive 
statistics. The phrumacokinetics of GS-9883 may be evaluated using 
population approaches. T AF and FTC concentrations may be 
analyzed and PK pru·ameters may be summarized as applicable. 
PPD 
Page 10 
21 October 2015 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 11
21 October 2015
Patient Reported 
Outcome:
Short Form 36 Health Survey (SF-36), HIV Symptoms Distress 
Module, Work Productivity and Activity Impairment Questionnaire 
(WPAI) and Pittsburgh Sleep Quality Index (PSQI) will be 
administered at Day 1, Weeks 4, 12 and 48.
Statistical Methods:
The primary analysis will consist of a non-inferiority test of 
switching to FDC GS-9883/F/TAF versus continuing DTG and 
ABC/3TC as the FDC of ABC/DTG/3TC, with respect to the 
proportion of subjects with virologic failure (HIV-1 RNA 
≥50 copies/mL) at Week 48 as defined by the modified US FDA 
snapshot algorithm. It will be concluded that GS-9883/F/TAF is 
non-inferior to the ABC/3TC/DTG if the upper bound of the 2-sided 
95% confidence interval (CI) of the difference between treatment 
groups (GS-9883/F/TAF – ABC/3TC/DTG) in the virologic failure 
rate is less than 4%; ie, a margin of 4% is applied to non-inferiority 
assessment. The 2-sided 95% CIs will be constructed based on the 
exact method.
The proportion of subjects with HIV-1 RNA < 50 copies/mL at 
Week 48 as defined by the US FDA snapshot algorithm will also be 
summarized. The 95% CIs will be constructed in the same manner 
as described for the primary efficacy endpoint.
The change from baseline in CD4+ cell count at Weeks 48 will be 
summarized by treatment using descriptive statistics. The 
differences and the associated 95% CIs will be constructed using an 
Analysis of Variance (ANOVA) model, including treatment 
(GS-9883/F/TAF vs. ABC/DTG/3TC) as a fixed effect in the model.
The percentage change from baseline in hip and spine BMD at 
Week 48 will be summarized by treatment using descriptive 
statistics. The differences and the associated 95% CIs will be 
conducted using an ANOVA model, including treatment group as a 
fixed effect in the model.
Adverse events, clinical laboratory assessment, and pharmacokinetic 
parameters will be summarized using descriptive statistics.
A total of approximately 520 HIV-1 infected subjects, randomized 
in a 1:1 ratio to 2 treatment groups (260 subjects per treatment 
group), achieves at least 90% power to detect a non-inferiority 
margin of 4% in Week 48 virologic failure rate (HIV-1 RNA
≥50 copies/mL) difference between the 2 treatment groups.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 12
21 October 2015
For sample size and power computation, it is assumed that both 
treatment groups have a virologic failure rate of 2% (based on the 
historical Gilead E/C/F/TAF and STB studies), that a non-inferiority 
margin is 4%, and that the significance level of the test is at a 
one-sided 0.025 level
This study will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 13
21 October 2015
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C
degrees Celsius
F
degrees Fahrenheit
ABC/3TC
abacavir/lamivudine, EpzicomKivexa
ABC/DTG/3TC
abacavir/dolutegravir/lamivudine, Triumeq
AE
adverse event
ALT
alanine aminotransferase
ANC
absolute neutrophil counts
ARV
antiretroviral
AST
aspartate aminotransferase
AUC
area under the plasma/serum/peripheral blood mononuclear cell concentration 
versus time curve
BID
twice a day 
BUN
blood urea nitrogen
CBC
complete blood count
CI
confidence interval
CLcr
creatinine clearance
Cmax
the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
CMH
Cochran-Mantel-Haenszel
CNS
central nervous system
COBI, /co
cobicistat (GS-9350)
Ctau
the observed drug concentration at the end of the dosing interval
CPK
creatine phosphokinase
CRF
case report form(s)
CRO
contract (or clinical) research organization 
CYP
cytochrome P450
DHHS
Department of Health and Human Services
DNA
deoxyribonucleic acid
DSPH
Drug Safety and Public Health
DTG
dolutegravir, Tivicay
ECG
electrocardiogram
eCRF
electronic case report form(s)
eGFR
estimated glomerular filtration rate
EVG
elvitegravir
E/C/F/TAF
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide 
E/C/F/TDF
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate, Stribild
FAS
full analysis set
FDA
(United States) Food and Drug Administration
FDC
fFixed dose combination


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 14
21 October 2015
FTC/TAF 
emtricitabine/tenofovir alafenamide 
FSH
follicle-stimulating hormone
FTC, F
emtricitabine, Emtriva
GCP
Good Clinical Practice (Guidelines)
GGT
gamma glutamyl transferase
GLSM
geometric least squares mean
GSI
Gilead Sciences, Inc.
GS-9883/F/TAF
GS-9883/emtricitabine/tenofovir alafenamide
HAART
highly active antiretroviral therapy
HBV
hepatitis B virus
HBcAb
hepatitis B core antibody
HBsAb
hepatitis B surface antibody
HBsAg
hepatitis B surface antigen
HCV
hepatitis C virus
HDPE
high-density polyethylene
hERG
human Ether-à-go-go-Related Gene
HIV
Human Immunodeficiency Virus
HIV Sx
HIV Symptoms  Distress Module
HLA
human leukocyte antigen
IB
investigator’s brochure
ICH
International Conference on Harmonisation
IDMC
Independent Data Monitoring Committee
IND
Investigational New Drug (Application)
INSTI
integrase strand-transfer inhibitors
IRB
institutional review board
IWRS
interactive web response system
KS
Kaposi’s sarcoma
LDH
lactate dehydrogenase
LLN
lower limit of the normal range
MedDRA
Medical Dictionary for Regulatory Activities
mg
milligram
MH
Mantel-Haenszel
min
minute
mmHg
millimeters mercury
NNRTI
non-nucleoside reverse transcriptase inhibitor
NOAEL
no observed adverse effect level
NRTI
nucleoside/nucleotide reverse transcriptase inhibitor
P-gp
P-glycoprotein
PI
protease inhibitor
PK
Pharmacokinetic


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 15
21 October 2015
PSQI
Pittsburgh Sleep Quality Index
PT
preferred term 
PT
prothrombin time 
PTM
placebo-to-match
QD
once daily 
RAL
raltegravir
RNA
ribonucleic acid
SA
single agent
SAE
serious adverse eventt
SF-36
Short Form 36 Health Survey
SUSAR
Suspected Unexpected Serious Adverse Reaction
TAF
tenofovir alafenamide 
TDF
tenofovir disoproxil fumarate, Viread
TFV-DP
tenofovir diphosphate (TFVpp)
tmax
the time (observed time point) of Cmax
TSH
thyroid stimulating hormone
UGT1A1
uridine 5'-diphospho-glucuronosyltransferase 
UGT
uridine glucuronosyltransferase
ULN
upper limit of the normal range
UK
United Kingdom
US
United States
WPAI
Work Productivity and Activity Impairment Questionnaire


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 16
21 October 2015
1.
INTRODUCTION
1.1.
Background
Human immunodeficiency virus-1 (HIV-1) infection is a life-threatening and serious disease that 
is of major public health interest around the world. There are approximately 2.4 million people in 
North America and Western and Central Europe living with HIV-1 and 36 million people 
worldwide {36201}. The infection, if left untreated or suboptimally treated, is characterized by 
deterioration in immune function, ultimately resulting in death. Therapeutic strategies for the 
treatment of HIV-1 disease have been significantly advanced by the availability of highly active 
antiretroviral therapy (HAART); the introduction of HAART was associated with a dramatic 
decrease in acquired immune deficiency syndrome (AIDS)-related morbidity and mortality 
{27881}, {5125}, {8284}.
The success of potent and well-tolerated ART means that morbidity and mortality in the 
HIV-infected population is increasingly driven by non-AIDS–associated comorbidities. Clinical 
attention has become more focused on the optimization of tolerability, long-term safety, and 
adherence of potent ART regimens {29705}. In addition, there remains a significant medical need 
for new, effective therapies that take into consideration HIV genetic variability, the aging 
HIV-infected population, ARV resistance, non-HIV comorbidities, and regimen simplification.
For ART-naive HIV-infected patients, current treatment guidelines suggest that initial therapy 
consist of 2 nucleos(t)ide reverse transcriptase inhibitors (N[t]RTI) and either an integrase 
strand-transfer inhibitor (INSTI) or the boosted protease inhibitor darunavir {34898}. 
Virologically suppressed, HIV-infected patients may switch from their current regimen because 
of safety or tolerability concerns or for regimen simplification. All patient populations may 
benefit from once-daily fixed-dose combination (FDC) regimens as these have been shown to 
provide increased adherence and improved clinical and virologic outcomes {21053}, {29702}
Tenofovir (TFV) is a nucleotide analog that inhibits HIV-1 reverse transcription. While tenofovir 
disoproxil fumarate (TDF), an oral prodrug of TFV, is a preferred NtRTI for initial therapy, 
nephrotoxicity is an identified risk, and reductions in bone mineral density (BMD) have been 
shown that are larger than those seen with other NRTIs. Tenofovir alafenamide (TAF) is also an 
oral prodrug of TFV. TAF is more stable in plasma than TDF, provides higher intracellular 
levels of the active phosphorylated metabolite tenofovir diphosphate (TFV-DP), and
approximately 90% lower circulating levels of TFV relative to TDF at the clinical doses. 
The distinct metabolism of TAF offers the potential for an improved clinical profile compared 
with TDF.
GS-9883 is a potent inhibitor of HIV-1 integrase that is being evaluated for the treatment of 
HIV-1 infection.  Antiviral testing has shown that GS-9883 is active against a broad panel of 
HIV-1 viral lab strains and clinical isolates.  GS-9883 is fully active against a panel of mutant 
viruses with resistance to NRTIs, non-nucleoside reverse-transcriptase inhibitors (NNRTIs), and 
protease inhibitors (PIs).  Integrase mutant viruses that are resistant to the INSTIs raltegravir 
(RAL) and elvitegravir (EVG) remain largely sensitive to GS-9883.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 17
21 October 2015
Gilead Sciences (Gilead) has coformulated GS-9883 with the NRTI emtricitabine (FTC; F) and 
the NtRTI tenofovir alafenamide (TAF) into an FDC tablet that is suitable for once-daily use. 
This GS-9883/F/TAF FDC may provide a potent, convenient, tolerable, and practical regimen 
for the long-term treatment of patients with HIV infection.
1.2.
GS-9883
1.2.1.
General Information
GS-9883, a potent inhibitor of HIV-1 integrase is being evaluated for the treatment of HIV 
infection. Antiviral testing has shown that GS-9883 is active against a broad panel of HIV-1 viral 
lab strains and clinical isolates. GS-9883 is fully active against a panel of mutant viruses with 
resistance to NRTIs, NNRTIs, and PIs. Integrase mutant viruses that are resistant to the INSTIs
RAL and EVG remain largely sensitive to GS-9883.
1.2.2.
Preclinical Pharmacology and Toxicology
A core battery of safety pharmacology studies have been conducted with GS-9883. These 
include assessments of cytotoxicity, off-target receptor and ion-channel binding, effects on 
human Ether-à-go-go-Related Gene (hERG) potassium current and papillary muscle action 
potential, and in vivo studies in rats and dogs that evaluated effects of GS-9883 on all major 
organ systems. The volume of distribution of GS-9883 ranged between 0.09 and 0.22 L/kg in the 
preclinical species, which indicates that the distribution of GS-9883 is limited to the extracellular 
compartment due to its high binding to plasma proteins. The projected half-life of GS-9883 in 
humans is approximately 20 hours based upon the estimates of clearance and volume of 
distribution.
1.2.2.1.
Pharmacology
GS-9883 has IC50 values ranging from 1.5 to 2.4 nM, similar to the inhibitory effect of DTG and 
EVG. GS-9883 is highly potent against HIV replication in MT4 cells with an EC50 (50% 
effective inhibitory concentration) value of 1.9 nM and a protein adjusted EC95 value of 361 nM. 
GS-9883 does not show significant cytotoxicity against dividing and non-dividing human 
PBMCs, primary human hepatocytes and various non-target human cell lines.
GS-9883 is mainly metabolized by uridine 5'-diphospho-glucuronosyltransferase (UGT1A1) and 
CYP3A. GS-9883 does not inhibit major human CYP isoforms or UGT1A1 at concentrations up 
to 25 M. Consequently, GS-9883 is unlikely to be a clinically relevant inhibitor of these
enzymes, and is not expected to inhibit the metabolic clearance of drugs metabolized by these 
enzymes. GS-9883 only modestly inhibits renal transporter OCT2 (IC50 = 0.42 M). As a result, 
GS-9883 is not expected to significantly interfere with the key transporter responsible for 
creatinine tubular elimination at the clinically projected Cmax. Additionally, the risk that GS-9883 
will affect the OCT2-mediated excretion of co-administered drugs is considered to be low.
GS-9883 does not activate AhR and only weakly activates PXR at concentrations up to 50 M 
(less than 5% and 40% of activation, respectively, compared to positive control compound). 
Therefore, GS-9883 is not expected to act as an inducer through PXR- or AhR-mediated 
pathways at the doses and exposure levels projected in clinical use.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 18
21 October 2015
1.2.2.2.
Toxicology
Single oral doses of GS-9883 up to 1000 mg/kg were well-tolerated in rats (AD-141-2286). The 
increase in exposure was limited (< 2-fold) between 100 and 300 mg/kg and similar exposure 
was observed between 300 and 1000 mg/kg suggesting saturation of absorption at 300 mg/kg 
(AUC0-24 2205 gh/mL and 1931 gh/mL, respectively). In monkeys, single oral doses of 
GS-9883 up to 1000 mg/kg were well-tolerated (AD-141-2284). The increase in exposure was 
limited (< 2-fold) between 300 to 1000 mg/kg (AUC0-24 803 gh/mL and 1078 g h/mL, 
respectively).
In 2-week (TX-141-2029) and 26-week (TX-141-2031) oral toxicity studies in rats at doses up to 
300 mg/kg/day, GS-9883 was well-tolerated with no GS-9883-related effects on clinical 
observations, body weight, food consumption, ophthalmic examinations, and anatomic 
pathology.  The high dose of 300 mg/kg/day was considered the maximum feasible dose based 
upon saturation of absorption. The no observed effect level (NOEL) in the 26-week study was 
considered to be the high dose of 300 mg/kg/day.  At the NOEL, GS-9883 exposures in the rat 
were considered to be approximately 12-/31-fold higher (males/females) than the projected 
steady state human exposure of GS-9883 following administration of GS-9883/F/TAF 
(50/200/25 mg) QD under fed conditions.
In a 39-week study in monkeys (TX-141-2032), following administration of 1000 mg/kg/day 
(high dose) of GS-9883 for 39 weeks, pathology data indicated minimal to marked bile duct 
hyperplasia and minimal or moderate hepatocyte hypertrophy in both sexes, and minimal 
regenerative hyperplasia and minimal or slight neutrophil infiltrate in males.  The macroscopic 
finding of rough surface on the liver in one male administered 1000 mg/kg/day correlated with 
moderate hepatocyte hypertrophy and marked bile duct hyperplasia. After a 4-week recovery 
period, GS-9883-related microscopic liver findings included marked bile duct hyperplasia, slight 
hepatocyte hypertrophy, minimal regenerative hyperplasia, and slight lymphocyte infiltrate in 
one male and slight bile duct hyperplasia in one female administered 1000 mg/kg/day, while the 
other two animals in the high dose group had no hepatobiliary findings. Minimally to mildly 
increased ALT activities (≤3.5-fold versus baseline values), likely associated with liver findings, 
exhibited reversibility. There were no other adverse findings in the study, including clinical 
observations, or effects on body weight, body weight change, food consumption, ECGs, 
hematology, coagulation, clinical chemistry, urinalysis, and ophthalmoscopy.
No GS-9883-related effects were observed in the mid-dose group (200 mg/kg/day) which was 
considered the no-observed-effect-level (NOEL).  The estimated margin of exposure at the 
NOEL was approximately 4.7-fold based on expected human exposure with the once daily 
dosing of the GS-9883/F/TAF (50/200/25 mg) tablet.
A standard battery of in vitro and in vivo studies was performed to assess the genotoxic potential 
of GS-9883. There was no evidence of mutagenic or clastogenic activity in an in vitro bacterial 
reverse mutation assay (Study TX-141-2026), a chromosomal aberration assay in human 
lymphocytes (Study TX-141-2027), or in a rat micronucleus test (Study TX-141-2029).


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 19
21 October 2015
1.2.3.
Clinical Trials of GS-9883
Clinical trials entailing the use of GS-9883 include:

GS-US-141-1218, a Phase 1 double blind, randomized, placebo-controlled, first-in-human, 
single- and multiple-ascending dose study evaluating the safety, tolerability, and PK of oral 
GS-9883 in healthy subjects and a randomized, open-label, 2-cohort, 3-period, crossover, PK 
study evaluating the drug interaction potential between F/TAF FDC tablet and GS-9883 in 
healthy subjects (completed)

GS-US-141-1219, a Phase 1b randomized, double-blinded, sequential cohort
placebo-controlled study of the safety, PK, and antiviral activity of GS-9883 in HIV-1 
infected subjects study of the pharmacokinetics and antiviral activity of GS-7340 
(8 mg, 25 mg, 40 mg) in HIV infected subjects (completed)
GS-US-141-1233, a Phase 1,Open-label, Two-Cohort, Multiple-Period, Fixed-Sequence,
Crossover Study to Evaluate 1) the Relative Bioavailability of
Two GS-9883/Emtricitabine/Tenofovir Alafenamide (75/200/25 mg and 50/200/25 mg)
Fixed-Dose Combination Tablets Versus a GS-9883 (75 mg) Tablet and a Emtricitabine/Tenofovir 
Alafenamide (200/25 mg) Fixed-Dose Combination Tablet Administered Simultaneously and 
2) the Effect of Food on the Pharmacokinetics of GS-9883, Emtricitabine and Tenofovir 
Alafenamide When Administered as GS-9883/Emtricitabine/Tenofovir Alafenamide 
(75/200/25 mg and 50/200/25 mg) Fixed-Dose Combination Tablets (ongoing)

GS-US-141-1479, a Phase 1, open-label, parallel-group, adaptive single-dose study to 
evaluate the PK of GS-9883 in subjects with normal and impaired renal function (completed)

GS-US-141-1480, a Phase 1 partially-blinded, randomized, placebo- and positive-controlled 
study to evaluate the effect of GS-9883 on the QT/QTc interval in healthy subjects 
(completed)

GS-US-141-1481, a Phase 1 study to evaluate the pharmacokinetics, metabolism, and 
excretion of GS-9883 in healthy subjects (completed)

GS-US-141-1485, a Phase 1 adaptive study to evaluate transporter, CYP-mediated and 
UGT1A1 drug-drug interactions between GS-9883 and probe drugs (ongoing)

GS-US-141-1487, a Phase 1 randomized, Blinded, Placebo-Controlled Phase 1 Study 
Evaluating the Effect of GS-9883 on Renal Function as Assessed by Markers of Glomerular 
Filtration Rate (ongoing)

GS-US-311-1790, a Phase 1Randomized, Open Label, Drug Interaction Study Evaluating the 
Effect of F/TAF FDC Tablet or GS-9883 on the Pharmacokinetics of a Representative 
Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol (ongoing)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 20
21 October 2015

GS-US-380-1761, a Phase 1 Study to Evaluate Pharmacokinetic Drug-Drug Interaction 
Potential between GS-9883/Emtricitabine/Tenofovir Alafenamide Fumarate 
(GS-9883/F/TAF) and Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) 
Tablets (ongoing)

GS-US-141-1475, a Phase 2 Randomized, Double-Blinded Study of the Safety and Efficacy 
of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + 
Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive 
Adults (ongoing)

Please refer to the GS-9883/F/TAF Investigators’ Brochure for further information about 
these
1.2.3.1.
Phase 1 Safety and Pharmacokinetics
Study GS-US-141-1218 was a four part, first-in-human study.  Parts A and B were randomized, 
double-blind, placebo-controlled, single and multiple ascending dose studies of GS-9883 in 
healthy male and female subjects.  Part C was an open label, fixed sequence food effect study 
evaluating the effect of food on the PK of GS-9883.  Part D was a randomized, open-label, 
2-cohort, 3-period, crossover PK study evaluating the drug interaction potential between 
FTC/TAF FDC tablet and GS-9883 in healthy subjects.
There was no difference in the overall incidence or type of AEs when GS-9883 was administered 
in the fasted and fed states. There was no difference in the overall incidence of AEs when 
GS-9883 or FTC/TAF was each administered alone or in combination.
No deaths or pregnancies were reported. No Grade 3 or 4 AEs or SAEs, were reported in any 
cohort.
Increases in serum creatinine were observed in this study, presumably via inhibition of the renal 
transporter OCT2.  In the MAD cohorts (fasted), serum creatinine change at Day 14 ranged from 
0.05 mg/dL for the 5 mg cohort to 0.18 mg/dL for the 300 mg/dL cohort. In Part D (DDI), 
conducted in the fed state (regular meal), subjects received 100 mg GS-9883 monotherapy for 
7 days and 100 mg GS-9883 with FTC/TAF for 7 days, the mean serum creatinine change at 
Day 7 was 0.14 mg/dL following GS-9883 and 0.17 mg/dL following GS-9883 + FTC/TAF. All 
changes returned to baseline after discontinuation of GS-9883.
The majority of laboratory abnormalities were Grade 1 or Grade 2 in severity. Grade 3 laboratory 
abnormalities included 10 subjects with Grade 3 urine dipstick tests for blood. All of these 
subjects were female, none of the labs were considered by the Investigator to be clinically 
significant, and all were associated with menstruation. No other Grade 3 or 4 laboratory 
abnormalities were observed.
Based on results in study GS-US-141-1218, pharmacokinetic profile of GS-9883 was 
characterized by rapid absorption with time to peak plasma concentrations (median tmax of 
cohorts) ranging between 1 and 4 hours following administration under fasted conditions. 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 21
21 October 2015
GS-9883 exposures were appropriately dose proportional following single dose 25-100 mg dose 
administration, with decreasing dose proportional at higher doses.  The half-life of GS-9883 was 
approximately 18 hours, with no changes observed across studied dose range as evidenced by 
parallel terminal phase slopes. A high-fat meal increased AUCinf and Cmax (geometric mean, 
84% and 101%, respectively) following 100 mg single dose administration. Steady state was 
achieved after 4-6 days of once daily dosing of GS-9883 with average accumulation ratios for 
AUC24hr of 1.6.
Table 1-1.
GS-US-141-1218: GS-9883 Mean (%CV) PK Parameters Following 
Single Doses of GS-9883 in Healthy Subjects (GS-9883 PK Analysis 
Set; Part A: Single Dosing)
GS-9883 PK 
Parameter
Mean 
(%CV)
5mg
(N=6)
25 mg
(N=6)
50 mg
(N=6)
100 mg
(N=6)
300 mg
(N=6)
600 mg
(N=6)
Cmax (ng/mL)
691.2
(22.1)
1618.3
(26.7)
3965.0
(40.1)
6998.3
(36.1)
14605.0 
(27.1)
20050.0
(7.5)
Tmax (hr)
1.25 
(1.00-1.50)
2.00
(1.00-3.00)
3.00
(1.50-4.00)
2.25
(1.50-3.00)
3.50
(2.00-6.00)
3.5
(2.00-4.00)
AUCinf 
(ng.hr/mL)
13059.7
(25.1)
35718.2 
(21.3)
78399.5 
(29.7)
163028.2 
(24.3)
355917.3 
(32.9)
454446.8 
(19.9)
T1/2 (hr)
18.51
(16.81-19.99)
18.08
(16.63-19.64)
16.72
(15.77-17.11)
18.90
(17.96-20.05)
18.14
(17.86-20.53)
17.89
(16.38-19.52)
T1/2 and Tmax: Median (Q1, Q3)
Table 1-2 presents GS-9883 plasma PK parameters following administration of GS-9883 
(5, 25, 50, 100, and 300 mg) once daily for 7 days. Following administration of either GS-9883 
(5, 25, 50, 100, or 300 mg) once daily for 7 days, the PK absorption profile observed on Days 1 
and 7 was similar to that observed in Part A (SAD). The median Tmax values ranged from 1.5 to 
2.5 hours on Day 1 and 1.5 to 4.0 hours on Day 7. Linearity was observed comparing GS-9883 
AUC and Cmax on Days 1 and 7 over the dose range of 25 to 50 mg. Steady state levels of 
GS-9883 were achieved between Study Days 4 to 6 of dosing and maintained through Day 14. 
Accumulation is approximately 1.6-fold, which is consistent with the observed half-life of the 
GS-9883 (approximately 18 hours).


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 22
21 October 2015
Table 1-2.
GS-US-141-1218: GS-9883 Plasma Pharmacokinetic Parameters by 
GS-9883 Dose Following Multiple-Dose Administration of GS-9883 
(Analysis Set: GS-9883 PK Part B: Multiple-Dose)
GS-9883 PK Parameter Mean
(%CV)a
Multiple-Dose GS-9883
5 mg
(N = 6)
25 mg
(N = 6)
50 mg
(N = 6)
100 mg
(N = 6)
300 mg
(N = 6)
Day 1
AUC0-24 (hr*ng/mL)
9033.6
(8.2)
27,775.1
(28.3)
58,371.4
(18.9)
79,773.8
(18.9)
180,714.3
(17.6)
Cmax (ng/mL)
709.7
(9.5)
2220.0
(35.6)
4648.3
(18.7)
6248.3
(26.8)
13,716.7
(19.1)
Tmax (hr)
1.50
(1.50, 1.50)
1.75
(1.00, 3.00)
1.50
(1.00, 2.00)
2.50
(2.00, 3.00)
2.50
(2.00, 4.00)
Day 7
AUCtau (hr*ng/mL)
14,392.0
(16.7)
50,008.2
(26.6)
89,710.1
(22.7)
126,785.8 
(23.7)
277,200.2 
(16.7)
Cmax (ng/mL)
982.5
(7.9)
3455.0
(24.1)
6538.3
(17.6)
9396.7
(20.8)
19,900.0 
(21.2)
Ctau (ng/mL)
400.83
(26.9)
1322.00
(27.8)
2241.67
(28.2)
3145.00 
(26.1)
6758.33 
(21.6)
Tmax (hr)
1.50
(1.00, 2.00)
3.00
(2.00, 3.00)
1.75
(1.50, 2.00)
1.75
(1.50, 3.00)
4.00
(2.00, 4.00)
Accumulation Ratio of AUC (%)
160.5
(19.0)
182.2
(17.1)
154.0
(15.9)
158.5
(12.1)
157.5
(22.6)
a
Data are presented as mean (%CV), except for Tmax, and t½, which are presented as median (Q1, Q3)
Table 1-3 presents the GLSM ratios and associated 90% CIs for the test (fed) versus reference 
(fasted) treatments for the primary plasma PK parameters of GS-9883. Administration of a single 
dose of GS-9883 100 mg with food (high-calorie/high-fat breakfast) increased the GLSM values 
of Cmax and AUCinf 101% (90% CI of GLSM ratio 165.93% to 242.74%) and 84% (90% CI of 
GLSM ratio 152.05% to 222.59%), respectively. There were no apparent changes in clearance 
and t1/2 following administration with food, indicating that food enhanced the bioavailability of 
GS-9883 by improving its solubility and/or absorption.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 23
21 October 2015
Table 1-3.
GS-US-141-1218: Statistical Comparison of GS-9883 Pharmacokinetic 
Parameters Following Single-Dose Administration of GS-9883 in the 
Fasted and Fed States (GS-9883 PK Analysis Set)
GS-9883 PK Parameter 
Mean (%CV)
% GLSM Ratio 
(90% CI)
Test
GS-9883 100 mg Fed
(n=8)
Reference
GS-9883 100 mg Fasted
(n=8)
AUCinf (hr*ng/mL)
214,146.3 (15.9)
117,777.1 (23.3)
183.97 (152.05, 222.59)
AUClast (hr*ng/mL)
209,259.9 (15.1)
115,681.7 (24.0)
183.58 (151.91, 221.86)
Cmax (ng/mL)
11,268.8 (15.1)
5885.0 (34.9)
200.69 (165.93, 242.74)
CI = confidence interval; GLSM = geometric least squares mean
1.2.3.2.
Phase 1b Proof of Concept
The first HIV-1 positive human subjects were dosed in the fasted state with 10 days of GS-9883 
in study (GS-US-141-1219).  Four cohorts of 5 subjects each were randomized 4:1 to receive 
GS-9883 or placebo to match at doses of 5 mg, 25 mg, 50 mg, and 100 mg once daily for 
10 days.
GS-9883 was generally well tolerated at the doses evaluated. A total of 9 of 20 subjects had an 
AE in this study. The most frequently reported AEs across all subjects were diarrhea (2 subjects), 
and headache (3 subjects).  No other AE was reported in more than 1 subject. There was no 
increase in the incidence of AEs with increasing doses of GS-9883.
The majority of AEs were considered by the investigator to be not related to study drug. A total 
of 2 subjects experienced mild diarrhea that was considered related to study drug (1 in the 5 mg 
cohort, 1 in the 100 mg cohort).
No deaths or pregnancies were reported. No Grade 3 or 4 AEs, SAEs, or AEs leading to 
discontinuation of study drug were reported in any cohort.
The majority of laboratory abnormalities were Grade 1 or Grade 2 in severity. No Grade 3 
treatment emergent laboratory abnormalities were observed. Median serum creatinine changes at 
Day 10 were: 0.05 mg/dL (5 mg), 0.04 mg/dL (25 mg), 0.06 mg/dL (50 mg), and 0.15 mg/dL 
(100 mg). These changes in serum creatinine appeared to be transient and returned close to 
baseline values on discontinuation of study drug. One Grade 4 new onset laboratory abnormality 
was seen in 1 subject who received 5 mg GS-9883. This was a Grade 4 CPK seen on Day 17, 
7 days following his last dose of study medication. The subject was asymptomatic. The 
Investigator felt that this was unrelated to study medication and was due to resumption of crystal 
methamphetamine use by the subject. An adverse event of elevated CK was reported unrelated to
study medication.
Based on PK information collected in study GS-US-141-1219, which was in line with PK 
observed in study GS-US-141-1218, the median IQ for each dose were calculated and are 
presented in the Table below.


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Final 
Gilead Sciences, Inc. 
Original 
Table 1-4. 
Trough GS-9883 Plasma Concentrations at Steady State Following 
GS-9883 Administration Under Fasting Conditions and 
Corresponding Protein-Adjusted IQ9s Values (GS-9883 PK Analysis 
Set) 
GS-9883 dose 
n 
Median (range) C 1au,ss (ng!mL) 
Median (range) paiQ95• 
5mg 
4 
206.5 (146.0 to 342.0) 
1.3 (0.9 to 2.1) 
25mg 
4 
797.5 (714.0 to 1900.0) 
4.9 ( 4.4 to 11. 7) 
50mg 
4 
2170.0 (852.0 to 3020.0) 
13.4 (5.3 to 18.6) 
100mg 
4 
4190.0 (3730.0 to 5970.0) 
25.9 (23.0 to 36.9) 
a. 
The protein adjusted IQ95 (paiQ95) value is estimated based on steady-state Ctau values and the in vitro paiC95 value for 
wild-type HIV-1 (162 ng/ml). 
The mean and 95% Cis of change from baseline in HIV -1 RNA (log10 copies/mL) are presented 
in Figure 1-1. 
Figure 1-1. 
G$-9883 5 mg (n= ): 
G$-9883 25 mg (n= ): 
G$-9883 50 mg (n= ): 
G$-9883 100 mg (n=): 
Placebo (n=): 
GS-US-141-1219: Mean and 95% Cis of Change from Baseline in 
HIV-1 RNA (log10 copies/mL) (PP Analysis Set) 
• = GS-9883 5 mg 
0 = GS-9883 25 mg 
b. = GS-9883 50 mg 
0 = GS-9883 100 mg 
0 =Placebo 
BL 
2 
3 
3 
3 
3 
4 
3 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
7 
8 
3 
3 
3 
4 
4 
4 
4 
4 
3 
4 
4 
4 
4 
4 
9 
10 
11 
Day 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
14 
3 
4 
4 
4 
4 
17 
3 
3 
4 
4 
4 
NOTE: Baseline value was the last available value collected prior to the time of tl1e ftrst dose of study drug. 
2 
-1 
-2 
-3 
CONFIDENTIAL 
Page 24 
21 October 2015 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 25
21 October 2015
Mean viral load change on Day 11 was -2.08 log10 in the 25 mg cohort, -2.06 log10 in the 50 mg 
cohort, and -2.43 log10 in the 100 mg cohort. Time weighted average change from baseline at 
Day 11 (DAVG11) was -0.92 log10 in the 5 mg cohort, -1.33 log10 in the 25 mg 
cohort, -1.37 log10 in the 50 mg cohort and -1.61 log10 in the 100 mg cohort.  Viral suppression 
(HIV-1 RNA < 50 copies/mL) was ever achieved by the end of the study (Day 17) by 1 subject 
(25.0%) in the GS-9883 50 mg group and 2 subjects (50%) in the GS-9883 100 mg group.
1.2.3.3.
Summary of Phase 2 Study (GS-US-141-1475)
Study GS-US-141-1475 is an ongoing Phase 2, randomized, double-blind, multicenter, 
active-controlled study to assess the safety and efficacy of a regimen containing 
GS-9883+F/TAF versus dolutegravir (DTG)+F/TAF in HIV-infected, antiretroviral therapy 
(ART)-naive adult subjects.
Eligible subjects were randomized in a 2:1 ratio to one of the following treatment groups, 
stratified by HIV-1 RNA level (≤ 100,000 copies/mL, 100,000 copies/mL 
to400,000 copies/mL, or > 400,000 copies/mL) at screening:

Treatment Group 1: GS-9883 75 mg + F/TAF (200/25 mg) + placebo-to-match DTG 
50 mg once daily

Treatment Group 2: DTG 50 mg + F/TAF (200/25 mg) + placebo-to-match GS-9883 
75 mg once daily
Interim data at Week 12 are summarized below.  Data from the Week 24 primary endpoint are 
included in the GS-9883/F/TAF Investigator’s Brochure.
1.2.3.4.
Subject Disposition and Baseline Characteristics
A total of 98 subjects were randomized and treated in the study: 65 subjects in the 
GS-9883+F/TAF group and 33 subjects in the DTG+F/TAF group. At the time of the Week 12 
data analysis, 2 subjects (2.0%) had prematurely discontinued study treatment, one in each 
treatment group; both subjects were lost to follow-up.
Demographic and baseline characteristics were similar between the 2 treatment groups.
Key baseline disease characteristics (ie, viral load, CD4 cell count, and estimated glomerular 
filtration rate [eGFR] using the Cockcroft-Gault method [eGFRCG]) were similar between the 
2 treatment groups (Table 1-4).
Median (Q1, Q3) baseline HIV-1 RNA was 4.45 (3.96, 4.79) log10 copies/mL, with 82.7% of 
subjects having ≤ 100,000 copies/mL at baseline; 5 subjects had > 400,000 copies/mL at 
baseline; 4 of these subjects were randomized to GS-9883+F/TAF and 1 subject was randomized 
to DTG+F/TAF.

Median (Q1, Q3) baseline CD4 cell count was 444 (316, 595) cells/μL, with 41.8% of 
subjects having ≥ 500 cells/μL at baseline. Median (Q1, Q3) baseline eGFRCG was 
125.3 (105.7, 147.0) mL/min.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 26
21 October 2015
1.2.3.5.
Efficacy Results
Virologic success at Week 12 when assessed using the US FDA snapshot algorithm, defined as 
plasma HIV-1 RNA < 50 copies/mL, was similar between the 2 treatment groups as follows: 
GS-9883+F/TAF 93.8%; DTG+F/TAF 93.9% (stratum-adjusted difference in percentages: 
−1.3%; 95% CI: −12.9% to 10.2%; p = 0.79).
Following initiation of study drug, the increases from baseline in CD4 cell count were similar 
between treatment groups. Mean (SD) baseline CD4 cell counts were as follows: 
GS-9883+F/TAF 471 (190.9) cells/μL; DTG+F/TAF 507 (271.0) cells/μL; p = 0.35. The mean 
(SD) change in CD4 cell count from baseline to Week 12 was similar between the 2 treatment 
groups as follows: GS-9883+F/TAF +170 (150.0) cells/μL; DTG+F/TAF +173 (220.5) cells/μL 
(difference in LSM: 0; 95% CI: −76 to 76; p = 1.00).
Interim Virology Resistance Data
Through Week 12, no emergent drug resistance was detected.
1.2.3.6.
Safety Results
Adverse Events
The overall incidence of treatment-emergent AEs was balanced between treatment groups as 
follows: GS-9883+F/TAF 58.5%, 38 subjects; DTG+F/TAF 57.6%, 19 subjects).The most 
common TEAEs (occurring in > 1 subject) by treatment group were as follows:

GS-9883+F/TAF: diarrhea and headache (6.2%, 4 subjects each); and fatigue and nausea 
(3.1%, 2 subjects each)

DTG+F/TAF: nausea (12.1%, 4 subjects); diarrhea (9.1%, 3 subjects); and fatigue, 
flatulence, and furuncle (6.1%, 2 subjects each)
Most treatment-emergent AEs were Grade 1 in severity. Grade 3 or 4 AEs were reported in only 
1 subject (diabetic ketoacidosis); this event was also reported as an SAE, and 1 other SAE 
(appendicitis) was reported. Neither SAE was considered related to study drug by the 
investigator, resulted in study drug discontinuation, or required interruption of study drug, and 
both SAEs resolved.
The overall incidence of study drug-related treatment-emergent AEs was balanced between 
treatment groups as follows: GS-9883+F/TAF 12.3%, 8 subjects; DTG+F/TAF 15.2%, 
5 subjects. Most study drug-related treatment-emergent AEs were Grade 1 in severity. Grade 2 
study drug-related treatment-emergent AEs (somnolence and headache) were reported in 
1 subject. No Grade 3 or 4 treatment-emergent AEs or treatment-emergent SAEs were 
considered related to study drug.
No deaths, pregnancies, or AEs leading to premature study drug discontinuation were reported.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 27
21 October 2015
Clinical Laboratory Evaluations
The percentage of subjects with at least 1 treatment-emergent laboratory abnormality (ie, at least 
1 grade level increase from baseline in graded abnormality) was similar between treatment 
groups as follows: GS-9883+F/TAF 70.3%, 45 subjects; DTG+F/TAF 75.0%, 24 subjects. The 
majority of treatment-emergent laboratory abnormalities were Grade 1 or 2 in severity. The 
percentage of subjects with at least 1 Grade 3 or 4 treatment-emergent laboratory abnormality 
was similar between treatment groups as follows: GS-9883+F/TAF 10.9%, 7 subjects; 
DTG+F/TAF 12.5%, 4 subjects. Grade 4 treatment-emergent laboratory abnormalities 
(creatine kinase) were reported in only 2 subjects.
There were no clinically significant changes from baseline or differences between treatment 
groups in the median values for hematology, chemistry, or metabolic parameters. Changes from 
baseline in serum creatinine were similar between treatment groups. Median (Q1, Q3) changes in 
serum creatinine at Week 12 were as follows: GS-9883+F/TAF 0.11 (0.06, 0.16) mg/dL; 
DTG+F/TAF 0.14 (0.06, 0.24) mg/dL. Changes from baseline in eGFR were similar between
treatment groups. Median (Q1, Q3) changes in eGFR at Week 12 were as follows: 
GS-9883+F/TAF −12.2 (−18.0, −6.4) mL/min; DTG+F/TAF −15.8 (−30.1, −9.5) mL/min.
1.3.
Information about Emtricitabine (Emtriva®, FTC)
Emtricitabine (5-fluoro-1-[(2R, 5S)-2-(hydroxymethyl)-[1, 3]-oxathiolan-5-yl] cytosine, FTC) is 
a NRTI that has demonstrated potent and selective inhibition of the HIV. In HIV-infected adults, 
FTC is administered as a 200 mg QD dose concurrently with other ARVdrugs. The 200 mg FTC 
capsule formulation was approved by the US Food and Drug Administration (FDA) for 
marketing on 2 July 2003 and is available under the name Emtriva®. In the European Union 
(EU), marketing authorization was granted for both the 200 mg Emtrivacapsule formulation 
and a 10 mg/mL Emtrivaoral Solution formulation on 24 October 2003, with indications for 
the treatment of HIV infection concurrently with other antiretroviral drugs in both adult and 
pediatric patients.
Further information is available in the current Prescribing Information for Emtriva®.
1.4.
Information about Tenofovir alafenamide (TAF, GS-7340)
Tenofovir alafenamide (GS-7340, TAF) is a second generation oral prodrug of tenofovir (TFV), 
a nucleotide analog that inhibits HIV-1 reverse transcription. Tenofovir is metabolized 
intracellularly to the active metabolite, tenofovir diphosphate (TFV-DP), a competitive inhibitor 
of HIV-1 reverse transcriptase (RT) that terminates the elongation of the viral DNA chain. The 
intracellular metabolism of TAF and TFV are consistent with the 600-fold enhancement in 
anti-HIV activity in cell culture of TAF over TFV.
Please refer to the GS-9883/F/TAF Investigator’s Brochure for further information.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 28
21 October 2015
1.4.1.
Clinical Trials of Single Agent Tenofovir Alafenamide (TAF, GS-7340) or
Fixed Dose Combination emtricitabine/tenofovir alafenamide (FTC/TAF)
Clinical trials entailing the use of tenofovir alafenamide include:

GS-US-120-1101, a Phase 1/2 study of the pharmacokinetics and antiviral activity of 
GS-7340 (50 mg and 150 mg) in HIV-infected subjects (completed)

GS-US-120-0104, a Phase 1b study of the pharmacokinetics and antiviral activity of 
GS-7340 (8 mg, 25 mg, 40 mg) in HIV infected subjects (completed)

GS-US-120-0107, a Phase 1, partially-blinded, randomized, placebo- and positive controlled 
study to evaluate the effect of GS-7340 on the QT/QTc interval in healthy subjects 
(completed)

GS-US-120-0108, a Phase 1, open-label, parallel-design study to evaluate the 
pharmacokinetics of GS-7340 in subjects with severe renal impairment (completed)

GS-US-120-0109, a Phase 1 study to evaluate the pharmacokinetics, metabolism and 
excretion of GS-7340 (completed)

GS-US-120-0114, a Phase 1, open-label, parallel-group, single dose study to evaluate the 
pharmacokinetics of tenofovir alafenamide in subjects with normal and impaired hepatic 
function (completed)

GS-US-120-0117, a Phase 1 single-dose study evaluating the pharmacokinetic drug 
interaction potential between rilpivirine and tenofovir alafenamide (completed)

GS-US-120-0118, a Pharmacokinetic study evaluating the drug interaction potential of
tenofovir alafenamide with a boosted protease inhibitor or unboosted integrase inhibitor in
healthy subjects (completed)

GS-US-311-1386, a Phase 1 study to determine the effect of food on the pharmacokinetics of 
tenofovir alafenamide when administered as F/TAF FDC in healthy volunteers (completed)

GS-US-311-0101, a Phase 1 healthy volunteer study evaluating the drug interaction potential
between once-daily FTC/GS-7340 fixed-dose combination and efavirenz (EFV) or
COBI-boosted darunavir (DRV) (completed)

GS-US-311-1088, a Phase 1, Relative Bioavailability Study of Emtricitabine/Tenofovir
Alafenamide Fixed Dose Combination Tablet to evaluate the formulation performance of
emtricitabine (FTC) and tenofovir alafenamide (TAF) fixed dose combination tablets relative
to co-administration of individual agents (completed)

GS-US-311-1089, a Phase 3 study of the safety and efficacy of FTC/TAF in HIV infected,
virologically suppressed patients (ongoing)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 29
21 October 2015
In Study GS-US-311-1386, the effect of food (high-calorie, high-fat meal) on the PK of the TAF 
component of the F/TAF FDC was evaluated. The GLSM ratio of the AUClast of TAF when 
administered with a high-fat meal was 177% (90% CI: 166% to 188%), and the TAF Cmax
GLSM ratio was 84.5% (90% CI: 74.9% to 95.4%). This ~75% increase in TAF plasma 
exposure and ~15% decrease in TAF plasma Cmax when administered with food was 
accompanied by a delay in Tmax (increase from 1.00 hour under fasted conditions to 2.00 hours 
under fed conditions). The exposures of TAF observed under fed or fasted conditions in this 
study are within the range of exposures observed in the E/C/F/TAF clinical development 
program and are commensurate with safe and effective plasma levels of TAF (see investigator 
brochure for further details). Therefore, the changes in TAF exposures when F/TAF is 
administered with food should not result in differences in efficacy and thus are not clinically 
relevant. TAF can be administered without regard for food and these findings can be 
extrapolated to F/TAF (as FTC can be taken without regard to food). 
1.4.2.
Clinical Trials of FTC/TAF as part of 
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)
Clinical trials using tenofovir alafenamide, coformulated into the E/C/F/TAF STR include: 

GS-US-292-0101, a Phase 1 healthy volunteer study evaluating the relative bioavailability of 
EVG, FTC, TFV, and COBI administered as E/C/F/TAF STR relative to E/C/F/TDF or TAF
(completed)

GS-US-292-0103, a Phase 1 healthy volunteer study to evaluate the pharmacokinetics and 
relative bioavailability of the E/C/F/TAF STR relative to the individual components at 
GS-7340 doses of 10 mg (STR) or 25 mg Single Agent (SA) (completed)

GS-US-292-0102, a Phase 2 randomized, double-blinded study of the safety and efficacy of 
E/C/F/TAF STR versus E/C/F/TDF STR in HIV-1 infected, antiretroviral treatment-naive 
adults (ongoing)

GS-US-292-0104 and GS-US-292-0111, Phase 3 randomized, double-blinded study of the 
safety and efficacy of E/C/F/TAF STR versus E/C/F/TDF STR in HIV-1 infected, 
antiretroviral treatment-naive adults (ongoing)

GS-US-292-0109, a Phase 3 open-label study to evaluate switching from a TDF-containing 
combination regimen to a TAF-containing combination single tablet regimen (STR) in 
virologically-suppressed, HIV-1 positive subjects (ongoing)

GS-US-292-0112, a Phase 3 Open-label Safety Study of 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide single-tablet Regimen in HIV-1 
positive patients with mild to moderate renal impairment (ongoing)

GS-US-292-0117, a Phase 3, two-part study to evaluate the efficacy of Tenofovir 
Alafenamide versus placebo added to a failing regimen followed by treatment with 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 positive, 
antiretroviral treatment-experienced adults (ongoing)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 30
21 October 2015

GS-US-292-0119, a Phase 3 open-label study to evaluate switching from optimized stable 
antiretroviral regimens containing darunavir to 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) single tablet 
regimen (STR) plus darunavir (DRV) in treatment experienced HIV-1 positive adults
(ongoing)

GS-US-292-0106, a Phase 2/3, open-label study of the pharmacokinetics, safety, and 
antiviral activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 
(E/C/F/TAF) single tablet regimen (STR) in HIV-1 infected antiretroviral treatment-naive 
adolescents (ongoing)
Study GS-US-292-0101 is a Phase 1 study of 40 subjects evaluating the relative bioavailability 
of two different formulations of E/C/F/TAF STR, each with TAF dose of 25 mg or 40 mg, versus 
E/C/F/TDF STR or TAF 25 mg alone. Exposures of EVG, COBI, and FTC were comparable 
between E/C/F/TAF vs E/C/F/TDF regardless of formulation (monolayer or bi-layer). In 
contrast, TAF exposures were ~2.2-fold higher (and corresponding tenofovir exposures ~ 3-fold 
higher) when administered as E/C/F/TAF (25 mg) vs TAF single agent (SA) 25 mg for both 
formulations of the E/C/F/TAF, likely mediated by inhibition of P-gp-mediated intestinal
secretion of TAF by COBI.
Study GS-US-292-0103 is a completed Phase 1 healthy volunteer study which evaluated the PK
and relative bioavailability of the E/C/F/TAF STR relative to the individual components at TAF
doses of 10 (STR) or 25 mg SA. Results indicate that when dosed as the E/C/F/TAF 10 mg STR, 
TAF and TFV exposures were comparable to those observed with TAF 25 mg dosed alone. 
Exposures of EVG, COBI, and FTC were also comparable between the STR and individually 
dosed formulations. 
Study GS-US-292-0102 is an ongoing, randomized, active-controlled Phase 2 study, compares 
E/C/F/TAF (10 mg) versus Stribild® (STB, E/C/F/TDF) in treatment-naïve, HIV-1 infected 
subjects. At Week 48, the E/C/F/TAF demonstrated potent antiviral efficacy (HIV-1 RNA 
< 50 copies/mL) similar to STB (88.4% [99/112] vs 87.9% [51/58] using the snapshot 
algorithm); in the E/C/F/TAF group, no patient had emergent resistance to 1 or more components 
of the E/C/F/TAF. Importantly, E/C/F/TAF demonstrated a potential benefit over E/C/F/TDF in 
terms of renal and bone safety: smaller median decreases in eGFR (mL/min) (at Week 48, 
E/C/F/TAF -5.5 vs E/C/F/TDF -10.0 [P<0.001) and smaller median percentage decreases in 
BMD (at Week 48, spine E/C/F/TAF -1.00 vs E/C/F/TDF -3.37 [p<0.001], hip -0.62 
vs -2.39 [p<0.001]).
Studies GS-US-292-0104 and GS-US-292-0111 are ongoing, Phase 3 randomized, 
double-blinded studies of the safety and efficacy of E/C/F/TAF versus E/C/F/TDF in HIV-1 
infected, antiretroviral treatment-naive adults. The interim Week 48 key conclusions from pooled 
data showed that E/C/F/TAF once daily was noninferior to STB once daily when administered 
for 48 weeks to HIV-infected, ART-naive adults, as assessed using the US Food and Drug 
Administration (FDA)-defined snapshot algorithm with HIV-1 RNA < 50 copies/mL 
(E/C/F/TAF 92.4%; STB 90.4%; difference in percentages: 2.0%, 95% CI: -0.7% to 4.7%). 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 31
21 October 2015
Administration of E/C/F/TAF resulted in > 90% lower plasma TFV and higher intracellular 
TFV-DP relative to STB.  E/C/F/TAF showed an improved renal and bone safety profile with 
significantly less decline in hip and spine BMD, less increase in serum creatinine and reduction 
in estimated glomerular filtration rate (eGFR).
1.5.
Information about GS-9883/emtricitabine/tenofovir alafenamide 
(GS-9883/F/TAF)
Please refer to the GS-9883/F/TAF Investigator’s Brochure for further information.
1.5.1.
GS-US-141-1233: Relative Bioavailability of GS-9883, FTC, and TAF 
between GS-9883/F/TAF and GS-9883 + F/TAF
Study GS-US-141-1233 is an ongoing Phase 1, open-label, 2-cohort, multiple-period,
fixed-sequence, crossover study conducted at a single center in the US to evaluate 1) the relative 
bioavailability (BA) of 2 GS-9883/F/TAF (75/200/25 mg and 50/200/25 mg) FDC tablets 
compared with the GS-9883 (75 mg) tablet and the F/TAF (200/25 mg) FDC tablet administered 
simultaneously and 2) the effect of food on the PK of GS-9883, FTC, and TAF when 
administered as GS-9883/F/TAF (75/200/25 mg and 50/200/25 mg) FDC tablets. 
Cohort 1 evaluated the relative BA and food effect of GS-9883/F/TAF (75/200/25 mg) FDC 
tablet in a 3-period sequence. Following review of preliminary data from Cohort 1, Cohort 2 was 
added to the study via protocol amendment. Cohort 2 will evaluate the relative BA and food 
effect of GS-9883/F/TAF (50/200/25 mg) FDC tablet in a 4-period sequence. 
The in-life portion of Cohort 1 is complete; preliminary results are summarized below. The 
in-life portion of Cohort 2 is ongoing.
Cohort 1 Results:

Pharmacokinetic Results

Under fasted conditions, GS-9883 AUCinf and Cmax were 27% and 31% higher, respectively, 
following GS-9883/F/TAF (75/200/25 mg) FDC administration than following 
administration of single-agent GS-9883 (75 mg ) with the F/TAF (200/25 mg) FDC. FTC and 
TAF exposure was similar following administration of GS-9883/F/TAF (75/200/25 mg) or 
single-agent GS-9883 (75 mg) with the F/TAF (200/25 mg) FDC. Compared with 
administration under fasted conditions, administration of the GS-9883/F/TAF 
(75/200/25 mg) FDC with a high-fat meal resulted in a 46% higher GS-9883 AUCinf and a 
27% higher GS-9883 Cmax. The impact of food on TAF and FTC exposure was similar to that 
previously observed for F/TAF (Study GS-US-311-1386). GS-9883/F/TAF may be taken 
without regard to food.  Based on these results, Cohort 2 was added to the study via protocol 
amendment to evaluate the relative BA of the GS-9883/F/TAF (50/200/25 mg) FDC tablet 
compared with the single-agent GS-9883 (75 mg) tablet and the F/TAF (200/25 mg) FDC 
tablet administered simultaneously.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 32
21 October 2015
Safety Results
Of the 28 subjects included in the Safety Analysis Set for Cohort 1, 12 subjects (43%) had at 
least 1 treatment-emergent AE. All treatment emergent AEs were assessed as Grade 1 or 2 in 
severity. No deaths or other SAEs occurred during this study, and no subject discontinued the 
study due to an AE.
1.6.
Information about abacavir/dolutegravir/lamivudine (ABC/DTG/3TC 
Triumeq®)
For more detailed information, refer to the current Prescribing Information and local product 
labeling for abacavir/dolutegravir/lamivudine.
1.7.
Rationale for this Study
HIV standard of care has relied upon nucleos(t)ide backbones for effective and durable virologic 
suppression, but nucleos(t)ide-associated toxicities are increasingly important as HIV-infected 
patients are often diagnosed earlier, initiate therapy earlier, and look toward lifelong therapy 
(often greater than 50 years). Where patients have access to treatment, morbidity and mortality 
are driven by non–AIDS-associated comorbidities, which are observed earlier than in 
HIV-uninfected age-matched controls despite the best available ART. The contribution of 
specific nucleos(t)ides, including abacavir and tenofovir disoproxil fumarate, to long-term 
morbidity and mortality is increasingly important in this context.
The GS-9883/F/TAF FDC has the potential to offer a simple, once-daily regimen containing a 
second generation INSTI that provides a high barrier to resistance, does not require a boosting 
agent, and offers an effective and safer alternative to standard nucleos(t)ide based regimens, 
without the need for HLA testing or close monitoring of renal or bone toxicities. It could provide 
a FDC treatment that avoids the risk of hypersensitivity reactions, would not contribute to an 
increased risk of cardiovascular events; could be used in patients with chronic hepatitis B or C 
infection or renal impairment, and that could be continued as patients age and confront 
non-HIV-related comorbidities.
The objective of this study is to evaluate the efficacy of switching from a regimen of DTG and 
ABC/3TC or a Fixed dose combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF
versus continuing DTG and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed 
HIV-1 infected subjects as determined by the proportion of subjects with virologic failure 
(HIV-1 RNA ≥ 50 copies/mL) at Week 48. ABC/DTG/3TC was selected as the active 
comparator for this study as it is a second-generation integrase inhibitor-based, once-daily fixed 
dose combination, and is a DHHS Guidelines preferred regimen that includes the 3TC/ABC 
backbone. Use of ABC/DTG/3TC as a comparator in this study will therefore allow comparison
of two single tablet regiments containing second generation, unboosted INSTIs.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 33
21 October 2015
1.8.
Risk/Benefit Assessment for the Study
All patients with HIV-1 infection should receive effective antiretroviral therapy. Potential risks 
associated with all classes of ARVs include immune reconstitution syndrome, lipodystrophy, and 
lactic acidosis with steatosis.  The risk of class effects is considered to be low.  Important 
identified risks appropriately managed by study inclusion/exclusion criteria as well as through 
close clinical and laboratory monitoring during the study, are as follows: hypersensitivity 
reaction to abacavir and allergy to any components of the tablets.  Some observational studies 
have shown increased risk of cardiovascular disease with abacavir.  Interim data will also be 
reviewed by an independent data monitoring committee.  Potential benefits may include 
provision of a new antiretroviral therapy that is not currently available and which may have 
fewer side effects than alternative therapies.  Other potential benefits include provisions of fixed 
dose combination therapy, and the knowledge that patient participation will contribute to the 
body of knowledge of HIV therapies.
The overall benefit-risk assessment for GS-9883/F/TAF is favorable at this time.
1.9.
Rationale for Dose Selection
FTC
The 200 mg dose of FTC represents the marketed dose for this agent that is currently available as 
single agent capsules (EMTRIVA) and as a component of a number of fixed-dose combination 
tablets, including: TRUVADA, ATRIPLA, COMPLERA (EVIPLERA), and STRIBILD.
TAF
Based upon results of the Phase 1 Study GS-US-120-0104, in which various doses of TAF 
(8 mg, 25 mg, and 40 mg) were administered to HIV-infected subjects in 10 days of 
monotherapy, the range of exposure achieved with TAF 25 mg was chosen as the reference 
exposure. In this study, TAF 25 mg resulted in near-maximal antiviral activity and plasma TFV 
exposure > 90% lower relative to TDF.
The recommended dose of TAF is based on ensuring that patients have a TAF systemic exposure 
that is within the range of the reference exposure achieved with TAF 25 mg, or with TAF 10 mg 
when administered with the boosting agent COBI as E/C/F/TAF, for which an extensive safety 
and efficacy database exists. Specifically, TAF 25 mg is recommended with third agents that do 
not have a clinically relevant effect on TAF exposure. Study GS-US-141-1418 showed that 
GS-9883 does not have a clinically relevant effect on TAF exposure. Therefore, the dose of TAF 
25 mg is appropriate for the GS-9883/F/TAF FDC.
GS-9883
The dose of GS-9883 for Phase 2 was selected based upon data from Study GS-US-141-1219 
(Table 1-5), in which HIV-1-infected subjects were administered 5, 25, 50, or 100 mg doses of 
GS-9883 monotherapy under fasting conditions for 10 days.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 34
21 October 2015
Table 1-5.
GS-US-141-1219: Trough GS-9883 Plasma Concentrations at Steady 
State Following GS-9883 Administration Under Fasting Conditions 
and Corresponding Protein-Adjusted IQ95 Values
GS-9883 dose
n
Median (range) Ctau,SS (ng/mL)
Median (range) paIQ95
a
5 mg
4
206.5 (146.0 – 342.0)
1.3 (0.9 – 2.1)
25 mg
4
797.5 (714.0 – 1900.0)
4.9 (4.4 – 12)
50 mg
4
2170.0 (852.0 – 3020.0)
13 (5.3 – 19)
100 mg
4
4190.0 (3730.0 – 5970.0)
26 (23 – 37)
a
The paIQ95 value is estimated based on steady-state Ctau values and the in vitro paIC95 value for wild-type HIV-1 
(162 ng/mL).
Source: Data on File
Single-agent GS-9883 was well tolerated at all doses administered. The range of GS-9883 
plasma exposure at steady state (Ctau,SS) observed in the 50-mg cohort correlated with protein 
adjusted 95% inhibitory quotient (paIQ95) values ranging from 5.3 to 19, while the range of 
GS-9883 plasma exposure at steady state (Ctau,SS) observed in the 100-mg cohort correlated with 
paIQ95 values ranging from 23 to 37 (Table 1-5).
Based on PK/PD analyses, exposure following a 75-mg dose of single-agent GS-9883 is 
expected to provide near-maximal virologic response, with a predicted paIQ95 of approximately 
20, providing considerable coverage above the target concentration of 162 ng/mL (paIC95).
GS-9883 (75 mg) single agent coadministered with F/TAF (200/25 mg) is currently being 
evaluated in a Phase 2 study, GS-US-141-1475 (GS-9883+F/TAF vs DTG+F/TAF). The 
Week 12 interim data from this study, support the safety and efficacy of GS-9883 exposures 
obtained with the 75 mg dose of the single agent.
GS-9883/F/TAF FDC Dose Selection
A fixed dose formulation of GS-9883/F/TAF is being developed for use in Phase 3 studies. 
Preliminary results from the relative bioavailability (rBA) study (GS-US-141-1233) of 
GS-9883/F/TAF (75/200/25 mg) showed that GS-9883 plasma exposure was higher (with Cmax
and AUCinf increase of 31% and 27%, respectively) following administration of the FDC as 
compared with exposure following administration of GS-9883 (75 mg) + F/TAF (200/25 mg) 
under fasted conditions. The increase in GS-9883 exposures associated with the FDC 
formulation results in an estimated mean paIQ95 of 24.3, compared to an estimated mean paIQ95
of 19.2 for the GS-9883 (75 mg) single agent coadministered with F/TAF, in the fasted state.
In order to bridge exposures of GS-9883 in the FDC to the exposure observed with GS-9883 
75 mg administered as a single agent, and to bridge to the safe and effective exposures observed 
in the Phase 2 study GS-US-141-1475, a lower strength GS-9883/F/TAF FDC is being 
developed for use in the Phase 3 studies. Comparability of GS-9883 exposures will be confirmed 
in an rBA study of GS-9883/F/TAF (50/200/25 mg) and GS-9883 (75 mg) + F/TAF prior to 
initiation of dosing in the Phase 3 studies.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 35
21 October 2015
1.10.
Compliance
This study will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory requirements.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 36
21 October 2015
2.
OBJECTIVES
The primary objective of this study is:

To evaluate the efficacy of switching from a regimen of DTG and ABC/3TC or a fixed dose 
combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF versus continuing DTG 
and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed HIV-1 infected 
subjects as determined by the proportion of subjects with virologic failure (HIV-1 RNA 
≥50 copies/mL) at Week 48
The secondary objectives of this study are:

To evaluate the safety, and tolerability of the two treatment groups through Week 48

To evaluate the bone safety of the two treatment groups as determined by the percentage 
change from baseline in hip and spine bone mineral density (BMD) through Week 48


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 37
21 October 2015
3.
STUDY DESIGN
3.1.
Endpoints
The primary efficacy endpoint is:

The proportion of subjects with virologic failure (HIV-1 RNA ≥50 copies/mL) at Week 48 
as defined by the modified US FDA snapshot algorithm.
The secondary endpoints of this study include:

The proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the 
US FDA snapshot algorithm

The change from baseline in CD4+ cell count at Week 48

The percentage change from baseline in hip and spine BMD at Week 48
3.2.
Study Design
This protocol describes a randomized, double-blind, multicenter, active-controlled study to 
evaluate the safety and efficacy of switching to GS-9883/F/TAF FDC versus continuing 
DTG + ABC/3TC as the FDC ABC/DTG/3TC in HIV-1 infected subjects who are virologically 
suppressed (HIV-1 RNA < 50 copies/mL) on a stable regimen (of DTG + ABC/3TC or the FDC 
ABC/DTG/3TC) for ≥ 3 months prior to screening.
3.3.
Study Treatments
Subjects who provide written informed consent and meet all eligibility criteria will be 
randomized in a 1:1 ratio to one of the following two treatment groups:
Treatment Group 1: FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir alafenamide 
25 mg (GS-9883/F/TAF) + Placebo to match FDC of abacavir 600 mg/ dolutegravir 
50 mg/lamivudine 300 mg (ABC/DTG/3TC) administered orally, once daily, without regard to 
food (n=260)
Treatment Group 2: FDC of abacavir 600 mg/dolutegravir 50 mg/ lamivudine 300 mg 
(ABC/DTG/3TC) QD + Placebo to match FDC of GS-9883 50 mg/ emtricitabine 
200 mg/ tenofovir alafenamide 25 mg (GS-9883/F/TAF) administered orally, once daily, without 
regard to food (n=260)
3.4.
Duration of Treatment
Subjects will be treated for at least 48 weeks. Subjects’ treatments will be unblinded after the last 
subject completes the Week 48 visit and Gilead completes the Week 48 analysis. Subjects will 
continue to take their blinded study drug and attend visits every 12 weeks until treatment 


GS-9883/Fff AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
Final 
Original 
assignments have been unblinded. At the Unblinding Visit, subjects in a countiy where 
GS-9883/F/TAF FDC is not available will be given the option to receive GS-9883/F/TAF FDC 
in an open label extension phase for 48 weeks, or until the product becomes accessible to 
subjects through an access program, or until Gilead Sciences elects to discontinue the study in 
that countiy, whichever occurs first. 
After Week 48 Visit, subjects in the United Kingdom and Sweden will stop taking study dmg 
and complete a 30 day follow up visit and retum to the standard of care. 
Figure 3-1. 
Screening 
:S JO da>'S prior 
lo Day l 
Study Schema 
Week.tS•b 
Primary Endpoint 
Treatment Ann 1: S"·itch to FDC ofGS-9883 FI'OTAF • 
QD - Plac~bo to match FDC ABC DTG 3TC QD C\•260) 
Troumonr Ann 2: FDC ofA.BCDTC 3TC QD- Pbeebo ~ 
to match FDC ofGS-9883 FTCTAF QD (.:\•260) 
% 
:% 
Jfthyfti 
a. 
Following the Day 1 visit, subjects will be required to retum for study visits at Weeks 4, 8, 12, and then every 12 weeks 
through Week 48. 
b. 
After Week 48, subjects will continue to take their blinded study drug and attend visits every 12 V.'l!eks until treatment 
assignments have been tmblinded. Subjects' treatments will be tmblinded after the last subject completes the Week 48 visit 
and Gilead completes the Week 48 analysis. After Week 48 Visit, subjects in the United Kingdom and Sweden will stop 
taking study drug and complete a 30 day follow up visit and retum to the standard of care. 
c. 
Once Gilead Sciences provides unblinded treatment assignments to the Investigators, all subjects willretwn to the clinic 
(preferably within 30 days) for an Unblinding Visit. At the Unblinding Visit, subjects in a cotmtry where GS-9883/FffAF 
FDC is not available will be given the option to receive GS-9883/FffAF FDC in an open label extension for 48 weeks, or 
tmtil the product becomes accessible to subjects thmugh an access program, or until Gilead Sciences elects to discontinue 
the study in that cotmtly, whichever occurs ftrst. 
d. 
Subjects who complete the study through the Unblinding Visit and do not continue on the open-label GS-9883/F/TAF FDC 
extension phase will be required to retwn to the clinic 30 days after the completion of study dmgs for a 30-Day Follow-Up 
Visit. 
3_5_ 
Biomarker Testing 
3_5_1_ 
Biomarker Samples for Optional Pharmacogenomic Research 
PPD 
CONFIDENTIAL 
Page 38 
21 October 2015 


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
PD 
3.5.2. 
Additional Sample Storage 
Final 
Original 
For subjects who provide additional consent, residual blood and urine samples taken throughout 
the study will be stored. Stored samples may be used by the Sponsor or its research partners to 
help answer questions about the study dmg, and HIV disease and its associated conditions, or to 
provide additional safety data. At the conclusion of this study, these samples may be retained in 
storage by Gilead Sciences for a period up to 15 years. 
CONFIDENTIAL 
Page 39 
21 October 2015 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 40
21 October 2015
4.
SUBJECT POPULATION
4.1.
Number of Subjects and Subject Selection
Approximately 520 subjects who meet the eligibility criteria will be enrolled.
4.2.
Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study.
1) The ability to understand and sign a written informed consent form, which must be obtained 
prior to initiation of study procedures
2) Age 18 years
3) Currently receiving an antiretroviral regimen of DTG + ABC/3TC, or ABC/DTG/3TC FDC
for ≥ 3 months prior to the screening visit
4) HIV RNA < 50 copies/mL at the screening visit
5) Normal ECG (or if abnormal, determined by the Investigator to be not clinically significant)
6) Adequate renal function:
Estimated glomerular filtration rate ≥50 mL/min (≥0.83 mL/sec) according to the 
Cockcroft-Gault formula {2202}:
a) Male:
(140 – age in years) (wt in kg) CLcr (mL/min)
72 (serum creatinine in mg/dL)
        (140 – age in years) (wt in kg)          CLcr (mL/sec)
72 (serum creatinine in umol/L) 0.6786
b) Female:
(140 – age in years) (wt in kg) 0.85 CLcr (mL/min)
72 (serum creatinine in mg/dL)
        (140 – age in years) (wt in kg)           0.85 CLcr (mL/sec)
72 (serum creatinine in umol/L) 0. 6786
7) Hepatic transaminases (AST and ALT) 5 upper limit of normal (ULN)
8) Total bilirubin 1.5 mg/dL (26 umol/L), or normal direct bilirubin
9) Adequate hematologic function (absolute neutrophil count ≥750/mm3 (≥ 0.75 GI/L); 
platelets ≥50,000/mm3 (≥50 GI/L); hemoglobin ≥ 8.5 g/dL (≥85 g/L))
10) Serum amylase ≤ 5 × ULN (subjects with serum amylase > 5 × ULN will remain eligible if 
serum lipase is ≤5 × ULN)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 41
21 October 2015
11) Females of childbearing potential must agree to utilize protocol recommended highly 
effective contraceptive methods or be non-heterosexually active or practice sexual abstinence 
(as defined in Appendix 6) from screening, throughout the duration of the study period, and 
for 30 days following the last dose of study drug.
a) Female subjects who utilize hormonal contraceptive as one of their birth control methods 
must have used the same method for at least 3 months prior to study drug dosing.
12) Male subjects who engage in heterosexual intercourse must agree to use protocol specified 
method(s) of contraception (as described in Appendix 6) throughout the study period and for 
90 days following the last dose of study drug.
13) Male subjects must agree to refrain from sperm donation from first study drug dose until at 
least 90 days following the last study drug dose
14) Life expectancy ≥ 1 year
15) Currently on the first or second antiretroviral regimen with documented plasma HIV-1 RNA 
< 50 copies/mL on a stable regimen (or undetectable HIV-1 RNA level according to the local 
assay being used if the limit of detection is ≥50 copies/mL) for ≥ 3 months preceding the 
Screening visit.
Prior changes in antiretroviral regimen are only allowed due to tolerability issues or for 
regimen simplification. Unconfirmed virologic elevations of ≥ 50 copies/mL (transient 
detectable viremia, or “blip”) prior to screening are acceptable. If the lower limit of detection 
of the local HIV-1 RNA assay is <50 copies/mL (eg, <20 copies/mL), the plasma HIV-1 
RNA level cannot exceed 50 copies/mL on two consecutive HIV-1 RNA tests.
16) Have no documented or suspected resistance to FTC, TFV, DTG, ABC or 3TC including, but 
not limited, to the reverse transcriptase resistance mutations K65R and M184V/I
4.3.
Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study.
1) An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to 
screening (refer to Appendix 5)
2) Subjects experiencing decompensated cirrhosis (e.g, ascites, encephalopathy, or variceal 
bleeding)
3) Have been treated with immunosuppressant therapies or chemotherapeutic agents within 
3 months of study screening, or expected to receive these agents or systemic steroids during 
the study (e.g, corticosteroids, immunoglobulins, and other immune- or cytokine-based 
therapies)
4) Current alcohol or substance use judged by the Investigator to potentially interfere with 
subject study compliance


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 42
21 October 2015
5) A history of or ongoing malignancy (including untreated carcinoma in-situ) other than 
cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous 
squamous carcinoma. Subjects with biopsy-confirmed cutaneous KS are eligible, but must 
not have received any systemic therapy for KS within 30 days of Day 1 and are not 
anticipated to require systemic therapy during the study
6) Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or 
antifungal therapy within 30 days prior to Day 1
7) Participation in any other clinical trial, including observational studies,  without prior 
approval from the sponsor is prohibited while participating in this trial
8) Any other clinical condition or prior therapy that, in the opinion of the Investigator, would 
make the subject unsuitable for the study or unable to comply with the dosing requirements
9) Any known allergies to the excipients of GS-9883/F/TAF FDC or ABC/DTG/3TC FDC 
tablets
10) Females who are pregnant (as confirmed by positive serum pregnancy test)
11) Females who are breastfeeding
12) Subjects receiving ongoing therapy with any of the following medications in the table below, 
including drugs not to be used with FTC, TAF, GS-9883, DTG, ABC and 3TC
Drug Class
Agents Disallowed*
Antiarrhythmic Agent
Dofetilide
Anticonvulsants
Phenobarbital, Phenytoin, Carbamazepine, Oxcarbazepine
Antimycobacterials
Rifampin, Rifapentine
Antiretrovirals
Any antiretroviral drug that is not part of the study regimen
GI Motility Agents
Cisapride
Herbal/Natural Supplements
St. John’s Wort, Echinaccea
*
Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the
duration of the study.
13) Acute hepatitis in the 30 days prior to study entry
14) Chronic Hepatitis B Virus (HBV) infection, as determined by either: 
a) Positive HBV surface antigen and negative HBV surface antibody, regardless of HBV 
core antibody status, at the screening visit
b) Positive HBV core antibody and negative HBV surface antibody, regardless of HBV 
surface antigen status, at the screening visit
15) Active tuberculosis infection


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 43
21 October 2015
5.
INVESTIGATIONAL MEDICINAL PRODUCTS
5.1.
Randomization, Blinding and Treatment Codes
Subjects will be assigned a screening number at the time of consent. Randomization and Day 1 
visits cannot occur until subject eligibility has been confirmed.
Once eligibility has been confirmed and prior to or during the Day 1, visit the Investigator or 
designee will randomize the subject using the Interactive Web Response System (IWRS). Once a 
subject number has been assigned to a subject, it will not be reassigned to any other subject. The 
subject number assignment and randomization may be performed up to 3 days prior to the 
in-clinic Day 1 visit provided that all screening procedures have been completed and subject 
eligibility has been confirmed.
Subjects will be randomized in a 1:1 ratio to Treatment Group 1 or Treatment Group 2.
The IWRS will assign study drug bottle numbers of blinded FDC of GS-9883/F/TAF + Placebo 
to match FDC of ABC/DTG/3TC, or FDC of ABC/DTG/3TC + Placebo to match FDC of 
GS-9883/F/TAF at each study visit for each subject. 
5.1.1.
Procedures for Breaking Treatment Codes
In the event of a medical emergency where breaking the blind is required to provide medical care 
to the subject, the investigator may obtain treatment assignment directly from the IWRS system 
for that subject. Gilead strongly recommends but does not require that the investigator contact 
the Gilead medical monitor before breaking the blind. Treatment assignment should remain 
blinded unless that knowledge is necessary to determine subject emergency medical care. The 
rationale for unblinding must be clearly explained in source documentation and on the electronic 
case report form (eCRF), along with the date on which the treatment assignment was 
obtained. The investigator is requested to contact the Gilead medical monitor promptly in case of 
any treatment unblinding.
Blinding of study treatment is critical to the integrity of this clinical trial and therefore, if a 
subject’s treatment assignment is disclosed to the investigator, the subject will have study 
treatment discontinued. All subjects will be followed until study completion unless consent to do 
so is specifically withdrawn by the subject.
Gilead Drug Safety and Public Health (DSPH) may independently unblind cases for expedited 
reporting of suspected unexpected serious adverse reactions (SUSARs).


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 44
21 October 2015
5.2.
Description and Handling
5.2.1.
Formulation
5.2.1.1.
GS-9883/Emtricitabine/Tenofovir alafenamide (GS-9883/F/TAF) 
50 mg/200 mg/25 mg and Placebo to Match Tablets
GS-9883 50 mg/Emtricitabine 200 mg/Tenofovir alafenamide 25 mg tablets are capsule-shaped, 
film-coated purplish-brown, debossed with "GSI" on one side of the tablet and "9883" on the 
other side of the tablet. Each tablet core contains 50 mg of GS-9883, 200 mg of emtricitabine, 
and 25 mg of tenofovir alafenamide. In addition to the active ingredients, the GS-9883/F/TAF
tablets contain croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The 
tablet cores are film-coated with iron oxide red, iron oxide black, polyethylene glycol, polyvinyl 
alcohol, talc, and titanium dioxide.
The placebo to match (PTM) GS-9883/F/TAF tablets are capsule-shaped, film-coated 
purplish-brown, debossed with "GSI" on one side of the tablet and "9883" on the other side and 
are identical in physical appearance to GS-9883/F/TAF tablets. The placebo tablets contain 
microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and magnesium stearate. 
The tablet cores are film-coated with iron oxide red, iron oxide black, polyethylene glycol, 
polyvinyl alcohol, talc, and titanium dioxide.
5.2.1.2.
Abacavir/Dolutegravir/Lamivudine (ABC/DTG/3TC Triumeq®) 
600 mg/50 mg/300 mg and Placebo to Match Tablets
Abacavir 600 mg/Dolutegravir 50 mg/Lamivudine 300 mg tablets are oval, film coated purple, 
and debossed with “572 Tri” on one side. Each tablet core contains 600 mg of abacavir, 50 mg of 
dolutegravir, and 300 mg of lamivudine. In addition to the active ingredients, the 
ABC/DTG/3TC tablets contain the inactive ingredients D-mannitol, magnesium stearate, 
microcrystalline cellulose, povidone, and sodium starch glycolate. The tablet cores are film 
coated with iron oxide black, iron oxide red, polyethylene glycol, polyvinyl alcohol, talc, and 
titanium oxide.
The PTM ABC/DTG/3TC tablets are oval, film coated purple, and debossed with “572 Tri” on 
one side. The placebo tablets are identical in physical appearance to ABC/DTG/3TC tablets. The
placebo tablets contain microcrystalline cellulose, lactose monohydrate, croscarmellose sodium 
and magnesium stearate.  The tablet cores are film-coated with iron oxide black, iron oxide red, 
polyethylene glycol, polyvinyl alcohol, talc, and titanium oxide.
5.2.2.
Packaging and Labeling
5.2.2.1.
GS-9883/Emtricitabine/Tenofovir alafenamide (GS-9883/F/TAF) 
50 mg/200 mg/25 mg and Placebo to Match Tablets
GS-9883/F/TAF tablets and PTM GS-9883/F/TAF tablets are packaged in white, high density 
polyethylene (HDPE) bottles. Each bottle contains 30 tablets, silica gel desiccant and polyester 
packing material.  Each bottle is enclosed with a white, continuous thread, child-resistant 
polypropylene screw cap with an induction-sealed and aluminum-faced liner.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 45
21 October 2015
Study drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the United States Food and Drug Administration 
(FDA), EU Guideline to Good Manufacturing Practice - Annex 13 (Investigational Medicinal 
Products), and/or other local regulations
5.2.2.2.
Abacavir/Dolutegravir/Lamivudine (ABC/DTG/3TC Triumeq®) 
600 mg/50 mg/300 mg and Placebo to Match Tablets
ABC/DTG/3TC tablets and PTM ABC/DTG/3TC tablets are packaged in white, high density 
polyethylene (HDPE) bottles. Each bottle contains 30 tablets and silica gel desiccant. Each bottle 
is enclosed with a white, continuous thread, child-resistant polypropylene screw cap with an 
induction-sealed and aluminum-faced liner.
Study drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the United States Food and Drug Administration 
(FDA), EU Guideline to Good Manufacturing Practice - Annex 13 (Investigational Medicinal 
Products), and/or other local regulations.
5.2.3.
Storage and Handling
Study drug GS-9883/F/TAF FDC, ABC/DTG/3TC FDC and placebo-to-match tablets for both 
FDCs should be stored at controlled room temperature of 25°C (77°F); excursions are permitted 
between 15°C and 30°C (59°F and 86°F). Storage conditions are specified on the label. Until 
dispensed to the subjects, all bottles of study drugs should be stored in a securely locked area, 
accessible only to authorized site personnel.
To ensure the stability and proper identification, study drug(s) should not be stored in a container 
other than the container in which they were supplied.
Consideration should be given to handling, preparation, and disposal through measures that 
minimize drug contact with the body. Appropriate precautions should be followed to avoid direct 
eye contact or exposure through inhalation when handling.
5.3.
Dosage and Administration of GS-9883/Emtricitabine/Tenofovir alafenamide 
and Abacavir/Dolutegravir/Lamivudine
Study drug GS-9883/F/TAF FDC, ABC/DTG/3TC FDC and placebo-to-match tablets for both 
FDCs will be provided by Gilead Sciences.
Treatment Group 1: FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir alafenamide 
25 mg (GS-9883/F/TAF) + Placebo to match FDC of abacavir 600 mg/ dolutegravir 
50 mg/lamivudine 300 mg (ABC/DTG/3TC) administered orally, once daily, without regard to 
food
Treatment Group 2: FDC of abacavir 600 mg/dolutegravir 50 mg/ lamivudine 300 mg 
(ABC/DTG/3TC) + Placebo to match FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir 
alafenamide 25 mg (GS-9883/F/TAF) administered orally, once daily, without regard to food


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 46
21 October 2015
Subjects will be instructed to bring all study medication in the original container at each clinic 
visit for drug accountability. The Investigator will be responsible for maintaining accurate 
records for all study drug bottles dispensed and tablets returned. The inventory and dispensing 
logs must be available for inspection by the study monitor. Study medication supplies, including 
partially used or empty bottles, must be accounted for by the study monitor prior to destruction 
or return.
5.4.
Prior and Concomitant Medications

The use of medications for the treatment of HIV, other than study drug, is prohibited.

Medications listed in the following table and use of herbal/natural supplements are excluded 
or should be used with caution while subjects are participating in the study.  Subjects will 
refrain from consumption of grapefruit juice and Seville orange juice throughout 
participation in the study.
Table 5-1.
Prior and Concomitant Medications
Drug Class
Agents Disallowed*
Use Discouraged and To Be Used With 
Caution
Acid Reducing Agents
Antacids
Buffered medications 
Concentration of study drug may 
decrease with antacids. Subjects may not 
take antacids (eg, Tums or Rolaids); the 
ulcer medication sucralfate (Carafate); or 
vitamin or mineral supplements that 
contain calcium, iron or zinc for a 
minimum of 2 hours before and 6 hours 
after any dose of study drug.
Antiarrhythmic Agent
Dofetilide
Anticonvulsants
Phenobarbital, Phenytoin, 
Carbamazepine, Oxcarbazepine
Antimycobacterials
Rifampin, Rifapentine
Antiretrovirals
Any antiretroviral drug that is not part of 
the study regimen
GI Motility Agents
Cisapride
Herbal/Natural 
Supplements
St. John’s Wort, Echinaccea
Oral Hypoglycemic Agent
Metformin: close monitoring is 
recommended. A dose adjustment of 
Metformin may be necessary. Limit total 
daily doses of Metformin to 1000mg 
when initiating study medication or if 
initiating metformin while on study drug.
*
Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the 
duration of the study. 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 47
21 October 2015
Should subjects have a need to initiate treatment with any excluded concomitant medication, the 
Gilead Sciences Medical Monitor must be consulted prior to initiation of the new medication. In 
instances where an excluded medication is initiated prior to discussion with the Sponsor, the 
Investigator must notify Gilead Sciences as soon as he/she is aware of the use of the excluded 
medication.
5.5.
Accountability for Investigational Medicinal Product (IMP)
The investigator is responsible for ensuring adequate accountability of all used and unused IMP.
This includes acknowledgement of receipt of each shipment of IMP (quantity and condition). All 
used and unused IMP dispensed to subjects must be returned to the site.
Study Drug accountability records will be provided to each study site to:

Record the date received and quantity of IMP kits

Record the date, subject number, subject initials, the IMP kit number dispensed

Record the date, quantity of used and unused IMP returned, along with the initials of the 
person recording the information
5.5.1.
Investigational Medicinal Product Return or Disposal
Study drug return and disposal will be performed as outlined in Section 9.1.7.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 48
21 October 2015
6.
STUDY PROCEDURES
The study procedures to be conducted for each subject enrolled in the study are presented in 
tabular form in Appendix 2 and described in the text that follows.
The investigator must document any deviation from protocol procedures and notify the sponsor 
or contract research organization (CRO).
6.1.
Subject Enrollment and Treatment Assignment
It is the responsibility of the Investigator to ensure that subjects are eligible for study prior to
enrollment. Please refer to Section 6.2.2 for details about randomization and treatment 
assignment.
6.2.
Pretreatment Assessments
6.2.1.
Screening Visit
Subjects will be screened within 30-days before Day 1 to determine eligibility for participation in 
the study. The following will be performed and documented at screening:

Obtain written informed consent

Obtain medical history including history of HIV-1 disease-related events, smoking history
and prior medications within 30 days of the screening visit

Complete physical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)

12-lead ECG performed supine

Height

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

Urine collection for the following laboratory procedures:
Urinalysis

Blood sample collection for the following laboratory analyses:
Serum pregnancy test (females of childbearing potential only). If the test is positive, the 
subject will not be enrolled


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 49
21 October 2015
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, 
amylase (reflex lipase testing is performed in subjects with total amylase 1.5 ULN) 
and TSH.
Estimated glomerular filtration rate according to the Cockcroft-Gault formula:
■
Male:
(140 – age in years) (wt in kg) CLcr (mL/min)
72 (serum creatinine in mg/dL)
          (140 – age in years) (wt in kg)        CLcr (mL/sec)
72 (serum creatinine in umol/L) 0.6786
■
Female:
(140 – age in years) (wt in kg) 0.85 CLcr (mL/min)
72 (serum creatinine in mg/dL)
          (140 – age in years) (wt in kg)        0.85 CLcr (mL/sec)
72 (serum creatinine in umol/L) 0. 6786
Hematology profile: complete blood count (CBC) with differential and platelet count
CD4+ cell count
Plasma HIV-1 RNA
Hepatitis B virus surface antigen serology (HBsAg)
Hepatitis B surface antibody (HBsAb)
Hepatitis B virus core antibody (HBcAb)
Hepatitis C virus (HCVAb) serology. Subjects who are HCVAb positive will have a 
HCV RNA test performed.

Review of adverse events and concomitant medications
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within 30-days after screening for Day 1 Visit into the study. Subjects must continue to 
take their prior treatment regimen up until their scheduled Day 1 visit.
From the time of obtaining informed consent through the first administration of investigational 
medicinal product, record all serious adverse events (SAEs), as well as any adverse events 
related to protocol-mandated procedures on the adverse events case report form (eCRF). All 
other untoward medical occurrences observed during the screening period, including 
exacerbation or changes in medical history are to be captured on the medical history eCRF. See 
Section 7 Adverse Events and Toxicity Management for additional details.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 50
21 October 2015
6.2.2.
Day 1 Assessments
The following evaluations are to be completed at the Day 1 Visit. The Investigator must have 
confirmed eligibility before proceeding with the Day 1 visit. The subject must complete all 
study procedures, except DXA, before being administered the study drug:

DXA Scan (spine and hip). For subjects in Germany, DXA scans will not be performed.
The DXA scan will be performed on subjects once eligibility is confirmed. The scan may 
be performed prior to or within 24 hours of the Day 1 Visit.

Review of AEs and changes in concomitant medications

Complete physical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

12-lead ECG performed supine

Short Form 36 Health Survey (SF-36), HIV Symptoms Distress Module, Work Productivity 
and Activity Impairment Questionnaire (WPAI) and Pittsburgh Sleep Quality Index (PSQI) 
to be completed by the subject.  Subject is to read questionnaire by himself/herself and 
write/mark answers directly onto questionnaires.

Urine collection for the following laboratory procedures:
Urinalysis
Urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2
microglobulin
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test. If the test is positive, the subject will not be 
able to participate
Urine storage sample for possible additional clinical testing

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, phosphorus, magnesium, potassium, sodium, uric acid, and amylase 
(reflex lipase testing is performed in subjects with total amylase 1.5 ULN) and TSH


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
Final 
Original 
-
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and 
triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the 
subject must retum within 72 hours in a fasted state to draw blood for the metabolic 
assessments. 
-
Estimated glomemlar filtration rate according to the Cockcroft-Gault f01mula 
-
Hematology profile: complete blood cmmt (CBC) with differential and platelet cmmt 
-
Plasma HIV-1 RNA 
-
CD4+ cell count 
-
Evaluations of inflammation and immlme activation, may include but not limited to 
cystatin C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163 
-
Evaluations of platelet function, including but not limited to soluble glycoprotein VI 
(sGPVI), P-selectin, and soluble CD40 ligand. 
-
Plasma storage sample for safety, virology, or PK testing 
-
Whole blood sample for potential HIV DNA genotyping 
• 
Optional blood sample collection for the following laboratory analyses if 
pharmacogenomics consent is obtained 
I 
I 
I 
I 
6.3. 
Randomization 
Once eligibility has been confmned and prior to or during the Day 1 visit, the Investigator or 
designee will randomize the subject using the Interactive Web Response System (IWRS). Once a 
subject number has been assigned to a subject, it will not be reassigned to any other subject. The 
subject number assignment and randomization may be perf01med up to 3 days prior to the 
in-clinic Day 1 visit provided that all screening procedures have been completed and subject 
eligibility has been confi1med. 
CONFIDENTIAL 
Page 51 
21 October 2015 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 52
21 October 2015
6.4.
Treatment Assessments (Week 4 - 48)
The following evaluations are to be completed at the end of Weeks 4, 8, 12, 24, 36, and 48 unless 
otherwise specified.
Study visits are to be completed within ± 2 days of the protocol-specified visit date based on the 
Day 1 visit through Week 12 and completed within ± 6 days of the protocol-specified visit date
through Week 36, unless otherwise specified.  The visit window at Week 48 will be ± 6 weeks of 
the protocol-specified visit date, and these clinical visit windows coincide with the Week 48 
statistical analysis window for HIV-1 RNA.
Regularly scheduled evaluations will be made on all subjects whether or not they continue to 
receive study drug.

Review of AEs and changes in concomitant medications

DXA scans (spine and hip) for all subjects who are on study drug (Weeks 24 and 48 
±10 days). For subjects in Germany, DXA scans will not be performed.

Complete physical examination (Weeks 24 and 48) (urogenital/anorectal exams will be 
performed at the discretion of the Investigator) or symptom-directed physical examination as 
needed

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

12-lead ECG performed supine (Weeks 24 and 48)

Short Form 36 Health Survey (SF-36), HIV Symptoms Distress Module, Work Productivity 
and Activity Impairment Questionnaire (WPAI) and Pittsburgh Sleep Quality Index (PSQI) 
to be completed by the subject at Weeks 4, 12 and 48. Subject is to read questionnaire by 
himself/herself and write/mark answers directly onto questionnaires.

Urine collection for the following laboratory procedures:
Urinalysis
Urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2
microglobulin. (Weeks 24 and 48)
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test. If the test is positive, the subject will be 
discontinued
Urine storage sample for possible additional clinical testing


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 53
21 October 2015

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amylase 1.5 ULN). 
At Weeks 12, 24 and 48, analyses of glucose will be done as part of the fasting metabolic 
assessments and not as part of the chemistry profile. At Weeks 24 and 48, TSH will also 
be analyzed.
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and 
triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments. (Weeks 12, 24, and 48)
Estimated glomerular filtration rate according to the Cockcroft-Gault formula
Hematology profile: complete blood count (CBC) with differential and platelet count
Plasma HIV-1 RNA
CD4+ cell count
Evaluations of inflammation and immune activation, may include but not limited to 
cystatin C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163 (Weeks 24 and 48)
Evaluations of platelet function, may include but not limited to soluble glycoprotein VI 
(sGPVI), P-selectin, and soluble CD40 ligand (Weeks 24 and 48)
Plasma storage sample for safety, virology, or PK testing

Pharmacokinetic Blood Collection for subjects who are on study drug. Details of 
pharmacokinetic blood sampling procedures and sample management will be documented in 
the Pharmacokinetic Sample Collection, Processing, Storage, and Shipment Manual.
Single Anytime, Trough and Post Dose PK Sample for all Subjects on Study Drug:
■
Subjects will have a single anytime pre or post-dose PK blood sample at Weeks 8, 24 
and 36.
■
Observed dosing at the clinic: Subjects will have a trough PK blood sample collected 
between 20-28 hours following their last dose at Weeks 4 and 12. Subjects must be 
instructed to not take their study drugs on the morning of their visit for the trough 
sample collection.   Subjects will then take an observed dose of study drug at the 
clinic.  A single post dose PK blood sample will be collected between 1 and 4 hours


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
Final 
Original 
post dose. If the subject has taken their dose of study dmgs prior to the visit, the visit 
may proceed, but the subject must retum within 72 homs for the trough PK blood 
sample collection. In the event a subject routinely takes their study dmg in the 
evening, a single post dose sample may be drawn at Weeks 4 and 12 as the subject 
will not be instmcted to change their dosing time to accommodate this trough PK 
draw. 
• 
Dosing diaries will be collected from subjects for the single anytime PK and trough 
PK collection. If a dosing diaty is not retumed the site may ask the subject for the 
time of the last dose and if it was taken with or without food. 
-
Optional Pharmacokinetic (PK) Substudy: 
• 
PD 
• 
Provide subject dosing diaty to all subjects. (Weeks 4, 8, 12 and 24) 
• 
Document study dmg dispensation and accountability for all study mugs dispensed. 
• 
Subjects who meet the criteria for virologic failme will be managed according to the 
Management ofVirologic Rebound Section 6.13.1 and 6.13.2. 
6.5. 
Treatment Assessments (Post Week 48 until the Unblinding Visit) 
6.5.1. 
Post Week 48 Assessments 
After Week 48, subjects will continue to take their blinded study dt11gs and attend visits evety 
12 weeks until treatment assignments have been unblinded, at which point they will retum for an 
Unblinding Visit (refer to Section 6.5.2) Study visits are to be completed within ± 6 days of the 
protocol-specified visit date unless othetwise specified. 
CONFIDENTIAL 
Page 54 
21 October 2015 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 55
21 October 2015
At the Week 48 visit, subjects in the United Kingdom and Sweden will stop taking drug and 
complete a 30 day follow up visit and return to standard of care.

Review of AEs and changes in concomitant medications

Symptom-directed physical examination as needed

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

Urine collection for the following laboratory procedures:
Urinalysis 
Urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2
microglobulin. (Every 24 weeks)
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test. If the test is positive, the subject will be 
discontinued.
Urine storage sample for possible additional clinical testing

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amylase 1.5 ULN). 
Every 24 weeks, analyses of glucose will be done as part of the fasting metabolic 
assessments and not as part of the chemistry profile. In addition, TSH will also be 
analyzed every 24 weeks.
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and 
triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments. (Every 24 weeks)
Estimated glomerular filtration rate according to the Cockcroft-Gault formula
Hematology profile: complete blood count (CBC) with differential and platelet count
Plasma HIV-1 RNA
CD4+ cell count


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 56
21 October 2015
Evaluations of inflammation and immune activation, including but not limited to cystatin
C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163 (Every 24 weeks)
Evaluations of platelet function, including but not limited to soluble glycoprotein VI 
(sGPVI), P-selectin, and soluble CD40 ligand (Every 24 weeks)
Plasma storage sample for safety, virology, or PK testing

Document study drug dispensation and accountability for all study drugs dispensed.

Subjects who meet the criteria for virologic failure will be managed according to the 
Management of Virologic Rebound Section 6.13.1. and 6.13.2
6.5.2.
Unblinding Visit
Once Gilead Sciences provides unblinded treatment assignments to the Investigators, all subjects 
will return to the clinic (within 30 days ± 6 days) for an Unblinding Visit. At the Unblinding 
Visit, subjects in a country where GS-9883/F/TAF FDC is not available will be given the option 
to receive GS-9883/F/TAF FDC in an open label extension phase for 48 weeks, or until the 
product becomes accessible to subjects through an access program, or until Gilead Sciences 
elects to discontinue the study in that country, whichever occurs first.
Subjects who receive the open-label GS-9883/F/TAF FDC will return for study visits every 
12 weeks.
Subjects who choose to not receive the open label GS-9883/F/TAF FDC will be required to 
return to the clinic for a 30-Day Follow-up visit following the Unblinding Visit. Subjects who 
have discontinued drug study prior to the Unblinding Visit will not be eligible for the open-label 
rollover extension; these subjects will be asked to continue attending the scheduled study visits 
through the Unblinding Visit and discontinue the study after the Unblinding Visit.
The following will be performed at the Unblinding Visit:

Review of AEs and changes in concomitant medications

DXA scans (spine and hip) for all subjects who are on study drug (±10 days). For subjects in 
Germany, DXA scans will not be performed.

Complete physical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

12-lead ECG performed supine


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 57
21 October 2015

Urine collection for the following laboratory procedures:
Urinalysis
Uurine albumin, urine creatinine, urine protein, retinol binding protein and beta-2
microglobulin.
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test. If the test is positive, the subject will not be 
able to participate.
Urine storage sample for possible additional clinical testing

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, phosphorus, magnesium, potassium, sodium, uric acid, and amylase 
(reflex lipase testing is performed in subjects with total amylase 1.5 ULN), and TSH
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and 
triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments
Estimated glomerular filtration rate according to the Cockcroft-Gault formula
Hematology profile: complete blood count (CBC) with differential and platelet count
Plasma HIV-1 RNA
CD4+ cell count
Evaluations of inflammation and immune activation, may include but not limited to 
cystatin C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163
Evaluations of platelet function, including but not limited to soluble glycoprotein VI 
(sGPVI), P-selectin, and soluble CD40 ligand
Plasma storage sample for safety, virology, or PK testing

Document study drug dispensation, if applicable, and accountability for all study drugs 
dispensed

Subjects who wish to continue in the Open-Label Rollover extension study will receive open 
label GS-9883/F/TAF.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 58
21 October 2015
6.6.
Post-treatment Assessments
6.6.1.
Early Study Drugs Discontinuation Assessments
If the subject discontinues study drug prior to the Unblinding Visit, the subject will be asked to 
return to the clinic within 72 hours of stopping study drugs for the Early Study Drugs 
Discontinuation Visit. The subject will be asked to continue attending the scheduled study visits 
through the Unblinding Visit.
At the Early Study Drugs Discontinuation Visit, any evaluations showing abnormal results 
indicating that there is a possible or probable causal relationship with the study drug, will
be repeated weekly (or as often as deemed prudent by the Investigator) until the 
abnormality is resolved, returns to Day 1, or is otherwise explained.
The following evaluations are to be completed at the Early Study Drugs Discontinuation Visit:

Review of AEs and changes in concomitant medications

DXA scan required (spine and hip) for all subjects who are on study drug (±10 days) if last 
scan was acquired > 12 weeks from the date of the ESDD Visit. For subjects in Germany, 
DXA scans will not be performed.

Complete physical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)

12-lead ECG performed supine

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

Urine collection for the following laboratory procedures:
Urinalysis
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test
Urine storage sample for possible additional clinical testing

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and
amylase (reflex lipase testing is performed in subjects with total amylase 1.5 ULN), 
and TSH


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 59
21 October 2015
Estimated glomerular filtration rate according to the Cockcroft-Gault formula
Hematology profile: complete blood count (CBC) with differential and platelet count
Plasma HIV-1 RNA
CD4+ cell count
Plasma storage sample for safety, virology, or PK testing
HIV-1 genotype/phenotype testing for subjects with  virologic failure

Drug accountability
6.6.2.
30 Day Follow Up
Subjects who complete the study through the Unblinding visit and who do not wish to participate 
in the open-label rollover extension, will be required to return to the clinic 30 days after the 
completion of study drug for the 30 Day Follow Up visit.
Subjects in the United Kingdom and Sweden will complete a 30 day follow up visit after the 
completion of the Week 48 visit and return to standard of care.
Subjects who permanently discontinue study drug during the blinded phase and refuse to 
continue in the study through the Unblinding Visit will be asked to return to the clinic 30 days 
after the completion of the Early Study Drugs Discontinuation Visit for the 30-Day Follow-Up 
Visit.
Those subjects who permanently discontinue study drug and continue in the study through 
at least one subsequent visit after the Early Study Drug Discontinuation Visit will not be 
required to complete the 30-Day Follow-Up Visit.
For the purpose of scheduling a 30-Day Follow-Up Visit, a 6 days window may be used. 
The following evaluations are to be completed at the 30-Day Follow-Up Visit:

Review of AEs and changes in concomitant medications

Symptom-directed physical examination

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

Urine collection for the following laboratory procedures:
Urinalysis
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 60
21 October 2015

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amylase 1.5 ULN).
Estimated glomerular filtration rate according to the Cockcroft-Gault formula
Hematology profile: complete blood count (CBC) with differential and platelet count
Plasma HIV-1 RNA
CD4+ cell count
At the 30-Day Follow-Up Visit, any evaluations showing abnormal results believed to be a 
reasonable possibility of a causal relationship with the study drugs will be repeated weekly (or as 
often as deemed prudent by the Investigator) until the abnormality is resolved, returns to 
baseline, or is otherwise explained. 
6.7.
Criteria for Discontinuation of Study Treatment
Study medication may be discontinued in the following instances:

Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree. Following resolution of intercurrent illness, the subject 
may resume study dosing at the discretion of the investigator

Unacceptable toxicity, or toxicity that, in the judgment of the investigator, compromises the 
ability to continue study-specific procedures or is considered to not be in the subject’s best 
interest

Lack of efficacy

Subject request to discontinue for any reason

Subject noncompliance

Pregnancy during the study; refer to Appendix 6

Development of active tuberculosis infection

Discontinuation of the study at the request of Gilead, a regulatory agency or an institutional 
review board or independent ethics committee (IRB/IEC)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 61
21 October 2015
6.8.
Bone Mineral Density Evaluations
For all subjects who are on study drug, excluding those enrolled in sites based in Germany, dual 
energy x-ray absorptiometry (DXA) scans will be performed prior to or within 24 hours of 
Day 1, Weeks 24, 48, Unblinding Visit and the Early Study Drug Discontinuation Visit (if the 
last scan was acquired > 12 weeks from the date of the ESDD Visit).  Scans will cover the spine 
and hip to measure changes in bone mineral density. DXA scan results will be provided to study 
sites.
A complete description of the procedures performed for the DXA scans will be provided in a 
DXA manual.
6.9.
Other Evaluations
6.9.1.
Markers of Renal Tubular Function
For all subjects, urine will be collected for selected evaluations of renal tubular function, which 
will include urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2
microglobulin at Day 1 Visit, Weeks 24, 48, every 24 weeks post Week 48 and the Unblinding 
Visit.
6.9.2.
Markers of Inflammation and Immune Activation
For all subjects, blood will be collected at Day 1 Visit, Weeks 24, 48, every 24 weeks post 
Week 48 and the Unblinding Visit for selected evaluations of inflammation and immune 
activation, which may include but not limited to cystatin C, IL 6, hs CRP, d-dimer, sCD14, and 
sCD163.
6.9.3.
Markers of Platelet Function
For all subjects, blood will be collected at Day 1 Visit, Weeks 24, 48, every 24 weeks post 
Week 48 and the Unblinding Visit for selected evaluations of platelet function, which may 
include but not limited to soluble glycoprotein VI (sGPVI), P-selectin, and soluble CD40 ligand
6.9.4.
Blood and Urine Storage
A portion of the blood and urine samples drawn at all visits (except the Screening Visit, 30-day 
follow-up Visit and Unscheduled Visits) will be frozen and stored. These stored blood and urine 
samples may be used by the Sponsor or its research partners for HIV-1 genotyping/phenotyping 
assays or their development, for retesting the amount of HIV-1 in the blood, for measurement of 
antiviral drug levels in the blood, or for testing to learn more about how the study drug has 
worked against HIV-1 or clinical laboratory testing to provide additional safety data. No human 
genetic testing will be performed without expressed consent of study subjects. At the conclusion 
of this study, these samples may be retained in storage by Gilead Sciences for a period up to 
15 years.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 62
21 October 2015
6.10.
Assessments for Premature Discontinuation from Study
If a subject discontinues study dosing (for example, as a result of an AE), every attempt should 
be made to keep the subject in the study and continue to perform the required study-related 
follow-up and procedures (see Section 6.7, Criteria for Discontinuation of Study Treatment). If 
this is not possible or acceptable to the subject or investigator, the subject may be withdrawn 
from the study.
6.11.
End of Study
The end of study will be the last patient’s last observation (or visit).
6.12.
Post Study Care
After a subject has completed/terminated their participation in the study, long-term care for the
subject will remain the responsibility of their primary treating physician.
6.13.
Virologic Failure
Virologic failure is defined as virologic rebound or having HIV-1 RNA ≥50 copies/mL at study
drug discontinuation, or Week 48.
6.13.1.
Management of Virologic Rebound
Subjects who meet the criteria listed below will be considered to have virologic rebound:

At any post Day 1 visit, a rebound in HIV-1 RNA ≥50 copies/mL, which is subsequently 
confirmed at the following scheduled or unscheduled visit; OR

Any subject with HIV RNA ≥ 50 copies/mL at study drug discontinuation
Following the unconfirmed virologic rebound, subjects will be asked to return to the clinic for a 
scheduled or unscheduled blood draw (2 to 3 weeks after the date of the original test that resulted 
in HIV-1 RNA virologic rebound) for confirmation of virologic rebound. If virologic rebound is 
confirmed at the scheduled or unscheduled visit and the HIV-1 RNA is ≥200 copies/mL, the 
blood sample from the confirmation visit will be the primary sample used for HIV-1 genotypic 
and phenotypic testing.  Subjects with documented non-adherence within 72 hours of the visit 
may not be tested for resistance. After a subject’s first post-baseline resistance test, additional 
testing will be conducted on a case-by-case basis.     Any subject may be discontinued at 
Investigator’s discretion or per local treatment guidelines.
If no resistance is detected from the genotype or phenotype, the subject may remain on study 
drugs and HIV-1 RNA test should be repeated (2 to 3 weeks after date of test with HIV-1 RNA 
≥50 copies/mL). Investigators should carefully evaluate the benefits and risks of remaining on 
study drug for each individual subject and document this assessment in the on-site medical 
record.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 63
21 October 2015
Subjects who are noncompliant on an ongoing basis will be considered for discontinuation per 
the Investigator’s discretion or local treatment guidelines. Investigators who opt to discontinue 
study drugs for an individual subject must discuss with the Medical Monitor prior to study drug 
discontinuation.
For subjects who are off study drug but remain on study, it will be the Investigator’s discretion to 
manage virologic rebound.
Please refer to Figure 6-1 for the management of subjects who meet the criteria for virologic 
rebound.
Figure 6-1.
Virologic Rebound Schema
a.
If virologic rebound is not confirmed, the subject will remain on their current regimen.
b.
If virologic rebound is confirmed and the HIV-1 RNA is ≥200 copies/mL, the HIV-1 genotype and phenotype (reverse 
transcriptase, protease and integrase) will be analyzed.
c.
Based on the results of the genotypic and phenotypic assays, the subject will remain on study drugs or study drugs will be 
discontinued. If genotyping or phenotyping fails, a new ARV regimen may be configured at the discretion of the 
Investigator.
d.
If no resistance is detected, HIV-1 RNA will be repeated (2-3 weeks later).  Investigator reviews study drug 
continuation/discontinuation options and discuss with the Medical Monitor prior to study drug discontinuation
e.
A new ARV regimen will be configured, at the Investigator’s discretion, and the subject will remain in the study.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 64
21 October 2015
6.13.2.
Subjects with HIV-1 RNA ≥50 copies/mL at Study Drug Discontinuation, or 
Week 48
Subjects with HIV-1 RNA ≥50 copies/mL at study drug discontinuation or last visit will be 
considered virologic failures. Subjects with HIV-1 RNA ≥50 copies/mL at Week 48 will be 
asked to return for an unscheduled visit within the visit window for a retest. 
Subjects with HIV-1 RNA ≥200 copies/mL at study drug discontinuation, last visit or Week 48, 
will also have resistance testing conducted. 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 65
21 October 2015
7.
ADVERSE EVENTS AND TOXICITY MANAGEMENT
7.1.
Definitions of Adverse Events, Adverse Reactions, and Serious Adverse 
Events
7.1.1.
Adverse Events
An adverse event (AE) is any untoward medical occurrence in a clinical study subject 
administered a medicinal product, which does not necessarily have a causal relationship with the 
treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease 
temporally associated with the use of a medicinal product, whether or not considered related to 
the medicinal product. AEs may also include pre- or post-treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or 
occupational exposure. Preexisting events that increase in severity or change in nature during or 
as a consequence of participation in the clinical study will also be considered AEs.
An AE does not include the following:

Medical or surgical procedures such as surgery, endoscopy, tooth extraction, and transfusion. 
The condition that led to the procedure may be an adverse event and must be reported.

Pre-existing diseases, conditions, or laboratory abnormalities present or detected before the 
screening visit that do not worsen

Situations where an untoward medical occurrence has not occurred (e.g., hospitalization for 
elective surgery, social and/or convenience admissions)

Overdose without clinical sequelae (see Section 7.6.1)

Any medical condition or clinically significant laboratory abnormality with an onset date 
before the consent form is signed and not related to a protocol-associated procedure is not an 
AE. It is considered to be pre-existing and should be documented on the medical history 
eCRF.
7.1.2.
Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at any dose, results in the following:

Death

Life-threatening (Note: The term “life-threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that hypothetically might have caused death if it were more severe.)

In-patient hospitalization or prolongation of existing hospitalization


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 66
21 October 2015

Persistent or significant disability/incapacity

A congenital anomaly/birth defect

A medically important event or reaction: such events may not be immediately 
life-threatening or result in death or hospitalization but may jeopardize the subject or may 
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; and development of drug dependency or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medically important event and subject to expedited reporting 
requirements.
7.1.3.
Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory abnormalities (eg, clinical chemistry, hematology, and urinalysis) that 
require medical or surgical intervention or lead to IMP interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. In addition, 
laboratory or other abnormal assessments (eg, electrocardiogram, x-rays, vital signs) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they meet the 
definition of an AE or SAE as described in Sections 7.1.1 and 7.1.2. If the laboratory 
abnormality is part of a syndrome, record the syndrome or diagnosis (eg, anemia), not the 
laboratory result (ie, decreased hemoglobin).
For specific information on handling of clinical laboratory abnormalities in this study, please 
refer to Section 7.5.
7.2.
Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality and severity, and for final review and confirmation of accuracy of event information 
and assessments.
7.2.1.
Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing the relationship to IMP
therapy using clinical judgment and the following considerations:

No: Evidence exists that the adverse event has an etiology other than the IMP. For SAEs, an 
alternative causality must be provided (eg, pre-existing condition, underlying disease, 
intercurrent illness, or concomitant medication).

Yes: There is reasonable possibility that the event may have been caused by the 
investigational medicinal product.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 67
21 October 2015
It should be emphasized that ineffective treatment should not be considered as causally related in 
the context of adverse event reporting.
The relationship to study procedures (eg, invasive procedures such as venipuncture or biopsy) 
should be assessed using the following considerations:

No: Evidence exists that the adverse event has an etiology other than the study procedure.

Yes: The adverse event occurred as a result of protocol procedures, (eg, venipuncture)
7.2.2.
Assessment of Severity
AE severity should be recorded and graded according to the GSI Grading Scale for Severity of 
Adverse Events and Laboratory Abnormalities (Appendix 4). For adverse events associated with 
laboratory abnormalities, the event should be graded on the basis of the clinical severity in the 
context of the underlying conditions; this may or may not be in agreement with the grading of 
the laboratory abnormality.
The distinction between the seriousness and the severity of an adverse event should be noted. 
Severe is a measure of intensity; thus, a severe reaction is not necessarily a serious reaction. For 
example, a headache may be severe in intensity, but would not be classified as serious unless it 
met one of the criteria for serious events.
For AEs associated with laboratory abnormalities, the event should be graded on the basis of the 
clinical severity in the context of the underlying conditions; this may or may not be in agreement 
with the grading of the laboratory abnormality.
7.3.
Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead
Requirements for collection prior to study drug initiation:
After informed consent, but prior to initiation of study medication, the following types of events 
should be reported on the eCRF:

all SAEs and adverse events related to protocol-mandated procedures.
7.3.1.
Adverse Events
Following initiation of study medication, collect all AEs, regardless of cause or relationship, 
until 30-days after last administration of study IMP must be reported to the eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Sciences may request that certain AEs be followed beyond the protocol defined follow up 
period.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 68
21 October 2015
7.3.2.
Serious Adverse Events
All SAEs, regardless of cause or relationship, that occurs after the subject first consents to 
participate in the study (i.e, signing the informed consent) and throughout the duration of the 
study, including the protocol-required post treatment follow-up period, must be reported to the 
eCRF database and Gilead Drug Safety and Public Health (DSPH) as instructed. This also 
includes any SAEs resulting from protocol-associated procedures performed after informed 
consent is signed.
Any SAEs and deaths that occur after the post treatment follow-up visit but within 30-days of the 
last dose of study IMP, regardless of causality, should also be reported.
Investigators are not obligated to actively seek SAEs after the protocol defined follow up period; 
however, if the investigator learns of any SAEs that occur after study participation has concluded 
and the event is deemed relevant to the use of IMP, he/she should promptly document and report 
the event to Gilead DSPH.
Electronic Serious Adverse Event (eSAE) Reporting Process

Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.

If for any reason it is not possible to record the SAE information electronically, ie, the eCRF 
database is not functioning, record the SAE on the paper serious adverse event reporting 
form and submit within 24 hours to:
Gilead DSPH contact 
information:
Email: Safety_FC@gilead.com
Fax: +1 (650) 522-5477

As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.

If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.

All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline.

Additional information may be requested to ensure the timely completion of accurate safety 
reports.

Any medications necessary for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s eCRF and the event description section of the SAE form


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 69
21 October 2015

For fatal or life-threatening events, copies of hospital case reports, autopsy reports, and other 
documents are also to be submitted by e-mail or fax only when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability of a document to the subject identifiers.
7.4.
Gilead Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country-specific legislation or regulations, Gilead may be required to expedite to 
worldwide regulatory agencies reports of SAEs, serious adverse drug reactions (SADRs), or 
suspected unexpected serious adverse reactions (SUSARs). In accordance with the EU Clinical 
Trials Directive (2001/20/EC), Gilead or a specified designee will notify worldwide regulatory 
agencies and the relevant IEC in concerned Member States of applicable SUSARs as outlined in 
current regulations.
Assessment of expectedness for SAEs will be determined by Gilead using reference safety 
information specified in the investigator’s brochure or relevant local label as applicable.
All investigators will receive a safety letter notifying them of relevant SUSAR reports associated 
with any study IMP. The investigator should notify the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required by local regulatory agencies, and in accordance with the local 
institutional policy.
7.5.
Toxicity Management
All clinical and clinically significant laboratory toxicities will be managed according to uniform 
guidelines detailed in Appendix 3 as outlined below.

Clinical events and clinically significant laboratory abnormalities will be graded according to 
the GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities 
(Appendix 4)

Grade 3 and 4 clinically significant laboratory abnormalities should be confirmed by repeat 
testing within 3 calendar days of receipt of results and before investigational medicinal 
product discontinuation, unless such a delay is not consistent with good medical practice

Any questions regarding toxicity management should be directed to the Gilead Medical 
Monitor.
7.5.1.
Grades 1 and 2 Laboratory Abnormality or Clinical Event
Continue study drug at the discretion of the Investigator.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 70
21 October 2015
7.5.2.
Grade 3 Laboratory Abnormality or Clinical Event

For Grade 3 clinically significant laboratory abnormality or clinical event, investigational 
medicinal product may be continued if the event is considered to be unrelated t 
investigational medicinal product.

For a Grade 3 clinical event, or clinically significant laboratory abnormality confirmed by 
repeat testing, that is considered to be related to investigational medicinal product, 
investigational medicinal product should be withheld until the toxicity returns to 
Grade 2.When restarting investigational medicinal product following resolution of the 
adverse event, the investigational medicinal product should be restarted at full dose upon 
discussion with the Gilead Sciences Medical Monitor.

If a laboratory abnormality recurs to Grade 3 following rechallenge with investigational 
medicinal product and is considered related to investigational medicinal product, then 
investigational medicinal product should be permanently discontinued and the subject 
managed according to local practice. Recurrence of laboratory abnormalities considered 
unrelated to investigational medicinal product may not require permanent discontinuation but 
requires discussion with the Gilead Sciences Medical Monitor.
7.5.3.
Grade 4 Laboratory Abnormality or Clinical Event

For a Grade 4 clinical event or clinically significant Grade 4 laboratory abnormality 
confirmed by repeat testing that is considered related to investigational medicinal product, 
investigational medicinal product should be permanently discontinued and the subject 
managed according to local practice. The subject should be followed as clinically indicated 
until the laboratory abnormality returns to baseline or is otherwise explained, whichever 
occurs first. A clinically significant Grade 4 laboratory abnormality that is not confirmed by 
repeat testing should be managed according to the algorithm for the new toxicity grade.

Investigational medicinal product may be continued without dose interruption for a clinically 
non-significant Grade 4 laboratory abnormality (eg, Grade 4 CK after strenuous exercise, or 
triglyceride elevation that is nonfasting or that can be medically managed) or a clinical event 
considered unrelated to investigational medicinal product requires discussion with the 
Gilead Sciences Medical Monitor.
7.5.4.
Management of Possible Abacavir Hypersensitivity Reaction
Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to increased 
risk of hypersensitivity reaction, unless no other therapeutic option is available based on the 
treatment history and resistance testing.
In a clinical study, 3.4 % of subjects with a negative HLA-B*5701 status receiving abacavir 
developed a hypersensitivity reaction. Therefore, even in the absence of HLA-B*5701 allele, it is 
important to permanently discontinue abacavir and not rechallenge with abacavir if a 
hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe 
or even fatal reaction.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 71
21 October 2015
Hypersensitivity reactions are characterized by the appearance of symptoms indicating 
multi-organ system involvement. Almost all hypersensitivity reactions will have fever and/or 
rash as part of the syndrome. Other signs and symptoms may include respiratory signs and 
symptoms such as dyspnoea, sore throat, cough, and abnormal chest x-ray findings
(predominantly infiltrates, which can be localized), gastrointestinal symptoms, such as nausea, 
vomiting, diarrhea, or abdominal pain, and may lead to misdiagnosis of hypersensitivity as 
respiratory disease (pneumonia, bronchitis, pharyngitis), or gastroenteritis. Other frequently 
observed signs or symptoms of the hypersensitivity reaction may include lethargy or malaise and 
musculoskeletal symptoms (myalgia, rarely myolysis, arthralgia). The symptoms related to this 
hypersensitivity reaction worsen with continued therapy and can be life- threatening. 
These symptoms usually resolve upon discontinuation of abacavir.
Hypersensitivity reaction symptoms usually appear within the first six weeks of initiation of 
treatment with abacavir, although these reactions may occur at any time during therapy. Patients 
should be monitored closely, especially during the first two months of treatment with abacavir.
Regardless of their HLA-B*5701 status, patients who are diagnosed with a hypersensitivity 
reaction whilst on therapy MUST discontinue study drug immediately and MUST NEVER be 
restarted. Restarting study drug following a hypersensitivity reaction results in a prompt return of 
symptoms within hours. This recurrence is usually more severe than on initial presentation, and 
may include life-threatening hypotension and death. To avoid a delay in diagnosis and minimize 
the risk of a life-threatening hypersensitivity reaction, study drug must be permanently 
discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible 
(respiratory diseases, flu-like illness, gastroenteritis or reactions to other medicinal products) 
{25149}.
7.5.5.
On-Treatment Hepatitis C Management
If a subject tests positive for HCV RNA at screening or develops signs or symptoms of active 
Hepatitis C virus Gilead recommends that local medical practice is followed at the discretion of 
the Investigator. Investigational medicinal product may be continued without dose 
interruption. Should the Investigator decide to initiate Hepatitis C treatment the Investigator 
must contact the Gilead Medical Monitor to confirm that no drug-drug interactions are expected.
Subjects should return to the clinic for scheduled or unscheduled follow up visit(s) according to 
local medical practice for laboratory evaluations. If Hepatitis C treatment is initiated, 
Investigators should use the Gilead provided retest laboratory kits to manage the active 
Hepatitis C.
7.6.
Special Situations Reports
7.6.1.
Definitions of Special Situations
Special situation reports include all reports of medication error, abuse, misuse, overdose, reports 
of adverse events associated with product complaints, and pregnancy reports regardless of an 
associated AE.  


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 72
21 October 2015
Medication error is any unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by a 
subject.
Misuse is defined as any intentional and inappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing information.
An overdose is defined as an accidental or intentional administration of a quantity of a medicinal 
product given per administration or cumulatively which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the daily dose of the subject in 
question). In cases of a discrepancy in drug accountability, overdose will be established only 
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.
7.6.2.
Instructions for Reporting Special Situations
7.6.2.1.
Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study subjects that are identified after 
initiation of study medication and throughout the study, including the post study drug follow-up 
period, to the Gilead DSPH using the pregnancy report form within 24 hours of becoming aware 
of the pregnancy. 
Refer to below and the eCRF completion guidelines for full instructions on the mechanism of 
pregnancy reporting.
The pregnancy itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy without medical reasons.
Any premature termination of pregnancy (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported within 24 hours as an 
SAE. The underlying medical reason for this procedure should be recorded as the AE term.
A spontaneous abortion is always considered to be an SAE and will be reported as described in 
Section 7.3. Furthermore, any SAE occurring as an adverse pregnancy outcome post study must 
be reported to Gilead DSPH.
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy. The outcome should be reported to Gilead DSPH using the pregnancy outcome report 
form. If the end of the pregnancy occurs after the study has been completed, the outcome should 
be reported directly to Gilead DSPH. Gilead DSPH contact information is as follows:


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 73
21 October 2015
Email: Safety_FC@gilead.com and Fax: +1 (650) 522-5477.
Pregnancies of female partners of male study subjects exposed to Gilead or other study drugs 
must also be reported and relevant information should be submitted to Gilead DSPH using the 
pregnancy and pregnancy outcome forms within 24 hours. Monitoring of the subject should 
continue until the conclusion of the pregnancy. If the end of the pregnancy occurs after the study 
has been completed, the outcome should be reported directly to Gilead DSPH, fax number 
+1 650 522-5477 or email Safety_FC@gilead.com.
Refer to Appendix 6 for Pregnancy Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
7.6.2.2.
Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to Gilead DSPH within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that involve study IMP and/or Gilead concomitant 
medications, but do not apply to non-Gilead concomitant medications.
Special situations involving non-Gilead concomitant medications does not need to be reported on 
the special situations report form; however, for special situations that result in AEs due to a 
non-Gilead concomitant medication, the AE should be reported on the AE form. 
Any inappropriate use of concomitant medications prohibited by this protocol should not be 
reported as “misuse,” but may be more appropriately documented as a protocol deviation.
Refer to Section 7.3 and the eCRF completion guidelines for full instructions on the mechanism 
of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the symptoms and 
signs, clinical management, and outcome will be reported, when available.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 74
21 October 2015
8.
STATISTICAL CONSIDERATIONS
8.1.
Analysis Objectives and Endpoints
8.1.1.
Analysis Objectives
The primary objective of this study is:

To evaluate the efficacy of switching from a regimen of DTG and ABC/3TC or a FDC of 
ABC/DTG/3TC to a FDC of GS-9883/F/TAF versus continuing DTG and ABC/3TC as the 
FDC ABC/DTG/3TC in virologically suppressed HIV-1 infected subjects as determined by 
the proportion of subjects with virologic failure (HIV-1 RNA ≥50 copies/mL) at Week 48
The secondary objectives of this study are:

To evaluate the safety, and tolerability of the two treatment groups through Week 48

To evaluate the bone safety of the two treatment groups as determined by the percentage 
change from baseline in hip and spine BMD through Week 48
8.1.2.
Primary Endpoint
The primary efficacy endpoint is the proportion of subjects with virologic failure (HIV-1 RNA
≥50 copies/mL) at Week 48 as defined by the modified US FDA snapshot algorithm.
8.1.3.
Secondary Endpoint
Secondary endpoints include:

The proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the 
US FDA snapshot algorithm

The change from baseline in CD4+ cell count at Week 48

The percentage change from baseline in hip and spine BMD at Week 48
8.2.
Analysis Conventions
8.2.1.
Analysis Sets
8.2.1.1.
All Randomized
The randomized analysis set includes all subjects who are randomized into the study. This is the 
primary analysis set for by-subject listings.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 75
21 October 2015
8.2.1.2.
Efficacy
8.2.1.2.1.
Full Analysis Set (FAS)
The primary analysis set for efficacy analyses is defined as full analysis set (FAS), which will 
include all subjects who (1) are randomized into the study and (2) have received at least 1 dose 
of study drug. Subjects will be grouped according to the treatment to which they were 
randomized.
8.2.1.2.2.
Per-Protocol (PP) Analysis Set
The secondary analysis set for efficacy analyses is defined as per-protocol (PP) analysis set, 
which will include all subjects who (1) are randomized into the study, (2) have received at least 
1 dose of study drug, and (3) have not committed any major protocol violation, including the 
violation of key entry criteria. Subjects will be grouped according to the treatment they actually 
received.
Subjects meeting any of the following criteria will be excluded from the Week 48 PP analysis
set:

Subjects who do not have on-treatment HIV-1 RNA in the Week 48 analysis window, except 
when missing is due to discontinuation of study drug for lack of efficacy.

Subjects who meet the exclusion criterion for receiving ongoing therapy with any of the 
medications listed in the table in protocol Section 4.3 including drugs not to be used with 
GS-9883, FTC, TAF, ABC, 3TC, and DTG.

Nonadherence to study drug: subjects with adherence rate for active study drug up to the 
Week 48 Visit below the 2.5th percentile
8.2.1.3.
Safety
The primary analysis set for safety analyses is defined as safety analysis set, which will include 
all subjects who (1) are randomized into the study and (2) have received at least 1 dose of study 
drug. All the data collected up to 30 days after subjects permanently discontinue their study drug 
will be included in the safety summaries, unless specified otherwise. Subjects will be grouped 
according to the treatment they actually received.
8.2.1.4.
Pharmacokinetics
8.2.1.4.1.
Pharmacokinetic (PK) Substudy Analysis Set
The primary analysis set for intensive PK analyses is defined as the PK substudy analysis set, 
which will include all subjects who (1) are randomized into the study, (2) enrolled into the PK 
Substudy, (3) have received at least 1 dose of study drug, and (4) have at least 1 nonmissing 
intensive PK concentration data for the analyte under evaluation reported by the PK lab.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 76
21 October 2015
8.2.1.4.2.
Pharmacokinetic (PK) Analysis Set
The primary analysis set for general PK analyses is defined as the PK analysis set, which will 
include all subjects who (1) are randomized into the study, (2) have received at least 1 dose of 
study drug, and (3) have at least 1 nonmissing PK concentration data for the analyte under 
evaluation reported by the PK lab.
8.2.1.5.
DXA
8.2.1.5.1.
Hip DXA Analysis Set
The primary analysis set for hip BMD analyses is defined as the Hip DXA analysis set, which
will include all subjects who (1) are randomized into the study, (2) have received at least 1 dose 
of study drug, and (3) have nonmissing baseline hip BMD value. Subjects will be grouped 
according to the treatment they actually received.
8.2.1.5.2.
Spine DXA Analysis Set
The primary analysis set for spine BMD analyses is defined as the Spine DXA analysis set, 
which will include all subjects who (1) are randomized into the study, (2) have received at least 
1 dose of study drug, and (3) have nonmissing baseline spine BMD value. Subjects will be 
grouped according to the treatment they actually received.
8.3.
Data Handling Conventions
HIV-1 RNA results of ‘No HIV-1 RNA detected’ and “<20 cp/mL HIV-1 RNA Detected” will 
be imputed as 19 copies/mL for analysis purpose.
Natural logarithmic transformation of plasma concentrations and PK parameters will be applied 
for PK analysis.
Laboratory data that are continuous in nature but are less than the lower limit of quantitation or 
above the upper limit of quantitation will be imputed to the value of the lower or upper limit plus 
or minus one significant digit, respectively (eg, if the result of a continuous laboratory test is 
< 20, a value of 19 will be assigned).
Missing data can have an impact upon the interpretation of the trial data. In general, values for 
missing data will not be imputed. However, a missing pre-treatment laboratory result would be 
treated as normal (ie, no toxicity grade) for the laboratory abnormality summary.
All available data for subjects that do not complete the study will be included in data listings.
8.4.
Demographic Data and Baseline Characteristics
Demographic and baseline characteristics will be summarized using standard descriptive 
methods including sample size, mean, SD, median, Q1, Q3, minimum, and maximum for 
continuous variables and frequency and percentages for categorical variables.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 77
21 October 2015
Demographic data will include sex, race, ethnicity, and age.
Baseline characteristics will include body weight, height, body mass index, eGFR, HIV-1 
infection, and enrollment distribution will be summarized.
For categorical demographic and baseline characteristics, the Cochran–Mantel–Haenszel (CMH)
test will be used to compare treatment groups. For continuous demographic and baseline 
characteristics, the Wilcoxon rank sum test will be used to compare treatment groups.
8.5.
Efficacy Analysis
8.5.1.
Primary Analysis
The primary efficacy endpoint is the proportion of subjects with virologic failure (HIV-1 RNA
≥50 copies/mL) at Week 48 as defined by the modified US FDA snapshot algorithm. The 
primary analysis of the efficacy will be based on the FAS.
8.5.1.1.
Modified US FDA Snapshot Algorithm
The US FDA snapshot algorithm has been modified to classify subjects who discontinue study 
drug due to adverse event or death and have the last available on-treatment HIV-1 RNA value 
≥50 copies/mL as a Virologic Failure. In the original US FDA snapshot alogrithim, these 
subjects would be classified as having No Virologic Data in the Week 48 Analysis Window.
The modified US FDA snapshot algorithm appears below.
The analysis window at Week 48 is defined as from Study Day 294 to Study Day 377, inclusive. 
All HIV-1 RNA data collected on-treatment (ie, including data collected up to 1 day after the last 
dose date of study drug) will be used in the snapshot algorithm. Virologic outcome will be 
defined as the following categories:

Virologic Success: this includes subjects who have the last available on-treatment HIV-1 
RNA < 50 copies/mL in the Week 48 analysis window 

Virologic Failure: this include subjects
a) Who have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 
analysis window, or
b) Who do not have on-treatment HIV-1 RNA data in the Week 48 analysis window and
1) Who discontinue study drug prior to or in the Week 48 analysis window due to lack 
of efficacy, or
2) Who discontinue study drug prior to or in the Week 48 analysis window due to reason 
other than lack of efficacy and have the last available on-treatment HIV-1 RNA 
≥50 copies/mL


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 78
21 October 2015

No Virologic Data in the Week 48 Analysis Window: this includes subjects who do not 
have on-treatment HIV-1 RNA data in the Week 48 analysis window because of the 
following:
a) Discontinuation of study drug prior to or in the Week 48 analysis window due to reasons
other than lack of efficacy and the last available on-treatment HIV-1 RNA 
< 50 copies/mL, or
b) Missing data during the window but on study drug
8.5.1.2.
Analysis of Primary Efficacy Endpoint
The null hypothesis is that the proportion of subjects with virologic failure (HIV-1 RNA 
≥50 copies/mL) at Week 48 in the GS-9883/F/TAF group is at least 4% higher than the 
virologic failure rate in the ABC/DTG/3TC group; the alternative hypothesis is that the virolgoic 
failure rate in the GS-9883/F/TAF group is less than 4% higher than that in the ABC/DTG/3TC 
group.
Non-inferiority will be assessed using the conventional confidence interval (CI) approach. The 
point estimate of treatment difference (GS-9883/F/TAF – ABC/DTG/3TC) and the associated 
2-sided 95% CI will be constructed based on the exact method.
It will be concluded that GS-9883/F/TAF is non-inferior to ABC/3TC/DTG if the upper bound of 
the 2-sided 95% CI of the difference between treatment groups 
(GS-9883/F/TAF - ABC/3TC/DTG) in the virologic failure rate is less than 4%.
If non-inferiority of GS-9883/F/TAF to ABC/DTG/3TC is established, the upper bound of the 
95% CI will be compared to 0; if the upper bound of the 95% CI is less than 0, superiority of 
GS-9883/F/TAF over ABC/DTG/3TC will be established.
8.5.2.
Secondary Analyses
The proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the US 
FDA snapshot algorithm will also be evaluated. The 95% CIs will be constructed in the same 
manner as for the primary efficacy endpoint. However, non-inferiority will be assessed using a 
margin of 10%. It will be concluded that GS-9883/F/TAF is non- inferior to ABC/DTG/3TC if 
the lower bound of the 2-sided 95% CI of the difference between treatment groups
(GS-9883/F/TAF – ABC/DTG/3TC) in the response rate is greater than -10%.
The changes from baseline in CD4+ cell count at Weeks 48 will be summarized by treatment 
using descriptive statistics. The differences in changes from baseline in CD4+ cell count between 
the 2 treatment groups and the associated 95% CIs will be constructed using ANOVA models, 
including treatment (GS-9883/F/TAF vs. ABC/DTG/3TC) as a fixed effect in the model.
In addition, missing CD4+ cell count will be imputed using Last Observation Carried Forward 
(LOCF) method and analyzed similarly.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 79
21 October 2015
8.6.
Safety Analysis
All safety analyses will be performed using the safety analysis set.
All safety data collected on or after the date that the study drug was first administered up to the 
date of the last dose of study drug plus 30 days, unless specified otherwise, will be summarized 
for subjects in the safety analysis set according to the study drug received.
Data for the pretreatment period and the period post the date of last dose of study drug plus 
30 days will be included in data listings for all enrolled subjects.
8.6.1.
Extent of Exposure
A subject’s extent of exposure to study drug will be generated from the study drug
administration page in eCRF. Exposure data will be summarized by treatment.
Duration of exposure to study drug will be expressed as the number of weeks between the first 
and last dose of the study drug, inclusive, regardless of temporary interruptions in study drug
administration and summarized by treatment.
Dosing information for individual subjects will be listed.
8.6.2.
Adverse Events
Clinical and laboratory adverse events will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA). System Organ Class (SOC), High-Level Group Term 
(HLGT), High-Level Term (HLT), Preferred Term (PT), and Lower-Level Term (LLT) will be 
attached to the clinical database.
Events will be summarized on the basis of the date of onset for the event. A treatment-emergent 
adverse event will be defined as any adverse event with onset date on or after the study drug start 
date and no later than 30 days after the study drug stop date; or any adverse event leading to 
study drug discontinuation.
Summaries (number and percentage of subjects) of treatment-emergent adverse events (by SOC, 
HLT [if applicable], and PT) will be provided by treatment. Additional summaries will include 
summaries for adverse events by grade, Investigator’s assessment of relationship to study drug, 
and effect on study drug dosing.
On an ongoing basis adverse events will be reviewed for events that might meet the definition of 
Stage 3 Opportunistic Illnesses in HIV are indicative of an AIDS-Defining Diagnoses. The 
Gilead medical personnel will review the possible Stage 3 events and approve the events that 
meet the definition. Those events that do meet the Stage 3 Opportunistic Illness definition of an 
AIDS-Defining Diagnosis will be listed.
A listing of Stage 3 Opportunistic Illnesses in HIV can be found in Appendix 5.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 80
21 October 2015
8.6.3.
Laboratory Evaluations
Selected laboratory data (using conventional units) will be summarized using only observed data. 
Absolute values and changes from baseline at all scheduled visits will be summarized.
Graded laboratory abnormalities will be defined using the grading scheme defined in Grading of 
laboratory abnormalities attached in Appendix 4.
Incidence of treatment-emergent laboratory abnormalities, defined as values that increase at least 
1 toxicity grade from baseline at any time post baseline up to and including the date of last dose 
of study drug plus 30 days, will be summarized by treatment. If baseline data are missing, then 
any graded abnormality (ie, at least a Grade 1) will be considered treatment emergent. The 
maximum postbaseline toxicity grade will be summarized by laboratory parameter.
Laboratory abnormalities that occur before the first dose of study drug or after the last dose of 
study drug plus 30 days will be included in a data listing.
8.6.4.
Bone Safety Evaluations
The percentage changes from baseline in hip/spine BMD at Weeks 48 will be summarized by 
treatment using descriptive statistics. The differences in percentage changes from baseline in 
hip/spine BMD between 2 treatment groups and the associated 95% confidence intervals will be 
constructed using ANOVA models, including treatment as a fixed effect in the model.
In addition, missing values for BMD will be imputed using LOCF method and analyzed 
similarly.
8.6.5.
Other Safety Evaluations
Vital signs and safety ECG data will be summarized as appropriate.
8.7.
Pharmacokinetic Analysis
For the intensive PK substudy, plasma concentrations of GS-9883 may be summarized by 
nominal sampling time using descriptive statistics. Pharmacokinetic parameters (Cmax, Tmax, Ctau, 
AUCtau, and T½, as appropriate) may be listed and summarized using descriptive statistics (eg, 
sample size, arithmetic mean, geometric mean, coefficient of variation %, SD, median, Q1, Q3, 
minimum, and maximum). Plasma concentrations over time will be plotted in semi-logarithmic 
and linear formats as mean ± standard deviation, and median (Q1, Q3).
For the general PK analyses, the pharmacokinetics of GS-9883 may be evaluated using 
descriptive statistics or population approaches.
TAF and FTC concentrations may be analyzed and PK parameters summarized as applicable.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 81
21 October 2015
8.8.
Biomarker Analysis
For each biomarker of inflammation, immune activation, platelet function, and renal tubular 
function, the percentage changes from baseline will be summarized by treatment and visit using 
descriptive statistics. Differences in percentage changes from baseline in each biomarker
between the 2 treatment groups will be tested using a Wilcoxon rank sum test.
8.9.
Patient Reported Outcomes (PRO)
The PRO measures based on questionnaires (eg, SF-36 and HIV Symptoms Distress Module) 
will be summarized by treatment and visit using descriptive statistics.
8.10.
Sample Size
A total of approximately 520 HIV-1 infected subjects, randomized in a 1:1 ratio to 2 treatment
groups (260 subjects per treatment group), achieves at least 90% power to detect a 
non-inferiority margin of 4% in Week 48 virologic failure rate (HIV-1 RNA ≥50 copies/mL) 
difference between the 2 treatment groups. For the sample size and power computation, it is 
assumed that both treatment groups have a virologic failure rate of 2% (based on the historical 
Gilead ECF/TAF and STB studies), that the non-inferiority margin is 4%, and that the 
significance level of the test is at a one-sided 0.025 level.
8.11.
Data Monitoring Committee
An external Independent Data Monitoring Committee (IDMC) will review the progress, efficacy, 
and safety data of this study while the study is ongoing. The committee will convene after the 
first 260 subjects enrolled have completed Week 12 of the study or prematurely discontinues 
from the study drug, as well as after all subjects have completed Week 24 of the study or 
prematurely discontinues from the study drug. However, Gilead will defer to the IDMC for any 
decision to convene earlier or more frequently. The IDMC will examine the safety results of the 
trial and also focus on logistical issues such as accrual, retention, quality of clinical and 
laboratory data, and implications of results of external studies. Blinding will be preserved during 
the conduct of the study and access to unblinded data will be limited to designated parties.
No formal stopping rules will be used by the IDMC for safety outcomes. Rather, a clinical 
assessment will be made to determine if the nature, frequency, and severity of adverse events 
associated with a study regimen warrant the early termination of the study in the best interest of 
the participants.
For each IDMC analysis performed prior to the analysis of the primary efficacy endpoint, an 
alpha penalty of 0.00001 will be applied for the primary analysis of the primary endpoint.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 82
21 October 2015
9.
RESPONSIBILITIES
9.1.
Investigator Responsibilities
9.1.1.
Good Clinical Practice
The investigator will ensure that this study is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Tokyo, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (ICH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study subject. These standards are consistent with the European Union Clinical 
Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, 
part 50, 1998, and 21 CFR, part 56, 1998.
The investigator and all applicable subinvestigators will comply with 21 CFR, Part 54, 1998, 
providing documentation of their financial interest or arrangements with Gilead, or proprietary 
interests in the investigational drug under study. This documentation must be provided prior to 
the investigator’s (and any subinvestigator’s) participation in the study. The investigator and 
subinvestigator agree to notify Gilead of any change in reportable interests during the study and 
for 1 year following completion of the study. Study completion is defined as the date when the 
last subject completes the protocol-defined activities.
9.1.2.
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and any accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study used to obtain 
informed consent) to an IRB/IEC. The investigator will not begin any study subject activities 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/IEC any modifications made to the protocol or any accompanying material to be 
provided to the subject after initial IRB/IEC approval, with the exception of those necessary to 
reduce immediate risk to study subjects.
9.1.3.
Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study and before undertaking any study-related procedures. The 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 83
21 October 2015
investigator must use the most current IRB- or IEC-approved consent form for documenting 
written informed consent. Each informed consent (or assent as applicable) will be appropriately 
signed and dated by the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, and also by an impartial witness if required by IRB or IEC or
local requirements. The consent form will inform subjects about pharmacogenomic testing and 
sample retention, and their right to receive clinically relevant pharmacogenomic analysis results.
9.1.4.
Confidentiality
The investigator must assure that subjects’ anonymity will be strictly maintained and that their 
identities are protected from unauthorized parties. Only subject initials, date of birth, another 
unique identifier (as allowed by local law) and an identification code will be recorded on any 
form or biological sample submitted to the Sponsor, or laboratory. Laboratory specimens must 
be labeled in such a way as to protect subject identity while allowing the results to be recorded to 
the proper subject. Refer to specific laboratory instructions. NOTE: The investigator must keep a 
screening log showing codes, names, and addresses for all subjects screened and for all subjects 
enrolled in the trial. Subject data will be processed in accordance with all applicable regulations.
The investigator agrees that all information received from Gilead, including but not limited to the 
investigator brochure, this protocol, eCRF, the IMP, and any other study information, remain the 
sole and exclusive property of Gilead during the conduct of the study and thereafter. This 
information is not to be disclosed to any third party (except employees or agents directly 
involved in the conduct of the study or as required by law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure by any employee or agent of the study site to any third party or otherwise into the 
public domain.
9.1.5.
Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified. These documents should 
be classified into at least the following two categories: (1) investigator’s study file, and 
(2) subject clinical source documents.
The investigator’s study file will contain the protocol/amendments, eCRF and query forms, IRB 
or IEC and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:

Subject identification (name, date of birth, gender);

Documentation that subject meets eligibility criteria, ie, history, physical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 84
21 October 2015

Documentation of the reason(s) a consented subject is not enrolled

Participation in study (including study number);

Study discussed and date of informed consent;

Dates of all visits;

Documentation that protocol specific procedures were performed;

Results of efficacy parameters, as required by the protocol;

Start and end date (including dose regimen) of IMP, including dates of dispensing and return;

Record of all adverse events and other safety parameters (start and end date, and including 
causality and severity);

Concomitant medication (including start and end date, dose if relevant; dose changes);

Date of study completion and reason for early discontinuation, if it occurs.
All clinical study documents must be retained by the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (ie, United States, Europe, or Japan) and until there are no pending or planned 
marketing applications in an ICH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory 
authorities have been notified. Investigators may be required to retain documents longer if 
specified by regulatory requirements, by local regulations, or by an agreement with Gilead. The 
investigator must notify Gilead before destroying any clinical study records.
Should the investigator wish to assign the study records to another party or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study site for any or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securely away from the site so that they can be returned sealed to the investigator 
in case of an inspection. When source documents are required for the continued care of the
subject, appropriate copies should be made for storage away from the site.
9.1.6.
Case Report Forms
For each subject consented, an eCRF will be completed by an authorized study staff member 
whose training for this function is documented according to study procedures. eCRF should be 
completed on the day of the subject visit to enable the sponsor to perform central monitoring of 
safety data.  The Eligibility Criteria eCRF should be completed only after all data related to 
eligibility have been received.  Subsequent to data entry, a study monitor will perform source 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 85
21 October 2015
data verification within the EDC system. Original entries as well as any changes to data fields 
will be stored in the audit trail of the system.  Prior to database lock (or any interim time points 
as described in the clinical data management plan), the investigator will use his/her log in 
credentials to confirm that the forms have been reviewed, and that the entries accurately reflect 
the information in the source documents. The eCRF capture the data required per the protocol 
schedule of events and procedures. System-generated or manual queries will be issued to the 
investigative site staff as data discrepancies are identified by the monitor or internal Gilead staff, 
who routinely review the data for completeness, correctness, and consistency. The site 
coordinator is responsible for responding to the queries in a timely manner, within the system, 
either by confirming the data as correct or updating the original entry, and providing the reason 
for the update (e.g. data entry error). At the conclusion of the trial, Gilead will provide the site 
with a read-only archive copy of the data entered by that site. This archive must be stored in 
accordance with the records retention requirements outlined in Section 9.1.5.
9.1.7.
Investigational Medicinal Product Accountability and Return
Gilead recommends that used and unused IMP supplies be returned to the shipping facility from 
which it came for eventual destruction. The study monitor will provide instructions for return. If 
return is not possible, the study monitor will evaluate each study center’s IMP disposal 
procedures and provide appropriate instruction for destruction of unused IMP supplies. If the site 
has an appropriate standard operating procedure (SOP) for drug destruction as determined by 
Gilead QA, the site may destroy used (empty or partially empty) and unused IMP supplies in 
accordance with that site’s approved SOP. A copy of the site’s approved SOP will be obtained 
for central files.
If IMP is destroyed on site, the investigator must maintain accurate records for all IMP
destroyed. Records must show the identification and quantity of each unit destroyed, the method 
of destruction, and the person who disposed of the IMP. Upon study completion, copies of the 
IMP accountability records must be filed at the site. Another copy will be returned to Gilead.
The study monitor will review IMP supplies and associated records at periodic intervals.
9.1.8.
Inspections
The investigator will make available all source documents and other records for this trial to 
Gilead’s appointed study monitors, to IRBs or IECs, or to regulatory authority or health authority 
inspectors.
9.1.9.
Protocol Compliance
The investigator is responsible for ensuring the study is conducted in accordance with the 
procedures and evaluations described in this protocol.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 86
21 October 2015
9.2.
Sponsor Responsibilities
9.2.1.
Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study subjects, may be 
made only by Gilead. The investigator must submit all protocol modifications to the IRB or IEC 
in accordance with local requirements and receive documented IRB or IEC approval before 
modifications can be implemented.
9.2.2.
Study Report and Publications
A clinical study report (CSR) will be prepared and provided to the regulatory agency(ies). Gilead 
will ensure that the report meets the standards set out in the ICH Guideline for Structure and 
Content of Clinical Study Reports (ICH E3). Note that an abbreviated report may be prepared in 
certain cases.
Investigators in this study may communicate, orally present, or publish in scientific journals or 
other scholarly media only after the following conditions have been met:
the results of the study in their entirety have been publicly disclosed by or with the consent of 
Gilead in an abstract, manuscript, or presentation form or the study has been completed at all 
study sites for at least 2 years
The investigator will submit to Gilead any proposed publication or presentation along with the 
respective scientific journal or presentation forum at least 30 days before submission of the 
publication or presentation.
No such communication, presentation, or publication will include Gilead’s confidential 
information (see Section 9.1.4).
The investigator will comply with Gilead’s request to delete references to its confidential 
information (other than the study results) in any paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary.
9.3.
Joint Investigator/Sponsor Responsibilities
9.3.1.
Payment Reporting
Investigators and their study staff may be asked to provide services performed under this 
protocol, e.g. attendance at Investigator's Meetings.  If required under the applicable statutory 
and regulatory requirements, Gilead will capture and disclose to Federal and State agencies any 
expenses paid or reimbursed for such services, including any clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any other transfer of value.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 87
21 October 2015
9.3.2.
Access to Information for Monitoring
In accordance with regulations and guidelines, the study monitor must have direct access to the 
investigator’s source documentation in order to verify the accuracy of the data recorded in the 
eCRF.
The monitor is responsible for routine review of the eCRF at regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency, and accuracy of the 
data being entered on them. The monitor should have access to any subject records needed to 
verify the entries on the eCRF. The investigator agrees to cooperate with the monitor to ensure 
that any problems detected through any type of monitoring (central, on site) are resolved.
9.3.3.
Access to Information for Auditing or Inspections
Representatives of regulatory authorities or of Gilead may conduct inspections or audits of the 
clinical study. If the investigator is notified of an inspection by a regulatory authority the 
investigator agrees to notify the Gilead medical monitor immediately. The investigator agrees to 
provide to representatives of a regulatory agency or Gilead access to records, facilities, and 
personnel for the effective conduct of any inspection or audit.
9.3.4.
Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the study at any time. Should 
this be necessary, both parties will arrange discontinuation procedures and notify the appropriate 
regulatory authority(ies), IRBs, and IECs. In terminating the study, Gilead and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 88
21 October 2015
10.
REFERENCES
2202
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum 
creatinine. Nephron 1976;16:31-41.
5125
Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. 
Changing patterns of mortality across Europe in patients infected with HIV-1. 
Lancet 1998;352 (9142):1725-30.
8284
Sterne J, Hernán M, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-term 
effectiveness of potent antiretroviral therapy in preventing AIDS and death: a 
prospective cohort study. Lancet 2005;366 (9483):378-84.
13585
Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT. 
Revised surveillance case definitions for HIV infection among adults, 
adolescents, and children aged <18 months and for HIV infection and AIDS 
among children aged 18 months to <13 years--United States, 2008. MMWR 
Recomm Rep 2008;57 (RR-10):1-12.
21053
Sterrantino G, Santoro L, Bartolozzi D, Trotta M, Zaccarelli M. Self-reported 
adherence supports patient preference for the single tablet regimen (STR) in the 
current cART era. Patient preference and adherence 2012;6:427-33.
25149
Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 
2000. Lancet 2003;362 (9387):847-52.
27881
Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. 
Declining Morbidity and Mortality Among Patients With Advanced Human 
Immunodeficiency Virus Infection. N Eng J Med 1998;338 (13):853-60.
29702
Aldir I, Horta A, Serrado M. Single-tablet regimens in HIV: does it really make a 
difference? Curr Med Res Opin 2013;30 (1):89-97.
29705
Costagliola D. Demographics of HIV and aging. Curr Opin HIV AIDS 2014;9 
(4):294-301.
34898
Department for Health and Human Services (DHHS). Guidelines for the Use of 
Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by 
the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A 
Working Group of the Office of AIDS Research Advisory Council (OARAC). 
Downloaded from http://aidsinfo.nih.gov/guidelines on 5/11/2015. Last Updated 
08 April, 2015.
36201
The Joint United Nations Programme oHAU. Fact Sheet: 2014 Global Statistics. 
Available at: 
http://www.unaids.org/sites/default/files/media_asset/20150714_FS_MDG6_Rep
ort_en.pdf.  2014.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 89
21 October 2015
11.
APPENDICES
Appendix 1.
Investigator Signature Page
Appendix 2.
Study Procedures Table (Blinded Phase)
Appendix 3.
Management of Clinical and Laboratory Adverse Events
Appendix 4.
GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5.
Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines)
Appendix 6.
Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements


GS-9883/F/TAF 
Protocol GS-US-380- I 844 
Final 
Gilead Sciences, Inc. 
Original 
Appendix l. 
Investigator Signature Page 
GILEAD SCIENCES, fNC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT 
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 
Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination 
(FDC) of ABC/DTG/3TC to a FDC ofGS-9883/F/TAF in HJV-1 Infected Subjects who are 
Virologically Suppressed 
GS-US-380-1844 Original, 21 October 2015 
This protocol has been approved by Gilead Sciences, Inc. The following signature documents 
this approval. 
PPD 
Date 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator Name (Printed) 
Signature 
Date 
Site Number 
CONFIDENTIAL 
Page 90 
21 October 20 I 5 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 91
21 October 2015
Appendix 2.
Study Procedures Table (Blinded Phase)
Study Procedures
Screeninga
Day 1b
End of Weeke, p
Post-Week 48e, q
Unblinding 
Visit
30-Day 
Follow-upo
Early 
Study 
Drugs 
DCc
4
8
12
24
36
48
Every 12 Weeks
Informed Consent
X
Medical History
X
Concomitant Medications
X
X
X
X
X
X
X
X
X
X
X
X
Adverse Events
X
X
X
X
X
X
X
X
X
X
Xf
Xf
Complete/Symptom-Directed 
Physical Exam
X
X
Xd
Xd
Xd
X
Xd
X
Xd
X
Xd,f
Xf
12-Lead ECG (performed 
supine)
X
X
X
X
X
X
Questionnaires
X
X
X
X
DXA scan (spine & hip)g
X
X
X
X
X
Height
X
Vital signs (blood pressure, 
pulse, respiration rate, and 
temperature), including 
Weight
X
X
X
X
X
X
X
X
X
X
X
X
Urinalysis
X
X
X
X
X
X
X
X
X
X
Xf
Xf
Urine Pregnancy Testh
X
X
X
X
X
X
X
X
X
X
X
Serum Pregnancy Test
X
Chemistry Profilei
X
X
X
X
X
X
X
X
X
X
Xf
Xf
Metabolic Assessmentsj
X
X
X
X
Xr
X


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
Study Procedures 
Estimated Glomemlar 
Filtration Rate 
Hematology Profilek 
Plasma HIV -1 RNA 
CD4+ Cell Connt 
Evaluations of inflanunation 
and immnne activation, 
platelet fimction and renal 
tubular fimction 
Plasma & Urine Storage 
Sample 
Whole Blood sample for 
potential HIV DNA 
genotyping 
HBV and HCV Serology 
HIV -1 Genotype/Phenotype e 
Single PK Sample1 
Trough PK Samplesm 
Optional PPD 
I' 
I 
~ 
CONFIDENTIAL 
Screening• 
Day l b 
4 
8 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
End ofWeek•,p 
Post-Week 48•,q 
12 
24 
36 
48 
Every 12 Weeks 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
xr 
X 
X 
X 
X 
X 
X 
X 
X 
Page 92 
Unblinding 
Visit 
X 
X 
X 
X 
X 
X 
30-Day 
Follow-up
0 
xr 
xr 
X 
X 
Final 
Original 
Early 
Study 
Drugs 
nc< 
X 
xr 
X 
X 
X 
xe 
21 October 2015 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 93
21 October 2015
Study Procedures
Screeninga
Day 1b
End of Weeke, p
Post-Week 48e, q
Unblinding 
Visit
30-Day 
Follow-upo
Early 
Study 
Drugs 
DCc
4
8
12
24
36
48
Every 12 Weeks
Randomizationt
X
Provide subject dosing diary 
to subjects
X
X
X
X
X
Optional PK Substudyn
X
X
Study Drug Dispensation
Xb
X
X
X
X
X
X
X
Xs
Study Drug Accountability
X
X
X
X
X
X
X
X
X
a
Evaluations to be completed within 30 days prior to Day 1.
b
Initiation of the first dose of study drug is to take place in-clinic following completion of study procedures at the Day 1 visit, with the exception of DXA.
c
Early Study Drugs Discontinuation visit to occur within 72 hours of last dose of study drug. Subjects will be asked to continue attending the scheduled study visits through the 
Unblinding Visit even if the subject discontinues study drug.
d
Symptom-directed physical examination as needed.
e
HIV-1 genotype and phenotype testing for subjects with virologic failure. Following virologic rebound, subjects will be asked to return to the clinic (2-3 weeks later) prior to 
the next scheduled visit or at the next scheduled study visit, for a HIV-1 RNA and HIV-1 genotype and phenotype (reverse transcriptase, protease, and integrase genotype and 
phenotype) blood draw. Based on the results of this testing, subjects should be managed according to the Virologic Rebound Schema (Section 6.13.1 and 6.13.2).
f
Any adverse event or test showing abnormal results that is believed to have a possible or probable causal relationship with the study drug will be repeated weekly (or as often 
as deemed prudent by the Investigator) until the abnormality is resolved, returns to Day 1, or is otherwise explained.
g
DXA scans to be performed in all eligible subjects on study drug, except for those in Germany, prior to or within 24 hours of the Day 1 Visit, Weeks 24, 48 (±10 days), and at
Unblinding Visit (±10 days) and the ESDD visit (if the last scan was acquired > 12 weeks from the date of the ESDD Visit).
h
Females of childbearing potential only. Positive urine pregnancy tests will be confirmed with a serum test.
i
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid and amylase (reflex lipase testing is performed in subjects with total amylase 
1.5 ULN) At Day 1, Weeks 12, 24, 48 and Unblinding Visit, analyses of glucose will be done as part of the fasting metabolic assessments and not as part of the chemistry 
profile. Additionally: TSH will be analyzed at Screening, Day 1, Weeks 24 and 48 followed by every 24 weeks post Week 48, Unblinding Visit and Early Study Drugs 
Discontinuation visit.
j
Fasting (no food or drinks, except water, at least 8 hours prior to blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, triglycerides). If the subject has 
not fasted prior to the visit, the visit may proceed, but the subject must return within 72 hours in a fasted state to draw blood for the metabolic assessments.
k
CBC with differential and platelet count.
l
A single PK blood sample will be collected at any time pre or post-dose 
m
A trough PK blood sample will be collected between 20-28 hours following the last dose. Following an observed dose, a single post dose blood sample will be collected 
between 1 and 4 hours post dose.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 94
21 October 2015
n
A PK substudy will be performed in a subset of subjects (n=30) at selected study sites.  The pharmacokinetic substudy visit must occur at the Week 4 or Week 8 visits. The 
substudy will include intensive PK profiling in plasma
o
Only required for those subjects not enrolling in the open-label rollover extension or those subjects who permanently discontinue study drugs and do not continue in the study 
through at least one subsequent visit after the Early Study Drugs Discontinuation Visit. For the purpose of scheduling a 30-Day Follow-Up Visit, a 6 days window may be 
used.
p
Study visits are to be completed within ± 2 days of the protocol-specified visit date based on the Day 1 visit through Week 12 and completed within ± 6 days through to 
Week 36, unless otherwise specified. The visit window at Weeks 48 will be ± 6 weeks of the protocol-specified visit date. 
q
After Week 48, subjects will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded. Visit window of 
6 days for study visits post Week 48.  After Week 48 Visit, subjects in the United Kingdom (UK) and Sweden (SWE) will stop taking study drug and complete a 30 day 
follow up visit.
r
To be performed every 24 weeks after Week 48 until Unblinding Visit.
s
Open label study drug, GS-9883/F/TAF FDC will be dispensed to subjects participating in the Open-Label Rollover extension.
t
Randomization may be performed up to 3 days prior to the in-clinic Day 1 visit provided that all screening procedures have been completed and subject eligibility has been 
confirmed.


GS-9883/Fff AF 
Protocol GS-US-380-1844 
Final 
Gilead Sciences, Inc. 
Original 
Appendix 3. 
Management of Clinical and Laboratory Adverse Events 
Grade 1 
L------G-ra_d_e_2----~~ 
~~ ______ 
G_rn_d_e_3----~~ 
~~ _________ G_rn_d_e_4--------~ 
! 
! 
May continue dosing 
Repeat lab to 
at the discretion of 
confirm toxicity 
the investigator 
grade 
If confmned and possibly and/or probably related to investigational 
medicinal products: 
I. Withhold investigational medicinal products until ~ Grade 2 
2. 
Restart all investigational medicinal products at full dose 
1 
If Grade 3 or 4 recurrence that is confirmed and possibly or probably 
related to investigational medicinal products, discontinue all 
investigational medicinal products dosing permanently 
1 
Repeat lab to 
confirm toxicity 
grade 
1 
If confirmed and 
possibly or probably 
If c onfirmed and unrelated to 
stigational medicinal products, 
tng may continue at the discretion 
the investigator 
---+ related to 
investigational 
medicinal products, 
discontinue 
investigational 
medicinal products 
dosing permanently and 
follow at periodic 
intervals at least weekly 
until a return to 
inve 
dos 
of 
baseline or is otherwise 
explained 
If Grade 3 or 4 recurrence that is considered unrelated to 
investigational medicinal products, continue all investigational 
medicinal products at the same dose at the discretion of the 
investigator 
CONFIDENTIAL 
Page 95 
21 October 2015 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 96
21 October 2015
Appendix 4.
GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1
Grade 2
Grade 3
Grade 4
Hemoglobin
HIV POSITIVE
Adult and Pediatric 57 Days
8.5 to 10.0 g/dL 
85 to 100 g/L
7.5 to 8.5 g/dL 
75 to 85 g/L
6.5 to 7.5 g/dL 
65 to 75 g/L
6.5 g/dL
65 g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 
10.0 to 10.9 g/dL
100 to 109 g/L
OR
Any decrease from Baseline
2.5 to 3.5 g/dL
25 to 35 g/L
9.0 to 10.0 g/dL
90 to 100 g/L
OR
Any decrease from Baseline
3.5 to 4.5 g/dL
35 to 45 g/L
7.0 to 9.0 g/dL
70 to 90 g/L
OR
Any decrease from Baseline
4.5 g/dL
45 g/L
7.0 g/dL
70 g/L
Infant, 36–56 Days
(HIV POSITIVE OR
NEGATIVE)
8.5 to 9.4 g/dL
85 to 94 g/L
7.0 to 8.5 g/dL
70 to 85 g/L
6.0 to 7.0 g/dL
60 to < 70 g/L
6.0 g/dL
< 60 g/L
Infant, 22–35 Days
(HIV POSITIVE OR
NEGATIVE)
9.5 to 10.5 g/dL
95 to 105 g/L
8.0 to 9.5 g/dL
80 to 95 g/L
7.0 to 8.0 g/dL
70 to 80 g/L
7.0 g/dL
70 g/L
Infant, 1–21 Days
(HIV POSITIVE OR
NEGATIVE)
12.0 to 13.0 g/dL
120 to 130 g/L
10.0 to 12.0 g/dL
100 to 120 g/L
9.0 to 10.0 g/dL
90 to 100 g/L
9.0 g/dL
90 g/L
Absolute Neutrophil Count 
(ANC)
Adult and Pediatric, 
≥ 7 Months#
1000 to 1300/mm3
750 to 1000/mm3
500 to 750/mm3
500/mm3
1.00 to 1.30 GI/L
0.75 to 1.00 GI/L
0.50 to 0.75 GI/L
0.50 GI/L


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 97
21 October 2015
HEMATOLOGY
Grade 1
Grade 2
Grade 3
Grade 4
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
> 13 Years
300 to 400/mm3
300 to 400/μL
200 to 300/mm3
200 to 300/μL
100 to 200/mm3
100 to 200/μL
100/mm3
100/μL
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13 Years
600 to 650/mm3
0.60 to 0.65 GI/L
500 to 600/mm3
0.50 to 0.60 GI/L
350 to 500/mm3
0.35 to 0.50 GI/L
350/mm3
0.35 GI/L
Platelets 
100,000 to < 125,000/mm3
100 to 125 GI/L
50,000 to 100,000/mm3
50 to 100 GI/L
25,000 to 50,000/mm3
25 to 50 GI/L
25,000/mm3
25 GI/L
WBCs 
2000/mm3 to 2500/mm3
1,500 to 2,000/mm3
1000 to 1,500/mm3
1000/mm3
2.00 GI/L to 2.50 GI/L
1.50 to 2.00 GI/L
1.00 to 1.50 GI/L
1.00 GI/L
Hypofibrinogenemia
100 to 200 mg/dL
75 to 100 mg/dL
50 to 75 mg/dL
50 mg/dL
1.00 to 2.00 g/L
0.75 to 1.00 g/L
0.50 to 0.75 g/L
0.50 g/L
Hyperfibrinogenemia
ULN to 600 mg/dL
600 mg/dL
—
—
ULN  to 6.0 g/L
6.0 g/L
—
—
Fibrin Split Product 
20 to 40 μg/mL
40 to 50 μg/mL
50 to 60 μg/mL
60 μg/mL
20 to 40 mg/L
40 to 50 mg/L
50 to 60 mg/L
60 mg/L
Prothrombin Time (PT)
1.00 to 1.25 ULN
1.25 to 1.50 ULN 
1.50 to 3.00 ULN 
3.00 ULN 
International Normalized Ratio 
of prothrombin time (INR)
1.1 to 1.5 x ULN
>1.5 to 2.0 x ULN
>2.0 to 3.0 x ULN
>3.0 x ULN


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 98
21 October 2015
HEMATOLOGY
Grade 1
Grade 2
Grade 3
Grade 4
Activated Partial
Thromboplastin Time (APTT)
1.00 to 1.66 ULN
1.66 to 2.33 ULN
2.33 to 3.00 ULN
3.00 ULN
Methemoglobin 
5.0 to 10.0%
10.0 to 15.0%
15.0 to 20.0%
20.0%
#
An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects.  Please follow the Gilead convention of grading 
any result within the LLN and ULN a 0.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 99
21 October 2015
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hyponatremia 
130 to <LLN mEq/L
125 to 130 mEq/L
121 to 125 mEq/L
121 mEq/L
130 to <LLN mmol/L
125 to 130 mmol/L
121 to 125 mmol/L
121 mmol/L
Hypernatremia 
>ULN  to 150 mEq/L
150 to 154 mEq/L
154 to 159 mEq/L
159 mEq/L
>ULN  to 150 mmol/L
150 to 154 mmol/L
154 to 159 mmol/L
159 mmol/L
Hypokalemia 
Adult and Pediatric
1 Year
3.0 to  <LLN mEq/L
2.5 to 3.0 mEq/L
2.0 to 2.5 mEq/L
2.0 mEq/L
3.0 to <LLN mmol/L
2.5 to 3.0 mmol/L
2.0 to 2.5 mmol/L
2.0 mmol/L
Infant <1 Year 
3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L
2.5 to 3.0 mEq/L                
2.5 to <3.0 mmolL
2.0 to 2.5 mEq/L                 
2.0 t o <2.5 mmolL
2.0 mEq/L                         
<2.0 mmolL
Hyperkalemia 
Adult and Pediatric
1 Year
5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L
6.0 to 6.5 mEq/L
6.0 to 6.5 mmol/L
6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L
7.0 mEq/L
7.0 mmol/L
Infant <1 Year
>ULN to 6.0 mEq/L           
>ULN to 6.0 mmol/L
> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L
6.5 to 7.0 mEq/L             
6.5 to 7.0 mmol/L
7.0 mEq/L                  
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1 Month
55 to 64 mg/dL
3.03 to 3.58 mmol/L
40 to 55 mg/dL
2.20 to 3.03 mmol/L
30 to 40 mg/dL
1.64 to 2.20 mmol/L
30 mg/dL
1.64 mmol/L
Infant, 1 Month
50 to 54 mg/dL
2.8 to 3.0 mmol/L
40 to 50 mg/dL
2.2 to 2.8 mmol/L
30 to 40 mg/dL
1.7 to 2.2 mmol/L
30 mg/dL
1.7 mmol/L


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 100
21 October 2015
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hyperglycemia, Nonfasting 
116 to 160 mg/dL
160 to 250 mg/dL
250 to 500 mg/dL
500 mg/dL
6.42 to 8.91 mmol/L
8.91 to 13.90 mmol/L
13.90 to 27.79 mmol/L
27.79 mmol/L
Hyperglycemia, Fasting
110 to 125 mg/dL
6.08 to 6.96 mmol/L
>125 to 250 mg/dL
>6.96 to 13.90 mmol/L
>250 to 500 mg/dL
>13.90 to 27.79 mmol/L
>500 mg/dL
>27.79 mmol/L
Hypocalcemia 
(corrected for albumin if 
appropriate*)
Adult and Pediatric
2 Years
7.8 <LLN mg/dL
1.94 to <LLN mmol/L
7.0 to 7.8 mg/dL
1.74 to 1.94 mmol/L
6.1 to 7.0 mg/dL
1.51 to 1.74 mmol/L
6.1 mg/dL
1.51 mmol/L
Pediatric ≥7 days -2 Years
7.8 to 8.4 mg/dL                          
1.94 to 2.10 mmol/L
7.0 to <7.8 mg/dL              
1.74 to <1.94 mmolL
6.1 to  <7.0 mg/dL                      
1.51 to < 1.74 mmolL
< 6.1 mg/dL                           
< 1.51 mmol/L
Infant, 7 Days
6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L
6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L
5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 
5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate*)
Adult and Pediatric 
7 Days
>ULN to 11.5 mg/dL
11.5 to 12.5 mg/dL
12.5 to 13.5 mg/dL
13.5 mg/dL
>ULN to 2.88 mmol/L
2.88 to 3.13 mmol/L
3.13 to 3.38 mmol/L
3.38 mmol/L
Infant, 7 Days
11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L
12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L
12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L
13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized)
3.0 mg/dL to LLN
2.5 to < 3.0 mg/dL
2.0 to 2.5 mg/dL
2.0 mg/dL
0.74 mmol/L to LLN
0.62 to 0.74 mmol/L
0.49 to 0.62 mmol/L
0.49 mmol/L


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 101
21 October 2015
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hypercalcemia (ionized)
ULN to 6.0 mg/dL
6.0 to 6.5 mg/dL
6.5 to 7.0 mg/dL
7.0 mg/dL
ULN to 1.50 mmol/L
1.50 to 1.63 mmol/L
1.63 to 1.75 mmol/L
1.75 mmol/L
Hypomagnesemia
1.40 to <LLN mg/dL
1.2 to <LLN mEq/L
1.04 to 1.40 mg/dL
0.9 to   1.2 mEq/L
0.67 to 1.04 mg/dL
0.6 to 0.9 mEq/L
0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmol/L
0.43 to 0.58 mmol/L
0.28 to 0.43 mmol/L
0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14 Years
2.0 to < LLN mg/dL
0.63  to LLN mmol/L
1.5 to 2.0 mg/dL
0.47 to 0.63 mmol/L
1.0 to 1.5 mg/dL
0.31 to 0.47 mmol/L
1.0 mg/dL
0.31 mmol/L
Pediatric 1 Year–14 Years 
3.0 to <LLN mg/dL
0.96 to <LLN mmol/L
2.5 to 3.0 mg/dL
0.80 to < 0.96 mmol/L
1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L
1.5 mg/dL
< 0.47 mmol/L
Pediatric 1 Year
3.5 to <LLN mg/dL
1.12 to <LLN mmol/L
2.5 to 3.5 mg/dL
0.80 to < 1.12 mmol/L
1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L
1.5 mg/dL
< 0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
> 14 Days
1.0 to 1.5 ULN 
1.5 to 2.5 ULN
2.5 to 5.0 ULN 
5.0 ULN 
Infant, 14 Days
(non-hemolytic)
NA
20.0 to 25.0 mg/dL
342 to 428 μmol/L
25.0 to 30.0 mg/dL
> 428 to 513 μmol/L
30.0 mg/dL
> 513 μmol/L
Infant, 14 Days
(hemolytic)
NA
NA
20.0 to 25.0 mg/dL
342 to 428 μmol/L
25.0 mg/dL
> 428 μmol/L


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 102
21 October 2015
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Blood Urea Nitrogen
1.25 to 2.50 ULN 
2.50 to 5.00 ULN 
5.00 to 10.00 ULN 
10.00 ULN
Hyperuricemia
>ULN to 10.0 mg/dL 
10.0 to 12.0 mg/dL 
12.0 to 15.0 mg/dL 
15.0 mg/dL
>ULN to 597 μmol/L
597 to 716 μmol/L
716 to 895 μmol/L
895 μmol/L
Hypouricemia               
Adult and Pediatric           
≥ 1 year   
Infant  < 1 Year
1.5 mg/dL to LLN
87 μmol/L to LLN
1.0 to 1.5 mg/dL
57 to 87 μmol/L
0.5 to 1.0 mg/dL
27 to 57 μmol/L
0.5 mg/dL
27 μmol/L
N/A
1.0 mg/dl to <LLN-
57 μmol to <LLN
0.5 to 1.0 mg/dL
27 to 57 μmol/L
0.5 mg/dL
27 μmol/L
Creatinine** 
1.50 to 2.00 mg/dL
133 to 177 μmol/L
2.00 to 3.00 mg/dL
177 to 265 μmol/L
3.00 to 6.00 mg/dL 
265 to 530 μmol/L
6.00 mg/dL
530 μmol/L
Bicarbonate
Adult and Pediatric 
≥ 4 Years
16.0 mEq/L to LLN 
11.0 to 16.0 mEq/L
8.0 to 11.0 mEq/L
8.0 mEq/L
16.0 mmol/L to LLN
11.0 to 16.0 mmol/L
8.0 to 11.0 mmol/L
8.0 mmol/L
Pediatric < 4 Years
NA
11.0 mEq/Lto <LLN
8.0 to 11.0 mEq/L
8.0 mEq/L
11.0 mmol/L to <LLN
8.0 to 11.0 mmol/L
8.0 mmol/L
Triglycerides
(Fasting)
NA
500 to 750 mg/dL
5.64–8.47 mmol/L
750 to 1200 mg/dL
8.47–13.55 mmol/L
1200 mg/dL
13.55 mmol/L


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 103
21 October 2015
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
LDL (Fasting)
Adult
130 to 160 mg/dL
>160 to 190 mg/dL
> 190 mg/dL
NA
3.35 to 4.15 mmol/L
>4.15 to 4.92 mmol/L
>4.92 mmol/L
LDL (Fasting)
Pediatric >2 to <18 years
110 to 130 mg/dL
>130 to 190 mg/dL
> 190 mg/dL
NA
2.84 to 3.37 mmol/L
>3.37 to  4.92 mmol/L
>4.92 mmol/L
Hypercholesterolemia
(Fasting)
200 to 239 mg/dL
239 to 300 mg/dL
300 mg/dL
NA
5.16 to 6.19 mmol/L
6.19 to 7.77 mmol/L
7.77 mmol/L
Pediatric 18 Years
170 to 199 mg/dL
4.39 to 5.15 mmol/L
199 to 300 mg/dL
5.15 to 7.77 mmol/L
300 mg/dL
7.77 mmol/L
NA
Creatine Kinase
3.0 to 6.0 ULN
6.0 to 10.0 ULN
10.0 to 20.0 ULN
20.0 ULN
*
Calcium should be corrected for albumin if albumin is < 4.0 g/dL
**
An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may result for Male subjects >70 yrs. Please follow the Gilead convention of grading any 
result within the LLN and ULN a 0.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 104
21 October 2015
ENZYMES
Grade 1
Grade 2
Grade 3
Grade 4
AST (SGOT) 
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
ALT (SGPT) 
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
GGT
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
Alkaline Phosphatase 
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
Total Amylase
1.0 to 1.5 ULN
1.5 to 2.0 ULN
2.0 to 5.0 ULN
5.0 ULN
Pancreatic Amylase
1.0 to 1.5 ULN
1.5 to 2.0 ULN
2.0 to 5.0 ULN
5.0 ULN
Lipase 
1.0 to 1.5 ULN
1.5 to 3.0 ULN
3.0 to 5.0 ULN
5.0 ULN
Albumin
Pediatrics <16 years
≥ 16 years
-
2.0 to LLN g/dL
20 to LLN g/L
2.0 g/dL
20 g/L
NA
3.0 g/dL to LLN
30 g/L to LLN
2.0 to 3.0 g/dL
20 to 30 g/L
2.0 g/dL
20 g/L
NA


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 105
21 October 2015
URINALYSIS
Grade 1
Grade 2
Grade 3
Grade 4
Hematuria (Dipstick) 
1
2
3-4+
NA
Hematuria (Quantitative) 
See Note below
                              Females
>ULN - 10 RBC/HPF
10-75 RBC/HPF
> 75 RBC/HPF
NA
                              Males
6-10 RBC/HPF
10-75 RBC/HPF
> 75 RBC/HPF
NA
Proteinuria (Dipstick)
1
2–3
4
NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years
200 to 999 mg/24 h
>999 to 1999 mg/24 h
>1999 to 3500 mg/24 h
3500 mg/24 h
Pediatric 3 Mo to 
< 10 Years
201 to 499 mg/m2/24 h
>499 to 799 mg/m2/24 h
>799 to 1000 mg/m2/24 h
1000 mg/ m2/24 h
Glycosuria (Dipstick)
1+
2-3
4
NA
Notes:

Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratories, toxicity grades will only be assigned to 
Dipstick Hematuria.

With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigned Grade 0.

If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for 
the AE.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 106
21 October 2015
CARDIOVASCULAR
Grade 1
Grade 2
Grade 3
Grade 4
Cardiac Arrhythmia (general)
(By ECG or physical exam)
Asymptomatic AND No 
intervention indicated
Asymptomatic AND Non-
urgent medical intervention 
indicated
Symptomatic, non-life-
threatening AND Non-
urgent medical intervention 
indicated 
Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac-ischemia/Infarction
NA
NA
Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia 
Unstable angina OR Acute 
myocardial infarction
Hemorrhage (significant acute 
blood loss)
NA
Symptomatic AND No 
transfusion indicated
Symptomatic AND 
Transfusion of 2 units 
packed RBCs (for children 
10 cc/kg) indicated 
Life-threatening hypotension 
OR Transfusion of 2 units 
packed RBCs indicated (for 
children 10 cc/kg) indicated
Hypertension (with repeat 
testing at same visit)
140–159 mmHg systolic 
OR 
90–99 mmHg diastolic
159–179 mmHg systolic 
OR 
99–109 mmHg diastolic
179 mmHg systolic 
OR 
109 mmHg diastolic
Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization (other than 
ER visit) indicated
Pediatric 17 Years (with 
repeat testing at same visit)
NA
91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)
≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)
Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization indicated 
(other than emergency room 
visit)
Hypotension
NA
Symptomatic, corrected with 
oral fluid replacement
Symptomatic, IV fluids 
indicated
Shock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion
Asymptomatic, small 
effusion requiring no 
intervention
Asymptomatic, moderate or 
larger effusion requiring no 
intervention
Effusion with non-life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicated
Life-threatening consequences 
(eg, tamponade) OR Urgent 
intervention indicated


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 107
21 October 2015
CARDIOVASCULAR
Grade 1
Grade 2
Grade 3
Grade 4
Prolonged PR Interval
PR interval 
0.21 to 0.25 sec
PR interval
0.25 sec
Type II 2nd degree AV 
block OR Ventricular pause 
3.0 sec
Complete AV block 
Pediatric 16 Years
1st degree AV block
(PR > normal for age and 
rate)
Type I 2nd degree AV block 
Type II 2nd degree AV 
block 
Complete AV block
Prolonged QTc
Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baseline
Asymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baseline
Asymptomatic, QTc interval 
0.50 sec OR Increase in 
interval 0.06 sec above 
baseline
Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16 Years
Asymptomatic, QTc interval 
0.450 to 0.464 sec 
Asymptomatic, QTc interval 
0.465 to 0.479 sec 
Asymptomatic, QTc interval 
0.480 sec 
Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism
NA
Deep vein thrombosis AND 
No intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) 
Deep vein thrombosis AND 
Intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) 
Embolic event (eg, pulmonary 
embolism, life-threatening 
thrombus) 
Vasovagal Episode (associated
with a procedure of any kind)
Present without loss of 
consciousness 
Present with transient loss of 
consciousness
NA 
NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)
NA
Asymptomatic diagnostic 
finding AND intervention 
indicated
New onset with symptoms 
OR Worsening symptomatic 
CHF
Life-threatening CHF


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 108
21 October 2015
RESPIRATORY
Grade 1
Grade 2
Grade 3
Grade 4
Bronchospasm (acute)
FEV1 or peak flow reduced to 
70% to 80%
FEV1 or peak flow 50% to 69%
FEV1 or peak flow 25% to 
49% 
Cyanosis OR FEV1 or peak flow 
25% OR Intubation
Dyspnea or Respiratory 
Distress
Dyspnea on exertion with no 
or minimal interference with 
usual social & functional 
activities 
Dyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activities 
Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
Respiratory failure with 
ventilatory support indicated
Pediatric 14 Years
Wheezing OR minimal 
increase in respiratory rate for 
age
Nasal flaring OR Intercostal 
retractions OR Pulse oximetry 
90% to 95%
Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%
Respiratory failure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1
Grade 2
Grade 3
Grade 4
Uveitis
Asymptomatic but detectable 
on exam
Symptomatic anterior uveitis OR 
Medical intervention indicated
Posterior or pan-uveitis OR 
Operative intervention 
indicated
Disabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)
Visual changes causing no or 
minimal interference with 
usual social & functional 
activities
Visual changes causing greater 
than minimal interference with 
usual social & functional 
activities
Visual changes causing 
inability to perform usual 
social & functional activities
Disabling visual loss in affected 
eye(s)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 109
21 October 2015
SKIN
Grade 1
Grade 2
Grade 3
Grade 4
Alopecia
Thinning detectable by 
study participant or  
caregiver (for disabled 
adults)
Thinning or patchy hair loss 
detectable by health care 
provider
Complete hair loss
NA
Cutaneous Reaction – Rash
Localized macular rash 
Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions 
Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one site
Extensive or generalized 
bullous lesions OR 
Stevens-Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epidermal 
necrolysis (TEN)
Hyperpigmentation
Slight or localized
Marked or generalized
NA
NA
Hypopigmentation
Slight or localized 
Marked or generalized
NA
NA
Pruritis (itching – no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)
Itching causing no or 
minimal interference with 
usual social & functional 
activities
Itching causing greater than 
minimal interference with 
usual social & functional 
activities
Itching causing inability to 
perform usual social & 
functional activities 
NA


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 110
21 October 2015
GASTROINTESTINAL
Grade 1
Grade 2
Grade 3
Grade 4
Anorexia
Loss of appetite without 
decreased oral intake
Loss of appetite associated with 
decreased oral intake without 
significant weight loss 
Loss of appetite associated 
with significant weight loss 
Life-threatening consequences 
OR Aggressive intervention 
indicated [eg, tube feeding or 
total parenteral nutrition]
Ascites
Asymptomatic
Symptomatic AND Intervention
indicated (eg, diuretics or 
therapeutic paracentesis)
Symptomatic despite 
intervention
Life-threatening consequences
Cholecystitis
NA
Symptomatic AND Medical 
intervention indicated
Radiologic, endoscopic, or 
operative intervention 
indicated
Life-threatening consequences 
(eg, sepsis or perforation) 
Constipation 
NA
Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemas 
Obstipation with manual 
evacuation indicated
Life-threatening consequences 
(eg, obstruction)
Diarrhea 
Adult and Pediatric 
1 Year
Transient or intermittent 
episodes of unformed stools 
OR Increase of 3 stools 
over baseline/24 hr
Persistent episodes of unformed 
to watery stools OR Increase of 
4–6 stools over baseline per 
24 hrs. 
Bloody diarrhea OR Increase 
of 7 stools per 24-hour 
period OR IV fluid 
replacement indicated
Life-threatening consequences 
(eg, hypotensive shock)
Pediatric 1 Year
Liquid stools (more 
unformed than usual) but 
usual number of stools
Liquid stools with increased 
number of stools OR Mild 
dehydration
Liquid stools with moderate 
dehydration
Liquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicated OR Hypotensive 
shock
Dysphagia-Odynophagia 
Symptomatic but able to eat 
usual diet
Symptoms causing altered 
dietary intake without medical 
intervention indicated
Symptoms causing severely 
altered dietary intake with 
medical intervention indicated
Life-threatening reduction in 
oral intake


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 111
21 October 2015
GASTROINTESTINAL
Grade 1
Grade 2
Grade 3
Grade 4
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, 
Dysphagia-Odynophagia
Erythema of the mucosa
Patchy pseudomembranes or 
ulcerations 
Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor trauma
Tissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life-threatening 
consequences (eg, aspiration, 
choking)
Nausea 
Transient (24 hours) or 
intermittent nausea with no 
or minimal interference with 
oral intake
Persistent nausea resulting in 
decreased oral intake for 24–48 
hours
Persistent nausea resulting in 
minimal oral intake for 48 
hours OR Aggressive 
rehydration indicated (eg, 
IV fluids)
Life-threatening consequences 
(eg, hypotensive shock)
Pancreatitis
NA
Symptomatic AND 
Hospitalization not indicated 
(other than ER visit)
Symptomatic AND 
Hospitalization indicated 
(other than ER visit)
Life-threatening consequences 
(eg, sepsis, circulatory failure, 
hemorrhage)
Proctitis (functional-
symptomatic)
Also see Mucositis/ 
Stomatitis for Clinical 
Exam
Rectal discomfort AND No 
intervention indicated
Symptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated 
Symptoms causing inability to 
perform usual social/
functional activities OR 
Operative intervention 
indicated 
Life-threatening consequences 
(eg, perforation)
Vomiting
Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intake
Frequent episodes of vomiting 
with no or mild dehydration
Persistent vomiting resulting 
in orthostatic hypotension OR 
Aggressive rehydration 
indicated
Life-threatening consequences 
(eg, hypotensive shock)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 112
21 October 2015
NEUROLOGICAL
Grade 1
Grade 2
Grade 3
Grade 4
Alteration in Personality-
Behavior or in Mood (eg, 
agitation, anxiety, 
depression, mania, 
psychosis)
Alteration causing no or 
minimal interference with 
usual social & functional 
activities 
Alteration causing greater than 
minimal interference with 
usual social & functional 
activities 
Alteration causing inability to 
perform usual social & 
functional activities 
Behavior potentially harmful 
to self or others (eg, 
suicidal/homicidal ideation or 
attempt, acute psychosis) OR 
Causing inability to perform 
basic self-care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)
Changes causing no or 
minimal interference with 
usual social & functional 
activities
Mild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activities
Confusion, memory 
impairment, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activities
Delirium OR obtundation, OR 
coma
Ataxia 
Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activities
Symptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activities
Symptomatic ataxia causing 
inability to perform usual 
social & functional activities 
Disabling ataxia causing 
inability to perform basic self-
care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) 
Disability causing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicated
Disability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part-time basis 
indicated
Disability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicated
Disability causing inability to 
perform basic self-care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)
NA
NA
Transient ischemic attack
Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 113
21 October 2015
NEUROLOGICAL
Grade 1
Grade 2
Grade 3
Grade 4
Developmental delay –
Pediatric 16 Years
Mild developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate 
for the setting 
Moderate developmental 
delay, either motor or 
cognitive, as determined by 
comparison with a 
developmental screening tool 
appropriate for the setting 
Severe developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting 
Developmental regression, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting
Headache 
Symptoms causing no or 
minimal interference with 
usual social & functional 
activities
Symptoms causing greater 
than minimal interference with 
usual social & functional 
activities
Symptoms causing inability to 
perform usual social & 
functional activities
Symptoms causing inability to 
perform basic self-care 
functions OR Hospitalization 
indicated (other than ER visit) 
OR Headache with significant 
impairment of alertness or
other neurologic function 
Insomnia
NA
Difficulty sleeping causing 
greater than minimal 
interference with usual 
social/functional activities
Difficulty sleeping causing 
inability to perform usual 
social & functional activities
Disabling insomnia causing 
inability to perform basic self-
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) 
Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak-
ness causing no or minimal 
interference with usual 
social & functional activities
Muscle weakness causing 
greater than minimal 
interference with usual social 
& functional activities
Muscle weakness causing 
inability to perform usual 
social & functional activities 
Disabling muscle weakness 
causing inability to perform 
basic self-care functions OR 
Respiratory muscle weakness 
impairing ventilation
Neurosensory Alteration 
(including paresthesia and 
painful neuropathy)
Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social &
functional activities 
Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities 
Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activities
Disabling sensory alteration or 
paresthesia causing inability to 
perform basic self-care 
functions


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 114
21 October 2015
NEUROLOGICAL
Grade 1
Grade 2
Grade 3
Grade 4
Seizure: (new onset) 
NA
1 seizure 
2–4 seizures 
Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or difficult 
to control (eg, refractory 
epilepsy)
Seizure: (pre-existing) 
For Worsening of Existing 
Epilepsy the Grades Should 
Be Based on an Increase 
from Previous Level of 
Control to Any of These 
Levels
NA
Increased frequency of pre-
existing seizures (non-
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorder
Change in seizure character 
from baseline either in 
duration or quality (eg, 
severity or focality) 
Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or difficult 
to control (eg, refractory 
epilepsy)
Seizure 
– Pediatric 18 Years
Seizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5 minutes with < 24 hours 
post ictal state
Seizure, generalized onset 
with or without secondary 
generalization, lasting 5–20 
minutes with 
< 24 hours post ictal state
Seizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes 
Seizure, generalized onset 
with or without secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)
NA
Present
NA
NA
Vertigo
Vertigo causing no or 
minimal interference with 
usual social & functional 
activities
Vertigo causing greater than 
minimal interference with 
usual social & functional 
activities 
Vertigo causing inability to 
perform usual social & 
functional activities
Disabling vertigo causing 
inability to perform basic self-
care functions


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 115
21 October 2015
MUSCULOSKELETAL
Grade 1
Grade 2
Grade 3
Grade 4
Arthralgia
See also Arthritis
Joint pain causing no or 
minimal interference with 
usual social & functional 
activities
Joint pain causing greater than 
minimal interference with usual 
social & functional activities
Joint pain causing inability 
to perform usual social & 
functional activities
Disabling joint pain causing 
inability to perform basic self-
care functions
Arthritis
See also Arthralgia
Stiffness or joint swelling 
causing no or minimal 
interference with usual 
social & functional activities
Stiffness or joint swelling causing 
greater than minimal interference 
with usual social & functional 
activities
Stiffness or joint swelling 
causing inability to perform 
usual social & functional 
activities
Disabling joint stiffness or 
swelling causing inability to 
perform basic self-care 
functions
Bone Mineral Loss
BMD t-score or z-score
–2.5 to –1.0 
BMD t-score or z-score –2.5
Pathological fracture 
(including loss of vertebral 
height)
Pathologic fracture causing 
life-threatening consequences 
Pediatric 21 Years
BMD z-score 
–2.5 to –1.0
BMD z-score < –2.5
Pathological fracture 
(including loss of vertebral 
height)
Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)
Muscle pain causing no or 
minimal interference with 
usual social & functional 
activities
Muscle pain causing greater than 
minimal interference with usual 
social & functional activities
Muscle pain causing 
inability to perform usual 
social & functional activities
Disabling muscle pain causing 
inability to perform basic self-
care functions
Osteonecrosis
NA
Asymptomatic with radiographic 
findings AND No operative 
intervention indicated
Symptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicated
Disabling bone pain with 
radiographic findings causing 
inability to perform basic self-
care functions


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 116
21 October 2015
SYSTEMIC
Grade 1
Grade 2
Grade 3
Grade 4
Acute Systemic Allergic 
Reaction 
Localized urticaria 
(wheals) with no medical 
intervention indicated
Localized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicated
Generalized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasm
Acute anaphylaxis OR Life-
threatening bronchospasm OR 
laryngeal edema
Chills
Symptoms causing no or 
minimal interference with 
usual social & functional 
activities
Symptoms causing greater than 
minimal interference with usual 
social & functional activities 
Symptoms causing inability to 
perform usual social & 
functional activities
NA
Fatigue
Malaise
Symptoms causing no or 
minimal interference with 
usual social & functional 
activities
Symptoms causing greater than 
minimal interference with usual 
social & functional activities
Symptoms causing inability to 
perform usual social & 
functional activities
Incapacitating fatigue/malaise 
symptoms causing inability to 
perform basic self-care 
functions
Fever (nonaxillary)
37.7C to 38.6C
99.8F to 101.5F
38.7C to 39.3C
101.6F to 102.8F
39.4C to 40.5C
102.9F to 104.9F
40.5C 
104.9F
Pain- Indicate Body Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and Myalgia
Pain causing no or 
minimal interference with 
usual social & functional 
activities
Pain causing greater than minimal 
interference with usual social & 
functional activities
Pain causing inability to 
perform usual social & 
functional activities
Disabling pain causing 
inability to perform basic self-
care functions OR 
Hospitalization (other than ER 
visit) indicated
Unintentional Weight 
Loss
NA
5% to 9% loss in body weight from 
baseline
10% to 19% loss in body 
weight from baseline
20% loss in body weight 
from baseline OR  Aggressive 
intervention indicated [eg, 
tube feeding or total parenteral 
nutrition]


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 117
21 October 2015
INJECTION SITE REACTION
Grade 1
Grade 2
Grade 3
Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when 
area is touched) 
Pain/tenderness causing no 
or minimal limitation of use 
of limb
Pain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activities
Pain/tenderness causing 
inability to perform usual 
social & functional activities
Pain/tenderness causing inability 
to perform basic self-care 
function OR Hospitalization 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15 Years
Erythema OR Induration
of 5 5 cm to 9 9 cm (or 
2581 cm2)
Erythema OR Induration OR 
Edema 9 cm any diameter 
(or 81 cm2)
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR Drainage
Necrosis (involving dermis and 
deeper tissue)
Pediatric 15 Years
Erythema OR Induration 
OR Edema present but 
2.5 cm diameter
Erythema OR Induration 
OR Edema > 2.5 cm 
diameter but < 50% surface 
area of the extremity 
segment (eg, upper 
arm/thigh)
Erythema OR Induration 
OR Edema involving 
50% surface area of the 
extremity segment (eg, 
upper arm/thigh) OR 
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR 
Drainage
Necrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching—no skin lesions)
Itching localized to injection 
site AND Relieved 
spontaneously or with 
48 h treatment 
Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48 h treatment 
Generalized itching causing 
inability to perform usual 
social & functional activities
NA


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 118
21 October 2015
ENDOCRINE/METABOLIC
Grade 1
Grade 2
Grade 3
Grade 4
Lipodystrophy (eg, back 
of neck, breasts, 
abdomen)
Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)
Detectable on physical exam by 
health care provider
Disfiguring OR Obvious 
changes on casual visual 
inspection
NA
Diabetes Mellitus
NA
New onset without need to initiate 
medication OR Modification of 
current meds to regain glucose 
control
New onset with initiation of 
indicated med OR Diabetes 
uncontrolled despite treatment 
modification
Life-threatening consequences 
(eg, ketoacidosis, 
hyperosmolar non-ketotic 
coma) 
Gynecomastia
Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)
Detectable on physical exam by 
health care provider
Disfiguring OR Obvious on 
casual visual inspection
NA
Hyperthyroidism 
Asymptomatic
Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid suppression therapy 
indicated
Symptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification 
Life-threatening consequences 
(eg, thyroid storm)
Hypothyroidism
Asymptomatic
Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicated
Symptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification 
Life-threatening consequences 
(eg, myxedema coma)
Lipoatrophy (eg, fat loss 
from the face, extremities, 
buttocks)
Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)
Detectable on physical exam by 
health care provider
Disfiguring OR Obvious on 
casual visual inspection
NA


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 119
21 October 2015
GENITOURINARY
Grade 1
Grade 2
Grade 3
Grade 4
Intermenstrual Bleeding 
(IMB)
Spotting observed by participant 
OR Minimal blood observed 
during clinical or colposcopic 
exam
Intermenstrual bleeding not 
greater in duration or amount 
than usual menstrual cycle
Intermenstrual bleeding greater 
in duration or amount than usual 
menstrual cycle
Hemorrhage with life-
threatening hypotension OR 
Operative intervention 
indicated
Urinary Tract 
obstruction (eg, stone)
NA
Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunction
Signs or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunction
Obstruction causing life-
threatening consequences
INFECTION
Grade 1
Grade 2
Grade 3
Grade 4
Infection (any other 
than HIV infection)
Localized, no systemic antiμbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activities
Systemic antiμbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional activities
Systemic antiμbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than simple 
incision and drainage) indicated
Life-threatening 
consequences (eg, septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, pursuing a hobby, etc.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 120
21 October 2015
Appendix 5.
Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC 
Guidelines)
1. Candidiasis of bronchi, trachea, or lungs
2. Candidiasis of esophagus
3. Cervical cancer, invasive
4. Coccidioidomycosis, disseminated or extrapulmonary
5. Cryptococcosis, extrapulmonary
6. Cryptosporidiosis, chronic intestinal (1 month duration)
7. Cytomegalovirus disease (other than liver, spleen or nodes)
8. Cytomegalovirus retinitis (with loss of vision)
9. Encephalopathy, HIV-related
10. Herpes simplex: chronic ulcer(s) (1 month duration); or bronchitis, pneumonitis or 
esophagitis
11. Histoplasmosis, disseminated or extrapulmonary
12. Isosporiasis, chronic intestinal (1 month duration)
13. Kaposi’s sarcoma
14. Lymphoma, Burkitt’s (or equivalent term)
15. Lymphoma, immunoblastic (or equivalent term)
16. Lymphoma, primary, of brain
17. Mycobacterium avium complex or Myobacterium kansasii, disseminated or extrapulmonary
18. Mycobacterium tuberculosis, of any site,  pulmonary, disseminated or extrapulmonary
19. Mycobacterium, other species or unidentified species, disseminated or extrapulmonary
20. Pneumocystis jirovecii (previously known as “Pneumocystis carinii) pneumonia
21. Pneumonia, recurrent
22. Progressive multifocal leukoencephalopathy
23. Salmonella septicemia, recurrent
24. Toxoplasmosis of brain
25. Wasting syndrome attributed to HIV infection
CDC Stage-3-Defining Opportunistic Illnesses in HIV Infection - 2014 {13585}


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 121
21 October 2015
Appendix 6.
Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)
Definitions
a)
Definition of Childbearing Potential
For the purposes of this study, a female born subject is considered of childbearing potential 
following the initiation of puberty (Tanner stage 2) until becoming post-menopausal, unless 
permanently sterile or with medically documented ovarian failure.
Women are considered to be in a postmenopausal state when they are > 54 years of age with 
cessation of previously occurring menses for > 12 months without an alternative cause. In 
addition, women of any age with amenorrhea of > 12 months may also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they are not using hormonal contraception or hormonal replacement therapy.
Permanent sterilization includes hysterectomy, bilateral oophorectomy, or bilateral 
salpingectomy in a female subject of any age.
b)
Definition of Male Fertility
For the purposes of this study, a male born subject is considered to be fertile after the initiation 
of puberty unless permanently sterile by bilateral orchidectomy or medical documentation.
2)
Contraception Requirements for Female Subjects
a)
Study Drug Effects on Pregnancy and Hormonal Contraception
The data on GS-9883/F/TAF in pregnant women is limited or not available. There is no 
suspicion of human teratogenicity based on class effects or genotoxic potential. Relevant non-
clinical reproductive studies for human pregnancy do not indicate a strong suspicion of human 
teratogenicity/fetotoxicity. Data from clinical pharmacokinetic interaction studies of GS-9883 
and F/TAF have demonstrated that there is no reduction in the clinical efficacy of hormonal 
contraception or that the effect on hormonal contraception is insignificant. Please refer to the 
latest version of the GS-9883/F/TAF investigator’s brochure and the current Prescribing 
Information and local product labeling for ABC/DTG/3TC for additional information.
b)
Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highly effective 
contraceptive measures.  They must have a negative serum pregnancy test at Screening and a 
negative pregnancy test on the Day 1 visit prior to randomization. At minimum a pregnancy test 
will be performed at the end of relevant systemic exposure. In the event of a delayed menstrual 
period (over one month between menstruations), a pregnancy test must be performed to rule out 
pregnancy. This is true even for women of childbearing potential with infrequent or irregular 
periods. Female subjects must agree to one of the following from Screening until 30 days 
following the end of relevant systemic exposure.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 122
21 October 2015

Complete abstinence from intercourse of reproductive potential.  Abstinence is an acceptable 
method of contraception only when it is in line with the subject’s preferred and usual 
lifestyle. 
Or

Consistent and correct use of 1 of the following methods of birth control listed below.
Intrauterine device (IUD) with a failure rate of <1% per year
Intrauterine hormone-releasing system (IUS) with a failure rate of <1% per year
Tubal sterilization
Essure micro-insert system (provided confirmation of success 3 months after procedure)
Vasectomy in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Or

Consistent and correct use of one hormonal method and one barrier method
Barrier methods
■
Diaphragm with spermicide
■
Cervical cap with spermicide
■
Male condom (with or without spermicide)
Hormonal methods
■
Oral contraceptives (either combined or progesterone only)
■
Injectable progesterone
■
Implants of levonorgestrel
■
Transdermal contraceptive patch
■
Contraceptive vaginal ring
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 30 days after the end of relevant systemic exposure.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Original
CONFIDENTIAL
Page 123
21 October 2015
3)
Contraception Requirements for Male Subjects
It is theoretically possible that a relevant systemic concentration may be achieved in a female 
partner from exposure of the male subject’s seminal fluid.  Therefore, male subjects with female 
partners of childbearing potential must use condoms during treatment and until 90 days after the 
end of relevant systemic exposure.  Additional contraception recommendations should also be 
considered if the female partner is not pregnant.
Male subjects must also refrain from sperm donation during treatment and until at least 90 days 
after the end of relevant systemic exposure.
4)
Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, 
ovulation, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides 
only, and lactational amenorrhea method (LAM).  Female condom and male condom should not 
be used together.
5)
Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify the investigator if they become pregnant at any time during 
the study, or if they become pregnant within 30 days of last study drug dose. Subjects who 
become pregnant or who suspect that they are pregnant during the study must report the 
information to the investigator and discontinue study drug immediately. Subjects whose partner 
has become pregnant or suspects she is pregnant during the study must report the information to 
the investigator.  Instructions for reporting pregnancy, partner pregnancy, and pregnancy 
outcome are outlined in Section 7.3.

Prot_006.pdf: 
Study Title: 
Sponsor: 
IND Number: 
EudraCT Number: 
Clinical Trials.gov 
Identifier: 
Indication: 
Protocol ID: 
Gilead Study Clinical 
Program Manager: 
Gilead Medical 
Monitor: 
(rJ GILEAU 
CLINICAL STUDY PROTOCOL 
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety 
and Efficacy of Switching from a Regimen of Dolutegravir and 
ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC 
to a FDC of GS-9883/F IT AF in HIV -1 Infected Subjects who are 
Virologically Suppressed 
Gilead Sciences, Inc. 
333 Lakeside Drive 
Foster City, CA 94404 
125589 
2015-004025-14 
NCT02603120 
HIV -1 Infection 
GS-US-3 80-1844 
Name: 
PPD 
Telephone: PPD 
Fax: 
PPD 
Name: 
Telephone: 
Fax: 
Mobile: 
...._ ____ _, 
Hal Mrui in, MD, MPH 
PPD 
PPD 
PPD 
Protocol Version/Date: 
Original: 
21 October 2015 
19 Febmruy 2016 
19 October 2016 
Amendment 1 
Amendment2 
CONFIDENTIALITY STATEMENT 
The inf01mation contained in this document, prui iculru·ly unpublished data, is the prope1iy or 
under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review by you, your staff, and an applicable Institutional 
Review Board or Independent Ethics Committee. The infonnation is only to be used by you in 
connection with authorized clinical studies of the investigational dmg described in the protocol. 
You will not disclose any of the infonnation to others without written authorization from 
Gilead Sciences, Inc., except to the extent necessa1y to obtain infonned consent from those 
persons to whom the dmg may be administered. 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 2
19 October 2016
TABLE OF CONTENTS
TABLE OF CONTENTS ..............................................................................................................................................2
LIST OF IN-TEXT TABLES........................................................................................................................................5
LIST OF IN-TEXT FIGURES ......................................................................................................................................5
PROTOCOL SYNOPSIS ..............................................................................................................................................6
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS....................................................................13
1.
INTRODUCTION ..............................................................................................................................................16
1.1.
Background ............................................................................................................................................16
1.2.
GS-9883 .................................................................................................................................................17
1.2.1.
General Information .............................................................................................................17
1.2.2.
Preclinical Pharmacology and Toxicology...........................................................................17
1.2.3.
Clinical Trials of GS-9883 ...................................................................................................19
1.3.
Information about Emtricitabine (Emtriva®, FTC).................................................................................29
1.4.
Information about Tenofovir alafenamide (TAF, GS-7340)..................................................................29
1.4.1.
Clinical Trials of Single Agent Tenofovir Alafenamide (TAF, GS-7340)
or Fixed Dose Combination emtricitabine/tenofovir alafenamide 
(FTC/TAF)...........................................................................................................................29
1.4.2.
Clinical Trials of FTC/TAF as part of 
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) ...........................31
1.5.
Information about GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) ...........................33
1.5.1.
GS-US-141-1233: Relative Bioavailability of GS-9883, FTC, and TAF 
between GS-9883/F/TAF and GS-9883 + F/TAF................................................................33
1.6.
Information about abacavir/dolutegravir/lamivudine (ABC/DTG/3TC Triumeq®)...............................34
1.7.
Rationale for this Study..........................................................................................................................34
1.8.
Risk/Benefit Assessment for the Study..................................................................................................35
1.9.
Rationale for Dose Selection..................................................................................................................36
1.10.
Compliance ............................................................................................................................................37
2.
OBJECTIVES.....................................................................................................................................................38
3.
STUDY DESIGN................................................................................................................................................39
3.1.
Endpoints ...............................................................................................................................................39
3.2.
Study Design..........................................................................................................................................39
3.3.
Study Treatments ...................................................................................................................................39
3.4.
Duration of Treatment............................................................................................................................39
3.5.
Biomarker Testing..................................................................................................................................41
3.5.1.
Biomarker Samples for Optional Pharmacogenomic Research............................................41
3.5.2.
Additional Sample Storage...................................................................................................41
4.
SUBJECT POPULATION..................................................................................................................................42
4.1.
Number of Subjects and Subject Selection ............................................................................................42
4.2.
Inclusion Criteria....................................................................................................................................42
4.3.
Exclusion Criteria...................................................................................................................................43
5.
INVESTIGATIONAL MEDICINAL PRODUCTS ...........................................................................................45
5.1.
Randomization, Blinding and Treatment Codes ....................................................................................45
5.1.1.
Procedures for Breaking Treatment Codes...........................................................................45
5.2.
Description and Handling.......................................................................................................................46
5.2.1.
Formulation..........................................................................................................................46
5.2.2.
Packaging and Labeling .......................................................................................................46


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 3
19 October 2016
5.2.3.
Storage and Handling...........................................................................................................47
5.3.
Dosage and Administration of GS-9883/Emtricitabine/Tenofovir alafenamide and 
Abacavir/Dolutegravir/Lamivudine .......................................................................................................47
5.4.
Prior and Concomitant Medications.......................................................................................................48
5.5.
Accountability for Investigational Medicinal Product (IMP).................................................................49
5.5.1.
Investigational Medicinal Product Return or Disposal.........................................................49
6.
STUDY PROCEDURES ....................................................................................................................................50
6.1.
Subject Enrollment and Treatment Assignment.....................................................................................50
6.2.
Pretreatment Assessments......................................................................................................................50
6.2.1.
Screening Visit .....................................................................................................................50
6.2.2.
Day 1 Assessments...............................................................................................................52
6.3.
Randomization .......................................................................................................................................53
6.4.
Treatment Assessments (Week 4 - 48)...................................................................................................54
6.5.
Treatment Assessments (Post Week 48 until the Open-Label Rollover Extension) ..............................57
6.5.1.
Post Week 48 Assessments ..................................................................................................57
6.5.2.
End of Blinded Treatment Visit ...........................................................................................58
6.5.3.
Treatment Assessments (Open-Label Rollover Extension)..................................................60
6.6.
Post-treatment Assessments ...................................................................................................................62
6.6.1.
Early Study Drugs Discontinuation Assessments.................................................................62
6.6.2.
30 Day Follow Up................................................................................................................63
6.7.
Criteria for Discontinuation of Study Treatment....................................................................................65
6.8.
Bone Mineral Density Evaluations.........................................................................................................65
6.9.
Other Evaluations...................................................................................................................................65
6.9.1.
Markers of Renal Tubular Function .....................................................................................65
6.9.2.
Markers of Inflammation and Immune Activation...............................................................66
6.9.3.
Markers of Platelet Function ................................................................................................66
6.9.4.
Blood and Urine Storage......................................................................................................66
6.10.
Assessments for Premature Discontinuation from Study.......................................................................66
6.11.
End of Study...........................................................................................................................................66
6.12.
Post Study Care......................................................................................................................................66
6.13.
Virologic Failure....................................................................................................................................67
6.13.1.
Management of Virologic Rebound .....................................................................................67
6.13.2.
Subjects with HIV-1 RNA ≥50 copies/mL at Study Drug 
Discontinuation, or Week 48................................................................................................68
7.
ADVERSE EVENTS AND TOXICITY MANAGEMENT...............................................................................69
7.1.
Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events.................................69
7.1.1.
Adverse Events.....................................................................................................................69
7.1.2.
Serious Adverse Events........................................................................................................69
7.1.3.
Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events .........................................................................70
7.2.
Assessment of Adverse Events and Serious Adverse Events.................................................................70
7.2.1.
Assessment of Causality for Study Drugs and Procedures...................................................70
7.2.2.
Assessment of Severity ........................................................................................................71
7.3.
Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead.......................................................................................................................71
7.3.1.
Adverse Events.....................................................................................................................71
7.3.2.
Serious Adverse Events........................................................................................................72
7.4.
Gilead Reporting Requirements.............................................................................................................73
7.5.
Toxicity Management ............................................................................................................................73
7.5.1.
Grades 1 and 2 Laboratory Abnormality or Clinical Event..................................................73
7.5.2.
Grade 3 Laboratory Abnormality or Clinical Event.............................................................74
7.5.3.
Grade 4 Laboratory Abnormality or Clinical Event.............................................................74


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 4
19 October 2016
7.5.4.
Management of Possible Abacavir Hypersensitivity Reaction.............................................74
7.5.5.
Management of Potential Hepatobiliary Toxicity ................................................................75
7.5.6.
On-Treatment Hepatitis C Management...............................................................................75
7.6.
Special Situations Reports......................................................................................................................76
7.6.1.
Definitions of Special Situations..........................................................................................76
7.6.2.
Instructions for Reporting Special Situations.......................................................................76
8.
STATISTICAL CONSIDERATIONS................................................................................................................78
8.1.
Analysis Objectives and Endpoints........................................................................................................78
8.1.1.
Analysis Objectives..............................................................................................................78
8.1.2.
Primary Endpoint .................................................................................................................78
8.1.3.
Secondary Endpoint .............................................................................................................78
8.2.
Analysis Conventions.............................................................................................................................78
8.2.1.
Analysis Sets ........................................................................................................................78
8.3.
Data Handling Conventions ...................................................................................................................80
8.4.
Demographic Data and Baseline Characteristics ...................................................................................80
8.5.
Efficacy Analysis ...................................................................................................................................81
8.5.1.
Primary Analysis..................................................................................................................81
8.5.2.
Secondary Analyses .............................................................................................................82
8.6.
Safety Analysis.......................................................................................................................................83
8.6.1.
Extent of Exposure...............................................................................................................83
8.6.2.
Adverse Events.....................................................................................................................83
8.6.3.
Laboratory Evaluations ........................................................................................................84
8.6.4.
Bone Safety Evaluations ......................................................................................................84
8.6.5.
Other Safety Evaluations......................................................................................................84
8.7.
Pharmacokinetic Analysis......................................................................................................................84
8.8.
Inflammation, Immune Activation, Platelet and Renal Tubular Function Analysis...............................85
8.9.
Patient Reported Outcomes (PRO).........................................................................................................85
8.10.
Sample Size............................................................................................................................................85
8.11.
Data Monitoring Committee ..................................................................................................................85
8.12.
Analysis Schedule ..................................................................................................................................86
9.
RESPONSIBILITIES..........................................................................................................................................87
9.1.
Investigator Responsibilities ..................................................................................................................87
9.1.1.
Good Clinical Practice..........................................................................................................87
9.1.2.
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval...........................................................................................................87
9.1.3.
Informed Consent.................................................................................................................87
9.1.4.
Confidentiality......................................................................................................................88
9.1.5.
Study Files and Retention of Records ..................................................................................88
9.1.6.
Case Report Forms...............................................................................................................89
9.1.7.
Investigational Medicinal Product Accountability and Return.............................................90
9.1.8.
Inspections............................................................................................................................90
9.1.9.
Protocol Compliance............................................................................................................90
9.2.
Sponsor Responsibilities ........................................................................................................................91
9.2.1.
Protocol Modifications.........................................................................................................91
9.2.2.
Study Report and Publications .............................................................................................91
9.3.
Joint Investigator/Sponsor Responsibilities ...........................................................................................91
9.3.1.
Payment Reporting...............................................................................................................91
9.3.2.
Access to Information for Monitoring..................................................................................92
9.3.3.
Access to Information for Auditing or Inspections ..............................................................92
9.3.4.
Study Discontinuation..........................................................................................................92
10.
REFERENCES ...................................................................................................................................................93


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 5
19 October 2016
11.
APPENDICES ....................................................................................................................................................95
Appendix 1.
Investigator Signature Page....................................................................................................96
Appendix 2.
Study Procedures Table (Blinded Phase) ...............................................................................97
Appendix 3.
Study Procedures Table (Open-Label Rollover Extension)..................................................100
Appendix 4.
Management of Clinical and Laboratory Adverse Events....................................................102
Appendix 5.
GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities.............103
Appendix 6.
Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines) ...........................125
Appendix 7.
Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements.................................................................................................126
LIST OF IN-TEXT TABLES
Table 1-1.
GS-US-141-1218: GS-9883 Mean (%CV) PK Parameters Following Single Doses 
of GS-9883 in Healthy Subjects (GS-9883 PK Analysis Set; Part A: Single Dosing) ...........22
Table 1-2.
GS-US-141-1218: GS-9883 Plasma Pharmacokinetic Parameters by GS-9883 Dose 
Following Multiple-Dose Administration of GS-9883 (Analysis Set: GS-9883 PK 
Part B: Multiple-Dose) ...........................................................................................................23
Table 1-3.
GS-US-141-1218: Statistical Comparison of GS-9883 Pharmacokinetic Parameters 
Following Single-Dose Administration of GS-9883 in the Fasted and Fed States 
(GS-9883 PK Analysis Set)....................................................................................................24
Table 1-4.
Trough GS-9883 Plasma Concentrations at Steady State Following GS-9883 
Administration Under Fasting Conditions and Corresponding Protein-Adjusted 
IQ95 Values (GS-9883 PK Analysis Set)...............................................................................25
Table 1-5.
GS-US-141-1219: Trough GS-9883 Plasma Concentrations at Steady State 
Following GS-9883 Administration Under Fasting Conditions and Corresponding 
Protein-Adjusted IQ95 Values.................................................................................................36
Table 5-1.
Prior and Concomitant Medications.......................................................................................48
LIST OF IN-TEXT FIGURES
Figure 1-1.
GS-US-141-1219: Mean and 95% CIs of Change from Baseline in HIV-1 RNA 
(log10 copies/mL) (PP Analysis Set).......................................................................................25
Figure 3-1.
Study Schema.........................................................................................................................40
Figure 6-1.
Virologic Rebound Schema....................................................................................................68


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 6
19 October 2016
PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Study Title: 
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety 
and Efficacy of Switching from a Regimen of Dolutegravir and 
ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC
to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects who are 
Virologically Suppressed
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:
125589
2015-004025-14
NCT02603120
Study Centers Planned:
Approximately 100 centers in North America, Europe and 
Asia Pacific
Objectives:
The primary objective of this study is:

To evaluate the efficacy of switching from a regimen of DTG 
and ABC/3TC or a fixed dose combination (FDC) of 
ABC/DTG/3TC to a FDC of GS-9883/F/TAF versus continuing 
DTG and ABC/3TC as the FDC ABC/DTG/3TC in 
virologically suppressed HIV-1 infected subjects as determined 
by the proportion of subjects with HIV-1 RNA ≥50 copies/mL 
at Week 48
The secondary objectives of this study are:

To evaluate the safety and tolerability of the two treatment 
groups through Week 48

To evaluate the bone safety of the two treatment groups as 
determined by the percentage change from baseline in hip and 
spine bone mineral density (BMD) through Week 48
Study Design:
Randomized, double-blind, multicenter, active-controlled study to 
evaluate the safety and efficacy of switching to a FDC of 
GS-9883/F/TAF tablet versus continuing DTG and ABC/3TC as the 
FDC ABC/DTG/3TC in HIV-1 infected subjects who are 
virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable 
regimen of DTG + ABC/3TC or ABC/DTG/3TC FDC for 
3 months prior to screening.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 7
19 October 2016
Subjects who provide written consent and meet all eligibility criteria 
will be randomized in a 1:1 ratio to one of the following 2 treatment 
groups:
Treatment Group 1: FDC of GS-9883 50 mg/ emtricitabine 
200 mg/ tenofovir alafenamide 25 mg (GS-9883/F/TAF) + Placebo 
to match FDC of abacavir 600 mg/ dolutegravir 50 mg/lamivudine 
300 mg (ABC/DTG/3TC) administered orally, once daily, without 
regard to food (n=260)
Treatment Group 2: FDC of abacavir 600 mg/dolutegravir 
50 mg/ lamivudine 300 mg (ABC/DTG/3TC) + Placebo to match 
FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir 
alafenamide 25 mg (GS-9883/F/TAF) administered orally, 
once daily, without regard to food (n=260)
Number of Subjects 
Planned:
Approximately 520 subjects in total.
260 subjects in each Treatment Group 1 and Treatment Group 2
Target Population:
HIV-1 infected adult subjects who are virologically suppressed 
(HIV-1 RNA < 50 copies/mL) on a stable regimen of
DTG + ABC/3TC or ABC/DTG/3TC FDC for 3 months prior to 
screening.
Duration of 
Treatment:
Subjects will be treated for at least 48 weeks during the blinded
treatment phase. After Week 48, all subjects will continue to take 
their blinded study drug and attend visits every 12 weeks until the 
End of Blinded Treatment Visit. Once the last subject completes the 
Week 48 visit and Gilead completes the Week 48 analysis, all 
subjects will return to the clinic (preferable within 30 days) for an 
End of Blinded Treatment Visit. At the End of Blinded Treatment 
Visit, if safety and efficacy of GS-9883/F/TAF is demonstrated 
following review of unblinded data, subjects in a country where 
GS-9883/F/TAF FDC is not available will be given the option to 
receive GS-9883/F/TAF FDC in an open-label (OL) extension phase 
for up to 96 weeks, or until the product becomes accessible to 
subjects through an access program, or until Gilead Sciences elects 
to discontinue the study in that country, whichever occurs first.
All subjects participating in the open-label extension phase, without 
regard to their blinded treatment regimen, will return for study visits 
at Week 12 OL and every 12 weeks thereafter for up to 96 weeks. 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 8
19 October 2016
Subjects who complete the study through the End of Blinded 
Treatment Visit and do not continue on the open-label 
GS-9883/F/TAF FDC extension phase, will be required to return to 
the clinic 30 days after the End of Blinded Treatment visit for a 
30-Day Follow-Up Visit.
Treatment assignments will be provided to the investigators within 
30 days of the last subject completing the End of Blinded Treatment 
Visit.
Diagnosis and Main 
Eligibility Criteria:
Medically stable HIV-1 infected subjects who meet the following 
criteria:

Currently receiving an antiretroviral regimen of 
DTG + ABC/3TC, or ABC/DTG/3TC FDC for 3 months prior 
to screening

Currently on a stable regimen for ≥ 3 months preceding the 
Screening visit with documented plasma HIV 1 RNA 
< 50 copies/mL for ≥ 3 months preceding the Screening visit (or 
undetectable HIV-1 RNA level according to the local assay 
being used if the limit of detection is ≥50 copies/mL).
Prior changes in antiretroviral regimen are only allowed due 
to tolerability issues or for regimen simplification. 
Unconfirmed virologic elevations of ≥50 copies/mL 
(transient detectable viremia, or “blip”) prior to screening are 
acceptable. If the lower limit of detection of the local HIV-1 
RNA assay is <50 copies/mL (eg, <20 copies/mL), the 
plasma HIV-1 RNA level cannot exceed 50 copies/mL on 
two consecutive HIV-1 RNA tests.

Estimated GFR 50 mL/min according to the Cockcroft-Gault 
formula for creatinine clearance

No chronic Hepatitis B Virus (HBV) infection, as determined by 
either
Positive HBV surface antigen and negative HBV surface 
antibody, regardless of HBV core antibody status, at the 
screening visit
Positive HBV core antibody and negative HBV surface 
antibody, regardless of HBV surface antigen status, at the 
screening visit


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 9
19 October 2016
Study Procedures/
Frequency:
After screening procedures, eligible subjects will be randomized 1:1 
to Treatment Group 1 or Treatment Group 2 and treated for 
48 weeks. Following the Day 1 visit, subjects will return for study 
visits at Weeks 4, 8, and 12, and then every 12 weeks through 
Week 48. After Week 48, all subjects will continue to take their 
blinded study drugs and attend study visits every 12 weeks until the 
End of Blinded Treatment Visit.
For all eligible subjects, blood will be collected at Day 1, Weeks 4, 
8, 12, and then every 12 weeks through the End of Blinded 
Treatment visit. Laboratory analyses (hematology, chemistry, and 
urinalysis), HIV-1 RNA, CD4+ cell count, and complete or 
symptom-directed physical examinations will be performed at the 
Screening, Day 1 and all subsequent study visits.
In addition, blood will be collected and stored for possible 
evaluation of markers of inflammation and immune activation, 
which may include but not limited to: cystatin C, IL-6, hs-CRP, 
d-dimer, sCD14, and sCD163. Platelet function evaluations may 
also be assessed, including but not limited to soluble glycoprotein 
VI (sGPVI), P-selectin, and soluble CD40 ligand. Urine will be 
collected for evaluations of renal tubular function including urine 
albumin, urine creatinine, urine protein, retinol binding protein and 
beta-2 microglobulin.
For all subjects on study drug, except subjects located in Germany, 
dual energy x-ray absorptiometry (DXA) scans will be performed 
prior to or within 24 hours of the Day 1 Visit, and then at Weeks 24, 
48 and at the End of Blinded Treatment Visit or Early Study Drug 
Discontinuation Visit (blinded treatment phase only), if > 12 weeks 
since last scan. DXA scan results will be provided to study sites 
when available.
Adverse events and concomitant medications will be assessed at 
each visit.
Test Product, Dose, and 
Mode of 
Administration:
FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir 
alafenamide 25 mg (GS-9883/F/TAF) administered orally, 
once daily without regard to food.
Reference Therapy, 
Dose, and Mode of 
Administration:
FDC of abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg 
(ABC/DTG/3TC) administered orally, once daily without regard to 
food.


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
Criteria for Evaluation: 
Safety: 
Efficacy: 
Phrumacokinetics: 
Optional Genomic 
Testing: 
CONFIDENTIAL 
Adverse events, clinical laborat01y tests and DXA 
The prima1y efficacy endpoint is: 
Final 
Amendment 2 
• 
The prop01iion of subjects with HN -1 RNA ~ 50 copies/mL at 
Week 48 as defmed by the United States (US) Food and Dmg 
Administration (FDA)-defmed snapshot algorithm 
The secondruy endpoints include: 
• 
The prop01iion of subjects with HN -1 RNA < 50 copies/mL at 
Week 48 as defmed by the US FDA-defined snapshot algorithm 
• 
The change from baseline in CD4+ cell count at Week 48 
An intensive phrumacokinetic (PK) substudy will be perf01med at 
the Weeks 4 or 8 visits in a subset of subjects (target n=30) at study 
sites able to conduct this testing. 
For all subjects on study dmg a single anytime pre or post-dose PK 
blood srunple will be collected at Weeks 8, 24 and 36. 
For all subjects on study dmg a trough PK blood saiUple will be 
obtained 20-28 hours following the last dose at Weeks 4 and 12. 
Following an observed dose, one post-dose PK blood sample will be 
collected between 1 and 4 hours post-dose. 
For intensive PK substudy, the following PK paraiUeters for 
GS-9883 may be explored as applicable: 
Cmax, Tmax, Clast, Tiast, Ctau,Tll2, AUCtau,AUCo-Iast, VzJF, CLss/F 
The concentration of GS-9883 may be summarized using descriptive 
statistics. The phrumacokinetics of GS-9883 may be evaluated using 
population approaches. T AF and FTC concentrations may be 
analyzed and PK pru·ameters may be sUilllnru·ized as applicable. 
PPD 
Page 10 
19 October 2016 


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
Patient Rep01ted 
Outcome: 
Statistical Methods: 
CONFIDENTIAL 
PPD 
Final 
Amendment2 
Sho1t F01m 36 Health Survey (SF-36), HIV SymptolllS Distress 
Module, Work Productivity and Activity Impanment Questionnan·e 
(WPAI) and Pittsburgh Sleep Quality Index (PSQI) will be 
administered at Day 1, Weeks 4, 12 and 48. 
The primmy analysis will consist of a non-inferiority test of 
switching to FDC GS-9883/FffAF versus continuing DTG and 
ABC/3TC as the FDC of ABC/DTG/3TC, with respect to the 
prop01tion of subjects with HIV-1 RNA ~ 50 copies/mL at Week 48 
as defmed by the US FDA-defmed snapshot algorithm. It will be 
concluded that GS-9883/FffAF is non-inferior to the 
ABC/3TC/DTG if the upper bound of the 2-sided 95% confidence 
interval (CI) of the difference between treatment groups 
(GS-9883/F/TAF - ABC/3TC/DTG) in the percentage of subjects 
with HIV -1 RNA ~ 50 copies/mL is less than 4%; ie, a margin of 
4% is applied to non-inferiority assessment. The 2-sided 95% Cis 
will be constmcted based on the exact method. 
The prop01tion of subjects with HIV-1 RNA < 50 copies/mL at 
Week 48 as defmed by the US FDA-defined snapshot algorithm will 
also be summarized. The 95% Cis will be constructed in the same 
manner as described for the primmy efficacy endpoint. 
The change from baseline in CD4+ cell cmmt at Weeks 48 will be 
summarized by tr·eatlnent using descriptive statistics. The 
differences and the associated 95% Cis will be constructed using an 
Analysis ofVariance (ANOVA) model, including tr·eatment 
(GS-9883/F/TAF vs. ABC/DTG/3TC) as a fixed effect in the model. 
The percentage change from baseline in hip and spine BMD at 
Week 48 will be summarized by tr·eatrnent using descriptive 
statistics. The differences and the associated 95% Cis will be 
conducted using an ANOV A model, including tr·eatlnent group as a 
fixed effect in the model. 
Adverse events, clinical laborat01y assessment, and phmmacokinetic 
pm·aiUeters will be smnmm·ized using descriptive statistics. 
Page 11 
19 October 2016 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 12
19 October 2016
A total of approximately 520 HIV-1 infected subjects, randomized 
in a 1:1 ratio to 2 treatment groups (260 subjects per treatment 
group), achieves at least 90% power to detect a non-inferiority 
margin of 4% in difference in percentage of subjects with HIV-1 
RNA ≥50 copies/mL at Week 48 between the 2 treatment groups.
For sample size and power computation, it is assumed that both 
treatment groups have 2% of subjects with HIV-1 RNA 
≥50 copies/mL at Week 48 (based on the historical Gilead 
E/C/F/TAF and STB studies), that a non-inferiority margin is 4%, 
and that the significance level of the test is at a one-sided 
0.025 level.
This study will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 13
19 October 2016
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C
degrees Celsius
F
degrees Fahrenheit
ABC/3TC
abacavir/lamivudine, EpzicomKivexa
ABC/DTG/3TC
abacavir/dolutegravir/lamivudine, Triumeq
AE
adverse event
ALT
alanine aminotransferase
ANC
absolute neutrophil counts
ARV
antiretroviral
AST
aspartate aminotransferase
AUC
area under the plasma/serum/peripheral blood mononuclear cell concentration 
versus time curve
BID
twice a day 
BUN
blood urea nitrogen
CBC
complete blood count
CI
confidence interval
CLcr
creatinine clearance
Cmax
the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
CMH
Cochran-Mantel-Haenszel
CNS
central nervous system
COBI, /co
cobicistat (GS-9350)
Ctau
the observed drug concentration at the end of the dosing interval
CPK
creatine phosphokinase
CRF
case report form(s)
CRO
contract (or clinical) research organization 
CYP
cytochrome P450
DHHS
Department of Health and Human Services
DNA
deoxyribonucleic acid
DSPH
Drug Safety and Public Health
DTG
dolutegravir, Tivicay
ECG
electrocardiogram
eCRF
electronic case report form(s)
eGFR
estimated glomerular filtration rate
EVG
elvitegravir
E/C/F/TAF
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide 
E/C/F/TDF
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate, Stribild
FAS
full analysis set
FDA
(United States) Food and Drug Administration
FDC
fixed dose combination


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 14
19 October 2016
FTC/TAF 
emtricitabine/tenofovir alafenamide 
FSH
follicle-stimulating hormone
FTC, F
emtricitabine, Emtriva
GCP
Good Clinical Practice (Guidelines)
GGT
gamma glutamyl transferase
GLSM
geometric least squares mean
GSI
Gilead Sciences, Inc.
GS-9883/F/TAF
GS-9883/emtricitabine/tenofovir alafenamide
HAART
highly active antiretroviral therapy
HBV
hepatitis B virus
HBcAb
hepatitis B core antibody
HBsAb
hepatitis B surface antibody
HBsAg
hepatitis B surface antigen
HCV
hepatitis C virus
HDPE
high-density polyethylene
hERG
human Ether-à-go-go-Related Gene
HIV
human immunodeficiency virus
HIV Sx
HIV Symptoms  Distress Module
HLA
human leukocyte antigen
IB
investigator’s brochure
ICH
International Conference on Harmonisation
IDMC
Independent Data Monitoring Committee
IND
Investigational New Drug (Application)
INSTI
integrase strand-transfer inhibitors
IRB
institutional review board
IWRS
interactive web response system
KS
Kaposi’s sarcoma
LDH
lactate dehydrogenase
LLN
lower limit of the normal range
MedDRA
Medical Dictionary for Regulatory Activities
mg
milligram
MH
Mantel-Haenszel
min
minute
mmHg
millimeters mercury
NNRTI
non-nucleoside reverse transcriptase inhibitor
NOAEL
no observed adverse effect level
NRTI
nucleoside/nucleotide reverse transcriptase inhibitor
OL
open-label
P-gp
P-glycoprotein
PI
protease inhibitor


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 15
19 October 2016
PK
pharmacokinetic
PSQI
Pittsburgh Sleep Quality Index
PT
preferred term 
PT
prothrombin time 
PTM
placebo-to-match
QD
once daily 
RAL
raltegravir
RNA
ribonucleic acid
SA
single agent
SAE
serious adverse eventt
SF-36
Short Form 36 Health Survey
SmPC
Summary of Product Characteristics
SUSAR
Suspected Unexpected Serious Adverse Reaction
TAF
tenofovir alafenamide 
TDF
tenofovir disoproxil fumarate, Viread
TFV-DP
tenofovir diphosphate (TFVpp)
tmax
the time (observed time point) of Cmax
TSH
thyroid stimulating hormone
UGT1A1
uridine 5'-diphospho-glucuronosyltransferase 
UGT
uridine glucuronosyltransferase
ULN
upper limit of the normal range
US
United States
WPAI
Work Productivity and Activity Impairment Questionnaire


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 16
19 October 2016
1.
INTRODUCTION
1.1.
Background
Human immunodeficiency virus-1 (HIV-1) infection is a life-threatening and serious disease that 
is of major public health interest around the world. There are approximately 2.4 million people in 
North America and Western and Central Europe living with HIV-1 and 36 million people 
worldwide {The Joint United Nations Programme on HIV/AIDS (UNAIDS) 2014}. The infection, if 
left untreated or suboptimally treated, is characterized by deterioration in immune function, 
ultimately resulting in death. Therapeutic strategies for the treatment of HIV-1 disease have been 
significantly advanced by the availability of highly active antiretroviral therapy (HAART); the 
introduction of HAART was associated with a dramatic decrease in acquired immune deficiency 
syndrome (AIDS)-related morbidity and mortality {Palella et al 1998}, {Mocroft et al 1998}, 
{Sterne et al 2005}.
The success of potent and well-tolerated ART means that morbidity and mortality in the 
HIV-infected population is increasingly driven by non-AIDS–associated comorbidities. Clinical 
attention has become more focused on the optimization of tolerability, long-term safety, and 
adherence of potent ART regimens {Costagliola 2014}. In addition, there remains a significant 
medical need for new, effective therapies that take into consideration HIV genetic variability, the 
aging HIV-infected population, ARV resistance, non-HIV comorbidities, and regimen 
simplification.
For ART-naive HIV-infected patients, current treatment guidelines suggest that initial therapy 
consist of 2 nucleos(t)ide reverse transcriptase inhibitors (N[t]RTI) and either an integrase 
strand-transfer inhibitor (INSTI) or the boosted protease inhibitor darunavir {Department for 
Health and Human Services (DHHS) 2015}. Virologically suppressed, HIV-infected patients 
may switch from their current regimen because of safety or tolerability concerns or for regimen 
simplification. All patient populations may benefit from once-daily fixed-dose combination 
(FDC) regimens as these have been shown to provide increased adherence and improved clinical 
and virologic outcomes {Sterrantino et al 2012}, {Aldir et al 2014}
Tenofovir (TFV) is a nucleotide analog that inhibits HIV-1 reverse transcription. While tenofovir 
disoproxil fumarate (TDF), an oral prodrug of TFV, is a preferred NtRTI for initial therapy, 
nephrotoxicity is an identified risk, and reductions in bone mineral density (BMD) have been 
shown that are larger than those seen with other NRTIs. Tenofovir alafenamide (TAF) is also an 
oral prodrug of TFV. TAF is more stable in plasma than TDF, provides higher intracellular 
levels of the active phosphorylated metabolite tenofovir diphosphate (TFV-DP), and 
approximately 90% lower circulating levels of TFV relative to TDF at the clinical doses. 
The distinct metabolism of TAF offers the potential for an improved clinical profile compared 
with TDF.
GS-9883 is a potent inhibitor of HIV-1 integrase that is being evaluated for the treatment of 
HIV-1 infection.  Antiviral testing has shown that GS-9883 is active against a broad panel of 
HIV-1 viral lab strains and clinical isolates.  GS-9883 is fully active against a panel of mutant 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 17
19 October 2016
viruses with resistance to NRTIs, non-nucleoside reverse-transcriptase inhibitors (NNRTIs), and 
protease inhibitors (PIs).  Integrase mutant viruses that are resistant to the INSTIs raltegravir 
(RAL) and elvitegravir (EVG) remain largely sensitive to GS-9883.
Gilead Sciences (Gilead) has coformulated GS-9883 with the NRTI emtricitabine (FTC; F) and 
the NtRTI tenofovir alafenamide (TAF) into an FDC tablet that is suitable for once-daily use. 
This GS-9883/F/TAF FDC may provide a potent, convenient, tolerable, and practical regimen 
for the long-term treatment of patients with HIV infection.
1.2.
GS-9883
1.2.1.
General Information
GS-9883, a potent inhibitor of HIV-1 integrase is being evaluated for the treatment of HIV 
infection. Antiviral testing has shown that GS-9883 is active against a broad panel of HIV-1 viral 
lab strains and clinical isolates. GS-9883 is fully active against a panel of mutant viruses with 
resistance to NRTIs, NNRTIs, and PIs. Integrase mutant viruses that are resistant to the INSTIs
RAL and EVG remain largely sensitive to GS-9883.
1.2.2.
Preclinical Pharmacology and Toxicology
A core battery of safety pharmacology studies have been conducted with GS-9883. These 
include assessments of cytotoxicity, off-target receptor and ion-channel binding, effects on 
human Ether-à-go-go-Related Gene (hERG) potassium current and papillary muscle action 
potential, and in vivo studies in rats and dogs that evaluated effects of GS-9883 on all major 
organ systems. The volume of distribution of GS-9883 ranged between 0.09 and 0.22 L/kg in the 
preclinical species, which indicates that the distribution of GS-9883 is limited to the extracellular 
compartment due to its high binding to plasma proteins. The projected half-life of GS-9883 in 
humans is approximately 20 hours based upon the estimates of clearance and volume of 
distribution.
1.2.2.1.
Pharmacology
GS-9883 has IC50 values ranging from 1.5 to 2.4 nM, similar to the inhibitory effect of DTG and 
EVG. GS-9883 is highly potent against HIV replication in MT4 cells with an EC50 (50% 
effective inhibitory concentration) value of 1.9 nM and a protein adjusted EC95 value of 361 nM. 
GS-9883 does not show significant cytotoxicity against dividing and non-dividing human 
PBMCs, primary human hepatocytes and various non-target human cell lines.
GS-9883 is mainly metabolized by uridine 5'-diphospho-glucuronosyltransferase (UGT1A1) and 
CYP3A. GS-9883 does not inhibit major human CYP isoforms or UGT1A1 at concentrations up 
to 25 M. Consequently, GS-9883 is unlikely to be a clinically relevant inhibitor of these
enzymes, and is not expected to inhibit the metabolic clearance of drugs metabolized by these 
enzymes. GS-9883 only modestly inhibits renal transporter OCT2 (IC50 = 0.42 M). As a result, 
GS-9883 is not expected to significantly interfere with the key transporter responsible for 
creatinine tubular elimination at the clinically projected Cmax. Additionally, the risk that GS-9883 
will affect the OCT2-mediated excretion of co-administered drugs is considered to be low.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 18
19 October 2016
GS-9883 does not activate AhR and only weakly activates PXR at concentrations up to 50 M 
(less than 5% and 40% of activation, respectively, compared to positive control compound). 
Therefore, GS-9883 is not expected to act as an inducer through PXR- or AhR-mediated 
pathways at the doses and exposure levels projected in clinical use.
1.2.2.2.
Toxicology
Single oral doses of GS-9883 up to 1000 mg/kg were well-tolerated in rats (AD-141-2286). The 
increase in exposure was limited (< 2-fold) between 100 and 300 mg/kg and similar exposure 
was observed between 300 and 1000 mg/kg suggesting saturation of absorption at 300 mg/kg 
(AUC0-24 2205 gh/mL and 1931 gh/mL, respectively). In monkeys, single oral doses of 
GS-9883 up to 1000 mg/kg were well-tolerated (AD-141-2284). The increase in exposure was 
limited (< 2-fold) between 300 to 1000 mg/kg (AUC0-24 803 gh/mL and 1078 g h/mL, 
respectively).
In 2-week (TX-141-2029) and 26-week (TX-141-2031) oral toxicity studies in rats at doses up to 
300 mg/kg/day, GS-9883 was well-tolerated with no GS-9883-related effects on clinical 
observations, body weight, food consumption, ophthalmic examinations, and anatomic 
pathology.  The high dose of 300 mg/kg/day was considered the maximum feasible dose based 
upon saturation of absorption. The no observed effect level (NOEL) in the 26-week study was 
considered to be the high dose of 300 mg/kg/day.  At the NOEL, GS-9883 exposures in the rat 
were considered to be approximately 12-/31-fold higher (males/females) than the projected 
steady state human exposure of GS-9883 following administration of GS-9883/F/TAF 
(50/200/25 mg) QD under fed conditions.
In a 39-week study in monkeys (TX-141-2032), following administration of 1000 mg/kg/day 
(high dose) of GS-9883 for 39 weeks, pathology data indicated minimal to marked bile duct 
hyperplasia and minimal or moderate hepatocyte hypertrophy in both sexes, and minimal 
regenerative hyperplasia and minimal or slight neutrophil infiltrate in males.  The macroscopic 
finding of rough surface on the liver in one male administered 1000 mg/kg/day correlated with 
moderate hepatocyte hypertrophy and marked bile duct hyperplasia. After a 4-week recovery 
period, GS-9883-related microscopic liver findings included marked bile duct hyperplasia, slight 
hepatocyte hypertrophy, minimal regenerative hyperplasia, and slight lymphocyte infiltrate in 
one male and slight bile duct hyperplasia in one female administered 1000 mg/kg/day, while the 
other two animals in the high dose group had no hepatobiliary findings. Minimally to mildly 
increased ALT activities (≤3.5-fold versus baseline values), likely associated with liver findings, 
exhibited reversibility. There were no other adverse findings in the study, including clinical 
observations, or effects on body weight, body weight change, food consumption, ECGs, 
hematology, coagulation, clinical chemistry, urinalysis, and ophthalmoscopy.
No GS-9883-related effects were observed in the mid-dose group (200 mg/kg/day) which was 
considered the no-observed-effect-level (NOEL).  The estimated margin of exposure at the 
NOEL was approximately 5.1-fold based on expected human exposure with the once daily 
dosing of the GS-9883/F/TAF (50/200/25 mg) tablet.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 19
19 October 2016
A standard battery of in vitro and in vivo studies was performed to assess the genotoxic potential 
of GS-9883. There was no evidence of mutagenic or clastogenic activity in an in vitro bacterial 
reverse mutation assay (Study TX-141-2026), a chromosomal aberration assay in human 
lymphocytes (Study TX-141-2027), or in a rat micronucleus test (Study TX-141-2029).
1.2.3.
Clinical Trials of GS-9883
Clinical trials entailing the use of GS-9883 include:

GS-US-141-1218, a Phase 1 double blind, randomized, placebo-controlled, first-in-human, 
single- and multiple-ascending dose study evaluating the safety, tolerability, and PK of oral 
GS-9883 in healthy subjects and a randomized, open-label, 2-cohort, 3-period, crossover, PK 
study evaluating the drug interaction potential between F/TAF FDC tablet and GS-9883 in 
healthy subjects (completed)

GS-US-141-1219, a Phase 1b randomized, double-blinded, sequential cohort
placebo-controlled study of the safety, PK, and antiviral activity of GS-9883 in HIV-1 
infected subjects (5 mg, 25 mg, 50 mg, 100 mg) (completed)

GS-US-141-1233, a Phase 1,Open-label, Two-Cohort, Multiple-Period, Fixed-Sequence,
Crossover Study to Evaluate 1) the Relative Bioavailability of
Two GS-9883/Emtricitabine/Tenofovir Alafenamide (75/200/25 mg and 50/200/25 mg)
Fixed-Dose Combination Tablets Versus a GS-9883 (75 mg) Tablet and a 
Emtricitabine/Tenofovir Alafenamide (200/25 mg) Fixed-Dose Combination Tablet 
Administered Simultaneously and 2) the Effect of Food on the Pharmacokinetics of 
GS-9883, Emtricitabine and Tenofovir Alafenamide When Administered as 
GS-9883/Emtricitabine/Tenofovir Alafenamide (75/200/25 mg and 50/200/25 mg)
Fixed-Dose Combination Tablets (completed)

GS-US-141-1478, a Phase 1, Open-Label, Parallel Group, Adaptive, Single-Dose Study to 
Evaluate the Pharmacokinetics of GS-9883 in Subjects with Normal and Impaired Hepatic 
Function (in life portion completed)

GS-US-141-1479, a Phase 1, open-label, parallel-group, adaptive single-dose study to 
evaluate the PK of GS-9883 in subjects with normal and impaired renal function (completed)

GS-US-141-1480, a Phase 1 partially-blinded, randomized, placebo- and positive-controlled 
study to evaluate the effect of GS-9883 on the QT/QTc interval in healthy subjects 
(completed)

GS-US-141-1481, a Phase 1 study to evaluate the pharmacokinetics, metabolism, and 
excretion of GS-9883 in healthy subjects (completed)

GS-US-141-1485, a Phase 1 adaptive study to evaluate transporter, CYP-mediated and 
UGT1A1 drug-drug interactions between GS-9883 and probe drugs (completed)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 20
19 October 2016

GS-US-141-1487, a Phase 1 randomized, Blinded, Placebo-Controlled Phase 1 Study 
Evaluating the Effect of GS-9883 on Renal Function as Assessed by Markers of Glomerular 
Filtration Rate (completed)

GS-US-311-1790, a Phase 1Randomized, Open Label, Drug Interaction Study Evaluating the 
Effect of F/TAF FDC Tablet or GS-9883 on the Pharmacokinetics of a Representative 
Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol (completed)

GS-US-380-1761, a Phase 1 Study to Evaluate Pharmacokinetic Drug-Drug Interaction 
Potential between GS-9883/Emtricitabine/Tenofovir Alafenamide Fumarate 
(GS-9883/F/TAF) and Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) 
Tablets (completed)

GS-US-380-1991, a Phase I Single and Multiple Dose Study Evaluating the 
Pharmacokinetics, Safety, and Tolerability of GS-9883/Emtricitabine/Tenofovir Alafenamide 
Fumarate (GS-9883/FTC/TAF) in Healthy Japanese and Caucasian Subjects (ongoing)

GS-US-380-1999, a Phase 1 Multiple Dose Study to Evaluate the Pharmacokinetic 
Drug-Drug Interaction Potential between GS-9883/Emtricitabine/Tenofovir Alafenamide 
Fumarate and Sofosbuvir/Velpatasvir/GS-9857 in Healthy Subjects (completed)

GS-US-380-3908, a Phase 1, Blinded, Placebo-controlled, Two-period Crossover Drug 
Interaction Study to Assess the Effect of GS-9883/F/TAF on Metformin Pharmacokinetics in 
Healthy Subjects (completed)

GS-US-380-3909, a Phase 1, Open Label, Multiple-Cohort, Multiple-Period, 
Fixed-Sequence, Drug Interaction Study to Evaluate the Effect of Antacid and Mineral 
Supplements on GS-9883 Pharmacokinetics (completed)

GS-US-141-1475, a Phase 2 Randomized, Double-Blinded Study of the Safety and Efficacy 
of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + 
Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive 
Adults (ongoing)
Please refer to the GS-9883/F/TAF Investigators’ Brochure for further information about these
studies.
1.2.3.1.
Phase 1 Safety and Pharmacokinetics
Study GS-US-141-1218 was a four part, first-in-human study.  Parts A and B were randomized, 
double-blind, placebo-controlled, single and multiple ascending dose studies of GS-9883 in 
healthy male and female subjects.  Part C was an open label, fixed sequence food effect study 
evaluating the effect of food on the PK of GS-9883.  Part D was a randomized, open-label, 
2-cohort, 3-period, crossover PK study evaluating the drug interaction potential between 
FTC/TAF FDC tablet and GS-9883 in healthy subjects.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 21
19 October 2016
There was no difference in the overall incidence or type of AEs when GS-9883 was administered 
in the fasted and fed states. There was no difference in the overall incidence of AEs when 
GS-9883 or FTC/TAF was each administered alone or in combination.
No deaths or pregnancies were reported. No Grade 3 or 4 AEs or SAEs, were reported in any 
cohort.
Increases in serum creatinine were observed in this study, presumably via inhibition of the renal 
transporter OCT2.  In the MAD cohorts (fasted), serum creatinine change at Day 14 ranged from 
0.05 mg/dL for the 5 mg cohort to 0.18 mg/dL for the 300 mg/dL cohort. In Part D (DDI), 
conducted in the fed state (regular meal), subjects received 100 mg GS-9883 monotherapy for 
7 days and 100 mg GS-9883 with FTC/TAF for 7 days, the mean serum creatinine change at 
Day 7 was 0.14 mg/dL following GS-9883 and 0.17 mg/dL following GS-9883 + FTC/TAF. All 
changes returned to baseline after discontinuation of GS-9883.
The majority of laboratory abnormalities were Grade 1 or Grade 2 in severity. Grade 3 laboratory 
abnormalities included 10 subjects with Grade 3 urine dipstick tests for blood. All of these 
subjects were female, none of the labs were considered by the Investigator to be clinically 
significant, and all were associated with menstruation. No other Grade 3 or 4 laboratory 
abnormalities were observed.
Based on results in study GS-US-141-1218, pharmacokinetic profile of GS-9883 was 
characterized by rapid absorption with time to peak plasma concentrations (median Tmax of 
cohorts) ranging between 1 and 4 hours following administration under fasted conditions. 
GS-9883 exposures were appropriately dose proportional following single dose 25-100 mg dose 
administration, with decreasing dose proportional at higher doses.  The half-life of GS-9883 was 
approximately 18 hours, with no changes observed across studied dose range as evidenced by 
parallel terminal phase slopes. A high-fat meal increased AUCinf and Cmax (geometric mean, 
84% and 101%, respectively) following 100 mg single dose administration. Steady state was 
achieved after 4-6 days of once daily dosing of GS-9883 with average accumulation ratios for 
AUC24hr of 1.6.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 22
19 October 2016
Table 1-1.
GS-US-141-1218: GS-9883 Mean (%CV) PK Parameters Following 
Single Doses of GS-9883 in Healthy Subjects (GS-9883 PK Analysis 
Set; Part A: Single Dosing)
GS-9883 PK 
Parameter
Mean (%CV)
5mg
(N=6)
25 mg
(N=6)
50 mg
(N=6)
100 mg
(N=6)
300 mg
(N=6)
600 mg
(N=6)
Cmax (ng/mL)
691.2
(22.1)
1618.3
(26.7)
3965.0
(40.1)
6998.3
(36.1)
14605.0 
(27.1)
20050.0
(7.5)
Tmax (hr)
1.25 
(1.00-1.50)
2.00
(1.00-3.00)
3.00
(1.50-4.00)
2.25
(1.50-3.00)
3.50
(2.00-6.00)
3.5
(2.00-4.00)
AUCinf (ng.hr/mL)
13059.7
(25.1)
35718.2 
(21.3)
78399.5 
(29.7)
163028.2 
(24.3)
355917.3 
(32.9)
454446.8 
(19.9)
T1/2 (hr)
18.51
(16.81-19.99)
18.08
(16.63-19.64)
16.72
(15.77-
17.11)
18.90
(17.96-
20.05)
18.14
(17.86-20.53)
17.89
(16.38-
19.52)
T1/2 and Tmax: Median (Q1, Q3)
Table 1-2 presents GS-9883 plasma PK parameters following administration of GS-9883 
(5, 25, 50, 100, and 300 mg) once daily for 7 days. Following administration of either GS-9883 
(5, 25, 50, 100, or 300 mg) once daily for 7 days, the PK absorption profile observed on Days 1 
and 7 was similar to that observed in Part A (SAD). The median Tmax values ranged from 1.5 to 
2.5 hours on Day 1 and 1.5 to 4.0 hours on Day 7. Linearity was observed comparing GS-9883 
AUC and Cmax on Days 1 and 7 over the dose range of 25 to 50 mg. Steady state levels of 
GS-9883 were achieved between Study Days 4 to 6 of dosing and maintained through Day 14. 
Accumulation is approximately 1.6-fold, which is consistent with the observed half-life of the 
GS-9883 (approximately 18 hours).


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 23
19 October 2016
Table 1-2.
GS-US-141-1218: GS-9883 Plasma Pharmacokinetic Parameters by 
GS-9883 Dose Following Multiple-Dose Administration of GS-9883 
(Analysis Set: GS-9883 PK Part B: Multiple-Dose)
GS-9883 PK Parameter Mean
(%CV)a
Multiple-Dose GS-9883
5 mg
(N = 6)
25 mg
(N = 6)
50 mg
(N = 6)
100 mg
(N = 6)
300 mg
(N = 6)
Day 1
AUC0-24 (hr*ng/mL)
9033.6
(8.2)
27,775.1
(28.3)
58,371.4
(18.9)
79,773.8
(18.9)
180,714.3
(17.6)
Cmax (ng/mL)
709.7
(9.5)
2220.0
(35.6)
4648.3
(18.7)
6248.3
(26.8)
13,716.7
(19.1)
Tmax (hr)
1.50
(1.50, 1.50)
1.75
(1.00, 3.00)
1.50
(1.00, 2.00)
2.50
(2.00, 3.00)
2.50
(2.00, 4.00)
Day 7
AUCtau (hr*ng/mL)
14,392.0
(16.7)
50,008.2
(26.6)
89,710.1
(22.7)
126,785.8 
(23.7)
277,200.2 
(16.7)
Cmax (ng/mL)
982.5
(7.9)
3455.0
(24.1)
6538.3
(17.6)
9396.7
(20.8)
19,900.0 
(21.2)
Ctau (ng/mL)
400.83
(26.9)
1322.00
(27.8)
2241.67
(28.2)
3145.00 
(26.1)
6758.33 
(21.6)
Tmax (hr)
1.50
(1.00, 2.00)
3.00
(2.00, 3.00)
1.75
(1.50, 2.00)
1.75
(1.50, 3.00)
4.00
(2.00, 4.00)
Accumulation Ratio of AUC (%)
160.5
(19.0)
182.2
(17.1)
154.0
(15.9)
158.5
(12.1)
157.5
(22.6)
a
Data are presented as mean (%CV), except for Tmax, and t½, which are presented as median (Q1, Q3)
Table 1-3 presents the GLSM ratios and associated 90% CIs for the test (fed) versus reference 
(fasted) treatments for the primary plasma PK parameters of GS-9883. Administration of a single 
dose of GS-9883 100 mg with food (high-calorie/high-fat breakfast) increased the GLSM values 
of Cmax and AUCinf 101% (90% CI of GLSM ratio 165.93% to 242.74%) and 84% (90% CI of 
GLSM ratio 152.05% to 222.59%), respectively. There were no apparent changes in clearance 
and T1/2 following administration with food, indicating that food enhanced the bioavailability of 
GS-9883 by improving its solubility and/or absorption.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 24
19 October 2016
Table 1-3.
GS-US-141-1218: Statistical Comparison of GS-9883 Pharmacokinetic 
Parameters Following Single-Dose Administration of GS-9883 in the 
Fasted and Fed States (GS-9883 PK Analysis Set)
GS-9883 PK Parameter 
Mean (%CV)
% GLSM Ratio 
(90% CI)
Test
GS-9883 100 mg Fed
(n=8)
Reference
GS-9883 100 mg Fasted
(n=8)
AUCinf (hr*ng/mL)
214,146.3 (15.9)
117,777.1 (23.3)
183.97 (152.05, 222.59)
AUClast (hr*ng/mL)
209,259.9 (15.1)
115,681.7 (24.0)
183.58 (151.91, 221.86)
Cmax (ng/mL)
11,268.8 (15.1)
5885.0 (34.9)
200.69 (165.93, 242.74)
CI = confidence interval; GLSM = geometric least squares mean
1.2.3.2.
Phase 1b Proof of Concept
The first HIV-1 positive human subjects were dosed in the fasted state with 10 days of GS-9883 
in study (GS-US-141-1219).  Four cohorts of 5 subjects each were randomized 4:1 to receive 
GS-9883 or placebo to match at doses of 5 mg, 25 mg, 50 mg, and 100 mg once daily for 
10 days.
GS-9883 was generally well tolerated at the doses evaluated. A total of 9 of 20 subjects had an 
AE in this study. The most frequently reported AEs across all subjects were diarrhea (2 subjects), 
and headache (3 subjects).  No other AE was reported in more than 1 subject. There was no 
increase in the incidence of AEs with increasing doses of GS-9883.
The majority of AEs were considered by the investigator to be not related to study drug. A total 
of 2 subjects experienced mild diarrhea that was considered related to study drug (1 in the 5 mg 
cohort, 1 in the 100 mg cohort).
No deaths or pregnancies were reported. No Grade 3 or 4 AEs, SAEs, or AEs leading to 
discontinuation of study drug were reported in any cohort.
The majority of laboratory abnormalities were Grade 1 or Grade 2 in severity. No Grade 3 
treatment emergent laboratory abnormalities were observed. Median serum creatinine changes at 
Day 10 were: 0.05 mg/dL (5 mg), 0.04 mg/dL (25 mg), 0.06 mg/dL (50 mg), and 0.15 mg/dL 
(100 mg). These changes in serum creatinine appeared to be transient and returned close to 
baseline values on discontinuation of study drug. One Grade 4 new onset laboratory abnormality 
was seen in 1 subject who received 5 mg GS-9883. This was a Grade 4 CPK seen on Day 17, 
7 days following his last dose of study medication. The subject was asymptomatic. The 
Investigator felt that this was unrelated to study medication and was due to resumption of crystal 
methamphetamine use by the subject. An adverse event of elevated CK was reported unrelated to
study medication.
Based on PK information collected in study GS-US-141-1219, which was in line with PK 
observed in study GS-US-141-1218, the median IQ for each dose were calculated and are 
presented in Table 1-4 below.


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Final 
Gilead Sciences, Inc. 
Amendment 2 
Table 1-4. 
Trough GS-9883 Plasma Concentrations at Steady State Following 
GS-9883 Administration Under Fasting Conditions and 
Corresponding Protein-Adjusted IQ9s Values (GS-9883 PK Analysis 
Set) 
GS-9883 dose 
n 
Median (range) C 1au, ss (ng!mL) 
Median (range) pai Q95• 
5mg 
4 
206.5 (146.0 to 342.0) 
1.3 (0.9 to 2.1) 
25mg 
4 
797.5 (714.0 to 1900.0) 
4.9 ( 4.4 to 11. 7) 
50mg 
4 
2170.0 (852.0 to 3020.0) 
13.4 (5.3 to 18.6) 
100mg 
4 
4190.0 (3730.0 to 5970.0) 
25.9 (23.0 to 36.9) 
a. 
The protein adjusted IQ95 (paiQ95) value is estimated based on steady-state Ctau values and the in vitro paiC95 value for 
wild-type HIV-1 (162 ng/ml). 
The mean and 95% Cis of change from baseline in HIV -1 RNA (log10 copies/mL) are presented 
in Figure 1-1. 
Figure 1-1. 
G$-9883 5 mg (~): 
G$-9883 25 mg (~): 
G$-9883 50 mg (~): 
G$-9883 100 mg (~ ): 
Placebo (n= ): 
GS-US-141-1219: Mean and 95% Cis of Change from Baseline in 
HIV-1 RNA (log10 copies/mL) (PP Analysis Set) 
• 
= GS-9883 5 mg 
0 
= GS-9883 25 mg 
/:; = GS-9883 50 mg 
0 = GS-9883 100 mg 
<> = Placebo 
BL 
2 
3 
3 
3 
3 
4 
3 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
7 
8 
9 
Day 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
3 
4 
4 
4 
4 
4 
4 
4 
10 
11 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
14 
3 
4 
4 
4 
4 
17 
3 
3 
4 
4 
4 
NOTE: Baseline value was the last available value collected prior to the time of the first dose of study drug. 
2 
-1 
-2 
-3 
Mean viral load change on Day 11 was -2.08 log10 in the 25 mg coh011, -2.06 log10 in the 50 mg 
coh01i , and -2.43 log10 in the 100 mg cohort. Time weighted average change from baseline at 
Day 11 (DA VG 11) was -0.92 log10 in the 5 mg coh01i, -1.33 log10 in the 25 mg 
CONFIDENTIAL 
Page25 
19 October 2016 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 26
19 October 2016
cohort, -1.37 log10 in the 50 mg cohort and -1.61 log10 in the 100 mg cohort.  Viral suppression 
(HIV-1 RNA < 50 copies/mL) was ever achieved by the end of the study (Day 17) by 1 subject 
(25.0%) in the GS-9883 50 mg group and 2 subjects (50%) in the GS-9883 100 mg group.
1.2.3.3.
Summary of Phase 2 Study (GS-US-141-1475)
Study GS-US-141-1475 is an ongoing Phase 2, randomized, double-blind, multicenter, 
active-controlled study to assess the safety and efficacy of a regimen containing 
GS-9883+F/TAF versus dolutegravir (DTG)+F/TAF in HIV-infected, ART-naive adult subjects.
Eligible subjects were randomized in a 2:1 ratio to one of the following treatment groups, 
stratified by HIV-1 RNA level (≤ 100,000 copies/mL, 100,000 copies/mL to 
400,000 copies/mL, or > 400,000 copies/mL) at screening:

Treatment Group 1: GS-9883 75 mg + F/TAF (200/25 mg) + placebo-to-match DTG 50 mg 
once daily

Treatment Group 2: DTG 50 mg + F/TAF (200/25 mg) + placebo-to-match GS-9883 75 mg 
once daily
Week 24 interim data are summarized below. 
Subject Disposition and Baseline Characteristics
A total of 98 subjects were randomized and treated in the study: 65 subjects in the 
GS-9883+F/TAF group and 33 subjects in the DTG+F/TAF group. At the time of the Week 24 
data analysis, 2 subjects (2.0%) had prematurely discontinued from the study, 1 in each treatment 
group; both subjects were lost to follow-up.
Demographic and baseline characteristics were similar between the 2 treatment groups.
Key baseline disease characteristics (ie, viral load, CD4 cell count, and eGFRCG) were similar 
between the 2 treatment groups.
Median (first quartile [Q1], third quartile [Q3]) baseline HIV-1 RNA was 4.45 (3.96, 
4.79) log10 copies/mL, with 82.7% of subjects having ≤ 100,000 copies/mL at baseline; 
5 subjects had > 400,000 copies/mL at baseline; 4 of these subjects were randomized to 
GS-9883+F/TAF and 1 subject was randomized to DTG+F/TAF.
Median (Q1, Q3) baseline CD4 cell count was 444 (316, 595) cells/μL, with 41.8% of subjects 
having ≥ 500 cells/μL at baseline. Median (Q1, Q3) baseline eGFRCG was 125.3 (105.7, 
147.0) mL/min.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 27
19 October 2016
Efficacy Results
Virologic success at Weeks 12 and 24 was assessed using the US FDA-defined snapshot 
algorithm, defined as plasma HIV-1 RNA < 50 copies/mL. At Weeks 12 and 24, virologic 
success was high and similar between the 2 treatment groups as follows: Week 12 
GS-9883+F/TAF 93.8%, DTG+F/TAF 93.9% (stratum-adjusted difference in percentages: 
−1.3%; 95% CI: −12.9% to 10.2%; p = 0.79); Week 24 GS-9883+F/TAF 95.4%, DTG+F/TAF 
93.9% (1.0%; 95% CI: −10.7% to 12.7%; p = 0.84).
Of the 5 subjects with baseline viral load > 400,000 copies/mL, 4 had HIV-1 RNA 
< 50 copies/mL at Week 24, and had 60 copies/mL. 
Following initiation of study drug, the increases from baseline in CD4 cell count were similar 
between treatment groups. Mean (SD) baseline CD4 cell counts were as follows: 
GS-9883+F/TAF 471 (190.9) cells/μL; DTG+F/TAF 507 (271.0) cells/μL; p = 0.35. The mean 
(SD) change in CD4 cell count from baseline to Week 12 was similar between the 2 treatment 
groups as follows: GS-9883+F/TAF, +170 (150.0) cells/μL; DTG+F/TAF, +173 (220.5) cells/μL 
(difference in least squares mean [LSM]: 0; 95% CI: −76 to 76; p = 1.00). There were similar 
increases in the mean (SD) CD4 cell count in both treatment groups Week 24: GS-9883+F/TAF, 
+189 (177.8) cells/μL; DTG+F/TAF, +157 (163.2) cells/μL (difference in LSM: 39; 95% CI: 
−35 to 113; p = 0.30).
Interim Virology Resistance Data
Through Week 24, no emergent drug resistance was detected.
Safety Results
Adverse Events
The overall incidence of treatment-emergent AEs was balanced between treatment groups as 
follows: GS-9883+F/TAF 66.2%, 43 subjects; DTG+F/TAF 57.6%, 19 subjects. The most 
common treatment-emergent AEs (occurring in > 2 subjects) by treatment group were as 
follows:

GS-9883+F/TAF: diarrhea and headache (7.7%, 5 subjects each); and nausea, decreased 
appetite, arthralgia, and cough (4.6%, 3 subjects each)

DTG+F/TAF: nausea (12.1%, 4 subjects); diarrhea (9.1%, 3 subjects)
Most treatment-emergent AEs were Grade 1 in severity. Grade 3 or 4 AEs were reported in only 
1 subject (Grade 3 diabetic ketoacidosis), in the GS-9883+F/TAF group; this event was also 
reported as an SAE. One other SAE (appendicitis), also in the GS-9883+F/TAF group, was 
reported. Neither SAE was considered related to study drug by the investigator or resulted in 
study drug discontinuation or interruption, and both SAEs resolved.
The overall incidence of study drug-related treatment-emergent AEs was balanced between 
treatment groups as follows: GS-9883+F/TAF 15.4%, 10 subjects; DTG+F/TAF 18.2%, 
6 subjects. Most study drug-related treatment-emergent AEs were Grade 1 in severity. Grade 2


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 28
19 October 2016
study drug-related treatment-emergent AEs were reported in 1 subject in the GS-9883+F/TAF 
group (somnolence and headache) and 1 subject in the DTG+F/TAF group (vomiting). There 
were no Grade 3 or 4 treatment-emergent AEs or SAEs reported that were considered related to 
study drug.
No Grade 4 AEs, deaths, pregnancies, or AEs leading to premature study drug discontinuation 
were reported in either treatment group.
Clinical Laboratory Evaluations
The percentage of subjects with at least 1 treatment-emergent laboratory abnormality (ie, at least 
1 grade level increase from baseline in graded abnormality) was similar between treatment 
groups as follows: GS-9883+F/TAF 76.6%, 49 subjects; DTG+F/TAF 78.1%, 25 subjects. The 
majority of treatment-emergent laboratory abnormalities were Grade 1 or 2 in severity. The 
percentage of subjects with at least 1 Grade 3 or 4 treatment-emergent laboratory abnormality 
was similar between treatment groups as follows: GS-9883+F/TAF 17.2%, 11 subjects; 
DTG+F/TAF 12.5%, 4 subjects. Grade 3 or 4 laboratory abnormalities occurring in at least 
2 subjects in either treatment group were as follows: creatine kinase (GS-9883+F/TAF, 7.8% 
[5 subjects]), fasting serum glucose (DTG+F/TAF, 6.3% [2 subjects]), aspartate 
aminotransferase (AST) (GS-9883+F/TAF, 3.1% [2 subjects]), and fasting low-density 
lipoprotein (LDL) (GS-9883+F/TAF, 3.1% [2 subjects]). The only Grade 4 laboratory 
abnormalities were for creatine kinase, reported in 2 subjects (3.1%) in the GS-9883+F/TAF 
group. All increased creatine kinase values appeared to be transient, and none were associated 
with AEs. Of the 2 subjects with increased AST, 1 subject had Grade 3 AST and Grade 3 ALT at 
Week 24 in the setting of alcohol abuse; the other subject had Grade 3 AST at Week 8 that 
returned to normal by Week 24.
There were no clinically significant changes from baseline or differences between treatment 
groups in the median values for hematology, chemistry, or metabolic parameters. There were 
similar increases from baseline in median (Q1, Q3) serum creatinine in both treatment groups at 
Week 24: GS-9883+F/TAF 0.12 (0.06, 0.18) mg/dL; DTG+F/TAF 0.13 (0.05, 0.21) mg/dL. 
There were decreases in median (Q1, Q3) eGFRCG at Week 24, which were smaller in the 
GS-9883+F/TAF compared with the DTG+F/TAF group: GS-9883+F/TAF 
−13.3 (−19.9, −4.0) mL/min; DTG+F/TAF −17.2 (−25.7, −6.9) mL/min.
Conclusions
Key Week 24 conclusions from Study GS-US-141-1475 include the following:

Virologic success at Week 24 when assessed using the US FDA-defined snapshot algorithm, 
defined as plasma HIV-1 RNA < 50 copies/mL, was similar between the 2 treatment groups 
as follows: GS-9883+F/TAF 95.4%; DTG+F/TAF 93.9%; stratum-adjusted difference in 
percentages: 1.0%; 95% CI: −10.7% to 12.7%; p = 0.84. There was a similar increase in the 
mean (SD) CD4 cell count between the 2 treatment groups, GS-9883+F/TAF,
+189 (177.8) cells/μL; DTG+F/TAF, +157 (163.2) cells/μL (difference in LSM: 39; 95% CI: 
−35 to 113; p = 0.30).


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 29
19 October 2016

No resistance to any INSTIs, NRTIs, NNRTIs, or PIs was detected through Week 24.

No AEs led to study drug discontinuation in either treatment group.
Both GS-9883+F/TAF and DTG+F/TAF were generally well tolerated through 24 weeks of 
treatment. The most commonly reported treatment-emergent AEs were diarrhea and headache 
(7.7% each) in the GS-9883+F/TAF group and nausea (12.1%) and diarrhea (9.1%) in the 
DTG+F/TAF group. There were 2 SAEs, 1 of which was also a Grade 3 AE; neither of these 
events was considered related to study drug by the investigator, or led to study drug 
discontinuation. There were no other Grade 3 or 4 AEs, and no deaths, pregnancies, or AEs 
leading to premature study drug discontinuation reported. The percentage of subjects with at 
least 1 treatment-emergent laboratory abnormality was similar between treatment groups. The 
majority of treatment-emergent laboratory abnormalities were Grade 1 or 2 in severity. There 
were similar increases from baseline in serum creatinine in both treatment groups at Week 24.
1.3.
Information about Emtricitabine (Emtriva®, FTC)
Emtricitabine (5-fluoro-1-[(2R, 5S)-2-(hydroxymethyl)-[1, 3]-oxathiolan-5-yl] cytosine, FTC) is 
a NRTI that has demonstrated potent and selective inhibition of the HIV. In HIV-infected adults, 
FTC is administered as a 200 mg QD dose concurrently with other ARVdrugs. The 200 mg FTC 
capsule formulation was approved by the US FDA for marketing on 2 July 2003 and is available 
under the name Emtriva®. In the European Union (EU), marketing authorization was granted for 
both the 200 mg Emtrivacapsule formulation and a 10 mg/mL Emtrivaoral Solution 
formulation on 24 October 2003, with indications for the treatment of HIV infection concurrently 
with other antiretroviral drugs in both adult and pediatric patients.
Further information is available in the current Prescribing Information for Emtriva®.
1.4.
Information about Tenofovir alafenamide (TAF, GS-7340)
Tenofovir alafenamide (GS-7340, TAF) is a second generation oral prodrug of tenofovir (TFV), 
a nucleotide analog that inhibits HIV-1 reverse transcription. Tenofovir is metabolized 
intracellularly to the active metabolite, tenofovir diphosphate (TFV-DP), a competitive inhibitor 
of HIV-1 reverse transcriptase (RT) that terminates the elongation of the viral DNA chain. The 
intracellular metabolism of TAF and TFV are consistent with the 600-fold enhancement in 
anti-HIV activity in cell culture of TAF over TFV.
Please refer to the GS-9883/F/TAF Investigator’s Brochure for further information.
1.4.1.
Clinical Trials of Single Agent Tenofovir Alafenamide (TAF, GS-7340) or
Fixed Dose Combination emtricitabine/tenofovir alafenamide (FTC/TAF)
Clinical trials entailing the use of tenofovir alafenamide include:

GS-US-120-1101, a Phase 1/2 study of the pharmacokinetics and antiviral activity of 
GS-7340 (50 mg and 150 mg) in HIV-infected subjects (completed)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 30
19 October 2016

GS-US-120-0104, a Phase 1b study of the pharmacokinetics and antiviral activity of 
GS-7340 (8 mg, 25 mg, 40 mg) in HIV infected subjects (completed)

GS-US-120-0107, a Phase 1, partially-blinded, randomized, placebo- and positive controlled 
study to evaluate the effect of GS-7340 on the QT/QTc interval in healthy subjects 
(completed)

GS-US-120-0108, a Phase 1, open-label, parallel-design study to evaluate the 
pharmacokinetics of GS-7340 in subjects with severe renal impairment (completed)

GS-US-120-0109, a Phase 1 study to evaluate the pharmacokinetics, metabolism and 
excretion of GS-7340 (completed)

GS-US-120-0114, a Phase 1, open-label, parallel-group, single dose study to evaluate the 
pharmacokinetics of tenofovir alafenamide in subjects with normal and impaired hepatic 
function (completed)

GS-US-120-0117, a Phase 1 single-dose study evaluating the pharmacokinetic drug 
interaction potential between rilpivirine and tenofovir alafenamide (completed)

GS-US-120-0118, a Pharmacokinetic study evaluating the drug interaction potential of
tenofovir alafenamide with a boosted protease inhibitor or unboosted integrase inhibitor in
healthy subjects (completed)

GS-US-120-1538, a Fixed-Sequence, Open-Label, Study Evaluating the Pharmacokinetics 
and Drug Interaction Potential between Tenofovir Alafenamide and Midazolam (Oral and 
Intravenous) in Healthy Volunteers (completed) 

GS-US-120-1554, a Fixed-Sequence, Randomized, Open-Label, 2-Cohort, 2-Period, 
Multiple-Dose Study Evaluating the Pharmacokinetics and Drug Interaction Potential 
between Tenofovir Alafenamide and Rilpivirine in Healthy Subjects (completed)

GS-US-311-1386, a Phase 1 study to determine the effect of food on the pharmacokinetics of 
tenofovir alafenamide when administered as F/TAF FDC in healthy volunteers (completed)

GS-US-311-0101, a Phase 1 healthy volunteer study evaluating the drug interaction potential
between once-daily FTC/GS-7340 fixed-dose combination and efavirenz (EFV) or
COBI-boosted darunavir (DRV) (completed)

GS-US-311-1088, a Phase 1, Relative Bioavailability Study of Emtricitabine/Tenofovir
Alafenamide Fixed Dose Combination Tablet to evaluate the formulation performance of
emtricitabine (FTC) and tenofovir alafenamide (TAF) fixed dose combination tablets relative
to co-administration of individual agents (completed)

GS-US-311-1089, a Phase 3 study of the safety and efficacy of FTC/TAF in HIV infected,
virologically suppressed patients (ongoing)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 31
19 October 2016
In Study GS-US-311-1386, the effect of food (high-calorie, high-fat meal) on the PK of the TAF 
component of the F/TAF FDC was evaluated. The GLSM ratio of the AUClast of TAF when 
administered with a high-fat meal was 177% (90% CI: 166% to 188%), and the TAF Cmax
GLSM ratio was 84.5% (90% CI: 74.9% to 95.4%). This ~75% increase in TAF plasma 
exposure and ~15% decrease in TAF plasma Cmax when administered with food was 
accompanied by a delay in Tmax (increase from 1.00 hour under fasted conditions to 2.00 hours 
under fed conditions). The exposures of TAF observed under fed or fasted conditions in this 
study are within the range of exposures observed in the E/C/F/TAF clinical development 
program and are commensurate with safe and effective plasma levels of TAF (see investigator 
brochure for further details). Therefore, the changes in TAF exposures when F/TAF is 
administered with food should not result in differences in efficacy and thus are not clinically 
relevant. TAF can be administered without regard for food and these findings can be 
extrapolated to F/TAF (as FTC can be taken without regard to food). 
1.4.2.
Clinical Trials of FTC/TAF as part of 
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)
Clinical trials using tenofovir alafenamide, coformulated into the E/C/F/TAF STR include: 

GS-US-292-0101, a Phase 1 healthy volunteer study evaluating the relative bioavailability of 
EVG, FTC, TFV, and COBI administered as E/C/F/TAF STR relative to E/C/F/TDF or TAF
(completed)

GS-US-292-0103, a Phase 1 healthy volunteer study to evaluate the pharmacokinetics and 
relative bioavailability of the E/C/F/TAF STR relative to the individual components at 
GS-7340 doses of 10 mg (STR) or 25 mg Single Agent (SA) (completed)

GS-US-292-0102, a Phase 2 randomized, double-blinded study of the safety and efficacy of 
E/C/F/TAF STR versus E/C/F/TDF STR in HIV-1 infected, antiretroviral treatment-naive 
adults (ongoing)

GS-US-292-0104 and GS-US-292-0111, Phase 3 randomized, double-blinded study of the 
safety and efficacy of E/C/F/TAF STR versus E/C/F/TDF STR in HIV-1 infected, 
antiretroviral treatment-naive adults (ongoing)

GS-US-292-0109, a Phase 3 open-label study to evaluate switching from a TDF-containing 
combination regimen to a TAF-containing combination single tablet regimen (STR) in 
virologically-suppressed, HIV-1 positive subjects (ongoing)

GS-US-292-0112, a Phase 3 Open-label Safety Study of 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide single-tablet Regimen in HIV-1 
positive patients with mild to moderate renal impairment (ongoing)

GS-US-292-0117, a Phase 3, two-part study to evaluate the efficacy of Tenofovir 
Alafenamide versus placebo added to a failing regimen followed by treatment with 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 positive, 
antiretroviral treatment-experienced adults (ongoing)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 32
19 October 2016

GS-US-292-0119, a Phase 3 open-label study to evaluate switching from optimized stable 
antiretroviral regimens containing darunavir to 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) single tablet 
regimen (STR) plus darunavir (DRV) in treatment experienced HIV-1 positive adults
(ongoing)

GS-US-292-0106, a Phase 2/3, open-label study of the pharmacokinetics, safety, and 
antiviral activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 
(E/C/F/TAF) single tablet regimen (STR) in HIV-1 infected antiretroviral treatment-naive 
adolescents (ongoing)
Study GS-US-292-0101 is a Phase 1 study of 40 subjects evaluating the relative bioavailability 
of two different formulations of E/C/F/TAF STR, each with TAF dose of 25 mg or 40 mg, versus 
E/C/F/TDF STR or TAF 25 mg alone. Exposures of EVG, COBI, and FTC were comparable 
between E/C/F/TAF vs E/C/F/TDF regardless of formulation (monolayer or bi-layer). In 
contrast, TAF exposures were ~2.2-fold higher (and corresponding tenofovir exposures ~ 3-fold 
higher) when administered as E/C/F/TAF (25 mg) vs TAF single agent (SA) 25 mg for both 
formulations of the E/C/F/TAF, likely mediated by inhibition of P-gp-mediated intestinal
secretion of TAF by COBI.
Study GS-US-292-0103 is a completed Phase 1 healthy volunteer study which evaluated the PK
and relative bioavailability of the E/C/F/TAF STR relative to the individual components at TAF
doses of 10 (STR) or 25 mg SA. Results indicate that when dosed as the E/C/F/TAF 10 mg STR, 
TAF and TFV exposures were comparable to those observed with TAF 25 mg dosed alone. 
Exposures of EVG, COBI, and FTC were also comparable between the STR and individually 
dosed formulations. 
Study GS-US-292-0102 is an ongoing, randomized, active-controlled Phase 2 study, compares 
E/C/F/TAF (10 mg) versus Stribild® (STB, E/C/F/TDF) in treatment-naïve, HIV-1 infected 
subjects. At Week 48, the E/C/F/TAF demonstrated potent antiviral efficacy (HIV-1 RNA 
< 50 copies/mL) similar to STB (88.4% [99/112] vs 87.9% [51/58] using the snapshot 
algorithm); in the E/C/F/TAF group, no patient had emergent resistance to 1 or more components 
of the E/C/F/TAF. Importantly, E/C/F/TAF demonstrated a potential benefit over E/C/F/TDF in 
terms of renal and bone safety: smaller median decreases in eGFR (mL/min) (at Week 48, 
E/C/F/TAF -5.5 vs E/C/F/TDF -10.0 [P<0.001) and smaller median percentage decreases in 
BMD (at Week 48, spine E/C/F/TAF -1.00 vs E/C/F/TDF -3.37 [p<0.001], hip -0.62 
vs -2.39 [p<0.001]).
Studies GS-US-292-0104 and GS-US-292-0111 are ongoing, Phase 3 randomized, 
double-blinded studies of the safety and efficacy of E/C/F/TAF versus E/C/F/TDF in HIV-1 
infected, antiretroviral treatment-naive adults. The interim Week 48 key conclusions from pooled 
data showed that E/C/F/TAF once daily was noninferior to STB once daily when administered 
for 48 weeks to HIV-infected, ART-naive adults, as assessed using the US FDA-defined 
snapshot algorithm with HIV-1 RNA < 50 copies/mL (E/C/F/TAF 92.4%; STB 90.4%; 
difference in percentages: 2.0%, 95% CI: -0.7% to 4.7%). Administration of E/C/F/TAF resulted 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 33
19 October 2016
in > 90% lower plasma TFV and higher intracellular TFV-DP relative to STB.  E/C/F/TAF 
showed an improved renal and bone safety profile with significantly less decline in hip and spine 
BMD, less increase in serum creatinine and reduction in estimated glomerular filtration rate 
(eGFR).
1.5.
Information about GS-9883/emtricitabine/tenofovir alafenamide 
(GS-9883/F/TAF)
Please refer to the GS-9883/F/TAF Investigator’s Brochure for further information.
1.5.1.
GS-US-141-1233: Relative Bioavailability of GS-9883, FTC, and TAF 
between GS-9883/F/TAF and GS-9883 + F/TAF
Study GS-US-141-1233 is an ongoing Phase 1, open-label, 2-cohort, multiple-period,
fixed-sequence, crossover study conducted at a single center in the US to evaluate 1) the relative 
bioavailability (BA) of 2 GS-9883/F/TAF (75/200/25 mg and 50/200/25 mg) FDC tablets 
compared with the GS-9883 (75 mg) tablet and the F/TAF (200/25 mg) FDC tablet administered 
simultaneously and 2) the effect of food on the PK of GS-9883, FTC, and TAF when 
administered as GS-9883/F/TAF (75/200/25 mg and 50/200/25 mg) FDC tablets. 
Cohort 1 evaluated the relative BA and food effect of GS-9883/F/TAF (75/200/25 mg) FDC 
tablet in a 3-period sequence. Following review of preliminary data from Cohort 1, Cohort 2 was 
added to the study via protocol amendment. Cohort 2 evaluated the relative BA and food effect 
of GS-9883/F/TAF (50/200/25 mg) FDC tablet in a 4-period sequence. 
The in-life portion of Cohorts 1 and 2 are complete. Preliminary results are summarized below.
Cohort 1 Results:

Pharmacokinetic Results

Under fasted conditions, GS-9883 AUCinf and Cmax were 27% and 31% higher, respectively, 
following GS-9883/F/TAF (75/200/25 mg) FDC administration than following 
administration of single-agent GS-9883 (75 mg ) with the F/TAF (200/25 mg) FDC. FTC and 
TAF exposure was similar following administration of GS-9883/F/TAF (75/200/25 mg) or 
single-agent GS-9883 (75 mg) with the F/TAF (200/25 mg) FDC. Compared with 
administration under fasted conditions, administration of the GS-9883/F/TAF 
(75/200/25 mg) FDC with a high-fat meal resulted in a 46% higher GS-9883 AUCinf and a 
27% higher GS-9883 Cmax. The impact of food on TAF and FTC exposure was similar to that 
previously observed for F/TAF (Study GS-US-311-1386). GS-9883/F/TAF may be taken 
without regard to food.  Based on these results, Cohort 2 was added to the study via protocol 
amendment to evaluate the relative BA of the GS-9883/F/TAF (50/200/25 mg) FDC tablet 
compared with the single-agent GS-9883 (75 mg) tablet and the F/TAF (200/25 mg) FDC 
tablet administered simultaneously.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 34
19 October 2016
Safety Results
Of the 28 subjects included in the Safety Analysis Set for Cohort 1, 12 subjects (43%) had at 
least 1 treatment-emergent AE. All treatment emergent AEs were assessed as Grade 1 or 2 in 
severity. No deaths or other SAEs occurred during this study, and no subject discontinued the 
study due to an AE.
Cohort 2 Results:
Pharmacokinetic Results
The PK results from Study GS-US-141-1233 demonstrated that the GS-9883 AUCinf and Cmax
following administration of the 50mg GS-9883 FDC tablets was 79% and 78%, respectively of 
those observed in the same study following co-administration of GS-9883 75 mg single agent 
with F/TAF (200/25 mg) under fasted conditions. The GS-9883 exposures of 50 and 75 mg fixed 
dose combination tablets were approximately dose proportional under fasted and fed conditions 
and a high fat and moderate fat meal had similar impact on GS-9883 with AUCinf increasing by 
24%. The steady state paIQ95 of GS-9883/F/TAF (50/200/25 mg) was predicted to be 
17 (fasted)-23 (fed). The exposures of TAF and FTC of the 50 mg GS-9883 FDC were similar 
to those of GS-9883 75 mg single agent with F/TAF FDC, and the food effect on TAF and FTC 
was similar to the historical results.  
Safety Results
Of the 28 subjects included in the Safety Analysis Set for Cohort 2, 12 subjects (43%) had at 
least 1 treatment-emergent AE. All treatment emergent AEs were assessed as Grade 1 or 2 in 
severity. No deaths or other SAEs occurred during this study, and no subject discontinued the 
study due to an AE. 
1.6.
Information about abacavir/dolutegravir/lamivudine (ABC/DTG/3TC 
Triumeq®)
For more detailed information, refer to the current Prescribing Information and local product 
labeling for abacavir/dolutegravir/lamivudine.
1.7.
Rationale for this Study
HIV standard of care has relied upon nucleos(t)ide backbones for effective and durable virologic 
suppression, but nucleos(t)ide-associated toxicities are increasingly important as HIV-infected 
patients are often diagnosed earlier, initiate therapy earlier, and look toward lifelong therapy 
(often greater than 50 years). Where patients have access to treatment, morbidity and mortality 
are driven by non–AIDS-associated comorbidities, which are observed earlier than in 
HIV-uninfected age-matched controls despite the best available ART. The contribution of 
specific nucleos(t)ides, including abacavir and tenofovir disoproxil fumarate, to long-term 
morbidity and mortality is increasingly important in this context.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 35
19 October 2016
The GS-9883/F/TAF FDC has the potential to offer a simple, once-daily regimen containing a 
second generation INSTI that provides a high barrier to resistance, does not require a boosting 
agent, and offers an effective and safer alternative to standard nucleos(t)ide based regimens, 
without the need for HLA testing or close monitoring of renal or bone toxicities. It could provide 
a FDC treatment that avoids the risk of hypersensitivity reactions, would not contribute to an 
increased risk of cardiovascular events; could be used in patients with chronic hepatitis B or C 
infection or renal impairment, and that could be continued as patients age and confront 
non-HIV-related comorbidities.
The objective of this study is to evaluate the efficacy of switching from a regimen of DTG and 
ABC/3TC or a Fixed dose combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF
versus continuing DTG and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed 
HIV-1 infected subjects as determined by the proportion of subjects with virologic failure 
(HIV-1 RNA ≥ 50 copies/mL) at Week 48. ABC/DTG/3TC was selected as the active 
comparator for this study as it is a second-generation integrase inhibitor-based, once-daily fixed 
dose combination, and is a DHHS Guidelines preferred regimen that includes the 3TC/ABC 
backbone. Use of ABC/DTG/3TC as a comparator in this study will therefore allow comparison
of two single tablet regiments containing second generation, unboosted INSTIs.
1.8.
Risk/Benefit Assessment for the Study
All patients with HIV-1 infection should receive effective antiretroviral therapy. Potential risks 
associated with all classes of ARVs include immune reconstitution syndrome, lipodystrophy, and 
lactic acidosis with steatosis.  The risk of class effects is considered to be low.  Important 
identified risks appropriately managed by study inclusion/exclusion criteria as well as through 
close clinical and laboratory monitoring during the study, are as follows: hypersensitivity 
reaction to abacavir and allergy to any components of the tablets.  Some observational studies 
have shown increased risk of cardiovascular disease with abacavir.  Interim data will also be 
reviewed by an independent data monitoring committee.  Potential benefits may include 
provision of a new antiretroviral therapy that is not currently available and which may have 
fewer side effects than alternative therapies.  Other potential benefits include provisions of fixed 
dose combination therapy, and the knowledge that patient participation will contribute to the 
body of knowledge of HIV therapies.
Following a chronic 39 week study in monkeys, animals administered the highest dose of 
GS-9883 (1000 mg/kg/day) had bile duct hyperplasia (increased cell growth) and hypertrophy 
(increased cell size), and some increased cell growth and inflammation in nearby liver cells. 
These effects were not seen in monkeys administered the mid-level dose (200 mg/kg/day), and 
these animals had plasma GS-9883 exposures that were approximately 5-fold above human 
exposures when given the  GS-9883/F/TAF FDC.   No adverse drug reactions associated with 
liver or bile duct problems has been identified in humans treated with GS-9883. Potential 
hepatobiliary toxicity is appropriately managed by study inclusion/exclusion criteria, close 
clinical and laboratory monitoring, as well as specific toxicity management guidance to 
investigators (Refer to Section 7.5.5).
The overall benefit-risk assessment for GS-9883/F/TAF is favorable at this time. 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 36
19 October 2016
1.9.
Rationale for Dose Selection
FTC
The 200 mg dose of FTC represents the marketed dose for this agent that is currently available as 
single agent capsules (EMTRIVA) and as a component of a number of fixed-dose combination 
tablets, including: TRUVADA, ATRIPLA, COMPLERA (EVIPLERA), and STRIBILD.
TAF
Based upon results of the Phase 1 Study GS-US-120-0104, in which various doses of TAF 
(8 mg, 25 mg, and 40 mg) were administered to HIV-infected subjects in 10 days of 
monotherapy, the range of exposure achieved with TAF 25 mg was chosen as the reference 
exposure. In this study, TAF 25 mg resulted in near-maximal antiviral activity and plasma TFV 
exposure > 90% lower relative to TDF.
The recommended dose of TAF is based on ensuring that patients have a TAF systemic exposure 
that is within the range of the reference exposure achieved with TAF 25 mg, or with TAF 10 mg 
when administered with the boosting agent COBI as E/C/F/TAF, for which an extensive safety 
and efficacy database exists. Specifically, TAF 25 mg is recommended with third agents that do 
not have a clinically relevant effect on TAF exposure. Study GS-US-141-1418 showed that 
GS-9883 does not have a clinically relevant effect on TAF exposure. Therefore, the dose of TAF 
25 mg is appropriate for the GS-9883/F/TAF FDC.
GS-9883
The dose of GS-9883 for Phase 2 was selected based upon data from Study GS-US-141-1219 
(Table 1-5), in which HIV-1-infected subjects were administered 5, 25, 50, or 100 mg doses of 
GS-9883 monotherapy under fasting conditions for 10 days.
Table 1-5.
GS-US-141-1219: Trough GS-9883 Plasma Concentrations at Steady 
State Following GS-9883 Administration Under Fasting Conditions 
and Corresponding Protein-Adjusted IQ95 Values
GS-9883 dose
N
Median (range) Ctau,SS (ng/mL)
Median (range) paIQ95
a
5 mg
4
206.5 (146.0 – 342.0)
1.3 (0.9 – 2.1)
25 mg
4
797.5 (714.0 – 1900.0)
4.9 (4.4 – 12)
50 mg
4
2170.0 (852.0 – 3020.0)
13 (5.3 – 19)
100 mg
4
4190.0 (3730.0 – 5970.0)
26 (23 – 37)
a
The paIQ95 value is estimated based on steady-state Ctau values and the in vitro paIC95 value for wild-type HIV-1 
(162 ng/mL).
Source: Data on File


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 37
19 October 2016
Single-agent GS-9883 was well tolerated at all doses administered. The range of GS-9883 
plasma exposure at steady state (Ctau,SS) observed in the 50-mg cohort correlated with protein 
adjusted 95% inhibitory quotient (paIQ95) values ranging from 5.3 to 19, while the range of 
GS-9883 plasma exposure at steady state (Ctau,SS) observed in the 100-mg cohort correlated with 
paIQ95 values ranging from 23 to 37 (Table 1-5).
Based on PK/PD analyses, exposure following a 75-mg dose of single-agent GS-9883 is 
expected to provide near-maximal virologic response, with a predicted paIQ95 of approximately 
20, providing considerable coverage above the target concentration of 162 ng/mL (paIC95).
GS-9883 (75 mg) single agent coadministered with F/TAF (200/25 mg) is currently being 
evaluated in a Phase 2 study, GS-US-141-1475 (GS-9883+F/TAF vs DTG+F/TAF). The 
Week 24 data from this study support the safety and efficacy of GS-9883 exposures obtained 
with the 75 mg dose of the single agent.
GS-9883/F/TAF FDC Dose Selection
A fixed dose formulation of GS-9883/F/TAF was developed for use in Phase 3 studies. 
Preliminary results from the relative bioavailability (rBA) study (GS-US-141-1233) of 
GS-9883/F/TAF (75/200/25 mg) showed that GS-9883 plasma exposure was higher (with Cmax
and AUCinf increase of 31% and 27%, respectively) following administration of the FDC as 
compared with exposure following administration of GS-9883 (75 mg) + F/TAF (200/25 mg) 
under fasted conditions. The increase in GS-9883 exposures associated with the FDC 
formulation results in an estimated mean paIQ95 of 24.3, compared to an estimated mean paIQ95
of 19.2 for the GS-9883 (75 mg) single agent coadministered with F/TAF, in the fasted state.
In order to bridge exposures of GS-9883 in the FDC to the exposure observed with GS-9883 
75 mg administered as a single agent, and to bridge to the safe and effective exposures observed 
in the Phase 2 study GS-US-141-1475, a lower strength GS-9883/F/TAF FDC was developed for 
use in the Phase 3 studies. Comparability of GS-9883 exposures was confirmed in an rBA study 
of GS-9883/F/TAF (50/200/25 mg) and GS-9883 (75 mg) + F/TAF prior to initiation of dosing 
in the Phase 3 studies.
1.10.
Compliance
This study will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory requirements.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 38
19 October 2016
2.
OBJECTIVES
The primary objective of this study is:

To evaluate the efficacy of switching from a regimen of DTG and ABC/3TC or a fixed dose 
combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF versus continuing DTG 
and ABC/3TC as the FDC ABC/DTG/3TC in virologically suppressed HIV-1 infected 
subjects as determined by the proportion of subjects with HIV-1 RNA ≥50 copies/mL at 
Week 48
The secondary objectives of this study are:

To evaluate the safety, and tolerability of the two treatment groups through Week 48

To evaluate the bone safety of the two treatment groups as determined by the percentage 
change from baseline in hip and spine bone mineral density (BMD) through Week 48


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 39
19 October 2016
3.
STUDY DESIGN
3.1.
Endpoints
The primary efficacy endpoint is:

The proportion of subjects with HIV-1 RNA ≥50 copies/mL at Week 48 as defined by the 
US FDA-defined snapshot algorithm.
The secondary endpoints of this study include:

The proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the 
US FDA-defined snapshot algorithm

The change from baseline in CD4+ cell count at Week 48

The percentage change from baseline in hip and spine BMD at Week 48
3.2.
Study Design
This protocol describes a randomized, double-blind, multicenter, active-controlled study to 
evaluate the safety and efficacy of switching to GS-9883/F/TAF FDC versus continuing 
DTG + ABC/3TC as the FDC ABC/DTG/3TC in HIV-1 infected subjects who are virologically 
suppressed (HIV-1 RNA < 50 copies/mL) on a stable regimen (of DTG + ABC/3TC or the FDC 
ABC/DTG/3TC) for ≥ 3 months prior to screening.
3.3.
Study Treatments
Subjects who provide written informed consent and meet all eligibility criteria will be 
randomized in a 1:1 ratio to one of the following two treatment groups:
Treatment Group 1: FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir alafenamide 
25 mg (GS-9883/F/TAF) + Placebo to match FDC of abacavir 600 mg/ dolutegravir 
50 mg/lamivudine 300 mg (ABC/DTG/3TC) administered orally, once daily, without regard to 
food (n=260)
Treatment Group 2: FDC of abacavir 600 mg/dolutegravir 50 mg/ lamivudine 300 mg 
(ABC/DTG/3TC) QD + Placebo to match FDC of GS-9883 50 mg/ emtricitabine 
200 mg/ tenofovir alafenamide 25 mg (GS-9883/F/TAF) administered orally, once daily, without 
regard to food (n=260)
3.4.
Duration of Treatment
Subjects will be treated for at least 48 weeks during the blinded treatment phase. After Week 48, 
all subjects will continue to take their blinded study drug and attend visits every 12 weeks until 
the End of Blinded Treatment Visit. Once the last subject completes the Week 48 visit and 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 40
19 October 2016
Gilead completes the Week 48 analysis, all subjects will return to the clinic (preferable within 
30 days) for an End of Blinded Treatment Visit. At the End of Blinded Treatment Visit, if safety 
and efficacy of GS-9883/F/TAF is demonstrated following review of unblinded data, subjects in 
a country where GS-9883/F/TAF FDC is not available will be given the option to receive 
GS-9883/F/TAF FDC in an open label extension phase for up to 96 weeks, or until the product 
becomes accessible to subjects through an access program, or until Gilead Sciences elects to 
discontinue the study in that country, whichever occurs first.
All subjects participating in the open label extension phase, without regard to their blinded 
treatment regimen, will return for study visits at Week 12 OL and every 12 weeks thereafter for 
up to 96 weeks.
Subjects who complete the study through the End of Blinded Treatment Visit and do not 
continue on the open-label GS-9883/F/TAF FDC extension phase, will be required to return to 
the clinic 30 days after the End of Blinded Treatment visit for a 30-Day Follow-Up Visit.
Treatment assignments will be provided to the investigators within 30 days of the last subject 
completing the End of Blinded Treatment Visit.
Figure 3-1.
Study Schema
a.
Following the Day 1 visit, subjects will be required to return for study visits at Weeks 4, 8, 12, and then every 12 weeks 
through Week 48.
b.
After Week 48, subjects will continue to take their blinded study drug and attend visits every 12 weeks until the End of 
Blinded Treatment Visit.  
c.
Once the last subject completes the Week 48 visit and Gilead completes the Week 48 analysis, all subjects will return to the 
clinic (preferably within 30 days) for an End of Blinded Treatment Visit. At the End of Blinded Treatment Visit, if safety 
and efficacy of GS-9883/F/TAF is demonstrated following review of unblinded data, subjects in a country where 
GS-9883/F/TAF FDC is not available will be given the option to receive GS-9883/F/TAF FDC in an open-label extension 
for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences 
elects to discontinue the study in that country, whichever occurs first.
d.
Subjects who complete the study through the End of Blinded Treatment Visit and do not continue on the open-label 
GS-9883/F/TAF FDC extension phase will be required to return to the clinic 30 days after the completion of study drugs for 
a 30-Day Follow-Up Visit.


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
3.5. 
Biomarker Testing 
3.5.1. 
Biomarker Samples for Optional Pharmacogenomic Research 
PPD 
3.5.2. 
Additional Sample Storage 
Final 
Amendment2 
For subjects who provide additional consent, residual blood and urine samples taken throughout 
the study will be stored. Stored samples may be used by the Sponsor or its research partners to 
help answer questions about the study dmg, and HIV disease and its associated conditions, or to 
provide additional safety data. At the conclusion of this study, these samples may be retained in 
storage by Gilead Sciences for a period up to 15 years. 
CONFIDENTIAL 
Page41 
19 October 2016 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 42
19 October 2016
4.
SUBJECT POPULATION
4.1.
Number of Subjects and Subject Selection
Approximately 520 subjects who meet the eligibility criteria will be enrolled.
4.2.
Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study.
1) The ability to understand and sign a written informed consent form, which must be obtained 
prior to initiation of study procedures
2) Age 18 years
3) Currently receiving an antiretroviral regimen of DTG + ABC/3TC, or ABC/DTG/3TC FDC
for ≥ 3 months prior to the screening visit
4) HIV RNA < 50 copies/mL at the screening visit
5) Normal ECG (or if abnormal, determined by the Investigator to be not clinically significant)
6) Adequate renal function:
Estimated glomerular filtration rate ≥50 mL/min (≥0.83 mL/sec) according to the 
Cockcroft-Gault formula {Cockcroft et al 1976}:
a) Male:
(140 – age in years) (wt in kg) CLcr (mL/min)
72 (serum creatinine in mg/dL)
        (140 – age in years) (wt in kg)          CLcr (mL/sec)
72 (serum creatinine in umol/L) 0.6786
b) Female:
(140 – age in years) (wt in kg) 0.85 CLcr (mL/min)
72 (serum creatinine in mg/dL)
        (140 – age in years) (wt in kg)           0.85 CLcr (mL/sec)
72 (serum creatinine in umol/L) 0. 6786
7) Hepatic transaminases (AST and ALT) 5 upper limit of normal (ULN)
8) Total bilirubin 1.5 mg/dL (26 umol/L), or normal direct bilirubin
9) Adequate hematologic function (absolute neutrophil count ≥750/mm3 (≥ 0.75 GI/L); 
platelets ≥50,000/mm3 (≥50 GI/L); hemoglobin ≥ 8.5 g/dL (≥85 g/L))
10) Serum amylase ≤ 5 × ULN (subjects with serum amylase > 5 × ULN will remain eligible if 
serum lipase is ≤5 × ULN)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 43
19 October 2016
11) Females of childbearing potential must agree to utilize protocol recommended highly 
effective contraceptive methods or be non-heterosexually active or practice sexual abstinence 
(as defined in Appendix 7) from screening, throughout the duration of the study period, and 
for 30 days following the last dose of study drug.
a) Female subjects who utilize hormonal contraceptive as one of their birth control methods 
must have used the same method for at least 3 months prior to study drug dosing.
12) Male subjects who engage in heterosexual intercourse must agree to use protocol specified 
method(s) of contraception (as described in Appendix 7) throughout the study period and for 
90 days following the last dose of study drug.
13) Male subjects must agree to refrain from sperm donation from first study drug dose until at 
least 90 days following the last study drug dose
14) Life expectancy ≥ 1 year
15) Currently on a stable regimen for ≥ 3 months preceding the screening visit with documented 
plasma HIV-1 RNA < 50 copies/mL for ≥ 3 months preceding the Screening visit (or 
undetectable HIV-1 RNA level according to the local assay being used if the limit of 
detection is ≥50 copies/mL).
Prior changes in antiretroviral regimen are only allowed due to tolerability issues or for 
regimen simplification. Unconfirmed virologic elevations of ≥ 50 copies/mL (transient 
detectable viremia, or “blip”) prior to screening are acceptable. If the lower limit of detection 
of the local HIV-1 RNA assay is <50 copies/mL (eg, <20 copies/mL), the plasma HIV-1 
RNA level cannot exceed 50 copies/mL on two consecutive HIV-1 RNA tests.
16) Have no documented or suspected resistance to FTC, TFV, DTG, ABC or 3TC including, but 
not limited, to the reverse transcriptase resistance mutations K65R and M184V/I
4.3.
Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study.
1) An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to 
screening (refer to Appendix 6)
2) Subjects experiencing decompensated cirrhosis (e.g, ascites, encephalopathy, or variceal 
bleeding)
3) Have been treated with immunosuppressant therapies or chemotherapeutic agents within 
3 months of study screening, or expected to receive these agents or systemic steroids during 
the study (e.g, corticosteroids, immunoglobulins, and other immune- or cytokine-based 
therapies)
4) Current alcohol or substance use judged by the Investigator to potentially interfere with 
subject study compliance


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 44
19 October 2016
5) A history of or ongoing malignancy (including untreated carcinoma in-situ) other than 
cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous 
squamous carcinoma. Subjects with biopsy-confirmed cutaneous KS are eligible, but must 
not have received any systemic therapy for KS within 30 days of Day 1 and are not 
anticipated to require systemic therapy during the study
6) Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or 
antifungal therapy within 30 days prior to Day 1
7) Participation in any other clinical trial, including observational studies,  without prior 
approval from the sponsor is prohibited while participating in this trial
8) Any other clinical condition or prior therapy that, in the opinion of the Investigator, would 
make the subject unsuitable for the study or unable to comply with the dosing requirements
9) Any known allergies to the excipients of GS-9883/F/TAF FDC or ABC/DTG/3TC FDC 
tablets
10) Females who are pregnant (as confirmed by positive serum pregnancy test)
11) Females who are breastfeeding
12) Subjects receiving ongoing therapy with any of the following medications in the table below, 
including drugs not to be used with FTC, TAF, GS-9883, DTG, ABC and 3TC
Drug Class
Agents Disallowed*
Antiarrhythmic Agent
Dofetilide
Anticonvulsants
Phenobarbital, Phenytoin, Carbamazepine, Oxcarbazepine
Antimycobacterials
Rifampin, Rifapentine
Antiretrovirals
Any antiretroviral drug that is not part of the study regimen
GI Motility Agents
Cisapride
Herbal/Natural Supplements
St. John’s Wort, Echinacea
*
Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the
duration of the study.
13) Acute hepatitis in the 30 days prior to study entry
14) Chronic Hepatitis B Virus (HBV) infection, as determined by either: 
a) Positive HBV surface antigen and negative HBV surface antibody, regardless of HBV 
core antibody status, at the screening visit
b) Positive HBV core antibody and negative HBV surface antibody, regardless of HBV 
surface antigen status, at the screening visit
15) Active tuberculosis infection


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 45
19 October 2016
5.
INVESTIGATIONAL MEDICINAL PRODUCTS
5.1.
Randomization, Blinding and Treatment Codes
Subjects will be assigned a screening number at the time of consent. Randomization and Day 1 
visits cannot occur until subject eligibility has been confirmed.
Once eligibility has been confirmed and prior to or during the Day 1, visit the Investigator or 
designee will randomize the subject using the Interactive Web Response System (IWRS). Once a 
subject number has been assigned to a subject, it will not be reassigned to any other subject. The 
subject number assignment and randomization may be performed up to 3 days prior to the 
in-clinic Day 1 visit provided that all screening procedures have been completed and subject 
eligibility has been confirmed.
Subjects will be randomized in a 1:1 ratio to Treatment Group 1 or Treatment Group 2.
The IWRS will assign study drug bottle numbers of blinded FDC of GS-9883/F/TAF + Placebo 
to match FDC of ABC/DTG/3TC, or FDC of ABC/DTG/3TC + Placebo to match FDC of 
GS-9883/F/TAF at each study visit for each subject. 
5.1.1.
Procedures for Breaking Treatment Codes
In the event of a medical emergency where breaking the blind is required to provide medical care 
to the subject, the investigator may obtain treatment assignment directly from the IWRS system 
for that subject. Gilead strongly recommends but does not require that the investigator contact 
the Gilead medical monitor before breaking the blind. Treatment assignment should remain 
blinded unless that knowledge is necessary to determine subject emergency medical care. The 
rationale for unblinding must be clearly explained in source documentation and on the electronic 
case report form (eCRF), along with the date on which the treatment assignment was 
obtained. The investigator is requested to contact the Gilead medical monitor promptly in case of 
any treatment unblinding.
Blinding of study treatment is critical to the integrity of this clinical trial and therefore, if a 
subject’s treatment assignment is disclosed to the investigator, the subject will have study 
treatment discontinued. All subjects will be followed until study completion unless consent to do 
so is specifically withdrawn by the subject.
Gilead Drug Safety and Public Health (DSPH) may independently unblind cases for expedited 
reporting of suspected unexpected serious adverse reactions (SUSARs).


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 46
19 October 2016
5.2.
Description and Handling
5.2.1.
Formulation
5.2.1.1.
GS-9883/Emtricitabine/Tenofovir alafenamide (GS-9883/F/TAF) 
50 mg/200 mg/25 mg and Placebo to Match Tablets
GS-9883 50 mg/Emtricitabine 200 mg/Tenofovir alafenamide 25 mg tablets are capsule-shaped, 
film-coated purplish-brown, debossed with "GSI" on one side of the tablet and "9883" on the 
other side of the tablet. Each tablet core contains 50 mg of GS-9883, 200 mg of emtricitabine, 
and 25 mg of tenofovir alafenamide. In addition to the active ingredients, the GS-9883/F/TAF
tablets contain croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The 
tablet cores are film-coated with iron oxide red, iron oxide black, polyethylene glycol, polyvinyl 
alcohol, talc, and titanium dioxide.
The placebo to match (PTM) GS-9883/F/TAF tablets are capsule-shaped, film-coated 
purplish-brown, debossed with "GSI" on one side of the tablet and "9883" on the other side and 
are identical in physical appearance to GS-9883/F/TAF tablets. The placebo tablets contain 
microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and magnesium stearate. 
The tablet cores are film-coated with iron oxide red, iron oxide black, polyethylene glycol, 
polyvinyl alcohol, talc, and titanium dioxide.
5.2.1.2.
Abacavir/Dolutegravir/Lamivudine (ABC/DTG/3TC Triumeq®) 
600 mg/50 mg/300 mg and Placebo to Match Tablets
Abacavir 600 mg/Dolutegravir 50 mg/Lamivudine 300 mg tablets are oval, film coated purple, 
and debossed with “572 Tri” on one side. Each tablet core contains 600 mg of abacavir, 50 mg of 
dolutegravir, and 300 mg of lamivudine. In addition to the active ingredients, the 
ABC/DTG/3TC tablets contain the inactive ingredients D-mannitol, magnesium stearate, 
microcrystalline cellulose, povidone, and sodium starch glycolate. The tablet cores are film 
coated with iron oxide black, iron oxide red, polyethylene glycol, polyvinyl alcohol, talc, and 
titanium oxide.
The PTM ABC/DTG/3TC tablets are oval, film coated purple, and debossed with “572 Tri” on 
one side. The placebo tablets are identical in physical appearance to ABC/DTG/3TC tablets. The 
placebo tablets contain microcrystalline cellulose, lactose monohydrate, croscarmellose sodium 
and magnesium stearate.  The tablet cores are film-coated with iron oxide black, iron oxide red, 
polyethylene glycol, polyvinyl alcohol, talc, and titanium oxide.
5.2.2.
Packaging and Labeling
5.2.2.1.
GS-9883/Emtricitabine/Tenofovir alafenamide (GS-9883/F/TAF) 
50 mg/200 mg/25 mg and Placebo to Match Tablets
GS-9883/F/TAF tablets and PTM GS-9883/F/TAF tablets are packaged in white, high density 
polyethylene (HDPE) bottles. Each bottle contains 30 tablets, silica gel desiccant and polyester 
packing material.  Each bottle is enclosed with a white, continuous thread, child-resistant 
polypropylene screw cap with an induction-sealed and aluminum-faced liner.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 47
19 October 2016
Study drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the US FDA, EU Guideline to Good Manufacturing 
Practice - Annex 13 (Investigational Medicinal Products), and/or other local regulations
5.2.2.2.
Abacavir/Dolutegravir/Lamivudine (ABC/DTG/3TC Triumeq®) 
600 mg/50 mg/300 mg and Placebo to Match Tablets
ABC/DTG/3TC tablets and PTM ABC/DTG/3TC tablets are packaged in white, high density 
polyethylene (HDPE) bottles. Each bottle contains 30 tablets and silica gel desiccant. Each bottle 
is enclosed with a white, continuous thread, child-resistant polypropylene screw cap with an 
induction-sealed and aluminum-faced liner.
Study drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the US FDA, EU Guideline to Good Manufacturing 
Practice - Annex 13 (Investigational Medicinal Products), and/or other local regulations.
5.2.3.
Storage and Handling
Study drug GS-9883/F/TAF FDC, ABC/DTG/3TC FDC and placebo-to-match tablets for both 
FDCs should be stored at controlled room temperature of 25°C (77°F); excursions are permitted 
between 15°C and 30°C (59°F and 86°F). Storage conditions are specified on the label. Until 
dispensed to the subjects, all bottles of study drugs should be stored in a securely locked area, 
accessible only to authorized site personnel.
To ensure the stability and proper identification, study drug(s) should not be stored in a container 
other than the container in which they were supplied.
Consideration should be given to handling, preparation, and disposal through measures that 
minimize drug contact with the body. Appropriate precautions should be followed to avoid direct 
eye contact or exposure through inhalation when handling.
5.3.
Dosage and Administration of GS-9883/Emtricitabine/Tenofovir alafenamide 
and Abacavir/Dolutegravir/Lamivudine
Study drug GS-9883/F/TAF FDC, ABC/DTG/3TC FDC and placebo-to-match tablets for both 
FDCs will be provided by Gilead Sciences.
Treatment Group 1: FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir alafenamide 
25 mg (GS-9883/F/TAF) + Placebo to match FDC of abacavir 600 mg/ dolutegravir 
50 mg/lamivudine 300 mg (ABC/DTG/3TC) administered orally, once daily, without regard to 
food
Treatment Group 2: FDC of abacavir 600 mg/dolutegravir 50 mg/ lamivudine 300 mg 
(ABC/DTG/3TC) + Placebo to match FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir 
alafenamide 25 mg (GS-9883/F/TAF) administered orally, once daily, without regard to food


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 48
19 October 2016
After the End of Blinded Treatment Visit, all subjects who choose to participate in the open-label 
extension will receive GS-9883/F/TAF FDC once daily for up to 96 weeks.
Subjects will be instructed to bring all study medication in the original container at each clinic 
visit for drug accountability. The Investigator will be responsible for maintaining accurate 
records for all study drug bottles dispensed and tablets returned. The inventory and dispensing 
logs must be available for inspection by the study monitor. Study medication supplies, including 
partially used or empty bottles, must be accounted for by the study monitor prior to destruction 
or return.
5.4.
Prior and Concomitant Medications

The use of medications for the treatment of HIV, other than study drug, is prohibited.

Medications listed in the following table and use of herbal/natural supplements are excluded 
or should be used with caution while subjects are participating in the study.  Subjects will 
refrain from consumption of grapefruit juice and Seville orange juice throughout 
participation in the study.
Table 5-1.
Prior and Concomitant Medications
Drug Class
Agents Disallowed*
Use Discouraged and To Be Used With 
Caution
Acid Reducing Agents
Antacids
Buffered medications 
Concentration of study drug may decrease with 
antacids. Subjects may not take antacids (eg, 
Tums or Rolaids); the ulcer medication 
sucralfate (Carafate); or vitamin or mineral 
supplements that contain calcium, iron or zinc 
for a minimum of 6 hours before and 2 hours 
after any dose of study drug.
Antiarrhythmic Agent
Dofetilide
Anticonvulsants
Phenobarbital, Phenytoin, 
Carbamazepine, Oxcarbazepine
Antimycobacterials
Rifampin, Rifapentine
Antiretrovirals
Any antiretroviral drug that is not 
part of the study regimen
GI Motility Agents
Cisapride
Herbal/Natural Supplements
St. John’s Wort, Echinacea
Oral Hypoglycemic Agent
Metformin: close monitoring is recommended. 
A dose adjustment of Metformin may be 
necessary. Limit total daily doses of Metformin 
to 1000mg when initiating study medication or 
if initiating metformin while on study drug.
*
Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the 
duration of the study. 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 49
19 October 2016
Should subjects have a need to initiate treatment with any excluded concomitant medication, the 
Gilead Sciences Medical Monitor must be consulted prior to initiation of the new medication. In 
instances where an excluded medication is initiated prior to discussion with the Sponsor, the 
Investigator must notify Gilead Sciences as soon as he/she is aware of the use of the excluded 
medication.
5.5.
Accountability for Investigational Medicinal Product (IMP)
The investigator is responsible for ensuring adequate accountability of all used and unused IMP.
This includes acknowledgement of receipt of each shipment of IMP (quantity and condition). All 
used and unused IMP dispensed to subjects must be returned to the site.
Study Drug accountability records will be provided to each study site to:

Record the date received and quantity of IMP kits

Record the date, subject number, subject initials, the IMP kit number dispensed

Record the date, quantity of used and unused IMP returned, along with the initials of the 
person recording the information
5.5.1.
Investigational Medicinal Product Return or Disposal
Study drug return and disposal will be performed as outlined in Section 9.1.7.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 50
19 October 2016
6.
STUDY PROCEDURES
The study procedures to be conducted for each subject enrolled in the study are presented in 
tabular form in Appendix 2, Appendix 3 and described in the text that follows.
The investigator must document any deviation from protocol procedures and notify the sponsor 
or contract research organization (CRO).
6.1.
Subject Enrollment and Treatment Assignment
It is the responsibility of the Investigator to ensure that subjects are eligible for study prior to 
enrollment. Please refer to Section 6.2.2 for details about randomization and treatment 
assignment.
6.2.
Pretreatment Assessments
6.2.1.
Screening Visit
Subjects will be screened within 30-days before Day 1 to determine eligibility for participation in 
the study. The following will be performed and documented at screening:

Obtain written informed consent

Obtain medical history including history of HIV-1 disease-related events, smoking history
and prior medications within 30 days of the screening visit

Complete physical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)

12-lead ECG performed supine

Height

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

Urine collection for the following laboratory procedures:
Urinalysis

Blood sample collection for the following laboratory analyses:
Serum pregnancy test (females of childbearing potential only). If the test is positive, the 
subject will not be enrolled


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 51
19 October 2016
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, 
amylase (reflex lipase testing is performed in subjects with total amylase 1.5 ULN) 
and TSH.
Estimated glomerular filtration rate according to the Cockcroft-Gault formula:
■
Male:
(140 – age in years) (wt in kg) CLcr (mL/min)
72 (serum creatinine in mg/dL)
          (140 – age in years) (wt in kg)        CLcr (mL/sec)
72 (serum creatinine in umol/L) 0.6786
■
Female:
(140 – age in years) (wt in kg) 0.85 CLcr (mL/min)
72 (serum creatinine in mg/dL)
          (140 – age in years) (wt in kg)        0.85 CLcr (mL/sec)
72 (serum creatinine in umol/L) 0. 6786
Hematology profile: complete blood count (CBC) with differential and platelet count
CD4+ cell count
Plasma HIV-1 RNA
Hepatitis B virus surface antigen serology (HBsAg)
Hepatitis B surface antibody (HBsAb)
Hepatitis B virus core antibody (HBcAb)
Hepatitis C virus (HCVAb) serology. Subjects who are HCVAb positive will have a 
HCV RNA test performed.

Review of adverse events and concomitant medications
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within 30-days after screening for Day 1 Visit into the study. Subjects must continue to 
take their prior treatment regimen up until their scheduled Day 1 visit.
From the time of obtaining informed consent through the first administration of investigational 
medicinal product, record all serious adverse events (SAEs), as well as any adverse events 
related to protocol-mandated procedures on the adverse events case report form (eCRF). All 
other untoward medical occurrences observed during the screening period, including 
exacerbation or changes in medical history are to be captured on the medical history eCRF. See 
Section 7 Adverse Events and Toxicity Management for additional details.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 52
19 October 2016
6.2.2.
Day 1 Assessments
The following evaluations are to be completed at the Day 1 Visit. The Investigator must have 
confirmed eligibility before proceeding with the Day 1 visit. The subject must complete all 
study procedures, except DXA, before being administered the study drug:

DXA Scan (spine and hip). For subjects in Germany, DXA scans will not be performed.
The DXA scan will be performed on subjects once eligibility is confirmed. The scan may 
be performed prior to or within 24 hours of the Day 1 Visit.

Review of AEs and changes in concomitant medications

Complete physical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

12-lead ECG performed supine

Short Form 36 Health Survey (SF-36), HIV Symptoms Distress Module, Work Productivity 
and Activity Impairment Questionnaire (WPAI) and Pittsburgh Sleep Quality Index (PSQI) 
to be completed by the subject.  Subject is to read questionnaire by himself/herself and 
write/mark answers directly onto questionnaires.

Urine collection for the following laboratory procedures:
Urinalysis
Urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2
microglobulin
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test. If the test is positive, the subject will not be 
able to participate
Urine storage sample for possible additional clinical testing

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, phosphorus, magnesium, potassium, sodium, uric acid, and amylase 
(reflex lipase testing is performed in subjects with total amylase 1.5 ULN) and TSH


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
Final 
Amendment2 
-
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 homs prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and 
triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the 
subject must retum within 72 homs in a fasted state to draw blood for the metabolic 
assessments. 
-
Estimated glomemlar filtration rate according to the Cockcroft-Gault f01mula 
-
Hematology profile: complete blood cmmt (CBC) with differential and platelet cmmt 
-
Plasma HIV-1 RNA 
-
CD4+ cell count 
-
Evaluations of inflammation and immlme activation, may include but not limited to 
cystatin C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163 
-
Evaluations of platelet function, may include but not limited to soluble glycoprotein VI 
(sGPVI), P-selectin, and soluble CD40 ligand. 
-
Plasma storage sample for safety, virology, or PK testing 
-
Whole blood sample for potential HIV DNA genotyping 
• 
Optional blood sample collection for the following laboratory analyses if 
pharmacogenomics consent is obtained 
I 
I 
I 
I 
6.3. 
Randomization 
Once eligibility has been confmned and prior to or dming the Day 1 visit, the Investigator or 
designee will randomize the subject using the Interactive Web Response System (IWRS). Once a 
subject number has been assigned to a subject, it will not be reassigned to any other subject. The 
subject number assignment and randomization may be perf01med up to 3 days prior to the 
in-clinic Day 1 visit provided that all screening procedmes have been completed and subject 
eligibility has been confi1med. 
CONFIDENTIAL 
Page 53 
19 October 2016 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 54
19 October 2016
6.4.
Treatment Assessments (Week 4 - 48)
The following evaluations are to be completed at the end of Weeks 4, 8, 12, 24, 36, and 48 unless 
otherwise specified.
Study visits are to be completed within ± 2 days of the protocol-specified visit date based on the 
Day 1 visit through Week 12 and completed within ± 6 days of the protocol-specified visit date 
through Week 36, unless otherwise specified.  The visit window at Week 48 will be ± 6 weeks of 
the protocol-specified visit date, and these clinical visit windows coincide with the Week 48 
statistical analysis window for HIV-1 RNA.
Regularly scheduled evaluations will be made on all subjects whether or not they continue to 
receive study drug.

Review of AEs and changes in concomitant medications

DXA scans (spine and hip) for all subjects who are on study drug (Weeks 24 and 48 
±10 days). For subjects in Germany, DXA scans will not be performed.

Complete physical examination (Weeks 24 and 48) (urogenital/anorectal exams will be 
performed at the discretion of the Investigator) or symptom-directed physical examination as 
needed

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

12-lead ECG performed supine (Weeks 24 and 48)

Short Form 36 Health Survey (SF-36), HIV Symptoms Distress Module, Work Productivity 
and Activity Impairment Questionnaire (WPAI) and Pittsburgh Sleep Quality Index (PSQI) 
to be completed by the subject at Weeks 4, 12 and 48. Subject is to read questionnaire by 
himself/herself and write/mark answers directly onto questionnaires.

Urine collection for the following laboratory procedures:
Urinalysis
Urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2
microglobulin. (Weeks 24 and 48)
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test. If the test is positive, the subject will be 
discontinued
Urine storage sample for possible additional clinical testing


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 55
19 October 2016

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium,
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amylase 1.5 ULN). 
At Weeks 12, 24 and 48, analyses of glucose will be done as part of the fasting metabolic 
assessments and not as part of the chemistry profile. At Weeks 24 and 48, TSH will also 
be analyzed.
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and 
triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments. (Weeks 12, 24, and 48)
Estimated glomerular filtration rate according to the Cockcroft-Gault formula
Hematology profile: complete blood count (CBC) with differential and platelet count
Plasma HIV-1 RNA
CD4+ cell count
Evaluations of inflammation and immune activation, may include but not limited to 
cystatin C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163 (Weeks 24 and 48)
Evaluations of platelet function, may include but not limited to soluble glycoprotein VI 
(sGPVI), P-selectin, and soluble CD40 ligand (Weeks 24 and 48)
Hepatitis B virus surface antigen serology (HBsAg). Subjects who have HBVsAg 
positive will have a reflex test for HBV DNA (viral load). (Week 48)
Hepatitis B surface antibody (HBsAb) (Week 48)
Hepatitis B virus core antibody (HBcAb) (Week 48)
Hepatitis C virus (HCVAb) serology. Subjects who are HCVAb positive will have a 
HCV RNA test performed. (Week 48)
Plasma storage sample for safety, virology, or PK testing


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
Final 
Amendment2 
• 
Phrumacokinetic Blood Collection for subjects who ru·e on study dmg. Details of 
phrumacokinetic blood sampling procedures and sample management will be documented in 
the Phrumacokinetic Sample Collection, Processing, Storage, and Shipment Manual. 
I 
-
Single Anytime, Trough and Post Dose PK Sample for all Subjects on Study Drug: 
• 
Subjects will have a single anytime pre or post-dose PK blood sample at Weeks 8, 24 
and 36. 
• 
Observed dosing at the clinic: Subjects will have a trough PK blood sample collected 
between 20-28 hours following their last dose at Weeks 4 and 12. Subjects must be 
instructed to not take their study <hugs on the moming of their visit for the t:I·ough 
sample collection. Subjects will then take an observed dose of study <hug at the 
clinic. A single post dose PK blood sample will be collected between 1 and 4 hours 
post dose. If the subject has taken their dose of study dmgs prior to the visit, the visit 
may proceed, but the subject must retum within 72 hours for the n·ough PK blood 
sample collection. In the event a subject routinely takes their study <hug in the 
evening, a single post dose sample may be <h·awn at Weeks 4 and 12 as the subject 
will not be inst:I11cted to change their dosing time to accommodate this n·ough PK 
<h·aw. 
• 
Dosing diru·ies will be collected from subjects for the single anytime PK and n·ough 
PK collection. If a dosing diruy is not retumed the site may ask the subject for the 
time of the last dose and if it was taken with or without food. 
-
Optional Pharmacokinetic (PK) Substudy: 
CONFIDENTIAL 
Page 56 
19 October 2016 


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
Final 
Amendment2 
IT 
I 
6.5. 
Treatment Assessments (Post Week 48 until the Open-Label Rollover 
Extension) 
6.5.1. 
Post Week 48 Assessments 
After Week 48, all subjects will continue to take their blinded study dmgs and attend visits evety 
12 weeks until the End of Blinded Treatment Visit. Once the last subject completes the Week 48 
visit and Gilead completes the Week 48 analysis, all subjects will retum to the clinic (preferably 
within 30 days) for an End of Blinded Treatment Visit. Study visits are to be completed within 
± 6 days of the protocol-specified visit date lmless othetw ise specified. 
• 
Review of AEs and changes in concomitant medications 
• 
Complete physical examination (Every 48 weeks) (mogenital/anorectal exams will be 
perf01med at the discretion of the Investigator) or symptom-directed physical examination as 
needed 
• 
Vital signs measmement (blood pressme, pulse, respiration rate, and temperatme ), including 
weight 
• 
12-lead ECG perfonned supine (Every 48 weeks) 
• 
Urine collection for the following laborat01y procedmes: 
-
Urinalysis 
-
Urine albumin, mine creatinine, mine protein, retinol binding protein and beta-2 
microglobulin. (Every 24 weeks) 
-
Urine pregnancy test (females of childbearing potential only); positive mine pregnancy 
tests will be confnmed with a sennn test. If the test is positive, the subject will be 
discontinued. 
-
Urine storage sample for possible additional clinical testing 
• 
Blood sample collection for the following laborat01y analyses: 
-
Chemistiy profile: alkaline phosphatase, AST, ALT, GGT, total bilimbin, direct and 
indirect bilimbin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphoms, magnesium, potassium, sodium, mic acid, and 
amylase (reflex lipase testing is perfonned in subjects with total amylase > 1.5 x ULN). 
Evety 24 weeks, analyses of glucose will be done as pati of the fasting metabolic 
assessments and not as pati of the chemistiy profile. In addition, TSH will also be 
analyzed evety 24 weeks. 
CONFIDENTIAL 
Page 57 
19 October 2016 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 58
19 October 2016
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and 
triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments. (Every 24 weeks)
Estimated glomerular filtration rate according to the Cockcroft-Gault formula
Hematology profile: complete blood count (CBC) with differential and platelet count
Plasma HIV-1 RNA
CD4+ cell count
Evaluations of inflammation and immune activation, may include but not limited to 
cystatin C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163 (Every 24 weeks)
Evaluations of platelet function, may include but not limited to soluble glycoprotein VI 
(sGPVI), P-selectin, and soluble CD40 ligand (Every 24 weeks)
Hepatitis B virus surface antigen serology (HBsAg). Subjects who have HBVsAg 
positive will have a reflex test for HBV DNA (viral load). (Every 48 weeks)
Hepatitis B surface antibody (HBsAb) (Every 48 weeks)
Hepatitis B virus core antibody (HBcAb) (Every 48 weeks)
Hepatitis C virus (HCVAb) serology. Subjects who are HCVAb positive will have a 
HCV RNA test performed. (Every 48 weeks)
Plasma storage sample for safety, virology, or PK testing

Document study drug dispensation and accountability for all study drugs dispensed.

Subjects who meet the criteria for virologic failure will be managed according to the 
Management of Virologic Rebound Sections 6.13.1. and 6.13.2
6.5.2.
End of Blinded Treatment Visit
Once the last subject completes the Week 48 visit and Gilead completes the Week 48 analysis, 
all subjects will return to the clinic (preferably within 30 days)) for an End of Blinded Treatment
Visit. At the End of Blinded Treatment Visit, if safety and efficacy of GS-9883/F/TAF is 
demonstrated following review of unblinded data, subjects in a country where GS-9883/F/TAF 
FDC is not available, will be given the option to receive GS-9883/F/TAF FDC in an open-label 
extension phase for up to 96 weeks, or until the product becomes accessible to subjects through 
an access program, or until Gilead Sciences elects to discontinue the study in that country, 
whichever occurs first.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 59
19 October 2016
Subjects who receive the open-label GS-9883/F/TAF FDC will return for study visits every 
12 weeks.
Subjects who choose to not receive the open-label GS-9883/F/TAF FDC will be required to 
return to the clinic for a 30-Day Follow-up visit following the End of Blinded Treatment Visit.
Subjects who have discontinued drug study prior to the End of Blinded Treatment Visit will not 
be eligible for the open-label rollover extension; these subjects will be asked to continue 
attending the scheduled study visits through the End of Blinded Treatment Visit and discontinue 
the study after the End of Blinded Treatment Visit.
Treatment assignments will be provided to the investigators within 30 days of the last subject 
completing the End of Blinded Treatment Visit.
The following will be performed at the End of Blinded Treatment Visit:

Review of AEs and changes in concomitant medications

DXA scans (spine and hip) for all subjects who are on study drug (±10 days) if last scan was 
acquired > 12 weeks from the date of the End of Blinded Treatment Visit. For subjects in 
Germany, DXA scans will not be performed.

Complete physical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

12-lead ECG performed supine

Urine collection for the following laboratory procedures:
Urinalysis
Urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2
microglobulin.
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test. If the test is positive, the subject will not be 
able to participate.
Urine storage sample for possible additional clinical testing

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, phosphorus, magnesium, potassium, sodium, uric acid, and amylase 
(reflex lipase testing is performed in subjects with total amylase 1.5 ULN), and TSH


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 60
19 October 2016
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and 
triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments
Estimated glomerular filtration rate according to the Cockcroft-Gault formula
Hematology profile: complete blood count (CBC) with differential and platelet count
Plasma HIV-1 RNA
CD4+ cell count
Evaluations of inflammation and immune activation, may include but not limited to 
cystatin C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163
Evaluations of platelet function, may include but not limited to soluble glycoprotein VI 
(sGPVI), P-selectin, and soluble CD40 ligand
Plasma storage sample for safety, virology, or PK testing

Document study drug dispensation, if applicable, and accountability for all study drugs 
dispensed

Subjects who wish to continue in the Open-Label Rollover Extension study will receive 
open-label GS-9883/F/TAF FDC.
6.5.3.
Treatment Assessments (Open-Label Rollover Extension)
For purposes of study visit identification during the open-label rollover extension, study visits 
will be identified by the number of weeks that have elapsed between the End of Blinded 
Treatment Visit and the corresponding open-label study visit, and labeled with “OL” (eg. 
Week 12 OL, Week 24 OL, etc.).
All subjects participating in the open-label extension phase, without regard to their blinded 
treatment regimen, will return for study visits at Week 12 OL, and every 12 weeks thereafter for 
up to 96 weeks.
Study visits are to be completed within ± 6 days of the protocol-specified visit date based on the 
End of Blinded Treatment Visit date, unless otherwise specified.
The following will be performed at the Open-Label Extension Visits:

Review of AEs and changes in concomitant medications


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 61
19 October 2016

Complete physical examination (Weeks 48 OL and 96 OL) (urogenital/anorectal exams will 
be performed at the discretion of the Investigator) or symptom-directed physical examination 
as needed

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

12-lead ECG performed supine (Weeks 48 OL and 96 OL)

Urine collection for the following laboratory procedures:
Urinalysis 
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test. If the test is positive, the subject will be 
discontinued.
Urine storage sample for possible additional clinical testing

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amylase 1.5 ULN). 
Every 24 weeks, analyses of glucose will be done as part of the fasting metabolic 
assessments and not as part of the chemistry profile. In addition, TSH will also be 
analyzed every 24 weeks.
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and 
triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments. (Every 24 weeks)
Estimated glomerular filtration rate according to the Cockcroft-Gault formula
Hematology profile: complete blood count (CBC) with differential and platelet count
Plasma HIV-1 RNA
CD4+ cell count
Hepatitis B virus surface antigen serology (HBsAg).  Subjects who have HBVsAg 
positive will have a reflex test for HBV DNA (viral load). (Weeks 48 OL and 96 OL)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 62
19 October 2016
Hepatitis B surface antibody (HBsAb) (Weeks 48 OL and 96 OL)
Hepatitis B virus core antibody (HBcAb) (Weeks 48 OL and 96 OL)
Hepatitis C virus (HCVAb) serology. Subjects who are HCVAb positive will have a 
HCV RNA test performed. (Weeks 48 OL and 96 OL)
Plasma storage sample for safety, virology, or PK testing

Document study drug dispensation and accountability for all study drugs dispensed.

Subjects who meet the criteria for virologic failure will be managed according to the 
Management of Virologic Rebound Sections 6.13.1. and 6.13.2
6.6.
Post-treatment Assessments
6.6.1.
Early Study Drugs Discontinuation Assessments
If the subject discontinues study drug prior to the End of Blinded Treatment Visit, the subject 
will be asked to return to the clinic within 72 hours of stopping study drugs for the Early Study 
Drugs Discontinuation Visit. The subject will be asked to continue attending the scheduled study 
visits through the End of Blinded Treatment Visit.
If the subject discontinues study drug during the Open-Label Rollover Extension, the subject will 
be asked to return to the clinic within 72 hours of stopping the study drug for the Early Study 
Drugs Discontinuation Visit.
At the Early Study Drugs Discontinuation Visit, any evaluations showing abnormal results 
indicating that there is a possible or probable causal relationship with the study drug, will
be repeated weekly (or as often as deemed prudent by the Investigator) until the 
abnormality is resolved, returns to baseline, or is otherwise explained.
The following evaluations are to be completed at the Early Study Drugs Discontinuation Visit:

Review of AEs and changes in concomitant medications

DXA scan required (spine and hip) for all subjects who are on study drug (±10 days) if last 
scan was acquired > 12 weeks from the date of the ESDD Visit (blinded treatment phase 
only). For subjects in Germany, DXA scans will not be performed.

Complete physical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)

12-lead ECG performed supine (blinded treatment phase only)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 63
19 October 2016

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

Urine collection for the following laboratory procedures:
Urinalysis
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test
Urine storage sample for possible additional clinical testing

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amylase 1.5 ULN), 
and TSH
Estimated glomerular filtration rate according to the Cockcroft-Gault formula
Hematology profile: complete blood count (CBC) with differential and platelet count
Plasma HIV-1 RNA
CD4+ cell count
Plasma storage sample for safety, virology, or PK testing
HIV-1 genotype/phenotype testing for subjects with virologic failure

Drug accountability
6.6.2.
30 Day Follow Up
Subjects who complete the study drug through the End of Blinded Treatment visit and who do 
not wish to participate in the open-label rollover extension, will be required to return to the clinic 
30 days after the completion of study drug for the 30 Day Follow Up visit.
Subjects who prematurely discontinue study drug during the blinded phase and refuse to 
continue in the study through the End of Blinded Treatment Visit will be asked to return to the 
clinic 30 days after the completion of the Early Study Drugs Discontinuation Visit for the 
30-Day Follow-Up Visit.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 64
19 October 2016
Those subjects who prematurely discontinue study drug during the blinded phase and 
continue in the study through at least one subsequent visit after the Early Study Drug 
Discontinuation Visit will not be required to complete the 30-Day Follow-Up Visit.
Subjects who prematurely discontinue study drug during the Open-Label Rollover Extension will 
be asked to return to the clinic 30 days after the completion of the Early Study Drugs 
Discontinuation Visit for the 30-day Follow-Up Visit. The subject will not continue attending the 
scheduled study visits.
Subjects who complete the Open-Label Rollover Extension will be asked to return to the clinic 
30 days after the completion of study drugs for the 30-day Follow-Up Visit.
For the purpose of scheduling a 30-Day Follow-Up Visit, a 6 days window may be used. 
The following evaluations are to be completed at the 30-Day Follow-Up Visit:

Review of AEs and changes in concomitant medications

Symptom-directed physical examination

Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including 
weight

Urine collection for the following laboratory procedures:
Urinalysis
Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confirmed with a serum test.

Blood sample collection for the following laboratory analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amylase 1.5 ULN).
Estimated glomerular filtration rate according to the Cockcroft-Gault formula
Hematology profile: complete blood count (CBC) with differential and platelet count
Plasma HIV-1 RNA
CD4+ cell count
At the 30-Day Follow-Up Visit, any evaluations showing abnormal results believed to be a 
reasonable possibility of a causal relationship with the study drugs will be repeated weekly (or as 
often as deemed prudent by the Investigator) until the abnormality is resolved, returns to 
baseline, or is otherwise explained. 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 65
19 October 2016
6.7.
Criteria for Discontinuation of Study Treatment
Study medication will be discontinued in the following instances:

Unacceptable toxicity, or toxicity that, in the judgment of the investigator, compromises the 
ability to continue study-specific procedures or is considered to not be in the subject’s best 
interest

Subject request to discontinue for any reason

Pregnancy during the study; refer to Appendix 7

Development of active tuberculosis infection
Study medication may be discontinued in the following instances:

Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree. Following resolution of intercurrent illness, the subject 
may resume study dosing at the discretion of the investigator

Lack of efficacy

Subject noncompliance

Discontinuation of the study at the request of Gilead, a regulatory agency or an institutional 
review board or independent ethics committee (IRB/IEC)
6.8.
Bone Mineral Density Evaluations
For all subjects who are on study drug, excluding those enrolled in sites based in Germany, dual 
energy x-ray absorptiometry (DXA) scans will be performed prior to or within 24 hours of 
Day 1, Weeks 24, 48, End of Blinded Treatment Visit and the Early Study Drug Discontinuation 
Visit (if the last scan was acquired > 12 weeks from the date of the ESDD Visit) during the 
blinded treatment phase.  Scans will cover the spine and hip to measure changes in bone mineral 
density. DXA scan results will be provided to study sites.
A complete description of the procedures performed for the DXA scans will be provided in a 
DXA manual.
6.9.
Other Evaluations
6.9.1.
Markers of Renal Tubular Function
For all subjects, urine will be collected for selected evaluations of renal tubular function, which 
will include urine albumin, urine creatinine, urine protein, retinol binding protein and beta-2
microglobulin at Day 1 Visit, Weeks 24, 48, every 24 weeks post Week 48, and the End of 
Blinded Treatment Visit. Samples may be stored for a period of 15 years at the end of the


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 66
19 October 2016
study.
6.9.2.
Markers of Inflammation and Immune Activation
For all subjects, blood will be collected at Day 1 Visit, Weeks 24, 48, every 24 weeks post 
Week 48, and the End of Blinded Treatment Visit for selected evaluations of inflammation and 
immune activation, which may include but not limited to cystatin C, IL 6, hs CRP, d-dimer, 
sCD14, and sCD163. Samples may be stored for a period of 15 years at the end of the
study.
6.9.3.
Markers of Platelet Function
For all subjects, blood will be collected at Day 1 Visit, Weeks 24, 48, every 24 weeks post 
Week 48, and the End of Blinded Treatment Visit for selected evaluations of platelet function,
which may include but not limited to soluble glycoprotein VI (sGPVI), P-selectin, and soluble 
CD40 ligand. Samples may be stored for a period of 15 years at the end of the
study.
6.9.4.
Blood and Urine Storage
A portion of the blood and urine samples drawn at all visits (except the Screening Visit, 30-day 
follow-up Visit and Unscheduled Visits) will be frozen and stored. These stored blood and urine 
samples may be used by the Sponsor or its research partners for HIV-1 genotyping/phenotyping 
assays or their development, for retesting the amount of HIV-1 in the blood, for measurement of 
antiviral drug levels in the blood, or for testing to learn more about how the study drug has 
worked against HIV-1 or clinical laboratory testing to provide additional safety data. No human 
genetic testing will be performed without expressed consent of study subjects. At the conclusion 
of this study, these samples may be retained in storage by Gilead Sciences for a period up to 
15 years.
6.10.
Assessments for Premature Discontinuation from Study
If a subject discontinues study dosing (for example, as a result of an AE), every attempt should 
be made to keep the subject in the study and continue to perform the required study-related 
follow-up and procedures (see Section 6.7, Criteria for Discontinuation of Study Treatment). If 
this is not possible or acceptable to the subject or investigator, the subject may be withdrawn 
from the study.
6.11.
End of Study
The end of study will be the last patient’s last observation (or visit).
6.12.
Post Study Care
After a subject has completed/terminated their participation in the study, long-term care for the
subject will remain the responsibility of their primary treating physician.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 67
19 October 2016
6.13.
Virologic Failure
Virologic failure is defined as virologic rebound or having HIV-1 RNA ≥50 copies/mL at study
drug discontinuation, or Week 48.
6.13.1.
Management of Virologic Rebound
Subjects who meet the criteria listed below will be considered to have virologic rebound:

At any post Day 1 visit, a rebound in HIV-1 RNA ≥50 copies/mL, which is subsequently 
confirmed at the following scheduled or unscheduled visit; OR

Any subject with HIV RNA ≥ 50 copies/mL at study drug discontinuation
Following the unconfirmed virologic rebound, subjects will be asked to return to the clinic for a 
scheduled or unscheduled blood draw (2 to 3 weeks after the date of the original test that resulted 
in HIV-1 RNA virologic rebound) for confirmation of virologic rebound. If virologic rebound is 
confirmed at the scheduled or unscheduled visit and the HIV-1 RNA is ≥200 copies/mL, the 
blood sample from the confirmation visit will be the primary sample used for HIV-1 genotypic 
and phenotypic testing.  Subjects with documented non-adherence within 72 hours of the visit 
may not be tested for resistance. After a subject’s first post-baseline resistance test, additional 
testing will be conducted on a case-by-case basis.     Any subject may be discontinued at 
Investigator’s discretion or per local treatment guidelines.
If no resistance is detected from the genotype or phenotype, the subject may remain on study 
drugs and HIV-1 RNA test should be repeated (2 to 3 weeks after date of test with HIV-1 RNA 
≥50 copies/mL). Investigators should carefully evaluate the benefits and risks of remaining on 
study drug for each individual subject and document this assessment in the on-site medical 
record.
Subjects who are noncompliant on an ongoing basis will be considered for discontinuation per 
the Investigator’s discretion or local treatment guidelines. Investigators who opt to discontinue 
study drugs for an individual subject must discuss with the Medical Monitor prior to study drug 
discontinuation.
For subjects who are off study drug but remain on study, it will be the Investigator’s discretion to 
manage virologic rebound.
Please refer to Figure 6-1 for the management of subjects who meet the criteria for virologic 
rebound.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 68
19 October 2016
Figure 6-1.
Virologic Rebound Schema
a.
If virologic rebound is not confirmed, the subject will remain on their current regimen.
b.
If virologic rebound is confirmed and the HIV-1 RNA is ≥200 copies/mL, the HIV-1 genotype and phenotype (reverse 
transcriptase, protease and integrase) will be analyzed.
c.
Based on the results of the genotypic and phenotypic assays, the subject will remain on study drugs or study drugs will be 
discontinued. If genotyping or phenotyping fails, a new ARV regimen may be configured at the discretion of the 
Investigator.
d.
If no resistance is detected, HIV-1 RNA will be repeated (2-3 weeks later).  Investigator reviews study drug 
continuation/discontinuation options and discusses with the Medical Monitor prior to study drug discontinuation
e.
A new ARV regimen will be configured, at the Investigator’s discretion, and the subject will remain in the study.
6.13.2.
Subjects with HIV-1 RNA ≥50 copies/mL at Study Drug Discontinuation, or 
Week 48
Subjects with HIV-1 RNA ≥50 copies/mL at study drug discontinuation or last visit will be 
considered virologic failures. Subjects with HIV-1 RNA ≥50 copies/mL at Week 48 will be 
asked to return for an unscheduled visit within the visit window for a retest. 
Subjects with HIV-1 RNA ≥200 copies/mL at study drug discontinuation, last visit or Week 48, 
will also have resistance testing conducted. 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 69
19 October 2016
7.
ADVERSE EVENTS AND TOXICITY MANAGEMENT
7.1.
Definitions of Adverse Events, Adverse Reactions, and Serious Adverse 
Events
7.1.1.
Adverse Events
An adverse event (AE) is any untoward medical occurrence in a clinical study subject 
administered a medicinal product, which does not necessarily have a causal relationship with the 
treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease 
temporally associated with the use of a medicinal product, whether or not considered related to 
the medicinal product. AEs may also include pre- or post-treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or 
occupational exposure. Preexisting events that increase in severity or change in nature during or 
as a consequence of participation in the clinical study will also be considered AEs.
An AE does not include the following:

Medical or surgical procedures such as surgery, endoscopy, tooth extraction, and transfusion. 
The condition that led to the procedure may be an adverse event and must be reported.

Pre-existing diseases, conditions, or laboratory abnormalities present or detected before the 
screening visit that do not worsen

Situations where an untoward medical occurrence has not occurred (e.g., hospitalization for 
elective surgery, social and/or convenience admissions)

Overdose without clinical sequelae (see Section 7.6.1)

Any medical condition or clinically significant laboratory abnormality with an onset date 
before the consent form is signed and not related to a protocol-associated procedure is not an 
AE. It is considered to be pre-existing and should be documented on the medical history 
eCRF.
7.1.2.
Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at any dose, results in the following:

Death

Life-threatening (Note: The term “life-threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that hypothetically might have caused death if it were more severe.)

In-patient hospitalization or prolongation of existing hospitalization


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 70
19 October 2016

Persistent or significant disability/incapacity

A congenital anomaly/birth defect

A medically important event or reaction: such events may not be immediately 
life-threatening or result in death or hospitalization but may jeopardize the subject or may 
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; and development of drug dependency or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medically important event and subject to expedited reporting 
requirements.
7.1.3.
Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory abnormalities (eg, clinical chemistry, hematology, and urinalysis) that 
require medical or surgical intervention or lead to IMP interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. In addition, 
laboratory or other abnormal assessments (eg, electrocardiogram, x-rays, vital signs) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they meet the 
definition of an AE or SAE as described in Sections 7.1.1 and 7.1.2. If the laboratory 
abnormality is part of a syndrome, record the syndrome or diagnosis (eg, anemia), not the 
laboratory result (ie, decreased hemoglobin).
For specific information on handling of clinical laboratory abnormalities in this study, please 
refer to Section 7.5.
7.2.
Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality and severity, and for final review and confirmation of accuracy of event information 
and assessments.
7.2.1.
Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing the relationship to IMP
therapy using clinical judgment and the following considerations:

No: Evidence exists that the adverse event has an etiology other than the IMP. For SAEs, an 
alternative causality must be provided (eg, pre-existing condition, underlying disease, 
intercurrent illness, or concomitant medication).

Yes: There is reasonable possibility that the event may have been caused by the 
investigational medicinal product.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 71
19 October 2016
It should be emphasized that ineffective treatment should not be considered as causally related in 
the context of adverse event reporting.
The relationship to study procedures (eg, invasive procedures such as venipuncture or biopsy) 
should be assessed using the following considerations:

No: Evidence exists that the adverse event has an etiology other than the study procedure.

Yes: The adverse event occurred as a result of protocol procedures, (eg, venipuncture)
7.2.2.
Assessment of Severity
AE severity should be recorded and graded according to the GSI Grading Scale for Severity of 
Adverse Events and Laboratory Abnormalities (Appendix 5). For adverse events associated with 
laboratory abnormalities, the event should be graded on the basis of the clinical severity in the 
context of the underlying conditions; this may or may not be in agreement with the grading of 
the laboratory abnormality.
The distinction between the seriousness and the severity of an adverse event should be noted. 
Severe is a measure of intensity; thus, a severe reaction is not necessarily a serious reaction. For 
example, a headache may be severe in intensity, but would not be classified as serious unless it 
met one of the criteria for serious events.
For AEs associated with laboratory abnormalities, the event should be graded on the basis of the 
clinical severity in the context of the underlying conditions; this may or may not be in agreement 
with the grading of the laboratory abnormality.
7.3.
Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead
Requirements for collection prior to study drug initiation:
After informed consent, but prior to initiation of study medication, the following types of events 
should be reported on the eCRF:

all SAEs and adverse events related to protocol-mandated procedures.
7.3.1.
Adverse Events
Following initiation of study medication, collect all AEs, regardless of cause or relationship, 
until 30-days after last administration of study IMP must be reported to the eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Sciences may request that certain AEs be followed beyond the protocol defined follow up 
period.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 72
19 October 2016
7.3.2.
Serious Adverse Events
All SAEs, regardless of cause or relationship, that occurs after the subject first consents to 
participate in the study (i.e, signing the informed consent) and throughout the duration of the 
study, including the protocol-required post treatment follow-up period, must be reported to the 
eCRF database and Gilead Drug Safety and Public Health (DSPH) as instructed. This also 
includes any SAEs resulting from protocol-associated procedures performed after informed 
consent is signed.
Any SAEs and deaths that occur after the post treatment follow-up visit but within 30-days of the 
last dose of study IMP, regardless of causality, should also be reported.
Investigators are not obligated to actively seek SAEs after the protocol defined follow up period; 
however, if the investigator learns of any SAEs that occur after study participation has concluded 
and the event is deemed relevant to the use of IMP, he/she should promptly document and report 
the event to Gilead DSPH.
Electronic Serious Adverse Event (eSAE) Reporting Process

Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.

If for any reason it is not possible to record the SAE information electronically, ie, the eCRF 
database is not functioning, record the SAE on the paper serious adverse event reporting 
form and submit within 24 hours to:
Gilead DSPH contact 
information:
Email: Safety_FC@gilead.com
Fax: +1 (650) 522-5477

As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.

If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.

All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline.

Additional information may be requested to ensure the timely completion of accurate safety 
reports.

Any medications necessary for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s eCRF and the event description section of the SAE form


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 73
19 October 2016

For fatal or life-threatening events, copies of hospital case reports, autopsy reports, and other 
documents are also to be submitted by e-mail or fax only when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability of a document to the subject identifiers.
7.4.
Gilead Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country-specific legislation or regulations, Gilead may be required to expedite to 
worldwide regulatory agencies reports of SAEs, serious adverse drug reactions (SADRs), or 
suspected unexpected serious adverse reactions (SUSARs). In accordance with the EU Clinical 
Trials Directive (2001/20/EC), Gilead or a specified designee will notify worldwide regulatory 
agencies and the relevant IEC in concerned Member States of applicable SUSARs as outlined in 
current regulations.
Assessment of expectedness for SAEs will be determined by Gilead using reference safety 
information specified in the investigator’s brochure, EU Summary of Product Characteristics 
(SmPC), or relevant local label as applicable.
All investigators will receive a safety letter notifying them of relevant SUSAR reports associated 
with any study IMP. The investigator should notify the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required by local regulatory agencies, and in accordance with the local 
institutional policy.
7.5.
Toxicity Management
All clinical and clinically significant laboratory toxicities will be managed according to uniform 
guidelines detailed in Appendix 4 as outlined below.

Clinical events and clinically significant laboratory abnormalities will be graded according to 
the GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities 
(Appendix 5)

Grade 3 and 4 clinically significant laboratory abnormalities should be confirmed by repeat 
testing within 3 calendar days of receipt of results and before investigational medicinal 
product discontinuation, unless such a delay is not consistent with good medical practice

Any questions regarding toxicity management should be directed to the Gilead Medical 
Monitor.
7.5.1.
Grades 1 and 2 Laboratory Abnormality or Clinical Event
Continue study drug at the discretion of the Investigator.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 74
19 October 2016
7.5.2.
Grade 3 Laboratory Abnormality or Clinical Event

For Grade 3 clinically significant laboratory abnormality or clinical event, investigational 
medicinal product may be continued if the event is considered to be unrelated to
investigational medicinal product.

For a Grade 3 clinical event, or clinically significant laboratory abnormality confirmed by 
repeat testing, that is considered to be related to investigational medicinal product, 
investigational medicinal product will be withheld until the toxicity returns to Grade 2.
When restarting investigational medicinal product following resolution of the adverse event, 
the investigational medicinal product should be restarted at full dose upon discussion with 
the Gilead Sciences Medical Monitor.

If a laboratory abnormality recurs to Grade 3 following rechallenge with investigational 
medicinal product and is considered related to investigational medicinal product, then 
investigational medicinal product will be permanently discontinued and the subject managed 
according to local practice. Recurrence of laboratory abnormalities considered unrelated to 
investigational medicinal product may not require permanent discontinuation but requires 
discussion with the Gilead Sciences Medical Monitor.
7.5.3.
Grade 4 Laboratory Abnormality or Clinical Event

For a Grade 4 clinical event or clinically significant Grade 4 laboratory abnormality 
confirmed by repeat testing that is considered related to investigational medicinal product, 
investigational medicinal product will be permanently discontinued and the subject managed 
according to local practice. The subject should be followed as clinically indicated until the 
laboratory abnormality returns to baseline or is otherwise explained, whichever occurs first. 
A clinically significant Grade 4 laboratory abnormality that is not confirmed by repeat testing 
should be managed according to the algorithm for the new toxicity grade.

Investigational medicinal product may be continued without dose interruption for a clinically 
non-significant Grade 4 laboratory abnormality (eg, Grade 4 CK after strenuous exercise, or 
triglyceride elevation that is nonfasting or that can be medically managed) or a clinical event 
considered unrelated to investigational medicinal product requires discussion with the 
Gilead Sciences Medical Monitor.
7.5.4.
Management of Possible Abacavir Hypersensitivity Reaction
Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to increased 
risk of hypersensitivity reaction, unless no other therapeutic option is available based on the 
treatment history and resistance testing.
In a clinical study, 3.4 % of subjects with a negative HLA-B*5701 status receiving abacavir 
developed a hypersensitivity reaction. Therefore, even in the absence of HLA-B*5701 allele, it is 
important to permanently discontinue abacavir and not rechallenge with abacavir if a 
hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe 
or even fatal reaction.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 75
19 October 2016
Hypersensitivity reactions are characterized by the appearance of symptoms indicating 
multi-organ system involvement. Almost all hypersensitivity reactions will have fever and/or 
rash as part of the syndrome. Other signs and symptoms may include respiratory signs and 
symptoms such as dyspnoea, sore throat, cough, and abnormal chest x-ray findings 
(predominantly infiltrates, which can be localized), gastrointestinal symptoms, such as nausea, 
vomiting, diarrhea, or abdominal pain, and may lead to misdiagnosis of hypersensitivity as 
respiratory disease (pneumonia, bronchitis, pharyngitis), or gastroenteritis. Other frequently 
observed signs or symptoms of the hypersensitivity reaction may include lethargy or malaise and 
musculoskeletal symptoms (myalgia, rarely myolysis, arthralgia). The symptoms related to this 
hypersensitivity reaction worsen with continued therapy and can be life- threatening. 
These symptoms usually resolve upon discontinuation of abacavir.
Hypersensitivity reaction symptoms usually appear within the first six weeks of initiation of 
treatment with abacavir, although these reactions may occur at any time during therapy. Patients 
should be monitored closely, especially during the first two months of treatment with abacavir.
Regardless of their HLA-B*5701 status, patients who are diagnosed with a hypersensitivity 
reaction whilst on therapy MUST discontinue study drug immediately and MUST NEVER be 
restarted. Restarting study drug following a hypersensitivity reaction results in a prompt return of 
symptoms within hours. This recurrence is usually more severe than on initial presentation, and 
may include life-threatening hypotension and death. To avoid a delay in diagnosis and minimize 
the risk of a life-threatening hypersensitivity reaction, study drug must be permanently 
discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible 
(respiratory diseases, flu-like illness, gastroenteritis or reactions to other medicinal products) 
{Ezzati et al 2003}.
7.5.5.
Management of Potential Hepatobiliary Toxicity
Monkeys given a high dose (1000 mg/kg/day) for 39 weeks had evidence of biliary hyperplasia 
and hepatocyte hypertrophy on histopathologic examination. The risk to humans given the 
clinical dose of GS-9883 (50 mg/day) is unknown. Investigators should be aware of this potential 
toxicity. Any study subject exhibiting signs/symptoms or laboratory abnormalities suggestive of 
possible hepatobiliary toxicity should undergo thorough examination and clinical workup as 
deemed appropriate by the Investigator, and the Investigator must communicate promptly with 
the Gilead Medical Monitor. Consideration should be given to appropriate imaging studies (for 
example, ultrasound of the liver and biliary tree) and potential consultation with a 
gastroenterologist with specialty training in hepatobiliary diseases. Management of graded 
laboratory and clinical abnormalities will be managed as outlined in Section 7.5.
7.5.6.
On-Treatment Hepatitis C Management
If a subject tests positive for HCV RNA at screening or develops signs or symptoms of active 
Hepatitis C virus Gilead recommends that local medical practice is followed at the discretion of 
the Investigator. Investigational medicinal product may be continued without dose 
interruption. Should the Investigator decide to initiate Hepatitis C treatment the Investigator 
must contact the Gilead Medical Monitor to confirm that no drug-drug interactions are expected.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 76
19 October 2016
Subjects should return to the clinic for scheduled or unscheduled follow up visit(s) according to 
local medical practice for laboratory evaluations. If Hepatitis C treatment is initiated, 
Investigators should use the Gilead provided retest laboratory kits to manage the active 
Hepatitis C.
7.6.
Special Situations Reports
7.6.1.
Definitions of Special Situations
Special situation reports include all reports of medication error, abuse, misuse, overdose, reports 
of adverse events associated with product complaints, reports of adverse reactions in infants 
following exposure from breastfeeding, occupational exposure with an adverse event, and 
pregnancy reports regardless of an associated AE.  
Medication error is any unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by a 
subject.
Misuse is defined as any intentional and inappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing information.
An overdose is defined as an accidental or intentional administration of a quantity of a medicinal 
product given per administration or cumulatively which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the daily dose of the subject in 
question). In cases of a discrepancy in drug accountability, overdose will be established only 
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.
7.6.2.
Instructions for Reporting Special Situations
7.6.2.1.
Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study subjects that are identified after 
initiation of study medication and throughout the study, including the post study drug follow-up 
period, to the Gilead DSPH using the pregnancy report form within 24 hours of becoming aware 
of the pregnancy. 
Refer to below and the eCRF completion guidelines for full instructions on the mechanism of 
pregnancy reporting.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 77
19 October 2016
The pregnancy itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy without medical reasons.
Any premature termination of pregnancy (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported within 24 hours as an 
SAE. The underlying medical reason for this procedure should be recorded as the AE term.
A spontaneous abortion is always considered to be an SAE and will be reported as described in 
Section 7.3. Furthermore, any SAE occurring as an adverse pregnancy outcome post study must 
be reported to Gilead DSPH.
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy. The outcome should be reported to Gilead DSPH using the pregnancy outcome report 
form. If the end of the pregnancy occurs after the study has been completed, the outcome should 
be reported directly to Gilead DSPH. Gilead DSPH contact information is as follows:
Email: Safety_FC@gilead.com and Fax: +1 (650) 522-5477.
Pregnancies of female partners of male study subjects exposed to Gilead or other study drugs 
must also be reported and relevant information should be submitted to Gilead DSPH using the 
pregnancy and pregnancy outcome forms within 24 hours. Monitoring of the subject should 
continue until the conclusion of the pregnancy. If the end of the pregnancy occurs after the study 
has been completed, the outcome should be reported directly to Gilead DSPH, fax number 
+1 650 522-5477 or email Safety_FC@gilead.com.
Refer to Appendix 7 for Pregnancy Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
7.6.2.2.
Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to Gilead DSPH within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that involve study IMP and/or Gilead concomitant 
medications, but do not apply to non-Gilead concomitant medications.
Special situations involving non-Gilead concomitant medications does not need to be reported on 
the special situations report form; however, for special situations that result in AEs due to a 
non-Gilead concomitant medication, the AE should be reported on the AE form. 
Any inappropriate use of concomitant medications prohibited by this protocol should not be 
reported as “misuse,” but may be more appropriately documented as a protocol deviation.
Refer to Section 7.3 and the eCRF completion guidelines for full instructions on the mechanism 
of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the symptoms and 
signs, clinical management, and outcome will be reported, when available.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 78
19 October 2016
8.
STATISTICAL CONSIDERATIONS
8.1.
Analysis Objectives and Endpoints
8.1.1.
Analysis Objectives
The primary objective of this study is:

To evaluate the efficacy of switching from a regimen of DTG and ABC/3TC or a FDC of 
ABC/DTG/3TC to a FDC of GS-9883/F/TAF versus continuing DTG and ABC/3TC as the 
FDC ABC/DTG/3TC in virologically suppressed HIV-1 infected subjects as determined by 
the proportion of subjects with HIV-1 RNA ≥50 copies/mL at Week 48
The secondary objectives of this study are:

To evaluate the safety, and tolerability of the two treatment groups through Week 48

To evaluate the bone safety of the two treatment groups as determined by the percentage 
change from baseline in hip and spine BMD through Week 48
8.1.2.
Primary Endpoint
The primary efficacy endpoint is the proportion of subjects with HIV-1 RNA ≥50 copies/mL at 
Week 48 as defined by the US FDA-defined snapshot algorithm.
8.1.3.
Secondary Endpoint
Secondary endpoints include:

The proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the 
US FDA-defined snapshot algorithm

The change from baseline in CD4+ cell count at Week 48

The percentage change from baseline in hip and spine BMD at Week 48
8.2.
Analysis Conventions
8.2.1.
Analysis Sets
8.2.1.1.
All Randomized
The randomized analysis set includes all subjects who are randomized into the study. This is the 
primary analysis set for by-subject listings.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 79
19 October 2016
8.2.1.2.
Efficacy
8.2.1.2.1.
Full Analysis Set (FAS)
The primary analysis set for efficacy analyses is defined as full analysis set (FAS), which will 
include all subjects who (1) are randomized into the study and (2) have received at least 1 dose 
of study drug. Subjects will be grouped according to the treatment to which they were 
randomized.
8.2.1.2.2.
Per-Protocol (PP) Analysis Set
The secondary analysis set for efficacy analyses is defined as per-protocol (PP) analysis set, 
which will include all subjects who (1) are randomized into the study, (2) have received at least 
1 dose of study drug, and (3) have not committed any major protocol violation, including the 
violation of key entry criteria. Subjects will be grouped according to the treatment they actually 
received.
Subjects meeting any of the following criteria will be excluded from the Week 48 PP analysis
set:

Subjects who do not have on-treatment HIV-1 RNA in the Week 48 analysis window, except 
when missing is due to discontinuation of study drug for lack of efficacy.

Subjects who meet the exclusion criterion for receiving ongoing therapy with any of the 
medications listed in the table in protocol Section 4.3 including drugs not to be used with 
GS-9883, FTC, TAF, ABC, 3TC, and DTG.

Nonadherence to study drug: subjects with adherence rate for active study drug up to the 
Week 48 Visit below the 2.5th percentile
8.2.1.3.
Safety
The primary analysis set for safety analyses is defined as safety analysis set, which will include 
all subjects who (1) are randomized into the study and (2) have received at least 1 dose of study 
drug. All the data collected up to 30 days after subjects permanently discontinue their study drug 
will be included in the safety summaries, unless specified otherwise. Subjects will be grouped 
according to the treatment they actually received.
8.2.1.4.
Pharmacokinetics
8.2.1.4.1.
Pharmacokinetic (PK) Substudy Analysis Set
The primary analysis set for intensive PK analyses is defined as the PK substudy analysis set, 
which will include all subjects who (1) are randomized into the study, (2) enrolled into the PK 
Substudy, (3) have received at least 1 dose of GS-9883/F/TAF, and (4) have at least 1 
nonmissing intensive PK concentration data for any analyte of interest reported by the PK lab.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 80
19 October 2016
8.2.1.4.2.
Pharmacokinetic (PK) Analysis Set
The primary analysis set for general PK analyses is defined as the PK analysis set, which will 
include all subjects who (1) are randomized into the study, (2) have received at least 1 dose of 
GS-9883/F/TAF, and (3) have at least 1 nonmissing PK concentration data for any analyte of 
interest reported by the PK lab.
8.2.1.5.
DXA
8.2.1.5.1.
Hip DXA Analysis Set
The primary analysis set for hip BMD analyses is defined as the Hip DXA analysis set, which
will include all subjects who (1) are randomized into the study, (2) have received at least 1 dose 
of study drug, and (3) have nonmissing baseline hip BMD value. Subjects will be grouped 
according to the treatment they actually received.
8.2.1.5.2.
Spine DXA Analysis Set
The primary analysis set for spine BMD analyses is defined as the Spine DXA analysis set, 
which will include all subjects who (1) are randomized into the study, (2) have received at least 
1 dose of study drug, and (3) have nonmissing baseline spine BMD value. Subjects will be 
grouped according to the treatment they actually received.
8.3.
Data Handling Conventions
HIV-1 RNA results of ‘No HIV-1 RNA detected’ and “<20 cp/mL HIV-1 RNA Detected” will 
be imputed as 19 copies/mL for analysis purpose.
Natural logarithmic transformation of plasma concentrations and PK parameters will be applied 
for PK analysis.
Laboratory data that are continuous in nature but are less than the lower limit of quantitation or 
above the upper limit of quantitation will be imputed to the value of the lower or upper limit plus 
or minus one significant digit, respectively (eg, if the result of a continuous laboratory test is 
< 20, a value of 19 will be assigned).
Missing data can have an impact upon the interpretation of the trial data. In general, values for 
missing data will not be imputed. However, a missing pre-treatment laboratory result would be 
treated as normal (ie, no toxicity grade) for the laboratory abnormality summary.
All available data for subjects that do not complete the study will be included in data listings.
8.4.
Demographic Data and Baseline Characteristics
Demographic and baseline characteristics will be summarized using standard descriptive 
methods including sample size, mean, SD, median, Q1, Q3, minimum, and maximum for 
continuous variables and frequency and percentages for categorical variables.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 81
19 October 2016
Demographic data will include sex, race, ethnicity, and age.
Baseline characteristics will include body weight, height, body mass index, eGFR, HIV-1 
infection, and enrollment distribution will be summarized.
For categorical demographic and baseline characteristics, the Cochran–Mantel–Haenszel (CMH)
test will be used to compare treatment groups. For continuous demographic and baseline 
characteristics, the Wilcoxon rank sum test will be used to compare treatment groups.
8.5.
Efficacy Analysis
8.5.1.
Primary Analysis
The primary efficacy endpoint is the proportion of subjects with HIV-1 RNA ≥50 copies/mL at 
Week 48 as defined by the US FDA-defined snapshot algorithm. The primary analysis of the 
efficacy endpoint will be based on the FAS.
8.5.1.1.
US FDA-defined Snapshot Algorithm
The analysis window at Week 48 is defined as from Study Day 295 to Study Day 378, inclusive. 
All HIV-1 RNA data collected on-treatment (ie, including data collected up to 1 day after the last 
dose date of study drug) will be used in the snapshot algorithm. Virologic outcome will be 
defined as the following categories:

HIV-1 RNA < 50 copies/mL: this includes subjects who have the last available on-treatment 
HIV-1 RNA < 50 copies/mL in the Week 48 analysis window 

HIV-1 RNA ≥50 copies/mL: this include subjects
a) Who have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 
analysis window, or
b) Who do not have on-treatment HIV-1 RNA data in the Week 48 analysis window and
1) Who discontinue study drug prior to or in the Week 48 analysis window due to lack 
of efficacy, or
2) Who discontinue study drug prior to or in the Week 48 analysis window due to reason 
other than lack of efficacy and have the last available on-treatment HIV-1 RNA 
≥50 copies/mL


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 82
19 October 2016

No Virologic Data in the Week 48 Analysis Window: this includes subjects who do not 
have on-treatment HIV-1 RNA data in the Week 48 analysis window because of the 
following:
a) Discontinuation of study drug prior to or in the Week 48 analysis window due to reasons
other than lack of efficacy and the last available on-treatment HIV-1 RNA 
< 50 copies/mL, or
b) Missing data during the window but on study drug
8.5.1.2.
Analysis of Primary Efficacy Endpoint
The null hypothesis is that the proportion of subjects with HIV-1 RNA ≥50 copies/mL at 
Week 48 in the GS-9883/F/TAF group is at least 4% higher than that in the ABC/DTG/3TC 
group; the alternative hypothesis is that the proportion of subjects with HIV-1 RNA 
≥50 copies/mL in the GS-9883/F/TAF group is less than 4% higher than that in the 
ABC/DTG/3TC group.
Non-inferiority will be assessed using the conventional confidence interval (CI) approach. The 
point estimate of treatment difference (GS-9883/F/TAF – ABC/DTG/3TC) and the associated 
2-sided 95% CI will be constructed based on the exact method.
It will be concluded that GS-9883/F/TAF is non-inferior to ABC/3TC/DTG if the upper bound of 
the 2-sided 95% CI of the difference between treatment groups 
(GS-9883/F/TAF - ABC/3TC/DTG) in the percentage of subjects with HIV-1 RNA 
≥50 copies/mL is less than 4%.
If non-inferiority of GS-9883/F/TAF to ABC/DTG/3TC is established, the upper bound of the 
95% CI will be compared to 0; if the upper bound of the 95% CI is less than 0, superiority of 
GS-9883/F/TAF over ABC/DTG/3TC will be established.
8.5.2.
Secondary Analyses
The proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the US 
FDA-defined snapshot algorithm will also be evaluated. The 95% CIs will be constructed in the 
same manner as for the primary efficacy endpoint. However, non-inferiority will be assessed 
using a margin of 10%. It will be concluded that GS-9883/F/TAF is non- inferior to 
ABC/DTG/3TC if the lower bound of the 2-sided 95% CI of the difference between treatment 
groups (GS-9883/F/TAF – ABC/DTG/3TC) in the response rate is greater than -10%.
The changes from baseline in CD4+ cell count at Weeks 48 will be summarized by treatment 
using descriptive statistics. The differences in changes from baseline in CD4+ cell count between 
the 2 treatment groups and the associated 95% CIs will be constructed using ANOVA models, 
including treatment (GS-9883/F/TAF vs. ABC/DTG/3TC) as a fixed effect in the model.
In addition, missing CD4+ cell count will be imputed using Last Observation Carried Forward 
(LOCF) method and analyzed similarly.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 83
19 October 2016
8.6.
Safety Analysis
All safety analyses will be performed using the safety analysis set.
All safety data collected on or after the date that the study drug was first administered up to the 
date of the last dose of study drug plus 30 days, unless specified otherwise, will be summarized 
for subjects in the safety analysis set according to the study drug received.
Data for the pretreatment period and the period post the date of last dose of study drug plus 
30 days will be included in data listings for all enrolled subjects.
8.6.1.
Extent of Exposure
A subject’s extent of exposure to study drug will be generated from the study drug
administration page in eCRF. Exposure data will be summarized by treatment.
Duration of exposure to study drug will be expressed as the number of weeks between the first 
and last dose of the study drug, inclusive, regardless of temporary interruptions in study drug
administration and summarized by treatment.
Dosing information for individual subjects will be listed.
8.6.2.
Adverse Events
Clinical and laboratory adverse events will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA). System Organ Class (SOC), High-Level Group Term 
(HLGT), High-Level Term (HLT), Preferred Term (PT), and Lower-Level Term (LLT) will be 
attached to the clinical database.
Events will be summarized on the basis of the date of onset for the event. A treatment-emergent 
adverse event will be defined as any adverse event with onset date on or after the study drug start 
date and no later than 30 days after the study drug stop date; or any adverse event leading to 
study drug discontinuation.
Summaries (number and percentage of subjects) of treatment-emergent adverse events (by SOC, 
HLT [if applicable], and PT) will be provided by treatment. Additional summaries will include 
summaries for adverse events by grade, Investigator’s assessment of relationship to study drug, 
and effect on study drug dosing.
On an ongoing basis adverse events will be reviewed for events that might meet the definition of 
Stage 3 Opportunistic Illnesses in HIV are indicative of an AIDS-Defining Diagnoses. The 
Gilead medical personnel will review the possible Stage 3 events and approve the events that 
meet the definition. Those events that do meet the Stage 3 Opportunistic Illness definition of an 
AIDS-Defining Diagnosis will be listed.
A listing of Stage 3 Opportunistic Illnesses in HIV can be found in Appendix 6.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 84
19 October 2016
8.6.3.
Laboratory Evaluations
Selected laboratory data (using conventional units) will be summarized using only observed data. 
Absolute values and changes from baseline at all scheduled visits will be summarized.
Graded laboratory abnormalities will be defined using the grading scheme defined in Grading of 
laboratory abnormalities attached in Appendix 5.
Incidence of treatment-emergent laboratory abnormalities, defined as values that increase at least 
1 toxicity grade from baseline at any time post baseline up to and including the date of last dose 
of study drug plus 30 days, will be summarized by treatment. If baseline data are missing, then 
any graded abnormality (ie, at least a Grade 1) will be considered treatment emergent. The 
maximum postbaseline toxicity grade will be summarized by laboratory parameter.
Laboratory abnormalities that occur before the first dose of study drug or after the last dose of 
study drug plus 30 days will be included in a data listing.
8.6.4.
Bone Safety Evaluations
The percentage changes from baseline in hip/spine BMD at Weeks 48 will be summarized by 
treatment using descriptive statistics. The differences in percentage changes from baseline in 
hip/spine BMD between 2 treatment groups and the associated 95% confidence intervals will be 
constructed using ANOVA models, including treatment as a fixed effect in the model.
In addition, missing values for BMD will be imputed using LOCF method and analyzed 
similarly.
8.6.5.
Other Safety Evaluations
Vital signs and safety ECG data will be summarized as appropriate.
8.7.
Pharmacokinetic Analysis
For the intensive PK substudy, plasma concentrations of GS-9883 may be summarized by 
nominal sampling time using descriptive statistics. Pharmacokinetic parameters (Cmax, Tmax, Ctau, 
AUCtau, and T½, as appropriate) may be listed and summarized using descriptive statistics (eg, 
sample size, arithmetic mean, geometric mean, coefficient of variation %, SD, median, Q1, Q3, 
minimum, and maximum). Plasma concentrations over time will be plotted in semi-logarithmic 
and linear formats as mean ± standard deviation, and median (Q1, Q3).
For the general PK analyses, the pharmacokinetics of GS-9883 may be evaluated using 
descriptive statistics or population approaches.
TAF and FTC concentrations may be analyzed and PK parameters summarized as applicable.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 85
19 October 2016
8.8.
Inflammation, Immune Activation, Platelet and Renal Tubular Function 
Analysis
For each selected test of inflammation, immune activation, platelet function, and renal tubular 
function, the percentage changes from baseline will be summarized by treatment and visit using 
descriptive statistics. Differences in percentage changes from baseline in each selected test 
between the 2 treatment groups will be tested using a Wilcoxon rank sum test.
8.9.
Patient Reported Outcomes (PRO)
The PRO measures based on questionnaires (eg, SF-36 and HIV Symptoms Distress Module) 
may be summarized by treatment and visit using descriptive statistics.
8.10.
Sample Size
A total of approximately 520 HIV-1 infected subjects, randomized in a 1:1 ratio to 2 treatment
groups (260 subjects per treatment group), achieves at least 90% power to detect a 
non-inferiority margin of 4% difference in the percentage of subjects with HIV-1 RNA 
≥50 copies/mL at Week 48 between the 2 treatment groups. For the sample size and power 
computation, it is assumed that both treatment groups have 2% of subjects with HIV-1 RNA 
≥50 copies/mL at Week 48 (based on the historical Gilead E/C/F/TAF and STB studies), that the
non-inferiority margin is 4%, and that the significance level of the test is at a one-sided 
0.025 level. Sample size and power calculations were made using the statistical software package 
nQuery Advisor (Version 6.0).
8.11.
Data Monitoring Committee
An external Independent Data Monitoring Committee (IDMC) will review the progress, efficacy, 
and safety data of this study while the study is ongoing. The committee will convene after 
approximately the first 50% of subjects enrolled have completed their Week 12 Visit or 
prematurely discontinued from the study drug, as well as after all subjects have completed their 
Week 24 Visit or prematurely discontinued from the study drug. However, Gilead will defer to 
the IDMC for any decision to convene earlier or more frequently. The IDMC will examine the 
safety results of the trial and also focus on logistical issues such as accrual, retention, quality of 
clinical and laboratory data, and implications of results of external studies. Blinding will be 
preserved during the conduct of the study and access to unblinded data will be limited to 
designated parties.
No formal stopping rules will be used by the IDMC for safety outcomes. Rather, a clinical 
assessment will be made to determine if the nature, frequency, and severity of adverse events 
associated with a study regimen warrant the early termination of the study in the best interest of 
the participants.
For each IDMC analysis performed prior to the analysis of the primary efficacy endpoint, an 
alpha penalty of 0.00001 will be applied for the primary analysis of the primary endpoint.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 86
19 October 2016
8.12.
Analysis Schedule
The Week 48 analysis will be conducted after all subjects either complete their Week 48 visit or 
prematurely discontinue from the study drug, respectively. Final analysis will be performed after 
all subjects complete the study or prematurely discontinue from the study.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 87
19 October 2016
9.
RESPONSIBILITIES
9.1.
Investigator Responsibilities
9.1.1.
Good Clinical Practice
The investigator will ensure that this study is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Tokyo, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (ICH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study subject. These standards are consistent with the European Union Clinical 
Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, 
part 50, 1998, and 21 CFR, part 56, 1998.
The investigator and all applicable subinvestigators will comply with 21 CFR, Part 54, 1998, 
providing documentation of their financial interest or arrangements with Gilead, or proprietary 
interests in the investigational drug under study. This documentation must be provided prior to 
the investigator’s (and any subinvestigator’s) participation in the study. The investigator and 
subinvestigator agree to notify Gilead of any change in reportable interests during the study and 
for 1 year following completion of the study. Study completion is defined as the date when the 
last subject completes the protocol-defined activities.
9.1.2.
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and any accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study used to obtain 
informed consent) to an IRB/IEC. The investigator will not begin any study subject activities 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/IEC any modifications made to the protocol or any accompanying material to be 
provided to the subject after initial IRB/IEC approval, with the exception of those necessary to 
reduce immediate risk to study subjects.
9.1.3.
Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study and before undertaking any study-related procedures. The 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 88
19 October 2016
investigator must use the most current IRB- or IEC-approved consent form for documenting 
written informed consent. Each informed consent (or assent as applicable) will be appropriately 
signed and dated by the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, and also by an impartial witness if required by IRB or IEC or
local requirements. The consent form will inform subjects about pharmacogenomic testing and 
sample retention, and their right to receive clinically relevant pharmacogenomic analysis results.
9.1.4.
Confidentiality
The investigator must assure that subjects’ anonymity will be strictly maintained and that their 
identities are protected from unauthorized parties. Only subject initials, date of birth, another 
unique identifier (as allowed by local law) and an identification code will be recorded on any 
form or biological sample submitted to the Sponsor, or laboratory. Laboratory specimens must 
be labeled in such a way as to protect subject identity while allowing the results to be recorded to 
the proper subject. Refer to specific laboratory instructions. NOTE: The investigator must keep a 
screening log showing codes, names, and addresses for all subjects screened and for all subjects 
enrolled in the trial. Subject data will be processed in accordance with all applicable regulations.
The investigator agrees that all information received from Gilead, including but not limited to the 
investigator brochure, this protocol, eCRF, the IMP, and any other study information, remain the 
sole and exclusive property of Gilead during the conduct of the study and thereafter. This 
information is not to be disclosed to any third party (except employees or agents directly 
involved in the conduct of the study or as required by law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure by any employee or agent of the study site to any third party or otherwise into the 
public domain.
9.1.5.
Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified. These documents should 
be classified into at least the following two categories: (1) investigator’s study file, and 
(2) subject clinical source documents.
The investigator’s study file will contain the protocol/amendments, eCRF and query forms, IRB 
or IEC and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:

Subject identification (name, date of birth, gender);

Documentation that subject meets eligibility criteria, ie, history, physical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 89
19 October 2016

Documentation of the reason(s) a consented subject is not enrolled

Participation in study (including study number);

Study discussed and date of informed consent;

Dates of all visits;

Documentation that protocol specific procedures were performed;

Results of efficacy parameters, as required by the protocol;

Start and end date (including dose regimen) of IMP, including dates of dispensing and return;

Record of all adverse events and other safety parameters (start and end date, and including 
causality and severity);

Concomitant medication (including start and end date, dose if relevant; dose changes);

Date of study completion and reason for early discontinuation, if it occurs.
All clinical study documents must be retained by the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (ie, United States, Europe, or Japan) and until there are no pending or planned 
marketing applications in an ICH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory 
authorities have been notified. Investigators may be required to retain documents longer if 
specified by regulatory requirements, by local regulations, or by an agreement with Gilead. The 
investigator must notify Gilead before destroying any clinical study records.
Should the investigator wish to assign the study records to another party or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study site for any or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securely away from the site so that they can be returned sealed to the investigator 
in case of an inspection. When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away from the site.
9.1.6.
Case Report Forms
For each subject consented, an eCRF will be completed by an authorized study staff member 
whose training for this function is documented according to study procedures. eCRF should be 
completed on the day of the subject visit to enable the sponsor to perform central monitoring of 
safety data.  The Eligibility Criteria eCRF should be completed only after all data related to 
eligibility have been received.  Subsequent to data entry, a study monitor will perform source 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 90
19 October 2016
data verification within the EDC system. Original entries as well as any changes to data fields 
will be stored in the audit trail of the system.  Prior to database lock (or any interim time points 
as described in the clinical data management plan), the investigator will use his/her log in 
credentials to confirm that the forms have been reviewed, and that the entries accurately reflect 
the information in the source documents. The eCRF capture the data required per the protocol 
schedule of events and procedures. System-generated or manual queries will be issued to the 
investigative site staff as data discrepancies are identified by the monitor or internal Gilead staff, 
who routinely review the data for completeness, correctness, and consistency. The site 
coordinator is responsible for responding to the queries in a timely manner, within the system, 
either by confirming the data as correct or updating the original entry, and providing the reason 
for the update (e.g. data entry error). At the conclusion of the trial, Gilead will provide the site 
with a read-only archive copy of the data entered by that site. This archive must be stored in 
accordance with the records retention requirements outlined in Section 9.1.5.
9.1.7.
Investigational Medicinal Product Accountability and Return
Gilead recommends that used and unused IMP supplies be returned to the shipping facility from 
which it came for eventual destruction. The study monitor will provide instructions for return. If 
return is not possible, the study monitor will evaluate each study center’s IMP disposal 
procedures and provide appropriate instruction for destruction of unused IMP supplies. If the site 
has an appropriate standard operating procedure (SOP) for drug destruction as determined by 
Gilead QA, the site may destroy used (empty or partially empty) and unused IMP supplies in 
accordance with that site’s approved SOP. A copy of the site’s approved SOP will be obtained 
for central files.
If IMP is destroyed on site, the investigator must maintain accurate records for all IMP
destroyed. Records must show the identification and quantity of each unit destroyed, the method 
of destruction, and the person who disposed of the IMP. Upon study completion, copies of the 
IMP accountability records must be filed at the site. Another copy will be returned to Gilead.
The study monitor will review IMP supplies and associated records at periodic intervals.
9.1.8.
Inspections
The investigator will make available all source documents and other records for this trial to 
Gilead’s appointed study monitors, to IRBs or IECs, or to regulatory authority or health authority 
inspectors.
9.1.9.
Protocol Compliance
The investigator is responsible for ensuring the study is conducted in accordance with the 
procedures and evaluations described in this protocol.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 91
19 October 2016
9.2.
Sponsor Responsibilities
9.2.1.
Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study subjects, may be 
made only by Gilead. The investigator must submit all protocol modifications to the IRB or IEC 
in accordance with local requirements and receive documented IRB or IEC approval before 
modifications can be implemented.
9.2.2.
Study Report and Publications
A clinical study report (CSR) will be prepared and provided to the regulatory agency(ies). Gilead 
will ensure that the report meets the standards set out in the ICH Guideline for Structure and 
Content of Clinical Study Reports (ICH E3). Note that an abbreviated report may be prepared in 
certain cases.
Investigators in this study may communicate, orally present, or publish in scientific journals or 
other scholarly media only after the following conditions have been met:
the results of the study in their entirety have been publicly disclosed by or with the consent of 
Gilead in an abstract, manuscript, or presentation form or the study has been completed at all 
study sites for at least 2 years
The investigator will submit to Gilead any proposed publication or presentation along with the 
respective scientific journal or presentation forum at least 30 days before submission of the 
publication or presentation.
No such communication, presentation, or publication will include Gilead’s confidential 
information (see Section 9.1.4).
The investigator will comply with Gilead’s request to delete references to its confidential 
information (other than the study results) in any paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary.
9.3.
Joint Investigator/Sponsor Responsibilities
9.3.1.
Payment Reporting
Investigators and their study staff may be asked to provide services performed under this 
protocol, e.g. attendance at Investigator's Meetings.  If required under the applicable statutory 
and regulatory requirements, Gilead will capture and disclose to Federal and State agencies any 
expenses paid or reimbursed for such services, including any clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any other transfer of value.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 92
19 October 2016
9.3.2.
Access to Information for Monitoring
In accordance with regulations and guidelines, the study monitor must have direct access to the 
investigator’s source documentation in order to verify the accuracy of the data recorded in the 
eCRF.
The monitor is responsible for routine review of the eCRF at regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency, and accuracy of the 
data being entered on them. The monitor should have access to any subject records needed to 
verify the entries on the eCRF. The investigator agrees to cooperate with the monitor to ensure 
that any problems detected through any type of monitoring (central, on site) are resolved.
9.3.3.
Access to Information for Auditing or Inspections
Representatives of regulatory authorities or of Gilead may conduct inspections or audits of the 
clinical study. If the investigator is notified of an inspection by a regulatory authority the 
investigator agrees to notify the Gilead medical monitor immediately. The investigator agrees to 
provide to representatives of a regulatory agency or Gilead access to records, facilities, and 
personnel for the effective conduct of any inspection or audit.
9.3.4.
Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the study at any time. Should 
this be necessary, both parties will arrange discontinuation procedures and notify the appropriate 
regulatory authority(ies), IRBs, and IECs. In terminating the study, Gilead and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 93
19 October 2016
10.
REFERENCES
Aldir I, Horta A, Serrado M. Single-tablet regimens in HIV: does it really make a difference? 
Curr Med Res Opin 2014;30 (1):89-97.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31-41.
Costagliola D. Demographics of HIV and aging. Curr Opin HIV AIDS 2014;9 (4):294-301.
Department for Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral 
Agents in HIV-1-Infected Adults and Adolescents. Developed by the DHHS 
Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working 
Group of the Office of AIDS Research Advisory Council (OARAC). Downloaded 
from http://aidsinfo.nih.gov/guidelines on 5/11/2015. Last Updated 08 April, 
2015.
Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 
2003;362 (9387):847-52.
Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of 
mortality across Europe in patients infected with HIV-1. Lancet 1998;352 
(9142):1725-30.
Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining 
Morbidity and Mortality Among Patients With Advanced Human 
Immunodeficiency Virus Infection. N Eng J Med 1998;338 (13):853-60.
Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT. Revised 
surveillance case definitions for HIV infection among adults, adolescents, and 
children aged <18 months and for HIV infection and AIDS among children aged 
18 months to <13 years--United States, 2008. MMWR Recomm Rep 2008;57 
(RR-10):1-12.
Sterne J, Hernán M, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-term effectiveness 
of potent antiretroviral therapy in preventing AIDS and death: a prospective 
cohort study. Lancet 2005;366 (9483):378-84.
Sterrantino G, Santoro L, Bartolozzi D, Trotta M, Zaccarelli M. Self-reported adherence supports 
patient preference for the single tablet regimen (STR) in the current cART era. 
Patient preference and adherence 2012;6:427-33.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 94
19 October 2016
The Joint United Nations Programme on HIV/AIDS (UNAIDS). Fact Sheet: 2014 Global 
Statistics. Available at: 
http://www.unaids.org/sites/default/files/media_asset/20150714_FS_MDG6_Rep
ort_en.pdf.  2014.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 95
19 October 2016
11.
APPENDICES
Appendix 1.
Investigator Signature Page
Appendix 2.
Study Procedures Table (Blinded Phase)
Appendix 3.
Study Procedures Table (Open-Label Rollover Extension)
Appendix 4.
Management of Clinical and Laboratory Adverse Events
Appendix 5.
GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 6.
Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines)
Appendix 7.
Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Final 
Gilead Sciences, Inc. 
Amendment 2 
Appendix 1. 
Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT 
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 
Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination 
(FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/T AF in HIV-1 Infected Subjects who are 
Virologically Suppressed 
GS-US-380-1844 Amendment 2, 19 October 2016 
This protocol has been approved by Gilead Sciences, Inc. The following signature documents 
this approval. 
PPD 
Hal Martin, MD, MPH (Printed) 
Date 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. l will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure 
that they are fu lly infonned about the drugs and the study. 
Principal Investigator Name (Printed) 
Signature 
Date 
Site Number 
CONFIDENTlAL 
Page 96 
I 9 October 20 16 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 97
19 October 2016
Appendix 2.
Study Procedures Table (Blinded Phase)
Study Procedures
Screeninga
Day 1b
End of Weeke, p
Post-Week 48e, q
End of Blinded 
Treatment Visit
30-Day 
Follow-upo
Early Study 
Drugs DCc
4
8
12
24
36
48
Every 12 Weeks
Informed Consent
X
Medical History
X
Concomitant Medications
X
X
X
X
X
X
X
X
X
X
X
X
Adverse Events
X
X
X
X
X
X
X
X
X
X
Xf
Xf
Complete/Symptom-Directed 
Physical Exam
X
X
Xd
Xd
Xd
X
Xd
X
Xd
X
Xd,f
Xf
12-Lead ECG (performed supine)
X
X
X
X
X
X
Questionnaires
X
X
X
X
DXA scan (spine & hip)g
X
X
X
X
X
Height
X
Vital signs (blood pressure, pulse, 
respiration rate, and temperature), 
including Weight
X
X
X
X
X
X
X
X
X
X
X
X
Urinalysis
X
X
X
X
X
X
X
X
X
X
Xf
Xf
Urine Pregnancy Testh
X
X
X
X
X
X
X
X
X
X
X
Serum Pregnancy Test
X
Chemistry Profilei
X
X
X
X
X
X
X
X
X
X
Xf
Xf
Metabolic Assessmentsj
X
X
X
X
Xr
X
Estimated Glomerular Filtration 
Rate
X
X
X
X
X
X
X
X
X
X
Xf
X
Hematology Profilek
X
X
X
X
X
X
X
X
X
X
Xf
Xf
Plasma HIV-1 RNA
X
X
X
X
X
X
X
X
X
X
X
X
CD4+ Cell Count 
X
X
X
X
X
X
X
X
X
X
X
X


GS-9883/F/T AF 
Protocol GS-US-380-1844 
Gilead Sciences, Inc. 
Study Procedures 
Evaluations of inflanunation and 
inuntme activation, platelet 
ftmction and renal tubular ftmction 
Plasma & Urine Storage Sample 
Whole Blood sample for potential 
HIV DNA genotyping 
HBV and HCV Serology 
HIV-1 Genotype/Phenotypee 
Single PK Sample1 
Trough PK Samplesm 
OptionalPPD 
.-1 
r 
I 
Randomization1 
Provide subject dosing diaty to 
subjects 
Optional PK Substudyl' 
Study Drug Dispensation 
Study Drug Accotmtability 
Screening• 
Day l b 
X 
X 
X 
X 
X 
X 
X 
xb 
a 
Evaluations to be completed within 30 days prior to Day 1. 
4 
X 
X 
X 
X 
X 
X 
End of Week•·P 
Post-Week 48e,q 
8 
12 
24 
36 
48 
Every 12 Weeks 
X 
X 
X' 
X 
X 
X 
X 
X 
X 
X 
xu 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
End of Blinded 
30-Day 
Treatment Visit 
Follow-up
0 
X 
X 
x• 
X 
Final 
Amendment2 
Early Study 
Drugs DC< 
X 
xe 
X 
b 
Initiation of the ftrst dose of study drug is to take place in-clinic following completion of study procedures at the Day 1 visit, with the exception of DXA. 
c 
Early Study Drugs Discontinuation visit to occtu· within 72 hours of last dose of study drug. Subjects will be asked to continue attending the scheduled study visits tlu·ough the 
End of Blinded Treatment Visit even if the subject discontinues study drug. 
d 
Symptom-directed physical examination as needed. 
e 
HIV-1 genotype and phenotype testing for subjects with virologic failure. Following virologic rebound, subjects will be asked to return to the clinic (2-3 weeks later) prior to 
the next scheduled visit or at the next scheduled study visit, for a HIV -1 RNA and HIV -1 genotype and phenotype (reverse transcriptase, protease, and integrase genotype and 
phenotype) blood draw. Based on the results of this testing, subjects should be managed according to the Virologic Rebotmd Schema (Sections 6.13 .1 and 6.13 .2). 
f 
Any adverse event or test showing abn01malresults that is believed to have a possible or probable causal relationship with the study drug will be repeated weekly (or as often 
as deemed prudent by the Investigator) tmtil the abn01mality is resolved, rettuns to baseline, or is otherwise explained. 
CONFIDENTIAL 
Page 98 
19 October 2016 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 99
19 October 2016
g
DXA scans to be performed in all eligible subjects on study drug, except for those in Germany, prior to or within 24 hours of the Day 1 Visit, Weeks 24, 48 (±10 days), at End 
of Blinded Treatment Visit (±10 days) and the ESDD visit (if the last scan was acquired > 12 weeks from the date of the End of Blinded Treatment Visit or ESDD Visit).
h
Females of childbearing potential only. Positive urine pregnancy tests will be confirmed with a serum test.
i
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid and amylase (reflex lipase testing is performed in subjects with total amylase 
1.5 ULN) At Day 1, Weeks 12, 24, 48 and End of Blinded Treatment Visit, analyses of glucose will be done as part of the fasting metabolic assessments and not as part of 
the chemistry profile. Additionally: TSH will be analyzed at Screening, Day 1, Weeks 24 and 48 followed by every 24 weeks post Week 48, End of Blinded Treatment Visit, 
and Early Study Drugs Discontinuation visit.
j
Fasting (no food or drinks, except water, at least 8 hours prior to blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, triglycerides). If the subject has 
not fasted prior to the visit, the visit may proceed, but the subject must return within 72 hours in a fasted state to draw blood for the metabolic assessments.
k
CBC with differential and platelet count.
l
A single PK blood sample will be collected at any time pre or post-dose 
m
A trough PK blood sample will be collected between 20-28 hours following the last dose. Following an observed dose, a single post dose blood sample will be collected 
between 1 and 4 hours post dose.
n
A PK substudy will be performed in a subset of subjects (n=30) at selected study sites.  The pharmacokinetic substudy visit must occur at the Week 4 or Week 8 visits. The 
substudy will include intensive PK profiling in plasma
o
Only required for those subjects not enrolling in the Open-Label Rollover Extension, those subjects who prematurely discontinue study drugs and do not continue in the study 
through at least one subsequent visit after the Early Study Drugs Discontinuation Visit. For the purpose of scheduling a 30-Day Follow-Up Visit, a 6 days window may be 
used.
p
Study visits are to be completed within ± 2 days of the protocol-specified visit date based on the Day 1 visit through Week 12 and completed within ± 6 days through to 
Week 36, unless otherwise specified. The visit window at Weeks 48 will be ± 6 weeks of the protocol-specified visit date. 
q
After Week 48, all subjects will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Visit window of 6 days 
for study visits post Week 48.
r
To be performed every 24 weeks after Week 48 until End of Blinded Treatment Visit.
s
Open label study drug, GS-9883/F/TAF FDC will be dispensed to subjects participating in the Open-Label Rollover Extension for up to 96 weeks.
t
Randomization may be performed up to 3 days prior to the in-clinic Day 1 visit provided that all screening procedures have been completed and subject eligibility has been 
confirmed.
u
To be performed every 48 weeks.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 100
19 October 2016
Appendix 3.
Study Procedures Table (Open-Label Rollover Extension)
Study Procedures
End of Blinded 
Treatment Visita
End of Weeke, l
30-Day 
Follow-upk
Early Study 
Drugs DCc
12 OL
24 OL
36 OL
48 OL
60 OL
72 OL
84 OL
96 OL
Concomitant Medications
X
X
X
X
X
X
X
X
X
X
X
Adverse Events
X
X
X
X
X
X
X
X
X
Xf
Xf
Complete/Symptom-Directed 
Physical Exam
X
Xd
Xd
Xd
X
Xd
Xd
Xd
X
Xd,f
Xf
12-Lead ECG (performed supine)
X
X
X
DXA scan (spine & hip)m
X
Vital signs (blood pressure, pulse, 
respiration rate, and temperature), 
including Weight
X
X
X
X
X
X
X
X
X
X
X
Urinalysis
X
X
X
X
X
X
X
X
X
Xf
Xf
Urine Pregnancy Testg
X
X
X
X
X
X
X
X
X
X
X
Chemistry Profileh
X
X
X
X
X
X
X
X
X
Xf
Xf
Metabolic Assessmentsi
X
X
X
X
X
Estimated Glomerular Filtration 
Rate
X
X
X
X
X
X
X
X
X
Xf
X
Hematology Profilej
X
X
X
X
X
X
X
X
X
Xf
Xf
Plasma HIV-1 RNA
X
X
X
X
X
X
X
X
X
X
X
CD4+ Cell Count 
X
X
X
X
X
X
X
X
X
X
X
Evaluations of inflammation and 
immune activation, platelet 
function and renal tubular 
function
X
Plasma & Urine Storage Sample 
X
X
X
X
X
X
X
X
X
X
HBV and HCV Serology
X
X
HIV-1 Genotype/Phenotypee
Xe


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 101
19 October 2016
Study Procedures
End of Blinded 
Treatment Visita
End of Weeke, l
30-Day 
Follow-upk
Early Study 
Drugs DCc
12 OL
24 OL
36 OL
48 OL
60 OL
72 OL
84 OL
96 OL
Study Drug Dispensationb
X
X
X
X
X
X
X
X
Study Drug Accountability
X
X
X
X
X
X
X
X
X
X
a.
Once the last subject completes the Week 48 visit and Gilead completes the Week 48 analysis, all subjects will return to the clinic (preferably within 30 days) for an End of 
Blinded Treatment Visit. At the End of Blinded Treatment Visit, if safety and efficacy of GS-9883/F/TAF is demonstrated following review of unblinded data, subjects in a 
country where GS-9883/F/TAF FDC is not available, will be given the option to receive GS-9883/F/TAF FDC in an open-label extension phase for up to 96 weeks, or until 
the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.
Treatment assignments will be provided to the investigators within 30 days of the last subject completing the End of Blinded Treatment Visit.
b.
Open-label study drug, GS-9883/F/TAF FDC will be dispensed to subjects participating in the Open-Label Rollover Extension for up to 96 weeks.
c.
Subjects who discontinue study drug during the open-label rollover extension portion of the study will be asked to return to the clinic within 72 hours of stopping study drugs 
for the Early Study Drugs Discontinuation Visit followed by a 30-Day Follow-Up Visit.  The subject will not continue attending the scheduled study visits.
d.
Symptom-directed physical examination as needed.
e.
HIV-1 genotype and phenotype testing for subjects with virologic failure. Following virologic rebound, subjects will be asked to return to the clinic (2-3 weeks later) prior to 
the next scheduled visit or at the next scheduled study visit, for a HIV-1 RNA and HIV-1 genotype and phenotype (reverse transcriptase, protease, and integrase genotype and 
phenotype) blood draw. Based on the results of this testing, subjects should be managed according to the Virologic Rebound Schema (Sections 6.13.1 and 6.13.2).
f.
Any adverse event or test showing abnormal results that is believed to have a possible or probable causal relationship with the study drug will be repeated weekly (or as often 
as deemed prudent by the Investigator) until the abnormality is resolved, returns to baseline, or is otherwise explained.
g.
Females of childbearing potential only. Positive urine pregnancy tests will be confirmed with a serum test.
h.
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid and amylase (reflex lipase testing is performed in subjects with total amylase 
1.5 ULN). At the End of Blinded Treatment Visit, Week 24 OL and Week 48 OL, analyses of glucose will be done as part of the fasting metabolic assessments and not as 
part of the chemistry profile. For all subjects, TSH will be done at the End of Blinded Treatment Visit, Week 24 OL, Week 48 OL, Week 72 OL, Week 96 OL and Early 
Study Drug Discontinuation Visit.
i.
Fasting (no food or drinks, except water, at least 8 hours prior to blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, triglycerides). If the subject has 
not fasted prior to the visit, the visit may proceed, but the subject must return within 72 hours in a fasted state to draw blood for the metabolic assessments.
j.
CBC with differential and platelet count.
k.
Subjects who complete the Open-Label Rollover Extension will be required to return to the clinic 30 days after the completion of study drugs for the 30-Day Follow-Up Visit. 
Subjects who permanently discontinue study drugs during the Open-Label Rollover Extension will be asked to return to the clinic 30 days after the completion of the Early 
Study Drugs Discontinuation Visit for the 30-Day Follow-Up Visit. For the purpose of scheduling a 30-Day Follow-Up Visit, a ± 6 days window may be used.
l.
Study visits are to be completed within ± 6 days of the protocol-specified visit date based on the End of Blinded Treatment Visit date, unless otherwise specified.
m.
DXA scans to be performed in all eligible subjects on study drug, except for those in Germany, at the End of Blinded Treatment Visit (±10 days) if the last scan was acquired 
> 12 weeks from the date of the End of Blinded Treatment Visit.


GS-9883/Fff AF 
Protocol GS-US-380-1844 
Final 
Gilead Sciences, Inc. 
Amendment 2 
Appendix 4. 
Management of Clinical and Laboratory Adverse Events 
Grade I 
~-----G-r_a_d_e-2----~~ 
~~ ______ G_r_a_de-3------~ 
~~ __________ G_m_d_e_4--------~ 
! 
May continue dosing 
Repeat lab to 
at the discretion of 
confrrm toxicity 
the investigator 
grade 
If confrrmed and possibly and/or probably related to investigational 
medicinal products: 
I. Withhold investigational medicinal products until :5 Grade 2 
2. 
Restart all investigational medicinal products at full dose 
1 
If Grade 3 or 4 recurrence that is confirmed and possibly or probably 
related to investigational medicinal products, discontinue all 
investigational medicinal products dosing permanently 
1 
lfc 
Repeat lab to 
confirm toxicity 
grade 
1 
inve 
onfirmed and unrelated to 
stigational medicinal products, 
ng may continue at the discretion 
he investigator 
dosi 
oft 
If confirmed and 
possibly or probably 
_. related to 
investigational 
medicinal products, 
discontinue 
investigational 
medicinal products 
dosing permanently and 
follow at periodic 
intervals at least weekly 
until a return to 
baseline or is otherwise 
explained 
If Grade 3 or 4 recurrence that is considered unrelated to 
investigational medicinal products, continue all investigational 
medicinal products at the same dose at the discretion of the 
investigator 
CONFIDENTIAL 
Page 102 
19 October 2016 


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 103
19 October 2016
Appendix 5.
GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1
Grade 2
Grade 3
Grade 4
Hemoglobin
HIV POSITIVE
Adult and Pediatric 57 Days
8.5 to 10.0 g/dL 
85 to 100 g/L
7.5 to 8.5 g/dL 
75 to 85 g/L
6.5 to 7.5 g/dL 
65 to 75 g/L
6.5 g/dL
65 g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 
10.0 to 10.9 g/dL
100 to 109 g/L
OR
Any decrease from Baseline
2.5 to 3.5 g/dL
25 to 35 g/L
9.0 to 10.0 g/dL
90 to 100 g/L
OR
Any decrease from Baseline
3.5 to 4.5 g/dL
35 to 45 g/L
7.0 to 9.0 g/dL
70 to 90 g/L
OR
Any decrease from Baseline
4.5 g/dL
45 g/L
7.0 g/dL
70 g/L
Infant, 36–56 Days
(HIV POSITIVE OR
NEGATIVE)
8.5 to 9.4 g/dL
85 to 94 g/L
7.0 to 8.5 g/dL
70 to 85 g/L
6.0 to 7.0 g/dL
60 to < 70 g/L
6.0 g/dL
< 60 g/L
Infant, 22–35 Days
(HIV POSITIVE OR
NEGATIVE)
9.5 to 10.5 g/dL
95 to 105 g/L
8.0 to 9.5 g/dL
80 to 95 g/L
7.0 to 8.0 g/dL
70 to 80 g/L
7.0 g/dL
70 g/L
Infant, 1–21 Days
(HIV POSITIVE OR
NEGATIVE)
12.0 to 13.0 g/dL
120 to 130 g/L
10.0 to 12.0 g/dL
100 to 120 g/L
9.0 to 10.0 g/dL
90 to 100 g/L
9.0 g/dL
90 g/L
Absolute Neutrophil Count 
(ANC)
Adult and Pediatric, 
≥ 7 Months#
1000 to 1300/mm3
750 to 1000/mm3
500 to 750/mm3
500/mm3
1.00 to 1.30 GI/L
0.75 to 1.00 GI/L
0.50 to 0.75 GI/L
0.50 GI/L


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 104
19 October 2016
HEMATOLOGY
Grade 1
Grade 2
Grade 3
Grade 4
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
> 13 Years
300 to 400/mm3
300 to 400/μL
200 to 300/mm3
200 to 300/μL
100 to 200/mm3
100 to 200/μL
100/mm3
100/μL
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13 Years
600 to 650/mm3
0.60 to 0.65 GI/L
500 to 600/mm3
0.50 to 0.60 GI/L
350 to 500/mm3
0.35 to 0.50 GI/L
350/mm3
0.35 GI/L
Platelets 
100,000 to < 125,000/mm3
100 to 125 GI/L
50,000 to 100,000/mm3
50 to 100 GI/L
25,000 to 50,000/mm3
25 to 50 GI/L
25,000/mm3
25 GI/L
WBCs 
2000/mm3 to 2500/mm3
1,500 to 2,000/mm3
1000 to 1,500/mm3
1000/mm3
2.00 GI/L to 2.50 GI/L
1.50 to 2.00 GI/L
1.00 to 1.50 GI/L
1.00 GI/L
Hypofibrinogenemia
100 to 200 mg/dL
75 to 100 mg/dL
50 to 75 mg/dL
50 mg/dL
1.00 to 2.00 g/L
0.75 to 1.00 g/L
0.50 to 0.75 g/L
0.50 g/L
Hyperfibrinogenemia
ULN to 600 mg/dL
600 mg/dL
—
—
ULN  to 6.0 g/L
6.0 g/L
—
—
Fibrin Split Product 
20 to 40 μg/mL
40 to 50 μg/mL
50 to 60 μg/mL
60 μg/mL
20 to 40 mg/L
40 to 50 mg/L
50 to 60 mg/L
60 mg/L
Prothrombin Time (PT)
1.00 to 1.25 ULN
1.25 to 1.50 ULN 
1.50 to 3.00 ULN 
3.00 ULN 
International Normalized Ratio 
of prothrombin time (INR)
1.1 to 1.5 x ULN
>1.5 to 2.0 x ULN
>2.0 to 3.0 x ULN
>3.0 x ULN
Activated Partial
Thromboplastin Time (APTT)
1.00 to 1.66 ULN
1.66 to 2.33 ULN
2.33 to 3.00 ULN
3.00 ULN
Methemoglobin 
5.0 to 10.0%
10.0 to 15.0%
15.0 to 20.0%
20.0%
#
An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects.  Please follow the Gilead convention of grading 
any result within the LLN and ULN a 0.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 105
19 October 2016
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hyponatremia 
130 to <LLN mEq/L
125 to 130 mEq/L
121 to 125 mEq/L
121 mEq/L
130 to <LLN mmol/L
125 to 130 mmol/L
121 to 125 mmol/L
121 mmol/L
Hypernatremia 
>ULN  to 150 mEq/L
150 to 154 mEq/L
154 to 159 mEq/L
159 mEq/L
>ULN  to 150 mmol/L
150 to 154 mmol/L
154 to 159 mmol/L
159 mmol/L
Hypokalemia 
Adult and Pediatric
1 Year
3.0 to  <LLN mEq/L
2.5 to 3.0 mEq/L
2.0 to 2.5 mEq/L
2.0 mEq/L
3.0 to <LLN mmol/L
2.5 to 3.0 mmol/L
2.0 to 2.5 mmol/L
2.0 mmol/L
Infant <1 Year 
3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L
2.5 to 3.0 mEq/L                
2.5 to <3.0 mmolL
2.0 to 2.5 mEq/L                 
2.0 to <2.5 mmolL
2.0 mEq/L                         
<2.0 mmolL
Hyperkalemia 
Adult and Pediatric
1 Year
5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L
6.0 to 6.5 mEq/L
6.0 to 6.5 mmol/L
6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L
7.0 mEq/L
7.0 mmol/L
Infant <1 Year
>ULN to 6.0 mEq/L           
>ULN to 6.0 mmol/L
> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L
6.5 to 7.0 mEq/L             
6.5 to 7.0 mmol/L
7.0 mEq/L                  
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1 Month
55 to 64 mg/dL
3.03 to 3.58 mmol/L
40 to 55 mg/dL
2.20 to 3.03 mmol/L
30 to 40 mg/dL
1.64 to 2.20 mmol/L
30 mg/dL
1.64 mmol/L
Infant, 1 Month
50 to 54 mg/dL
2.8 to 3.0 mmol/L
40 to 50 mg/dL
2.2 to 2.8 mmol/L
30 to 40 mg/dL
1.7 to 2.2 mmol/L
30 mg/dL
1.7 mmol/L


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 106
19 October 2016
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hyperglycemia, Nonfasting 
116 to 160 mg/dL
160 to 250 mg/dL
250 to 500 mg/dL
500 mg/dL
6.42 to 8.91 mmol/L
8.91 to 13.90 mmol/L
13.90 to 27.79 mmol/L
27.79 mmol/L
Hyperglycemia, Fasting
110 to 125 mg/dL
6.08 to 6.96 mmol/L
>125 to 250 mg/dL
>6.96 to 13.90 mmol/L
>250 to 500 mg/dL
>13.90 to 27.79 mmol/L
>500 mg/dL
>27.79 mmol/L
Hypocalcemia 
(corrected for albumin if 
appropriate*)
Adult and Pediatric
2 Years
7.8 <LLN mg/dL
1.94 to <LLN mmol/L
7.0 to 7.8 mg/dL
1.74 to 1.94 mmol/L
6.1 to 7.0 mg/dL
1.51 to 1.74 mmol/L
6.1 mg/dL
1.51 mmol/L
Pediatric ≥7 days -2 Years
7.8 to 8.4 mg/dL                          
1.94 to 2.10 mmol/L
7.0 to <7.8 mg/dL              
1.74 to <1.94 mmolL
6.1 to  <7.0 mg/dL                      
1.51 to < 1.74 mmolL
< 6.1 mg/dL                           
< 1.51 mmol/L
Infant, 7 Days
6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L
6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L
5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 
5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate*)
Adult and Pediatric 
7 Days
>ULN to 11.5 mg/dL
11.5 to 12.5 mg/dL
12.5 to 13.5 mg/dL
13.5 mg/dL
>ULN to 2.88 mmol/L
2.88 to 3.13 mmol/L
3.13 to 3.38 mmol/L
3.38 mmol/L
Infant, 7 Days
11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L
12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L
12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L
13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized)
3.0 mg/dL to LLN
2.5 to < 3.0 mg/dL
2.0 to 2.5 mg/dL
2.0 mg/dL
0.74 mmol/L to LLN
0.62 to 0.74 mmol/L
0.49 to 0.62 mmol/L
0.49 mmol/L


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 107
19 October 2016
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hypercalcemia (ionized)
ULN to 6.0 mg/dL
6.0 to 6.5 mg/dL
6.5 to 7.0 mg/dL
7.0 mg/dL
ULN to 1.50 mmol/L
1.50 to 1.63 mmol/L
1.63 to 1.75 mmol/L
1.75 mmol/L
Hypomagnesemia
1.40 to <LLN mg/dL
1.2 to <LLN mEq/L
1.04 to 1.40 mg/dL
0.9 to   1.2 mEq/L
0.67 to 1.04 mg/dL
0.6 to 0.9 mEq/L
0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmol/L
0.43 to 0.58 mmol/L
0.28 to 0.43 mmol/L
0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14 Years
2.0 to < LLN mg/dL
0.63  to LLN mmol/L
1.5 to 2.0 mg/dL
0.47 to 0.63 mmol/L
1.0 to 1.5 mg/dL
0.31 to 0.47 mmol/L
1.0 mg/dL
0.31 mmol/L
Pediatric 1 Year–14 Years 
3.0 to <LLN mg/dL
0.96 to <LLN mmol/L
2.5 to 3.0 mg/dL
0.80 to < 0.96 mmol/L
1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L
1.5 mg/dL
< 0.47 mmol/L
Pediatric 1 Year
3.5 to <LLN mg/dL
1.12 to <LLN mmol/L
2.5 to 3.5 mg/dL
0.80 to < 1.12 mmol/L
1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L
1.5 mg/dL
< 0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
> 14 Days
1.0 to 1.5 ULN 
1.5 to 2.5 ULN
2.5 to 5.0 ULN 
5.0 ULN 
Infant, 14 Days
(non-hemolytic)
NA
20.0 to 25.0 mg/dL
342 to 428 μmol/L
25.0 to 30.0 mg/dL
> 428 to 513 μmol/L
30.0 mg/dL
> 513 μmol/L
Infant, 14 Days
(hemolytic)
NA
NA
20.0 to 25.0 mg/dL
342 to 428 μmol/L
25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen
1.25 to 2.50 ULN 
2.50 to 5.00 ULN 
5.00 to 10.00 ULN 
10.00 ULN


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 108
19 October 2016
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hyperuricemia
>ULN to 10.0 mg/dL 
10.0 to 12.0 mg/dL 
12.0 to 15.0 mg/dL 
15.0 mg/dL
>ULN to 597 μmol/L
597 to 716 μmol/L
716 to 895 μmol/L
895 μmol/L
Hypouricemia               
Adult and Pediatric           
≥ 1 year   
Infant  < 1 Year
1.5 mg/dL to LLN
87 μmol/L to LLN
1.0 to 1.5 mg/dL
57 to 87 μmol/L
0.5 to 1.0 mg/dL
27 to 57 μmol/L
0.5 mg/dL
27 μmol/L
N/A
1.0 mg/dl to <LLN-
57 μmol to <LLN
0.5 to 1.0 mg/dL
27 to 57 μmol/L
0.5 mg/dL
27 μmol/L
Creatinine** 
1.50 to 2.00 mg/dL
133 to 177 μmol/L
2.00 to 3.00 mg/dL
177 to 265 μmol/L
3.00 to 6.00 mg/dL 
265 to 530 μmol/L
6.00 mg/dL
530 μmol/L
Bicarbonate
Adult and Pediatric 
≥ 4 Years
16.0 mEq/L to LLN 
11.0 to 16.0 mEq/L
8.0 to 11.0 mEq/L
8.0 mEq/L
16.0 mmol/L to LLN
11.0 to 16.0 mmol/L
8.0 to 11.0 mmol/L
8.0 mmol/L
Pediatric < 4 Years
NA
11.0 mEq/Lto <LLN
8.0 to 11.0 mEq/L
8.0 mEq/L
11.0 mmol/L to <LLN
8.0 to 11.0 mmol/L
8.0 mmol/L
Triglycerides
(Fasting)
NA
500 to 750 mg/dL
5.64–8.47 mmol/L
750 to 1200 mg/dL
8.47–13.55 mmol/L
1200 mg/dL
13.55 mmol/L
LDL (Fasting)
Adult
130 to 160 mg/dL
>160 to 190 mg/dL
> 190 mg/dL
NA
3.35 to 4.15 mmol/L
>4.15 to 4.92 mmol/L
>4.92 mmol/L
LDL (Fasting)
Pediatric >2 to <18 years
110 to 130 mg/dL
>130 to 190 mg/dL
> 190 mg/dL
NA
2.84 to 3.37 mmol/L
>3.37 to  4.92 mmol/L
>4.92 mmol/L


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 109
19 October 2016
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hypercholesterolemia
(Fasting)
200 to 239 mg/dL
239 to 300 mg/dL
300 mg/dL
NA
5.16 to 6.19 mmol/L
6.19 to 7.77 mmol/L
7.77 mmol/L
Pediatric 18 Years
170 to 199 mg/dL
4.39 to 5.15 mmol/L
199 to 300 mg/dL
5.15 to 7.77 mmol/L
300 mg/dL
7.77 mmol/L
NA
Creatine Kinase
3.0 to 6.0 ULN
6.0 to 10.0 ULN
10.0 to 20.0 ULN
20.0 ULN
*
Calcium should be corrected for albumin if albumin is < 4.0 g/dL
**
An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may result for Male subjects >70 yrs. Please follow the Gilead convention of grading any 
result within the LLN and ULN a 0.
ENZYMES
Grade 1
Grade 2
Grade 3
Grade 4
AST (SGOT) 
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
ALT (SGPT) 
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
GGT
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
Alkaline Phosphatase 
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
Total Amylase
1.0 to 1.5 ULN
1.5 to 2.0 ULN
2.0 to 5.0 ULN
5.0 ULN
Pancreatic Amylase
1.0 to 1.5 ULN
1.5 to 2.0 ULN
2.0 to 5.0 ULN
5.0 ULN
Lipase 
1.0 to 1.5 ULN
1.5 to 3.0 ULN
3.0 to 5.0 ULN
5.0 ULN
Albumin
Pediatrics <16 years
≥ 16 years
-
2.0 to LLN g/dL
20 to LLN g/L
2.0 g/dL
20 g/L
NA
3.0 g/dL to LLN
30 g/L to LLN
2.0 to 3.0 g/dL
20 to 30 g/L
2.0 g/dL
20 g/L
NA


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 110
19 October 2016
URINALYSIS
Grade 1
Grade 2
Grade 3
Grade 4
Hematuria (Dipstick) 
1
2
3-4+
NA
Hematuria (Quantitative) 
See Note below
                              Females
>ULN - 10 RBC/HPF
10-75 RBC/HPF
> 75 RBC/HPF
NA
                              Males
6-10 RBC/HPF
10-75 RBC/HPF
> 75 RBC/HPF
NA
Proteinuria (Dipstick)
1
2–3
4
NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years
200 to 999 mg/24 h
>999 to 1999 mg/24 h
>1999 to 3500 mg/24 h
3500 mg/24 h
Pediatric 3 Mo to 
< 10 Years
201 to 499 mg/m2/24 h
>499 to 799 mg/m2/24 h
>799 to 1000 mg/m2/24 h
1000 mg/ m2/24 h
Glycosuria (Dipstick)
1+
2-3
4
NA
Notes:

Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratories, toxicity grades will only be assigned to 
Dipstick Hematuria.

With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigned Grade 0.

If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for 
the AE.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 111
19 October 2016
CARDIOVASCULAR
Grade 1
Grade 2
Grade 3
Grade 4
Cardiac Arrhythmia (general)
(By ECG or physical exam)
Asymptomatic AND No 
intervention indicated
Asymptomatic AND Non-
urgent medical intervention 
indicated
Symptomatic, non-life-
threatening AND Non-
urgent medical intervention 
indicated 
Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac-ischemia/Infarction
NA
NA
Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia 
Unstable angina OR Acute 
myocardial infarction
Hemorrhage (significant acute 
blood loss)
NA
Symptomatic AND No 
transfusion indicated
Symptomatic AND 
Transfusion of 2 units 
packed RBCs (for children 
10 cc/kg) indicated 
Life-threatening hypotension 
OR Transfusion of 2 units 
packed RBCs indicated (for 
children 10 cc/kg) indicated
Hypertension (with repeat 
testing at same visit)
140–159 mmHg systolic 
OR 
90–99 mmHg diastolic
159–179 mmHg systolic 
OR 
99–109 mmHg diastolic
179 mmHg systolic 
OR 
109 mmHg diastolic
Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization (other than 
ER visit) indicated
Pediatric 17 Years (with 
repeat testing at same visit)
NA
91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)
≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)
Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization indicated 
(other than emergency room 
visit)
Hypotension
NA
Symptomatic, corrected with 
oral fluid replacement
Symptomatic, IV fluids 
indicated
Shock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion
Asymptomatic, small 
effusion requiring no 
intervention
Asymptomatic, moderate or 
larger effusion requiring no 
intervention
Effusion with non-life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicated
Life-threatening consequences 
(eg, tamponade) OR Urgent 
intervention indicated


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 112
19 October 2016
CARDIOVASCULAR
Grade 1
Grade 2
Grade 3
Grade 4
Prolonged PR Interval
PR interval 
0.21 to 0.25 sec
PR interval
0.25 sec
Type II 2nd degree AV 
block OR Ventricular pause 
3.0 sec
Complete AV block 
Pediatric 16 Years
1st degree AV block
(PR > normal for age and 
rate)
Type I 2nd degree AV block 
Type II 2nd degree AV 
block 
Complete AV block
Prolonged QTc
Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baseline
Asymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baseline
Asymptomatic, QTc interval 
0.50 sec OR Increase in 
interval 0.06 sec above 
baseline
Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16 Years
Asymptomatic, QTc interval 
0.450 to 0.464 sec 
Asymptomatic, QTc interval 
0.465 to 0.479 sec 
Asymptomatic, QTc interval 
0.480 sec 
Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism
NA
Deep vein thrombosis AND 
No intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) 
Deep vein thrombosis AND 
Intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) 
Embolic event (eg, pulmonary 
embolism, life-threatening 
thrombus) 
Vasovagal Episode (associated
with a procedure of any kind)
Present without loss of 
consciousness 
Present with transient loss of 
consciousness
NA 
NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)
NA
Asymptomatic diagnostic 
finding AND intervention 
indicated
New onset with symptoms 
OR Worsening symptomatic 
CHF
Life-threatening CHF


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 113
19 October 2016
RESPIRATORY
Grade 1
Grade 2
Grade 3
Grade 4
Bronchospasm (acute)
FEV1 or peak flow reduced to 
70% to 80%
FEV1 or peak flow 50% to 69%
FEV1 or peak flow 25% to 
49% 
Cyanosis OR FEV1 or peak flow 
25% OR Intubation
Dyspnea or Respiratory 
Distress
Dyspnea on exertion with no 
or minimal interference with 
usual social & functional 
activities 
Dyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activities 
Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
Respiratory failure with 
ventilatory support indicated
Pediatric 14 Years
Wheezing OR minimal 
increase in respiratory rate for 
age
Nasal flaring OR Intercostal 
retractions OR Pulse oximetry 
90% to 95%
Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%
Respiratory failure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1
Grade 2
Grade 3
Grade 4
Uveitis
Asymptomatic but detectable 
on exam
Symptomatic anterior uveitis OR 
Medical intervention indicated
Posterior or pan-uveitis OR 
Operative intervention 
indicated
Disabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)
Visual changes causing no or 
minimal interference with 
usual social & functional 
activities
Visual changes causing greater 
than minimal interference with 
usual social & functional 
activities
Visual changes causing 
inability to perform usual 
social & functional activities
Disabling visual loss in affected 
eye(s)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 114
19 October 2016
SKIN
Grade 1
Grade 2
Grade 3
Grade 4
Alopecia
Thinning detectable by 
study participant or  
caregiver (for disabled 
adults)
Thinning or patchy hair loss 
detectable by health care 
provider
Complete hair loss
NA
Cutaneous Reaction – Rash
Localized macular rash 
Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions 
Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one site
Extensive or generalized 
bullous lesions OR 
Stevens-Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epidermal 
necrolysis (TEN)
Hyperpigmentation
Slight or localized
Marked or generalized
NA
NA
Hypopigmentation
Slight or localized 
Marked or generalized
NA
NA
Pruritis (itching – no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)
Itching causing no or 
minimal interference with 
usual social & functional 
activities
Itching causing greater than 
minimal interference with 
usual social & functional 
activities
Itching causing inability to 
perform usual social & 
functional activities 
NA


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 115
19 October 2016
GASTROINTESTINAL
Grade 1
Grade 2
Grade 3
Grade 4
Anorexia
Loss of appetite without 
decreased oral intake
Loss of appetite associated with 
decreased oral intake without 
significant weight loss 
Loss of appetite associated 
with significant weight loss 
Life-threatening consequences 
OR Aggressive intervention 
indicated [eg, tube feeding or 
total parenteral nutrition]
Ascites
Asymptomatic
Symptomatic AND Intervention
indicated (eg, diuretics or 
therapeutic paracentesis)
Symptomatic despite 
intervention
Life-threatening consequences
Cholecystitis
NA
Symptomatic AND Medical 
intervention indicated
Radiologic, endoscopic, or 
operative intervention 
indicated
Life-threatening consequences 
(eg, sepsis or perforation) 
Constipation 
NA
Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemas 
Obstipation with manual 
evacuation indicated
Life-threatening consequences 
(eg, obstruction)
Diarrhea 
Adult and Pediatric 
1 Year
Transient or intermittent 
episodes of unformed stools 
OR Increase of 3 stools 
over baseline/24 hr
Persistent episodes of unformed 
to watery stools OR Increase of 
4–6 stools over baseline per 
24 hrs. 
Bloody diarrhea OR Increase 
of 7 stools per 24-hour 
period OR IV fluid 
replacement indicated
Life-threatening consequences 
(eg, hypotensive shock)
Pediatric 1 Year
Liquid stools (more 
unformed than usual) but 
usual number of stools
Liquid stools with increased 
number of stools OR Mild 
dehydration
Liquid stools with moderate 
dehydration
Liquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicated OR Hypotensive 
shock
Dysphagia-Odynophagia 
Symptomatic but able to eat 
usual diet
Symptoms causing altered 
dietary intake without medical 
intervention indicated
Symptoms causing severely 
altered dietary intake with 
medical intervention indicated
Life-threatening reduction in 
oral intake


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 116
19 October 2016
GASTROINTESTINAL
Grade 1
Grade 2
Grade 3
Grade 4
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, 
Dysphagia-Odynophagia
Erythema of the mucosa
Patchy pseudomembranes or 
ulcerations 
Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor trauma
Tissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life-threatening 
consequences (eg, aspiration, 
choking)
Nausea 
Transient (24 hours) or 
intermittent nausea with no 
or minimal interference with 
oral intake
Persistent nausea resulting in 
decreased oral intake for 24–48 
hours
Persistent nausea resulting in 
minimal oral intake for 48 
hours OR Aggressive 
rehydration indicated (eg, 
IV fluids)
Life-threatening consequences 
(eg, hypotensive shock)
Pancreatitis
NA
Symptomatic AND 
Hospitalization not indicated 
(other than ER visit)
Symptomatic AND 
Hospitalization indicated 
(other than ER visit)
Life-threatening consequences 
(eg, sepsis, circulatory failure, 
hemorrhage)
Proctitis (functional-
symptomatic)
Also see Mucositis/ 
Stomatitis for Clinical 
Exam
Rectal discomfort AND No 
intervention indicated
Symptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated 
Symptoms causing inability to 
perform usual social/
functional activities OR 
Operative intervention 
indicated 
Life-threatening consequences 
(eg, perforation)
Vomiting
Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intake
Frequent episodes of vomiting 
with no or mild dehydration
Persistent vomiting resulting 
in orthostatic hypotension OR 
Aggressive rehydration 
indicated
Life-threatening consequences 
(eg, hypotensive shock)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 117
19 October 2016
NEUROLOGICAL
Grade 1
Grade 2
Grade 3
Grade 4
Alteration in Personality-
Behavior or in Mood (eg, 
agitation, anxiety, 
depression, mania, 
psychosis)
Alteration causing no or 
minimal interference with 
usual social & functional 
activities 
Alteration causing greater than 
minimal interference with 
usual social & functional 
activities 
Alteration causing inability to 
perform usual social & 
functional activities 
Behavior potentially harmful 
to self or others (eg, 
suicidal/homicidal ideation or 
attempt, acute psychosis) OR 
Causing inability to perform 
basic self-care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)
Changes causing no or 
minimal interference with 
usual social & functional 
activities
Mild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activities
Confusion, memory 
impairment, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activities
Delirium OR obtundation, OR 
coma
Ataxia 
Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activities
Symptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activities
Symptomatic ataxia causing 
inability to perform usual 
social & functional activities 
Disabling ataxia causing 
inability to perform basic self-
care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) 
Disability causing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicated
Disability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part-time basis 
indicated
Disability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicated
Disability causing inability to 
perform basic self-care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)
NA
NA
Transient ischemic attack
Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
Developmental delay –
Pediatric 16 Years
Mild developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate 
for the setting 
Moderate developmental 
delay, either motor or 
cognitive, as determined by 
comparison with a 
developmental screening tool 
appropriate for the setting 
Severe developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting 
Developmental regression, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 118
19 October 2016
NEUROLOGICAL
Grade 1
Grade 2
Grade 3
Grade 4
Headache 
Symptoms causing no or 
minimal interference with 
usual social & functional 
activities
Symptoms causing greater 
than minimal interference with 
usual social & functional 
activities
Symptoms causing inability to 
perform usual social & 
functional activities
Symptoms causing inability to 
perform basic self-care 
functions OR Hospitalization 
indicated (other than ER visit) 
OR Headache with significant 
impairment of alertness or
other neurologic function 
Insomnia
NA
Difficulty sleeping causing 
greater than minimal 
interference with usual 
social/functional activities
Difficulty sleeping causing 
inability to perform usual 
social & functional activities
Disabling insomnia causing 
inability to perform basic self-
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) 
Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak-
ness causing no or minimal 
interference with usual 
social & functional activities
Muscle weakness causing 
greater than minimal 
interference with usual social 
& functional activities
Muscle weakness causing 
inability to perform usual 
social & functional activities 
Disabling muscle weakness 
causing inability to perform 
basic self-care functions OR 
Respiratory muscle weakness 
impairing ventilation
Neurosensory Alteration 
(including paresthesia and 
painful neuropathy)
Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social &
functional activities 
Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities 
Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activities
Disabling sensory alteration or 
paresthesia causing inability to 
perform basic self-care 
functions
Seizure: (new onset) 
NA
1 seizure 
2–4 seizures 
Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or difficult 
to control (eg, refractory 
epilepsy)


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 119
19 October 2016
NEUROLOGICAL
Grade 1
Grade 2
Grade 3
Grade 4
Seizure: (pre-existing) 
For Worsening of Existing 
Epilepsy the Grades Should 
Be Based on an Increase 
from Previous Level of 
Control to Any of These 
Levels
NA
Increased frequency of pre-
existing seizures (non-
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorder
Change in seizure character 
from baseline either in 
duration or quality (eg, 
severity or focality) 
Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or difficult 
to control (eg, refractory 
epilepsy)
Seizure 
– Pediatric 18 Years
Seizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5 minutes with < 24 hours 
post ictal state
Seizure, generalized onset 
with or without secondary 
generalization, lasting 5–20 
minutes with 
< 24 hours post ictal state
Seizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes 
Seizure, generalized onset 
with or without secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)
NA
Present
NA
NA
Vertigo
Vertigo causing no or 
minimal interference with 
usual social & functional 
activities
Vertigo causing greater than 
minimal interference with 
usual social & functional 
activities 
Vertigo causing inability to 
perform usual social & 
functional activities
Disabling vertigo causing 
inability to perform basic self-
care functions


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 120
19 October 2016
MUSCULOSKELETAL
Grade 1
Grade 2
Grade 3
Grade 4
Arthralgia
See also Arthritis
Joint pain causing no or 
minimal interference with 
usual social & functional 
activities
Joint pain causing greater than 
minimal interference with usual 
social & functional activities
Joint pain causing inability 
to perform usual social & 
functional activities
Disabling joint pain causing 
inability to perform basic self-
care functions
Arthritis
See also Arthralgia
Stiffness or joint swelling 
causing no or minimal 
interference with usual 
social & functional activities
Stiffness or joint swelling causing 
greater than minimal interference 
with usual social & functional 
activities
Stiffness or joint swelling 
causing inability to perform 
usual social & functional 
activities
Disabling joint stiffness or 
swelling causing inability to 
perform basic self-care 
functions
Bone Mineral Loss
BMD t-score or z-score
–2.5 to –1.0 
BMD t-score or z-score –2.5
Pathological fracture 
(including loss of vertebral 
height)
Pathologic fracture causing 
life-threatening consequences 
Pediatric 21 Years
BMD z-score 
–2.5 to –1.0
BMD z-score < –2.5
Pathological fracture 
(including loss of vertebral 
height)
Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)
Muscle pain causing no or 
minimal interference with 
usual social & functional 
activities
Muscle pain causing greater than 
minimal interference with usual 
social & functional activities
Muscle pain causing 
inability to perform usual 
social & functional activities
Disabling muscle pain causing 
inability to perform basic self-
care functions
Osteonecrosis
NA
Asymptomatic with radiographic 
findings AND No operative 
intervention indicated
Symptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicated
Disabling bone pain with 
radiographic findings causing 
inability to perform basic self-
care functions


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 121
19 October 2016
SYSTEMIC
Grade 1
Grade 2
Grade 3
Grade 4
Acute Systemic Allergic 
Reaction 
Localized urticaria 
(wheals) with no medical 
intervention indicated
Localized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicated
Generalized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasm
Acute anaphylaxis OR Life-
threatening bronchospasm OR 
laryngeal edema
Chills
Symptoms causing no or 
minimal interference with 
usual social & functional 
activities
Symptoms causing greater than 
minimal interference with usual 
social & functional activities 
Symptoms causing inability to 
perform usual social & 
functional activities
NA
Fatigue
Malaise
Symptoms causing no or 
minimal interference with 
usual social & functional 
activities
Symptoms causing greater than 
minimal interference with usual 
social & functional activities
Symptoms causing inability to 
perform usual social & 
functional activities
Incapacitating fatigue/malaise 
symptoms causing inability to 
perform basic self-care 
functions
Fever (nonaxillary)
37.7C to 38.6C
99.8F to 101.5F
38.7C to 39.3C
101.6F to 102.8F
39.4C to 40.5C
102.9F to 104.9F
40.5C 
104.9F
Pain- Indicate Body Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and Myalgia
Pain causing no or 
minimal interference with 
usual social & functional 
activities
Pain causing greater than minimal 
interference with usual social & 
functional activities
Pain causing inability to 
perform usual social & 
functional activities
Disabling pain causing 
inability to perform basic self-
care functions OR 
Hospitalization (other than ER 
visit) indicated
Unintentional Weight 
Loss
NA
5% to 9% loss in body weight from 
baseline
10% to 19% loss in body 
weight from baseline
20% loss in body weight 
from baseline OR  Aggressive 
intervention indicated [eg, 
tube feeding or total parenteral 
nutrition]


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 122
19 October 2016
INJECTION SITE REACTION
Grade 1
Grade 2
Grade 3
Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when 
area is touched) 
Pain/tenderness causing no 
or minimal limitation of use 
of limb
Pain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activities
Pain/tenderness causing 
inability to perform usual 
social & functional activities
Pain/tenderness causing inability 
to perform basic self-care 
function OR Hospitalization 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15 Years
Erythema OR Induration
of 5 5 cm to 9 9 cm (or 
2581 cm2)
Erythema OR Induration OR 
Edema 9 cm any diameter 
(or 81 cm2)
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR Drainage
Necrosis (involving dermis and 
deeper tissue)
Pediatric 15 Years
Erythema OR Induration 
OR Edema present but 
2.5 cm diameter
Erythema OR Induration 
OR Edema > 2.5 cm 
diameter but < 50% surface 
area of the extremity 
segment (eg, upper 
arm/thigh)
Erythema OR Induration 
OR Edema involving 
50% surface area of the 
extremity segment (eg, 
upper arm/thigh) OR 
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR 
Drainage
Necrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching—no skin lesions)
Itching localized to injection 
site AND Relieved 
spontaneously or with 
48 h treatment 
Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48 h treatment 
Generalized itching causing 
inability to perform usual 
social & functional activities
NA


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 123
19 October 2016
ENDOCRINE/METABOLIC
Grade 1
Grade 2
Grade 3
Grade 4
Lipodystrophy (eg, back 
of neck, breasts, 
abdomen)
Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)
Detectable on physical exam by 
health care provider
Disfiguring OR Obvious 
changes on casual visual 
inspection
NA
Diabetes Mellitus
NA
New onset without need to initiate 
medication OR Modification of 
current meds to regain glucose 
control
New onset with initiation of 
indicated med OR Diabetes 
uncontrolled despite treatment 
modification
Life-threatening consequences 
(eg, ketoacidosis, 
hyperosmolar non-ketotic 
coma) 
Gynecomastia
Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)
Detectable on physical exam by 
health care provider
Disfiguring OR Obvious on 
casual visual inspection
NA
Hyperthyroidism 
Asymptomatic
Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid suppression therapy 
indicated
Symptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification 
Life-threatening consequences 
(eg, thyroid storm)
Hypothyroidism
Asymptomatic
Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicated
Symptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification 
Life-threatening consequences 
(eg, myxedema coma)
Lipoatrophy (eg, fat loss 
from the face, extremities, 
buttocks)
Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)
Detectable on physical exam by 
health care provider
Disfiguring OR Obvious on 
casual visual inspection
NA


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 124
19 October 2016
GENITOURINARY
Grade 1
Grade 2
Grade 3
Grade 4
Intermenstrual Bleeding 
(IMB)
Spotting observed by participant 
OR Minimal blood observed 
during clinical or colposcopic 
exam
Intermenstrual bleeding not 
greater in duration or amount 
than usual menstrual cycle
Intermenstrual bleeding greater 
in duration or amount than usual 
menstrual cycle
Hemorrhage with life-
threatening hypotension OR 
Operative intervention 
indicated
Urinary Tract 
obstruction (eg, stone)
NA
Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunction
Signs or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunction
Obstruction causing life-
threatening consequences
INFECTION
Grade 1
Grade 2
Grade 3
Grade 4
Infection (any other 
than HIV infection)
Localized, no systemic antiμbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activities
Systemic antiμbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional activities
Systemic antiμbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than simple 
incision and drainage) indicated
Life-threatening 
consequences (eg, septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, pursuing a hobby, etc.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 125
19 October 2016
Appendix 6.
Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC 
Guidelines)
1. Candidiasis of bronchi, trachea, or lungs
2. Candidiasis of esophagus
3. Cervical cancer, invasive
4. Coccidioidomycosis, disseminated or extrapulmonary
5. Cryptococcosis, extrapulmonary
6. Cryptosporidiosis, chronic intestinal (1 month duration)
7. Cytomegalovirus disease (other than liver, spleen or nodes)
8. Cytomegalovirus retinitis (with loss of vision)
9. Encephalopathy, HIV-related
10. Herpes simplex: chronic ulcer(s) (1 month duration); or bronchitis, pneumonitis or 
esophagitis
11. Histoplasmosis, disseminated or extrapulmonary
12. Isosporiasis, chronic intestinal (1 month duration)
13. Kaposi’s sarcoma
14. Lymphoma, Burkitt’s (or equivalent term)
15. Lymphoma, immunoblastic (or equivalent term)
16. Lymphoma, primary, of brain
17. Mycobacterium avium complex or Myobacterium kansasii, disseminated or extrapulmonary
18. Mycobacterium tuberculosis, of any site,  pulmonary, disseminated or extrapulmonary
19. Mycobacterium, other species or unidentified species, disseminated or extrapulmonary
20. Pneumocystis jirovecii (previously known as “Pneumocystis carinii) pneumonia
21. Pneumonia, recurrent
22. Progressive multifocal leukoencephalopathy
23. Salmonella septicemia, recurrent
24. Toxoplasmosis of brain
25. Wasting syndrome attributed to HIV infection
CDC Stage-3-Defining Opportunistic Illnesses in HIV Infection - 2014 {Schneider et al 2008}


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 126
19 October 2016
Appendix 7.
Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)
Definitions
a)
Definition of Childbearing Potential
For the purposes of this study, a female born subject is considered of childbearing potential 
following the initiation of puberty (Tanner stage 2) until becoming post-menopausal, unless 
permanently sterile or with medically documented ovarian failure.
Women are considered to be in a postmenopausal state when they are > 54 years of age with 
cessation of previously occurring menses for > 12 months without an alternative cause. In 
addition, women of any age with amenorrhea of > 12 months may also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they are not using hormonal contraception or hormonal replacement therapy.
Permanent sterilization includes hysterectomy, bilateral oophorectomy, or bilateral 
salpingectomy in a female subject of any age.
b)
Definition of Male Fertility
For the purposes of this study, a male born subject is considered to be fertile after the initiation 
of puberty unless permanently sterile by bilateral orchidectomy or medical documentation.
2)
Contraception Requirements for Female Subjects
a)
Study Drug Effects on Pregnancy and Hormonal Contraception
The data on GS-9883/F/TAF in pregnant women is limited or not available. There is no 
suspicion of human teratogenicity based on class effects or genotoxic potential. Relevant 
non-clinical reproductive studies for human pregnancy do not indicate a strong suspicion of 
human teratogenicity/fetotoxicity. Data from clinical pharmacokinetic interaction studies of
GS-9883 and F/TAF have demonstrated that there is no reduction in the clinical efficacy of 
hormonal contraception or that the effect on hormonal contraception is insignificant. Please refer 
to the latest version of the GS-9883/F/TAF investigator’s brochure and the current Prescribing 
Information and local product labeling for ABC/DTG/3TC for additional information.
b)
Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highly effective 
contraceptive measures.  They must have a negative serum pregnancy test at Screening and a 
negative pregnancy test on the Day 1 visit prior to randomization. At minimum a pregnancy test 
will be performed at the end of relevant systemic exposure. In the event of a delayed menstrual 
period (over one month between menstruations), a pregnancy test must be performed to rule out 
pregnancy. This is true even for women of childbearing potential with infrequent or irregular 
periods. Female subjects must agree to one of the following from Screening until 30 days 
following the end of relevant systemic exposure.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 127
19 October 2016

Complete abstinence from intercourse of reproductive potential.  Abstinence is an acceptable 
method of contraception only when it is in line with the subject’s preferred and usual 
lifestyle. 
Or

Consistent and correct use of 1 of the following methods of birth control listed below.
Intrauterine device (IUD) with a failure rate of <1% per year
Intrauterine hormone-releasing system (IUS) with a failure rate of <1% per year
Tubal sterilization
Essure micro-insert system (provided confirmation of success 3 months after procedure)
Vasectomy in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Or

Consistent and correct use of one hormonal method and one barrier method
Barrier methods
■
Diaphragm with spermicide
■
Cervical cap with spermicide
■
Male condom (with or without spermicide)
Hormonal methods
■
Oral contraceptives (either combined or progesterone only)
■
Injectable progesterone
■
Implants of levonorgestrel
■
Transdermal contraceptive patch
■
Contraceptive vaginal ring
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 30 days after the end of relevant systemic exposure.


GS-9883/F/TAF
Protocol GS-US-380-1844
Final
Gilead Sciences, Inc.
Amendment 2
CONFIDENTIAL
Page 128
19 October 2016
3)
Contraception Requirements for Male Subjects
It is theoretically possible that a relevant systemic concentration may be achieved in a female 
partner from exposure of the male subject’s seminal fluid.  Therefore, male subjects with female 
partners of childbearing potential must use condoms during treatment and until 90 days after the 
end of relevant systemic exposure.  Additional contraception recommendations should also be 
considered if the female partner is not pregnant.
Male subjects must also refrain from sperm donation during treatment and until at least 90 days 
after the end of relevant systemic exposure.
4)
Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, 
ovulation, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides 
only, and lactational amenorrhea method (LAM).  Female condom and male condom should not 
be used together.
5)
Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify the investigator if they become pregnant at any time during 
the study, or if they become pregnant within 30 days of last study drug dose. Subjects who 
become pregnant or who suspect that they are pregnant during the study must report the 
information to the investigator and discontinue study drug immediately. Subjects whose partner 
has become pregnant or suspects she is pregnant during the study must report the information to 
the investigator.  Instructions for reporting pregnancy, partner pregnancy, and pregnancy 
outcome are outlined in Section 7.3.